relation_token_span_ids	ent1_ent2_start	ent1	ent2	label	label_id	ent1_type	ent2_type	ent1_id	ent2_id	ent1_cui	ent2_cui	doc_id	text
	(3, 11)	azithromycin	ototoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	0	Intravenous [s1]azithromycin[e1] induced [s2]ototoxicity[e2] 
	(20, 40)	dihydrotachysterol	increased calcium-release	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1	Immobilization, while Paget's bone disease was present, and perhaps enhanced activation of [s1]dihydrotachysterol[e1] by rifampicin, could have led to [s2]increased calcium-release[e2] into the circulation.
	(5, 24)	hypercalcemia	dihydrotachysterol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2	Unaccountable severe [s1]hypercalcemia[e1] in a patient treated for hypoparathyroidism with [s2]dihydrotachysterol[e2] 
	(7, 15)	pseudoporphyria	naproxen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3	METHODS: We report two cases of [s1]pseudoporphyria[e1] caused by [s2]naproxen[e2] and oxaprozin.
	(7, 20)	pseudoporphyria	oxaprozin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4	METHODS: We report two cases of [s1]pseudoporphyria[e1] caused by naproxen and [s2]oxaprozin[e2] 
	(0, 32)	Naproxen	erythropoietic protoporphyria	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5	 [s1]Naproxen[e1]  the most common offender, has been associated with a dimorphic clinical pattern: a PCT-like presentation and one simulating [s2]erythropoietic protoporphyria[e2] in the pediatric population.
	(10, 47)	naproxen	cutaneous fragility	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6	RESULTS: A 44-year-old man taking [s1]naproxen[e1] for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and [s2]cutaneous fragility[e2] on the face and the back of the hands.
	(28, 47)	oxaprozin	cutaneous fragility	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	7	RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on [s1]oxaprozin[e1] for rheumatoid arthritis presented with tense bullae and [s2]cutaneous fragility[e2] on the face and the back of the hands.
	(10, 43)	naproxen	tense bullae	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	8	RESULTS: A 44-year-old man taking [s1]naproxen[e1] for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with [s2]tense bullae[e2] and cutaneous fragility on the face and the back of the hands.
	(28, 43)	oxaprozin	tense bullae	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	9	RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on [s1]oxaprozin[e1] for rheumatoid arthritis presented with [s2]tense bullae[e2] and cutaneous fragility on the face and the back of the hands.
	(12, 24)	clozapine	granulocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	10	BACKGROUND: How to best treat psychotic patients who have had past [s1]clozapine[e1] induced agranulocytosis or [s2]granulocytopenia[e2] remains a problem.
	(16, 22)	clozapine	granulocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	11	CONCLUSION: The results suggest that olanzapine may be useful in treating patients with [s1]clozapine[e1] induced [s2]granulocytopenia[e2] without the risk of recurrence of hematologic side effects.
	(2, 12)	5-fluorouracil	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	12	Prolonged severe [s1]5-fluorouracil[e1] associated [s2]neurotoxicity[e2] in a patient with dihydropyrimidine dehydrogenase deficiency.
	(6, 40)	5-FU	neurologic toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	13	We describe the side effects of [s1]5-FU[e1] in a colon cancer patient who suffered severe mucositis, desquamating dermatitis, prolonged myelosuppression, and [s2]neurologic toxicity[e2] that required admission to the intensive care unit.
	(6, 31)	5-FU	prolonged myelosuppression	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	14	We describe the side effects of [s1]5-FU[e1] in a colon cancer patient who suffered severe mucositis, desquamating dermatitis, [s2]prolonged myelosuppression[e2]  and neurologic toxicity that required admission to the intensive care unit.
	(6, 18)	5-FU	severe mucositis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	15	We describe the side effects of [s1]5-FU[e1] in a colon cancer patient who suffered [s2]severe mucositis[e2]  desquamating dermatitis, prolonged myelosuppression, and neurologic toxicity that required admission to the intensive care unit.
	(4, 44)	BH-AC	encephalopathy syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	16	This case suggests that [s1]BH-AC[e1]  a derivative of cytosine arabinoside (1-beta-D-arabinofuranosylcytosine) could be a cause of reversible [s2]encephalopathy syndrome[e2] 
	(8, 44)	encephalopathy syndrome	BH-AC	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	17	We report a case of reversible [s1]encephalopathy syndrome[e1] in a 16-year-old girl with acute myelogenous leukemia (AML), who is undergoing during consolidation chemotherapy composed of [s2]BH-AC[e2] (N4-behenoyl-1-beta-D-arabinofuranosyl cytosine) and idarubicin.
	(8, 74)	encephalopathy syndrome	idarubicin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	18	We report a case of reversible [s1]encephalopathy syndrome[e1] in a 16-year-old girl with acute myelogenous leukemia (AML), who is undergoing during consolidation chemotherapy composed of BH-AC (N4-behenoyl-1-beta-D-arabinofuranosyl cytosine) and [s2]idarubicin[e2] 
	(10, 24)	riluzole	hepatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	19	In one case, the readministration of [s1]riluzole[e1] was followed by the relapse of [s2]hepatitis[e2] 
	(10, 15)	hepatitis	riluzole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	20	We report the cases of two patients who developed acute [s1]hepatitis[e1] after taking [s2]riluzole[e2] at the recommended dose (100 mg daily) for 7 and 4 weeks, respectively.
	(0, 9)	Lupus-like syndrome	5-aminosalicylic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	21	 [s1]Lupus-like syndrome[e1] caused by [s2]5-aminosalicylic acid[e2] in patients with inflammatory bowel disease.
	(12, 26)	methemoglobinemia	lidocaine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	22	Although the two local anesthetics usually do not cause [s1]methemoglobinemia[e1]  we suspect that the displacement of [s2]lidocaine[e2] from protein binding by bupivacaine, in combination with metabolic acidosis and treatment with other oxidants, was the reason for the development of methemoglobinemia.
	(0, 14)	Methemoglobinemia	bupivacaine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	23	 [s1]Methemoglobinemia[e1] after axillary block with [s2]bupivacaine[e2] and additional injection of lidocaine in the operative field.
	(0, 22)	Methemoglobinemia	lidocaine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	24	 [s1]Methemoglobinemia[e1] after axillary block with bupivacaine and additional injection of [s2]lidocaine[e2] in the operative field.
	(19, 34)	methemoglobinemia	bupivacaine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	25	We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant [s1]methemoglobinemia[e1] after an axillary block with [s2]bupivacaine[e2] and additional injection of lidocaine in the operative field.
	(19, 42)	methemoglobinemia	lidocaine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	26	We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant [s1]methemoglobinemia[e1] after an axillary block with bupivacaine and additional injection of [s2]lidocaine[e2] in the operative field.
	(14, 20)	aspirin	asthma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	27	Detection of activated eosinophils in nasal polyps of an [s1]aspirin[e1] induced [s2]asthma[e2] patient.
	(6, 22)	encephalopathy	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	28	An episode of subacute [s1]encephalopathy[e1] after the infusion of a moderate dose of [s2]methotrexate[e2] (1500 mg/m2) (MTX) is reported in a young adult with metastastic gastric cancer.
	(12, 17)	MTX	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	29	We believe that this represents an unusual case of moderate-dose [s1]MTX[e1] induced [s2]neurotoxicity[e2] in a patient with gastric cancer, which has not previously been reported.
	(9, 18)	epoprostenol	pulmonary edema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	30	We describe a life threatening side effect of acute [s1]epoprostenol[e1] infusion  [s2]pulmonary edema[e2]  in a patient with pulmonary hypertension associated with limited scleroderma and discuss its management and potential etiology.
	(14, 24)	pruritic bullous eruption	prednisone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	31	A 14-year-old girl with newly diagnosed SLE developed a [s1]pruritic bullous eruption[e1] while on [s2]prednisone[e2] 
	(0, 7)	Hydroxyurea	acute interstitial pneumonitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	32	 [s1]Hydroxyurea[e1] induced [s2]acute interstitial pneumonitis[e2] in a patient with essential thrombocythemia.
	(6, 19)	interstitial pneumonitis	hydroxyurea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	33	The clinical course suggests that the [s1]interstitial pneumonitis[e1] was induced by [s2]hydroxyurea[e2] 
	(6, 13)	hydroxyurea	acute interstitial pneumonitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	34	This is the first case of [s1]hydroxyurea[e1] induced [s2]acute interstitial pneumonitis[e2] reported in the literature.
	(2, 12)	irritant contact dermatitis	calcipotriol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	35	Allergic and [s1]irritant contact dermatitis[e1] to [s2]calcipotriol[e2] 
	(0, 28)	Calcipotriol	allergic reactions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	36	 [s1]Calcipotriol[e1] (Daivonex R; Leo Pharmaceuticals, Zurich, Switzerland) may cause irritation of the skin, whereas [s2]allergic reactions[e2] are less common.
	(0, 22)	Calcipotriol	irritation of the skin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	37	 [s1]Calcipotriol[e1] (Daivonex R; Leo Pharmaceuticals, Zurich, Switzerland) may cause [s2]irritation of the skin[e2]  whereas allergic reactions are less common.
	(32, 43)	irritant type of reaction	calcipotriol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	38	The present observation suggests, that a batch of different testing doses, including lower testing doses may help to differentiate between an allergic type of contact dermatitis and an [s1]irritant type of reaction[e1] after treatment with [s2]calcipotriol[e2] 
	(0, 18)	Myotonia	pravastatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	39	 [s1]Myotonia[e1] associated with sarcoidosis: marked exacerbation with [s2]pravastatin[e2] 
	(0, 9)	Pravastatin	myotonia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	40	 [s1]Pravastatin[e1] is associated with [s2]myotonia[e2] in animals.
	(9, 21)	pravastatin	myotonia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	41	This case suggests that sarcoidosis and [s1]pravastatin[e1]  two entities not frequently associated with [s2]myotonia[e2]  may interact in a synergistic manner to produce severe clinical myotonia in humans.
	(5, 23)	aspirin	angioedema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	42	Hypersensitivity to [s1]aspirin[e1] can be manifested as acute asthma, urticaria and/or [s2]angioedema[e2]  or a systemic anaphylactoid reaction.
	(5, 30)	aspirin	systemic anaphylactoid reaction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	43	Hypersensitivity to [s1]aspirin[e1] can be manifested as acute asthma, urticaria and/or angioedema, or a [s2]systemic anaphylactoid reaction[e2] 
	(5, 17)	aspirin	urticaria	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	44	Hypersensitivity to [s1]aspirin[e1] can be manifested as acute asthma, [s2]urticaria[e2] and/or angioedema, or a systemic anaphylactoid reaction.
	(4, 20)	eruption	omeprazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	45	CONCLUSION: Fixed drug [s1]eruption[e1] is associated with many drugs but this is the first such report with [s2]omeprazole[e2] 
	(2, 9)	eruption	omeprazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	46	Fixed drug [s1]eruption[e1] in hands caused by [s2]omeprazole[e2] 
	(13, 19)	eruption	omeprazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	47	The objective of this report is to describe a case of fixed drug [s1]eruption[e1] that occurred during [s2]omeprazole[e2] treatment.
	(27, 59)	diffuse erythema	salazosulfapyridine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	48	A 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with [s1]diffuse erythema[e1] and pustules on his face and trunk, malaise, and fever up to 39 degrees C one day after the administration of [s2]salazosulfapyridine[e2] 
	(45, 59)	fever up to 39 degrees C	salazosulfapyridine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	49	A 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with diffuse erythema and pustules on his face and trunk, malaise, and [s1]fever up to 39 degrees C[e1] one day after the administration of [s2]salazosulfapyridine[e2] 
	(41, 58)	malaise	salazosulfapyridine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	50	A 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with diffuse erythema and pustules on his face and trunk, [s1]malaise[e1]  and fever up to 39 degrees C one day after the administration of [s2]salazosulfapyridine[e2] 
	(32, 59)	pustules	salazosulfapyridine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	51	A 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with diffuse erythema and [s1]pustules[e1] on his face and trunk, malaise, and fever up to 39 degrees C one day after the administration of [s2]salazosulfapyridine[e2] 
	(0, 15)	Acute generalized exanthematous pustulosis	salazosulfapyridine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	52	 [s1]Acute generalized exanthematous pustulosis[e1] induced by [s2]salazosulfapyridine[e2] in a patient with ulcerative colitis.
	(5, 24)	acute generalized exanthematous pustulosis	salazosulfapyridine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	53	We report a case of [s1]acute generalized exanthematous pustulosis[e1] (AGEP) induced by [s2]salazosulfapyridine[e2] in a patient with ulcerative colitis.
	(20, 27)	olanzapine	elevated serum CK concentration	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	54	CASE SUMMARY: A 39-year-old white Jewish schizophrenic man treated with [s1]olanzapine[e1] developed an [s2]elevated serum CK concentration[e2] with a peak concentration of 4000 IU/L (normal < 230).
	(2, 20)	Olanzapine	muscle injury with concomitant elevations of serum CK	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	55	DISCUSSION: [s1]Olanzapine[e1]  like other atypical antipsychotic drugs, may cause [s2]muscle injury with concomitant elevations of serum CK[e2] of muscle origin.
	(1, 12)	elevation of serum creatine kinase	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	56	Marked [s1]elevation of serum creatine kinase[e1] associated with [s2]olanzapine[e2] therapy.
	(8, 22)	elevation of serum creatine kinase	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	57	OBJECTIVE: To report a case of marked [s1]elevation of serum creatine kinase[e1] (CK) associated with [s2]olanzapine[e2] therapy.
	(0, 8)	Diclofenac	hepatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	58	 [s1]Diclofenac[e1] associated [s2]hepatitis[e2] 
	(17, 26)	hepatitis	diclofenac	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	59	This patient, who had a history of osteoarthritis, had severe [s1]hepatitis[e1] 5 weeks after being started on [s2]diclofenac[e2] for increasing pain in the joints.
	(0, 8)	2-CdA	lymphocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	60	 [s1]2-CdA[e1] induces [s2]lymphocytopenia[e2]  which may explain the improvement in this patient's psoriasis.
	(3, 10)	priapism	heparin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	61	One case of [s1]priapism[e1] occurred during [s2]heparin[e2] therapy for a previous surgical operation to the knee is reported.
	(0, 10)	Priapism	heparin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	62	 [s1]Priapism[e1] as a complication of [s2]heparin[e2] therapy.
	(3, 16)	heparin	abnormal platelet aggregation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	63	The association between [s1]heparin[e1] and priapism is often recognized; [s2]abnormal platelet aggregation[e2] could play a role in the pathogenesis of this side effect.
	(3, 9)	heparin	priapism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	64	The association between [s1]heparin[e1] and [s2]priapism[e2] is often recognized; abnormal platelet aggregation could play a role in the pathogenesis of this side effect.
	(13, 32)	agranulocytosis	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	65	It carries a well-known risk of neutropenia and [s1]agranulocytosis[e1]  which necessitates the immediate discontinuation of [s2]clozapine[e2] 
	(8, 33)	neutropenia	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	66	It carries a well-known risk of [s1]neutropenia[e1] and agranulocytosis, which necessitates the immediate discontinuation of [s2]clozapine[e2] 
	(13, 28)	clozapine	diurnal variation of the white blood cells	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	67	OBJECTIVE: We report a patient who developed neutropenia on [s1]clozapine[e1]  but behind the cell count decrease showed to be a [s2]diurnal variation of the white blood cells[e2] (WBC).
	(0, 13)	Acute neutrophilic dermatosis	all-trans-retinoic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	68	 [s1]Acute neutrophilic dermatosis[e1] induced by [s2]all-trans-retinoic acid[e2] treatment for acute promyelocytic leukemia.
	(16, 26)	hair loss	paroxetine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	69	Findings on discontinuation and rechallenge supported the assumption that the [s1]hair loss[e1] was a side effect of the [s2]paroxetine[e2] 
	(0, 6)	Hair loss	paroxetine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	70	 [s1]Hair loss[e1] associated with [s2]paroxetine[e2] treatment: a case report.
	(14, 19)	hair loss	paroxetine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	71	We report on a 37-year-old female who complained of moderate [s1]hair loss[e1] during [s2]paroxetine[e2] treatment.
	(4, 32)	insulin	protamine allergy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	72	CONCLUSION: Patients with [s1]insulin[e1] allergy may not have complete resolution of their symptoms after standard desensitization, particularly those patients with concomitant [s2]protamine allergy[e2] 
	(5, 18)	insulin	angioedema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	73	METHODS: The patient required [s1]insulin[e1] desensitization for severe urticaria, [s2]angioedema[e2]  and occasional wheezing resulting from her insulin dose.
	(5, 18)	insulin	angioedema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	74	METHODS: The patient required [s1]insulin[e1] desensitization for severe urticaria, [s2]angioedema[e2]  and occasional wheezing resulting from her insulin dose.
	(5, 13)	insulin	severe urticaria	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	75	METHODS: The patient required [s1]insulin[e1] desensitization for [s2]severe urticaria[e2]  angioedema, and occasional wheezing resulting from her insulin dose.
	(5, 13)	insulin	severe urticaria	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	76	METHODS: The patient required [s1]insulin[e1] desensitization for [s2]severe urticaria[e2]  angioedema, and occasional wheezing resulting from her insulin dose.
	(5, 25)	insulin	wheezing	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	77	METHODS: The patient required [s1]insulin[e1] desensitization for severe urticaria, angioedema, and occasional [s2]wheezing[e2] resulting from her insulin dose.
	(5, 25)	insulin	wheezing	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	78	METHODS: The patient required [s1]insulin[e1] desensitization for severe urticaria, angioedema, and occasional [s2]wheezing[e2] resulting from her insulin dose.
	(18, 33)	insulin	allergic symptoms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	79	OBJECTIVE: The purpose of this study was to determine whether desensitization to NPH [s1]insulin[e1]  as well as standard insulin desensitization, could control [s2]allergic symptoms[e2] in a patient allergic to both NPH and regular insulin.
	(16, 33)	NPH insulin	allergic symptoms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	80	OBJECTIVE: The purpose of this study was to determine whether desensitization to [s1]NPH insulin[e1]  as well as standard insulin desensitization, could control [s2]allergic symptoms[e2] in a patient allergic to both NPH and regular insulin.
	(2, 24)	neutral protamine Hagedorn (NPH) insulin	protamine hypersensitivity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	81	Patients receiving [s1]neutral protamine Hagedorn (NPH) insulin[e1] are at increased risk for the development of [s2]protamine hypersensitivity[e2] 
	(0, 12)	Protamine allergy	insulin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	82	 [s1]Protamine allergy[e1] as a complication of [s2]insulin[e2] hypersensitivity: A case report.
	(5, 20)	insulin	hives	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	83	She continued to receive regular [s1]insulin[e1] 4 times per day over the following 3 years with only occasional [s2]hives[e2] 
	(11, 41)	angioedema	insulin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	84	The patient had recurrence of urticaria and [s1]angioedema[e1] a year and a half later, at which point the NPH was stopped and she was desensitized to regular [s2]insulin[e2] 
	(11, 28)	angioedema	NPH	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	85	The patient had recurrence of urticaria and [s1]angioedema[e1] a year and a half later, at which point the [s2]NPH[e2] was stopped and she was desensitized to regular insulin.
	(7, 41)	urticaria	insulin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	86	The patient had recurrence of [s1]urticaria[e1] and angioedema a year and a half later, at which point the NPH was stopped and she was desensitized to regular [s2]insulin[e2] 
	(7, 28)	urticaria	NPH	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	87	The patient had recurrence of [s1]urticaria[e1] and angioedema a year and a half later, at which point the [s2]NPH[e2] was stopped and she was desensitized to regular insulin.
	(8, 21)	lethargic	brimonidine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	88	A 5-month-old infant became [s1]lethargic[e1] and poorly responsive after receiving 1 drop of [s2]brimonidine[e2] in each eye.
	(12, 21)	poorly responsive	brimonidine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	89	A 5-month-old infant became lethargic and [s1]poorly responsive[e1] after receiving 1 drop of [s2]brimonidine[e2] in each eye.
	(12, 22)	apneic	brimonidine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	90	An 11-day-old infant became lethargic and [s1]apneic[e1] after a single drop of [s2]brimonidine[e2] 
	(8, 22)	lethargic	brimonidine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	91	An 11-day-old infant became [s1]lethargic[e1] and apneic after a single drop of [s2]brimonidine[e2] 
	(1, 14)	central nervous system depression	brimonidine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	92	Apparent [s1]central nervous system depression[e1] in infants after the use of topical [s2]brimonidine[e2] 
	(3, 13)	brimonidine	central nervous system depression	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	93	CONCLUSIONS: Topical [s1]brimonidine[e1] may be associated with [s2]central nervous system depression[e2] in infants.
	(9, 18)	brimonidine	central nervous system depression	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	94	PURPOSE: To report two cases in which topical [s1]brimonidine[e1] resulted in apparent [s2]central nervous system depression[e2] and unresponsiveness in an infant.
	(24, 32)	ceftriaxone	elevated hepato-biliary enzymes	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	95	Ceftriaxone was approved in 1997 for the treatment of otitis media despite previous studies that documented an association of [s1]ceftriaxone[e1] with [s2]elevated hepato-biliary enzymes[e2] and transient biliary stasis.
	(24, 42)	ceftriaxone	transient biliary stasis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	96	Ceftriaxone was approved in 1997 for the treatment of otitis media despite previous studies that documented an association of [s1]ceftriaxone[e1] with elevated hepato-biliary enzymes and [s2]transient biliary stasis[e2] 
	(0, 12)	Hepato-biliary abnormalities	ceftriaxone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	97	 [s1]Hepato-biliary abnormalities[e1] secondary to [s2]ceftriaxone[e2] use: a case report.
	(0, 16)	Anterior lumbosacral radiculopathy	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	98	 [s1]Anterior lumbosacral radiculopathy[e1] after intrathecal [s2]methotrexate[e2] treatment.
	(6, 16)	progressive paraparesis	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	99	Reported are three children who developed [s1]progressive paraparesis[e1] after intrathecal [s2]methotrexate[e2] administration followed by complete or partial recovery.
	(5, 13)	arsenic trioxide	decrease in the D-dimers	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	100	During the first days of [s1]arsenic trioxide[e1] treatment a rapid [s2]decrease in the D-dimers[e2] was seen (normal values reached until day 7), together with a slight decrease in peripheral blood leukocytes.
	(5, 34)	arsenic trioxide	slight decrease in peripheral blood leukocytes	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	101	During the first days of [s1]arsenic trioxide[e1] treatment a rapid decrease in the D-dimers was seen (normal values reached until day 7), together with a [s2]slight decrease in peripheral blood leukocytes[e2] 
	(11, 44)	chills	minocycline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	102	A 22-year-old black man developed fever, [s1]chills[e1]  fatigue, night sweats, tender lymphadenopathy, and a generalized, pruritic, macular eruption 3 weeks after starting [s2]minocycline[e2] therapy for acne.
	(14, 44)	fatigue	minocycline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	103	A 22-year-old black man developed fever, chills, [s1]fatigue[e1]  night sweats, tender lymphadenopathy, and a generalized, pruritic, macular eruption 3 weeks after starting [s2]minocycline[e2] therapy for acne.
	(9, 44)	fever	minocycline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	104	A 22-year-old black man developed [s1]fever[e1]  chills, fatigue, night sweats, tender lymphadenopathy, and a generalized, pruritic, macular eruption 3 weeks after starting [s2]minocycline[e2] therapy for acne.
	(30, 45)	generalized, pruritic, macular eruption	minocycline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	105	A 22-year-old black man developed fever, chills, fatigue, night sweats, tender lymphadenopathy, and a [s1]generalized, pruritic, macular eruption[e1] 3 weeks after starting [s2]minocycline[e2] therapy for acne.
	(16, 44)	night sweats	minocycline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	106	A 22-year-old black man developed fever, chills, fatigue, [s1]night sweats[e1]  tender lymphadenopathy, and a generalized, pruritic, macular eruption 3 weeks after starting [s2]minocycline[e2] therapy for acne.
	(16, 28)	mononucleosis-like syndrome	minocycline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	107	With the negative viral serologies, the clinical picture was most consistent with an infectious [s1]mononucleosis-like syndrome[e1] produced by the [s2]minocycline[e2] ingestion.
	(12, 32)	5-FU	life-threatening toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	108	We conclude that the presence of this metabolic defect combined with topical [s1]5-FU[e1] (a drug demonstrating a narrow therapeutic index) results in the unusual presentation of [s2]life-threatening toxicity[e2] after treatment with a topical drug.
	(10, 20)	life-threatening complications	5-FU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	109	We now report the first known cancer patient who developed [s1]life-threatening complications[e1] after treatment with topical [s2]5-FU[e2] and was shown subsequently to have profound DPD deficiency.
	(1, 14)	acute ischaemic event	venlafaxine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	110	An [s1]acute ischaemic event[e1] associated with the use of [s2]venlafaxine[e2]  a case report and proposed pathophysiological mechanisms.
	(3, 12)	venlafaxine	ischaemic events	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	111	The association of [s1]venlafaxine[e1] treatment with [s2]ischaemic events[e2] could be explained by its unique pharmacological and haemodynamic properties.
	(11, 17)	acute cardiovascular event	venlafaxine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	112	This is the first report of a possible association between an [s1]acute cardiovascular event[e1] and [s2]venlafaxine[e2] 
	(26, 35)	venlafaxine	acute myocardial ischaemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	113	We present a case of an elderly woman with a pre-existing history of ischaemic heart disease, who was treated with [s1]venlafaxine[e1]  and developed [s2]acute myocardial ischaemia[e2] within the first week of treatment.
	(1, 15)	cyclophosphamide	embryopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	114	Apparent [s1]cyclophosphamide[e1] (cytoxan) [s2]embryopathy[e2]  a distinct phenotype?
	(15, 31)	CP	embryopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	115	The purpose of this report is to document a new case of in utero [s1]CP[e1] exposure with multiple congenital anomalies and to establish an apparent CP [s2]embryopathy[e2] phenotype.
	(15, 20)	CP	multiple congenital anomalies	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	116	The purpose of this report is to document a new case of in utero [s1]CP[e1] exposure with [s2]multiple congenital anomalies[e2] and to establish an apparent CP embryopathy phenotype.
	(9, 40)	cyclosposphamide	blepharophimosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	117	The reported cases of in utero exposure to [s1]cyclosposphamide[e1] shared the following manifestations with our patient: growth deficiency, developmental delay, craniosynostosis, [s2]blepharophimosis[e2]  flat nasal bridge, abnormal ears, and distal limb defects including hypoplastic thumbs and oligodactyly.
	(9, 33)	cyclosposphamide	craniosynostosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	118	The reported cases of in utero exposure to [s1]cyclosposphamide[e1] shared the following manifestations with our patient: growth deficiency, developmental delay, [s2]craniosynostosis[e2]  blepharophimosis, flat nasal bridge, abnormal ears, and distal limb defects including hypoplastic thumbs and oligodactyly.
	(9, 30)	cyclosposphamide	developmental delay	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	119	The reported cases of in utero exposure to [s1]cyclosposphamide[e1] shared the following manifestations with our patient: growth deficiency, [s2]developmental delay[e2]  craniosynostosis, blepharophimosis, flat nasal bridge, abnormal ears, and distal limb defects including hypoplastic thumbs and oligodactyly.
	(9, 55)	cyclosposphamide	distal limb defects	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	120	The reported cases of in utero exposure to [s1]cyclosposphamide[e1] shared the following manifestations with our patient: growth deficiency, developmental delay, craniosynostosis, blepharophimosis, flat nasal bridge, abnormal ears, and [s2]distal limb defects[e2] including hypoplastic thumbs and oligodactyly.
	(9, 47)	cyclosposphamide	flat nasal bridge	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	121	The reported cases of in utero exposure to [s1]cyclosposphamide[e1] shared the following manifestations with our patient: growth deficiency, developmental delay, craniosynostosis, blepharophimosis, [s2]flat nasal bridge[e2]  abnormal ears, and distal limb defects including hypoplastic thumbs and oligodactyly.
	(9, 59)	cyclosposphamide	hypoplastic thumbs	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	122	The reported cases of in utero exposure to [s1]cyclosposphamide[e1] shared the following manifestations with our patient: growth deficiency, developmental delay, craniosynostosis, blepharophimosis, flat nasal bridge, abnormal ears, and distal limb defects including [s2]hypoplastic thumbs[e2] and oligodactyly.
	(9, 65)	cyclosposphamide	oligodactyly	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	123	The reported cases of in utero exposure to [s1]cyclosposphamide[e1] shared the following manifestations with our patient: growth deficiency, developmental delay, craniosynostosis, blepharophimosis, flat nasal bridge, abnormal ears, and distal limb defects including hypoplastic thumbs and [s2]oligodactyly[e2] 
	(6, 16)	cyclophosphamide	human teratogen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	124	We conclude that (a) [s1]cyclophosphamide[e1] is a [s2]human teratogen[e2]  (b) a distinct phenotype exists, and (c) the safety of CP in pregnancy is in serious question.
	(4, 12)	seizures	phenytoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	125	In all cases, [s1]seizures[e1] were controlled by withdrawal of [s2]phenytoin[e2] and reduction of drug levels.
	(2, 6)	seizures	phenytoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	126	Paradoxical [s1]seizures[e1] in [s2]phenytoin[e2] toxicity.
	(7, 12)	seizures	phenytoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	127	We present three patients with paradoxical [s1]seizures[e1]  their serum [s2]phenytoin[e2] levels were 43.5 mcg/mL, 46.5 mcg/mL and 38.3 mcg/mL.
	(6, 16)	losartan	angioedema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	128	CONCLUSIONS: This case suggests that [s1]losartan[e1] can induce late-onset [s2]angioedema[e2] in patients with normal renal function and that the reaction can recur after initial resolution of the symptoms.
	(0, 6)	Losartan	angioedema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	129	 [s1]Losartan[e1] induced [s2]angioedema[e2] 
	(7, 15)	angioedema	losartan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	130	OBJECTIVE: To report a case of [s1]angioedema[e1] associated with [s2]losartan[e2] administration.
	(3, 11)	angioedema	losartan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	131	The incidence of [s1]angioedema[e1] secondary to [s2]losartan[e2]  an angiotensin II receptor antagonist, is unknown.
	(15, 26)	hepatic adenomas	danazol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	132	We report the case of a female acromegalic patient in whom multiple [s1]hepatic adenomas[e1] appeared soon after [s2]danazol[e2] treatment for uterine fibromatosis.
	(0, 6)	Heparin	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	133	 [s1]Heparin[e1] induced [s2]thrombocytopenia[e2] is a rare and serious complication of anticoagulation therapy.
	(1, 7)	heparin	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	134	Pediatric [s1]heparin[e1] induced [s2]thrombocytopenia[e2]  management with Danaparoid (orgaran).
	(30, 36)	heparin	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	135	There remains a paucity of information pertaining to alternative anticoagulation strategies for use during cardiopulmonary bypass concomitant with [s1]heparin[e1] induced [s2]thrombocytopenia[e2]  especially in children.
	(6, 20)	heparin	hemorrhagic complications	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	136	We report the successful treatment of [s1]heparin[e1] induced thrombocytopenia and subsequent [s2]hemorrhagic complications[e2] postoperatively in a 2-year-old child with Danaparoid (orgaran).
	(6, 12)	heparin	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	137	We report the successful treatment of [s1]heparin[e1] induced [s2]thrombocytopenia[e2] and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran).
	(0, 5)	Taxane	glaucoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	138	 [s1]Taxane[e1] induced [s2]glaucoma[e2] 
	(5, 13)	glaucoma	doxetaxel	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	139	We report a case of [s1]glaucoma[e1] induced by [s2]doxetaxel[e2] therapy for metastatic breast cancer.
	(1, 10)	hyperphosphatemia	sodium phosphate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	140	Acute [s1]hyperphosphatemia[e1] caused by [s2]sodium phosphate[e2] enema in a patient with liver dysfunction and chronic renal failure.
	(6, 22)	hyperphosphatemia	sodium biphosphate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	141	We report a case of acute [s1]hyperphosphatemia[e1] secondary to rectal administration of sodium phosphate and [s2]sodium biphosphate[e2] (Fleet enema).
	(6, 19)	hyperphosphatemia	sodium phosphate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	142	We report a case of acute [s1]hyperphosphatemia[e1] secondary to rectal administration of [s2]sodium phosphate[e2] and sodium biphosphate (Fleet enema).
	(0, 26)	Prolongation of the QT interval	amiodarone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	143	 [s1]Prolongation of the QT interval[e1] and ventricular tachyarrhymias have been described in patients on [s2]amiodarone[e2] therapy.
	(9, 26)	ventricular tachyarrhymias	amiodarone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	144	Prolongation of the QT interval and [s1]ventricular tachyarrhymias[e1] have been described in patients on [s2]amiodarone[e2] therapy.
	(7, 26)	torsades de pointes	amiodarone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	145	We report a case of recurrent [s1]torsades de pointes[e1] following treatment with pentavalent antimonial drugs and [s2]amiodarone[e2] 
	(7, 16)	diphenylhydantoin	gingival hyperplasia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	146	Emphasis is given to the differentiation of [s1]diphenylhydantoin[e1] induced [s2]gingival hyperplasia[e2] from the angiomatous enlargement of the gingiva before any treatment is planned.
	(15, 34)	anemia	D-Pen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	147	A 66-year-old Japanese woman with severe scleroderma developed [s1]anemia[e1] and thrombocytopenia due to D-penicillamine  [s2]D-Pen[e2]  treatment, although the leukopenia was not markedly severe.
	(15, 28)	anemia	D-penicillamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	148	A 66-year-old Japanese woman with severe scleroderma developed [s1]anemia[e1] and thrombocytopenia due to [s2]D-penicillamine[e2] (D-Pen) treatment, although the leukopenia was not markedly severe.
	(18, 34)	thrombocytopenia	D-Pen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	149	A 66-year-old Japanese woman with severe scleroderma developed anemia and [s1]thrombocytopenia[e1] due to D-penicillamine  [s2]D-Pen[e2]  treatment, although the leukopenia was not markedly severe.
	(18, 28)	thrombocytopenia	D-penicillamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	150	A 66-year-old Japanese woman with severe scleroderma developed anemia and [s1]thrombocytopenia[e1] due to [s2]D-penicillamine[e2] (D-Pen) treatment, although the leukopenia was not markedly severe.
	(4, 24)	D-Pen	bicytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	151	Cessation of [s1]D-Pen[e1] and the start of corticosteroid therapy were followed by recovery from [s2]bicytopenia[e2] 
	(2, 21)	inhibition of hematopoiesis	D-penicillamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	152	In vitro [s1]inhibition of hematopoiesis[e1] in a patient with systemic sclerosis treated with [s2]D-penicillamine[e2] 
	(4, 16)	bicytopenia	D-Pen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	153	These findings suggest that [s1]bicytopenia[e1] in this patient was caused by [s2]D-Pen[e2] and may be due to different sensitivities in the hematopoietic lineage.
	(17, 24)	methimazole	agranulocytosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	154	A 48-year-old woman who was treated for thyrotoxicosis with [s1]methimazole[e1] developed [s2]agranulocytosis[e2] 
	(3, 27)	hypocalcemic tetany	alendronate sodium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	155	Postoperative [s1]hypocalcemic tetany[e1] caused by fleet phospho-soda preparation in a patient taking [s2]alendronate sodium[e2]  report of a case.
	(3, 15)	hypocalcemic tetany	fleet phospho-soda	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	156	Postoperative [s1]hypocalcemic tetany[e1] caused by [s2]fleet phospho-soda[e2] preparation in a patient taking alendronate sodium: report of a case.
	(10, 34)	alendronate	hypocalcemic tetany	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	157	This case report describes a patient who was previously prescribed [s1]alendronate[e1] (Fosamax) and presented with postoperative hypophosphatemia and [s2]hypocalcemic tetany[e2] after bowel preparation with Fleet Phospho-Soda.
	(32, 47)	hypocalcemic tetany	Fleet Phospho-Soda	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	158	This case report describes a patient who was previously prescribed alendronate (Fosamax) and presented with postoperative hypophosphatemia and [s1]hypocalcemic tetany[e1] after bowel preparation with [s2]Fleet Phospho-Soda[e2] 
	(14, 32)	Fosamax	hypocalcemic tetany	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	159	This case report describes a patient who was previously prescribed alendronate  [s1]Fosamax[e1]  and presented with postoperative hypophosphatemia and [s2]hypocalcemic tetany[e2] after bowel preparation with Fleet Phospho-Soda.
	(10, 27)	alendronate	hypophosphatemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	160	This case report describes a patient who was previously prescribed [s1]alendronate[e1] (Fosamax) and presented with postoperative [s2]hypophosphatemia[e2] and hypocalcemic tetany after bowel preparation with Fleet Phospho-Soda.
	(25, 47)	hypophosphatemia	Fleet Phospho-Soda	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	161	This case report describes a patient who was previously prescribed alendronate (Fosamax) and presented with postoperative [s1]hypophosphatemia[e1] and hypocalcemic tetany after bowel preparation with [s2]Fleet Phospho-Soda[e2] 
	(14, 25)	Fosamax	hypophosphatemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	162	This case report describes a patient who was previously prescribed alendronate  [s1]Fosamax[e1]  and presented with postoperative [s2]hypophosphatemia[e2] and hypocalcemic tetany after bowel preparation with Fleet Phospho-Soda.
	(7, 33)	thrombotic microangiopathy	gemcitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	163	Described here are 2 patients who developed [s1]thrombotic microangiopathy[e1] of the kidneys after receiving high cumulative doses of the new anticancer drug [s2]gemcitabine[e2] 
	(9, 17)	renal failure	gemcitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	164	Thrombotic microangiopathy with [s1]renal failure[e1] in two patients undergoing [s2]gemcitabine[e2] chemotherapy.
	(0, 17)	Thrombotic microangiopathy	gemcitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	165	 [s1]Thrombotic microangiopathy[e1] with renal failure in two patients undergoing [s2]gemcitabine[e2] chemotherapy.
	(24, 48)	B-cell non-Hodgkin's lymphoma	infliximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	166	The first patient was a 61-year-old man with a 30-year history of fistulizing CD in whom [s1]B-cell non-Hodgkin's lymphoma[e1] was diagnosed 9 months after treatment with [s2]infliximab[e2] 
	(3, 12)	infliximab	lymphoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	167	The relationship between [s1]infliximab[e1] treatment and [s2]lymphoma[e2] in Crohn's disease.
	(14, 39)	nodular sclerosing Hodgkin's lymphoma	infliximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	168	The second is a 29-year-old man with CD in whom [s1]nodular sclerosing Hodgkin's lymphoma[e1] was diagnosed 3 weeks after infusion with [s2]infliximab[e2] 
	(20, 31)	lymphoma	infliximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	169	We describe the clinical course of 2 patients with Crohn's disease (CD) in whom [s1]lymphoma[e1] was diagnosed after treatment with [s2]infliximab[e2] 
	(0, 11)	Codeine intoxication	Codeine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	170	 [s1]Codeine intoxication[e1] in the neonate [s2]Codeine[e2] intoxication in the neonate.
	(5, 12)	codeine intoxication	codeine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	171	We report a case of [s1]codeine intoxication[e1]  [s2]codeine[e2] intoxication in the neonate, in which the drug was prescribed for cough control during an emergency department visit.
	(0, 25)	Hydroxyurea	increase fetal hemoglobin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	172	 [s1]Hydroxyurea[e1] (HU) and sodium phenylbutyrate (SPB) have been shown to [s2]increase fetal hemoglobin[e2] (Hb F) levels in patients with thalassemia intermedia.
	(8, 25)	sodium phenylbutyrate	increase fetal hemoglobin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	173	Hydroxyurea (HU) and [s1]sodium phenylbutyrate[e1] (SPB) have been shown to [s2]increase fetal hemoglobin[e2] (Hb F) levels in patients with thalassemia intermedia.
	(7, 12)	HU	increase in total Hb	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	174	Of the four patients who responded to [s1]HU[e1] with an [s2]increase in total Hb[e2]  all reported symptomatic improvement and three have not required further transfusions.
	(8, 35)	HU	hepatic toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	175	Prolonged responses were achieved with low doses of [s1]HU[e1] (3-10 mg/kg/day) and higher doses were associated with mild reversible hematologic or [s2]hepatic toxicity[e2] and no further increases in Hb.
	(8, 27)	HU	mild reversible hematologic	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	176	Prolonged responses were achieved with low doses of [s1]HU[e1] (3-10 mg/kg/day) and higher doses were associated with [s2]mild reversible hematologic[e2] or hepatic toxicity and no further increases in Hb.
	(12, 30)	HU	increasing Hb F	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	177	Sodium phenylbutyrate was added to treatment with [s1]HU[e1] in two patients, but failed to produce an increase in total Hb despite [s2]increasing Hb F[e2] levels.
	(0, 30)	Sodium phenylbutyrate	increasing Hb F	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	178	 [s1]Sodium phenylbutyrate[e1] was added to treatment with HU in two patients, but failed to produce an increase in total Hb despite [s2]increasing Hb F[e2] levels.
	(6, 19)	HU	increase total Hb	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	179	We conclude that low-dose [s1]HU[e1] therapy in patients with thalassemia intermedia may [s2]increase total Hb[e2] levels sufficiently to eliminate the need for transfusions.
	(9, 33)	increases in total Hb	HU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	180	We describe the clinical response, as determined by [s1]increases in total Hb[e1] and decreased transfusion needs, in five patients with thalassemia intermedia treated with [s2]HU[e2] alone or in combination with SPB.
	(9, 39)	increases in total Hb	SPB	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	181	We describe the clinical response, as determined by [s1]increases in total Hb[e1] and decreased transfusion needs, in five patients with thalassemia intermedia treated with HU alone or in combination with [s2]SPB[e2] 
	(17, 32)	oolong tea	delirious	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	182	A 36-y-o patient with schizophrenia, who had consumed gradually increasing quantities of [s1]oolong tea[e1] that eventually reached 15 L each day, became [s2]delirious[e2] and was admitted to a psychiatric hospital.
	(5, 12)	oolong tea	delirium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	183	After abstinence from [s1]oolong tea[e1] his [s2]delirium[e2] resolved.
	(17, 25)	caffeine intoxication	caffeine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	184	Severe rhabdomyolysis following massive ingestion of oolong tea: [s1]caffeine intoxication[e1]  [s2]caffeine[e2] intoxication with coexisting hyponatremia.
	(12, 18)	oolong tea	caffeine intoxication	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	185	Severe rhabdomyolysis following massive ingestion of [s1]oolong tea[e1]  [s2]caffeine intoxication[e2] with coexisting hyponatremia.
	(1, 19)	rhabdomyolysis	caffeine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	186	Severe [s1]rhabdomyolysis[e1] following massive ingestion of oolong tea: [s2]caffeine[e2] intoxication with coexisting hyponatremia.
	(1, 14)	rhabdomyolysis	oolong tea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	187	Severe [s1]rhabdomyolysis[e1] following massive ingestion of [s2]oolong tea[e2]  caffeine intoxication with coexisting hyponatremia.
	(5, 33)	caffeine	delirium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	188	The clinical course suggests that [s1]caffeine[e1]  which is present in oolong tea, was mainly responsible for the rhabdomyolysis as well as the [s2]delirium[e2]  although severe hyponatremia has been reported to cause rhabdomyolysis on rare occasions.
	(5, 39)	caffeine	hyponatremia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	189	The clinical course suggests that [s1]caffeine[e1]  which is present in oolong tea, was mainly responsible for the rhabdomyolysis as well as the delirium, although severe [s2]hyponatremia[e2] has been reported to cause rhabdomyolysis on rare occasions.
	(5, 24)	caffeine	rhabdomyolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	190	The clinical course suggests that [s1]caffeine[e1]  which is present in oolong tea, was mainly responsible for the [s2]rhabdomyolysis[e2] as well as the delirium, although severe hyponatremia has been reported to cause rhabdomyolysis on rare occasions.
	(5, 24)	caffeine	rhabdomyolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	191	The clinical course suggests that [s1]caffeine[e1]  which is present in oolong tea, was mainly responsible for the [s2]rhabdomyolysis[e2] as well as the delirium, although severe hyponatremia has been reported to cause rhabdomyolysis on rare occasions.
	(4, 29)	rhabdomyolysis	caffeine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	192	The possibility of severe [s1]rhabdomyolysis[e1] should be considered in a patient with water intoxication due to massive ingestion of [s2]caffeine[e2] containing beverages.
	(16, 29)	water intoxication	caffeine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	193	The possibility of severe rhabdomyolysis should be considered in a patient with [s1]water intoxication[e1] due to massive ingestion of [s2]caffeine[e2] containing beverages.
	(7, 13)	caffeine toxicity	caffeine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	194	We hypothesize that [s1]caffeine toxicity[e1]  [s2]caffeine[e2] toxicity injured the muscle cells, which were fragile due to the potassium depletion induced by the coexisting hyponatremia, to result in unusually severe rhabdomyolysis.
	(7, 31)	caffeine	coexisting hyponatremia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	195	We hypothesize that [s1]caffeine[e1] toxicity injured the muscle cells, which were fragile due to the potassium depletion induced by the [s2]coexisting hyponatremia[e2]  to result in unusually severe rhabdomyolysis.
	(7, 13)	caffeine	injured the muscle cells	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	196	We hypothesize that [s1]caffeine[e1] toxicity [s2]injured the muscle cells[e2]  which were fragile due to the potassium depletion induced by the coexisting hyponatremia, to result in unusually severe rhabdomyolysis.
	(7, 24)	caffeine	potassium depletion	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	197	We hypothesize that [s1]caffeine[e1] toxicity injured the muscle cells, which were fragile due to the [s2]potassium depletion[e2] induced by the coexisting hyponatremia, to result in unusually severe rhabdomyolysis.
	(7, 46)	caffeine	rhabdomyolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	198	We hypothesize that [s1]caffeine[e1] toxicity injured the muscle cells, which were fragile due to the potassium depletion induced by the coexisting hyponatremia, to result in unusually severe [s2]rhabdomyolysis[e2] 
	(4, 23)	citalopram	8-hydroacy-desmethylclomipramine plasma level decrease	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	199	After the addition of [s1]citalopram[e1]  a desmethylclomipramine plasma level increase and an [s2]8-hydroacy-desmethylclomipramine plasma level decrease[e2] were observed.
	(4, 11)	citalopram	desmethylclomipramine plasma level increase	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	200	After the addition of [s1]citalopram[e1]  a [s2]desmethylclomipramine plasma level increase[e2] and an 8-hydroacy-desmethylclomipramine plasma level decrease were observed.
	(16, 38)	angiolipomas	indinavir	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	201	We report 3 cases of HIV-1 infected patients who experienced symptomatic [s1]angiolipomas[e1] shortly after starting antiretroviral therapy including the protease inhibitor [s2]indinavir[e2] 
	(0, 9)	Elevated serum triglycerides	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	202	 [s1]Elevated serum triglycerides[e1] with [s2]clozapine[e2] resolved with risperidone in four patients.
	(3, 18)	clozapine	serum triglyceride levels increased	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	203	In two patients [s1]clozapine[e1] was reinstated after risperidone was discontinued; [s2]serum triglyceride levels increased[e2] 
	(3, 25)	clozapine	elevated serum triglyceride levels	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	204	This increase when [s1]clozapine[e1] was switched to risperidone and vice versa is consistent with our previous report of [s2]elevated serum triglyceride levels[e2] in clozapine-treated patients.
	(3, 11)	valproate	hypotension	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	205	Intravenous [s1]valproate[e1] associated with significant [s2]hypotension[e2] in the treatment of status epilepticus.
	(11, 23)	hypotension	valproate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	206	To our knowledge, this is the first report of significant [s1]hypotension[e1] associated with intravenous [s2]valproate[e2] in the treatment of status epilepticus in the pediatric population.
	(6, 18)	hypotension	valproate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	207	We report a case of severe [s1]hypotension[e1] associated with intravenous [s2]valproate[e2] used to treat status epilepticus in an 11-year-old girl.
	(4, 11)	rippling phenomena worsened	pyridostigmine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	208	In both patients the [s1]rippling phenomena worsened[e1] with [s2]pyridostigmine[e2] treatment but markedly improved after immunosuppression with azathioprine.
	(4, 11)	theophylline poisoning	theophylline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	209	A diagnosis of masked [s1]theophylline poisoning[e1]  [s2]theophylline[e2] poisoning should be considered in similar situations involving a rapid decrease of insulin requirements.
	(4, 13)	intoxication	theophylline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	210	Salicylate [s1]intoxication[e1] was excluded, and [s2]theophylline[e2] was finally incriminated.
	(0, 22)	Theophylline intoxication	Theophylline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	211	 [s1]Theophylline intoxication[e1] mimicking diabetic ketoacidosis in a child [s2]Theophylline[e2] intoxication mimicking diabetic ketoacidosis in a child.
	(16, 23)	theophylline poisoning	theophylline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	212	This compound, used by adults in the child's home, had caused accidental [s1]theophylline poisoning[e1]  [s2]theophylline[e2] poisoning, mimicking diabetic ketoacidosis.
	(9, 22)	ifosfamide-induced encephalopathy	ifosfamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	213	Methylene blue in the treatment and prevention of [s1]ifosfamide-induced encephalopathy[e1]  [s2]ifosfamide[e2] induced encephalopathy: report of 12 cases and a review of the literature.
	(8, 16)	ifosfamide	encephalopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	214	Ten to 15% of patients treated with [s1]ifosfamide[e1] develop an [s2]encephalopathy[e2] 
	(9, 22)	ifosfamide-induced encephalopathy	ifosfamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	215	We conclude that MB is an effective treatment for [s1]ifosfamide-induced encephalopathy[e1]  [s2]ifosfamide[e2] induced encephalopathy.
	(0, 33)	Portal vein thrombosis	F VIII	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	216	 [s1]Portal vein thrombosis[e1] in a patient with severe haemophilia A and F V G1691A mutation during continuous infusion of [s2]F VIII[e2] after intramural jejunal bleeding--successful thrombolysis under heparin therapy.
	(21, 34)	portal vein thrombosis	F VIII	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	217	We report on a 14-year-old boy with severe haemophilia A who developed a [s1]portal vein thrombosis[e1] during continuous infusion of [s2]F VIII[e2] 
	(18, 33)	acute icteric hepatitis-like illness	gliclazide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	218	A 60-year-old woman with diabetes mellitus (type 2) developed an [s1]acute icteric hepatitis-like illness[e1] 6 weeks after the initiation of [s2]gliclazide[e2] therapy.
	(0, 8)	Gliclazide	acute hepatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	219	 [s1]Gliclazide[e1] induced [s2]acute hepatitis[e2] 
	(8, 17)	gliclazide	acute icteric liver necro-inflammation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	220	In conclusion, this case strongly suggests that [s1]gliclazide[e1] can induce [s2]acute icteric liver necro-inflammation[e2] which may be misdiagnosed clinically as acute viral hepatitis.
	(9, 23)	acute hepatitis	gliclazide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	221	We believe that this is the first description of [s1]acute hepatitis[e1] caused by an idiosyncratic adverse reaction to [s2]gliclazide[e2] or to one of its metabolites.
	(5, 11)	acute hepatitis	gliclazide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	222	We describe the case of [s1]acute hepatitis[e1] induced by [s2]gliclazide[e2]  a second generation sulfonylurea.
	(13, 23)	TCA	Cushing's syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	223	Caution is, therefore, needed to prevent undesired accumulation of [s1]TCA[e1] that may lead to protracted [s2]Cushing's syndrome[e2] 
	(0, 13)	Cushing's syndrome	TCA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	224	 [s1]Cushing's syndrome[e1] persisted more than 6 months while [s2]TCA[e2] concentrations remained detectable for at least 80 days.
	(8, 14)	TCA	Cushing's syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	225	The presented patient was treated with 200 mg [s1]TCA[e1] and developed [s2]Cushing's syndrome[e2] 6 weeks later (cortisol and ACTH concentrations were below limits of detection, TCA concentrations were > 3 micrograms/l).
	(6, 18)	abnormal computed tomographic scans	nitrofurantoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	226	Both had impaired lung function and [s1]abnormal computed tomographic scans[e1]  and their condition improved when [s2]nitrofurantoin[e2] was withdrawn and corticosteroid treatment commenced.
	(2, 19)	impaired lung function	nitrofurantoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	227	Both had [s1]impaired lung function[e1] and abnormal computed tomographic scans, and their condition improved when [s2]nitrofurantoin[e2] was withdrawn and corticosteroid treatment commenced.
	(0, 17)	Bronchiolitis obliterans organising pneumonia	nitrofurantoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	228	 [s1]Bronchiolitis obliterans organising pneumonia[e1] associated with the use of [s2]nitrofurantoin[e2] 
	(17, 40)	nitrofurantoin	BOOP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	229	The case histories are presented of two patients who developed lung disease associated with the use of [s1]nitrofurantoin[e1] with histological features of bronchiolitis obliterans organising pneumonia  [s2]BOOP[e2] , a rare but recognised form of drug induced injury.
	(17, 30)	nitrofurantoin	bronchiolitis obliterans organising pneumonia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	230	The case histories are presented of two patients who developed lung disease associated with the use of [s1]nitrofurantoin[e1] with histological features of [s2]bronchiolitis obliterans organising pneumonia[e2] (BOOP), a rare but recognised form of drug induced injury.
	(10, 19)	lung disease	nitrofurantoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	231	The case histories are presented of two patients who developed [s1]lung disease[e1] associated with the use of [s2]nitrofurantoin[e2] with histological features of bronchiolitis obliterans organising pneumonia (BOOP), a rare but recognised form of drug induced injury.
	(10, 21)	fatal outcome	nitrofurantoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	232	The favourable outcome in these two patients contrasts with the [s1]fatal outcome[e1] of the two other reported cases of [s2]nitrofurantoin[e2] induced BOOP.
	(19, 29)	nitrofurantoin induced BOOP	nitrofurantoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	233	The favourable outcome in these two patients contrasts with the fatal outcome of the two other reported cases of [s1]nitrofurantoin induced BOOP[e1]  [s2]nitrofurantoin[e2] induced BOOP.
	(3, 10)	nitrofurantoin	lung injury	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	234	The spectrum of [s1]nitrofurantoin[e1]  [s2]lung injury[e2] continues to widen.
	(7, 15)	respiratory symptoms	nitrofurantoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	235	The two middle aged women presented with [s1]respiratory symptoms[e1] after prolonged treatment with [s2]nitrofurantoin[e2] 
	(7, 17)	nitrofurantoin induced lung injury	nitrofurantoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	236	"We suggest that the previous classification of [s1]nitrofurantoin induced lung injury[e1]  [s2]nitrofurantoin[e2] induced lung injury into ""acute"" and ""chronic"" injury is an oversimplification in view of the wide variety of pathological entities that have subsequently emerged."
	(16, 24)	akathisia	interferon-alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	237	Intravenous administration of levodopa ameliorated a refractory [s1]akathisia[e1] case induced by [s2]interferon-alpha[e2] 
	(11, 17)	akathisia	interferon-alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	238	The present report illustrates a rare case of refractory [s1]akathisia[e1] after [s2]interferon-alpha[e2] treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon-alpha.
	(15, 39)	interferon-alpha	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	239	The present report illustrates a rare case of refractory akathisia after [s1]interferon-alpha[e1] treatment and also that levodopa treatment would be theoretically and practically useful in reducing the [s2]neurotoxicity[e2] associated with interferon-alpha.
	(0, 9)	Acute erythroid leukemia	cyclophosphamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	240	 [s1]Acute erythroid leukemia[e1] after [s2]cyclophosphamide[e2] therapy for multiple myeloma: report of two cases.
	(9, 25)	carcinoma	cyclophosphamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	241	The development of erythroid leukemia plus [s1]carcinoma[e1] in these two men suggests mutagenic change secondary to [s2]cyclophosphamide[e2] therapy.
	(0, 18)	Scleroderma-like reaction	UFT	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	242	 [s1]Scleroderma-like reaction[e1] induced by uracil-tegafur  [s2]UFT[e2] , a second-generation anticancer agent.
	(0, 11)	Scleroderma-like reaction	uracil-tegafur	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	243	 [s1]Scleroderma-like reaction[e1] induced by [s2]uracil-tegafur[e2] (UFT), a second-generation anticancer agent.
	(6, 19)	UFT-induced scleroderma-like reaction	UFT	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	244	This is the first report of [s1]UFT-induced scleroderma-like reaction[e1]  [s2]UFT[e2] induced scleroderma-like reaction.
	(6, 22)	scleroderma-like reaction	UFT	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	245	We report a case of a [s1]scleroderma-like reaction[e1] induced by long-term administration of [s2]UFT[e2] 
	(0, 9)	Central nervous system manifestations	ibuprofen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	246	 [s1]Central nervous system manifestations[e1] of an [s2]ibuprofen[e2] overdose reversed by naloxone.
	(0, 14)	Ibuprofen	dizziness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	247	 [s1]Ibuprofen[e1] overdose is usually characterized by GI upset, [s2]dizziness[e2]  and mild sedation.
	(0, 11)	Ibuprofen	GI upset	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	248	 [s1]Ibuprofen[e1] overdose is usually characterized by [s2]GI upset[e2]  dizziness, and mild sedation.
	(0, 18)	Ibuprofen	mild sedation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	249	 [s1]Ibuprofen[e1] overdose is usually characterized by GI upset, dizziness, and [s2]mild sedation[e2] 
	(5, 14)	ibuprofen intoxication	ibuprofen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	250	Presently, treatment of acute [s1]ibuprofen intoxication[e1]  [s2]ibuprofen[e2] intoxication with complications requires supportive therapy until the symptoms resolve over 24 to 48 hours.
	(15, 26)	depressed level of consciousness	ibuprofen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	251	We report the case of an 11-month-old female infant with a [s1]depressed level of consciousness[e1] after ingestion of [s2]ibuprofen[e2] whose mental status markedly improved with administration of naloxone.
	(0, 13)	Flecainide	acute respiratory failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	252	 [s1]Flecainide[e1] associated pneumonitis with [s2]acute respiratory failure[e2] in a patient with the LEOPARD syndrome.
	(0, 7)	Flecainide	pneumonitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	253	 [s1]Flecainide[e1] associated [s2]pneumonitis[e2] with acute respiratory failure in a patient with the LEOPARD syndrome.
	(0, 11)	Flecainide	hypersensitivity pneumonitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	254	 [s1]Flecainide[e1] is a rare cause of [s2]hypersensitivity pneumonitis[e2]  and few cases have been reported.
	(5, 24)	interstitial hypoxaemiant pneumonitis	flecainide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	255	We describe a case of [s1]interstitial hypoxaemiant pneumonitis[e1] probably related to [s2]flecainide[e2] in a patient with the LEOPARD syndrome, a rare congenital disorder.
	(0, 19)	Sagittal sinus thrombosis	L-asparaginase	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	256	 [s1]Sagittal sinus thrombosis[e1] associated with transient free protein S deficiency after [s2]L-asparaginase[e2] treatment: case report and review of the literature.
	(11, 19)	transient free protein S deficiency	L-asparaginase	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	257	Sagittal sinus thrombosis associated with [s1]transient free protein S deficiency[e1] after [s2]L-asparaginase[e2] treatment: case report and review of the literature.
	(28, 35)	seizure	L-asparaginase	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	258	We report the case of an adult patient with acute lymphoblastic leukemia who presented with repeated transient ischemic attacks followed by a [s1]seizure[e1] during consolidation treatment with [s2]L-asparaginase[e2] 
	(20, 35)	transient ischemic attacks	L-asparaginase	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	259	We report the case of an adult patient with acute lymphoblastic leukemia who presented with repeated [s1]transient ischemic attacks[e1] followed by a seizure during consolidation treatment with [s2]L-asparaginase[e2] 
	(7, 22)	benign intracranial hypertension	minocycline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	260	We report on a young adolescent with [s1]benign intracranial hypertension[e1] which we attribute to the use of [s2]minocycline[e2] for acne.
	(6, 15)	polyarteritis nodosa	vaccination against hepatitis B	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	261	We report 2 patients who developed [s1]polyarteritis nodosa[e1] following [s2]vaccination against hepatitis B[e2] 
	(23, 37)	methotrexate	lung cancer	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	262	In this case, it was suspected that a combination of cigarette smoking, pulmonary fibrosis, and low-dose [s1]methotrexate[e1] therapy might have promoted the development of [s2]lung cancer[e2] 
	(39, 43)	cocaine	refractory coronary vasospasm	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	263	This case report illustrates the use of continuous high-dose intracoronary nitroglycerin infusion through a 6 French coronary guiding catheter in the treatment of a patient with [s1]cocaine[e1] induced [s2]refractory coronary vasospasm[e2] 
	(16, 23)	troglitazone	liver injury	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	264	However, as illustrated by these and other cases reported to date, the onset of [s1]troglitazone[e1] induced [s2]liver injury[e2] is insidious and temporally variable.
	(7, 17)	hepatotoxicity	troglitazone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	265	It remains to be seen whether the [s1]hepatotoxicity[e1] associated with [s2]troglitazone[e2] is a drug-class effect or specific to troglitazone.
	(7, 17)	hepatotoxicity	troglitazone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	266	It remains to be seen whether the [s1]hepatotoxicity[e1] associated with [s2]troglitazone[e2] is a drug-class effect or specific to troglitazone.
	(21, 29)	troglitazone	hepatotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	267	Other thiazolidinediones currently in clinical trials may be able to provide the therapeutic benefits of [s1]troglitazone[e1] without significant [s2]hepatotoxicity[e2] 
	(6, 27)	troglitazone	irreversible liver injury	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	268	The three reported cases demonstrate that [s1]troglitazone[e1] is an idiosyncratic hepatotoxin that can lead to [s2]irreversible liver injury[e2] 
	(0, 7)	Troglitazone	fulminant hepatic failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	269	 [s1]Troglitazone[e1] induced [s2]fulminant hepatic failure[e2] 
	(0, 8)	Nitrofurantoin	lung disease	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	270	 [s1]Nitrofurantoin[e1] induced [s2]lung disease[e2]  two cases demonstrating resolution of apparently irreversible CT abnormalities.
	(5, 30)	nitrofurantoin	distortion of the lung parenchyma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	271	We present two cases of [s1]nitrofurantoin[e1] induced pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated [s2]distortion of the lung parenchyma[e2]  thought to represent established fibrosis.
	(5, 43)	nitrofurantoin	fibrosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	272	We present two cases of [s1]nitrofurantoin[e1] induced pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma, thought to represent established [s2]fibrosis[e2] 
	(5, 13)	nitrofurantoin	pulmonary toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	273	We present two cases of [s1]nitrofurantoin[e1] induced [s2]pulmonary toxicity[e2] in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma, thought to represent established fibrosis.
	(5, 23)	nitrofurantoin	widespread reticular pattern	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	274	We present two cases of [s1]nitrofurantoin[e1] induced pulmonary toxicity in which the initial HRCT showed a [s2]widespread reticular pattern[e2] and associated distortion of the lung parenchyma, thought to represent established fibrosis.
	(0, 7)	Fluoxetine	death	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	275	 [s1]Fluoxetine[e1] related [s2]death[e2] in a child with cytochrome P-450 2D6 genetic deficiency.
	(7, 12)	death	fluoxetine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	276	The medical examiner's report indicated [s1]death[e1] caused by [s2]fluoxetine[e2] toxicity.
	(10, 17)	fluoxetine toxicity	fluoxetine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	277	The medical examiner's report indicated death caused by [s1]fluoxetine toxicity[e1]  [s2]fluoxetine[e2] toxicity.
	(7, 14)	fluoxetine	death	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	278	This is the first report of a [s1]fluoxetine[e1] related [s2]death[e2] in a child with a confirmed genetic polymorphism of the CYP2D6 gene that results in impaired drug metabolism.
	(28, 38)	spinal cord lesion	zolmitriptan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	279	A 50-year-old woman with a history of migraine without aura, predominantly occurring around her menstrual periods, developed a [s1]spinal cord lesion[e1] following the use of [s2]zolmitriptan[e2] 
	(0, 10)	Spinal cord infarction	zolmitriptan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	280	 [s1]Spinal cord infarction[e1] during use of [s2]zolmitriptan[e2]  a case report.
	(6, 20)	spinal cord infarction	zolmitriptan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	281	The temporal relationship suggests that the [s1]spinal cord infarction[e1] may be related to the use of [s2]zolmitriptan[e2] 
	(19, 27)	hypersensitivity	carboplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	282	CASE SUMMARY: A 10-year-old white girl with bilateral optic glioma developed a [s1]hypersensitivity[e1] reaction to [s2]carboplatin[e2] after nine courses.
	(11, 19)	hypersensitivity	carboplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	283	This regimen could prove useful for other patients who develop [s1]hypersensitivity[e1] reactions to [s2]carboplatin[e2] and allow therapy to continue.
	(9, 19)	renal insufficiency	nimesulide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	284	Perinatal vasoconstrictive [s1]renal insufficiency[e1] associated with maternal [s2]nimesulide[e2] use.
	(7, 21)	adverse effect of fetal renal circulation	nimesulide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	285	This is the first report of an [s1]adverse effect of fetal renal circulation[e1] by maternal ingestion of [s2]nimesulide[e2] 
	(2, 11)	t-AML	etoposide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	286	Although the [s1]t-AML[e1] developed following oral [s2]etoposide[e2] therapy, the child had previously received high-dose, multiagent chemotherapy, and rearrangement of the MLL gene was not demonstrated.
	(0, 16)	Secondary leukemia	etoposide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	287	 [s1]Secondary leukemia[e1] in a child with neuroblastoma while on oral [s2]etoposide[e2]  what is the cause?
	(6, 31)	t-AML	etoposide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	288	The authors present a case of [s1]t-AML[e1] that developed in a child with metastatic neuroblastoma 18 months after he received oral [s2]etoposide[e2]  given for palliation purpose.
	(2, 24)	Cyanamide	hepatic lesion with ground-glass inclusion bodies	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	289	BACKGROUND: [s1]Cyanamide[e1]  an aversive agent widely used in Japan, is known to induce various degrees of [s2]hepatic lesion with ground-glass inclusion bodies[e2] 
	(17, 29)	cyanamide	general fatigue	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	290	Case 2: A 43-year-old male alcoholic remained completely abstinent with [s1]cyanamide[e1] treatment for 5 years and complained of [s2]general fatigue[e2] 
	(14, 31)	fatigue	cyanamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	291	Case 3: A 29-year-old female alcoholic complained of general [s1]fatigue[e1] and a slight fever after 1.5 years of abstinence with [s2]cyanamide[e2] treatment.
	(18, 31)	fever	cyanamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	292	Case 3: A 29-year-old female alcoholic complained of general fatigue and a slight [s1]fever[e1] after 1.5 years of abstinence with [s2]cyanamide[e2] treatment.
	(19, 29)	cyanamide	elevation of serum transaminases	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	293	Case 4: A 61-year-old male alcoholic who remained completely abstinent while taking [s1]cyanamide[e1] for 3 years showed slight [s2]elevation of serum transaminases[e2] 
	(9, 33)	cyanamide	ground-glass hepatocytes	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	294	CONCLUSION: In some abstainers who take [s1]cyanamide[e1] for several years, thin septum-like liver fibrosis progresses along with the emergence of [s2]ground-glass hepatocytes[e2] 
	(9, 19)	cyanamide	septum-like liver fibrosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	295	CONCLUSION: In some abstainers who take [s1]cyanamide[e1] for several years, thin [s2]septum-like liver fibrosis[e2] progresses along with the emergence of ground-glass hepatocytes.
	(0, 6)	Cyanamide	liver dysfunction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	296	 [s1]Cyanamide[e1] induced [s2]liver dysfunction[e2] after abstinence in alcoholics: a long-term follow-up study on four cases.
	(1, 17)	cyanamide	inflammation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	297	When [s1]cyanamide[e1] treated alcoholics relapse into drinking, more severe [s2]inflammation[e2] develops in the liver.
	(14, 23)	tacrolimus	sudden cutaneous reaction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	298	A patient with an allergy to a macrolide antibiotic was given [s1]tacrolimus[e1] and developed a [s2]sudden cutaneous reaction[e2] 
	(17, 35)	nonconvulsive status epilepticus	morphine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	299	A 77-year-old woman with no history of epilepsy presented a probable [s1]nonconvulsive status epilepticus[e1] while receiving continuous intravenous [s2]morphine[e2] for back pain relating to vertebral metastasis of a malignant lymphoma.
	(1, 20)	generalized tonic-clonic seizure	naloxone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	300	A [s1]generalized tonic-clonic seizure[e1] occurred a few minutes after injection of the morphine antagonist [s2]naloxone[e2] 
	(0, 15)	Nonconvulsive status epilepticus	morphine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	301	 [s1]Nonconvulsive status epilepticus[e1]  the role of [s2]morphine[e2] and its antagonist.
	(1, 13)	bacterial peritonitis	vasopressin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	302	Spontaneous [s1]bacterial peritonitis[e1] induced by intraarterial [s2]vasopressin[e2] therapy.
	(7, 60)	risperidone	EPS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	303	Although the literature on the use of [s1]risperidone[e1] in elderly patients with dementia consists largely of uncontrolled trials, case reports, and chart reviews, it appears that this agent is effective for managing agitation in this population and does so with a low frequency of extrapyramidal symptoms  [s2]EPS[e2] .
	(7, 55)	risperidone	extrapyramidal symptoms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	304	Although the literature on the use of [s1]risperidone[e1] in elderly patients with dementia consists largely of uncontrolled trials, case reports, and chart reviews, it appears that this agent is effective for managing agitation in this population and does so with a low frequency of [s2]extrapyramidal symptoms[e2] (EPS).
	(8, 31)	multiple abscesses	CHOP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	305	Three months following splenectomy, [s1]multiple abscesses[e1] occurred in the muscles of both thighs while the patient was receiving the third course of the [s2]CHOP[e2] regimen.
	(16, 42)	ethambutol	anti-native DNA antibodies	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	306	After seven months' continuous treatment for suspected tuberculosis with rifampicin and [s1]ethambutol[e1] a nine-year-old boy developed polyarthritis, rash and hepatitis in association with [s2]anti-native DNA antibodies[e2] and positive antinuclear factor.
	(16, 38)	ethambutol	hepatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	307	After seven months' continuous treatment for suspected tuberculosis with rifampicin and [s1]ethambutol[e1] a nine-year-old boy developed polyarthritis, rash and [s2]hepatitis[e2] in association with anti-native DNA antibodies and positive antinuclear factor.
	(16, 31)	ethambutol	polyarthritis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	308	After seven months' continuous treatment for suspected tuberculosis with rifampicin and [s1]ethambutol[e1] a nine-year-old boy developed [s2]polyarthritis[e2]  rash and hepatitis in association with anti-native DNA antibodies and positive antinuclear factor.
	(16, 36)	ethambutol	rash	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	309	After seven months' continuous treatment for suspected tuberculosis with rifampicin and [s1]ethambutol[e1] a nine-year-old boy developed polyarthritis, [s2]rash[e2] and hepatitis in association with anti-native DNA antibodies and positive antinuclear factor.
	(7, 17)	anti-native DNA antibodies	ethambutol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	310	Polyarthritis, hepatitis and [s1]anti-native DNA antibodies[e1] after treatment with [s2]ethambutol[e2] and rifampicin.
	(7, 23)	anti-native DNA antibodies	rifampicin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	311	Polyarthritis, hepatitis and [s1]anti-native DNA antibodies[e1] after treatment with ethambutol and [s2]rifampicin[e2] 
	(5, 17)	hepatitis	ethambutol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	312	Polyarthritis, [s1]hepatitis[e1] and anti-native DNA antibodies after treatment with [s2]ethambutol[e2] and rifampicin.
	(5, 23)	hepatitis	rifampicin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	313	Polyarthritis, [s1]hepatitis[e1] and anti-native DNA antibodies after treatment with ethambutol and [s2]rifampicin[e2] 
	(0, 16)	Polyarthritis	ethambutol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	314	 [s1]Polyarthritis[e1]  hepatitis and anti-native DNA antibodies after treatment with [s2]ethambutol[e2] and rifampicin.
	(0, 22)	Polyarthritis	rifampicin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	315	 [s1]Polyarthritis[e1]  hepatitis and anti-native DNA antibodies after treatment with ethambutol and [s2]rifampicin[e2] 
	(3, 19)	normotensive scleroderma renal crisis	methylprednisolone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	316	A case of [s1]normotensive scleroderma renal crisis[e1] after high-dose [s2]methylprednisolone[e2] treatment.
	(0, 21)	HUS	mitomycin C	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	317	 [s1]HUS[e1] has been reported after several anticancer chemotherapies and most often after [s2]mitomycin C[e2] based chemotherapy regimens.
	(0, 20)	Severe hemolytic uremic syndrome	carboplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	318	 [s1]Severe hemolytic uremic syndrome[e1] in an advanced ovarian cancer patient treated with [s2]carboplatin[e2] and gemcitabine.
	(0, 25)	Severe hemolytic uremic syndrome	gemcitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	319	 [s1]Severe hemolytic uremic syndrome[e1] in an advanced ovarian cancer patient treated with carboplatin and [s2]gemcitabine[e2] 
	(5, 19)	HUS	carboplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	320	We present a case of [s1]HUS[e1] in an advanced ovarian cancer patient treated with [s2]carboplatin[e2] and gemcitabine, and described its favorable outcome after chemotherapy interruption and supportive care with a 1 year follow-up.
	(5, 24)	HUS	gemcitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	321	We present a case of [s1]HUS[e1] in an advanced ovarian cancer patient treated with carboplatin and [s2]gemcitabine[e2]  and described its favorable outcome after chemotherapy interruption and supportive care with a 1 year follow-up.
	(20, 34)	valproate	menstrual cycle disturbances	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	322	An evaluation of ovarian structure and function should be considered in women of reproductive age being treated with [s1]valproate[e1] for epilepsy, especially if they develop [s2]menstrual cycle disturbances[e2] during treatment.
	(23, 37)	hyperandrogenism	sodium valproate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	323	BACKGROUND: Reproductive endocrine disorders characterized by menstrual disorders, polycystic ovaries, and [s1]hyperandrogenism[e1] seem to be common among women treated with [s2]sodium valproate[e2] for epilepsy.
	(9, 36)	menstrual disorders	sodium valproate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	324	BACKGROUND: Reproductive endocrine disorders characterized by [s1]menstrual disorders[e1]  polycystic ovaries, and hyperandrogenism seem to be common among women treated with [s2]sodium valproate[e2] for epilepsy.
	(15, 36)	polycystic ovaries	sodium valproate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	325	BACKGROUND: Reproductive endocrine disorders characterized by menstrual disorders, [s1]polycystic ovaries[e1]  and hyperandrogenism seem to be common among women treated with [s2]sodium valproate[e2] for epilepsy.
	(2, 37)	Reproductive endocrine disorders	sodium valproate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	326	BACKGROUND: [s1]Reproductive endocrine disorders[e1] characterized by menstrual disorders, polycystic ovaries, and hyperandrogenism seem to be common among women treated with [s2]sodium valproate[e2] for epilepsy.
	(11, 22)	reproductive endocrine disorders	valproate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	327	CONCLUSIONS: The 3 cases presented here illustrate the development of [s1]reproductive endocrine disorders[e1] after the initiation of [s2]valproate[e2] therapy in women with epilepsy.
	(7, 13)	valproate	reproductive endocrine disorders	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	328	OBJECTIVE: To describe the development of [s1]valproate[e1] related [s2]reproductive endocrine disorders[e2] in women with epilepsy.
	(6, 16)	reproductive endocrine disorder	valproate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	329	PATIENTS: Three patients developed a [s1]reproductive endocrine disorder[e1] during treatment with [s2]valproate[e2] 
	(3, 19)	valproate	serum testosterone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	330	RESULTS: Replacing [s1]valproate[e1] with lamotrigine resulted in a decrease in [s2]serum testosterone[e2] concentrations in all 3 women.
	(17, 36)	valproate	amenorrhea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	331	The polycystic changes disappeared from the ovaries in 2 of the women after [s1]valproate[e1] therapy was discontinued, and the 2 women who had gained weight and developed [s2]amenorrhea[e2] while being treated with valproate lost weight and resumed menstruating after the change in medication.
	(17, 32)	valproate	gained weight	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	332	The polycystic changes disappeared from the ovaries in 2 of the women after [s1]valproate[e1] therapy was discontinued, and the 2 women who had [s2]gained weight[e2] and developed amenorrhea while being treated with valproate lost weight and resumed menstruating after the change in medication.
	(1, 19)	polycystic changes	valproate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	333	The [s1]polycystic changes[e1] disappeared from the ovaries in 2 of the women after [s2]valproate[e2] therapy was discontinued, and the 2 women who had gained weight and developed amenorrhea while being treated with valproate lost weight and resumed menstruating after the change in medication.
	(4, 17)	staphylococcus aureus sepsis	CyA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	334	However, recurrent [s1]staphylococcus aureus sepsis[e1] developed during [s2]CyA[e2] therapy.
	(6, 13)	lethal	cyclosporine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	335	Recurrent septicemia with [s1]lethal[e1] outcome during and after [s2]cyclosporine[e2] therapy in severe ulcerative colitis.
	(2, 13)	septicemia	cyclosporine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	336	Recurrent [s1]septicemia[e1] with lethal outcome during and after [s2]cyclosporine[e2] therapy in severe ulcerative colitis.
	(12, 26)	proximal muscle weakness	colchicine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	337	A 60 year-old woman with chronic renal failure developed acute [s1]proximal muscle weakness[e1] after receiving a regular dosage of [s2]colchicine[e2] 
	(0, 6)	Colchicine	myopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	338	 [s1]Colchicine[e1] induced [s2]myopathy[e2] in renal failure.
	(20, 26)	colchicine	myopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	339	Muscle biopsy revealed variation in muscle fiber size and few vacuolated fibers which were features of [s1]colchicine[e1] induced [s2]myopathy[e2] 
	(11, 22)	vacuolated fibers	colchicine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	340	Muscle biopsy revealed variation in muscle fiber size and few [s1]vacuolated fibers[e1] which were features of [s2]colchicine[e2] induced myopathy.
	(4, 22)	variation in muscle fiber size	colchicine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	341	Muscle biopsy revealed [s1]variation in muscle fiber size[e1] and few vacuolated fibers which were features of [s2]colchicine[e2] induced myopathy.
	(4, 32)	disabling neurotoxicity	paclitaxel	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	342	A third patient experienced [s1]disabling neurotoxicity[e1] in the extremity of a prior ulnar nerve and tendon transposition after receiving [s2]paclitaxel[e2] 
	(7, 13)	paclitaxel	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	343	Phantom limb pain as a manifestation of [s1]paclitaxel[e1]  [s2]neurotoxicity[e2] 
	(0, 9)	Phantom limb pain	paclitaxel	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	344	 [s1]Phantom limb pain[e1] as a manifestation of [s2]paclitaxel[e2] neurotoxicity.
	(5, 14)	PLP	paclitaxel	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	345	Physicians should be aware that [s1]PLP[e1] can occur after initiation of [s2]paclitaxel[e2] 
	(10, 21)	phantom limb pain	paclitaxel	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	346	We describe 2 patients with prior amputation who experienced [s1]phantom limb pain[e1] (PLP) after receiving [s2]paclitaxel[e2] therapy.
	(13, 19)	PLP	paclitaxel	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	347	We describe 2 patients with prior amputation who experienced phantom limb pain  [s1]PLP[e1]  after receiving [s2]paclitaxel[e2] therapy.
	(7, 16)	phenylbutazone	serum sickness-like reactions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	348	Skin manifestations of a case of [s1]phenylbutazone[e1] induced [s2]serum sickness-like reactions[e2] 
	(0, 9)	Skin manifestations	phenylbutazone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	349	 [s1]Skin manifestations[e1] of a case of [s2]phenylbutazone[e2] induced serum sickness-like reactions.
	(12, 19)	atenolol toxicity	atenolol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	350	Our experience supports hemodialysis for ESRF patients with [s1]atenolol toxicity[e1]  [s2]atenolol[e2] toxicity.
	(3, 13)	gemfibrozil	eosinophilic gastroenteritis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	351	Allergic reaction to [s1]gemfibrozil[e1] manifesting as [s2]eosinophilic gastroenteritis[e2] 
	(5, 15)	EGE	gemfibrozil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	352	We describe a case of [s1]EGE[e1] manifested as an allergy to [s2]gemfibrozil[e2] 
	(6, 21)	lactic acidosis	lamivudine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	353	This is the second report of [s1]lactic acidosis[e1] in a patient on stavudine and [s2]lamivudine[e2] 
	(6, 16)	lactic acidosis	stavudine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	354	This is the second report of [s1]lactic acidosis[e1] in a patient on [s2]stavudine[e2] and lamivudine.
	(9, 21)	lactic acidosis	lamivudine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	355	We present an AIDS patient with severe and prolonged [s1]lactic acidosis[e1] on stavudine and [s2]lamivudine[e2] 
	(9, 16)	lactic acidosis	stavudine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	356	We present an AIDS patient with severe and prolonged [s1]lactic acidosis[e1] on [s2]stavudine[e2] and lamivudine.
	(0, 6)	Ataxia	propafenone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	357	 [s1]Ataxia[e1] caused by [s2]propafenone[e2] has been reported to the pharmaceutical companies and drug monitoring agencies, but has not been well described or emphasized in the medical literature.
	(4, 17)	adverse central nervous system effects	propafenone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	358	A wide variety of [s1]adverse central nervous system effects[e1] have been reported in association with [s2]propafenone[e2]  dizziness is the most common.
	(15, 21)	propafenone	dizziness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	359	A wide variety of adverse central nervous system effects have been reported in association with [s1]propafenone[e1]  [s2]dizziness[e2] is the most common.
	(0, 7)	Propafenone	ataxia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	360	 [s1]Propafenone[e1] induced [s2]ataxia[e2]  report of three cases.
	(9, 19)	ataxia	propafenone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	361	We describe 3 elderly patients with moderate to severe [s1]ataxia[e1] that occurred while they were taking [s2]propafenone[e2] 
	(11, 47)	pilsicainide	loss of consciousness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	362	A 74-year-old man received oral administration of [s1]pilsicainide[e1]  a pure sodium channel blocker with slow recovery kinetics, to convert paroxysmal atrial fibrillation to sinus rhythm and developed [s2]loss of consciousness[e2] two days later.
	(1, 28)	pilsicainide	life-threatening arrhythmias	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	363	When [s1]pilsicainide[e1] is prescribed in patients with coronary artery disease or renal dysfunction, close attention must be paid to avoid [s2]life-threatening arrhythmias[e2] due to high plasma concentrations of the drug.
	(10, 23)	dystonia	risperidone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	364	The cases are important in documenting that drug-induced [s1]dystonia[e1]  do occur in patients with dementia, that [s2]risperidone[e2] appears to have contributed to dystonia among elderly patients, and that the categorization of dystonic reactions needs further clarification.
	(3, 17)	non-convulsive status epilepticus	tiagabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	365	Provocation of [s1]non-convulsive status epilepticus[e1] by [s2]tiagabine[e2] in three adolescent patients.
	(3, 20)	non-convulsive status epilepticus	tiagabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	366	The events of [s1]non-convulsive status epilepticus[e1] subsided following reduction in [s2]tiagabine[e2] dosages.
	(6, 21)	non-convulsive status epilepticus	tiagabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	367	This is the first report of [s1]non-convulsive status epilepticus[e1] provoked by [s2]tiagabine[e2] in adolescent patients.
	(7, 11)	lithium	organic brain syndromes	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	368	There have been many reports of probable [s1]lithium[e1] induced [s2]organic brain syndromes[e2] occurring when serum lithium levels are within or close to the therapeutic range.
	(13, 29)	intense anxiety	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	369	When the acute manic state is characterized by marked psychotic symptoms and [s1]intense anxiety[e1]  it may be associated with increased vulnerability to the development of severe [s2]lithium[e2] neurotoxicity.
	(28, 31)	lithium	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	370	When the acute manic state is characterized by marked psychotic symptoms and intense anxiety, it may be associated with increased vulnerability to the development of severe [s1]lithium[e1]  [s2]neurotoxicity[e2] 
	(10, 30)	psychotic symptoms	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	371	When the acute manic state is characterized by marked [s1]psychotic symptoms[e1] and intense anxiety, it may be associated with increased vulnerability to the development of severe [s2]lithium[e2] neurotoxicity.
	(6, 14)	carbamazepine toxicity	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	372	Protease inhibitor-induced [s1]carbamazepine toxicity[e1]  [s2]carbamazepine[e2] toxicity.
	(29, 37)	carbamazepine toxicity	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	373	Protease inhibitors (ritonavir and saquinavir) were added to the treatment and the patient developed progressive ataxia related to [s1]carbamazepine toxicity[e1]  [s2]carbamazepine[e2] toxicity.
	(4, 30)	ritonavir	carbamazepine toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	374	Protease inhibitors  [s1]ritonavir[e1] and saquinavir) were added to the treatment and the patient developed progressive ataxia related to [s2]carbamazepine toxicity[e2] 
	(10, 30)	saquinavir	carbamazepine toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	375	Protease inhibitors (ritonavir and [s1]saquinavir[e1]  were added to the treatment and the patient developed progressive ataxia related to [s2]carbamazepine toxicity[e2] 
	(24, 31)	progressive ataxia	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	376	Protease inhibitors (ritonavir and saquinavir) were added to the treatment and the patient developed [s1]progressive ataxia[e1] related to [s2]carbamazepine[e2] toxicity.
	(4, 25)	ritonavir	progressive ataxia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	377	Protease inhibitors  [s1]ritonavir[e1] and saquinavir) were added to the treatment and the patient developed [s2]progressive ataxia[e2] related to carbamazepine toxicity.
	(10, 25)	saquinavir	progressive ataxia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	378	Protease inhibitors (ritonavir and [s1]saquinavir[e1]  were added to the treatment and the patient developed [s2]progressive ataxia[e2] related to carbamazepine toxicity.
	(0, 34)	Ritonavir	clinical toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	379	 [s1]Ritonavir[e1] acted as a CYP3A4 inhibitor, diminishing carbamazepine metabolism and provoking an increase in serum levels and [s2]clinical toxicity[e2] 
	(0, 16)	Ritonavir	diminishing carbamazepine metabolism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	380	 [s1]Ritonavir[e1] acted as a CYP3A4 inhibitor, [s2]diminishing carbamazepine metabolism[e2] and provoking an increase in serum levels and clinical toxicity.
	(0, 29)	Ritonavir	increase in serum levels	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	381	 [s1]Ritonavir[e1] acted as a CYP3A4 inhibitor, diminishing carbamazepine metabolism and provoking an [s2]increase in serum levels[e2] and clinical toxicity.
	(5, 13)	carbamazepine toxicity	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	382	The patient was diagnosed with [s1]carbamazepine toxicity[e1]  [s2]carbamazepine[e2] toxicity related to the introduction of ritonavir.
	(5, 18)	carbamazepine toxicity	ritonavir	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	383	The patient was diagnosed with [s1]carbamazepine toxicity[e1] related to the introduction of [s2]ritonavir[e2] 
	(0, 8)	Anaphylaxis	calcitonin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	384	 [s1]Anaphylaxis[e1] to [s2]calcitonin[e2] 
	(8, 16)	anaphylaxis	calcitonin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	385	CONCLUSION: We have introduced a case of [s1]anaphylaxis[e1] by [s2]calcitonin[e2] that suggest an IgE mediated hypersensitivity reaction.
	(10, 20)	Miacalcic	anaphylactic reaction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	386	The intramuscular challenge test with 25 UI of [s1]Miacalcic[e1] was positive with an immediate [s2]anaphylactic reaction[e2] 
	(19, 37)	conjunctivitis	calcitonin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	387	We introduce a case of a sixty years old woman with several previous episodes of rhinitis, [s1]conjunctivitis[e1] and perspiration immediately after the administration of salmon [s2]calcitonin[e2] with nasal spray or intramuscular administration (Calsynar).
	(19, 49)	conjunctivitis	Calsynar	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	388	We introduce a case of a sixty years old woman with several previous episodes of rhinitis, [s1]conjunctivitis[e1] and perspiration immediately after the administration of salmon calcitonin with nasal spray or intramuscular administration  [s2]Calsynar[e2] .
	(25, 37)	perspiration	calcitonin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	389	We introduce a case of a sixty years old woman with several previous episodes of rhinitis, conjunctivitis and [s1]perspiration[e1] immediately after the administration of salmon [s2]calcitonin[e2] with nasal spray or intramuscular administration (Calsynar).
	(25, 49)	perspiration	Calsynar	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	390	We introduce a case of a sixty years old woman with several previous episodes of rhinitis, conjunctivitis and [s1]perspiration[e1] immediately after the administration of salmon calcitonin with nasal spray or intramuscular administration  [s2]Calsynar[e2] .
	(15, 36)	rhinitis	calcitonin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	391	We introduce a case of a sixty years old woman with several previous episodes of [s1]rhinitis[e1]  conjunctivitis and perspiration immediately after the administration of salmon [s2]calcitonin[e2] with nasal spray or intramuscular administration (Calsynar).
	(15, 48)	rhinitis	Calsynar	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	392	We introduce a case of a sixty years old woman with several previous episodes of [s1]rhinitis[e1]  conjunctivitis and perspiration immediately after the administration of salmon calcitonin with nasal spray or intramuscular administration  [s2]Calsynar[e2] .
	(0, 14)	Minocycline	autoimmune hepatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	393	 [s1]Minocycline[e1] as a cause of drug-induced [s2]autoimmune hepatitis[e2] 
	(0, 8)	Minocycline	autoimmune hepatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	394	 [s1]Minocycline[e1] induced [s2]autoimmune hepatitis[e2] is usually identical to sporadic autoimmune hepatitis.
	(17, 25)	minocycline	autoimmune hepatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	395	We describe the clinical and liver biopsy morphologic features for 4 patients with [s1]minocycline[e1] induced [s2]autoimmune hepatitis[e2] (group 1).
	(0, 14)	L-asparaginase	central nervous toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	396	 [s1]L-asparaginase[e1] provoked seizures as singular expression of [s2]central nervous toxicity[e2] 
	(0, 9)	L-asparaginase	seizures	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	397	 [s1]L-asparaginase[e1] provoked [s2]seizures[e2] as singular expression of central nervous toxicity.
	(3, 14)	L-asparaginase	hemorrhagic	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	398	Patients treated with [s1]L-asparaginase[e1] may present with [s2]hemorrhagic[e2] and thrombotic cerebrovascular events.
	(3, 20)	L-asparaginase	thrombotic cerebrovascular events	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	399	Patients treated with [s1]L-asparaginase[e1] may present with hemorrhagic and [s2]thrombotic cerebrovascular events[e2] 
	(5, 10)	seizure	L-asparaginase	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	400	We report a case of [s1]seizure[e1] associated with [s2]L-asparaginase[e2] therapy but no evidence of hemorrhagic or thrombotic cerebrovascular events.
	(14, 23)	cilastatin	neutropenic fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	401	Eighty-two patients with various malignancies who received imipenem [s1]cilastatin[e1] 143 times for [s2]neutropenic fever[e2] between March 1994 and October 1999 in Department of Pediatric Oncology, Gazi University, were identified.
	(11, 23)	imipenem	neutropenic fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	402	Eighty-two patients with various malignancies who received [s1]imipenem[e1] cilastatin 143 times for [s2]neutropenic fever[e2] between March 1994 and October 1999 in Department of Pediatric Oncology, Gazi University, were identified.
	(2, 14)	seizures	cilastatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	403	Incidence of [s1]seizures[e1] in pediatric cancer patients treated with imipenem [s2]cilastatin[e2] 
	(2, 11)	seizures	imipenem	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	404	Incidence of [s1]seizures[e1] in pediatric cancer patients treated with [s2]imipenem[e2] cilastatin.
	(0, 12)	Proconvulsive	cilastatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	405	 [s1]Proconvulsive[e1] tendency of imipenem [s2]cilastatin[e2] is one of its well-known side effects.
	(0, 9)	Proconvulsive	imipenem	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	406	 [s1]Proconvulsive[e1] tendency of [s2]imipenem[e2] cilastatin is one of its well-known side effects.
	(5, 16)	convulsions	cilastatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	407	Three of these patients had [s1]convulsions[e1] attributed to imipenem [s2]cilastatin[e2]  3.6% of the patients had seizure, or 2% of imipenem/cilastatin administrations was followed by a seizure attack.
	(5, 13)	convulsions	imipenem	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	408	Three of these patients had [s1]convulsions[e1] attributed to [s2]imipenem[e2] cilastatin; 3.6% of the patients had seizure, or 2% of imipenem/cilastatin administrations was followed by a seizure attack.
	(14, 28)	cilastatin	seizure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	409	Three of these patients had convulsions attributed to imipenem [s1]cilastatin[e1]  3.6% of the patients had [s2]seizure[e2]  or 2% of imipenem/cilastatin administrations was followed by a seizure attack.
	(11, 29)	imipenem	seizure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	410	Three of these patients had convulsions attributed to [s1]imipenem[e1] cilastatin; 3.6% of the patients had [s2]seizure[e2]  or 2% of imipenem/cilastatin administrations was followed by a seizure attack.
	(14, 28)	cilastatin	seizure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	411	Three of these patients had convulsions attributed to imipenem [s1]cilastatin[e1]  3.6% of the patients had [s2]seizure[e2]  or 2% of imipenem/cilastatin administrations was followed by a seizure attack.
	(11, 29)	imipenem	seizure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	412	Three of these patients had convulsions attributed to [s1]imipenem[e1] cilastatin; 3.6% of the patients had [s2]seizure[e2]  or 2% of imipenem/cilastatin administrations was followed by a seizure attack.
	(0, 10)	Gabapentin	hypomanic	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	413	 [s1]Gabapentin[e1] induced mood changes with [s2]hypomanic[e2] features in adults.
	(0, 7)	Gabapentin	mood changes	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	414	 [s1]Gabapentin[e1] induced [s2]mood changes[e2] with hypomanic features in adults.
	(6, 19)	gabapentin	behavioural side effects	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	415	We report two adults who received [s1]gabapentin[e1] (GBP) and subsequently developed [s2]behavioural side effects[e2] 
	(10, 17)	GBP	behavioural side effects	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	416	We report two adults who received gabapentin  [s1]GBP[e1]  and subsequently developed [s2]behavioural side effects[e2] 
	(0, 23)	Acute pancreatitis	5-aminosalicylic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	417	 [s1]Acute pancreatitis[e1] in a child with idiopathic ulcerative colitis on long-term [s2]5-aminosalicylic acid[e2] therapy.
	(17, 31)	acute pancreatitis	5-aminosalicylic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	418	We describe a 10-year-old boy with ulcerative colitis who developed [s1]acute pancreatitis[e1] while on long-term treatment with [s2]5-aminosalicylic acid[e2] 
	(3, 16)	visual field constriction	vigabatrin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	419	CONCLUSION: Marked [s1]visual field constriction[e1] appears to be associated with [s2]vigabatrin[e2] therapy.
	(29, 36)	vigabatrin	visual field constriction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	420	Electro-oculography, electroretinography, visual evoked potentials, and multifocal electroretinography in patients with [s1]vigabatrin[e1] attributed [s2]visual field constriction[e2] 
	(6, 19)	visual field constriction	vigabatrin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	421	PURPOSE: Symptomatic [s1]visual field constriction[e1] thought to be associated with [s2]vigabatrin[e2] has been reported.
	(18, 25)	vigabatrin	visual field loss	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	422	The current study investigated the visual fields and visual electrophysiology of eight patients with known [s1]vigabatrin[e1] attributed [s2]visual field loss[e2]  three of whom were reported previously.
	(1, 14)	field defects	vigabatrin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	423	The [s1]field defects[e1] and some electrophysiological abnormalities persist when [s2]vigabatrin[e2] therapy is withdrawn.
	(0, 7)	Depressive symptoms	interferon	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	424	 [s1]Depressive symptoms[e1] disappeared after [s2]interferon[e2] therapy was stopped.
	(10, 30)	IFN-alpha	psychiatric side effects	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	425	Treatment of chronic hepatitis C with interferon alpha  [s1]IFN-alpha[e1]  is relatively contraindicated in patients with psychiatric disorders because of possible severe [s2]psychiatric side effects[e2] 
	(6, 32)	interferon alpha	psychiatric side effects	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	426	Treatment of chronic hepatitis C with [s1]interferon alpha[e1] (IFN-alpha) is relatively contraindicated in patients with psychiatric disorders because of possible severe [s2]psychiatric side effects[e2] 
	(23, 43)	changes in serotonergic or noradrenergic neurotransmission	IFN-alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	427	While for ribavirin antidepressant effects are not known, we suppose that antidepressants may prevent [s1]changes in serotonergic or noradrenergic neurotransmission[e1] caused by [s2]IFN-alpha[e2] 
	(15, 22)	vancomycin toxicity	vancomycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	428	Intensive high-flux hemodiafiltration is often used in the management of [s1]vancomycin toxicity[e1]  [s2]vancomycin[e2] toxicity.
	(21, 28)	vancomycin toxicity	vancomycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	429	Management of hypophosphatemia induced by high-flux hemodiafiltration for the treatment of [s1]vancomycin toxicity[e1]  [s2]vancomycin[e2] toxicity: intravenous phosphorus therapy versus use of a phosphorus-enriched dialysate.
	(11, 20)	morbidity	hyperbaric oxygen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	430	We describe 2 children with cerebral palsy who suffered significant [s1]morbidity[e1] immediately after treatment with [s2]hyperbaric oxygen[e2] 
	(9, 34)	brown discolouration of the fingernails	0.1% tretinoin cream	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	431	A 33-year-old male presented with [s1]brown discolouration of the fingernails[e1] following the application of 4% hydroquinone in sorbolene cream and [s2]0.1% tretinoin cream[e2] to the face intermittently for 9 months.
	(9, 22)	brown discolouration of the fingernails	4% hydroquinone in sorbolene cream	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	432	A 33-year-old male presented with [s1]brown discolouration of the fingernails[e1] following the application of [s2]4% hydroquinone in sorbolene cream[e2] and 0.1% tretinoin cream to the face intermittently for 9 months.
	(0, 6)	Nail staining	hydroquinone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	433	 [s1]Nail staining[e1] from [s2]hydroquinone[e2] cream.
	(0, 9)	Gangrene	bleomycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	434	 [s1]Gangrene[e1] of the fingertips after [s2]bleomycin[e2] and methotrexate.
	(0, 14)	Gangrene	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	435	 [s1]Gangrene[e1] of the fingertips after bleomycin and [s2]methotrexate[e2] 
	(8, 16)	bleomycin	acral vascular toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	436	This supports the well-reported potential of [s1]bleomycin[e1] to trigger [s2]acral vascular toxicity[e2] 
	(20, 36)	acute digital ischemia	bleomycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	437	We describe a 57-year-old man with acral erythrocyanosis progressing to [s1]acute digital ischemia[e1] and gangrene that developed after combined chemotherapy  [s2]bleomycin[e2] and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx.
	(20, 42)	acute digital ischemia	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	438	We describe a 57-year-old man with acral erythrocyanosis progressing to [s1]acute digital ischemia[e1] and gangrene that developed after combined chemotherapy (bleomycin and [s2]methotrexate[e2]  used to treat a metastatic squamous cell carcinoma of the hypopharynx.
	(26, 36)	gangrene	bleomycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	439	We describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and [s1]gangrene[e1] that developed after combined chemotherapy  [s2]bleomycin[e2] and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx.
	(26, 42)	gangrene	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	440	We describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and [s1]gangrene[e1] that developed after combined chemotherapy (bleomycin and [s2]methotrexate[e2]  used to treat a metastatic squamous cell carcinoma of the hypopharynx.
	(0, 17)	Diarrhea-associated over-anticoagulation	warfarin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	441	 [s1]Diarrhea-associated over-anticoagulation[e1] in a patient taking [s2]warfarin[e2]  therapeutic role of cholestyramine.
	(21, 30)	diarrhea	warfarin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	442	We present a case of significant over-anticoagulation temporally associated with a bout of protracted [s1]diarrhea[e1] in a patient on [s2]warfarin[e2] therapy.
	(6, 30)	over-anticoagulation	warfarin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	443	We present a case of significant [s1]over-anticoagulation[e1] temporally associated with a bout of protracted diarrhea in a patient on [s2]warfarin[e2] therapy.
	(0, 13)	MI	PCCs	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	444	 [s1]MI[e1] related to the use of activated and non-activated [s2]PCCs[e2] predominantly affects young patients who often have no preceding history of, or risk factors for, MI and tends to be associated with large cumulative doses of concentrate.
	(13, 22)	prothrombin complex concentrate	myocardial infarction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	445	Recombinant VIIa concentrate in the management of bleeding following [s1]prothrombin complex concentrate[e1] related [s2]myocardial infarction[e2] in patients with haemophilia and inhibitors.
	(23, 28)	PCC	MI	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	446	We have safely used recombinant factor VIIa to treat bleeding in the immediate and long-term period following [s1]PCC[e1] related [s2]MI[e2] 
	(9, 24)	quinine	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	447	Even after a strict warning, he took another [s1]quinine[e1] tablet that evening, which triggered his fifth episode of severe [s2]thrombocytopenia[e2]  and confirmed the etiology of quinine-induced thrombocytopenia.
	(9, 24)	quinine	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	448	Even after a strict warning, he took another [s1]quinine[e1] tablet that evening, which triggered his fifth episode of severe [s2]thrombocytopenia[e2]  and confirmed the etiology of quinine-induced thrombocytopenia.
	(9, 24)	quinine	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	449	Even after a strict warning, he took another [s1]quinine[e1] tablet that evening, which triggered his fifth episode of severe [s2]thrombocytopenia[e2]  and confirmed the etiology of quinine-induced thrombocytopenia.
	(1, 6)	quinine	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	450	Occult [s1]quinine[e1] induced [s2]thrombocytopenia[e2] 
	(12, 39)	thrombocytopenia	quinine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	451	Only after three subsequent episodes of severe, symptomatic [s1]thrombocytopenia[e1] over the next four weeks did he say, upon repeat questioning, that he had continued to take [s2]quinine[e2] for night leg cramps.
	(17, 25)	colchicine intoxication	colchicine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	452	An 8-year-old child with familial Mediterranean fever exhibited signs of [s1]colchicine intoxication[e1]  [s2]colchicine[e2] intoxication while receiving prophylactic doses of the drug.
	(14, 22)	colchicine intoxication	colchicine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	453	CONCLUSION: To the best of our knowledge, this is the first time [s1]colchicine intoxication[e1]  [s2]colchicine[e2] intoxication in this age group has been described in the English literature.
	(3, 11)	colchicine intoxication	colchicine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	454	Near fatal acute [s1]colchicine intoxication[e1]  [s2]colchicine[e2] intoxication in a child.
	(0, 5)	Near fatal	colchicine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	455	 [s1]Near fatal[e1] acute [s2]colchicine[e2] intoxication in a child.
	(0, 23)	Acute myeloid leukemia	fludarabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	456	 [s1]Acute myeloid leukemia[e1] and lung cancer occurring in a chronic lymphocytic leukemia patient treated with [s2]fludarabine[e2] and autologous peripheral blood stem-cell transplantation.
	(6, 23)	lung cancer	fludarabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	457	Acute myeloid leukemia and [s1]lung cancer[e1] occurring in a chronic lymphocytic leukemia patient treated with [s2]fludarabine[e2] and autologous peripheral blood stem-cell transplantation.
	(6, 27)	AML	fludarabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	458	We describe the exceptional development of [s1]AML[e1] and lung cancer in a patient with previously diagnosed CLL in minimal residual disease status after [s2]fludarabine[e2] treatment followed by autologous peripheral blood stem-cell transplantation.
	(9, 27)	lung cancer	fludarabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	459	We describe the exceptional development of AML and [s1]lung cancer[e1] in a patient with previously diagnosed CLL in minimal residual disease status after [s2]fludarabine[e2] treatment followed by autologous peripheral blood stem-cell transplantation.
	(11, 29)	lithium carbonate	incontinence	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	460	In 2 of the 3 cases the patients were also taking [s1]lithium carbonate[e1] and beta-blockers, both of which could have contributed to the [s2]incontinence[e2] 
	(12, 29)	incontinence	paroxetine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	461	In the present paper the authors describe 2 female patients who developed [s1]incontinence[e1] secondary to the selective serotonin reuptake inhibitors [s2]paroxetine[e2] and sertraline, as well as a third who developed this side effect on venlafaxine.
	(12, 34)	incontinence	sertraline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	462	In the present paper the authors describe 2 female patients who developed [s1]incontinence[e1] secondary to the selective serotonin reuptake inhibitors paroxetine and [s2]sertraline[e2]  as well as a third who developed this side effect on venlafaxine.
	(12, 49)	incontinence	venlafaxine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	463	In the present paper the authors describe 2 female patients who developed [s1]incontinence[e1] secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on [s2]venlafaxine[e2] 
	(7, 15)	incontinence	venlafaxine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	464	This concerns 2 male patients who experienced [s1]incontinence[e1] while taking [s2]venlafaxine[e2] 
	(3, 9)	heparin	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	465	Case studies in [s1]heparin[e1] induced [s2]thrombocytopenia[e2] 
	(10, 19)	HIT	heparin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	466	Major points illustrated are, (1) occurrence of [s1]HIT[e1] with any dose or form of [s2]heparin[e2]  (2) misperceptions on the diagnostic criteria; (3) correct (thrombin inhibitors) and incorrect (platelet transfusions and warfarin) management; (4) influence of management strategy on clinical outcomes; (5) severity of the syndrome; and (6) potential for both anamnestic response to heparin and disappearance of HIT antibodies over time.
	(2, 8)	heparin	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	467	Type II [s1]heparin[e1] induced [s2]thrombocytopenia[e2] (HIT) is an immunological disorder characterized by antibodies to heparin-platelet factor 4 complexes and a high risk of thrombotic complications.
	(17, 23)	high blood lead level	lead	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	468	After several unrevealing medical work-ups, he was found to have a [s1]high blood lead level[e1]  [s2]lead[e2] level (122 microg/dL); he has a history of scraping and sanding lead paint without adequate protective measures.
	(20, 29)	lead	hypertension	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	469	It also highlights a current major etiologic question, that is, whether and to what degree [s1]lead[e1] exposure contributes to the development of [s2]hypertension[e2]  and raises the issue of whether lead-induced hypertension constitutes a subset of hypertension that is especially amenable to therapy with dietary calcium.
	(20, 38)	lead	lead-induced hypertension	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	470	It also highlights a current major etiologic question, that is, whether and to what degree [s1]lead[e1] exposure contributes to the development of hypertension, and raises the issue of whether [s2]lead-induced hypertension[e2] constitutes a subset of hypertension that is especially amenable to therapy with dietary calcium.
	(9, 13)	lead toxicity	lead	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	471	Poorly controlled hypertension in a painter with chronic [s1]lead toxicity[e1]  [s2]lead[e2] toxicity.
	(17, 48)	lead	lead toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	472	This case demonstrates an occupational activity (construction) that has now become the dominant source of [s1]lead[e1] exposure for U.S. adults, the importance of a good occupational history to suspecting and making a diagnosis, the possible outcomes of chronic [s2]lead toxicity[e2]  and the importance of preventing further exposure and using proper methods to treat acute toxicity.
	(0, 20)	Severe rash	nevirapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	473	 [s1]Severe rash[e1]  including the Stevens-Johnson syndrome (SJS), is the major toxicity of [s2]nevirapine[e2] and is described in the package labeling with a prominent, boxed warning.
	(9, 19)	SJS	nevirapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	474	Severe rash, including the Stevens-Johnson syndrome  [s1]SJS[e1] , is the major toxicity of [s2]nevirapine[e2] and is described in the package labeling with a prominent, boxed warning.
	(5, 21)	Stevens-Johnson syndrome	nevirapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	475	Severe rash, including the [s1]Stevens-Johnson syndrome[e1] (SJS), is the major toxicity of [s2]nevirapine[e2] and is described in the package labeling with a prominent, boxed warning.
	(0, 15)	Stevens-Johnson syndrome	nevirapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	476	 [s1]Stevens-Johnson syndrome[e1] caused by the antiretroviral drug [s2]nevirapine[e2] 
	(22, 28)	nevirapine	SJS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	477	Though physicians treating large populations of patients with HIV are well aware of this complication, only one other report of [s1]nevirapine[e1] associated [s2]SJS[e2] has been documented in the dermatology literature.
	(5, 11)	SJS	nevirapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	478	We describe 2 cases of [s1]SJS[e1] related to [s2]nevirapine[e2] use and review the literature on this newly recognized association.
	(3, 14)	acarbose	ileus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	479	Oral intake and [s1]acarbose[e1] were withheld and the [s2]ileus[e2] spontaneously resolved after 2 days.
	(13, 18)	losartan	increases urate excretion	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	480	There is evidence that the angiotensin II receptor antagonist, [s1]losartan[e1]  [s2]increases urate excretion[e2] by reducing reabsorption of urate in the renal proximal tubule.
	(0, 12)	Atrial fibrillation	etanercept	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	481	 [s1]Atrial fibrillation[e1] occurring in a patient taking [s2]etanercept[e2] plus methotrexate for rheumatoid arthritis.
	(0, 17)	Atrial fibrillation	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	482	 [s1]Atrial fibrillation[e1] occurring in a patient taking etanercept plus [s2]methotrexate[e2] for rheumatoid arthritis.
	(10, 26)	hepatic angiosarcoma	cyclophosphamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	483	A review of the literature revealed two other cases of [s1]hepatic angiosarcoma[e1] in patients after long-term [s2]cyclophosphamide[e2] treatment.
	(0, 12)	Hepatic angiosarcoma	cyclophosphamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	484	 [s1]Hepatic angiosarcoma[e1] occurring after [s2]cyclophosphamide[e2] therapy: case report and review of the literature.
	(3, 22)	cyclophosphamide	hepatic angiosarcoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	485	We propose that [s1]cyclophosphamide[e1] be added to the list of exposures potentially associated with [s2]hepatic angiosarcoma[e2] 
	(0, 9)	ARA-C	dermatologic toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	486	 [s1]ARA-C[e1] is frequently associated with [s2]dermatologic toxicity[e2]  but this is only the second case of toxic epidermal necrolysis described in connection with this drug.
	(0, 23)	ARA-C	toxic epidermal necrolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	487	 [s1]ARA-C[e1] is frequently associated with dermatologic toxicity, but this is only the second case of [s2]toxic epidermal necrolysis[e2] described in connection with this drug.
	(11, 31)	ARA-C	bullous lesions on the hands and soles that disseminated, evolving to necrosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	488	On the fifth day after administration of a high dose of [s1]ARA-C[e1] (2 g/m2 intravenously every 12 hours), she developed [s2]bullous lesions on the hands and soles that disseminated, evolving to necrosis[e2]  sepsis, and death on the 22nd day.
	(11, 54)	ARA-C	death	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	489	On the fifth day after administration of a high dose of [s1]ARA-C[e1] (2 g/m2 intravenously every 12 hours), she developed bullous lesions on the hands and soles that disseminated, evolving to necrosis, sepsis, and [s2]death[e2] on the 22nd day.
	(11, 50)	ARA-C	sepsis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	490	On the fifth day after administration of a high dose of [s1]ARA-C[e1] (2 g/m2 intravenously every 12 hours), she developed bullous lesions on the hands and soles that disseminated, evolving to necrosis, [s2]sepsis[e2]  and death on the 22nd day.
	(0, 16)	Toxic epidermal necrolysis	cytosine arabinoside	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	491	 [s1]Toxic epidermal necrolysis[e1] after the use of high-dose [s2]cytosine arabinoside[e2] 
	(13, 28)	TEN	ARA-C	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	492	We report a fatal case of toxic epidermal necrolysis  [s1]TEN[e1]  resulting from a high dose of cytosine arabinoside  [s2]ARA-C[e2] .
	(13, 22)	TEN	cytosine arabinoside	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	493	We report a fatal case of toxic epidermal necrolysis  [s1]TEN[e1]  resulting from a high dose of [s2]cytosine arabinoside[e2] (ARA-C).
	(6, 30)	toxic epidermal necrolysis	ARA-C	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	494	We report a fatal case of [s1]toxic epidermal necrolysis[e1] (TEN) resulting from a high dose of cytosine arabinoside  [s2]ARA-C[e2] .
	(6, 24)	toxic epidermal necrolysis	cytosine arabinoside	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	495	We report a fatal case of [s1]toxic epidermal necrolysis[e1] (TEN) resulting from a high dose of [s2]cytosine arabinoside[e2] (ARA-C).
	(0, 6)	Quetiapine	obsessive-compulsive symptoms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	496	 [s1]Quetiapine[e1] and [s2]obsessive-compulsive symptoms[e2] (OCS): case report and review of atypical antipsychotic-induced OCS.
	(0, 15)	Quetiapine	OCS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	497	 [s1]Quetiapine[e1] and obsessive-compulsive symptoms  [s2]OCS[e2] : case report and review of atypical antipsychotic-induced OCS.
	(0, 15)	Quetiapine	OCS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	498	 [s1]Quetiapine[e1] and obsessive-compulsive symptoms  [s2]OCS[e2] : case report and review of atypical antipsychotic-induced OCS.
	(5, 10)	quetiapine	exacerbating OCS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	499	The first known report of [s1]quetiapine[e1]  [s2]exacerbating OCS[e2] in a 43-year-old man with obsessive-compulsive disorder (OCD), trichotillomania, delusional disorder and bipolar II disorder is presented.
	(5, 15)	serotonin syndrome	clomipramine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	500	He was diagnosed with possible [s1]serotonin syndrome[e1]  his symptoms resolved after [s2]clomipramine[e2] was stopped but before clozapine was restarted eight days later.
	(9, 19)	serotonin syndrome	clomipramine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	501	OBJECTIVE: To report on the possible development of [s1]serotonin syndrome[e1] in a patient receiving [s2]clomipramine[e2] after clozapine was withdrawn from the treatment regimen.
	(9, 24)	serotonin syndrome	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	502	OBJECTIVE: To report on the possible development of [s1]serotonin syndrome[e1] in a patient receiving clomipramine after [s2]clozapine[e2] was withdrawn from the treatment regimen.
	(1, 9)	serotonin syndrome	clomipramine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	503	Possible [s1]serotonin syndrome[e1] associated with [s2]clomipramine[e2] after withdrawal of clozapine.
	(1, 16)	serotonin syndrome	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	504	Possible [s1]serotonin syndrome[e1] associated with clomipramine after withdrawal of [s2]clozapine[e2] 
	(14, 46)	clomipramine	agitated	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	505	The day after clozapine was stopped, while he was still receiving [s1]clomipramine[e1] 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, [s2]agitated[e2]  and confused.
	(3, 46)	clozapine	agitated	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	506	The day after [s1]clozapine[e1] was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, [s2]agitated[e2]  and confused.
	(14, 27)	clomipramine	behaving oddly	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	507	The day after clozapine was stopped, while he was still receiving [s1]clomipramine[e1] 150 mg/d, he began [s2]behaving oddly[e2]  started sweating profusely, shivering, and became tremulous, agitated, and confused.
	(3, 27)	clozapine	behaving oddly	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	508	The day after [s1]clozapine[e1] was stopped, while he was still receiving clomipramine 150 mg/d, he began [s2]behaving oddly[e2]  started sweating profusely, shivering, and became tremulous, agitated, and confused.
	(14, 49)	clomipramine	confused	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	509	The day after clozapine was stopped, while he was still receiving [s1]clomipramine[e1] 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, agitated, and [s2]confused[e2] 
	(3, 49)	clozapine	confused	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	510	The day after [s1]clozapine[e1] was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, agitated, and [s2]confused[e2] 
	(14, 38)	clomipramine	shivering	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	511	The day after clozapine was stopped, while he was still receiving [s1]clomipramine[e1] 150 mg/d, he began behaving oddly, started sweating profusely, [s2]shivering[e2]  and became tremulous, agitated, and confused.
	(3, 38)	clozapine	shivering	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	512	The day after [s1]clozapine[e1] was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started sweating profusely, [s2]shivering[e2]  and became tremulous, agitated, and confused.
	(14, 33)	clomipramine	sweating profusely	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	513	The day after clozapine was stopped, while he was still receiving [s1]clomipramine[e1] 150 mg/d, he began behaving oddly, started [s2]sweating profusely[e2]  shivering, and became tremulous, agitated, and confused.
	(3, 33)	clozapine	sweating profusely	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	514	The day after [s1]clozapine[e1] was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started [s2]sweating profusely[e2]  shivering, and became tremulous, agitated, and confused.
	(14, 42)	clomipramine	tremulous	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	515	The day after clozapine was stopped, while he was still receiving [s1]clomipramine[e1] 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became [s2]tremulous[e2]  agitated, and confused.
	(3, 42)	clozapine	tremulous	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	516	The day after [s1]clozapine[e1] was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became [s2]tremulous[e2]  agitated, and confused.
	(0, 5)	Quinine	coagulopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	517	 [s1]Quinine[e1] induced [s2]coagulopathy[e2] -a near fatal experience.
	(7, 24)	severe thrombocytopoaenia	quinine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	518	The cause of his bleeding was a [s1]severe thrombocytopoaenia[e1]  induced by chronic ingestion of [s2]quinine[e2] 
	(3, 9)	olanzapine	leukopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	519	Dose-dependent [s1]olanzapine[e1] associated [s2]leukopenia[e2]  three case reports.
	(16, 24)	agranulocytosis	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	520	These cases suggest the possibility that, in some patients, leukopenia or [s1]agranulocytosis[e1] during [s2]olanzapine[e2] treatment might be dose-related.
	(11, 24)	leukopenia	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	521	These cases suggest the possibility that, in some patients, [s1]leukopenia[e1] or agranulocytosis during [s2]olanzapine[e2] treatment might be dose-related.
	(8, 15)	leukopenia	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	522	We report three cases of patients who developed [s1]leukopenia[e1] during [s2]olanzapine[e2] treatment.
	(9, 23)	dermatologic and ocular 5-FU toxicities	5-FU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	523	CONCLUSION: This case illustrates a potential link between [s1]dermatologic and ocular 5-FU toxicities[e1]  [s2]5-FU[e2] toxicities.
	(20, 26)	5-FU	ectropion	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	524	Differential diagnoses included ocular rosacea with cicatrizing conjunctivitis and [s1]5-FU[e1] induced [s2]ectropion[e2] 
	(4, 10)	5-FU	ectropion	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	525	DISCUSSION: Patients with [s1]5-FU[e1] induced [s2]ectropion[e2] experience tender, red, scaled lids, making contact lens wear difficult.
	(4, 15)	5-FU	tender, red, scaled lids	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	526	DISCUSSION: Patients with [s1]5-FU[e1] induced ectropion experience [s2]tender, red, scaled lids[e2]  making contact lens wear difficult.
	(0, 12)	Ectropion	5-fluorouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	527	 [s1]Ectropion[e1] secondary to bolus injection of [s2]5-fluorouracil[e2] 
	(5, 10)	5-FU	dermatologic toxicities	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	528	Exacerbation of [s1]5-FU[e1]  [s2]dermatologic toxicities[e2] in patients with preexisting conditions suggests the importance of aggressive ocular prophylaxis, using frequent ocular lubrication and topical steroid preparations with concurrent medical management of pre-existing dermatologic conditions.
	(5, 12)	acute renal failure	acetazolamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	529	Presented is a case of [s1]acute renal failure[e1] induced by [s2]acetazolamide[e2] therapy for glaucoma.
	(0, 6)	Renal failure	acetazolamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	530	 [s1]Renal failure[e1] associated with [s2]acetazolamide[e2] therapy for glaucoma.
	(14, 22)	acetazolamide	calcium phosphate nephrolithiasis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	531	This sulfonamide like nephropathy should be differentiated from [s1]acetazolamide[e1] related [s2]calcium phosphate nephrolithiasis[e2] 
	(0, 12)	Ischaemic colitis	meloxicam	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	532	 [s1]Ischaemic colitis[e1] in a patient taking [s2]meloxicam[e2] 
	(2, 15)	endoscopic lesions	meloxicam	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	533	Symptoms and [s1]endoscopic lesions[e1] quickly regressed within 1 week of [s2]meloxicam[e2] withdrawal.
	(7, 17)	bloody diarrhoea	meloxicam	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	534	We describe a patient who presented with [s1]bloody diarrhoea[e1] after 15 mg [s2]meloxicam[e2] daily for 10 days for osteoarthritis.
	(3, 11)	meloxicam	intestinal toxic effects	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	535	We suggest that [s1]meloxicam[e1] might have [s2]intestinal toxic effects[e2] when taken in high doses, because of reduced COX-2 selectivity.
	(14, 37)	spironolactone	diarrhoea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	536	As these cases revealed, close monitoring of blood chemistry is mandatory after starting [s1]spironolactone[e1]  and patients should be advised to stop spironolactone immediately if [s2]diarrhoea[e2] develops.
	(7, 22)	spironolactone	serious and, occasionally, fatal hyperkalaemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	537	In patients with chronic heart failure, [s1]spironolactone[e1] added to conventional treatment may lead to [s2]serious and, occasionally, fatal hyperkalaemia[e2] 
	(8, 17)	spironolactone	diarrhoea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	538	In some cases this seems to happen because [s1]spironolactone[e1] causes [s2]diarrhoea[e2] 
	(0, 13)	Serious adverse events	spironolactone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	539	 [s1]Serious adverse events[e1] experienced by patients with chronic heart failure taking [s2]spironolactone[e2] 
	(25, 35)	oxaliplatin	dermnatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	540	We report a patient with advanced colonic carcinoma who was treated with concomitant chemoirradiation with [s1]oxaliplatin[e1] and developed a peculiar [s2]dermnatitis[e2] in the irradiated field after being exposed to subsequent chemotherapy with oxaliplatin.
	(9, 20)	severe enteropathy	clofazimine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	541	An 11-year-old boy developed a [s1]severe enteropathy[e1] 2 years after initiation of [s2]clofazimine[e2] treatment for graft-versus-host disease.
	(0, 6)	Clofazimine	enteropathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	542	 [s1]Clofazimine[e1]  [s2]enteropathy[e2] caused by crystal deposition can be life-threatening.
	(0, 15)	Clofazimine	life-threatening	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	543	 [s1]Clofazimine[e1] enteropathy caused by crystal deposition can be [s2]life-threatening[e2] 
	(0, 6)	Clofazimine	enteropathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	544	 [s1]Clofazimine[e1]  [s2]enteropathy[e2] in a pediatric bone marrow transplant recipient.
	(3, 17)	severe urticarial rash	Enoxaparin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	545	She developed a [s1]severe urticarial rash[e1] 3 weeks following initiation of therapy with [s2]Enoxaparin[e2] 
	(12, 26)	blurred vision	cibenzoline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	546	We cared for a patient with progressive renal impairment who presented with [s1]blurred vision[e1]  QRS broadening and cardiac failure due to chronic [s2]cibenzoline[e2] intoxication.
	(20, 27)	cardiac failure	cibenzoline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	547	We cared for a patient with progressive renal impairment who presented with blurred vision, QRS broadening and [s1]cardiac failure[e1] due to chronic [s2]cibenzoline[e2] intoxication.
	(25, 34)	cibenzoline intoxication	cibenzoline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	548	We cared for a patient with progressive renal impairment who presented with blurred vision, QRS broadening and cardiac failure due to chronic [s1]cibenzoline intoxication[e1]  [s2]cibenzoline[e2] intoxication.
	(15, 27)	QRS broadening	cibenzoline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	549	We cared for a patient with progressive renal impairment who presented with blurred vision, [s1]QRS broadening[e1] and cardiac failure due to chronic [s2]cibenzoline[e2] intoxication.
	(2, 13)	aspergillus arthritis	fludarabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	550	Indolent [s1]aspergillus arthritis[e1] complicating [s2]fludarabine[e2] based non-myeloablative stem cell transplantation.
	(5, 17)	aspergillus arthritis of the knee joint	fludarabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	551	We describe two patients with [s1]aspergillus arthritis of the knee joint[e1] following [s2]fludarabine[e2] based non-myeloablative stem cell transplantation.
	(7, 15)	fluvoxamine	increased libido	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	552	CONCLUSION: The present findings suggest that [s1]fluvoxamine[e1] can cause [s2]increased libido[e2] in some patients.
	(0, 11)	Increased libido	fluvoxamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	553	 [s1]Increased libido[e1] in a woman treated with [s2]fluvoxamine[e2]  a case report.
	(13, 20)	increased libido	fluvoxamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	554	OBJECTIVE: The aim of this paper is to describe a case of [s1]increased libido[e1] during [s2]fluvoxamine[e2] therapy.
	(22, 32)	increased libido	fluvoxamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	555	RESULTS: The patient, a 27-year-old married Japanese woman with borderline personality disorder, developed an [s1]increased libido[e1] with the administration of [s2]fluvoxamine[e2] 
	(1, 9)	increased libido	fluvoxamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	556	The [s1]increased libido[e1] disappeared after [s2]fluvoxamine[e2] was discontinued.
	(4, 11)	pancreatitis	meglumine antimoniate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	557	An infant who developed [s1]pancreatitis[e1] during [s2]meglumine antimoniate[e2] treatment for visceral leishmaniasis and who was successfully treated with a combination of allopurinol and ketoconazole is reported.
	(27, 35)	pancreatitis	meglumine antimoniate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	558	Successful treatment of visceral leishmaniasis with allopurinol plus ketoconazole in an infant who developed [s1]pancreatitis[e1] caused by [s2]meglumine antimoniate[e2] 
	(11, 20)	Hashimoto's disease	IFN-alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	559	CONCLUSIONS: This case report showed that the clinical appearance of [s1]Hashimoto's disease[e1] after [s2]IFN-alpha[e2] therapy for chronic C hepatitis in our patient was associated with a specific genetic predisposition (DR5) for this pathology.
	(31, 51)	autoimmune thyroiditis	IFN-alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	560	Further studies are necessary to evaluate whether the study of HLA antigens may be a very useful tool to detect the patients with a predisposition to develop [s1]autoimmune thyroiditis[e1]  in order to make a early diagnosis of thyroid disorders during the [s2]IFN-alpha[e2] treatment.
	(46, 52)	thyroid disorders	IFN-alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	561	Further studies are necessary to evaluate whether the study of HLA antigens may be a very useful tool to detect the patients with a predisposition to develop autoimmune thyroiditis, in order to make a early diagnosis of [s1]thyroid disorders[e1] during the [s2]IFN-alpha[e2] treatment.
	(0, 9)	Hashimoto's disease	interferon-alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	562	 [s1]Hashimoto's disease[e1] during [s2]interferon-alpha[e2] therapy in a patient with pre-treatment negative anti-thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease.
	(8, 22)	Hashimoto's disease	IFN-alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	563	OBJECTIVES: The authors described a case of [s1]Hashimoto's disease[e1] during interferon-alpha  [s2]IFN-alpha[e2]  treatment for chronic viral C hepatitis in a patient with the specific genetic susceptibility associated with the thyroid disease.
	(8, 17)	Hashimoto's disease	interferon-alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	564	OBJECTIVES: The authors described a case of [s1]Hashimoto's disease[e1] during [s2]interferon-alpha[e2] (IFN-alpha) treatment for chronic viral C hepatitis in a patient with the specific genetic susceptibility associated with the thyroid disease.
	(12, 46)	omeprazole	peripheral edema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	565	During dose-finding studies for intravenous proton pump inhibitors [s1]omeprazole[e1] and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed [s2]peripheral edema[e2] within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid.
	(17, 45)	pantoprazole	peripheral edema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	566	During dose-finding studies for intravenous proton pump inhibitors omeprazole and [s1]pantoprazole[e1]  three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed [s2]peripheral edema[e2] within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid.
	(0, 24)	Pheripheral edema	lansoprazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	567	 [s1]Pheripheral edema[e1] was observed in five female patients after taking proton pump inhibitors omeprazole, [s2]lansoprazole[e2]  or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses.
	(0, 19)	Pheripheral edema	omeprazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	568	 [s1]Pheripheral edema[e1] was observed in five female patients after taking proton pump inhibitors [s2]omeprazole[e2]  lansoprazole, or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses.
	(0, 30)	Pheripheral edema	pantoprazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	569	 [s1]Pheripheral edema[e1] was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or [s2]pantoprazole[e2] for 7-15 days for peptic acid diseases in recommended standard doses.
	(0, 11)	Motor fluctuations	levodopa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	570	 [s1]Motor fluctuations[e1] appear after 2-3 years of [s2]levodopa[e2] treatment, and affect at least 50% of patients after five years.
	(3, 23)	weight loss	leflunomide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	571	CONCLUSION: Significant [s1]weight loss[e1] is a potential adverse event in patients with rheumatoid arthritis treated with [s2]leflunomide[e2] 
	(0, 7)	Leflunomide	weight loss	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	572	 [s1]Leflunomide[e1] associated [s2]weight loss[e2] in rheumatoid arthritis.
	(22, 36)	weight loss	leflunomide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	573	METHODS: We queried 35 rheumatologists at the Robert Breck Brigham Arthritis Center to determine if [s1]weight loss[e1] had occurred as an adverse event in patients treated with [s2]leflunomide[e2] between November 1998 and January 2000.
	(7, 15)	weight loss	leflunomide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	574	OBJECTIVE: To determine the frequency of [s1]weight loss[e1] in patients treated with [s2]leflunomide[e2] for rheumatoid arthritis at an arthritis referral center.
	(9, 18)	leflunomide	weight loss	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	575	RESULTS: Five of 70 patients who had begun [s1]leflunomide[e1] therapy had significant [s2]weight loss[e2] that could not be linked to other identifiable etiologies.
	(9, 23)	valacyclovir	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	576	It is increasingly recognized that dose adjustment of oral [s1]valacyclovir[e1] in renal failure is necessary to avoid [s2]neurotoxicity[e2] 
	(0, 8)	Neurotoxicity	valacyclovir	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	577	 [s1]Neurotoxicity[e1] of [s2]valacyclovir[e2] in peritoneal dialysis: a pharmacokinetic study.
	(2, 15)	neurotoxicity	valacyclovir	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	578	She developed [s1]neurotoxicity[e1] with an adjustment dosage of [s2]valacyclovir[e2] for a cutaneous zoster infection.
	(0, 19)	Avascular necrosis of the femoral head	cyproterone acetate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	579	 [s1]Avascular necrosis of the femoral head[e1] in patients with prostate cancer treated with [s2]cyproterone acetate[e2] and radiotherapy.
	(42, 68)	cyproterone acetate	femoral head avascular necrosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	580	We report the case histories of two patients with histologically confirmed adenocarcinoma of the prostate, both of whom had been treated with steroidal anti-androgen therapy in the form of [s1]cyproterone acetate[e1] prior to radical or palliative pelvic irradiation, and who subsequently developed [s2]femoral head avascular necrosis[e2] 
	(0, 8)	Levofloxacin	polymorphic ventricular tachycardia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	581	 [s1]Levofloxacin[e1] induced [s2]polymorphic ventricular tachycardia[e2] with normal QT interval.
	(6, 28)	polymorphic ventricular tachycardia	levofloxacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	582	We report the first case of [s1]polymorphic ventricular tachycardia[e1] with normal QT interval associated with the oral use of [s2]levofloxacin[e2] in the absence of other etiologies known to cause these arrhythmias.
	(6, 13)	pulmonary side effects	ticlopidine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	583	So far, few cases of [s1]pulmonary side effects[e1] caused by [s2]ticlopidine[e2] have been reported.
	(6, 14)	pulmonary symptoms	ticlopidine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	584	Special care should be taken when [s1]pulmonary symptoms[e1] appear in association with [s2]ticlopidine[e2] treatment.
	(0, 8)	Ticlopidine	interstitial pulmonary disease	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	585	 [s1]Ticlopidine[e1] induced [s2]interstitial pulmonary disease[e2]  a case report.
	(5, 26)	interstitial pulmonary disease	ticlopidine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	586	We report a case of [s1]interstitial pulmonary disease[e1] that occurred together with lymphocytic colitis during treatment with [s2]ticlopidine[e2] 
	(14, 26)	lymphocytic colitis	ticlopidine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	587	We report a case of interstitial pulmonary disease that occurred together with [s1]lymphocytic colitis[e1] during treatment with [s2]ticlopidine[e2] 
	(4, 15)	methadone	myoclonus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	588	A patient that received [s1]methadone[e1] for cancer-associated pain developed [s2]myoclonus[e2] as a side effect.
	(0, 6)	Methadone	myoclonus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	589	 [s1]Methadone[e1] induced [s2]myoclonus[e2] in advanced cancer.
	(7, 15)	fatal hyperkalemia	succinylcholine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	590	OBJECTIVE: To report a case of [s1]fatal hyperkalemia[e1] owing to [s2]succinylcholine[e2] administration in a patient with mucositis secondary to chemotherapy.
	(0, 9)	Succinylcholine	hyperkalemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	591	 [s1]Succinylcholine[e1] induced [s2]hyperkalemia[e2] in a patient with mucositis secondary to chemotherapy.
	(14, 23)	fatal hyperkalemia	succinylcholine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	592	We believe that mucositis was a contributing factor to this case of [s1]fatal hyperkalemia[e1] after administration of [s2]succinylcholine[e2]  with a mechanism similar to that reported with thermal injury.
	(0, 13)	Cutaneous seeding	ethanol injection	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	593	 [s1]Cutaneous seeding[e1] after ultrasound-guided percutaneous [s2]ethanol injection[e2] for treatment of hepatocellular carcinoma.
	(8, 34)	cutaneous seeding	ethanol injection	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	594	We describe a case of needle-track [s1]cutaneous seeding[e1] of hepatocellular carcinoma (HCC) after sonographically guided percutaneous [s2]ethanol injection[e2] (PEI).
	(0, 6)	Adenosine	ventricular fibrillation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	595	 [s1]Adenosine[e1] induced [s2]ventricular fibrillation[e2] 
	(2, 28)	adenosine	acceleration of the ventricular rate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	596	However, [s1]adenosine[e1] shortens the antegrade refractoriness of accessory atrioventricular connections and may cause [s2]acceleration of the ventricular rate[e2] during atrial fibrillation.
	(2, 34)	ventricular fibrillation	adenosine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	597	We observed [s1]ventricular fibrillation[e1] in 2 patients who presented to the emergency department with pre-excited atrial fibrillation and were given 12 mg of [s2]adenosine[e2] 
	(4, 50)	methylprednisolone	psychotic reaction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	598	After the dose of [s1]methylprednisolone[e1] was reduced from 40 mg to 20 mg i.v. q6h and shifted to other anti-asthma treatment by procaterol metered dose inhaler via spacer, the [s2]psychotic reaction[e2] disappeared a few hours later.
	(8, 18)	seizures	CBZ	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	599	Continuous EEG monitoring is helpful in managing [s1]seizures[e1] that occur as a complication of [s2]CBZ[e2] OD, after the course of recovery or worsening, and in providing assistance with prognosis.
	(1, 20)	CBZ	cortical hyperexcitability	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	600	Massive [s1]CBZ[e1] OD may produce a reversible encephalopathy that includes [s2]cortical hyperexcitability[e2]  a profound burst-suppression EEG pattern, and cranial nerve areflexia.
	(1, 38)	CBZ	cranial nerve areflexia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	601	Massive [s1]CBZ[e1] OD may produce a reversible encephalopathy that includes cortical hyperexcitability, a profound burst-suppression EEG pattern, and [s2]cranial nerve areflexia[e2] 
	(1, 29)	CBZ	profound burst-suppression EEG pattern	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	602	Massive [s1]CBZ[e1] OD may produce a reversible encephalopathy that includes cortical hyperexcitability, a [s2]profound burst-suppression EEG pattern[e2]  and cranial nerve areflexia.
	(1, 10)	CBZ	reversible encephalopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	603	Massive [s1]CBZ[e1] OD may produce a [s2]reversible encephalopathy[e2] that includes cortical hyperexcitability, a profound burst-suppression EEG pattern, and cranial nerve areflexia.
	(8, 15)	methimazole	bone marrow toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	604	Massive plasmocytosis due to [s1]methimazole[e1] induced [s2]bone marrow toxicity[e2] 
	(0, 10)	Massive plasmocytosis	methimazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	605	 [s1]Massive plasmocytosis[e1] due to [s2]methimazole[e2] induced bone marrow toxicity.
	(15, 31)	MMI	massive plasmocytosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	606	To our knowledge this is the first report of pancytopenia due to [s1]MMI[e1]  where the usual hypoplasia found is replaced by [s2]massive plasmocytosis[e2] 
	(9, 17)	pancytopenia	MMI	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	607	To our knowledge this is the first report of [s1]pancytopenia[e1] due to [s2]MMI[e2]  where the usual hypoplasia found is replaced by massive plasmocytosis.
	(5, 17)	fulminant hepatic failure	didanosine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	608	We report a case of [s1]fulminant hepatic failure[e1] associated with [s2]didanosine[e2] and masquerading as a surgical abdomen and compare the clinical, biologic, histologic, and ultrastructural findings with reports described previously.
	(6, 28)	bilateral avascular necrosis of the femoral heads	dexamethasone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	609	This report details a case of [s1]bilateral avascular necrosis of the femoral heads[e1] in a patient receiving 'standard' doses of [s2]dexamethasone[e2] as part of the antiemetic regimen used in cisplatin-based combination chemotherapy.
	(30, 41)	hemorrhage	metformin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	610	Although no coagulation study was done and the Meckel's diverticulum is normally associated with bleeding, the particular intensity of the following [s1]hemorrhage[e1] may have been favored by [s2]metformin[e2] 
	(12, 26)	metformin	severe inferior digestive hemorrhage	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	611	An obese patient, not diabetic, treated with [s1]metformin[e1] for some weeks, was referred to us with [s2]severe inferior digestive hemorrhage[e2]  diagnosed with Meckel's diverticulum.
	(0, 21)	Digestive hemorrhage	metformin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	612	 [s1]Digestive hemorrhage[e1] caused by a Meckel's diverticulum in a [s2]metformin[e2] treated patient: is there any connection?
	(0, 12)	Ulcer became worse	gentamycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	613	 [s1]Ulcer became worse[e1] after tobramycin and [s2]gentamycin[e2] treatment for 2 days.
	(0, 7)	Ulcer became worse	tobramycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	614	 [s1]Ulcer became worse[e1] after [s2]tobramycin[e2] and gentamycin treatment for 2 days.
	(4, 11)	amprenavir	intracranial bleeding	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	615	Possible linkage of [s1]amprenavir[e1] with [s2]intracranial bleeding[e2] in an HIV-infected hemophiliac.
	(1, 11)	bleeding	APV	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	616	The [s1]bleeding[e1] resolved on discontinuation of [s2]APV[e2] 
	(6, 36)	intracranial bleeding	amprenavir	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	617	We report the occurrence of spontaneous [s1]intracranial bleeding[e1] in an human immunodeficiency virus (HIV)-infected adolescent with hemophilia A who was receiving [s2]amprenavir[e2] (APV).
	(12, 20)	gemcitabine	cutaneous eruption	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	618	According to the Naranjo probability scale, the relationship of [s1]gemcitabine[e1] treatment with [s2]cutaneous eruption[e2] in our patient is possible.
	(8, 15)	gemcitabine	LABD	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	619	CONCLUSIONS: We report the first case of [s1]gemcitabine[e1] induced [s2]LABD[e2] 
	(0, 17)	Linear immunoglobulin A bullous dermatosis	gemcitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	620	 [s1]Linear immunoglobulin A bullous dermatosis[e1] induced by [s2]gemcitabine[e2] 
	(24, 30)	LABD	gemcitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	621	OBJECTIVE: To report a case of linear immunoglobulin (Ig) A bullous dermatosis  [s1]LABD[e1]  induced by [s2]gemcitabine[e2] 
	(7, 32)	linear immunoglobulin (Ig) A bullous dermatosis	gemcitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	622	OBJECTIVE: To report a case of [s1]linear immunoglobulin (Ig) A bullous dermatosis[e1] (LABD) induced by [s2]gemcitabine[e2] 
	(8, 15)	gemcitabine	symmetric, bullous, herpetiform eruption	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	623	Twenty-four hours after the administration of [s1]gemcitabine[e1]  a [s2]symmetric, bullous, herpetiform eruption[e2] appeared on his trunk and upper limbs.
	(0, 21)	Vancomycin	LABD	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	624	 [s1]Vancomycin[e1] is the most frequently implicated drug, but other agents have been reported to cause [s2]LABD[e2] 
	(1, 16)	taxol	peripheral neuropathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	625	Although [s1]taxol[e1] has shown significant activity in advanced ovarian cancer, [s2]peripheral neuropathy[e2] is likely to become the major dose-limiting toxicity.
	(13, 23)	difficulty walking	paclitaxel	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	626	A rare case of advanced ovarian carcinoma who developed [s1]difficulty walking[e1] 25 days after treatment with weekly [s2]paclitaxel[e2] 
	(14, 41)	difficulty walking	taxol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	627	We describe a case of advanced ovarian carcinoma who developed [s1]difficulty walking[e1] because of marked pain in the lower extremities and loss of proprioception 25 days after treatment with weekly [s2]taxol[e2] (80 mg/m(2)x3).
	(28, 41)	loss of proprioception	taxol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	628	We describe a case of advanced ovarian carcinoma who developed difficulty walking because of marked pain in the lower extremities and [s1]loss of proprioception[e1] 25 days after treatment with weekly [s2]taxol[e2] (80 mg/m(2)x3).
	(18, 41)	marked pain	taxol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	629	We describe a case of advanced ovarian carcinoma who developed difficulty walking because of [s1]marked pain[e1] in the lower extremities and loss of proprioception 25 days after treatment with weekly [s2]taxol[e2] (80 mg/m(2)x3).
	(7, 12)	morphine	spasm	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	630	Relief by naloxone of [s1]morphine[e1] induced [s2]spasm[e2] of the sphincter of Oddi in a post-cholecystectomy patient.
	(21, 37)	morphine	biliary colic	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	631	We present the case of a patient who had undergone cholecystectomy previously, but in whom [s1]morphine[e1] given in the Emergency Department precipitated pain consistent with [s2]biliary colic[e2]  the pain resolved promptly after administration of naloxone.
	(21, 34)	morphine	pain	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	632	We present the case of a patient who had undergone cholecystectomy previously, but in whom [s1]morphine[e1] given in the Emergency Department precipitated [s2]pain[e2] consistent with biliary colic; the pain resolved promptly after administration of naloxone.
	(0, 13)	Myasthenia gravis	IFN-alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	633	 [s1]Myasthenia gravis[e1] during low-dose [s2]IFN-alpha[e2] therapy for chronic hepatitis C.
	(12, 26)	intrahepatic cholestasis	sodium aurothiomalate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	634	A patient with rheumatoid arthritis developed an acute [s1]intrahepatic cholestasis[e1] after 100 mg of [s2]sodium aurothiomalate[e2] 
	(0, 7)	Acute lung injury	5-fluorouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	635	 [s1]Acute lung injury[e1] associated with [s2]5-fluorouracil[e2] and oxaliplatinum combined chemotherapy.
	(0, 15)	Acute lung injury	oxaliplatinum	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	636	 [s1]Acute lung injury[e1] associated with 5-fluorouracil and [s2]oxaliplatinum[e2] combined chemotherapy.
	(16, 44)	bilateral patchy pulmonary infiltrates	5-fluorouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	637	Diarrhoea, T-CD4+ lymphopenia and [s1]bilateral patchy pulmonary infiltrates[e1] developed in a male 60 yrs of age, who was treated with oxaliplatinum and [s2]5-fluorouracil[e2] for unresectable rectum carcinoma.
	(16, 38)	bilateral patchy pulmonary infiltrates	oxaliplatinum	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	638	Diarrhoea, T-CD4+ lymphopenia and [s1]bilateral patchy pulmonary infiltrates[e1] developed in a male 60 yrs of age, who was treated with [s2]oxaliplatinum[e2] and 5-fluorouracil for unresectable rectum carcinoma.
	(0, 43)	Diarrhoea	5-fluorouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	639	 [s1]Diarrhoea[e1]  T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and [s2]5-fluorouracil[e2] for unresectable rectum carcinoma.
	(0, 37)	Diarrhoea	oxaliplatinum	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	640	 [s1]Diarrhoea[e1]  T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with [s2]oxaliplatinum[e2] and 5-fluorouracil for unresectable rectum carcinoma.
	(5, 44)	T-CD4+ lymphopenia	5-fluorouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	641	Diarrhoea, [s1]T-CD4+ lymphopenia[e1] and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and [s2]5-fluorouracil[e2] for unresectable rectum carcinoma.
	(5, 38)	T-CD4+ lymphopenia	oxaliplatinum	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	642	Diarrhoea, [s1]T-CD4+ lymphopenia[e1] and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with [s2]oxaliplatinum[e2] and 5-fluorouracil for unresectable rectum carcinoma.
	(17, 34)	pulmonary adverse reaction	5-fluorouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	643	It is concluded that the aforementioned pathological manifestations were due to chemotherapy and included a [s1]pulmonary adverse reaction[e1]  a feature never previously associated with oxaliplatinum and [s2]5-fluorouracil[e2] regimens.
	(17, 28)	pulmonary adverse reaction	oxaliplatinum	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	644	It is concluded that the aforementioned pathological manifestations were due to chemotherapy and included a [s1]pulmonary adverse reaction[e1]  a feature never previously associated with [s2]oxaliplatinum[e2] and 5-fluorouracil regimens.
	(2, 8)	Accutane	teratogenic	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	645	BACKGROUND: [s1]Accutane[e1] a [s2]teratogenic[e2] prescription drug licensed to treat severe, recalcitrant nodular acne.
	(6, 34)	Accutane	teratogenic	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	646	RESULTS: The estimated number of [s1]Accutane[e1] prescriptions for reproductive-aged women has more than doubled in the past 10 years; it is the most widely used [s2]teratogenic[e2] drug in the United States, with approximately 2.5 per 1,000 reproductive-aged women exposed to Accutane in 1999.
	(9, 30)	pranlukast	high fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	647	A 62-year-old woman treated with [s1]pranlukast[e1] for 2 months developed interstitial pneumonitis with a [s2]high fever[e2] 
	(9, 20)	pranlukast	interstitial pneumonitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	648	A 62-year-old woman treated with [s1]pranlukast[e1] for 2 months developed [s2]interstitial pneumonitis[e2] with a high fever.
	(1, 9)	interstitial pneumonia	ONO-1078	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	649	Acute [s1]interstitial pneumonia[e1] induced by [s2]ONO-1078[e2] (pranlukast), a leukotriene receptor antagonist.
	(1, 13)	interstitial pneumonia	pranlukast	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	650	Acute [s1]interstitial pneumonia[e1] induced by ONO-1078  [s2]pranlukast[e2] , a leukotriene receptor antagonist.
	(14, 23)	renal colicky pain	indinavir	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	651	An asymptomatic HIV-infected woman experienced right-sided [s1]renal colicky pain[e1] during treatment with [s2]indinavir[e2] 
	(0, 14)	Indinavir	interstitial nephritis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	652	 [s1]Indinavir[e1] associated nephrolithiasis and chronic [s2]interstitial nephritis[e2] were the only possible causes identified in this patient.
	(0, 6)	Indinavir	nephrolithiasis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	653	 [s1]Indinavir[e1] associated [s2]nephrolithiasis[e2] and chronic interstitial nephritis were the only possible causes identified in this patient.
	(0, 15)	Papillary necrosis	indinavir	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	654	 [s1]Papillary necrosis[e1] associated with the HIV protease inhibitor [s2]indinavir[e2] 
	(5, 10)	indinavir	nephrolithiasis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	655	Physicians should be aware that [s1]indinavir[e1]  [s2]nephrolithiasis[e2] may cause papillary necrosis.
	(5, 18)	indinavir	papillary necrosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	656	Physicians should be aware that [s1]indinavir[e1] nephrolithiasis may cause [s2]papillary necrosis[e2] 
	(6, 20)	indinavir	interstitial nephritis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	657	The HIV protease inhibitor [s1]indinavir[e1] may cause nephrolithiasis and [s2]interstitial nephritis[e2] 
	(6, 13)	indinavir	nephrolithiasis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	658	The HIV protease inhibitor [s1]indinavir[e1] may cause [s2]nephrolithiasis[e2] and interstitial nephritis.
	(4, 10)	indinavir	nephrotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	659	The renal consequences of [s1]indinavir[e1] associated [s2]nephrotoxicity[e2] are uncertain.
	(5, 17)	papillary necrosis	indinavir	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	660	We report a case of [s1]papillary necrosis[e1] in a patient treated with [s2]indinavir[e2] 
	(37, 69)	decline in glomerular filtration rate	rofecoxib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	661	We describe 2 male patients, a 49-year-old with psoriatic arthritis and impaired renal function and a 43-year-old renal transplant recipient, who both sustained a marked [s1]decline in glomerular filtration rate[e1] in conjunction with a selective inhibitor of cyclooxygenase-2 (COX-2), [s2]rofecoxib[e2] 
	(2, 16)	LTG	encephalopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	662	CONCLUSIONS: [s1]LTG[e1] overdose may result in a severe but reversible [s2]encephalopathy[e2]  a previously undescribed phenomenon.
	(2, 9)	elevated serum LTG levels	LTG	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	663	Evaluation revealed [s1]elevated serum LTG levels[e1]  [s2]LTG[e2] levels and no other etiology for encephalopathy.
	(10, 18)	stuporous	lamotrigine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	664	METHODS: A 55-year-old woman became [s1]stuporous[e1] after overdose with [s2]lamotrigine[e2] (LTG) and valproic acid (VPA) tablets.
	(10, 23)	stuporous	LTG	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	665	METHODS: A 55-year-old woman became [s1]stuporous[e1] after overdose with lamotrigine  [s2]LTG[e2]  and valproic acid (VPA) tablets.
	(10, 28)	stuporous	valproic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	666	METHODS: A 55-year-old woman became [s1]stuporous[e1] after overdose with lamotrigine (LTG) and [s2]valproic acid[e2] (VPA) tablets.
	(10, 32)	stuporous	VPA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	667	METHODS: A 55-year-old woman became [s1]stuporous[e1] after overdose with lamotrigine (LTG) and valproic acid  [s2]VPA[e2]  tablets.
	(6, 18)	lamotrigine	encephalopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	668	PURPOSE: To report that acute [s1]lamotrigine[e1] poisoning may result in severe [s2]encephalopathy[e2] 
	(0, 5)	Stupor	lamotrigine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	669	 [s1]Stupor[e1] from [s2]lamotrigine[e2] toxicity.
	(8, 15)	acute intoxication	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	670	The cause of death was determined to be [s1]acute intoxication[e1] by [s2]olanzapine[e2]  and the manner of death was accidental.
	(14, 23)	dead	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	671	This article describes the case of a 25-year-old man found [s1]dead[e1] at home who had been prescribed [s2]olanzapine[e2] for schizophrenia.
	(0, 8)	Lichenoid drug eruption	salsalate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	672	 [s1]Lichenoid drug eruption[e1] to [s2]salsalate[e2] 
	(1, 11)	eruption	salsalate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	673	This [s1]eruption[e1] emerged after 1 month of therapy with [s2]salsalate[e2]  persisted for as long as salsalate was administered, and cleared within 3 weeks of discontinuing the medication.
	(7, 17)	lichenoid eruption	salsalate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	674	We describe a patient who experienced a [s1]lichenoid eruption[e1] after the initiation of [s2]salsalate[e2] for relief of arthritic pain.
	(0, 8)	Amphotericin B	seizures	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	675	 [s1]Amphotericin B[e1] induced [s2]seizures[e2] in a patient with AIDS.
	(16, 28)	grand mal seizures	amphotericin B	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	676	CASE SUMMARY: A 46-year-old African-American man experienced recurrent [s1]grand mal seizures[e1] during intravenous infusion of [s2]amphotericin B[e2]  then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.
	(2, 17)	Amphotericin B	seizures	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	677	CONCLUSIONS: [s1]Amphotericin B[e1] seems to be the probable cause of the [s2]seizures[e2] 
	(14, 22)	seizures	amphotercin B	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	678	Despite administration of phenytoin and lorazepam, the [s1]seizures[e1] persisted and occurred only during [s2]amphotercin B[e2] administration.
	(0, 12)	Didanosine	seizures	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	679	 [s1]Didanosine[e1] also has a potential for inducing [s2]seizures[e2] 
	(10, 19)	seizure	amphotericin B	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	680	OBJECTIVE: To report a case of multiple episodes of [s1]seizure[e1] activity in an AIDS patent following [s2]amphotericin B[e2] infusion.
	(7, 19)	amphotericin B	seizures	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	681	The time course of events suggested that [s1]amphotericin B[e1] was the cause of the [s2]seizures[e2] in this AIDS patient.
	(7, 12)	seizures	amphotericin B	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	682	To date, only three cases of [s1]seizures[e1] associated with [s2]amphotericin B[e2] have been reported in the literature, but healthcare providers should be aware of the potential for this rare adverse effect.
	(0, 17)	Vocal cord paralysis	bupivacaine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	683	 [s1]Vocal cord paralysis[e1] as a consequence of peritonsillar infiltration with [s2]bupivacaine[e2] 
	(14, 29)	bilateral vocal cord paralysis	bupivacaine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	684	We present the case of a 5-year-old girl who developed [s1]bilateral vocal cord paralysis[e1] following preoperative peritonsillar [s2]bupivacaine[e2] infiltration.
	(20, 37)	right bundle branch block	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	685	A 53 year old Greenlandic male was admitted twice over a period of 4 years with a new complete [s1]right bundle branch block[e1] after ingestion of 10 g and 4 g of [s2]carbamazepine[e2] respectively.
	(0, 8)	Carbamazepine	right bundle branch block	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	686	 [s1]Carbamazepine[e1] induced [s2]right bundle branch block[e2] in a Greenlandic patient.
	(0, 13)	Cicatricial entropion	dipivefrin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	687	 [s1]Cicatricial entropion[e1] associated with chronic [s2]dipivefrin[e2] application.
	(38, 51)	dipivefrin	entropion	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	688	CONCLUSIONS: Cicatrization in the substantia propria of the conjunctiva by excessive lymphocytic infiltration after topically administered antiglaucoma drugs including [s1]dipivefrin[e1] is a possible mechanism of action for [s2]entropion[e2] 
	(24, 47)	cicatricial entropion	dipivefrin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	689	Nine eyes from 6 patients, 74 years to 90 years of age, referred by ophthalmologists for repair of [s1]cicatricial entropion[e1] after at least 2 years of twice-a-day application of [s2]dipivefrin[e2] 
	(19, 33)	cicatrical entropion	dipivefrin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	690	PURPOSE: To report patients who presented to the oculoplastics department for repair of [s1]cicatrical entropion[e1] after topical use of [s2]dipivefrin[e2] 
	(9, 37)	constellation of dermatitis	sulphasalazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	691	A 34-year-old lady developed a [s1]constellation of dermatitis[e1]  fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral [s2]sulphasalazine[e2] for sero-negative rheumatoid arthritis.
	(15, 37)	fever	sulphasalazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	692	A 34-year-old lady developed a constellation of dermatitis, [s1]fever[e1]  lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral [s2]sulphasalazine[e2] for sero-negative rheumatoid arthritis.
	(24, 37)	hepatitis	sulphasalazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	693	A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and [s1]hepatitis[e1]  beginning on the 17th day of a course of oral [s2]sulphasalazine[e2] for sero-negative rheumatoid arthritis.
	(17, 38)	lymphadenopathy	sulphasalazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	694	A 34-year-old lady developed a constellation of dermatitis, fever, [s1]lymphadenopathy[e1] and hepatitis, beginning on the 17th day of a course of oral [s2]sulphasalazine[e2] for sero-negative rheumatoid arthritis.
	(29, 44)	sulphasalazine	fatal	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	695	"It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called ""3-week [s1]sulphasalazine[e1] syndrome"", a rare, but often [s2]fatal[e2]  immunoallergic reaction to sulphasalazine."
	(29, 44)	sulphasalazine	fatal	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	696	"It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called ""3-week [s1]sulphasalazine[e1] syndrome"", a rare, but often [s2]fatal[e2]  immunoallergic reaction to sulphasalazine."
	(29, 46)	sulphasalazine	immunoallergic reaction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	697	"It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called ""3-week [s1]sulphasalazine[e1] syndrome"", a rare, but often fatal, [s2]immunoallergic reaction[e2] to sulphasalazine."
	(29, 46)	sulphasalazine	immunoallergic reaction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	698	"It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called ""3-week [s1]sulphasalazine[e1] syndrome"", a rare, but often fatal, [s2]immunoallergic reaction[e2] to sulphasalazine."
	(29, 37)	sulphasalazine syndrome	sulphasalazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	699	"It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called ""3-week [s1]sulphasalazine syndrome[e1]  [s2]sulphasalazine[e2] syndrome"", a rare, but often fatal, immunoallergic reaction to sulphasalazine."
	(29, 37)	sulphasalazine syndrome	sulphasalazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	700	"It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called ""3-week [s1]sulphasalazine syndrome[e1]  [s2]sulphasalazine[e2] syndrome"", a rare, but often fatal, immunoallergic reaction to sulphasalazine."
	(4, 12)	sulphasalazine syndrome	sulphasalazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	701	The 3-week [s1]sulphasalazine syndrome[e1]  [s2]sulphasalazine[e2] syndrome strikes again.
	(29, 44)	SIADH	CDDP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	702	Interestingly, the use of carboplatin (CBDCA) and VDS in the subsequent treatment course was well tolerated indicating that the [s1]SIADH[e1] was most likely to have been induced by administration of [s2]CDDP[e2] 
	(8, 14)	SIADH	cisplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	703	Syndrome of inappropriate secretion of ADH  [s1]SIADH[e1]  following [s2]cisplatin[e2] administration in a pulmonary adenocarcinoma patient with a malignant pleural effusion.
	(0, 16)	Syndrome of inappropriate secretion of ADH	cisplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	704	 [s1]Syndrome of inappropriate secretion of ADH[e1] (SIADH) following [s2]cisplatin[e2] administration in a pulmonary adenocarcinoma patient with a malignant pleural effusion.
	(25, 37)	SIADH	CDDP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	705	We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone  [s1]SIADH[e1]  following systemic chemotherapy with cisplatin  [s2]CDDP[e2]  and vindesine (VDS).
	(25, 34)	SIADH	cisplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	706	We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone  [s1]SIADH[e1]  following systemic chemotherapy with [s2]cisplatin[e2] (CDDP) and vindesine (VDS).
	(25, 45)	SIADH	VDS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	707	We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone  [s1]SIADH[e1]  following systemic chemotherapy with cisplatin (CDDP) and vindesine  [s2]VDS[e2] .
	(25, 42)	SIADH	vindesine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	708	We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone  [s1]SIADH[e1]  following systemic chemotherapy with cisplatin (CDDP) and [s2]vindesine[e2] (VDS).
	(14, 39)	syndrome of inappropriate secretion of antidiuretic hormone	CDDP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	709	We report a patient with pulmonary adenocarcinoma complicated by the [s1]syndrome of inappropriate secretion of antidiuretic hormone[e1] (SIADH) following systemic chemotherapy with cisplatin  [s2]CDDP[e2]  and vindesine (VDS).
	(14, 36)	syndrome of inappropriate secretion of antidiuretic hormone	cisplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	710	We report a patient with pulmonary adenocarcinoma complicated by the [s1]syndrome of inappropriate secretion of antidiuretic hormone[e1] (SIADH) following systemic chemotherapy with [s2]cisplatin[e2] (CDDP) and vindesine (VDS).
	(14, 47)	syndrome of inappropriate secretion of antidiuretic hormone	VDS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	711	We report a patient with pulmonary adenocarcinoma complicated by the [s1]syndrome of inappropriate secretion of antidiuretic hormone[e1] (SIADH) following systemic chemotherapy with cisplatin (CDDP) and vindesine  [s2]VDS[e2] .
	(14, 44)	syndrome of inappropriate secretion of antidiuretic hormone	vindesine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	712	We report a patient with pulmonary adenocarcinoma complicated by the [s1]syndrome of inappropriate secretion of antidiuretic hormone[e1] (SIADH) following systemic chemotherapy with cisplatin (CDDP) and [s2]vindesine[e2] (VDS).
	(12, 25)	anisocoria	scopolamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	713	After extensive neurological 'work up', we realized that the [s1]anisocoria[e1] was related to the transdermal [s2]scopolamine[e2] patch that we had prescribed for weaning off the opioid.
	(0, 10)	Anisocoria	scopolamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	714	 [s1]Anisocoria[e1] from transdermal [s2]scopolamine[e2] 
	(0, 12)	De novo absence status	lorazepam	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	715	 [s1]De novo absence status[e1] of late onset following withdrawal of [s2]lorazepam[e2]  a case report.
	(30, 47)	nonconvulsive generalized status epilepticus	lorazepam	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	716	The aim of this report is to describe the clinical and electroencephalographic findings seen in an elderly woman without previous history of seizures who developed a [s1]nonconvulsive generalized status epilepticus[e1] following acute withdrawal of [s2]lorazepam[e2] 
	(14, 28)	life-threatening vincristine neurotoxicity	vincristine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	717	Early recognition of hereditary motor and sensory neuropathy type 1 can avoid [s1]life-threatening vincristine neurotoxicity[e1]  [s2]vincristine[e2] neurotoxicity.
	(23, 40)	severe neurotoxicity	vincristine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	718	Recognizing early signs of HMSN, such as areflexia and pes cavus deformity, can prevent [s1]severe neurotoxicity[e1] of polychemotherapy by avoiding [s2]vincristine[e2] 
	(8, 19)	vincristine neurotoxicity	vincristine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	719	The disease predisposes to severe [s1]vincristine neurotoxicity[e1]  [s2]vincristine[e2] neurotoxicity.
	(34, 53)	severe motor neuropathy	vincristine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	720	We report a 31-year-old women with recurrent Hodgkin's lymphoma and unrecognized HMSN-1 who developed [s1]severe motor neuropathy[e1] 3 weeks after the first cycle of treatment including 2 mg of [s2]vincristine[e2] 
	(1, 20)	asymptomatic hepatitis	amodiaquine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	721	Acute [s1]asymptomatic hepatitis[e1] in a healthy normal volunteer exposed to 2 oral doses of [s2]amodiaquine[e2] and artesunate.
	(1, 26)	asymptomatic hepatitis	artesunate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	722	Acute [s1]asymptomatic hepatitis[e1] in a healthy normal volunteer exposed to 2 oral doses of amodiaquine and [s2]artesunate[e2] 
	(8, 22)	hepatitis	amodiaquine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	723	This report describes an unexpected drug-induced [s1]hepatitis[e1] in a previously healthy young woman exposed to 2 doses of [s2]amodiaquine[e2] and artesunate.
	(8, 28)	hepatitis	artesunate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	724	This report describes an unexpected drug-induced [s1]hepatitis[e1] in a previously healthy young woman exposed to 2 doses of amodiaquine and [s2]artesunate[e2] 
	(0, 9)	Systemic allergic contact dermatitis	8-methoxypsoralen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	725	 [s1]Systemic allergic contact dermatitis[e1] to [s2]8-methoxypsoralen[e2] (8-MOP).
	(0, 17)	Systemic allergic contact dermatitis	8-MOP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	726	 [s1]Systemic allergic contact dermatitis[e1] to 8-methoxypsoralen  [s2]8-MOP[e2] .
	(7, 16)	systemic allergic contact dermatitis	8-MOP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	727	We describe a patient who had a [s1]systemic allergic contact dermatitis[e1] to [s2]8-MOP[e2] develop during her second course of PUVA treatment for psoriasis.
	(12, 26)	benztropine	abdominal pain	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	728	A 33-year-old man with a history of recreational [s1]benztropine[e1] abuse presented to the emergency department with confusion, [s2]abdominal pain[e2]  and distention.
	(12, 24)	benztropine	confusion	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	729	A 33-year-old man with a history of recreational [s1]benztropine[e1] abuse presented to the emergency department with [s2]confusion[e2]  abdominal pain, and distention.
	(12, 30)	benztropine	distention	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	730	A 33-year-old man with a history of recreational [s1]benztropine[e1] abuse presented to the emergency department with confusion, abdominal pain, and [s2]distention[e2] 
	(0, 15)	Agranulocytosis	quetiapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	731	 [s1]Agranulocytosis[e1] and granulocytopenia associated with [s2]quetiapine[e2] 
	(6, 15)	granulocytopenia	quetiapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	732	Agranulocytosis and [s1]granulocytopenia[e1] associated with [s2]quetiapine[e2] 
	(20, 29)	agranulocytosis	quetiapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	733	CONCLUSION: Although a definite association has not been proven, clinicians should be aware of the possibility of [s1]agranulocytosis[e1] while using [s2]quetiapine[e2] 
	(9, 18)	haematological adverse effects	quetiapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	734	METHOD: We describe three case-reports concerning [s1]haematological adverse effects[e1] of [s2]quetiapine[e2] 
	(2, 21)	Quetiapine	agranulocytosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	735	RESULTS: [s1]Quetiapine[e1] was associated with leucopenia in two patients and clinically apparent [s2]agranulocytosis[e2] in one patient.
	(2, 10)	Quetiapine	leucopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	736	RESULTS: [s1]Quetiapine[e1] was associated with [s2]leucopenia[e2] in two patients and clinically apparent agranulocytosis in one patient.
	(9, 16)	ofloxacin	toxic epidermal necrolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	737	CONCLUSIONS: There is very little published information regarding [s1]ofloxacin[e1] induced [s2]toxic epidermal necrolysis[e2] 
	(13, 29)	Stevens-Johnson syndrome	ofloxacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	738	However, a large case-control study included three cases of either [s1]Stevens-Johnson syndrome[e1] or toxic epidermal necrolysis associated with [s2]ofloxacin[e2] use, but no details of the cases were given.
	(18, 29)	toxic epidermal necrolysis	ofloxacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	739	However, a large case-control study included three cases of either Stevens-Johnson syndrome or [s1]toxic epidermal necrolysis[e1] associated with [s2]ofloxacin[e2] use, but no details of the cases were given.
	(10, 17)	ofloxacin	toxic epidermal necrolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	740	It is hoped that this case report creates awareness that [s1]ofloxacin[e1] induced [s2]toxic epidermal necrolysis[e2] is possible.
	(8, 25)	toxic epidermal necrolysis	ofloxacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	741	OBJECTIVE: To report a fatal case of [s1]toxic epidermal necrolysis[e1] in a man who was treated with oral [s2]ofloxacin[e2] for epididymitis.
	(0, 10)	Ofloxacin	toxic epidermal necrolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	742	 [s1]Ofloxacin[e1]  a probable cause of [s2]toxic epidermal necrolysis[e2] 
	(7, 20)	toxic epidermal necrolysis	ofloxacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	743	This report rules out other causes of [s1]toxic epidermal necrolysis[e1] and implicates [s2]ofloxacin[e2] in what appears to be an atypical presentation of drug-induced toxic epidermal necrolysis.
	(7, 20)	toxic epidermal necrolysis	ofloxacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	744	This report rules out other causes of [s1]toxic epidermal necrolysis[e1] and implicates [s2]ofloxacin[e2] in what appears to be an atypical presentation of drug-induced toxic epidermal necrolysis.
	(15, 27)	multiple erythematous nodules	G-CSF	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	745	A boy with chronic neutropenia and recurrent inflammatory skin lesions developed [s1]multiple erythematous nodules[e1] following administration of [s2]G-CSF[e2] 
	(16, 40)	erythematous papular eruption	G-CSF	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	746	A girl with cystic fibrosis and cyclic neutropenia developed an [s1]erythematous papular eruption[e1] without fever or neutrophilia 7 months after commencing therapy with [s2]G-CSF[e2] 
	(0, 32)	Neutrophilic dermatoses	G-CSF	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	747	 [s1]Neutrophilic dermatoses[e1] in two children with idiopathic neutropenia: association with granulocyte colony-stimulating factor  [s2]G-CSF[e2]  therapy.
	(0, 24)	Neutrophilic dermatoses	granulocyte colony-stimulating factor	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	748	 [s1]Neutrophilic dermatoses[e1] in two children with idiopathic neutropenia: association with [s2]granulocyte colony-stimulating factor[e2] (G-CSF) therapy.
	(1, 24)	neutrophilic skin lesions	G-CSF	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	749	Painful [s1]neutrophilic skin lesions[e1] were observed in two children receiving granulocyte colony-stimulating factor  [s2]G-CSF[e2]  for treatment of idiopathic neutropenia.
	(1, 16)	neutrophilic skin lesions	granulocyte colony-stimulating factor	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	750	Painful [s1]neutrophilic skin lesions[e1] were observed in two children receiving [s2]granulocyte colony-stimulating factor[e2] (G-CSF) for treatment of idiopathic neutropenia.
	(0, 24)	Painful	G-CSF	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	751	 [s1]Painful[e1] neutrophilic skin lesions were observed in two children receiving granulocyte colony-stimulating factor  [s2]G-CSF[e2]  for treatment of idiopathic neutropenia.
	(0, 16)	Painful	granulocyte colony-stimulating factor	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	752	 [s1]Painful[e1] neutrophilic skin lesions were observed in two children receiving [s2]granulocyte colony-stimulating factor[e2] (G-CSF) for treatment of idiopathic neutropenia.
	(11, 28)	neutrophilic dermatoses	G-CSF	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	753	We believe that these skin eruptions belong to a spectrum of [s1]neutrophilic dermatoses[e1] that can be induced or aggravated by [s2]G-CSF[e2] therapy.
	(4, 28)	skin eruptions	G-CSF	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	754	We believe that these [s1]skin eruptions[e1] belong to a spectrum of neutrophilic dermatoses that can be induced or aggravated by [s2]G-CSF[e2] therapy.
	(7, 23)	liothyronine	hyperthyroidism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	755	There is a putative role of [s1]liothyronine[e1] administration in precipitating or activating [s2]hyperthyroidism[e2] 
	(0, 9)	Triiodothyronine	thyrotoxicosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	756	 [s1]Triiodothyronine[e1] induced [s2]thyrotoxicosis[e2] in ophthalmic Graves disease.
	(15, 30)	VFDs	tiagabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	757	This case report describes the development of asymptomatic visual field defects  [s1]VFDs[e1]  in a psychiatric patient with bipolar disorder receiving adjunctive [s2]tiagabine[e2] treatment.
	(12, 32)	visual field defects	tiagabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	758	This case report describes the development of asymptomatic [s1]visual field defects[e1] (VFDs) in a psychiatric patient with bipolar disorder receiving adjunctive [s2]tiagabine[e2] treatment.
	(0, 5)	Pulmonary toxicity	mefloquine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	759	 [s1]Pulmonary toxicity[e1] with [s2]mefloquine[e2] 
	(6, 19)	acute lung injury	mefloquine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	760	This is the second report of [s1]acute lung injury[e1] and diffuse alveolar damage caused by [s2]mefloquine[e2] 
	(10, 19)	diffuse alveolar damage	mefloquine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	761	This is the second report of acute lung injury and [s1]diffuse alveolar damage[e1] caused by [s2]mefloquine[e2] 
	(6, 17)	acute lung injury	mefloquine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	762	This report presents a case of [s1]acute lung injury[e1] developing within hours after administration of [s2]mefloquine[e2] for a low-level Plasmodium falciparum malaria, which was persistent despite halofantrine therapy.
	(5, 13)	central blindness	methanol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	763	An adult male presented with [s1]central blindness[e1] after ingesting [s2]methanol[e2] 
	(3, 9)	methanol	visual impairment	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	764	Reversal of severe [s1]methanol[e1] induced [s2]visual impairment[e2]  no evidence of retinal toxicity due to fomepizole.
	(7, 25)	octreotide	intrahepatic bile stasis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	765	Extra caution should be taken in using [s1]octreotide[e1] or its long-acting analog in patients otherwise predisposed to [s2]intrahepatic bile stasis[e2] 
	(3, 13)	bile sludge	octreotide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	766	Gallstones and [s1]bile sludge[e1] are common side effects of [s2]octreotide[e2] therapy but rarely become symptomatic or require treatment.
	(0, 13)	Gallstones	octreotide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	767	 [s1]Gallstones[e1] and bile sludge are common side effects of [s2]octreotide[e2] therapy but rarely become symptomatic or require treatment.
	(0, 16)	Hepatolithiasis	octreotide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	768	 [s1]Hepatolithiasis[e1] (intrahepatic stone) during [s2]octreotide[e2] therapy for acromegaly: a case report.
	(14, 19)	octreotide	alters bile acid composition	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	769	In addition to its known effect on gallbladder stasis, [s1]octreotide[e1]  [s2]alters bile acid composition[e2] and may thus hasten intrahepatic sludge and stone formation.
	(7, 15)	gallbladder stasis	octreotide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	770	In addition to its known effect on [s1]gallbladder stasis[e1]  [s2]octreotide[e2] alters bile acid composition and may thus hasten intrahepatic sludge and stone formation.
	(14, 27)	octreotide	hasten intrahepatic sludge	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	771	In addition to its known effect on gallbladder stasis, [s1]octreotide[e1] alters bile acid composition and may thus [s2]hasten intrahepatic sludge[e2] and stone formation.
	(14, 36)	octreotide	stone formation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	772	In addition to its known effect on gallbladder stasis, [s1]octreotide[e1] alters bile acid composition and may thus hasten intrahepatic sludge and [s2]stone formation[e2] 
	(7, 16)	hepatolithiasis	octreotide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	773	This is the first reported case of [s1]hepatolithiasis[e1] during [s2]octreotide[e2] therapy.
	(5, 41)	hepatolithiasis	octreotide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	774	We report a case of [s1]hepatolithiasis[e1] (intrahepatic stone) complicated by gram-negative sepsis in a 37 year old male with acromegaly being treated with [s2]octreotide[e2] 
	(25, 41)	tamoxifen	endometrial carcinoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	775	However, in the mid-to-late 1980s, a series of letters to the editor and case reports announced an association between [s1]tamoxifen[e1] therapy in women with breast cancer and the development of [s2]endometrial carcinoma[e2] 
	(10, 21)	endometrial carcinoma	tamoxifen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	776	In this healthy population, the relative risk of developing [s1]endometrial carcinoma[e1] in the [s2]tamoxifen[e2] arm was 2.54, although when stratified by age, in women over 50, the risk grew to 4.01.
	(0, 10)	INH	drug eruptions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	777	 [s1]INH[e1]  which is a leading cause of [s2]drug eruptions[e2] in the above group of drugs was withdrawn.
	(0, 12)	Isonicotinic acid hydrazide	anagen effluvium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	778	 [s1]Isonicotinic acid hydrazide[e1] induced [s2]anagen effluvium[e2] and associated lichenoid eruption.
	(0, 21)	Isonicotinic acid hydrazide	lichenoid eruption	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	779	 [s1]Isonicotinic acid hydrazide[e1] induced anagen effluvium and associated [s2]lichenoid eruption[e2] 
	(1, 16)	anagen effluvium	INH	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	780	Such [s1]anagen effluvium[e1] with lichenoid eruption following [s2]INH[e2] therapy has not been observed previously.
	(9, 16)	lichenoid eruption	INH	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	781	Such anagen effluvium with [s1]lichenoid eruption[e1] following [s2]INH[e2] therapy has not been observed previously.
	(0, 12)	Linear IgA bullous dermatosis	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	782	 [s1]Linear IgA bullous dermatosis[e1] occurring after [s2]carbamazepine[e2] 
	(6, 13)	LABD	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	783	We report a patient who experienced [s1]LABD[e1] shortly after starting [s2]carbamazepine[e2] therapy.
	(5, 24)	metoclopramide	agitation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	784	After a second dose of [s1]metoclopramide[e1]  these symptoms recurred and were associated with confusion, [s2]agitation[e2]  fever, diaphoresis, tachypnea, tachycardia, and hypertension.
	(5, 22)	metoclopramide	confusion	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	785	After a second dose of [s1]metoclopramide[e1]  these symptoms recurred and were associated with [s2]confusion[e2]  agitation, fever, diaphoresis, tachypnea, tachycardia, and hypertension.
	(5, 28)	metoclopramide	diaphoresis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	786	After a second dose of [s1]metoclopramide[e1]  these symptoms recurred and were associated with confusion, agitation, fever, [s2]diaphoresis[e2]  tachypnea, tachycardia, and hypertension.
	(5, 26)	metoclopramide	fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	787	After a second dose of [s1]metoclopramide[e1]  these symptoms recurred and were associated with confusion, agitation, [s2]fever[e2]  diaphoresis, tachypnea, tachycardia, and hypertension.
	(5, 44)	metoclopramide	hypertension	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	788	After a second dose of [s1]metoclopramide[e1]  these symptoms recurred and were associated with confusion, agitation, fever, diaphoresis, tachypnea, tachycardia, and [s2]hypertension[e2] 
	(5, 38)	metoclopramide	tachycardia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	789	After a second dose of [s1]metoclopramide[e1]  these symptoms recurred and were associated with confusion, agitation, fever, diaphoresis, tachypnea, [s2]tachycardia[e2]  and hypertension.
	(5, 33)	metoclopramide	tachypnea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	790	After a second dose of [s1]metoclopramide[e1]  these symptoms recurred and were associated with confusion, agitation, fever, diaphoresis, [s2]tachypnea[e2]  tachycardia, and hypertension.
	(17, 37)	extrapyramidal reactions	metoclopramide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	791	CONCLUSIONS: Clinicians should be aware of a risk of serotonin syndrome with serious [s1]extrapyramidal reactions[e1] in patients receiving sertraline or venlafaxine when [s2]metoclopramide[e2] is coadministered even in a single, conventional dose.
	(17, 27)	extrapyramidal reactions	sertraline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	792	CONCLUSIONS: Clinicians should be aware of a risk of serotonin syndrome with serious [s1]extrapyramidal reactions[e1] in patients receiving [s2]sertraline[e2] or venlafaxine when metoclopramide is coadministered even in a single, conventional dose.
	(17, 31)	extrapyramidal reactions	venlafaxine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	793	CONCLUSIONS: Clinicians should be aware of a risk of serotonin syndrome with serious [s1]extrapyramidal reactions[e1] in patients receiving sertraline or [s2]venlafaxine[e2] when metoclopramide is coadministered even in a single, conventional dose.
	(11, 37)	serotonin syndrome	metoclopramide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	794	CONCLUSIONS: Clinicians should be aware of a risk of [s1]serotonin syndrome[e1] with serious extrapyramidal reactions in patients receiving sertraline or venlafaxine when [s2]metoclopramide[e2] is coadministered even in a single, conventional dose.
	(11, 27)	serotonin syndrome	sertraline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	795	CONCLUSIONS: Clinicians should be aware of a risk of [s1]serotonin syndrome[e1] with serious extrapyramidal reactions in patients receiving [s2]sertraline[e2] or venlafaxine when metoclopramide is coadministered even in a single, conventional dose.
	(11, 31)	serotonin syndrome	venlafaxine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	796	CONCLUSIONS: Clinicians should be aware of a risk of [s1]serotonin syndrome[e1] with serious extrapyramidal reactions in patients receiving sertraline or [s2]venlafaxine[e2] when metoclopramide is coadministered even in a single, conventional dose.
	(13, 23)	extrapyramidal movement disorders	metoclopramide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	797	OBJECTIVE: To report 2 cases of serotonin syndrome with serious [s1]extrapyramidal movement disorders[e1] occurring when [s2]metoclopramide[e2] was coadministered with sertraline or venlafaxine.
	(13, 35)	extrapyramidal movement disorders	sertraline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	798	OBJECTIVE: To report 2 cases of serotonin syndrome with serious [s1]extrapyramidal movement disorders[e1] occurring when metoclopramide was coadministered with [s2]sertraline[e2] or venlafaxine.
	(13, 39)	extrapyramidal movement disorders	venlafaxine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	799	OBJECTIVE: To report 2 cases of serotonin syndrome with serious [s1]extrapyramidal movement disorders[e1] occurring when metoclopramide was coadministered with sertraline or [s2]venlafaxine[e2] 
	(7, 23)	serotonin syndrome	metoclopramide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	800	OBJECTIVE: To report 2 cases of [s1]serotonin syndrome[e1] with serious extrapyramidal movement disorders occurring when [s2]metoclopramide[e2] was coadministered with sertraline or venlafaxine.
	(7, 35)	serotonin syndrome	sertraline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	801	OBJECTIVE: To report 2 cases of [s1]serotonin syndrome[e1] with serious extrapyramidal movement disorders occurring when metoclopramide was coadministered with [s2]sertraline[e2] or venlafaxine.
	(7, 39)	serotonin syndrome	venlafaxine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	802	OBJECTIVE: To report 2 cases of [s1]serotonin syndrome[e1] with serious extrapyramidal movement disorders occurring when metoclopramide was coadministered with sertraline or [s2]venlafaxine[e2] 
	(0, 17)	Serotonin syndrome	metoclopramide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	803	 [s1]Serotonin syndrome[e1] caused by selective serotonin reuptake-inhibitors [s2]metoclopramide[e2] interaction.
	(3, 21)	metoclopramide	agitation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	804	She was administered [s1]metoclopramide[e1] because of nausea and, within 2 hours, developed [s2]agitation[e2]  dysarthria, diaphoresis, and a movement disorder.
	(3, 28)	metoclopramide	diaphoresis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	805	She was administered [s1]metoclopramide[e1] because of nausea and, within 2 hours, developed agitation, dysarthria, [s2]diaphoresis[e2]  and a movement disorder.
	(3, 23)	metoclopramide	dysarthria	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	806	She was administered [s1]metoclopramide[e1] because of nausea and, within 2 hours, developed agitation, [s2]dysarthria[e2]  diaphoresis, and a movement disorder.
	(3, 35)	metoclopramide	movement disorder	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	807	She was administered [s1]metoclopramide[e1] because of nausea and, within 2 hours, developed agitation, dysarthria, diaphoresis, and a [s2]movement disorder[e2] 
	(11, 20)	metoclopramide	movement disorder	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	808	She was admitted following a fall and, after being given [s1]metoclopramide[e1]  developed [s2]movement disorder[e2] and a period of unresponsiveness.
	(11, 26)	metoclopramide	unresponsiveness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	809	She was admitted following a fall and, after being given [s1]metoclopramide[e1]  developed movement disorder and a period of [s2]unresponsiveness[e2] 
	(10, 28)	malignant neuroleptic syndrome	haloperidol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	810	A patient suffering from a rare enzyme deficiency developed a [s1]malignant neuroleptic syndrome[e1] after having been treated with one single dose of [s2]haloperidol[e2] 
	(4, 12)	delated cutaneous reactions	captopril	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	811	BACKGROUND: reports on [s1]delated cutaneous reactions[e1] to [s2]captopril[e2] have been seldom reported.
	(0, 20)	Captopril	cutaneous side-effects	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	812	 [s1]Captopril[e1] is an angiotensin-converting enzyme (ACE) inhibitor and their [s2]cutaneous side-effects[e2] are documented, but little has been published concerning the usefulness of patch test when they occur.
	(0, 6)	Dermatitis	captopril	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	813	 [s1]Dermatitis[e1] to [s2]captopril[e2] 
	(10, 17)	cutaneous reaction	captopril	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	814	We presented the case of a patient who developed a [s1]cutaneous reaction[e1] induced by [s2]captopril[e2] with positive patch test.
	(17, 26)	warfarin	hematochezia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	815	A 62-year-old Caucasian man with atrial fibrillation who was taking [s1]warfarin[e1] reported an episode of [s2]hematochezia[e2]  his international normalized ratio (INR) was 1.74.
	(0, 6)	Warfarin	bleeding	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	816	 [s1]Warfarin[e1] associated [s2]bleeding[e2] complication saved life.
	(0, 6)	Warfarin	bleeding	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	817	 [s1]Warfarin[e1] associated [s2]bleeding[e2] generally is considered deleterious; however, in our patient it unmasked an early stage of colon cancer and thus may have saved the patient's life.
	(8, 18)	dilated cardiomyopathy	interferon alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	818	A case of polymyositis with [s1]dilated cardiomyopathy[e1] associated with [s2]interferon alpha[e2] treatment for hepatitis B.
	(3, 18)	polymyositis	interferon alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	819	A case of [s1]polymyositis[e1] with dilated cardiomyopathy associated with [s2]interferon alpha[e2] treatment for hepatitis B.
	(4, 16)	interferon alpha	cardiomyopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	820	In this case, [s1]interferon alpha[e1] induced polymyositis and [s2]cardiomyopathy[e2] is diagnosed in a 33-yr-old male patient with history of chronic hepatitis B.
	(4, 11)	interferon alpha	polymyositis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	821	In this case, [s1]interferon alpha[e1] induced [s2]polymyositis[e2] and cardiomyopathy is diagnosed in a 33-yr-old male patient with history of chronic hepatitis B.
	(0, 12)	Polymyositis	interferon alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	822	 [s1]Polymyositis[e1] is a rare complication of [s2]interferon alpha[e2] treatment as a result of immune-modulating role of the drug itself.
	(5, 18)	interferon alpha	muscle weakness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	823	To treat hepatitis B, [s1]interferon alpha[e1] was administered until the proximal [s2]muscle weakness[e2] developed.
	(7, 21)	neoplastic seeding	ethanol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	824	Long-term follow-up after [s1]neoplastic seeding[e1] complicating percutaneous [s2]ethanol[e2] injection for treatment of hepatocellular carcinoma.
	(5, 21)	subcutaneous metastasis	ethanol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	825	We describe a case of [s1]subcutaneous metastasis[e1] along the needle track after percutaneous [s2]ethanol[e2] injection (PEI) for treatment of hepatocellular carcinoma.
	(0, 17)	Aggressive endometrial carcinoma	tamoxifen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	826	 [s1]Aggressive endometrial carcinoma[e1] in a breast cancer patient treated with [s2]tamoxifen[e2] with normal transvaginal ultrasonography.
	(1, 10)	tamoxifen	endometrial disorders	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	827	Since [s1]tamoxifen[e1] therapy can induce [s2]endometrial disorders[e2]  surveillance schemes of women taking tamoxifen have been recommended.
	(1, 10)	tamoxifen	endometrial disorders	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	828	Since [s1]tamoxifen[e1] therapy can induce [s2]endometrial disorders[e2]  surveillance schemes of women taking tamoxifen have been recommended.
	(15, 24)	endometrial cancer	tamoxifen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	829	We described a very atypical case of a high stage, high grade [s1]endometrial cancer[e1] associated with [s2]tamoxifen[e2] in a 64-year-old woman with a past history of breast cancer.
	(11, 29)	itraconazole	cholangiopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	830	Beginning ductopenia was present in two, suggesting that [s1]itraconazole[e1] might be responsible for the occurrence of prolonged drug-induced [s2]cholangiopathy[e2] 
	(1, 13)	ductopenia	itraconazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	831	Beginning [s1]ductopenia[e1] was present in two, suggesting that [s2]itraconazole[e2] might be responsible for the occurrence of prolonged drug-induced cholangiopathy.
	(2, 15)	Itraconazole	cholestatic pattern of injury	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	832	CONCLUSIONS: [s1]Itraconazole[e1] induced liver injury presents with a [s2]cholestatic pattern of injury[e2] with damage to the interlobular bile ducts, possibly leading to ductopenia.
	(2, 23)	Itraconazole	damage to the interlobular bile ducts	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	833	CONCLUSIONS: [s1]Itraconazole[e1] induced liver injury presents with a cholestatic pattern of injury with [s2]damage to the interlobular bile ducts[e2]  possibly leading to ductopenia.
	(2, 36)	Itraconazole	ductopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	834	CONCLUSIONS: [s1]Itraconazole[e1] induced liver injury presents with a cholestatic pattern of injury with damage to the interlobular bile ducts, possibly leading to [s2]ductopenia[e2] 
	(2, 10)	Itraconazole	liver injury	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	835	CONCLUSIONS: [s1]Itraconazole[e1] induced [s2]liver injury[e2] presents with a cholestatic pattern of injury with damage to the interlobular bile ducts, possibly leading to ductopenia.
	(0, 10)	Hepatotoxicity	itraconazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	836	 [s1]Hepatotoxicity[e1] related to [s2]itraconazole[e2]  report of three cases.
	(6, 14)	itraconazole	liver injury	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	837	METHODS: Three patients with apparent [s1]itraconazole[e1] induced [s2]liver injury[e2] were studied.
	(4, 11)	hepatitis	ketoconazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	838	The occurrence of acute [s1]hepatitis[e1] is best known for [s2]ketoconazole[e2] 
	(8, 15)	liver damage	itraconazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	839	We report on three patients who developed acute [s1]liver damage[e1] during therapy with [s2]itraconazole[e2]  and in whom liver biopsy specimens were obtained.
	(3, 27)	itraconazole	vanishing bile duct syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	840	We suggest that [s1]itraconazole[e1] should be added to the list of drugs that may be responsible for a drug-induced [s2]vanishing bile duct syndrome[e2] 
	(1, 8)	itraconazole	hepatotoxic	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	841	With [s1]itraconazole[e1]  [s2]hepatotoxic[e2] reactions have only very rarely been reported, and histologic data are lacking.
	(0, 12)	Thrombotic stroke	porcine factor VIII	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	842	 [s1]Thrombotic stroke[e1] associated with the use of [s2]porcine factor VIII[e2] in a patient with acquired haemophilia.
	(16, 32)	thrombotic left middle cerebral artery distribution stroke	pFVIII	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	843	We have recently encountered a patient with acquired haemophilia who developed a [s1]thrombotic left middle cerebral artery distribution stroke[e1] while being treated with [s2]pFVIII[e2] 
	(9, 19)	pFVIII	thrombosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	844	We speculate that platelet activation induced by [s1]pFVIII[e1] may have contributed to [s2]thrombosis[e2] and suggest that pFVIII be used with caution in elderly patients with pre-existing cardiovascular risk factors.
	(0, 9)	Cutaneous sarcoidosis	interferon alfa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	845	 [s1]Cutaneous sarcoidosis[e1] during [s2]interferon alfa[e2] and ribavirin treatment of hepatitis C virus infection: two cases.
	(0, 14)	Cutaneous sarcoidosis	ribavirin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	846	 [s1]Cutaneous sarcoidosis[e1] during interferon alfa and [s2]ribavirin[e2] treatment of hepatitis C virus infection: two cases.
	(16, 23)	granulomatosis	interferon alfa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	847	There have been more than 20 observations of the appearance or aggravation of this [s1]granulomatosis[e1] with [s2]interferon alfa[e2] and more recently with the combination of interferon alfa plus ribavirin.
	(16, 23)	granulomatosis	interferon alfa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	848	There have been more than 20 observations of the appearance or aggravation of this [s1]granulomatosis[e1] with [s2]interferon alfa[e2] and more recently with the combination of interferon alfa plus ribavirin.
	(16, 39)	granulomatosis	ribavirin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	849	There have been more than 20 observations of the appearance or aggravation of this [s1]granulomatosis[e1] with interferon alfa and more recently with the combination of interferon alfa plus [s2]ribavirin[e2] 
	(6, 22)	sarcoidosis	interferon alfa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	850	We report two new cases of [s1]sarcoidosis[e1] in two patients with hepatitis C virus infection treated with [s2]interferon alfa[e2] and ribavirin.
	(6, 27)	sarcoidosis	ribavirin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	851	We report two new cases of [s1]sarcoidosis[e1] in two patients with hepatitis C virus infection treated with interferon alfa and [s2]ribavirin[e2] 
	(3, 24)	mirtazapine	SS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	852	CONCLUSIONS: Although [s1]mirtazapine[e1] offers clinicians a combination of strong efficacy and good safety, we suggest bearing [s2]SS[e2] in mind when prescribing this drug, especially in frail, elderly patients with underlying chronic conditions.
	(1, 16)	SS	mirtazapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	853	DISC [s1]SS[e1] ON: A review of the cases of SS with implication of [s2]mirtazapine[e2] as the cause was performed.
	(7, 18)	serotonin syndrome	mirtazapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	854	OBJECTIVE: To document a case of [s1]serotonin syndrome[e1] (SS) associated with [s2]mirtazapine[e2] monotherapy, review the previously reported cases of SS associated with this tetracyclic antidepressant, and discuss the possible pathogenic mechanisms leading to this serious adverse drug reaction.
	(11, 16)	SS	mirtazapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	855	OBJECTIVE: To document a case of serotonin syndrome  [s1]SS[e1]  associated with [s2]mirtazapine[e2] monotherapy, review the previously reported cases of SS associated with this tetracyclic antidepressant, and discuss the possible pathogenic mechanisms leading to this serious adverse drug reaction.
	(1, 9)	serotonin syndrome	mirtazapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	856	Severe [s1]serotonin syndrome[e1] induced by [s2]mirtazapine[e2] monotherapy.
	(0, 6)	Pulmonary toxicity	procarbazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	857	 [s1]Pulmonary toxicity[e1] secondary to [s2]procarbazine[e2] 
	(9, 17)	proteinuria	interferon (IFN)-beta	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	858	A 64-year-old man presented with [s1]proteinuria[e1] during postoperative [s2]interferon (IFN)-beta[e2] therapy against malignant melanoma.
	(0, 14)	Minimal change nephrotic syndrome	interferon-beta	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	859	 [s1]Minimal change nephrotic syndrome[e1] developing during postoperative [s2]interferon-beta[e2] therapy for malignant melanoma.
	(10, 27)	histological abnormalities of the glomerulus	IFN-beta	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	860	To our knowledge this is the first report that demonstrates [s1]histological abnormalities of the glomerulus[e1] associated with postoperative [s2]IFN-beta[e2] therapy for the malignant melanoma.
	(6, 19)	delayed elimination	ciprofloxacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	861	The authors report two cases of [s1]delayed elimination[e1] of methotrexate in patients receiving [s2]ciprofloxacin[e2]  with severe toxicity.
	(6, 11)	delayed elimination	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	862	The authors report two cases of [s1]delayed elimination[e1] of [s2]methotrexate[e2] in patients receiving ciprofloxacin, with severe toxicity.
	(17, 27)	ciprofloxacin	toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	863	The authors report two cases of delayed elimination of methotrexate in patients receiving [s1]ciprofloxacin[e1]  with severe [s2]toxicity[e2] 
	(12, 21)	thrombocytopenia	lansoprazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	864	CONCLUSIONS: Clinicians should be aware of the possible association of [s1]thrombocytopenia[e1] with [s2]lansoprazole[e2] and discontinue the drug if thrombocytopenia becomes apparent.
	(11, 22)	thrombocytopenia	lansoprazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	865	DISCUSSION: After exclusion of other causes, the onset of [s1]thrombocytopenia[e1] after administration of [s2]lansoprazole[e2]  the resolution of the adverse reaction after discontinuation of the drug, and the fact that no other medicines were introduced during this time frame lead us to believe that this was most likely an idiosyncratic thrombocytopenic response to lansoprazole.
	(20, 68)	lansoprazole	thrombocytopenic	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	866	DISCUSSION: After exclusion of other causes, the onset of thrombocytopenia after administration of [s1]lansoprazole[e1]  the resolution of the adverse reaction after discontinuation of the drug, and the fact that no other medicines were introduced during this time frame lead us to believe that this was most likely an idiosyncratic [s2]thrombocytopenic[e2] response to lansoprazole.
	(5, 23)	lansoprazole	platelet count decreased	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	867	He was started on oral [s1]lansoprazole[e1] 60 mg twice daily and, on hospital day 2, his [s2]platelet count decreased[e2] to 102 x 10(3)/mm(3); on hospital day 3, the platelet count was 36 x 10(3)/mm(3).
	(0, 7)	Lansoprazole	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	868	 [s1]Lansoprazole[e1] induced [s2]thrombocytopenia[e2] 
	(7, 20)	thrombocytopenia	lansoprazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	869	OBJECTIVE: To describe a case of [s1]thrombocytopenia[e1] associated with the administration of [s2]lansoprazole[e2] 
	(15, 25)	thrombocytopenia	lansoprazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	870	To date, this is the first reported case of what appears to be isolated [s1]thrombocytopenia[e1] associated with [s2]lansoprazole[e2] 
	(3, 12)	anaphylactoid reaction	amifostine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	871	Life-threatening [s1]anaphylactoid reaction[e1] to [s2]amifostine[e2] used with concurrent chemoradiotherapy for nasopharyngeal cancer in a patient with dermatomyositis: a case report with literature review.
	(7, 30)	amifostine	allergic reactions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	872	The most common side effects associated with [s1]amifostine[e1] are nausea, vomiting, hypotension, hypocalcemia and [s2]allergic reactions[e2] 
	(7, 24)	amifostine	hypocalcemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	873	The most common side effects associated with [s1]amifostine[e1] are nausea, vomiting, hypotension, [s2]hypocalcemia[e2] and allergic reactions.
	(7, 18)	amifostine	hypotension	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	874	The most common side effects associated with [s1]amifostine[e1] are nausea, vomiting, [s2]hypotension[e2]  hypocalcemia and allergic reactions.
	(7, 14)	amifostine	nausea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	875	The most common side effects associated with [s1]amifostine[e1] are [s2]nausea[e2]  vomiting, hypotension, hypocalcemia and allergic reactions.
	(7, 16)	amifostine	vomiting	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	876	The most common side effects associated with [s1]amifostine[e1] are nausea, [s2]vomiting[e2]  hypotension, hypocalcemia and allergic reactions.
	(4, 16)	life-threatening anaphylactoid reaction	amifostine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	877	The patient suffered a [s1]life-threatening anaphylactoid reaction[e1] to [s2]amifostine[e2] 
	(0, 8)	Agranulocytosis	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	878	 [s1]Agranulocytosis[e1] during [s2]clozapine[e2] therapy.
	(6, 22)	agranulocytosis	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	879	Granulocytopenia and [s1]agranulocytosis[e1] are considered among the most dangerous adverse effects of [s2]clozapine[e2] 
	(0, 22)	Granulocytopenia	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	880	 [s1]Granulocytopenia[e1] and agranulocytosis are considered among the most dangerous adverse effects of [s2]clozapine[e2] 
	(4, 19)	clozapine	agranulocytosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	881	The female patient received [s1]clozapine[e1] in a daily dose of 400 mg, which induced [s2]agranulocytosis[e2] after 2 months.
	(11, 23)	clozapine	agranulocytosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	882	The male patient was treated with 225-mg/day [s1]clozapine[e1] and the time to the diagnosis of [s2]agranulocytosis[e2] was 6 weeks.
	(8, 17)	NMS	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	883	A 53-year-old man developed [s1]NMS[e1] without rigidity while taking [s2]olanzapine[e2] 
	(3, 14)	neuroleptic malignant syndrome	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	884	Atypical [s1]neuroleptic malignant syndrome[e1] associated with [s2]olanzapine[e2] 
	(24, 52)	zuclopenthixol	painful erection	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	885	CASE SUMMARY: We report the case of a 31-year-old patient hospitalized due to behavioral alterations and treated with oral [s1]zuclopenthixol[e1]  an antipsychotic from the thioxanthene family, who developed an acute, [s2]painful erection[e2] 
	(2, 16)	Priapism	zuclopenthixol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	886	CONCLUSIONS: [s1]Priapism[e1] is an uncommon but potentially serious adverse effect of [s2]zuclopenthixol[e2] that practitioners, as with many other antipsychotics, should be aware of.
	(5, 16)	priapism	zuclopenthixol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	887	DISCUSSION: The occurrence of [s1]priapism[e1] in our patient was related to [s2]zuclopenthixol[e2] 
	(8, 17)	zuclopenthixol	priapism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	888	OBJECTIVE: To present a single case of [s1]zuclopenthixol[e1] induced [s2]priapism[e2] and a literature review.
	(0, 7)	Priapism	zuclopenthixol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	889	 [s1]Priapism[e1] associated with [s2]zuclopenthixol[e2] 
	(3, 13)	zuclopenthixol	priapism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	890	The capacity of [s1]zuclopenthixol[e1] to induce [s2]priapism[e2] is thought to be due to its antagonist activity on alpha-adrenergic receptors.
	(21, 27)	sepsis	metamizole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	891	After identification of the index patient, additional inquiry revealed that the patient's mother was hospitalized previously for overwhelming [s1]sepsis[e1] associated with [s2]metamizole[e2] use.
	(0, 30)	Metamizole	agranulocytosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	892	 [s1]Metamizole[e1]  a nonsteroidal antiinflammatory agent, is prohibited in the United States because of the risk of [s2]agranulocytosis[e2] but is widely used in Mexico and other countries.
	(10, 16)	mitomycin	hemolytic-uremic syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	893	Erythropoietin is beneficial in [s1]mitomycin[e1] induced [s2]hemolytic-uremic syndrome[e2] 
	(6, 13)	HUS	mitomycin C	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	894	We describe a patient who developed [s1]HUS[e1] after treatment with [s2]mitomycin C[e2] (total dose 144 mg/m2) due to a carcinoma of the ascending colon.
	(0, 8)	Levofloxacin	toxic epidermal necrolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	895	 [s1]Levofloxacin[e1] induced [s2]toxic epidermal necrolysis[e2] in an elderly patient.
	(12, 20)	levofloxacin	TEN	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	896	To our knowledge, this case is the first published report of [s1]levofloxacin[e1] induced [s2]TEN[e2] 
	(11, 29)	grand mal seizures	bleomycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	897	A 31-year-old female developed multiple episodes of [s1]grand mal seizures[e1] after combination chemotherapy with cisplatin, vinblastine and [s2]bleomycin[e2] for germ cell ovarian cancer stage Ic.
	(11, 20)	grand mal seizures	cisplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	898	A 31-year-old female developed multiple episodes of [s1]grand mal seizures[e1] after combination chemotherapy with [s2]cisplatin[e2]  vinblastine and bleomycin for germ cell ovarian cancer stage Ic.
	(11, 24)	grand mal seizures	vinblastine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	899	A 31-year-old female developed multiple episodes of [s1]grand mal seizures[e1] after combination chemotherapy with cisplatin, [s2]vinblastine[e2] and bleomycin for germ cell ovarian cancer stage Ic.
	(0, 15)	Posterior leukoencephalopathy	bleomycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	900	 [s1]Posterior leukoencephalopathy[e1] following cisplatin, [s2]bleomycin[e2] and vinblastine therapy for germ cell tumor of the ovary.
	(0, 11)	Posterior leukoencephalopathy	cisplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	901	 [s1]Posterior leukoencephalopathy[e1] following [s2]cisplatin[e2]  bleomycin and vinblastine therapy for germ cell tumor of the ovary.
	(0, 20)	Posterior leukoencephalopathy	vinblastine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	902	 [s1]Posterior leukoencephalopathy[e1] following cisplatin, bleomycin and [s2]vinblastine[e2] therapy for germ cell tumor of the ovary.
	(6, 15)	IL-2	hemorrhagic lesion	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	903	After 5 days of treatment with [s1]IL-2[e1]  the patient developed a [s2]hemorrhagic lesion[e2] that progressed to toxic epidermal necrolysis, as well as grade 4 pancytopenia.
	(6, 38)	IL-2	pancytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	904	After 5 days of treatment with [s1]IL-2[e1]  the patient developed a hemorrhagic lesion that progressed to toxic epidermal necrolysis, as well as grade 4 [s2]pancytopenia[e2] 
	(6, 25)	IL-2	toxic epidermal necrolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	905	After 5 days of treatment with [s1]IL-2[e1]  the patient developed a hemorrhagic lesion that progressed to [s2]toxic epidermal necrolysis[e2]  as well as grade 4 pancytopenia.
	(7, 21)	cutaneous and hematologic toxicity	IL-2	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	906	OBJECTIVE: To report a case of [s1]cutaneous and hematologic toxicity[e1] in a patient treated with [s2]IL-2[e2] 
	(3, 16)	IL-2	mortality rate <3	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	907	Subcutaneous [s1]IL-2[e1] is safe and well tolerated, with a [s2]mortality rate <3[e2] .
	(0, 11)	Toxic epidermal necrolysis	interleukin-2	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	908	 [s1]Toxic epidermal necrolysis[e1] associated with [s2]interleukin-2[e2] 
	(3, 17)	anaphylactoid reaction	Gelofusine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	909	A case of [s1]anaphylactoid reaction[e1] due solely to the use of [s2]Gelofusine[e2] in a patient with non-haemorrhagic hypovolaemia is presented, with a discussion on the management and the use of allergy identification jewellery.
	(0, 14)	Gelofusine allergy	Gelofusine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	910	 [s1]Gelofusine allergy[e1] -the need for identification jewellery [s2]Gelofusine[e2] allergy--the need for identification jewellery.
	(3, 9)	valproate	hyperammonemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	911	The authors describe [s1]valproate[e1] induced [s2]hyperammonemia[e2] and mental status changes in an 88-year-old man, the first known reported case in an elderly patient.
	(3, 14)	valproate	mental status changes	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	912	The authors describe [s1]valproate[e1] induced hyperammonemia and [s2]mental status changes[e2] in an 88-year-old man, the first known reported case in an elderly patient.
	(0, 14)	Valproate	altered mental status	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	913	 [s1]Valproate[e1] induced hyperammonemia as a cause of [s2]altered mental status[e2] 
	(0, 6)	Valproate	hyperammonemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	914	 [s1]Valproate[e1] induced [s2]hyperammonemia[e2] as a cause of altered mental status.
	(0, 13)	Leiomyosarcoma	cyclophosphamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	915	 [s1]Leiomyosarcoma[e1] in urinary bladder after [s2]cyclophosphamide[e2] therapy for retinoblastoma and review of bladder sarcomas.
	(5, 24)	NMS	amisulpride	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	916	The epivodes of [s1]NMS[e1] occured under treatment with clozapine, risperidone, and [s2]amisulpride[e2] 
	(5, 14)	NMS	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	917	The epivodes of [s1]NMS[e1] occured under treatment with [s2]clozapine[e2]  risperidone, and amisulpride.
	(5, 18)	NMS	risperidone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	918	The epivodes of [s1]NMS[e1] occured under treatment with clozapine, [s2]risperidone[e2]  and amisulpride.
	(11, 22)	cough	fludarabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	919	A 73-year-old woman presented with fever and [s1]cough[e1] 2 weeks after completing the third cycle of [s2]fludarabine[e2] for chronic lymphocytic leukemia (CLL).
	(9, 22)	fever	fludarabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	920	A 73-year-old woman presented with [s1]fever[e1] and cough 2 weeks after completing the third cycle of [s2]fludarabine[e2] for chronic lymphocytic leukemia (CLL).
	(0, 21)	Fludarabine	lung disease	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	921	 [s1]Fludarabine[e1] induced lung toxicity must be considered in all patients who develop unexplained [s2]lung disease[e2] while receiving fludarabine.
	(19, 25)	lung disease	fludarabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	922	Fludarabine induced lung toxicity must be considered in all patients who develop unexplained [s1]lung disease[e1] while receiving [s2]fludarabine[e2] 
	(0, 6)	Fludarabine	lung toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	923	 [s1]Fludarabine[e1] induced [s2]lung toxicity[e2] must be considered in all patients who develop unexplained lung disease while receiving fludarabine.
	(0, 10)	Multiple pulmonary nodules	fludarabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	924	 [s1]Multiple pulmonary nodules[e1]  an unusual presentation of [s2]fludarabine[e2] pulmonary toxicity: case report and review of literature.
	(9, 14)	fludarabine	pulmonary toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	925	Multiple pulmonary nodules: an unusual presentation of [s1]fludarabine[e1]  [s2]pulmonary toxicity[e2]  case report and review of literature.
	(6, 15)	fludarabine	pulmonary nodules	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	926	This case extends the spectrum of [s1]fludarabine[e1] pulmonary toxicity to include [s2]pulmonary nodules[e2] 
	(6, 11)	fludarabine	pulmonary toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	927	This case extends the spectrum of [s1]fludarabine[e1]  [s2]pulmonary toxicity[e2] to include pulmonary nodules.
	(7, 19)	interstitial pneumonitis	fludarabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	928	To our knowledge, four cases of [s1]interstitial pneumonitis[e1] associated with [s2]fludarabine[e2] have been reported in medical literature.
	(0, 13)	Epoprostenol	erythroderma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	929	 [s1]Epoprostenol[e1] may be associated rarely with severe [s2]erythroderma[e2] 
	(1, 14)	erythroderma	epoprostenol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	930	Severe [s1]erythroderma[e1] as a complication of continuous [s2]epoprostenol[e2] therapy.
	(29, 51)	epoprostenol	fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	931	We report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who, after 2 months of treatment with [s1]epoprostenol[e1]  presented with rapidly progressive erythema, scaling, nausea and vomiting, and [s2]fever[e2] 
	(29, 46)	epoprostenol	nausea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	932	We report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who, after 2 months of treatment with [s1]epoprostenol[e1]  presented with rapidly progressive erythema, scaling, [s2]nausea[e2] and vomiting, and fever.
	(29, 38)	epoprostenol	rapidly progressive erythema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	933	We report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who, after 2 months of treatment with [s1]epoprostenol[e1]  presented with [s2]rapidly progressive erythema[e2]  scaling, nausea and vomiting, and fever.
	(29, 44)	epoprostenol	scaling	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	934	We report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who, after 2 months of treatment with [s1]epoprostenol[e1]  presented with rapidly progressive erythema, [s2]scaling[e2]  nausea and vomiting, and fever.
	(29, 48)	epoprostenol	vomiting	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	935	We report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who, after 2 months of treatment with [s1]epoprostenol[e1]  presented with rapidly progressive erythema, scaling, nausea and [s2]vomiting[e2]  and fever.
	(19, 27)	ticlopidine	marrow aplasia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	936	A 50-year-old diabetic and hypertensive male patient is reported who had [s1]ticlopidine[e1] induced [s2]marrow aplasia[e2] partially responsive to colony-stimulating factors and corticosteroids, but experienced complete recovery with cyclosporine.
	(8, 16)	ticlopidine	marrow aplasia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	937	There is no consensus on the treatment of [s1]ticlopidine[e1] induced [s2]marrow aplasia[e2] 
	(0, 8)	Ticlopidine	marrow aplasia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	938	 [s1]Ticlopidine[e1] induced [s2]marrow aplasia[e2] treated with cyclosporine.
	(8, 17)	lower leg edema	rosiglitazone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	939	A 53-year-old man developed [s1]lower leg edema[e1] 4 weeks after [s2]rosiglitazone[e2] was increased from 4 mg once/day to 4 mg twice/day.
	(8, 25)	bilateral lower leg edema	pioglitazone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	940	A 75-year-old man developed [s1]bilateral lower leg edema[e1] 6 months after switching from troglitazone to [s2]pioglitazone[e2] 
	(8, 21)	ankle, hand, and facial swelling	rosiglitazone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	941	A 77-year-old man developed [s1]ankle, hand, and facial swelling[e1] 2 weeks after starting [s2]rosiglitazone[e2] 
	(3, 19)	polymorphic ventricular tachycardia	verapamil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	942	Two cases of [s1]polymorphic ventricular tachycardia[e1] induced by the administration of [s2]verapamil[e2] against paroxysmal supraventricular tachycardia.
	(0, 34)	Verapamil	proarrhythmic effect	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	943	 [s1]Verapamil[e1] is widely used for the termination of paroxysmal supraventricular tachycardia (PSVT) with little [s2]proarrhythmic effect[e2] 
	(11, 28)	non-sustained polymorphic ventricular tachycardia	verapamil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	944	We describe two cases of PSVT that changed to [s1]non-sustained polymorphic ventricular tachycardia[e1] after administration of [s2]verapamil[e2] 
	(0, 10)	Epsilon-aminocaproic acid	renal complications	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	945	 [s1]Epsilon-aminocaproic acid[e1] and [s2]renal complications[e2]  case report and review of the literature.
	(2, 11)	mydriasis	lidocaine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	946	Neonatal [s1]mydriasis[e1]  intravenous [s2]lidocaine[e2] adverse reaction.
	(13, 23)	pupillary mydriasis	lidocaine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	947	We present a neonate with a seizure disorder who acutely developed [s1]pupillary mydriasis[e1] secondary to [s2]lidocaine[e2] overdose.
	(14, 26)	lidocaine	dilated pupils	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	948	We suggest adding this side effect to the list of untoward effects of [s1]lidocaine[e1] and to the differential diagnosis of fixed [s2]dilated pupils[e2] in neonates treated with lidocaine.
	(8, 23)	acute myeloid leukemia	2-deoxycoformycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	949	Myelodysplasia terminating in [s1]acute myeloid leukemia[e1] in a hairy cell leukemia patient treated with [s2]2-deoxycoformycin[e2] 
	(0, 23)	Myelodysplasia	2-deoxycoformycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	950	 [s1]Myelodysplasia[e1] terminating in acute myeloid leukemia in a hairy cell leukemia patient treated with [s2]2-deoxycoformycin[e2] 
	(11, 31)	AML	2-chlorodeoxyadenosine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	951	To the best of our knowledge only two previous cases of [s1]AML[e1] have been linked to treatment of HCL with purine analogs, both with [s2]2-chlorodeoxyadenosine[e2] 
	(8, 26)	vasopressin	ischemic skin complications	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	952	CONCLUSIONS: Peripheral administration of low-dose [s1]vasopressin[e1] for septic shock should be discouraged because of the risk of [s2]ischemic skin complications[e2] 
	(8, 24)	skin necrosis	vasopressin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	953	OBJECTIVE: To describe a case of severe [s1]skin necrosis[e1] resulting from peripheral intravenous administration of low-dose [s2]vasopressin[e2] in a patient with catecholamine-resistant septic shock.
	(0, 13)	Skin necrosis	vasopressin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	954	 [s1]Skin necrosis[e1] after extravasation of low-dose [s2]vasopressin[e2] administered for septic shock.
	(0, 8)	Mitomycin-C	hemolytic uremic syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	955	 [s1]Mitomycin-C[e1] induced [s2]hemolytic uremic syndrome[e2]  a case report.
	(0, 30)	Mitomycin-C	hemolytic uremic syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	956	 [s1]Mitomycin-C[e1] is used widely in the treatment of malignancies and is associated with serious dose related adverse effects including the occurrence of [s2]hemolytic uremic syndrome[e2] 
	(1, 30)	vasculitis	cladribine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	957	Although [s1]vasculitis[e1] has been reported in the course of hairy cell leukaemia, it has only rarely been reported as the consequence of [s2]cladribine[e2] treatment.
	(0, 18)	Systemic vasculitis	cladribine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	958	 [s1]Systemic vasculitis[e1] complicating hairy cell leukaemia treatment with [s2]cladribine[e2] 
	(12, 33)	systemic vasculitis	cladribine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	959	We describe a 73-year-old woman who developed serious [s1]systemic vasculitis[e1] with associated thrombocytopenia in the course of treatment with [s2]cladribine[e2] 
	(19, 33)	thrombocytopenia	cladribine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	960	We describe a 73-year-old woman who developed serious systemic vasculitis with associated [s1]thrombocytopenia[e1] in the course of treatment with [s2]cladribine[e2] 
	(3, 19)	mammary hyperplasias	D-penicillamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	961	Drug-induced [s1]mammary hyperplasias[e1] have been reported as rare complications of [s2]D-penicillamine[e2] and Neothetazone.
	(3, 26)	mammary hyperplasias	Neothetazone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	962	Drug-induced [s1]mammary hyperplasias[e1] have been reported as rare complications of D-penicillamine and [s2]Neothetazone[e2] 
	(0, 8)	Gigantomastia	bucillamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	963	 [s1]Gigantomastia[e1] induced by [s2]bucillamine[e2] 
	(3, 17)	bucillamine	giant hypertrophy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	964	Retrospectively, [s1]bucillamine[e1] was believed to be the cause of the [s2]giant hypertrophy[e2] because of its structural similarity to D-penicillamine, which was the subject of an abundance of reports of mammary hyperplasia.
	(25, 43)	D-penicillamine	mammary hyperplasia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	965	Retrospectively, bucillamine was believed to be the cause of the giant hypertrophy because of its structural similarity to [s1]D-penicillamine[e1]  which was the subject of an abundance of reports of [s2]mammary hyperplasia[e2] 
	(7, 14)	bucillamine	giant mammary hyperplasia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	966	The authors report the first case of [s1]bucillamine[e1] induced [s2]giant mammary hyperplasia[e2] 
	(10, 26)	FVS	valproic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	967	The authors describe three families in whom the occurrence of [s1]FVS[e1] in all the siblings strongly suggests hereditary susceptibility to [s2]valproic acid[e2] induced adverse outcome.
	(2, 27)	valproate	developmental delay	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	968	The fetal [s1]valproate[e1] syndrome (FVS) is characterized by distinctive facial appearance, major and minor malformations, and [s2]developmental delay[e2] 
	(2, 15)	valproate	distinctive facial appearance	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	969	The fetal [s1]valproate[e1] syndrome (FVS) is characterized by [s2]distinctive facial appearance[e2]  major and minor malformations, and developmental delay.
	(1, 8)	fetal valproate syndrome	valproate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	970	The [s1]fetal valproate syndrome[e1]  [s2]valproate[e2] syndrome (FVS) is characterized by distinctive facial appearance, major and minor malformations, and developmental delay.
	(2, 8)	valproate	FVS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	971	The fetal [s1]valproate[e1] syndrome  [s2]FVS[e2]  is characterized by distinctive facial appearance, major and minor malformations, and developmental delay.
	(2, 19)	valproate	major and minor malformations	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	972	The fetal [s1]valproate[e1] syndrome (FVS) is characterized by distinctive facial appearance, [s2]major and minor malformations[e2]  and developmental delay.
	(0, 21)	Valproate embryopathy	Valproate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	973	 [s1]Valproate embryopathy[e1] in three sets of siblings: further proof of hereditary susceptibility [s2]Valproate[e2] embryopathy in three sets of siblings: further proof of hereditary susceptibility.
	(0, 12)	Generalised pustular psoriasis	cyclosporin a	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	974	 [s1]Generalised pustular psoriasis[e1] induced by [s2]cyclosporin a[e2] withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept.
	(34, 55)	cyclosporin A	aggravation of the joint condition	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	975	We report a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis, in whom the withdrawal of [s1]cyclosporin A[e1] induced a generalised pustular exacerbation and a [s2]aggravation of the joint condition[e2] 
	(34, 44)	cyclosporin A	generalised pustular exacerbation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	976	We report a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis, in whom the withdrawal of [s1]cyclosporin A[e1] induced a [s2]generalised pustular exacerbation[e2] and a aggravation of the joint condition.
	(14, 28)	aplastic anemia	ticlopidine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	977	The first case concerns a 70-year-old man who developed severe [s1]aplastic anemia[e1] 7 weeks after treatment with 500 mg of [s2]ticlopidine[e2] daily.
	(11, 39)	ticlopidine	marrow aplasia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	978	The second was an 82-year-old man receiving [s1]ticlopidine[e1] for 2 years when, during a febrile episode, he was found neutropenic with [s2]marrow aplasia[e2] 
	(11, 33)	ticlopidine	neutropenic	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	979	The second was an 82-year-old man receiving [s1]ticlopidine[e1] for 2 years when, during a febrile episode, he was found [s2]neutropenic[e2] with marrow aplasia.
	(0, 8)	Ticlopidine	aplastic anemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	980	 [s1]Ticlopidine[e1] induced [s2]aplastic anemia[e2] (TIAA) is considered very uncommon.
	(0, 12)	Ticlopidine	TIAA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	981	 [s1]Ticlopidine[e1] induced aplastic anemia  [s2]TIAA[e2]  is considered very uncommon.
	(0, 8)	Ticlopidine	aplastic anemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	982	 [s1]Ticlopidine[e1] induced [s2]aplastic anemia[e2]  two new case reports, review, and meta-analysis of 55 additional cases.
	(15, 24)	cytotoxic effect	ticlopidine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	983	When the data of the 57 patients are evaluated, a reversible direct [s1]cytotoxic effect[e1] of [s2]ticlopidine[e2] on the pluripotent/bipotent hematopoietic progenitor stem cell is proposed.
	(0, 6)	Fixed drug eruption	rofecoxib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	984	 [s1]Fixed drug eruption[e1] to [s2]rofecoxib[e2] 
	(0, 18)	Rofecoxib	herpetiform fixed drug eruption	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	985	 [s1]Rofecoxib[e1]  used for dysmenorrhea, caused a [s2]herpetiform fixed drug eruption[e2] predominantly involving the lips with classic clinical and histological findings in a red-brown lesion on the dorsal hand.
	(0, 38)	Rofecoxib	red-brown lesion	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	986	 [s1]Rofecoxib[e1]  used for dysmenorrhea, caused a herpetiform fixed drug eruption predominantly involving the lips with classic clinical and histological findings in a [s2]red-brown lesion[e2] on the dorsal hand.
	(10, 21)	thyroid hormone	hypothyroidism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	987	A patient who had been treated with large doses of [s1]thyroid hormone[e1] for several years developed features of secondary [s2]hypothyroidism[e2] after thyroid hormone withdrawal.
	(14, 21)	gemcitabine	hemolytic-uremic syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	988	BACKGROUND: Gemcitabine has mild renal toxicity, but cases of [s1]gemcitabine[e1] associated [s2]hemolytic-uremic syndrome[e2] (HUS) have been reported.
	(2, 22)	Gemcitabine	hemolytic-uremic syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	989	BACKGROUND: [s1]Gemcitabine[e1] has mild renal toxicity, but cases of gemcitabine-associated [s2]hemolytic-uremic syndrome[e2] (HUS) have been reported.
	(14, 29)	gemcitabine	HUS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	990	BACKGROUND: Gemcitabine has mild renal toxicity, but cases of [s1]gemcitabine[e1] associated hemolytic-uremic syndrome  [s2]HUS[e2]  have been reported.
	(2, 30)	Gemcitabine	HUS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	991	BACKGROUND: [s1]Gemcitabine[e1] has mild renal toxicity, but cases of gemcitabine-associated hemolytic-uremic syndrome  [s2]HUS[e2]  have been reported.
	(2, 10)	Gemcitabine	renal toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	992	BACKGROUND: [s1]Gemcitabine[e1] has mild [s2]renal toxicity[e2]  but cases of gemcitabine-associated hemolytic-uremic syndrome (HUS) have been reported.
	(10, 17)	gemcitabine	HUS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	993	CONCLUSION: There are only a few confirmed cases of [s1]gemcitabine[e1] associated [s2]HUS[e2] despite the widespread use of the drug.
	(0, 7)	Gemcitabine	hemolytic-uremic syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	994	 [s1]Gemcitabine[e1] associated [s2]hemolytic-uremic syndrome[e2] 
	(5, 15)	gemcitabine	HUS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	995	Mean time between initiation of [s1]gemcitabine[e1] therapy and onset of [s2]HUS[e2] was 7.4 +/- 3.5 months, or 21.9 +/- 10.9 doses of gemcitabine.
	(5, 15)	gemcitabine	HUS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	996	Mean time between initiation of [s1]gemcitabine[e1] therapy and onset of [s2]HUS[e2] was 7.4 +/- 3.5 months, or 21.9 +/- 10.9 doses of gemcitabine.
	(16, 30)	gemcitabine	HUS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	997	METHODS: A case is presented of a 45-year-old woman on prolonged [s1]gemcitabine[e1] treatment for ovarian cancer who developed [s2]HUS[e2] and recovered after drug discontinuation.
	(13, 20)	gemcitabine	HUS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	998	RESULTS: Including our own patient, a total of 26 cases of [s1]gemcitabine[e1] associated [s2]HUS[e2] were identified.
	(1, 6)	amiodarone	optic neuropathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	999	An [s1]amiodarone[e1]  [s2]optic neuropathy[e2] has been described.
	(6, 11)	amiodarone	corneal deposits	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1000	Biomicroscopy revealed [s1]amiodarone[e1]  [s2]corneal deposits[e2] 
	(7, 41)	amiodarone HCl	color vision anomalies	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1001	"CASE REPORT: Soon after initiation of [s1]amiodarone HCl[e1] (200 mg/day), a 76-year-old man came to us with symptoms of visual ""shining,"" glare, [s2]color vision anomalies[e2]  and gradually decreased vision."
	(7, 49)	amiodarone HCl	decreased vision	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1002	"CASE REPORT: Soon after initiation of [s1]amiodarone HCl[e1] (200 mg/day), a 76-year-old man came to us with symptoms of visual ""shining,"" glare, color vision anomalies, and gradually [s2]decreased vision[e2] "
	(7, 39)	amiodarone HCl	glare	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1003	"CASE REPORT: Soon after initiation of [s1]amiodarone HCl[e1] (200 mg/day), a 76-year-old man came to us with symptoms of visual ""shining,"" [s2]glare[e2]  color vision anomalies, and gradually decreased vision."
	(7, 34)	amiodarone HCl	"visual ""shining"	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1004	"CASE REPORT: Soon after initiation of [s1]amiodarone HCl[e1] (200 mg/day), a 76-year-old man came to us with symptoms of [s2]visual ""shining[e2] "" glare, color vision anomalies, and gradually decreased vision."
	(0, 8)	Visual changes	amiodarone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1005	 [s1]Visual changes[e1] secondary to initiation of [s2]amiodarone[e2]  a case report and review involving ocular management in cardiac polypharmacy.
	(2, 18)	amiodarone	ocular effects	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1006	While both [s1]amiodarone[e1] and digoxin can cause permanent visual changes, the [s2]ocular effects[e2] are often reversible.
	(6, 18)	digoxin	ocular effects	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1007	While both amiodarone and [s1]digoxin[e1] can cause permanent visual changes, the [s2]ocular effects[e2] are often reversible.
	(2, 14)	amiodarone	visual changes	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1008	While both [s1]amiodarone[e1] and digoxin can cause permanent [s2]visual changes[e2]  the ocular effects are often reversible.
	(6, 14)	digoxin	visual changes	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1009	While both amiodarone and [s1]digoxin[e1] can cause permanent [s2]visual changes[e2]  the ocular effects are often reversible.
	(4, 22)	circumoral and pharyngeal burns	benzalkonium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1010	Infant twins sustained severe [s1]circumoral and pharyngeal burns[e1] from a concentrated solution of [s2]benzalkonium[e2] (Zephiran) chloride prescribed for treatment of candidiasis.
	(4, 26)	circumoral and pharyngeal burns	Zephiran	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1011	Infant twins sustained severe [s1]circumoral and pharyngeal burns[e1] from a concentrated solution of benzalkonium  [s2]Zephiran[e2]  chloride prescribed for treatment of candidiasis.
	(7, 26)	rifabutin	side-effect on retinal function	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1012	CONCLUSION: Long-term treatment with [s1]rifabutin[e1] may have a reversible and previously undescribed [s2]side-effect on retinal function[e2] 
	(17, 29)	decreased vision	rifabutin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1013	PURPOSE: To describe the clinical and electrophysiological findings in a young boy with [s1]decreased vision[e1] possibly due to retinal damage by [s2]rifabutin[e2] 
	(22, 29)	retinal damage	rifabutin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1014	PURPOSE: To describe the clinical and electrophysiological findings in a young boy with decreased vision possibly due to [s1]retinal damage[e1] by [s2]rifabutin[e2] 
	(5, 15)	anterior segment deposits	rifabutin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1015	Retinal dysfunction and [s1]anterior segment deposits[e1] in a patient treated with [s2]rifabutin[e2] 
	(0, 15)	Retinal dysfunction	rifabutin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1016	 [s1]Retinal dysfunction[e1] and anterior segment deposits in a patient treated with [s2]rifabutin[e2] 
	(22, 29)	visual disturbance	rifabutin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1017	We suggest that objective evaluation of retinal function with electrophysiological methods should be performed in patients with [s1]visual disturbance[e1] during treatment with [s2]rifabutin[e2] 
	(9, 24)	benzodiazepine withdrawal symptoms	nefazodone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1018	A case is presented of a patient who experienced [s1]benzodiazepine withdrawal symptoms[e1] on discontinuation of [s2]nefazodone[e2]  an antidepressant that inhibits the cytochrome P450 3A4 isoenzyme.
	(3, 10)	SIADH	mizoribin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1019	A case of [s1]SIADH[e1] induced by [s2]mizoribin[e2] administration.
	(0, 19)	ADH hypersecretion	mizoribin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1020	 [s1]ADH hypersecretion[e1] in relation to plasma osmolality was reversed by [s2]mizoribin[e2] withdrawal, suggesting that bredinin might adversely induce SIADH.
	(25, 34)	bredinin	SIADH	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1021	ADH hypersecretion in relation to plasma osmolality was reversed by mizoribin withdrawal, suggesting that [s1]bredinin[e1] might adversely induce [s2]SIADH[e2] 
	(11, 23)	SIADH	mizoribin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1022	In summary, we report herein the first case of [s1]SIADH[e1] believed to be an adverse effect of [s2]mizoribin[e2]  which may therefore needed to be added to the list of drugs which can induce SIADH.
	(11, 23)	SIADH	mizoribin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1023	In summary, we report herein the first case of [s1]SIADH[e1] believed to be an adverse effect of [s2]mizoribin[e2]  which may therefore needed to be added to the list of drugs which can induce SIADH.
	(32, 44)	SIADH	mizoribin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1024	We describe a 74-year-old man with rheumatoid arthritis (RA) who developed syndrome of inappropriate secretion of antidiuretic hormone  [s1]SIADH[e1]  1.5 months after commencement of [s2]mizoribin[e2] prescription when his arthritis was improved.
	(21, 46)	syndrome of inappropriate secretion of antidiuretic hormone	mizoribin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1025	We describe a 74-year-old man with rheumatoid arthritis (RA) who developed [s1]syndrome of inappropriate secretion of antidiuretic hormone[e1] (SIADH) 1.5 months after commencement of [s2]mizoribin[e2] prescription when his arthritis was improved.
	(9, 28)	cyclosporin	lymphoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1026	The disease-modifying drugs he was taking, [s1]cyclosporin[e1] and methotrexate, were stopped, and the [s2]lymphoma[e2] resolved spontaneously without the use of chemotherapy.
	(15, 27)	methotrexate	lymphoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1027	The disease-modifying drugs he was taking, cyclosporin and [s1]methotrexate[e1]  were stopped, and the [s2]lymphoma[e2] resolved spontaneously without the use of chemotherapy.
	(3, 11)	nephrotic syndrome	interferon-alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1028	Acute onset of [s1]nephrotic syndrome[e1] during [s2]interferon-alpha[e2] retreatment for chronic active hepatitis C.
	(11, 19)	nephrotic syndrome	interferon-alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1029	We herein report this rare case of acute onset of [s1]nephrotic syndrome[e1] during [s2]interferon-alpha[e2] retreatment.
	(32, 39)	seizures	interferon beta-1a	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1030	A 21-year-old man with Tourette's syndrome, pedophilia, Asperger's syndrome, and multiple sclerosis experienced [s1]seizures[e1] after receiving therapy with [s2]interferon beta-1a[e2] 
	(2, 40)	extrapyramidal symptoms	clomipramine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1031	Seizures and [s1]extrapyramidal symptoms[e1] in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with interferon beta-1a and [s2]clomipramine[e2] 
	(2, 33)	extrapyramidal symptoms	interferon beta-1a	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1032	Seizures and [s1]extrapyramidal symptoms[e1] in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with [s2]interferon beta-1a[e2] and clomipramine.
	(0, 40)	Seizures	clomipramine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1033	 [s1]Seizures[e1] and extrapyramidal symptoms in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with interferon beta-1a and [s2]clomipramine[e2] 
	(0, 33)	Seizures	interferon beta-1a	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1034	 [s1]Seizures[e1] and extrapyramidal symptoms in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with [s2]interferon beta-1a[e2] and clomipramine.
	(16, 22)	collapsed	carboplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1035	A 68-year-old female patient with advanced ovarian carcinoma [s1]collapsed[e1] whilst receiving a [s2]carboplatin[e2] and cyclophosphamide infusion.
	(16, 27)	collapsed	cyclophosphamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1036	A 68-year-old female patient with advanced ovarian carcinoma [s1]collapsed[e1] whilst receiving a carboplatin and [s2]cyclophosphamide[e2] infusion.
	(0, 12)	Carboplatin	coronary vasospasm	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1037	 [s1]Carboplatin[e1] hypersensitivity presenting as [s2]coronary vasospasm[e2] - a case report.
	(5, 28)	carboplatin	hyperacute changes on ECG	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1038	Hypersensitivity to [s1]carboplatin[e1] is a rare but real complication of therapy and should be considered in patients presenting with [s2]hyperacute changes on ECG[e2] whilst receiving carboplatin therapy.
	(0, 7)	Hypersensitivity	carboplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1039	 [s1]Hypersensitivity[e1] to [s2]carboplatin[e2] is a rare but real complication of therapy and should be considered in patients presenting with hyperacute changes on ECG whilst receiving carboplatin therapy.
	(17, 32)	acute respiratory failure	methazolamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1040	A 60-year-old white man with chronic bronchitis was noted to develop [s1]acute respiratory failure[e1] and metabolic acidosis four days after being started on [s2]methazolamide[e2] (Neptazane) for an ophthalmologic problem.
	(17, 37)	acute respiratory failure	Neptazane	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1041	A 60-year-old white man with chronic bronchitis was noted to develop [s1]acute respiratory failure[e1] and metabolic acidosis four days after being started on methazolamide  [s2]Neptazane[e2]  for an ophthalmologic problem.
	(21, 32)	metabolic acidosis	methazolamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1042	A 60-year-old white man with chronic bronchitis was noted to develop acute respiratory failure and [s1]metabolic acidosis[e1] four days after being started on [s2]methazolamide[e2] (Neptazane) for an ophthalmologic problem.
	(21, 37)	metabolic acidosis	Neptazane	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1043	A 60-year-old white man with chronic bronchitis was noted to develop acute respiratory failure and [s1]metabolic acidosis[e1] four days after being started on methazolamide  [s2]Neptazane[e2]  for an ophthalmologic problem.
	(0, 10)	Capecitabine	allergic reactions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1044	 [s1]Capecitabine[e1] was discontinued and the [s2]allergic reactions[e2] resolved after the woman took diphenhydramine for 1 week.
	(22, 27)	allergic reactions	capecitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1045	CONCLUSIONS: The use of fluorouracil treatment with careful monitoring can be considered in a patient with mild [s1]allergic reactions[e1] to [s2]capecitabine[e2] 
	(6, 11)	allergic reactions	capecitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1046	Fluorouracil for [s1]allergic reactions[e1] to [s2]capecitabine[e2] 
	(6, 15)	allergic reaction	capecitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1047	It was postulated that the [s1]allergic reaction[e1] was most likely caused by [s2]capecitabine[e2] or the intermediate metabolites based on the immediate reappearance of symptoms from the rechallenge, pharmacokinetic data, and well-tolerance of fluorouracil.
	(21, 26)	allergic reactions	capecitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1048	OBJECTIVE: To report the safe use of fluorouracil in a patient with breast cancer who had [s1]allergic reactions[e1] to [s2]capecitabine[e2] 
	(13, 25)	dizziness	capecitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1049	She developed a generalized rash and itching, sore throat, and [s1]dizziness[e1] approximately 4 hours after the first dose of [s2]capecitabine[e2] 
	(3, 25)	generalized rash	capecitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1050	She developed a [s1]generalized rash[e1] and itching, sore throat, and dizziness approximately 4 hours after the first dose of [s2]capecitabine[e2] 
	(6, 24)	itching	capecitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1051	She developed a generalized rash and [s1]itching[e1]  sore throat, and dizziness approximately 4 hours after the first dose of [s2]capecitabine[e2] 
	(9, 24)	sore throat	capecitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1052	She developed a generalized rash and itching, [s1]sore throat[e1]  and dizziness approximately 4 hours after the first dose of [s2]capecitabine[e2] 
	(10, 21)	methylprednisolone	steroid diabetes	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1053	After five and six weeks of continuous oral administration of [s1]methylprednisolone[e1]  the boys developed [s2]steroid diabetes[e2] 
	(2, 21)	methylprednisolone	glycemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1054	Reduction of [s1]methylprednisolone[e1] dosage rather than insulin therapy resulted in better control of [s2]glycemia[e2] 
	(17, 26)	cytarabine	PPE	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1055	Contrary to previous recommendations, our experience cautions against the further use of high-dose [s1]cytarabine[e1] in patients who develop [s2]PPE[e2]  and is a timely reminder of the potential toxicity of this agent, which is now increasingly being used as first-line treatment in the management of haematologic malignancies.
	(5, 11)	PPE	cytarabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1056	It has been suggested that [s1]PPE[e1] caused by [s2]cytarabine[e2] does not recur with subsequent cytarabine re-challenge.
	(2, 22)	palmar-plantar erythrodysaesthesia	cytarabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1057	Recurrent [s1]palmar-plantar erythrodysaesthesia[e1] following high-dose [s2]cytarabine[e2] treatment for acute lymphoblastic leukemia.
	(20, 32)	bullous eruption	cytarabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1058	We report a patient with recurrent, increasingly severe episodes of PPE, ultimately complicated by a severe [s1]bullous eruption[e1]  following successive cycles of high-dose [s2]cytarabine[e2] for the treatment of acute lymphoblastic leukaemia.
	(12, 32)	PPE	cytarabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1059	We report a patient with recurrent, increasingly severe episodes of [s1]PPE[e1]  ultimately complicated by a severe bullous eruption, following successive cycles of high-dose [s2]cytarabine[e2] for the treatment of acute lymphoblastic leukaemia.
	(21, 28)	tamoxifen	malignant transformation of endometriosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1060	Atypical endometriosis may act as a precancerous lesion in the process of [s1]tamoxifen[e1] induced [s2]malignant transformation of endometriosis[e2] 
	(2, 26)	Ovarian cancer	tamoxifen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1061	BACKGROUND: [s1]Ovarian cancer[e1] arising from an endometriotic cyst in a postmenopausal woman under [s2]tamoxifen[e2] therapy is rare.
	(2, 10)	Tamoxifen	malignant transformation of endometriosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1062	CONCLUSION: [s1]Tamoxifen[e1] may cause [s2]malignant transformation of endometriosis[e2] through atypical endometriosis even in the postmenopausal state.
	(0, 32)	Ovarian endometrioid adenocarcinoma	tamoxifen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1063	 [s1]Ovarian endometrioid adenocarcinoma[e1] arising from an endometriotic cyst in a postmenopausal woman under [s2]tamoxifen[e2] therapy for breast cancer: a case report.
	(0, 18)	Clinical, spectroscopic, and imaging abnormalities	metronidazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1064	 [s1]Clinical, spectroscopic, and imaging abnormalities[e1] resolved with discontinuation of [s2]metronidazole[e2] 
	(6, 12)	lactate elevation	metronidazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1065	Proton MRS examination demonstrated a persistent [s1]lactate elevation[e1] during [s2]metronidazole[e2] treatment.
	(0, 14)	Reversible MR imaging and MR spectroscopy abnormalities	metronidazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1066	 [s1]Reversible MR imaging and MR spectroscopy abnormalities[e1] in association with [s2]metronidazole[e2] therapy.
	(11, 19)	anaphylaxis	cisplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1067	After nine previous uncomplicated cycles she developed severe [s1]anaphylaxis[e1] to [s2]cisplatin[e2] 
	(0, 8)	Anaphylaxis	cisplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1068	 [s1]Anaphylaxis[e1] to [s2]cisplatin[e2] following nine previous uncomplicated cycles.
	(0, 8)	Anaphylaxis	cisplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1069	 [s1]Anaphylaxis[e1] to [s2]cisplatin[e2] is an infrequent life-threatening complication which may occur even in patients who have received prior treatment with cisplatin.
	(1, 11)	isradipine	hepatocellular injury	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1070	Although [s1]isradipine[e1] has been associated with [s2]hepatocellular injury[e2]  there are no reports of fulminant liver failure with this agent, and our patient had been treated for >2 years without signs of toxicity.
	(7, 22)	clarithromycin	increasing the hepatic toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1071	A second possibility is an interaction between [s1]clarithromycin[e1] and isradipine, potentially [s2]increasing the hepatic toxicity[e2] of isradipine.
	(14, 21)	isradipine	increasing the hepatic toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1072	A second possibility is an interaction between clarithromycin and [s1]isradipine[e1]  potentially [s2]increasing the hepatic toxicity[e2] of isradipine.
	(14, 21)	isradipine	increasing the hepatic toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1073	A second possibility is an interaction between clarithromycin and [s1]isradipine[e1]  potentially [s2]increasing the hepatic toxicity[e2] of isradipine.
	(12, 29)	fulminant liver failure	clarithromycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1074	CASE SUMMARY: A 58-year-old white woman developed [s1]fulminant liver failure[e1] while being treated with the macrolide antibiotic [s2]clarithromycin[e2] for pneumonia.
	(2, 15)	Clarithromycin	fulminant liver failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1075	CONCLUSIONS: [s1]Clarithromycin[e1] may be a cause of [s2]fulminant liver failure[e2] either alone or by inhibiting the metabolism of other drugs.
	(0, 10)	Fulminant liver failure	clarithromycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1076	 [s1]Fulminant liver failure[e1] associated with [s2]clarithromycin[e2] 
	(7, 19)	fulminant liver failure	clarithromycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1077	OBJECTIVE: To report a patient developing [s1]fulminant liver failure[e1] while being treated with [s2]clarithromycin[e2] for pneumonia.
	(14, 34)	clarithromycin	fulminant hepatic failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1078	The most likely cause of liver failure in this patient was, therefore, [s1]clarithromycin[e1]  which undergoes hepatic metabolism and has been reported to cause [s2]fulminant hepatic failure[e2] 
	(5, 16)	liver failure	clarithromycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1079	The most likely cause of [s1]liver failure[e1] in this patient was, therefore, [s2]clarithromycin[e2]  which undergoes hepatic metabolism and has been reported to cause fulminant hepatic failure.
	(1, 9)	paradoxical ocular effect	brimonidine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1080	A [s1]paradoxical ocular effect[e1] of [s2]brimonidine[e2] 
	(6, 14)	brimonidine	paradoxical raised IOP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1081	CONCLUSION: Under certain circumstances topical [s1]brimonidine[e1] can cause [s2]paradoxical raised IOP[e2] necessitating vigilance in follow-up of patients on topical brimonidine.
	(6, 12)	paradoxical effect	brimonidine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1082	PURPOSE: We report an unusual [s1]paradoxical effect[e1] of [s2]brimonidine[e2] 
	(2, 12)	Brimonidine	IOP elevation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1083	RESULTS: [s1]Brimonidine[e1] was observed to cause [s2]IOP elevation[e2]  confirmed on rechallenge, scoring 8 (strong probability) on an adverse drug reaction probability score.
	(1, 16)	gabapentin	anxiety	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1084	Although [s1]gabapentin[e1] withdrawal has been previously reported and usually consists of [s2]anxiety[e2]  diaphoresis, and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal.
	(1, 18)	gabapentin	diaphoresis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1085	Although [s1]gabapentin[e1] withdrawal has been previously reported and usually consists of anxiety, [s2]diaphoresis[e2]  and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal.
	(1, 35)	gabapentin	generalized seizures	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1086	Although [s1]gabapentin[e1] withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with [s2]generalized seizures[e2] and status epilepticus secondary to gabapentin withdrawal.
	(1, 35)	gabapentin	generalized seizures	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1087	Although [s1]gabapentin[e1] withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with [s2]generalized seizures[e2] and status epilepticus secondary to gabapentin withdrawal.
	(1, 24)	gabapentin	palpitations	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1088	Although [s1]gabapentin[e1] withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and [s2]palpitations[e2]  this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal.
	(1, 38)	gabapentin	status epilepticus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1089	Although [s1]gabapentin[e1] withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and [s2]status epilepticus[e2] secondary to gabapentin withdrawal.
	(1, 38)	gabapentin	status epilepticus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1090	Although [s1]gabapentin[e1] withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and [s2]status epilepticus[e2] secondary to gabapentin withdrawal.
	(0, 9)	Gabapentin	status epilepticus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1091	 [s1]Gabapentin[e1] withdrawal presenting as [s2]status epilepticus[e2] 
	(29, 35)	altered mental status	zonisamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1092	Although visual hallucinations have not been reported as an adverse effect of this agent, we describe three patients who experienced complex visual hallucinations and [s1]altered mental status[e1] after [s2]zonisamide[e2] treatment was begun or its dosage increased.
	(1, 35)	visual hallucinations	zonisamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1093	Although [s1]visual hallucinations[e1] have not been reported as an adverse effect of this agent, we describe three patients who experienced complex visual hallucinations and altered mental status after [s2]zonisamide[e2] treatment was begun or its dosage increased.
	(0, 8)	Visual hallucinations	zonisamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1094	 [s1]Visual hallucinations[e1] associated with [s2]zonisamide[e2] 
	(0, 8)	Doxycycline	hypoglycemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1095	 [s1]Doxycycline[e1] induced [s2]hypoglycemia[e2] in a nondiabetic young man.
	(6, 14)	doxycycline	hypoglycemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1096	We report the first case of [s1]doxycycline[e1] induced [s2]hypoglycemia[e2] in a young nondiabetic man.
	(13, 21)	anaphylactic reactions	MTX	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1097	For patients who suffer from osteogenic sarcoma and have [s1]anaphylactic reactions[e1] to [s2]MTX[e2]  this desensitization protocol will allow these patients to continue with needed therapeutic or palliative chemotherapy.
	(14, 32)	MTX	chest tightness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1098	He had an immediate hypersensitivity reaction during the initiation of the [s1]MTX[e1] infusion with diffuse urticaria, facial swelling, cough, and [s2]chest tightness[e2] 
	(14, 29)	MTX	cough	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1099	He had an immediate hypersensitivity reaction during the initiation of the [s1]MTX[e1] infusion with diffuse urticaria, facial swelling, [s2]cough[e2]  and chest tightness.
	(14, 21)	MTX	diffuse urticaria	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1100	He had an immediate hypersensitivity reaction during the initiation of the [s1]MTX[e1] infusion with [s2]diffuse urticaria[e2]  facial swelling, cough, and chest tightness.
	(14, 26)	MTX	facial swelling	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1101	He had an immediate hypersensitivity reaction during the initiation of the [s1]MTX[e1] infusion with diffuse urticaria, [s2]facial swelling[e2]  cough, and chest tightness.
	(4, 16)	hypersensitivity reaction	MTX	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1102	He had an immediate [s1]hypersensitivity reaction[e1] during the initiation of the [s2]MTX[e2] infusion with diffuse urticaria, facial swelling, cough, and chest tightness.
	(7, 12)	allergy	MTX	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1103	He was later skin tested to confirm [s1]allergy[e1] to [s2]MTX[e2] 
	(9, 17)	methotrexate	systemic anaphylaxis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1104	Successful desensitization to high-dose [s1]methotrexate[e1] after [s2]systemic anaphylaxis[e2] 
	(15, 23)	anaphylactic reactions	MTX	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1105	The successful development and implementation of this protocol will have impact on patients who have [s1]anaphylactic reactions[e1] to [s2]MTX[e2] but require this medication for specific diseases.
	(6, 36)	Balint syndrome	cytarabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1106	The authors report a case of [s1]Balint syndrome[e1] with irreversible posterior leukoencephalopathy on MRI following intrathecal methotrexate and [s2]cytarabine[e2] 
	(6, 30)	Balint syndrome	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1107	The authors report a case of [s1]Balint syndrome[e1] with irreversible posterior leukoencephalopathy on MRI following intrathecal [s2]methotrexate[e2] and cytarabine.
	(14, 36)	posterior leukoencephalopathy	cytarabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1108	The authors report a case of Balint syndrome with irreversible [s1]posterior leukoencephalopathy[e1] on MRI following intrathecal methotrexate and [s2]cytarabine[e2] 
	(14, 30)	posterior leukoencephalopathy	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1109	The authors report a case of Balint syndrome with irreversible [s1]posterior leukoencephalopathy[e1] on MRI following intrathecal [s2]methotrexate[e2] and cytarabine.
	(6, 20)	GTBM	Melphalan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1110	We present a unique case of [s1]GTBM[e1] in a patient with myeloma following treatment with [s2]Melphalan[e2] 
	(15, 34)	L-asparaginase	cortical venous thrombosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1111	Patients with lymphoblastic lymphoma who had treatment with [s1]L-asparaginase[e1] and steroid are predisposed to the development of [s2]cortical venous thrombosis[e2] and may have this syndrome in addition to a dural puncture headache.
	(15, 52)	L-asparaginase	dural puncture headache	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1112	Patients with lymphoblastic lymphoma who had treatment with [s1]L-asparaginase[e1] and steroid are predisposed to the development of cortical venous thrombosis and may have this syndrome in addition to a [s2]dural puncture headache[e2] 
	(0, 12)	Interstitial pneumonitis	sirolimus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1113	 [s1]Interstitial pneumonitis[e1] associated with [s2]sirolimus[e2]  a dilemma for lung transplantation.
	(0, 10)	Rapamycin	pneumonitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1114	 [s1]Rapamycin[e1] sirolimus-induced [s2]pneumonitis[e2] has been described previously in renal transplant recipients, and this report describes a stable heart-lung transplant recipient who developed a pulmonary infiltrate that reversed after ceasing SR therapy.
	(3, 9)	sirolimus	pneumonitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1115	Rapamycin [s1]sirolimus[e1] induced [s2]pneumonitis[e2] has been described previously in renal transplant recipients, and this report describes a stable heart-lung transplant recipient who developed a pulmonary infiltrate that reversed after ceasing SR therapy.
	(0, 38)	Rapamycin	pulmonary infiltrate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1116	 [s1]Rapamycin[e1] sirolimus-induced pneumonitis has been described previously in renal transplant recipients, and this report describes a stable heart-lung transplant recipient who developed a [s2]pulmonary infiltrate[e2] that reversed after ceasing SR therapy.
	(3, 37)	sirolimus	pulmonary infiltrate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1117	Rapamycin [s1]sirolimus[e1] induced pneumonitis has been described previously in renal transplant recipients, and this report describes a stable heart-lung transplant recipient who developed a [s2]pulmonary infiltrate[e2] that reversed after ceasing SR therapy.
	(37, 47)	pulmonary infiltrate	SR	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1118	Rapamycin/sirolimus-induced pneumonitis has been described previously in renal transplant recipients, and this report describes a stable heart-lung transplant recipient who developed a [s1]pulmonary infiltrate[e1] that reversed after ceasing [s2]SR[e2] therapy.
	(13, 53)	Rapammune	hyperlipidemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1119	Rapamycin/sirolimus (SR), trade named [s1]Rapammune[e1] (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, hypertension, [s2]hyperlipidemia[e2]  and infection.
	(0, 52)	Rapamycin	hyperlipidemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1120	 [s1]Rapamycin[e1] sirolimus (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, hypertension, [s2]hyperlipidemia[e2]  and infection.
	(3, 52)	sirolimus	hyperlipidemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1121	Rapamycin [s1]sirolimus[e1] (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, hypertension, [s2]hyperlipidemia[e2]  and infection.
	(7, 51)	SR	hyperlipidemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1122	Rapamycin/sirolimus  [s1]SR[e1] , trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, hypertension, [s2]hyperlipidemia[e2]  and infection.
	(13, 50)	Rapammune	hypertension	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1123	Rapamycin/sirolimus (SR), trade named [s1]Rapammune[e1] (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, [s2]hypertension[e2]  hyperlipidemia, and infection.
	(0, 49)	Rapamycin	hypertension	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1124	 [s1]Rapamycin[e1] sirolimus (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, [s2]hypertension[e2]  hyperlipidemia, and infection.
	(3, 49)	sirolimus	hypertension	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1125	Rapamycin [s1]sirolimus[e1] (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, [s2]hypertension[e2]  hyperlipidemia, and infection.
	(7, 48)	SR	hypertension	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1126	Rapamycin/sirolimus  [s1]SR[e1] , trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, [s2]hypertension[e2]  hyperlipidemia, and infection.
	(13, 59)	Rapammune	infection	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1127	Rapamycin/sirolimus (SR), trade named [s1]Rapammune[e1] (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, hypertension, hyperlipidemia, and [s2]infection[e2] 
	(0, 58)	Rapamycin	infection	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1128	 [s1]Rapamycin[e1] sirolimus (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, hypertension, hyperlipidemia, and [s2]infection[e2] 
	(3, 58)	sirolimus	infection	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1129	Rapamycin [s1]sirolimus[e1] (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, hypertension, hyperlipidemia, and [s2]infection[e2] 
	(7, 57)	SR	infection	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1130	Rapamycin/sirolimus  [s1]SR[e1] , trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with myelosuppression, hypertension, hyperlipidemia, and [s2]infection[e2] 
	(13, 43)	Rapammune	myelosuppression	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1131	Rapamycin/sirolimus (SR), trade named [s1]Rapammune[e1] (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with [s2]myelosuppression[e2]  hypertension, hyperlipidemia, and infection.
	(0, 42)	Rapamycin	myelosuppression	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1132	 [s1]Rapamycin[e1] sirolimus (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with [s2]myelosuppression[e2]  hypertension, hyperlipidemia, and infection.
	(3, 42)	sirolimus	myelosuppression	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1133	Rapamycin [s1]sirolimus[e1] (SR), trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with [s2]myelosuppression[e2]  hypertension, hyperlipidemia, and infection.
	(7, 41)	SR	myelosuppression	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1134	Rapamycin/sirolimus  [s1]SR[e1] , trade named Rapammune (Wyeth-Ayerst, Sydney, Australia), is a potent immunosuppressive drug associated with [s2]myelosuppression[e2]  hypertension, hyperlipidemia, and infection.
	(8, 41)	fever	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1135	A 16-year-old boy developed [s1]fever[e1]  generalized rigidity, leukocytosis, and increased serum transaminase and creatine kinase levels while receiving treatment with olanzapine and [s2]lithium[e2] 
	(8, 37)	fever	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1136	A 16-year-old boy developed [s1]fever[e1]  generalized rigidity, leukocytosis, and increased serum transaminase and creatine kinase levels while receiving treatment with [s2]olanzapine[e2] and lithium.
	(10, 41)	generalized rigidity	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1137	A 16-year-old boy developed fever, [s1]generalized rigidity[e1]  leukocytosis, and increased serum transaminase and creatine kinase levels while receiving treatment with olanzapine and [s2]lithium[e2] 
	(10, 37)	generalized rigidity	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1138	A 16-year-old boy developed fever, [s1]generalized rigidity[e1]  leukocytosis, and increased serum transaminase and creatine kinase levels while receiving treatment with [s2]olanzapine[e2] and lithium.
	(21, 42)	increased serum transaminase and creatine kinase	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1139	A 16-year-old boy developed fever, generalized rigidity, leukocytosis, and [s1]increased serum transaminase and creatine kinase[e1] levels while receiving treatment with olanzapine and [s2]lithium[e2] 
	(21, 38)	increased serum transaminase and creatine kinase	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1140	A 16-year-old boy developed fever, generalized rigidity, leukocytosis, and [s1]increased serum transaminase and creatine kinase[e1] levels while receiving treatment with [s2]olanzapine[e2] and lithium.
	(14, 41)	leukocytosis	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1141	A 16-year-old boy developed fever, generalized rigidity, [s1]leukocytosis[e1]  and increased serum transaminase and creatine kinase levels while receiving treatment with olanzapine and [s2]lithium[e2] 
	(14, 37)	leukocytosis	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1142	A 16-year-old boy developed fever, generalized rigidity, [s1]leukocytosis[e1]  and increased serum transaminase and creatine kinase levels while receiving treatment with [s2]olanzapine[e2] and lithium.
	(6, 19)	lithium	NMS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1143	Concomitant administration of [s1]lithium[e1] with olanzapine may place patients at risk for [s2]NMS[e2] 
	(8, 19)	olanzapine	NMS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1144	Concomitant administration of lithium with [s1]olanzapine[e1] may place patients at risk for [s2]NMS[e2] 
	(0, 16)	Neuroleptic malignant syndrome	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1145	 [s1]Neuroleptic malignant syndrome[e1] in an adolescent receiving olanzapine [s2]lithium[e2] combination therapy.
	(0, 13)	Neuroleptic malignant syndrome	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1146	 [s1]Neuroleptic malignant syndrome[e1] in an adolescent receiving [s2]olanzapine[e2] lithium combination therapy.
	(1, 17)	6-MP	hepatotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1147	Both [s1]6-MP[e1] and AZA are widely used and are known to cause [s2]hepatotoxicity[e2] in a proportion of patients.
	(5, 17)	AZA	hepatotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1148	Both 6-MP and [s1]AZA[e1] are widely used and are known to cause [s2]hepatotoxicity[e2] in a proportion of patients.
	(0, 10)	Hepatotoxicity	6-thioguanine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1149	 [s1]Hepatotoxicity[e1] associated with [s2]6-thioguanine[e2] therapy for Crohn's disease.
	(29, 36)	thiopurine	hepatic injury	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1150	This case highlights the need to monitor liver enzymes in patients treated with 6-TG and identifies the need for additional research focused on the mechanism of [s1]thiopurine[e1] induced [s2]hepatic injury[e2] 
	(7, 30)	abnormal liver enzymes	6-TG	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1151	We believe the temporal association of the [s1]abnormal liver enzymes[e1] in this patient, in the absence of other offending agents, argues strongly in favor of [s2]6-TG[e2] as a cause of liver enzyme abnormalities.
	(28, 38)	6-TG	liver enzyme abnormalities	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1152	We believe the temporal association of the abnormal liver enzymes in this patient, in the absence of other offending agents, argues strongly in favor of [s1]6-TG[e1] as a cause of [s2]liver enzyme abnormalities[e2] 
	(6, 19)	elevation of serum transaminases	6-TG	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1153	We describe a case of significant [s1]elevation of serum transaminases[e1] in a patient treated with [s2]6-TG[e2] for a flare of Crohn's disease.
	(13, 20)	lisinopril	multiorgan failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1154	Early peritoneal dialysis has not previously been reported for [s1]lisinopril[e1] induced [s2]multiorgan failure[e2] 
	(3, 35)	panhypogammaglobulinaemia	cyclophosphamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1155	We observed transient [s1]panhypogammaglobulinaemia[e1] in a patient with neuropsychiatric SLE after treatment with prednisolone and [s2]cyclophosphamide[e2] 
	(3, 29)	panhypogammaglobulinaemia	prednisolone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1156	We observed transient [s1]panhypogammaglobulinaemia[e1] in a patient with neuropsychiatric SLE after treatment with [s2]prednisolone[e2] and cyclophosphamide.
	(0, 32)	Fulminant hepatic failure	propranolol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1157	 [s1]Fulminant hepatic failure[e1] developed in a 24-year-old black woman who had been treated with propylthiouracil and [s2]propranolol[e2] for hyperthyroidism.
	(0, 25)	Fulminant hepatic failure	propylthiouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1158	 [s1]Fulminant hepatic failure[e1] developed in a 24-year-old black woman who had been treated with [s2]propylthiouracil[e2] and propranolol for hyperthyroidism.
	(0, 18)	Fulminant hepatitis	propylthiouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1159	 [s1]Fulminant hepatitis[e1] and lymphocyte sensitization due to [s2]propylthiouracil[e2] 
	(17, 41)	propylthiouracil	hepatic injury	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1160	These observations indicate that submassive hepatic necrosis may result from treatment with [s1]propylthiouracil[e1] and are consistent with the notion that sensitization mechanisms may be responsible for the [s2]hepatic injury[e2] induced by this drug.
	(4, 19)	submassive hepatic necrosis	propylthiouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1161	These observations indicate that [s1]submassive hepatic necrosis[e1] may result from treatment with [s2]propylthiouracil[e2] and are consistent with the notion that sensitization mechanisms may be responsible for the hepatic injury induced by this drug.
	(3, 28)	hypothermia	risperidone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1162	The diagnosis of [s1]hypothermia[e1] was delayed until it was apparent for several days but resolved with the discontinuation of [s2]risperidone[e2] and continuation of clozapine.
	(9, 25)	hypothermia	risperidone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1163	This is a case report of subtle, mild [s1]hypothermia[e1] in a 54-year old female patient receiving [s2]risperidone[e2] for schizophrenia.
	(0, 24)	Akathisia	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1164	 [s1]Akathisia[e1] is a relatively rare side effect with the newer atypical antipsychotic agents, particularly [s2]clozapine[e2]  and is easily misdiagnosed in children.
	(0, 6)	Clozapine	akathisia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1165	 [s1]Clozapine[e1] induced [s2]akathisia[e2] in children with schizophrenia.
	(9, 15)	clozapine	akathisia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1166	Two cases of childhood-onset schizophrenia associated with [s1]clozapine[e1] induced [s2]akathisia[e2] responsive to beta-blocker treatment are described.
	(14, 27)	lithium	blindness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1167	After reviewing the literature we suggest the CPM was a complication of [s1]lithium[e1] toxicity which affected the lateral geniculate nucleus which produced [s2]blindness[e2] 
	(7, 16)	CPM	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1168	After reviewing the literature we suggest the [s1]CPM[e1] was a complication of [s2]lithium[e2] toxicity which affected the lateral geniculate nucleus which produced blindness.
	(0, 19)	Central pontine myelinolysis	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1169	 [s1]Central pontine myelinolysis[e1] manifested by temporary blindness: a possible complication of [s2]lithium[e2] toxicity.
	(9, 18)	temporary blindness	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1170	Central pontine myelinolysis manifested by [s1]temporary blindness[e1]  a possible complication of [s2]lithium[e2] toxicity.
	(5, 19)	propylthiouracil	elevated hepatic enzymes	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1171	Antithyroid treatment with [s1]propylthiouracil[e1] (PTU) resulted in [s2]elevated hepatic enzymes[e2] and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ).
	(11, 17)	PTU	elevated hepatic enzymes	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1172	Antithyroid treatment with propylthiouracil  [s1]PTU[e1]  resulted in [s2]elevated hepatic enzymes[e2] and after the 12th week of pregnancy treatment was changed to carbimazole (CBZ).
	(15, 22)	hepatic impairment	propylthiouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1173	Successful treatment with carbimazole of a hyperthyroid pregnancy with [s1]hepatic impairment[e1] after [s2]propylthiouracil[e2] administration: a case report.
	(5, 24)	IFN-alpha	MPGN	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1174	Interferon-alpha  [s1]IFN-alpha[e1]  may precipitate or exacerbate the occurrence of [s2]MPGN[e2] 
	(0, 26)	Interferon-alpha	MPGN	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1175	 [s1]Interferon-alpha[e1] (IFN-alpha) may precipitate or exacerbate the occurrence of [s2]MPGN[e2] 
	(0, 9)	Minimal change disease	IFN-alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1176	 [s1]Minimal change disease[e1] in a patient receiving [s2]IFN-alpha[e2] therapy for chronic hepatitis C virus infection.
	(21, 41)	chronic myeloid leukaemia	hydroxyurea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1177	A 58-yr-old male patient with essential thrombocythaemia (ET) developed [s1]chronic myeloid leukaemia[e1] (CML) after continuous uneventful treatment with [s2]hydroxyurea[e2] for 18 yr.
	(28, 39)	CML	hydroxyurea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1178	A 58-yr-old male patient with essential thrombocythaemia (ET) developed chronic myeloid leukaemia  [s1]CML[e1]  after continuous uneventful treatment with [s2]hydroxyurea[e2] for 18 yr.
	(2, 16)	Philadelphia positive chronic myeloid leukaemia	hydroxyurea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1179	Emergence of [s1]Philadelphia positive chronic myeloid leukaemia[e1] during treatment with [s2]hydroxyurea[e2] for Philadelphia negative essential thrombocythaemia.
	(12, 19)	CML	hydroxyurea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1180	There are no previous reports in the literature about the emergence of [s1]CML[e1] during treatment with [s2]hydroxyurea[e2] 
	(12, 20)	chloroquine toxicity	chloroquine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1181	His fever resolved, but he developed symptoms consistent with those of [s1]chloroquine toxicity[e1]  [s2]chloroquine[e2] toxicity.
	(7, 16)	severe chloroquine toxicity	chloroquine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1182	OBJECTIVE: To report a case of [s1]severe chloroquine toxicity[e1]  [s2]chloroquine[e2] toxicity in the presence of high-grade chloroquine-resistant Plasmodium vivax.
	(0, 5)	Toxicity	chloroquine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1183	 [s1]Toxicity[e1] related to [s2]chloroquine[e2] treatment of resistant vivax malaria.
	(21, 28)	fever	carbimazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1184	A 72-year-old woman with a history of thyrotoxicosis presented with sore throat and [s1]fever[e1] two weeks after starting [s2]carbimazole[e2] 
	(18, 28)	sore throat	carbimazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1185	A 72-year-old woman with a history of thyrotoxicosis presented with [s1]sore throat[e1] and fever two weeks after starting [s2]carbimazole[e2] 
	(2, 10)	carbimazole	agranulocytosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1186	Treatment of [s1]carbimazole[e1] induced [s2]agranulocytosis[e2] and sepsis with granulocyte colony stimulating factor.
	(2, 16)	carbimazole	sepsis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1187	Treatment of [s1]carbimazole[e1] induced agranulocytosis and [s2]sepsis[e2] with granulocyte colony stimulating factor.
	(5, 22)	agranulocytosis	carbimazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1188	We present the management of [s1]agranulocytosis[e1] and neutropenic sepsis secondary to [s2]carbimazole[e2] with recombinant human granulocyte colony stimulating factor (G-CSF).
	(11, 22)	neutropenic sepsis	carbimazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1189	We present the management of agranulocytosis and [s1]neutropenic sepsis[e1] secondary to [s2]carbimazole[e2] with recombinant human granulocyte colony stimulating factor (G-CSF).
	(0, 20)	Comeoscleral perforation	mitomycin C	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1190	 [s1]Comeoscleral perforation[e1] after pterygium excision and intraoperative [s2]mitomycin C[e2] 
	(7, 30)	corneoscleral melting	mitomycin C	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1191	To the best of our knowledge, [s1]corneoscleral melting[e1] in the first postoperative week after a single intraoperative application of [s2]mitomycin C[e2] has not been reported.
	(15, 23)	bullous drug reaction	sulfonamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1192	A 71-year-old man, who had a history of a previous [s1]bullous drug reaction[e1] to a [s2]sulfonamide[e2]  began receiving an ophthalmic preparation that contained sulfacetamide sodium.
	(9, 26)	sulfonamide	Stevens-Johnson syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1193	The patient received only the ophthalmic [s1]sulfonamide[e1]  and it was used for one day, but he developed [s2]Stevens-Johnson syndrome[e2] 
	(1, 15)	sulfonamides	erythema multiforme	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1194	The [s1]sulfonamides[e1] are the best verified drug-trigger for [s2]erythema multiforme[e2] and Stevens-Johnson syndrome.
	(1, 22)	sulfonamides	Stevens-Johnson syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1195	The [s1]sulfonamides[e1] are the best verified drug-trigger for erythema multiforme and [s2]Stevens-Johnson syndrome[e2] 
	(10, 19)	diabetes insipidus	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1196	Based on these findings, the patient was diagnosed with [s1]diabetes insipidus[e1] secondary to [s2]lithium[e2] therapy and was treated successfully with amiloride.
	(6, 10)	lithium toxicity	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1197	Clinicians have been aware of [s1]lithium toxicity[e1]  [s2]lithium[e2] toxicity for many years and traditionally have administered thiazide diuretics for lithium-induced polyuria and nephrogenic diabetes insipidus.
	(6, 31)	lithium	nephrogenic diabetes insipidus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1198	Clinicians have been aware of [s1]lithium[e1] toxicity for many years and traditionally have administered thiazide diuretics for lithium-induced polyuria and [s2]nephrogenic diabetes insipidus[e2] 
	(6, 31)	lithium	nephrogenic diabetes insipidus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1199	Clinicians have been aware of [s1]lithium[e1] toxicity for many years and traditionally have administered thiazide diuretics for lithium-induced polyuria and [s2]nephrogenic diabetes insipidus[e2] 
	(6, 28)	lithium	polyuria	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1200	Clinicians have been aware of [s1]lithium[e1] toxicity for many years and traditionally have administered thiazide diuretics for lithium-induced [s2]polyuria[e2] and nephrogenic diabetes insipidus.
	(6, 28)	lithium	polyuria	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1201	Clinicians have been aware of [s1]lithium[e1] toxicity for many years and traditionally have administered thiazide diuretics for lithium-induced [s2]polyuria[e2] and nephrogenic diabetes insipidus.
	(2, 6)	lithium	diabetes insipidus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1202	Treatment of [s1]lithium[e1] induced [s2]diabetes insipidus[e2] with amiloride.
	(0, 17)	Systemic capillary leak syndrome	G-CSF	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1203	 [s1]Systemic capillary leak syndrome[e1] after granulocyte colony-stimulating factor  [s2]G-CSF[e2] .
	(0, 9)	Systemic capillary leak syndrome	granulocyte colony-stimulating factor	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1204	 [s1]Systemic capillary leak syndrome[e1] after [s2]granulocyte colony-stimulating factor[e2] (G-CSF).
	(10, 22)	CLS	granulocyte colony-stimulating factor	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1205	We present two cases in which both patients suffered with [s1]CLS[e1]  which we believe was caused following administration of [s2]granulocyte colony-stimulating factor[e2]  to our knowledge not described in the intensive care patient previously.
	(0, 37)	FK506	neurologic abnormalities	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1206	 [s1]FK506[e1]  which began to be administered 12 days earlier, rose to a level of 44 ng/mL (normal range, 10-20 ng/mL) 1 day before [s2]neurologic abnormalities[e2] began.
	(3, 9)	speech loss	FK506	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1207	Rapid identification of [s1]speech loss[e1] linked to [s2]FK506[e2] may be important because reduction or cessation of the drug may be associated with reverse of speech loss.
	(4, 22)	FK506	mutism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1208	Tacrolimus  [s1]FK506[e1] , an immunosuppressant, has been associated with [s2]mutism[e2] in adults after liver transplant.
	(0, 24)	Tacrolimus	mutism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1209	 [s1]Tacrolimus[e1] (FK506), an immunosuppressant, has been associated with [s2]mutism[e2] in adults after liver transplant.
	(4, 11)	FK506	mutism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1210	Tacrolimus  [s1]FK506[e1] -induced [s2]mutism[e2] after liver transplant.
	(0, 13)	Tacrolimus	mutism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1211	 [s1]Tacrolimus[e1] (FK506)-induced [s2]mutism[e2] after liver transplant.
	(4, 26)	insulin	oedema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1212	Does the use of [s1]insulin[e1] in a patient with liver dysfunction increase water retention in the body, i.e. cause insulin [s2]oedema[e2] 
	(4, 23)	insulin	ascites	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1213	Soon after introduction of [s1]insulin[e1] therapy, she developed severe anasarca, including marked peripheral oedema, [s2]ascites[e2] and pleural effusion.
	(4, 18)	insulin	peripheral oedema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1214	Soon after introduction of [s1]insulin[e1] therapy, she developed severe anasarca, including marked [s2]peripheral oedema[e2]  ascites and pleural effusion.
	(4, 27)	insulin	pleural effusion	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1215	Soon after introduction of [s1]insulin[e1] therapy, she developed severe anasarca, including marked peripheral oedema, ascites and [s2]pleural effusion[e2] 
	(4, 11)	insulin	severe anasarca	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1216	Soon after introduction of [s1]insulin[e1] therapy, she developed [s2]severe anasarca[e2]  including marked peripheral oedema, ascites and pleural effusion.
	(17, 38)	insulin	hyperinsulinaemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1217	The induced hyperglycaemia could not be controlled sufficiently, despite a high dose of [s1]insulin[e1] (> 110 units/day), suggesting the existence of insulin insensitivity and [s2]hyperinsulinaemia[e2] 
	(17, 32)	insulin	insulin insensitivity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1218	The induced hyperglycaemia could not be controlled sufficiently, despite a high dose of [s1]insulin[e1] (> 110 units/day), suggesting the existence of [s2]insulin insensitivity[e2] and hyperinsulinaemia.
	(8, 13)	insulin	anti-natriuresis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1219	We conjectured that the side effects of [s1]insulin[e1]  such as [s2]anti-natriuresis[e2] and increased vascular permeability, might be pronounced in the presence of the hepatic dysfunction that accompanies insulin insensitivity, hyperinsulinaemia and hypoalbuminaemia.
	(8, 48)	insulin	hyperinsulinaemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1220	We conjectured that the side effects of [s1]insulin[e1]  such as anti-natriuresis and increased vascular permeability, might be pronounced in the presence of the hepatic dysfunction that accompanies insulin insensitivity, [s2]hyperinsulinaemia[e2] and hypoalbuminaemia.
	(8, 54)	insulin	hypoalbuminaemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1221	We conjectured that the side effects of [s1]insulin[e1]  such as anti-natriuresis and increased vascular permeability, might be pronounced in the presence of the hepatic dysfunction that accompanies insulin insensitivity, hyperinsulinaemia and [s2]hypoalbuminaemia[e2] 
	(8, 20)	insulin	increased vascular permeability	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1222	We conjectured that the side effects of [s1]insulin[e1]  such as anti-natriuresis and [s2]increased vascular permeability[e2]  might be pronounced in the presence of the hepatic dysfunction that accompanies insulin insensitivity, hyperinsulinaemia and hypoalbuminaemia.
	(8, 42)	insulin	insulin insensitivity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1223	We conjectured that the side effects of [s1]insulin[e1]  such as anti-natriuresis and increased vascular permeability, might be pronounced in the presence of the hepatic dysfunction that accompanies [s2]insulin insensitivity[e2]  hyperinsulinaemia and hypoalbuminaemia.
	(6, 21)	prednisolone	diabetic milieu deteriorated	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1224	While 40 mg/day of [s1]prednisolone[e1] improved hepatic dysfunction dramatically, her [s2]diabetic milieu deteriorated[e2] seriously.
	(3, 11)	methotrexate	acute cerebellar syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1225	Intrathecal [s1]methotrexate[e1] induced [s2]acute cerebellar syndrome[e2] 
	(6, 21)	acute cerebellar syndrome	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1226	We describe a patient who developed [s1]acute cerebellar syndrome[e1] after prophylactic intrathecal [s2]methotrexate[e2] administration and recovered spontaneously.
	(0, 21)	Angioimmunoblastic lymphadenopathy with dysproteinemia	doxycycline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1227	 [s1]Angioimmunoblastic lymphadenopathy with dysproteinemia[e1] following [s2]doxycycline[e2] administration.
	(5, 34)	AILD	doxycycline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1228	We report a case of [s1]AILD[e1] in an 80-year-old male who presented with a generalized pruritic maculopapular eruption and fever following [s2]doxycycline[e2] administration.
	(30, 34)	fever	doxycycline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1229	We report a case of AILD in an 80-year-old male who presented with a generalized pruritic maculopapular eruption and [s1]fever[e1] following [s2]doxycycline[e2] administration.
	(19, 34)	generalized pruritic maculopapular eruption	doxycycline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1230	We report a case of AILD in an 80-year-old male who presented with a [s1]generalized pruritic maculopapular eruption[e1] and fever following [s2]doxycycline[e2] administration.
	(0, 8)	Anaphylaxis	isoniazid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1231	 [s1]Anaphylaxis[e1] from [s2]isoniazid[e2] is a possible side effect to this commonly prescribed antibiotic.
	(0, 7)	Isoniazid	anaphylaxis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1232	 [s1]Isoniazid[e1] induced [s2]anaphylaxis[e2] 
	(15, 35)	low plasma parathyroid hormone	magnesium sulfate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1233	A case is reported in which severe hypocalcemia, with a [s1]low plasma parathyroid hormone[e1] (PTH) concentration, resulted from the therapeutic use of [s2]magnesium sulfate[e2] for toxemia of pregnancy.
	(21, 33)	PTH	magnesium sulfate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1234	A case is reported in which severe hypocalcemia, with a low plasma parathyroid hormone  [s1]PTH[e1]  concentration, resulted from the therapeutic use of [s2]magnesium sulfate[e2] for toxemia of pregnancy.
	(6, 34)	severe hypocalcemia	magnesium sulfate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1235	A case is reported in which [s1]severe hypocalcemia[e1]  with a low plasma parathyroid hormone (PTH) concentration, resulted from the therapeutic use of [s2]magnesium sulfate[e2] for toxemia of pregnancy.
	(0, 8)	Carbamazepine	hyponatremia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1236	 [s1]Carbamazepine[e1] related [s2]hyponatremia[e2] following cardiopulmonary bypass.
	(5, 13)	carbamazepine	hyponatremia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1237	We discuss the association between [s1]carbamazepine[e1] and [s2]hyponatremia[e2] and the causes of hyponatremia after cardiopulmonary bypass.
	(1, 10)	5-ASA	polyneuropathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1238	After [s1]5-ASA[e1] was discontinued, the [s2]polyneuropathy[e2] symptoms recovered gradually.
	(0, 10)	Sensorimotor polyneuropathy	5-aminosalicylic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1239	 [s1]Sensorimotor polyneuropathy[e1] with [s2]5-aminosalicylic acid[e2]  a case report.
	(6, 20)	sensorimotor polyneuropathy	5-ASA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1240	This clinical course suggests that the [s1]sensorimotor polyneuropathy[e1] may have been caused by [s2]5-ASA[e2] 
	(6, 34)	5-aminosalicylic acid	atrophy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1241	When SASP was changed to [s1]5-aminosalicylic acid[e1] (5-ASA), his skin eruptions were resolved, however, he developed weakness and [s2]atrophy[e2] in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance.
	(14, 32)	5-ASA	atrophy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1242	When SASP was changed to 5-aminosalicylic acid  [s1]5-ASA[e1] , his skin eruptions were resolved, however, he developed weakness and [s2]atrophy[e2] in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance.
	(6, 58)	5-aminosalicylic acid	gait disturbance	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1243	When SASP was changed to [s1]5-aminosalicylic acid[e1] (5-ASA), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and [s2]gait disturbance[e2] 
	(14, 56)	5-ASA	gait disturbance	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1244	When SASP was changed to 5-aminosalicylic acid  [s1]5-ASA[e1] , his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and [s2]gait disturbance[e2] 
	(6, 32)	5-aminosalicylic acid	weakness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1245	When SASP was changed to [s1]5-aminosalicylic acid[e1] (5-ASA), his skin eruptions were resolved, however, he developed [s2]weakness[e2] and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance.
	(14, 30)	5-ASA	weakness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1246	When SASP was changed to 5-aminosalicylic acid  [s1]5-ASA[e1] , his skin eruptions were resolved, however, he developed [s2]weakness[e2] and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance.
	(6, 45)	5-aminosalicylic acid	worsening of the dysesthesia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1247	When SASP was changed to [s1]5-aminosalicylic acid[e1] (5-ASA), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive [s2]worsening of the dysesthesia[e2] in his legs and gait disturbance.
	(14, 43)	5-ASA	worsening of the dysesthesia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1248	When SASP was changed to 5-aminosalicylic acid  [s1]5-ASA[e1] , his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive [s2]worsening of the dysesthesia[e2] in his legs and gait disturbance.
	(0, 16)	Disseminated cellulitic cryptococcosis	prednisone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1249	 [s1]Disseminated cellulitic cryptococcosis[e1] in the setting of [s2]prednisone[e2] monotherapy for pemphigus vulgaris.
	(13, 31)	atypical lymphocytosis	SASP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1250	In both cases, high fever, skin rash, liver dysfunction and [s1]atypical lymphocytosis[e1] developed 3 weeks after initiating treatment with [s2]SASP[e2] 
	(4, 30)	high fever	SASP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1251	In both cases, [s1]high fever[e1]  skin rash, liver dysfunction and atypical lymphocytosis developed 3 weeks after initiating treatment with [s2]SASP[e2] 
	(10, 31)	liver dysfunction	SASP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1252	In both cases, high fever, skin rash, [s1]liver dysfunction[e1] and atypical lymphocytosis developed 3 weeks after initiating treatment with [s2]SASP[e2] 
	(7, 30)	skin rash	SASP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1253	In both cases, high fever, [s1]skin rash[e1]  liver dysfunction and atypical lymphocytosis developed 3 weeks after initiating treatment with [s2]SASP[e2] 
	(14, 26)	infectious mononucleosis-like syndrome	salazosulfapyridine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1254	Slow acetylator genotypes as a possible risk factor for [s1]infectious mononucleosis-like syndrome[e1] induced by [s2]salazosulfapyridine[e2] 
	(5, 17)	infectious mononucleosis-like syndrome	salazosulfapyridine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1255	We report two patients with [s1]infectious mononucleosis-like syndrome[e1] induced by [s2]salazosulfapyridine[e2] (SASP).
	(5, 25)	infectious mononucleosis-like syndrome	SASP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1256	We report two patients with [s1]infectious mononucleosis-like syndrome[e1] induced by salazosulfapyridine  [s2]SASP[e2] .
	(24, 43)	infliximab	lupus-like syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1257	A 45-year-old woman with steroid-dependent Crohn's colitis, successfully managed with maintenance [s1]infliximab[e1] infusions and methotrexate, developed a [s2]lupus-like syndrome[e2] eight months after her initial infusion.
	(33, 42)	methotrexate	lupus-like syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1258	A 45-year-old woman with steroid-dependent Crohn's colitis, successfully managed with maintenance infliximab infusions and [s1]methotrexate[e1]  developed a [s2]lupus-like syndrome[e2] eight months after her initial infusion.
	(1, 10)	lupus-like syndrome	infliximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1259	A [s1]lupus-like syndrome[e1] associated with [s2]infliximab[e2] therapy.
	(0, 11)	Infliximab	lupus-like syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1260	 [s1]Infliximab[e1] therapy may cause a [s2]lupus-like syndrome[e2] that is reversible upon discontinuing this agent.
	(9, 22)	infliximab	lupus-like clinical syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1261	We report in detail an unusual adverse reaction to [s1]infliximab[e1] therapy, a drug-induced [s2]lupus-like clinical syndrome[e2] 
	(19, 29)	IFNalpha	renal dysfunction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1262	Chronic myelogenous leukemia (CML), hepatitis C, and interferon alpha  [s1]IFNalpha[e1]  have all been associated with [s2]renal dysfunction[e2] 
	(15, 31)	interferon alpha	renal dysfunction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1263	Chronic myelogenous leukemia (CML), hepatitis C, and [s1]interferon alpha[e1] (IFNalpha) have all been associated with [s2]renal dysfunction[e2] 
	(9, 15)	renal abnormalities	IFNalpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1264	Despite the underlying hepatitis C, this case represents [s1]renal abnormalities[e1] consistent with [s2]IFNalpha[e2] therapy for CML.
	(0, 8)	Interferon-alpha	focal segmental glomerulosclerosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1265	 [s1]Interferon-alpha[e1] induced [s2]focal segmental glomerulosclerosis[e2] in chronic myelogenous leukemia: a case report and review of the literature.
	(5, 31)	focal segmental glomerulosclerosis	IFNalpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1266	The renal biopsy showed [s1]focal segmental glomerulosclerosis[e1]  which has only been previously reported in two cases of CML treated with [s2]IFNalpha[e2] 
	(1, 13)	autoimmune hemolytic anemia	rituximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1267	Severe [s1]autoimmune hemolytic anemia[e1] following [s2]rituximab[e2] therapy in a patient with a lymphoproliferative disorder.
	(22, 31)	destruction of CD20 positive cells	rituximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1268	The pathophysiological mechanisms remain unknown, although the drug could act through massive cytokines liberation after [s1]destruction of CD20 positive cells[e1] by [s2]rituximab[e2] 
	(16, 31)	massive cytokines liberation	rituximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1269	The pathophysiological mechanisms remain unknown, although the drug could act through [s1]massive cytokines liberation[e1] after destruction of CD20 positive cells by [s2]rituximab[e2] 
	(11, 19)	rituximab	autoimmune hemolytic anemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1270	We report the first case, to our knowledge, of [s1]rituximab[e1] related [s2]autoimmune hemolytic anemia[e2] 
	(3, 11)	acute transverse myelitis	hepatitis B vaccination	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1271	Early-onset [s1]acute transverse myelitis[e1] following [s2]hepatitis B vaccination[e2] and respiratory infection: case report.
	(16, 34)	acute onset tetraparesia	hepatitis B vaccination	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1272	In this paper, we report a case of 3 years-old boy who developed [s1]acute onset tetraparesia[e1] following a viral respiratory infecction and [s2]hepatitis B vaccination[e2] 
	(14, 22)	diphenhydramine	cardiotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1273	Although it would be expected that, like other type IA toxicities, [s1]diphenhydramine[e1] induced [s2]cardiotoxicity[e2] could be responsive to hypertonic sodium bicarbonate, this finding is largely unappreciated.
	(0, 10)	Diphenhydramine	dysrhythmia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1274	 [s1]Diphenhydramine[e1] induced wide complex [s2]dysrhythmia[e2] responds to treatment with sodium bicarbonate.
	(3, 18)	diphenhydramine	cardiac toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1275	However, because [s1]diphenhydramine[e1] also exhibits type IA sodium channel blockade, [s2]cardiac toxicity[e2] is also possible.
	(5, 13)	diphenhydramine	cardiac toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1276	We describe 3 cases of [s1]diphenhydramine[e1] induced [s2]cardiac toxicity[e2] that were responsive to bicarbonate.
	(20, 30)	systemic candidiasis	cyclophosphamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1277	We describe a patient with extranodal non-Hodgkin lymphoma who developed [s1]systemic candidiasis[e1] after treatment with a [s2]cyclophosphamide[e2] based chemotherapy regimen.
	(0, 16)	Stevens-Johnson syndrome	prednisolone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1278	 [s1]Stevens-Johnson syndrome[e1] in a boy with nephrotic syndrome during [s2]prednisolone[e2] therapy.
	(5, 29)	SJS	prednisolone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1279	We report a case of [s1]SJS[e1] in a 14-year-old male with nephrotic syndrome, who was treated with oral [s2]prednisolone[e2] for 6 weeks.
	(24, 30)	reversal reaction	dapsone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1280	A 25-year-old man with a history of mid-borderline (BB) Hansen's disease developing a [s1]reversal reaction[e1] after starting [s2]dapsone[e2] and rifampin therapy is presented.
	(24, 34)	reversal reaction	rifampin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1281	A 25-year-old man with a history of mid-borderline (BB) Hansen's disease developing a [s1]reversal reaction[e1] after starting dapsone and [s2]rifampin[e2] therapy is presented.
	(6, 15)	neuropathic side effects	thalidomide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1282	However, in order to avoid [s1]neuropathic side effects[e1]  patients under [s2]thalidomide[e2] therapy should be monitored every 6 months with nerve conduction studies while taking the drug.
	(13, 29)	interferon alpha	neurological manifestations	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1283	After a two-month interruption of interferon administration, natural [s1]interferon alpha[e1] was given but followed by another episode of the same [s2]neurological manifestations[e2] 
	(12, 44)	bilateral optic neuritis	recombinant interferon alpha-2a	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1284	Case 1, a 62-year-old woman, developed [s1]bilateral optic neuritis[e1] with decreased sensation of vibration and increased deep tendon reflex in the lower extremities after a seven-month use of [s2]recombinant interferon alpha-2a[e2] for chronic active hepatitis C.
	(18, 44)	decreased sensation of vibration	recombinant interferon alpha-2a	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1285	Case 1, a 62-year-old woman, developed bilateral optic neuritis with [s1]decreased sensation of vibration[e1] and increased deep tendon reflex in the lower extremities after a seven-month use of [s2]recombinant interferon alpha-2a[e2] for chronic active hepatitis C.
	(23, 44)	increased deep tendon reflex	recombinant interferon alpha-2a	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1286	Case 1, a 62-year-old woman, developed bilateral optic neuritis with decreased sensation of vibration and [s1]increased deep tendon reflex[e1] in the lower extremities after a seven-month use of [s2]recombinant interferon alpha-2a[e2] for chronic active hepatitis C.
	(12, 45)	bilateral optic neuritis	recombinant interferon alpha-2b	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1287	Case 2, a 29-year-old woman, developed [s1]bilateral optic neuritis[e1] combined with numbness of the lower extremities as well as bowel and bladder dysfunction after a 22-month use of [s2]recombinant interferon alpha-2b[e2] for chronic myelogenous leukemia.
	(31, 45)	bowel and bladder dysfunction	recombinant interferon alpha-2b	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1288	Case 2, a 29-year-old woman, developed bilateral optic neuritis combined with numbness of the lower extremities as well as [s1]bowel and bladder dysfunction[e1] after a 22-month use of [s2]recombinant interferon alpha-2b[e2] for chronic myelogenous leukemia.
	(19, 45)	numbness of the lower extremities	recombinant interferon alpha-2b	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1289	Case 2, a 29-year-old woman, developed bilateral optic neuritis combined with [s1]numbness of the lower extremities[e1] as well as bowel and bladder dysfunction after a 22-month use of [s2]recombinant interferon alpha-2b[e2] for chronic myelogenous leukemia.
	(10, 37)	neurological signs	interferon alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1290	CONCLUSIONS: Optic neuritis in combination with other [s1]neurological signs[e1]  simulating multiple sclerosis, should be included in the list of adverse effects of recombinant and natural [s2]interferon alpha[e2] administration.
	(2, 38)	Optic neuritis	interferon alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1291	CONCLUSIONS: [s1]Optic neuritis[e1] in combination with other neurological signs, simulating multiple sclerosis, should be included in the list of adverse effects of recombinant and natural [s2]interferon alpha[e2] administration.
	(0, 11)	Multiple sclerosis-like disease	alpha interferon	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1292	 [s1]Multiple sclerosis-like disease[e1] secondary to [s2]alpha interferon[e2] 
	(4, 24)	bilateral optic neuritis	interferon alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1293	PURPOSE: To describe [s1]bilateral optic neuritis[e1] that occurred as an adverse effect of recombinant and natural [s2]interferon alpha[e2] administration.
	(0, 19)	Acute abdomen	tamoxifen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1294	 [s1]Acute abdomen[e1] due to endometriosis in a premenopausal woman taking [s2]tamoxifen[e2] 
	(4, 19)	endometriosis	tamoxifen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1295	Acute abdomen due to [s1]endometriosis[e1] in a premenopausal woman taking [s2]tamoxifen[e2] 
	(13, 33)	tamoxifen	endometriosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1296	We describe a premenopausal woman who, while having [s1]tamoxifen[e1] due to a diagnosis of in situ ductal carcinoma, developed [s2]endometriosis[e2] requiring surgery.
	(5, 11)	dapsone	agranulocytosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1297	A case report of fatal [s1]dapsone[e1] induced [s2]agranulocytosis[e2] in an Indian mid-borderline leprosy patient.
	(0, 16)	Fatal agranulocytosis	dapsone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1298	 [s1]Fatal agranulocytosis[e1] in an Indian male receiving 100mg of [s2]dapsone[e2] daily, hospitalized for mid-borderline leprosy in type I reaction with triple nerve paralysis is reported.
	(4, 10)	dapsone	agranulocytosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1299	Various case reports concerning [s1]dapsone[e1] induced [s2]agranulocytosis[e2] are reviewed.
	(0, 12)	Massive pulmonary embolism	heparin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1300	 [s1]Massive pulmonary embolism[e1] due to late-onset [s2]heparin[e2] induced thrombocytopenia following coronary artery bypass graft surgery: successful treatment with lepirudin.
	(10, 16)	heparin	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1301	Massive pulmonary embolism due to late-onset [s1]heparin[e1] induced [s2]thrombocytopenia[e2] following coronary artery bypass graft surgery: successful treatment with lepirudin.
	(9, 35)	heparin	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1302	Most cardiac surgical patients have had previous exposure to [s1]heparin[e1] for diagnostic or therapeutic interventions and hence have an increased susceptibility to developing heparin-induced [s2]thrombocytopenia[e2] (HIT) postoperatively.
	(0, 7)	Acute psychosis	levetiracetam	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1303	 [s1]Acute psychosis[e1] associated with [s2]levetiracetam[e2] 
	(21, 32)	acute psychosis	levetiracetam	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1304	A twelve year-old-girl with idiopathic partial epilepsy with secondary generalization, developed [s1]acute psychosis[e1] 10 days after the administration of [s2]levetiracetam[e2] 
	(1, 15)	psychotic behavior	levetiracetam	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1305	The [s1]psychotic behavior[e1] resolved completely soon after the discontinuation of [s2]levetiracetam[e2] 
	(23, 39)	obsessive-compulsive symptoms	risperidone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1306	"CASES: ""A"" was an 8-year-old boy with attention deficit and chronic tic disorder who developed [s1]obsessive-compulsive symptoms[e1] within 2 weeks of starting [s2]risperidone[e2] "
	(0, 17)	Obsessive-compulsive symptoms	risperidone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1307	 [s1]Obsessive-compulsive symptoms[e1] suddenly emerged 10 days after starting [s2]risperidone[e2] and resolved within 3 days of discontinuation.
	(0, 7)	Risperidone	obsessive-compulsive symptoms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1308	 [s1]Risperidone[e1] induced [s2]obsessive-compulsive symptoms[e2] in two children.
	(0, 16)	Proliferation of abnormal bone marrow histiocytes	granulocyte macrophage-colony-stimulating factor	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1309	 [s1]Proliferation of abnormal bone marrow histiocytes[e1]  an undesired effect of [s2]granulocyte macrophage-colony-stimulating factor[e2] therapy in a patient with Hurler's syndrome undergoing bone marrow transplantation.
	(1, 11)	heart failure exacerbation	rosiglitazone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1310	Possible [s1]heart failure exacerbation[e1] associated with [s2]rosiglitazone[e2]  case report and literature review.
	(0, 7)	Enoxaparin	generalized exanthem	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1311	 [s1]Enoxaparin[e1] induced [s2]generalized exanthem[e2] 
	(5, 15)	generalized maculopapular rash	enoxaparin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1312	Only one case of a [s1]generalized maculopapular rash[e1] with [s2]enoxaparin[e2] has been reported in Europe.
	(16, 29)	generalized exanthem	enoxaparin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1313	To our knowledge, this is the first case reported in the English literature of a [s1]generalized exanthem[e1] due to subcutaneous injection of [s2]enoxaparin[e2] 
	(5, 16)	clonazepam	aggression	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1314	Behavioral side effects associated with [s1]clonazepam[e1] may include agitation, [s2]aggression[e2]  hyperactivity, irritability, property destruction, and temper tantrums.
	(5, 14)	clonazepam	agitation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1315	Behavioral side effects associated with [s1]clonazepam[e1] may include [s2]agitation[e2]  aggression, hyperactivity, irritability, property destruction, and temper tantrums.
	(5, 18)	clonazepam	hyperactivity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1316	Behavioral side effects associated with [s1]clonazepam[e1] may include agitation, aggression, [s2]hyperactivity[e2]  irritability, property destruction, and temper tantrums.
	(5, 22)	clonazepam	irritability	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1317	Behavioral side effects associated with [s1]clonazepam[e1] may include agitation, aggression, hyperactivity, [s2]irritability[e2]  property destruction, and temper tantrums.
	(5, 26)	clonazepam	property destruction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1318	Behavioral side effects associated with [s1]clonazepam[e1] may include agitation, aggression, hyperactivity, irritability, [s2]property destruction[e2]  and temper tantrums.
	(5, 30)	clonazepam	temper tantrums	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1319	Behavioral side effects associated with [s1]clonazepam[e1] may include agitation, aggression, hyperactivity, irritability, property destruction, and [s2]temper tantrums[e2] 
	(12, 21)	behavioral exacerbation	clonazepam	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1320	This report describes an individual with mental retardation who experienced [s1]behavioral exacerbation[e1] associated with [s2]clonazepam[e2] prescribed at 2 mg/day (0.02 mg/kg/day) to treat aggression, self-injurious behavior, property destruction, and screaming, which was measured with a 15-minute partial interval recording measurement method.
	(0, 7)	Cefuroxime	immune hemolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1321	 [s1]Cefuroxime[e1] induced [s2]immune hemolysis[e2] 
	(6, 12)	IHA	cefuroxime	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1322	We report the first case of [s1]IHA[e1] associated with [s2]cefuroxime[e2] administration.
	(4, 17)	argatroban	bleeding	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1323	After 39 hours on [s1]argatroban[e1]  the infusion was stopped when minor [s2]bleeding[e2] was observed with a concurrent activated partial thromboplastin time (aPTT) of 100 seconds.
	(5, 11)	heparin	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1324	Argatroban for [s1]heparin[e1] induced [s2]thrombocytopenia[e2] in hepato-renal failure and CVVHD.
	(0, 36)	Argatroban	hepatic failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1325	 [s1]Argatroban[e1] is hepatically cleared and may be the preferred direct thrombin inhibitor in the presence of significant renal impairment, but conversely has prolonged effects in [s2]hepatic failure[e2] 
	(8, 20)	hepatic and renal failure	argatroban	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1326	OBJECTIVE: To report a case of significant [s1]hepatic and renal failure[e1] with the use of [s2]argatroban[e2] in a patient with heparin-induced thrombocytopenia (HIT) requiring continuous veno-veno hemodialysis (CVVHD).
	(26, 32)	heparin	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1327	OBJECTIVE: To report a case of significant hepatic and renal failure with the use of argatroban in a patient with [s1]heparin[e1] induced [s2]thrombocytopenia[e2] (HIT) requiring continuous veno-veno hemodialysis (CVVHD).
	(0, 10)	Schneiderian first-rank symptoms	fluvoxamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1328	 [s1]Schneiderian first-rank symptoms[e1] associated with [s2]fluvoxamine[e2] treatment: a case report.
	(17, 24)	first-rank symptoms	fluvoxamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1329	The patient, a 28-year-old man suffering from panic disorder, developed several [s1]first-rank symptoms[e1] during [s2]fluvoxamine[e2] administration.
	(7, 21)	Schneiderian first-rank symptoms	fluvoxamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1330	This communication describes a patient who developed [s1]Schneiderian first-rank symptoms[e1] in the course of treatment with [s2]fluvoxamine[e2] 
	(4, 15)	fluvoxamine	Schneiderian first-rank symptoms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1331	This finding suggests that [s1]fluvoxamine[e1] can precipitate [s2]Schneiderian first-rank symptoms[e2] in some susceptible patients.
	(17, 24)	clozapine	EPS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1332	We present a surprising case of a woman schizophrenic patient treated with [s1]clozapine[e1] suffering from [s2]EPS[e2] 
	(0, 7)	Hyperpigmentation	interferon-alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1333	 [s1]Hyperpigmentation[e1] during [s2]interferon-alpha[e2] therapy for chronic hepatitis C virus infection.
	(1, 21)	skin lesions	IFN	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1334	These [s1]skin lesions[e1] may be induced or worsened during antiviral therapy with interferon-alpha  [s2]IFN[e2] .
	(1, 16)	skin lesions	interferon-alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1335	These [s1]skin lesions[e1] may be induced or worsened during antiviral therapy with [s2]interferon-alpha[e2] (IFN).
	(9, 23)	hyperpigmented skin	IFN	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1336	We describe two dark-skinned patients who developed [s1]hyperpigmented skin[e1] and tongue lesions during combination therapy with [s2]IFN[e2] and ribavirin.
	(9, 26)	hyperpigmented skin	ribavirin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1337	We describe two dark-skinned patients who developed [s1]hyperpigmented skin[e1] and tongue lesions during combination therapy with IFN and [s2]ribavirin[e2] 
	(15, 23)	tongue lesions	IFN	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1338	We describe two dark-skinned patients who developed hyperpigmented skin and [s1]tongue lesions[e1] during combination therapy with [s2]IFN[e2] and ribavirin.
	(15, 26)	tongue lesions	ribavirin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1339	We describe two dark-skinned patients who developed hyperpigmented skin and [s1]tongue lesions[e1] during combination therapy with IFN and [s2]ribavirin[e2] 
	(7, 29)	ciprofloxacin	thrombocytosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1340	It is concluded that simultaneous administration of [s1]ciprofloxacin[e1] and tazobactam/piperacillin may cause marked [s2]thrombocytosis[e2] 
	(19, 28)	piperacillin	thrombocytosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1341	It is concluded that simultaneous administration of ciprofloxacin and tazobactam [s1]piperacillin[e1] may cause marked [s2]thrombocytosis[e2] 
	(14, 28)	tazobactam	thrombocytosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1342	It is concluded that simultaneous administration of ciprofloxacin and [s1]tazobactam[e1] piperacillin may cause marked [s2]thrombocytosis[e2] 
	(2, 25)	thrombocyte count started to increase	ciprofloxacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1343	Since the [s1]thrombocyte count started to increase[e1] immediately after initiation and dropped immediately after discontinuation of [s2]ciprofloxacin[e2] and tazobactam/piperacillin and all other drugs were discontinued already before or were started after the nadir of the thrombocyte count, these two antibiotics were regarded causative.
	(2, 37)	thrombocyte count started to increase	piperacillin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1344	Since the [s1]thrombocyte count started to increase[e1] immediately after initiation and dropped immediately after discontinuation of ciprofloxacin and tazobactam [s2]piperacillin[e2] and all other drugs were discontinued already before or were started after the nadir of the thrombocyte count, these two antibiotics were regarded causative.
	(2, 32)	thrombocyte count started to increase	tazobactam	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1345	Since the [s1]thrombocyte count started to increase[e1] immediately after initiation and dropped immediately after discontinuation of ciprofloxacin and [s2]tazobactam[e2] piperacillin and all other drugs were discontinued already before or were started after the nadir of the thrombocyte count, these two antibiotics were regarded causative.
	(0, 8)	Thrombocytosis	ciprofloxacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1346	 [s1]Thrombocytosis[e1] under [s2]ciprofloxacin[e2] and tazobactam/piperacillin.
	(0, 20)	Thrombocytosis	piperacillin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1347	 [s1]Thrombocytosis[e1] under ciprofloxacin and tazobactam [s2]piperacillin[e2] 
	(0, 15)	Thrombocytosis	tazobactam	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1348	 [s1]Thrombocytosis[e1] under ciprofloxacin and [s2]tazobactam[e2] piperacillin.
	(0, 11)	Anaphylaxis	chymopapain	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1349	 [s1]Anaphylaxis[e1] after the injection of [s2]chymopapain[e2] occurs in about 1% of such cases.
	(4, 14)	hypotensive	chymopapain	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1350	Both patients suddenly became [s1]hypotensive[e1] after injection of [s2]chymopapain[e2] into a disk.
	(0, 9)	Lethargy	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1351	 [s1]Lethargy[e1] in a newborn: [s2]lithium[e2] toxicity or lab error?
	(7, 11)	lithium toxicity	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1352	Lethargy in a newborn: [s1]lithium toxicity[e1]  [s2]lithium[e2] toxicity or lab error?
	(8, 20)	lethargy	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1353	The newborn manifested a four day course of [s1]lethargy[e1] with unexplained high [s2]lithium[e2] levels in the adult toxic range.
	(26, 47)	fever	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1354	A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, [s1]fever[e1]  leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of [s2]carbamazepine[e2] (CBZ; Tegretol) used against benign Rolandic epilepsy.
	(26, 52)	fever	CBZ	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1355	A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, [s1]fever[e1]  leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of carbamazepine  [s2]CBZ[e2]  Tegretol) used against benign Rolandic epilepsy.
	(26, 56)	fever	Tegretol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1356	A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, [s1]fever[e1]  leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of carbamazepine (CBZ; [s2]Tegretol[e2]  used against benign Rolandic epilepsy.
	(28, 48)	leukopenia	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1357	A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, fever, [s1]leukopenia[e1] and positive anti-nuclear antibody (ANA) two weeks after administration of [s2]carbamazepine[e2] (CBZ; Tegretol) used against benign Rolandic epilepsy.
	(28, 53)	leukopenia	CBZ	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1358	A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, fever, [s1]leukopenia[e1] and positive anti-nuclear antibody (ANA) two weeks after administration of carbamazepine  [s2]CBZ[e2]  Tegretol) used against benign Rolandic epilepsy.
	(28, 57)	leukopenia	Tegretol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1359	A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, fever, [s1]leukopenia[e1] and positive anti-nuclear antibody (ANA) two weeks after administration of carbamazepine (CBZ; [s2]Tegretol[e2]  used against benign Rolandic epilepsy.
	(33, 48)	positive anti-nuclear antibody	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1360	A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, fever, leukopenia and [s1]positive anti-nuclear antibody[e1] (ANA) two weeks after administration of [s2]carbamazepine[e2] (CBZ; Tegretol) used against benign Rolandic epilepsy.
	(33, 53)	positive anti-nuclear antibody	CBZ	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1361	A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, fever, leukopenia and [s1]positive anti-nuclear antibody[e1] (ANA) two weeks after administration of carbamazepine  [s2]CBZ[e2]  Tegretol) used against benign Rolandic epilepsy.
	(33, 57)	positive anti-nuclear antibody	Tegretol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1362	A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, rash, fever, leukopenia and [s1]positive anti-nuclear antibody[e1] (ANA) two weeks after administration of carbamazepine (CBZ; [s2]Tegretol[e2]  used against benign Rolandic epilepsy.
	(24, 47)	rash	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1363	A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, [s1]rash[e1]  fever, leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of [s2]carbamazepine[e2] (CBZ; Tegretol) used against benign Rolandic epilepsy.
	(24, 52)	rash	CBZ	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1364	A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, [s1]rash[e1]  fever, leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of carbamazepine  [s2]CBZ[e2]  Tegretol) used against benign Rolandic epilepsy.
	(24, 56)	rash	Tegretol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1365	A 14-year-old female developed systemic lupus erythematosus (SLE)-like symptoms, [s1]rash[e1]  fever, leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of carbamazepine (CBZ; [s2]Tegretol[e2]  used against benign Rolandic epilepsy.
	(8, 47)	systemic lupus erythematosus (SLE)-like symptoms	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1366	A 14-year-old female developed [s1]systemic lupus erythematosus (SLE)-like symptoms[e1]  rash, fever, leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of [s2]carbamazepine[e2] (CBZ; Tegretol) used against benign Rolandic epilepsy.
	(8, 52)	systemic lupus erythematosus (SLE)-like symptoms	CBZ	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1367	A 14-year-old female developed [s1]systemic lupus erythematosus (SLE)-like symptoms[e1]  rash, fever, leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of carbamazepine  [s2]CBZ[e2]  Tegretol) used against benign Rolandic epilepsy.
	(8, 56)	systemic lupus erythematosus (SLE)-like symptoms	Tegretol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1368	A 14-year-old female developed [s1]systemic lupus erythematosus (SLE)-like symptoms[e1]  rash, fever, leukopenia and positive anti-nuclear antibody (ANA) two weeks after administration of carbamazepine (CBZ; [s2]Tegretol[e2]  used against benign Rolandic epilepsy.
	(0, 8)	Carbamazepine	systemic lupus erythematosus-like disease	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1369	 [s1]Carbamazepine[e1] induced [s2]systemic lupus erythematosus-like disease[e2] 
	(3, 8)	CBZ	SLE	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1370	The cases of [s1]CBZ[e1] induced [s2]SLE[e2] reported in the literature were reviewed.
	(6, 13)	RH	bilateral gynaecomastia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1371	After four months, while receiving [s1]RH[e1]  he developed painful [s2]bilateral gynaecomastia[e2] 
	(0, 17)	Gynaecomastia	isoniazid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1372	 [s1]Gynaecomastia[e1] is a rarely reported adverse drug reaction due to [s2]isoniazid[e2] therapy.
	(0, 10)	Isoniazid	bilateral gynaecomastia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1373	 [s1]Isoniazid[e1] associated, painful, [s2]bilateral gynaecomastia[e2] 
	(4, 30)	heparin	acute renal failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1374	A patient suffering from [s1]heparin[e1] associated thrombocytopenia (HAT), recurrent arteriothromboses, and [s2]acute renal failure[e2] after treatment with standard heparin is described.
	(4, 30)	heparin	acute renal failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1375	A patient suffering from [s1]heparin[e1] associated thrombocytopenia (HAT), recurrent arteriothromboses, and [s2]acute renal failure[e2] after treatment with standard heparin is described.
	(4, 16)	heparin	HAT	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1376	A patient suffering from [s1]heparin[e1] associated thrombocytopenia  [s2]HAT[e2] , recurrent arteriothromboses, and acute renal failure after treatment with standard heparin is described.
	(4, 16)	heparin	HAT	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1377	A patient suffering from [s1]heparin[e1] associated thrombocytopenia  [s2]HAT[e2] , recurrent arteriothromboses, and acute renal failure after treatment with standard heparin is described.
	(4, 20)	heparin	recurrent arteriothromboses	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1378	A patient suffering from [s1]heparin[e1] associated thrombocytopenia (HAT), [s2]recurrent arteriothromboses[e2]  and acute renal failure after treatment with standard heparin is described.
	(4, 20)	heparin	recurrent arteriothromboses	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1379	A patient suffering from [s1]heparin[e1] associated thrombocytopenia (HAT), [s2]recurrent arteriothromboses[e2]  and acute renal failure after treatment with standard heparin is described.
	(4, 10)	heparin	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1380	A patient suffering from [s1]heparin[e1] associated [s2]thrombocytopenia[e2] (HAT), recurrent arteriothromboses, and acute renal failure after treatment with standard heparin is described.
	(4, 10)	heparin	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1381	A patient suffering from [s1]heparin[e1] associated [s2]thrombocytopenia[e2] (HAT), recurrent arteriothromboses, and acute renal failure after treatment with standard heparin is described.
	(11, 67)	platelet activation	Clexane	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1382	By means of the in vitro heparin-induced [s1]platelet activation[e1] (HIPA) assay it was shown that standard heparin and the LMW heparins Fragmin and Fraxiparin (Sanofi Labaz, Munich, FRG), as well as the enoxaparine [s2]Clexane[e2] (Nattermann, Cologne, FRG), all induced platelet activation with the patient's serum.
	(11, 38)	platelet activation	Fragmin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1383	By means of the in vitro heparin-induced [s1]platelet activation[e1] (HIPA) assay it was shown that standard heparin and the LMW heparins [s2]Fragmin[e2] and Fraxiparin (Sanofi Labaz, Munich, FRG), as well as the enoxaparine Clexane (Nattermann, Cologne, FRG), all induced platelet activation with the patient's serum.
	(11, 42)	platelet activation	Fraxiparin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1384	By means of the in vitro heparin-induced [s1]platelet activation[e1] (HIPA) assay it was shown that standard heparin and the LMW heparins Fragmin and [s2]Fraxiparin[e2] (Sanofi Labaz, Munich, FRG), as well as the enoxaparine Clexane (Nattermann, Cologne, FRG), all induced platelet activation with the patient's serum.
	(6, 12)	heparin	platelet activation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1385	By means of the in vitro [s1]heparin[e1] induced [s2]platelet activation[e2] (HIPA) assay it was shown that standard heparin and the LMW heparins Fragmin and Fraxiparin (Sanofi Labaz, Munich, FRG), as well as the enoxaparine Clexane (Nattermann, Cologne, FRG), all induced platelet activation with the patient's serum.
	(0, 6)	Heparin	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1386	 [s1]Heparin[e1] associated [s2]thrombocytopenia[e2]  successful therapy with the heparinoid Org 10172 in a patient showing cross-reaction to LMW heparins.
	(0, 8)	Hemodynamic collapse	labetalol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1387	 [s1]Hemodynamic collapse[e1] following [s2]labetalol[e2] administration in preeclampsia.
	(11, 27)	bromocriptine	pleuropulmonary abnormalities	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1388	A patient with Parkinson's disease, initially treated with [s1]bromocriptine[e1] and subsequently with cabergoline, developed progressive [s2]pleuropulmonary abnormalities[e2] during the latter therapy.
	(18, 26)	cabergoline	pleuropulmonary abnormalities	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1389	A patient with Parkinson's disease, initially treated with bromocriptine and subsequently with [s1]cabergoline[e1]  developed progressive [s2]pleuropulmonary abnormalities[e2] during the latter therapy.
	(0, 26)	Pleuropulmonary changes	cabergoline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1390	 [s1]Pleuropulmonary changes[e1] during treatment of Parkinson's disease with a long-acting ergot derivative, [s2]cabergoline[e2] 
	(8, 18)	pleuropulmonary abnormalities	bromocriptine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1391	Thus cabergoline may cause similar [s1]pleuropulmonary abnormalities[e1] to [s2]bromocriptine[e2] 
	(1, 10)	cabergoline	pleuropulmonary abnormalities	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1392	Thus [s1]cabergoline[e1] may cause similar [s2]pleuropulmonary abnormalities[e2] to bromocriptine.
	(0, 24)	Acute myopathy	methylprednisolone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1393	 [s1]Acute myopathy[e1] with selective degeneration of myosin filaments following status asthmaticus treated with [s2]methylprednisolone[e2] and vecuronium.
	(0, 31)	Acute myopathy	vecuronium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1394	 [s1]Acute myopathy[e1] with selective degeneration of myosin filaments following status asthmaticus treated with methylprednisolone and [s2]vecuronium[e2] 
	(6, 24)	degeneration of myosin filaments	methylprednisolone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1395	Acute myopathy with selective [s1]degeneration of myosin filaments[e1] following status asthmaticus treated with [s2]methylprednisolone[e2] and vecuronium.
	(6, 31)	degeneration of myosin filaments	vecuronium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1396	Acute myopathy with selective [s1]degeneration of myosin filaments[e1] following status asthmaticus treated with methylprednisolone and [s2]vecuronium[e2] 
	(0, 18)	Flaccid quadriparesis	vecuronium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1397	 [s1]Flaccid quadriparesis[e1] was noted after discontinuation of [s2]vecuronium[e2] 
	(18, 30)	vecuronium	respiratory failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1398	This entity is probably related to a combination of high doses of corticosteroids, [s1]vecuronium[e1] administration and metabolic abnormalities associated with [s2]respiratory failure[e2] 
	(13, 28)	diffuse pulmonary shadowing	sulfasalazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1399	A patient with ulcerative colitis developed skin pigmentation and [s1]diffuse pulmonary shadowing[e1] without respiratory symptomatology, while taking [s2]sulfasalazine[e2] 
	(9, 28)	skin pigmentation	sulfasalazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1400	A patient with ulcerative colitis developed [s1]skin pigmentation[e1] and diffuse pulmonary shadowing without respiratory symptomatology, while taking [s2]sulfasalazine[e2] 
	(0, 11)	Pulmonary infiltrates	sulfasalazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1401	 [s1]Pulmonary infiltrates[e1] and skin pigmentation associated with [s2]sulfasalazine[e2] 
	(4, 11)	skin pigmentation	sulfasalazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1402	Pulmonary infiltrates and [s1]skin pigmentation[e1] associated with [s2]sulfasalazine[e2] 
	(0, 8)	Sulfasalazine	lung disorder	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1403	 [s1]Sulfasalazine[e1] induced [s2]lung disorder[e2] is an extremely rare entity which must be considered in all ulcerative colitis patients while on sulfasalazine therapy, despite the absence of pulmonary symptomatology.
	(0, 21)	Sulfasalazine	ulcerative colitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1404	 [s1]Sulfasalazine[e1] induced lung disorder is an extremely rare entity which must be considered in all [s2]ulcerative colitis[e2] patients while on sulfasalazine therapy, despite the absence of pulmonary symptomatology.
	(20, 30)	ulcerative colitis	sulfasalazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1405	Sulfasalazine-induced lung disorder is an extremely rare entity which must be considered in all [s1]ulcerative colitis[e1] patients while on [s2]sulfasalazine[e2] therapy, despite the absence of pulmonary symptomatology.
	(3, 23)	sclerotic changes of lumbar spine and femur	isotretinoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1406	Reversible [s1]sclerotic changes of lumbar spine and femur[e1] due to long-term oral [s2]isotretinoin[e2] therapy.
	(6, 16)	bleomycin	scleroderma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1407	Although an association between exposure to [s1]bleomycin[e1] and the development of [s2]scleroderma[e2] has been suspected, few cases are reported.
	(10, 17)	bleomycin	scleroderma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1408	Our series of 3 patients supports a causal connection between [s1]bleomycin[e1] and [s2]scleroderma[e2] 
	(0, 12)	Scleroderma	bleomycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1409	 [s1]Scleroderma[e1] in association with the use of [s2]bleomycin[e2]  a report of 3 cases.
	(5, 22)	cutaneous scleroderma	bleomycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1410	We describe the development of [s1]cutaneous scleroderma[e1] in 3 patients coincident with the use of [s2]bleomycin[e2] in low cumulative doses of less than 100 U.
	(4, 19)	dilated cardiomyopathy	adrenaline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1411	A patient presented with [s1]dilated cardiomyopathy[e1] after many years of overusing an [s2]adrenaline[e2] inhaler.
	(0, 15)	Dilated cardiomyopathy	adrenaline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1412	 [s1]Dilated cardiomyopathy[e1] associated with chronic overuse of an [s2]adrenaline[e2] inhaler.
	(22, 35)	SLE	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1413	A 21-year-old woman suffering from bipolar affective disorder developed systemic lupus erythematosus  [s1]SLE[e1]  with characteristic laboratory findings, 18 months after starting [s2]carbamazepine[e2] maintenance treatment.
	(14, 37)	systemic lupus erythematosus	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1414	A 21-year-old woman suffering from bipolar affective disorder developed [s1]systemic lupus erythematosus[e1] (SLE) with characteristic laboratory findings, 18 months after starting [s2]carbamazepine[e2] maintenance treatment.
	(6, 38)	SLE	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1415	Although both the spontaneous occurrence of [s1]SLE[e1] and the psychosis as a sign of CNS involvement of SLE cannot be excluded, SLE could be considered as an adverse effect of [s2]carbamazepine[e2] 
	(6, 38)	SLE	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1416	Although both the spontaneous occurrence of [s1]SLE[e1] and the psychosis as a sign of CNS involvement of SLE cannot be excluded, SLE could be considered as an adverse effect of [s2]carbamazepine[e2] 
	(6, 38)	SLE	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1417	Although both the spontaneous occurrence of [s1]SLE[e1] and the psychosis as a sign of CNS involvement of SLE cannot be excluded, SLE could be considered as an adverse effect of [s2]carbamazepine[e2] 
	(0, 8)	Carbamazepine	systemic lupus erythematosus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1418	 [s1]Carbamazepine[e1] induced [s2]systemic lupus erythematosus[e2] 
	(0, 9)	SLE	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1419	 [s1]SLE[e1] receded after withdrawal of [s2]carbamazepine[e2] and treatment with anti-inflammatory drugs.
	(5, 17)	acne fulminans	13-cis-retinoic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1420	We report a case of [s1]acne fulminans[e1] occurring during treatment with [s2]13-cis-retinoic acid[e2] for cystic acne.
	(13, 20)	valproic acid	coma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1421	Carbamyl phosphate synthetase-1 deficiency discovered after [s1]valproic acid[e1] induced [s2]coma[e2] 
	(0, 7)	Valproic acid	coma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1422	 [s1]Valproic acid[e1] induced [s2]coma[e2] is presented in an adult patient without a history of metabolic disease.
	(0, 8)	Asterixis	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1423	 [s1]Asterixis[e1] induced by [s2]carbamazepine[e2] therapy.
	(20, 31)	asterixis	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1424	In this report we present four patients treated with a combination of different psychotropic drugs, in whom [s1]asterixis[e1] was triggered either by adding [s2]carbamazepine[e2] (CBZ) to a treatment regimen, or by increasing its dosage.
	(20, 36)	asterixis	CBZ	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1425	In this report we present four patients treated with a combination of different psychotropic drugs, in whom [s1]asterixis[e1] was triggered either by adding carbamazepine  [s2]CBZ[e2]  to a treatment regimen, or by increasing its dosage.
	(2, 47)	asterixis	CBZ	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1426	We consider [s1]asterixis[e1] to be an easily overlooked sign of neurotoxicity, which may occur even at low or moderate dosage levels, if certain drugs as lithium or clozapine are used in combination with [s2]CBZ[e2] 
	(2, 39)	asterixis	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1427	We consider [s1]asterixis[e1] to be an easily overlooked sign of neurotoxicity, which may occur even at low or moderate dosage levels, if certain drugs as lithium or [s2]clozapine[e2] are used in combination with CBZ.
	(2, 37)	asterixis	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1428	We consider [s1]asterixis[e1] to be an easily overlooked sign of neurotoxicity, which may occur even at low or moderate dosage levels, if certain drugs as [s2]lithium[e2] or clozapine are used in combination with CBZ.
	(13, 46)	neurotoxicity	CBZ	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1429	We consider asterixis to be an easily overlooked sign of [s1]neurotoxicity[e1]  which may occur even at low or moderate dosage levels, if certain drugs as lithium or clozapine are used in combination with [s2]CBZ[e2] 
	(13, 38)	neurotoxicity	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1430	We consider asterixis to be an easily overlooked sign of [s1]neurotoxicity[e1]  which may occur even at low or moderate dosage levels, if certain drugs as lithium or [s2]clozapine[e2] are used in combination with CBZ.
	(13, 36)	neurotoxicity	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1431	We consider asterixis to be an easily overlooked sign of [s1]neurotoxicity[e1]  which may occur even at low or moderate dosage levels, if certain drugs as [s2]lithium[e2] or clozapine are used in combination with CBZ.
	(0, 14)	Encephalopathy	alum	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1432	 [s1]Encephalopathy[e1] and seizures induced by intravesical [s2]alum[e2] irrigations.
	(6, 14)	seizures	alum	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1433	Encephalopathy and [s1]seizures[e1] induced by intravesical [s2]alum[e2] irrigations.
	(0, 16)	Hemorrhagic cystitis	cyclophosphamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1434	 [s1]Hemorrhagic cystitis[e1] is a significant toxic effect of [s2]cyclophosphamide[e2] therapy.
	(13, 18)	elevated aluminum levels	alum	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1435	We report four cases of encephalopathy coincident with [s1]elevated aluminum levels[e1]  [s2]alum[e2] num levels as well as one patient who developed seizures while receiving continuous bladder irrigations with alum.
	(5, 16)	encephalopathy	alum	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1436	We report four cases of [s1]encephalopathy[e1] coincident with elevated [s2]alum[e2] num levels as well as one patient who developed seizures while receiving continuous bladder irrigations with alum.
	(14, 28)	alum	seizures	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1437	We report four cases of encephalopathy coincident with elevated [s1]alum[e1] num levels as well as one patient who developed [s2]seizures[e2] while receiving continuous bladder irrigations with alum.
	(2, 13)	hyponatremia	desmopressin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1438	Seizure with [s1]hyponatremia[e1] in a child prescribed [s2]desmopressin[e2] for nocturnal enuresis.
	(0, 13)	Seizure	desmopressin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1439	 [s1]Seizure[e1] with hyponatremia in a child prescribed [s2]desmopressin[e2] for nocturnal enuresis.
	(13, 29)	grand mal seizure	desmopressin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1440	We report a case of hyponatremia associated with a [s1]grand mal seizure[e1] in a 28 month-old child after intra-nasal [s2]desmopressin[e2] administration for high fluid intake with nocturnal enuresis.
	(5, 29)	hyponatremia	desmopressin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1441	We report a case of [s1]hyponatremia[e1] associated with a grand mal seizure in a 28 month-old child after intra-nasal [s2]desmopressin[e2] administration for high fluid intake with nocturnal enuresis.
	(13, 23)	SIADH	Tegretol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1442	This case report describes a 38-year-old male in whom [s1]SIADH[e1] was strongly suspected secondary to [s2]Tegretol[e2] therapy to control a seizure disorder.
	(0, 26)	Gestational diabetes	norethisterone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1443	 [s1]Gestational diabetes[e1] was no less severe (degree of hyperglycaemia, need for insulin therapy) when associated with [s2]norethisterone[e2] 
	(14, 26)	norethisterone	diabetes mellitus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1444	However, follow-up revealed that gestational diabetes when associated with [s1]norethisterone[e1] had a lesser risk of emerging [s2]diabetes mellitus[e2] and impaired glucose tolerance.
	(7, 16)	gestational diabetes	norethisterone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1445	However, follow-up revealed that [s1]gestational diabetes[e1] when associated with [s2]norethisterone[e2] had a lesser risk of emerging diabetes mellitus and impaired glucose tolerance.
	(14, 31)	norethisterone	impaired glucose tolerance	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1446	However, follow-up revealed that gestational diabetes when associated with [s1]norethisterone[e1] had a lesser risk of emerging diabetes mellitus and [s2]impaired glucose tolerance[e2] 
	(15, 27)	gestational diabetes	norethisterone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1447	In a single practice during the 21 years 1971-1991, the incidence of [s1]gestational diabetes[e1] in pregnancies in which [s2]norethisterone[e2] was prescribed was 32.4% (22 of 69) in comparison with 7.1% in pregnancies in which the women did not take norethisterone (137 of 1,684) (p < 0.001).
	(22, 32)	norethisterone	clitoral hypertrophy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1448	Masculinization of a female fetus occurred in 5 of 39 (12.8%) exposed to [s1]norethisterone[e1]  all were cases of [s2]clitoral hypertrophy[e2] not requiring surgical treatment.
	(0, 24)	Masculinization of a female fetus	norethisterone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1449	 [s1]Masculinization of a female fetus[e1] occurred in 5 of 39 (12.8%) exposed to [s2]norethisterone[e2]  all were cases of clitoral hypertrophy not requiring surgical treatment.
	(0, 25)	Norethisterone	clitoral hypertrophy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1450	 [s1]Norethisterone[e1] in these 69 pregnancies accounted for 33.3% (5 of 15) cases of [s2]clitoral hypertrophy[e2] diagnosed in 100,756 consecutive births.
	(4, 15)	IFN	CHF	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1451	An adverse reaction to [s1]IFN[e1] was strongly suspected as the cause of [s2]CHF[e2] 
	(6, 17)	congestive heart failure	recombinant alpha-interferon	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1452	Multiple myeloma complicated by [s1]congestive heart failure[e1] following first administration of [s2]recombinant alpha-interferon[e2] 
	(7, 24)	IFN	CHF	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1453	Sixteen hours after the first administration of [s1]IFN[e1]  IFN was suspended by the symptoms of congestive heart failure  [s2]CHF[e2] .
	(7, 19)	IFN	congestive heart failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1454	Sixteen hours after the first administration of [s1]IFN[e1]  IFN was suspended by the symptoms of [s2]congestive heart failure[e2] (CHF).
	(0, 32)	Neutrophilic eccrine hidradenitis	cyclophosphamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1455	 [s1]Neutrophilic eccrine hidradenitis[e1] mimicking cutaneous vasculitis in a lupus patient: a complication of [s2]cyclophosphamide[e2] 
	(5, 24)	NEH	cyclophosphamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1456	We report a case of [s1]NEH[e1] masquerading as cutaneous vasculitis in a woman receiving [s2]cyclophosphamide[e2] for lupus nephritis.
	(0, 9)	Generalised cutaneous rash	ganciclovir	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1457	 [s1]Generalised cutaneous rash[e1] associated with [s2]ganciclovir[e2] therapy has rarely been reported in literature.
	(0, 11)	Skin rash	ganciclovir	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1458	 [s1]Skin rash[e1] and splinter hemorrhages from [s2]ganciclovir[e2] 
	(3, 11)	splinter hemorrhages	ganciclovir	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1459	Skin rash and [s1]splinter hemorrhages[e1] from [s2]ganciclovir[e2] 
	(8, 15)	betamethasone	acute pancreatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1460	Can roxithromycin and [s1]betamethasone[e1] induce [s2]acute pancreatitis[e2]  A case report.
	(1, 15)	roxithromycin	acute pancreatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1461	Can [s1]roxithromycin[e1] and betamethasone induce [s2]acute pancreatitis[e2]  A case report.
	(28, 35)	betamethasone	acute pancreatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1462	CASE REPORT: We report the case of a 58 year old patient who, after 2 days of treatment with roxithromycin and [s1]betamethasone[e1]  manifested [s2]acute pancreatitis[e2] 
	(21, 36)	roxithromycin	acute pancreatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1463	CASE REPORT: We report the case of a 58 year old patient who, after 2 days of treatment with [s1]roxithromycin[e1] and betamethasone, manifested [s2]acute pancreatitis[e2] 
	(0, 8)	Renal tubular acidosis	FK506	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1464	 [s1]Renal tubular acidosis[e1] secondary to [s2]FK506[e2] in living donor liver transplantation: a case report.
	(6, 16)	nephrotoxicity	FK506	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1465	RTA is one type of [s1]nephrotoxicity[e1] induced by [s2]FK506[e2]  and it is reversible in mild cases when appropriately treated.
	(0, 16)	RTA	FK506	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1466	 [s1]RTA[e1] is one type of nephrotoxicity induced by [s2]FK506[e2]  and it is reversible in mild cases when appropriately treated.
	(11, 18)	RTA	FK506	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1467	Surgeons and physicians should therefore be aware of the potential for [s1]RTA[e1] to occur with [s2]FK506[e2] after any organ transplantation.
	(3, 9)	RTA	FK506	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1468	The mechanism of [s1]RTA[e1] induced by [s2]FK506[e2] has not yet been clearly elucidated.
	(15, 27)	RTA	FK506	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1469	The treatment for acidosis and hyperkalaemia should be started as soon as [s1]RTA[e1] is diagnosed, and the dosage of [s2]FK506[e2] should also be reduced if possible.
	(5, 11)	RTA	FK506	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1470	We report a case of [s1]RTA[e1] secondary to [s2]FK506[e2] administration in liver transplantation.
	(18, 38)	unintended sleep episodes	L-dopa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1471	A 74-year-old patient with idiopathic Parkinson's disease was evaluated for [s1]unintended sleep episodes[e1] that occurred after long-term treatment with 400 mg/day of [s2]L-dopa[e2] 
	(0, 8)	L-DOPA	daytime sleepiness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1472	 [s1]L-DOPA[e1] induced excessive [s2]daytime sleepiness[e2] in PD: a placebo-controlled case with MSLT assessment.
	(6, 14)	L-dopa	daytime somnolence	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1473	The authors' results suggest that [s1]L-dopa[e1] may cause [s2]daytime somnolence[e2] in some patients with Parkinson's disease.
	(0, 11)	Neurotoxicity	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1474	 [s1]Neurotoxicity[e1] of intrathecal [s2]methotrexate[e2]  MR imaging findings.
	(9, 23)	cytotoxic edema	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1475	We attribute the clinical and radiographic findings to [s1]cytotoxic edema[e1] secondary to intrathecal [s2]methotrexate[e2] 
	(8, 27)	methotrexate	aphasia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1476	We report a case of intrathecal [s1]methotrexate[e1] neurotoxicity manifesting as left arm weakness and [s2]aphasia[e2] 
	(8, 23)	methotrexate	left arm weakness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1477	We report a case of intrathecal [s1]methotrexate[e1] neurotoxicity manifesting as [s2]left arm weakness[e2] and aphasia.
	(8, 15)	methotrexate	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1478	We report a case of intrathecal [s1]methotrexate[e1]  [s2]neurotoxicity[e2] manifesting as left arm weakness and aphasia.
	(3, 33)	lithium	Epstein's anomaly	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1479	In this article [s1]lithium[e1] is not discussed, although there are a number of concerns about lithium's potential teratogenicity, and it has been implicated in [s2]Epstein's anomaly[e2]  a congenital heart defect among infants born to women taking lithium; as with other medications, however, the data have specific limitations.
	(3, 33)	lithium	Epstein's anomaly	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1480	In this article [s1]lithium[e1] is not discussed, although there are a number of concerns about lithium's potential teratogenicity, and it has been implicated in [s2]Epstein's anomaly[e2]  a congenital heart defect among infants born to women taking lithium; as with other medications, however, the data have specific limitations.
	(3, 22)	lithium	teratogenicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1481	In this article [s1]lithium[e1] is not discussed, although there are a number of concerns about lithium's potential [s2]teratogenicity[e2]  and it has been implicated in Epstein's anomaly, a congenital heart defect among infants born to women taking lithium; as with other medications, however, the data have specific limitations.
	(3, 22)	lithium	teratogenicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1482	In this article [s1]lithium[e1] is not discussed, although there are a number of concerns about lithium's potential [s2]teratogenicity[e2]  and it has been implicated in Epstein's anomaly, a congenital heart defect among infants born to women taking lithium; as with other medications, however, the data have specific limitations.
	(18, 28)	glyburide	hypoglycemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1483	We present a case of a 20-year-old woman who ingested 900 mg of [s1]glyburide[e1] causing refractory [s2]hypoglycemia[e2] resistant to treatment with intravenous dextrose, glucagon, and diazoxide.
	(0, 10)	Ocular ethambutol toxicity	ethambutol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1484	 [s1]Ocular ethambutol toxicity[e1]  [s2]ethambutol[e2] toxicity.
	(7, 15)	ethambutol	optic neuropathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1485	The most commonly recognized toxic effect of [s1]ethambutol[e1] is [s2]optic neuropathy[e2]  which generally is considered uncommon and reversible in medical literature.
	(15, 23)	ethambutol toxicity	ethambutol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1486	This case and a review of the literature show the severe and unpredictable nature of [s1]ethambutol toxicity[e1]  [s2]ethambutol[e2] toxicity and its potential for irreversible vision loss despite careful ophthalmologic monitoring.
	(15, 31)	ethambutol	vision loss	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1487	This case and a review of the literature show the severe and unpredictable nature of [s1]ethambutol[e1] toxicity and its potential for irreversible [s2]vision loss[e2] despite careful ophthalmologic monitoring.
	(15, 25)	bilateral optic neuropathy	ethambutol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1488	We describe a 43-year-old man who developed signs and symptoms of [s1]bilateral optic neuropathy[e1] during treatment with [s2]ethambutol[e2] 
	(10, 20)	fatality	brompheniramine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1489	The case history and toxicological findings of an infant [s1]fatality[e1] involving pseudoephedrine, [s2]brompheniramine[e2]  and dextromethorphan are presented.
	(10, 27)	fatality	dextromethorphan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1490	The case history and toxicological findings of an infant [s1]fatality[e1] involving pseudoephedrine, brompheniramine, and [s2]dextromethorphan[e2] are presented.
	(10, 15)	fatality	pseudoephedrine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1491	The case history and toxicological findings of an infant [s1]fatality[e1] involving [s2]pseudoephedrine[e2]  brompheniramine, and dextromethorphan are presented.
	(1, 9)	overanticoagulation	acenocoumarol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1492	Early [s1]overanticoagulation[e1] with [s2]acenocoumarol[e2] due to a genetic polymorphism of cytochrome P450 CYP2C9.
	(13, 22)	overanticoagulation	acenocoumarol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1493	We report the case of a young healthy woman who presented an early [s1]overanticoagulation[e1] when receiving [s2]acenocoumarol[e2] for a first thromboembolic episode.
	(0, 6)	Colchicine	myopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1494	 [s1]Colchicine[e1] induced [s2]myopathy[e2] in a teenager with familial Mediterranean fever.
	(2, 8)	Colchicine	myopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1495	CONCLUSIONS: [s1]Colchicine[e1] induced [s2]myopathy[e2] should be excluded in patients with FMF who present with generalized muscle weakness.
	(2, 19)	Colchicine	myopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1496	DISCUSSION: [s1]Colchicine[e1]  the most important drug in treatment of FMF, can cause [s2]myopathy[e2] in patients with impaired renal and hepatic function.
	(14, 27)	colchicine	myopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1497	In our patient, an objective causality scale showed that therapeutic doses of [s1]colchicine[e1] for FMF were the definite cause of [s2]myopathy[e2]  even though his renal and hepatic function were normal.
	(7, 13)	colchicine	myopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1498	OBJECTIVE: To report a case of [s1]colchicine[e1] induced [s2]myopathy[e2] in a teenager with familial Mediterranean fever (FMF).
	(0, 18)	Angioedema	budesonide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1499	 [s1]Angioedema[e1] and dysphagia caused by contact allergy to inhaled [s2]budesonide[e2] 
	(5, 18)	dysphagia	budesonide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1500	Angioedema and [s1]dysphagia[e1] caused by contact allergy to inhaled [s2]budesonide[e2] 
	(22, 38)	dysphagia	Budefat	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1501	We report a 43-year-old woman who developed sore throat, swelling of the lips and oral cavity and [s1]dysphagia[e1]  2 weeks after the use of budesonide spray  [s2]Budefat[e2]  for treatment of bronchial asthma.
	(22, 34)	dysphagia	budesonide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1502	We report a 43-year-old woman who developed sore throat, swelling of the lips and oral cavity and [s1]dysphagia[e1]  2 weeks after the use of [s2]budesonide[e2] spray (Budefat) for treatment of bronchial asthma.
	(11, 38)	sore throat	Budefat	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1503	We report a 43-year-old woman who developed [s1]sore throat[e1]  swelling of the lips and oral cavity and dysphagia, 2 weeks after the use of budesonide spray  [s2]Budefat[e2]  for treatment of bronchial asthma.
	(11, 34)	sore throat	budesonide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1504	We report a 43-year-old woman who developed [s1]sore throat[e1]  swelling of the lips and oral cavity and dysphagia, 2 weeks after the use of [s2]budesonide[e2] spray (Budefat) for treatment of bronchial asthma.
	(14, 39)	swelling of the lips and oral cavity	Budefat	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1505	We report a 43-year-old woman who developed sore throat, [s1]swelling of the lips and oral cavity[e1] and dysphagia, 2 weeks after the use of budesonide spray  [s2]Budefat[e2]  for treatment of bronchial asthma.
	(14, 35)	swelling of the lips and oral cavity	budesonide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1506	We report a 43-year-old woman who developed sore throat, [s1]swelling of the lips and oral cavity[e1] and dysphagia, 2 weeks after the use of [s2]budesonide[e2] spray (Budefat) for treatment of bronchial asthma.
	(0, 5)	Infectious toxicity	dexamethasone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1507	 [s1]Infectious toxicity[e1] of [s2]dexamethasone[e2] during all remission-induction chemotherapy: report of two cases and literature review.
	(17, 68)	dexamethasone	infectious complications	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1508	We describe the infectious toxicities experienced by the first two patients in our institution treated with [s1]dexamethasone[e1] (10 mg/m(2)/day for 4 weeks with gradual tapering) during induction according to the dexamethasone arm of BFM 2000 and review the relevant literature that suggests an increased risk of [s2]infectious complications[e2] with dexamethasone.
	(3, 19)	infectious toxicities	dexamethasone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1509	We describe the [s1]infectious toxicities[e1] experienced by the first two patients in our institution treated with [s2]dexamethasone[e2] (10 mg/m(2)/day for 4 weeks with gradual tapering) during induction according to the dexamethasone arm of BFM 2000 and review the relevant literature that suggests an increased risk of infectious complications with dexamethasone.
	(6, 26)	NEH	cytarabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1510	We describe a patient who developed [s1]NEH[e1] on three separate occasions provoked by two different chemotherapeutic agents- [s2]cytarabine[e2] and mitoxantrone.
	(6, 31)	NEH	mitoxantrone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1511	We describe a patient who developed [s1]NEH[e1] on three separate occasions provoked by two different chemotherapeutic agents--cytarabine and [s2]mitoxantrone[e2] 
	(3, 11)	infliximab	lupus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1512	A diagnosis of [s1]infliximab[e1] induced [s2]lupus[e2] was made and the drug treatment was withdrawn.
	(0, 8)	Infliximab	lupus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1513	 [s1]Infliximab[e1] induced [s2]lupus[e2] in Crohn's disease: a case report.
	(14, 22)	infliximab	lupus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1514	This is the first case, to our knowledge, of onset of prolonged [s1]infliximab[e1] induced [s2]lupus[e2] 
	(2, 27)	infliximab	anti-double-stranded DNA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1515	Treatment with [s1]infliximab[e1] is known to produce an increase of autoantibodies (antinuclear antibodies, [s2]anti-double-stranded DNA[e2] , but not clinical disease.
	(2, 20)	infliximab	antinuclear antibodies	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1516	Treatment with [s1]infliximab[e1] is known to produce an increase of autoantibodies  [s2]antinuclear antibodies[e2]  anti-double-stranded DNA), but not clinical disease.
	(2, 14)	infliximab	increase of autoantibodies	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1517	Treatment with [s1]infliximab[e1] is known to produce an [s2]increase of autoantibodies[e2] (antinuclear antibodies, anti-double-stranded DNA), but not clinical disease.
	(0, 9)	Severe Raynaud's phenomenon	yohimbine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1518	 [s1]Severe Raynaud's phenomenon[e1] with [s2]yohimbine[e2] therapy for erectile dysfunction.
	(43, 55)	worsening of Raynaud's phenomenon	yohimbine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1519	We describe a patient with CREST syndrome (calcinosis, Raynaud's phenomenon, esophageal dysfunction, sclerodactyly, and telangiectasia) who paradoxically experienced [s1]worsening of Raynaud's phenomenon[e1] when using [s2]yohimbine[e2] for ED.
	(4, 35)	vitamin D3	serum level of calcium and urinary excretion of calcium increased	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1520	After initiation of topical [s1]vitamin D3[e1] ointment (20 micro g/g of tacalcitol) 10 g/day for the skin lesions, both the [s2]serum level of calcium and urinary excretion of calcium increased[e2] gradually.
	(3, 17)	hypercalcemia	1,24(OH)2D3	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1521	Iatrogenic [s1]hypercalcemia[e1] due to vitamin D3 ointment  [s2]1,24(OH)2D3[e2]  combined with thiazide diuretics in a case of psoriasis.
	(3, 29)	hypercalcemia	thiazide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1522	Iatrogenic [s1]hypercalcemia[e1] due to vitamin D3 ointment (1,24(OH)2D3) combined with [s2]thiazide[e2] diuretics in a case of psoriasis.
	(3, 11)	hypercalcemia	vitamin D3	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1523	Iatrogenic [s1]hypercalcemia[e1] due to [s2]vitamin D3[e2] ointment (1,24(OH)2D3) combined with thiazide diuretics in a case of psoriasis.
	(8, 23)	hypercalcemia	thiazide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1524	The present case is the first report of [s1]hypercalcemia[e1] induced by vitamin D3 ointment and [s2]thiazide[e2] simultaneously.
	(8, 16)	hypercalcemia	vitamin D3	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1525	The present case is the first report of [s1]hypercalcemia[e1] induced by [s2]vitamin D3[e2] ointment and thiazide simultaneously.
	(17, 41)	tacalcitol	hypercalcemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1526	We experienced a male patient with psoriasis and hypertension whose conditions were treated with [s1]tacalcitol[e1] ointment and thiazide, respectively, resulting in hypercalciuria and [s2]hypercalcemia[e2] 
	(25, 40)	thiazide	hypercalcemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1527	We experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and [s1]thiazide[e1]  respectively, resulting in hypercalciuria and [s2]hypercalcemia[e2] 
	(17, 36)	tacalcitol	hypercalciuria	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1528	We experienced a male patient with psoriasis and hypertension whose conditions were treated with [s1]tacalcitol[e1] ointment and thiazide, respectively, resulting in [s2]hypercalciuria[e2] and hypercalcemia.
	(25, 35)	thiazide	hypercalciuria	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1529	We experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and [s1]thiazide[e1]  respectively, resulting in [s2]hypercalciuria[e2] and hypercalcemia.
	(0, 14)	2-CdA	immunodeficiency	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1530	 [s1]2-CdA[e1] typically causes a long-lasting state of [s2]immunodeficiency[e2] and the profound influence of this drug on the immune system has raised questions concerning the emergence of secondary neoplasms after its use.
	(0, 37)	2-CdA	secondary neoplasms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1531	 [s1]2-CdA[e1] typically causes a long-lasting state of immunodeficiency and the profound influence of this drug on the immune system has raised questions concerning the emergence of [s2]secondary neoplasms[e2] after its use.
	(0, 32)	2-Chloro-deoxyadenosine	non-Hodgkin's lymphoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1532	 [s1]2-Chloro-deoxyadenosine[e1] induces durable complete remission in Castleman's disease but may accelerate its transformation to [s2]non-Hodgkin's lymphoma[e2] 
	(11, 47)	2-CdA	transformation of MCD to NHL	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1533	Therefore, it is reasonable to conclude that: 1) [s1]2-CdA[e1] can induce durable complete remission in MCD patients but unfortunately it cannot cure the disease; 2) the possibility that 2-CdA may accelerate the [s2]transformation of MCD to NHL[e2] cannot be ruled out.
	(11, 21)	DGTX	cardiac DGTX toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1534	Since this amount of FAB was insufficient to bind all [s1]DGTX[e1] present in the serum, [s2]cardiac DGTX toxicity[e2] (total AV-block) persisted.
	(11, 26)	DGTX	total AV-block	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1535	Since this amount of FAB was insufficient to bind all [s1]DGTX[e1] present in the serum, cardiac DGTX toxicity  [s2]total AV-block[e2]  persisted.
	(4, 32)	phenytoin	skin lesions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1536	All patients had taken [s1]phenytoin[e1] for variable time periods (range 16-80 days; mean: 40) and were on the medication when the [s2]skin lesions[e2] first appeared.
	(0, 10)	Erythema multiforme	phenytoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1537	 [s1]Erythema multiforme[e1] associated with [s2]phenytoin[e2] and cranial radiation therapy: a report of three patients and review of the literature.
	(3, 27)	RSDS	CyA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1538	In conclusion, [s1]RSDS[e1] is a relevant osteoarticular complication in patients receiving either anticalcineurinic drug  [s2]CyA[e2] or tacrolimus), even under monotherapy or with a low steroid dose.
	(3, 31)	RSDS	tacrolimus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1539	In conclusion, [s1]RSDS[e1] is a relevant osteoarticular complication in patients receiving either anticalcineurinic drug (CyA or [s2]tacrolimus[e2] , even under monotherapy or with a low steroid dose.
	(0, 22)	Reflex sympathetic dystrophy syndrome	tacrolimus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1540	 [s1]Reflex sympathetic dystrophy syndrome[e1] in renal transplanted patients under immunosuppression with [s2]tacrolimus[e2] 
	(6, 16)	RSDS	tacrolimus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1541	We now present four cases of [s1]RSDS[e1] in kidney transplant recipients treated with [s2]tacrolimus[e2] 
	(2, 39)	Topiramate	acute myopia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1542	CONCLUSIONS: [s1]Topiramate[e1] may be associated with ciliochoroidal effusion with forward displacement of the lens-iris diaphragm and anterior chamber shallowing, resulting in [s2]acute myopia[e2] and angle-closure glaucoma.
	(2, 44)	Topiramate	angle-closure glaucoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1543	CONCLUSIONS: [s1]Topiramate[e1] may be associated with ciliochoroidal effusion with forward displacement of the lens-iris diaphragm and anterior chamber shallowing, resulting in acute myopia and [s2]angle-closure glaucoma[e2] 
	(2, 32)	Topiramate	anterior chamber shallowing	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1544	CONCLUSIONS: [s1]Topiramate[e1] may be associated with ciliochoroidal effusion with forward displacement of the lens-iris diaphragm and [s2]anterior chamber shallowing[e2]  resulting in acute myopia and angle-closure glaucoma.
	(2, 11)	Topiramate	ciliochoroidal effusion	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1545	CONCLUSIONS: [s1]Topiramate[e1] may be associated with [s2]ciliochoroidal effusion[e2] with forward displacement of the lens-iris diaphragm and anterior chamber shallowing, resulting in acute myopia and angle-closure glaucoma.
	(2, 21)	Topiramate	displacement of the lens-iris diaphragm	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1546	CONCLUSIONS: [s1]Topiramate[e1] may be associated with ciliochoroidal effusion with forward [s2]displacement of the lens-iris diaphragm[e2] and anterior chamber shallowing, resulting in acute myopia and angle-closure glaucoma.
	(2, 8)	topiramate	acute-onset myopia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1547	Mechanism of [s1]topiramate[e1] induced [s2]acute-onset myopia[e2] and angle closure glaucoma.
	(2, 15)	topiramate	angle closure glaucoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1548	Mechanism of [s1]topiramate[e1] induced acute-onset myopia and [s2]angle closure glaucoma[e2] 
	(17, 25)	acute myopia	topiramate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1549	METHODS: In an institutional practice setting, two women, aged 25 and 45, developed [s1]acute myopia[e1] after starting [s2]topiramate[e2] for epilepsy.
	(0, 8)	Doxycycline	photo-onycholysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1550	 [s1]Doxycycline[e1] induced [s2]photo-onycholysis[e2] 
	(5, 18)	photo-onycholysis	doxycycline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1551	We present a case of [s1]photo-onycholysis[e1] in a patient treated with [s2]doxycycline[e2] for acne vulgaris.
	(4, 12)	minocycline	cutaneous hyperpigmentation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1552	A new type of [s1]minocycline[e1] induced [s2]cutaneous hyperpigmentation[e2] 
	(0, 23)	Pigmentary disorders	minocycline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1553	 [s1]Pigmentary disorders[e1] are recognized adverse effects of the semi-synthetic tetracycline derivative antibiotic, [s2]minocycline[e2] 
	(6, 13)	minocycline	hyperpigmentation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1554	This fourth type of cutaneous [s1]minocycline[e1]  [s2]hyperpigmentation[e2] may be a variant of Type I, but based on clinical, pathological and microanalytical differences, appears to be a new entity.
	(4, 12)	minocycline	cutaneous pigmentation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1555	Three distinct types of [s1]minocycline[e1] induced [s2]cutaneous pigmentation[e2] have been described.
	(14, 22)	minocycline	cutaneous pigmentation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1556	We report two patients with acne vulgaris with a fourth type of [s1]minocycline[e1] induced [s2]cutaneous pigmentation[e2] 
	(0, 9)	Ciprofloxacin	toxic epidermal necrolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1557	 [s1]Ciprofloxacin[e1] induced [s2]toxic epidermal necrolysis[e2] in a patient with systemic lupus erythematosus.
	(6, 12)	TEN	ciprofloxacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1558	We report here a case of [s1]TEN[e1] after administration of [s2]ciprofloxacin[e2] 
	(23, 31)	fever	amifostine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1559	A 56-year-old Caucasian man who received concomitant chemotherapy and radiation for head and neck cancer developed [s1]fever[e1] concurrent with the administration of [s2]amifostine[e2] 
	(0, 7)	Amifostine	fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1560	 [s1]Amifostine[e1] induced [s2]fever[e2]  case report and review of the literature.
	(2, 11)	amifostine	fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1561	Patients receiving [s1]amifostine[e1] who develop only [s2]fever[e2] should be evaluated for an adverse drug reaction, as well as for sepsis and fevers of neutropenia, and it may be necessary to discontinue the drug.
	(2, 28)	amifostine	fevers of neutropenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1562	Patients receiving [s1]amifostine[e1] who develop only fever should be evaluated for an adverse drug reaction, as well as for sepsis and [s2]fevers of neutropenia[e2]  and it may be necessary to discontinue the drug.
	(2, 25)	amifostine	sepsis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1563	Patients receiving [s1]amifostine[e1] who develop only fever should be evaluated for an adverse drug reaction, as well as for [s2]sepsis[e2] and fevers of neutropenia, and it may be necessary to discontinue the drug.
	(15, 22)	fever	amifostine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1564	To our knowledge, this is the first case report that demonstrates the occurrence of [s1]fever[e1] with low-dose [s2]amifostine[e2] therapy without the manifestation of accompanying rash or hypotension.
	(0, 12)	Acute interstitial nephritis	pantoprazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1565	 [s1]Acute interstitial nephritis[e1] due to [s2]pantoprazole[e2] 
	(9, 17)	pantoprazole	general malaise	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1566	After 5 weeks of therapy, she stopped taking [s1]pantoprazole[e1] due to [s2]general malaise[e2] 
	(25, 40)	acute interstitial nephritis	pantoprazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1567	OBJECTIVE: To describe what is believed, as of November 4, 2003, to be the first case published in the literature of [s1]acute interstitial nephritis[e1] (AIN) due to [s2]pantoprazole[e2] 
	(12, 16)	AIN	pantoprazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1568	The Naranjo probability scale suggests a highly probable relationship between [s1]AIN[e1] and [s2]pantoprazole[e2] therapy in this patient.
	(7, 14)	omeprazole	AIN	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1569	There have been several reported cases of [s1]omeprazole[e1] induced [s2]AIN[e2] 
	(5, 14)	finasteride	anterior subcapsular opacity on the lens	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1570	It was highly suspected that [s1]finasteride[e1] was associated with the [s2]anterior subcapsular opacity on the lens[e2]  and the patient therefore discontinued use of finasteride.
	(5, 14)	finasteride	anterior subcapsular opacity on the lens	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1571	It was highly suspected that [s1]finasteride[e1] was associated with the [s2]anterior subcapsular opacity on the lens[e2]  and the patient therefore discontinued use of finasteride.
	(0, 6)	Propecia	bilateral cataract	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1572	 [s1]Propecia[e1] associated [s2]bilateral cataract[e2] 
	(16, 22)	Propecia	cataract	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1573	To the best of the authors' knowledge, this is the first reported case of [s1]Propecia[e1] associated [s2]cataract[e2] 
	(0, 24)	Scleromyxedema	interferon beta-1a	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1574	 [s1]Scleromyxedema[e1] in a patient with multiple sclerosis and monoclonal gammopathy on [s2]interferon beta-1a[e2] 
	(11, 22)	methylphenidate	fixed drug eruption of the scrotum	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1575	CASE SUMMARY: Two children with attention deficit disorder treated with [s1]methylphenidate[e1] as a simple drug developed [s2]fixed drug eruption of the scrotum[e2] 
	(2, 9)	Fixed drug rash	methylphenidate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1576	CONCLUSIONS: [s1]Fixed drug rash[e1] induced by [s2]methylphenidate[e2] is a possible but rare phenomenon.
	(0, 12)	Fixed drug eruption of the scrotum	methylphenidate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1577	 [s1]Fixed drug eruption of the scrotum[e1] due to [s2]methylphenidate[e2] 
	(7, 14)	fixed drug eruption	methylphenidate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1578	OBJECTIVE: To report two cases of [s1]fixed drug eruption[e1] induced by [s2]methylphenidate[e2] 
	(0, 7)	Methotrexate	pneumonitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1579	 [s1]Methotrexate[e1]  [s2]pneumonitis[e2] in nonsurgical treatment of ectopic pregnancy.
	(5, 16)	pneumonitis	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1580	We describe a case of [s1]pneumonitis[e1] following local administration of [s2]methotrexate[e2] for nonsurgical termination of an ectopic pregnancy.
	(8, 22)	warfarin	haemorrhagic side-effects	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1581	BACKGROUND: The risk/benefit ratio of [s1]warfarin[e1] therapy changes in the over 75s, when [s2]haemorrhagic side-effects[e2] become more common.
	(13, 22)	warfarin	acute dissecting thoracic aortic aneurysm	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1582	CASE REPORT: A woman of 80 years, on long-term [s1]warfarin[e1] therapy presented with an [s2]acute dissecting thoracic aortic aneurysm[e2]  on investigation the only precipitating factor found was an international normalised ratio of 4.8.
	(0, 6)	Warfarin	thoracic aortic dissection	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1583	 [s1]Warfarin[e1] associated [s2]thoracic aortic dissection[e2] in an elderly woman.
	(0, 10)	Cutaneous vasculitis	ramipril	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1584	 [s1]Cutaneous vasculitis[e1] secondary to [s2]ramipril[e2] 
	(3, 9)	ramipril	cutaneous vasculitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1585	Here we report [s1]ramipril[e1] induced [s2]cutaneous vasculitis[e2] in a patient who required steroid therapy to control it.
	(0, 6)	Ramipril	cutaneous vasculitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1586	 [s1]Ramipril[e1] induced [s2]cutaneous vasculitis[e2] is particularly rare and our case was atypical because the patient had tolerated lisinopril before.
	(13, 26)	severe myelopathy	doxorubicin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1587	CONCLUSION: This is, to our knowledge, the first report of [s1]severe myelopathy[e1] following accidental intrathecal administration of [s2]doxorubicin[e2] 
	(6, 19)	toxic myelopathy	doxorubicin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1588	Neurological improvement and rehabilitation potential following [s1]toxic myelopathy[e1] due to intrathecal injection of [s2]doxorubicin[e2] 
	(10, 23)	severe myelopathy	doxorubicin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1589	RESULTS: Evidence of neurological improvement and rehabilitation potential after [s1]severe myelopathy[e1] due to intrathecal injection of [s2]doxorubicin[e2] 
	(16, 29)	toxic myelopathy	doxorubicin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1590	STUDY DESIGN: Case report of a 31-year-old woman who presented with [s1]toxic myelopathy[e1] due to intrathecal administration of [s2]doxorubicin[e2] 
	(1, 15)	infliximab	increase in the number of apneic events	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1591	After [s1]infliximab[e1] treatment, additional sleep studies revealed an [s2]increase in the number of apneic events[e2] and SaO2 dips suggesting that TNFalpha plays an important role in the pathophysiology of sleep apnea.
	(1, 25)	infliximab	SaO2 dips	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1592	After [s1]infliximab[e1] treatment, additional sleep studies revealed an increase in the number of apneic events and [s2]SaO2 dips[e2] suggesting that TNFalpha plays an important role in the pathophysiology of sleep apnea.
	(5, 29)	sleep disordered breathing	infliximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1593	Thus, clinical recognition of [s1]sleep disordered breathing[e1] should be taken into account when rheumatoid arthritis patients are to be treated with [s2]infliximab[e2] 
	(0, 16)	Hypernatraemia	Kayexalate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1594	 [s1]Hypernatraemia[e1] induced by sodium polystyrene sulphonate  [s2]Kayexalate[e2]  in two extremely low birth weight newborns.
	(0, 8)	Hypernatraemia	sodium polystyrene sulphonate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1595	 [s1]Hypernatraemia[e1] induced by [s2]sodium polystyrene sulphonate[e2] (Kayexalate) in two extremely low birth weight newborns.
	(15, 23)	Kayexalate	hypernatraemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1596	We describe two ELBW infants affected by hyperkalaemia, treated with [s1]Kayexalate[e1]  who developed serious [s2]hypernatraemia[e2]  that has never been reported before in preterm infants.
	(0, 12)	Bull's-eye maculopathy	quinacrine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1597	 [s1]Bull's-eye maculopathy[e1] associated with [s2]quinacrine[e2] therapy for malaria.
	(24, 36)	maculopathy	chloroquine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1598	CONCLUSIONS: Low dosages of quinacrine used for malaria prophylaxis can be associated with a delayed, severe [s1]maculopathy[e1] indistinguishable from [s2]chloroquine[e2] maculopathy in certain patients.
	(6, 25)	quinacrine	severe maculopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1599	CONCLUSIONS: Low dosages of [s1]quinacrine[e1] used for malaria prophylaxis can be associated with a delayed, [s2]severe maculopathy[e2] indistinguishable from chloroquine maculopathy in certain patients.
	(6, 23)	bilaterally symmetric bull's-eye maculopathy	quinacrine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1600	RESULTS: A patient developed a [s1]bilaterally symmetric bull's-eye maculopathy[e1] 45 years after taking [s2]quinacrine[e2] for 18 months as prophylaxis against malaria.
	(8, 23)	chloroquine	maculopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1601	The clinical picture was identical to that of [s1]chloroquine[e1] and hydroxychloroquine [s2]maculopathy[e2] 
	(14, 23)	hydroxychloroquine	maculopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1602	The clinical picture was identical to that of chloroquine and [s1]hydroxychloroquine[e1]  [s2]maculopathy[e2] 
	(0, 12)	Cerebral infarcts	phenylpropanolamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1603	 [s1]Cerebral infarcts[e1] in a pediatric patient secondary to [s2]phenylpropanolamine[e2]  a recalled medication.
	(0, 25)	Phenylpropanolamine	neurologic events	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1604	 [s1]Phenylpropanolamine[e1] (PPA) recently has been publicly implicated as a cause of stroke and other [s2]neurologic events[e2] 
	(7, 23)	PPA	neurologic events	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1605	Phenylpropanolamine  [s1]PPA[e1]  recently has been publicly implicated as a cause of stroke and other [s2]neurologic events[e2] 
	(0, 22)	Phenylpropanolamine	stroke	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1606	 [s1]Phenylpropanolamine[e1] (PPA) recently has been publicly implicated as a cause of [s2]stroke[e2] and other neurologic events.
	(7, 20)	PPA	stroke	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1607	Phenylpropanolamine  [s1]PPA[e1]  recently has been publicly implicated as a cause of [s2]stroke[e2] and other neurologic events.
	(15, 23)	extremely elevated levels of PPA	PPA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1608	The patient developed occipital infarcts and was found to have [s1]extremely elevated levels of PPA[e1]  [s2]PPA[e2] in his blood and dialysis fluid.
	(3, 21)	occipital infarcts	PPA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1609	The patient developed [s1]occipital infarcts[e1] and was found to have extremely elevated levels of [s2]PPA[e2] in his blood and dialysis fluid.
	(5, 9)	stroke	PPA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1610	We present a case of [s1]stroke[e1] after [s2]PPA[e2] ingestion that occurred 4 months after the recall in an 8-year-old boy on chronic peritoneal dialysis.
	(6, 35)	ciprofloxacin	hallucinations	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1611	Central nervous system effects secondary to [s1]ciprofloxacin[e1] treatment are uncommon and usually consist only of minor dizziness or mild headache, although rare occurrences of seizures and [s2]hallucinations[e2] have been reported.
	(6, 26)	ciprofloxacin	mild headache	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1612	Central nervous system effects secondary to [s1]ciprofloxacin[e1] treatment are uncommon and usually consist only of minor dizziness or [s2]mild headache[e2]  although rare occurrences of seizures and hallucinations have been reported.
	(6, 22)	ciprofloxacin	minor dizziness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1613	Central nervous system effects secondary to [s1]ciprofloxacin[e1] treatment are uncommon and usually consist only of [s2]minor dizziness[e2] or mild headache, although rare occurrences of seizures and hallucinations have been reported.
	(6, 33)	ciprofloxacin	seizures	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1614	Central nervous system effects secondary to [s1]ciprofloxacin[e1] treatment are uncommon and usually consist only of minor dizziness or mild headache, although rare occurrences of [s2]seizures[e2] and hallucinations have been reported.
	(0, 9)	Ciprofloxacin	psychosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1615	 [s1]Ciprofloxacin[e1] induced [s2]psychosis[e2] 
	(13, 23)	severe psychosis	ciprofloxacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1616	DATA SYNTHESIS: A 49-year-old man developed symptoms of [s1]severe psychosis[e1] concomitant with [s2]ciprofloxacin[e2] (250 mg bid) treatment.
	(7, 16)	ciprofloxacin	psychosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1617	OBJECTIVE: To report a case of [s1]ciprofloxacin[e1] induced [s2]psychosis[e2] and to discuss occurrence rates, risk factors, possible etiologies, preventive measures, and treatment courses for this adverse reaction.
	(0, 9)	Agranulocytosis	vancomycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1618	 [s1]Agranulocytosis[e1] induced by [s2]vancomycin[e2] in an ESRD patient on CAPD.
	(0, 15)	Agranulocytosis	vancomycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1619	 [s1]Agranulocytosis[e1] is a rare adverse effect associated with prolonged [s2]vancomycin[e2] therapy, and is potentially serious, especially in end stage renal disease (ESRD) patients.
	(20, 27)	vancomycin	agranulocytosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1620	We describe a continuous ambulatory peritoneal dialysis (CAPD) patient that developed [s1]vancomycin[e1] induced [s2]agranulocytosis[e2] during treatment for methicillin-resistant Staphylococcus aureus (MRSA)-associated external cuff infection and pneumonia.
	(6, 27)	dexamethasone	osteonecrosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1621	It is very likely that the [s1]dexamethasone[e1] used in the antiemetic drug regimen contributed to the development of [s2]osteonecrosis[e2] in these patients.
	(0, 18)	Osteonecrosis	dexamethasone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1622	 [s1]Osteonecrosis[e1] is a serious side effect of antiemetic treatment with [s2]dexamethasone[e2] and this serious complication should be incorporated in the current guidelines.
	(8, 17)	osteonecrosis	dexamethasone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1623	Patients should be informed about the risk of [s1]osteonecrosis[e1] when taking [s2]dexamethasone[e2] as an antiemetic drug.
	(2, 15)	Peyronie's disease	colchicine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1624	Development of [s1]Peyronie's disease[e1] during long-term [s2]colchicine[e2] treatment.
	(9, 15)	PD	colchicine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1625	However here we reported two patients, presenting with [s1]PD[e1] during high dose [s2]colchicine[e2] treatment for familiar mediterranean fever (FMF).
	(3, 14)	cholestatic hepatitis	nitrofurantoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1626	A patient developed [s1]cholestatic hepatitis[e1] while being treated with [s2]nitrofurantoin[e2] 
	(4, 19)	jaundice	furazolidone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1627	A second episode of [s1]jaundice[e1] followed the intravaginal administration of a mixture of [s2]furazolidone[e2] and nifuroxime.
	(4, 25)	jaundice	nifuroxime	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1628	A second episode of [s1]jaundice[e1] followed the intravaginal administration of a mixture of furazolidone and [s2]nifuroxime[e2] 
	(3, 10)	phenobarbital	exacerbation of a preexisting maladaptive behavior	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1629	A case of [s1]phenobarbital[e1]  [s2]exacerbation of a preexisting maladaptive behavior[e2] partially suppressed by chlorpromazine and misinterpreted as chlorpromazine efficacy.
	(12, 24)	phenobarbital	maladaptive behaviors	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1630	Ten years of behavioral data are presented to support the hypothesis that [s1]phenobarbital[e1] was exacerbating [s2]maladaptive behaviors[e2] 
	(14, 21)	phenobarbital	behavioral side effects	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1631	"This profile should trigger a ""red flag"" as to the possibility of [s1]phenobarbital[e1]  [s2]behavioral side effects[e2] or exacerbation of preexisting maladaptive behaviors."
	(14, 25)	phenobarbital	exacerbation of preexisting maladaptive behaviors	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1632	"This profile should trigger a ""red flag"" as to the possibility of [s1]phenobarbital[e1] behavioral side effects or [s2]exacerbation of preexisting maladaptive behaviors[e2] "
	(0, 15)	Pilocarpine toxicity	Pilocarpine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1633	 [s1]Pilocarpine toxicity[e1] and the treatment of xerostomia [s2]Pilocarpine[e2] toxicity and the treatment of xerostomia.
	(12, 22)	pilocarpine	bradycardia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1634	We report a case of unintentional overdose of oral [s1]pilocarpine[e1] tablets that resulted in [s2]bradycardia[e2]  mild hypotension, and muscarinic symptoms in a patient with Sjogren's syndrome.
	(12, 26)	pilocarpine	mild hypotension	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1635	We report a case of unintentional overdose of oral [s1]pilocarpine[e1] tablets that resulted in bradycardia, [s2]mild hypotension[e2]  and muscarinic symptoms in a patient with Sjogren's syndrome.
	(12, 34)	pilocarpine	muscarinic symptoms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1636	We report a case of unintentional overdose of oral [s1]pilocarpine[e1] tablets that resulted in bradycardia, mild hypotension, and [s2]muscarinic symptoms[e2] in a patient with Sjogren's syndrome.
	(3, 46)	belladonna	anticonvulsant hypersensitivity syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1637	Although combinations of [s1]belladonna[e1]  ergotamine, and phenobarbital have been used for medical treatment of menopausal symptoms since the 1960s, this is the first known case report of its association with [s2]anticonvulsant hypersensitivity syndrome[e2] 
	(7, 46)	ergotamine	anticonvulsant hypersensitivity syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1638	Although combinations of belladonna, [s1]ergotamine[e1]  and phenobarbital have been used for medical treatment of menopausal symptoms since the 1960s, this is the first known case report of its association with [s2]anticonvulsant hypersensitivity syndrome[e2] 
	(13, 47)	phenobarbital	anticonvulsant hypersensitivity syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1639	Although combinations of belladonna, ergotamine, and [s1]phenobarbital[e1] have been used for medical treatment of menopausal symptoms since the 1960s, this is the first known case report of its association with [s2]anticonvulsant hypersensitivity syndrome[e2] 
	(0, 14)	Anticonvulsant hypersensitivity syndrome	Bellamine S	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1640	 [s1]Anticonvulsant hypersensitivity syndrome[e1] associated with [s2]Bellamine S[e2]  a therapy for menopausal symptoms.
	(17, 34)	anticonvulsant hypersensitivity syndrome	belladonna alkaloids	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1641	We report a case of a previously healthy, postmenopausal woman who developed [s1]anticonvulsant hypersensitivity syndrome[e1] while taking Bellamine S  [s2]belladonna alkaloids[e2]  ergotamine; phenobarbital) for hot flashes.
	(17, 31)	anticonvulsant hypersensitivity syndrome	Bellamine S	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1642	We report a case of a previously healthy, postmenopausal woman who developed [s1]anticonvulsant hypersensitivity syndrome[e1] while taking [s2]Bellamine S[e2] (belladonna alkaloids; ergotamine; phenobarbital) for hot flashes.
	(17, 42)	anticonvulsant hypersensitivity syndrome	ergotamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1643	We report a case of a previously healthy, postmenopausal woman who developed [s1]anticonvulsant hypersensitivity syndrome[e1] while taking Bellamine S (belladonna alkaloids; [s2]ergotamine[e2]  phenobarbital) for hot flashes.
	(17, 47)	anticonvulsant hypersensitivity syndrome	phenobarbital	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1644	We report a case of a previously healthy, postmenopausal woman who developed [s1]anticonvulsant hypersensitivity syndrome[e1] while taking Bellamine S (belladonna alkaloids; ergotamine; [s2]phenobarbital[e2]  for hot flashes.
	(3, 23)	heatstroke	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1645	A case of [s1]heatstroke[e1] is reported in a 32-year-old man diagnosed with schizophrenia and on [s2]clozapine[e2] monotherapy.
	(0, 7)	Heat stroke	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1646	 [s1]Heat stroke[e1] in schizophrenia during [s2]clozapine[e2] treatment: rapid recognition and management.
	(0, 7)	Gemcitabine	radiation recall	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1647	 [s1]Gemcitabine[e1] related [s2]radiation recall[e2] preferentially involves internal tissue and organs.
	(8, 52)	myositis	gemcitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1648	The authors also determined that their case of [s1]myositis[e1] developing in the rectus abdominus muscle of a patient with pancreatic adenocarcinoma was the manifestation of radiation recall, thereby bringing the number of patients who developed radiation recall to [s2]gemcitabine[e2] and were discussed in the current study to 13.
	(36, 51)	radiation recall	gemcitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1649	The authors also determined that their case of myositis developing in the rectus abdominus muscle of a patient with pancreatic adenocarcinoma was the manifestation of [s1]radiation recall[e1]  thereby bringing the number of patients who developed radiation recall to [s2]gemcitabine[e2] and were discussed in the current study to 13.
	(36, 51)	radiation recall	gemcitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1650	The authors also determined that their case of myositis developing in the rectus abdominus muscle of a patient with pancreatic adenocarcinoma was the manifestation of [s1]radiation recall[e1]  thereby bringing the number of patients who developed radiation recall to [s2]gemcitabine[e2] and were discussed in the current study to 13.
	(7, 13)	radiation recall	gemcitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1651	The literature search found 12 cases of [s1]radiation recall[e1] caused by [s2]gemcitabine[e2] 
	(3, 10)	radiation recall reactions	gemcitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1652	The majority of [s1]radiation recall reactions[e1] attributed to [s2]gemcitabine[e2] are reported to affect internal tissue or organs.
	(0, 24)	Cystoid macular edema	bimatoprost	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1653	 [s1]Cystoid macular edema[e1] in a low-risk patient after switching from latanoprost to [s2]bimatoprost[e2] 
	(0, 18)	Cystoid macular edema	latanoprost	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1654	 [s1]Cystoid macular edema[e1] in a low-risk patient after switching from [s2]latanoprost[e2] to bimatoprost.
	(19, 37)	cystoid macula edema	bimatoprost	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1655	METHODS: A 68-year-old man developed intense conjunctival hyperemia and [s1]cystoid macula edema[e1] after switching from latanoprost to [s2]bimatoprost[e2] 9 months after cataract surgery in an eye at low-risk for this cystoid macular edema.
	(19, 31)	cystoid macula edema	latanoprost	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1656	METHODS: A 68-year-old man developed intense conjunctival hyperemia and [s1]cystoid macula edema[e1] after switching from [s2]latanoprost[e2] to bimatoprost 9 months after cataract surgery in an eye at low-risk for this cystoid macular edema.
	(35, 58)	bimatoprost	cystoid macular edema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1657	METHODS: A 68-year-old man developed intense conjunctival hyperemia and cystoid macula edema after switching from latanoprost to [s1]bimatoprost[e1] 9 months after cataract surgery in an eye at low-risk for this [s2]cystoid macular edema[e2] 
	(29, 58)	latanoprost	cystoid macular edema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1658	METHODS: A 68-year-old man developed intense conjunctival hyperemia and cystoid macula edema after switching from [s1]latanoprost[e1] to bimatoprost 9 months after cataract surgery in an eye at low-risk for this [s2]cystoid macular edema[e2] 
	(10, 37)	intense conjunctival hyperemia	bimatoprost	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1659	METHODS: A 68-year-old man developed [s1]intense conjunctival hyperemia[e1] and cystoid macula edema after switching from latanoprost to [s2]bimatoprost[e2] 9 months after cataract surgery in an eye at low-risk for this cystoid macular edema.
	(10, 31)	intense conjunctival hyperemia	latanoprost	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1660	METHODS: A 68-year-old man developed [s1]intense conjunctival hyperemia[e1] and cystoid macula edema after switching from [s2]latanoprost[e2] to bimatoprost 9 months after cataract surgery in an eye at low-risk for this cystoid macular edema.
	(12, 36)	cystoid macula edema	bimatoprost	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1661	PURPOSE: To report a case of angiographically documented [s1]cystoid macula edema[e1] occurring after switching a pseudophakic patient from latanoprost to [s2]bimatoprost[e2] 
	(12, 30)	cystoid macula edema	latanoprost	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1662	PURPOSE: To report a case of angiographically documented [s1]cystoid macula edema[e1] occurring after switching a pseudophakic patient from [s2]latanoprost[e2] to bimatoprost.
	(2, 13)	hemolytic reaction	oxaliplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1663	An immediate [s1]hemolytic reaction[e1] induced by repeated administration of [s2]oxaliplatin[e2] 
	(10, 40)	DAT-positive hemolytic episode	oxaliplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1664	CASE REPORT: We report a patient who developed a [s1]DAT-positive hemolytic episode[e1] after a red cell (RBC) transfusion was delivered during the infusion of her 17th cycle of [s2]oxaliplatin[e2] 
	(12, 21)	methotrexate	fatal acute neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1665	Although neurotoxicity is a frequent complication of [s1]methotrexate[e1] therapy, [s2]fatal acute neurotoxicity[e2] is extremely uncommon, especially in adults.
	(1, 14)	neurotoxicity	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1666	Although [s1]neurotoxicity[e1] is a frequent complication of [s2]methotrexate[e2] therapy, fatal acute neurotoxicity is extremely uncommon, especially in adults.
	(11, 33)	neurotoxicity	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1667	Clinicians should be aware of the signs and symptoms of [s1]neurotoxicity[e1] during treatment, as well as predisposing factors that put patients receiving [s2]methotrexate[e2] at risk for neurotoxic effects.
	(0, 19)	Fatal acute encephalomyelitis	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1668	 [s1]Fatal acute encephalomyelitis[e1] after a single dose of intrathecal [s2]methotrexate[e2] 
	(3, 16)	methotrexate	severe back pain	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1669	The day after [s1]methotrexate[e1] administration, the patient complained of [s2]severe back pain[e2] and urinary retention.
	(3, 20)	methotrexate	urinary retention	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1670	The day after [s1]methotrexate[e1] administration, the patient complained of severe back pain and [s2]urinary retention[e2] 
	(12, 27)	fatal encephalopathy	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1671	This patient rapidly progressed from mild neurotoxicity to [s1]fatal encephalopathy[e1] after one dose of intrathecal [s2]methotrexate[e2] during his third cycle of chemotherapy.
	(5, 27)	mild neurotoxicity	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1672	This patient rapidly progressed from [s1]mild neurotoxicity[e1] to fatal encephalopathy after one dose of intrathecal [s2]methotrexate[e2] during his third cycle of chemotherapy.
	(23, 34)	ampicillin	TEN	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1673	We report a third case of a 6-week-old infant with Escherichia coli sepsis who received [s1]ampicillin[e1] and other antibiotics and subsequently developed [s2]TEN[e2] 
	(3, 22)	large intramural esophageal hematoma	heparin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1674	One patient developed [s1]large intramural esophageal hematoma[e1] as a complication of [s2]heparin[e2] therapy.
	(0, 16)	Eosinophilic cystitis	dimethyl sulfoxide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1675	 [s1]Eosinophilic cystitis[e1] after bladder instillation with [s2]dimethyl sulfoxide[e2] 
	(10, 34)	eosinophilic cystitis	dimethyl sulfoxide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1676	We report the first case of an acute flare of [s1]eosinophilic cystitis[e1] in a 51-year-old woman after bladder instillation with [s2]dimethyl sulfoxide[e2] (DMSO) for presumed interstitial cystitis.
	(10, 40)	eosinophilic cystitis	DMSO	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1677	We report the first case of an acute flare of [s1]eosinophilic cystitis[e1] in a 51-year-old woman after bladder instillation with dimethyl sulfoxide  [s2]DMSO[e2]  for presumed interstitial cystitis.
	(0, 7)	Acute dystonia	pegylated interferon alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1678	 [s1]Acute dystonia[e1] during [s2]pegylated interferon alpha[e2] therapy in a case with chronic hepatitis B infection.
	(20, 32)	acute dystonia	pegylated interferon alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1679	In this case report, we present clinical and laboratory findings of a case with chronic hepatitis B that developed [s1]acute dystonia[e1] soon after the first dose of [s2]pegylated interferon alpha[e2] 
	(2, 27)	IFN-alpha	akathisia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1680	Therapy with [s1]IFN-alpha[e1] may be associated with a number of neuropsychiatric symptoms, such as Parkinsonism, [s2]akathisia[e2]  seizure, and depressive disorders.
	(2, 34)	IFN-alpha	depressive disorders	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1681	Therapy with [s1]IFN-alpha[e1] may be associated with a number of neuropsychiatric symptoms, such as Parkinsonism, akathisia, seizure, and [s2]depressive disorders[e2] 
	(2, 15)	IFN-alpha	neuropsychiatric symptoms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1682	Therapy with [s1]IFN-alpha[e1] may be associated with a number of [s2]neuropsychiatric symptoms[e2]  such as Parkinsonism, akathisia, seizure, and depressive disorders.
	(2, 24)	IFN-alpha	Parkinsonism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1683	Therapy with [s1]IFN-alpha[e1] may be associated with a number of neuropsychiatric symptoms, such as [s2]Parkinsonism[e2]  akathisia, seizure, and depressive disorders.
	(2, 31)	IFN-alpha	seizure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1684	Therapy with [s1]IFN-alpha[e1] may be associated with a number of neuropsychiatric symptoms, such as Parkinsonism, akathisia, [s2]seizure[e2]  and depressive disorders.
	(3, 18)	restless legs symptoms	IFN alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1685	A patient developed [s1]restless legs symptoms[e1] paralleling the course of interferon-alpha  [s2]IFN alpha[e2]  therapy for chronic hepatitis C.
	(3, 13)	restless legs symptoms	interferon-alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1686	A patient developed [s1]restless legs symptoms[e1] paralleling the course of [s2]interferon-alpha[e2] (IFN alpha) therapy for chronic hepatitis C.
	(0, 7)	Restless legs syndrome	interferon-alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1687	 [s1]Restless legs syndrome[e1] due to [s2]interferon-alpha[e2] 
	(0, 12)	Restless legs syndrome	IFN alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1688	 [s1]Restless legs syndrome[e1] may thus be an adverse effect of [s2]IFN alpha[e2] treatment.
	(10, 23)	hepatotoxicity	naltrexone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1689	Many clinicians appear to be concerned about the potential [s1]hepatotoxicity[e1] of the opiate antagonist [s2]naltrexone[e2] (NTX) and this may be one reason why it is not used more widely in treating both heroin and alcohol abusers.
	(10, 28)	hepatotoxicity	NTX	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1690	Many clinicians appear to be concerned about the potential [s1]hepatotoxicity[e1] of the opiate antagonist naltrexone  [s2]NTX[e2]  and this may be one reason why it is not used more widely in treating both heroin and alcohol abusers.
	(14, 33)	acute hepatitis B and C	naltrexone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1691	We describe a heroin abuser in whom clinical and laboratory manifestations of [s1]acute hepatitis B and C[e1] appeared a few days after the insertion of a subcutaneous [s2]naltrexone[e2] implant.
	(0, 8)	Sweet's syndrome	sargramostim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1692	 [s1]Sweet's syndrome[e1] associated with [s2]sargramostim[e2] (granulocyte-macrophage colony stimulating factor) treatment.
	(6, 30)	acute febrile neutrophilic dermatosis	filgrastim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1693	Sweet's syndrome is an [s1]acute febrile neutrophilic dermatosis[e1] that is a known complication of the administration of [s2]filgrastim[e2]  a drug that causes increased neutrophil proliferation and differentiation.
	(0, 30)	Sweet's syndrome	filgrastim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1694	 [s1]Sweet's syndrome[e1] is an acute febrile neutrophilic dermatosis that is a known complication of the administration of [s2]filgrastim[e2]  a drug that causes increased neutrophil proliferation and differentiation.
	(5, 14)	Sweet's syndrome	sargramostim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1695	We report a case of [s1]Sweet's syndrome[e1] in association with [s2]sargramostim[e2] treatment following chemotherapy for acute myelogenous leukemia.
	(5, 16)	hypersensitivity myocarditis	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1696	Sudden cardiac death due to [s1]hypersensitivity myocarditis[e1] during [s2]clozapine[e2] treatment.
	(0, 16)	Sudden cardiac death	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1697	 [s1]Sudden cardiac death[e1] due to hypersensitivity myocarditis during [s2]clozapine[e2] treatment.
	(12, 18)	clozapine	hypersensitivity myocarditis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1698	The autopsy findings and a detailed medical history supported the conclusion that [s1]clozapine[e1] induced [s2]hypersensitivity myocarditis[e2] was the most likely cause of death.
	(4, 17)	sudden death	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1699	The case concerns the [s1]sudden death[e1] of a 29-year-old male during [s2]clozapine[e2] therapy started 2 weeks before.
	(8, 35)	purple discoloration	phenytoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1700	Purple glove syndrome, named for its distinctive [s1]purple discoloration[e1] and swelling of the hands in the distribution of a glove, is an uncommon complication of intravenous [s2]phenytoin[e2] administration through small dorsal veins of the hands.
	(0, 34)	Purple glove syndrome	phenytoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1701	 [s1]Purple glove syndrome[e1]  named for its distinctive purple discoloration and swelling of the hands in the distribution of a glove, is an uncommon complication of intravenous [s2]phenytoin[e2] administration through small dorsal veins of the hands.
	(13, 35)	swelling of the hands	phenytoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1702	Purple glove syndrome, named for its distinctive purple discoloration and [s1]swelling of the hands[e1] in the distribution of a glove, is an uncommon complication of intravenous [s2]phenytoin[e2] administration through small dorsal veins of the hands.
	(19, 27)	phenytoin	purple glove syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1703	The findings were judged to be consistent with soft-tissue injury associated with intravenous administration of [s1]phenytoin[e1]  also termed [s2]purple glove syndrome[e2] 
	(8, 21)	soft-tissue injury	phenytoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1704	The findings were judged to be consistent with [s1]soft-tissue injury[e1] associated with intravenous administration of [s2]phenytoin[e2]  also termed purple glove syndrome.
	(21, 39)	levodopa	completely bald	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1705	Our patient was a 72-year-old man with advanced Parkinson's disease (PD) who received [s1]levodopa[e1] and anti-cholinergic drugs and whose head had become almost [s2]completely bald[e2] 
	(13, 26)	trichiasis	prostaglandin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1706	A patient with monocular open-angle glaucoma had [s1]trichiasis[e1]  a condition associated with the use of a [s2]prostaglandin[e2] analog.
	(0, 17)	Increased lash length	prostaglandin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1707	 [s1]Increased lash length[e1]  thickness, and pigmentation are well-documented side effects of [s2]prostaglandin[e2] analog glaucoma drops.
	(7, 18)	pigmentation	prostaglandin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1708	Increased lash length, thickness, and [s1]pigmentation[e1] are well-documented side effects of [s2]prostaglandin[e2] analog glaucoma drops.
	(0, 7)	Trichiasis	prostaglandin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1709	 [s1]Trichiasis[e1] associated with [s2]prostaglandin[e2] analog use.
	(0, 9)	Fatal pulmonary fibrosis	BCNU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1710	 [s1]Fatal pulmonary fibrosis[e1] associated with [s2]BCNU[e2]  the relative role of platelet-derived growth factor-B, insulin-like growth factor I, transforming growth factor-beta1 and cyclooxygenase-2.
	(0, 22)	Pulmonary fibrosis	BCNU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1711	 [s1]Pulmonary fibrosis[e1] is a severe complication associated with bis-chloronitrosourea  [s2]BCNU[e2]  therapy.
	(0, 13)	Pulmonary fibrosis	bis-chloronitrosourea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1712	 [s1]Pulmonary fibrosis[e1] is a severe complication associated with [s2]bis-chloronitrosourea[e2] (BCNU) therapy.
	(12, 17)	BCNU	pulmonary fibrosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1713	These novel findings may offer specific therapeutic targets in the treatment of [s1]BCNU[e1] associated [s2]pulmonary fibrosis[e2] 
	(78, 83)	BCNU	pulmonary fibrosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1714	We further used immunohistochemistry (IHC) to examine the relative role of platelet-derived growth factor-B (PDGF-B), insulin-like growth factor I (IGF-I), transforming growth factor-beta1 (TGF-beta1) and cyclooxygenase-2 (COX-2) in the pathogenesis of [s1]BCNU[e1] related [s2]pulmonary fibrosis[e2] 
	(23, 39)	severe pulmonary fibrosis	BCNU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1715	We report here a 26-year-old female with diffuse large B-cell lymphoma who died of [s1]severe pulmonary fibrosis[e1] 81 days after the administration of high-dose [s2]BCNU[e2] (600 mg/m2).
	(0, 7)	Dorzolamide	choroidal detachment	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1716	 [s1]Dorzolamide[e1] induced [s2]choroidal detachment[e2] in a surgically untreated eye.
	(27, 40)	choroidal detachment	dorzolamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1717	METHODS: A 76-year-old woman with primary open-angle glaucoma and no history of ocular surgery developed a [s1]choroidal detachment[e1] 12 hours after initiation of therapy with [s2]dorzolamide[e2] eye drops.
	(8, 17)	choroidal detachment	dorzolamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1718	We document the abrupt development of an extensive [s1]choroidal detachment[e1] after initiation of [s2]dorzolamide[e2] therapy in a surgically untreated eye with primary open-angle glaucoma.
	(0, 10)	Deepening of lid sulcus	bimatoprost	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1719	 [s1]Deepening of lid sulcus[e1] from topical [s2]bimatoprost[e2] therapy.
	(8, 30)	alteration of eyelid appearance	bimatoprost	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1720	In each of the three reported patients, [s1]alteration of eyelid appearance[e1] with deepening of the lid sulcus was evident as the result of topical [s2]bimatoprost[e2] therapy.
	(14, 30)	deepening of the lid sulcus	bimatoprost	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1721	In each of the three reported patients, alteration of eyelid appearance with [s1]deepening of the lid sulcus[e1] was evident as the result of topical [s2]bimatoprost[e2] therapy.
	(0, 8)	Lichen planus	hepatitis B vaccination	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1722	 [s1]Lichen planus[e1] induced by [s2]hepatitis B vaccination[e2]  a new case and review of the literature.
	(3, 16)	life-threatening hypoglycaemia	sulfadoxine-pyrimethamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1723	Case report: [s1]life-threatening hypoglycaemia[e1] associated with [s2]sulfadoxine-pyrimethamine[e2]  a commonly used antimalarial drug.
	(9, 21)	hypoglycaemic coma	SP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1724	In this report, we present a case of [s1]hypoglycaemic coma[e1] associated with [s2]SP[e2]  an adverse reaction that is likely to be underreported and expected to occur with greater frequency as the use of SP increases.
	(9, 21)	hypoglycaemic coma	SP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1725	In this report, we present a case of [s1]hypoglycaemic coma[e1] associated with [s2]SP[e2]  an adverse reaction that is likely to be underreported and expected to occur with greater frequency as the use of SP increases.
	(3, 33)	heparin	fatal intracerebral haemorrhage	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1726	Initial treatment with [s1]heparin[e1] was substituted with thrombolysis, which resulted in clinical improvement and dissolution of right heart thrombus but was followed by [s2]fatal intracerebral haemorrhage[e2] 
	(0, 14)	Extensive forearm deep venous thrombosis	infliximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1727	 [s1]Extensive forearm deep venous thrombosis[e1] following a severe [s2]infliximab[e2] infusion reaction.
	(16, 26)	infliximab	IIR	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1728	Here we describe a patient with Crohn's disease who developed a severe [s1]infliximab[e1] infusion reaction  [s2]IIR[e2] , complicated 1 day later by severe swelling of the forearm and hand ipsilateral to the site of infliximab infusion.
	(16, 26)	infliximab	IIR	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1729	Here we describe a patient with Crohn's disease who developed a severe [s1]infliximab[e1] infusion reaction  [s2]IIR[e2] , complicated 1 day later by severe swelling of the forearm and hand ipsilateral to the site of infliximab infusion.
	(15, 26)	severe infliximab infusion reaction	infliximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1730	Here we describe a patient with Crohn's disease who developed a [s1]severe infliximab infusion reaction[e1]  [s2]infliximab[e2] infusion reaction (IIR), complicated 1 day later by severe swelling of the forearm and hand ipsilateral to the site of infliximab infusion.
	(15, 26)	severe infliximab infusion reaction	infliximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1731	Here we describe a patient with Crohn's disease who developed a [s1]severe infliximab infusion reaction[e1]  [s2]infliximab[e2] infusion reaction (IIR), complicated 1 day later by severe swelling of the forearm and hand ipsilateral to the site of infliximab infusion.
	(16, 36)	infliximab	severe swelling of the forearm and hand ipsilateral	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1732	Here we describe a patient with Crohn's disease who developed a severe [s1]infliximab[e1] infusion reaction (IIR), complicated 1 day later by [s2]severe swelling of the forearm and hand ipsilateral[e2] to the site of infliximab infusion.
	(16, 36)	infliximab	severe swelling of the forearm and hand ipsilateral	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1733	Here we describe a patient with Crohn's disease who developed a severe [s1]infliximab[e1] infusion reaction (IIR), complicated 1 day later by [s2]severe swelling of the forearm and hand ipsilateral[e2] to the site of infliximab infusion.
	(19, 26)	hypersensitivity	infliximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1734	The site of thrombosis and the chronological relationship with the IIR implicates a [s1]hypersensitivity[e1] to [s2]infliximab[e2] in the causation of the venous thrombosis in this case.
	(13, 26)	IIR	infliximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1735	The site of thrombosis and the chronological relationship with the [s1]IIR[e1] implicates a hypersensitivity to [s2]infliximab[e2] in the causation of the venous thrombosis in this case.
	(24, 38)	infliximab	venous thrombosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1736	The site of thrombosis and the chronological relationship with the IIR implicates a hypersensitivity to [s1]infliximab[e1] in the causation of the [s2]venous thrombosis[e2] in this case.
	(11, 23)	indapamide	diabetes	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1737	After 3- to 13-month period of therapy without [s1]indapamide[e1]  glucose levels of all patients decreased and [s2]diabetes[e2] disappeared.
	(2, 7)	indapamide	glucose tolerance impairing	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1738	After stopping [s1]indapamide[e1]  [s2]glucose tolerance impairing[e2] may be reversed.
	(4, 11)	indapamide	diabetes	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1739	CONCLUSION: Therapy with [s1]indapamide[e1] may induce [s2]diabetes[e2] in essential hypertension patients.
	(6, 36)	indapamide	diabetes	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1740	OBJECTIVE: To study therapy with [s1]indapamide[e1] impairing carbohydrate metabolism in essential hypertension patients and achieve earlier prevention, diagnoses and treatment of [s2]diabetes[e2] induced by indapamide.
	(6, 36)	indapamide	diabetes	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1741	OBJECTIVE: To study therapy with [s1]indapamide[e1] impairing carbohydrate metabolism in essential hypertension patients and achieve earlier prevention, diagnoses and treatment of [s2]diabetes[e2] induced by indapamide.
	(6, 11)	indapamide	impairing carbohydrate metabolism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1742	OBJECTIVE: To study therapy with [s1]indapamide[e1]  [s2]impairing carbohydrate metabolism[e2] in essential hypertension patients and achieve earlier prevention, diagnoses and treatment of diabetes induced by indapamide.
	(3, 12)	diabetes	indapamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1743	Possible induction of [s1]diabetes[e1] by treatment of hypertension with [s2]indapamide[e2] (with four case reports).
	(28, 78)	fosinopril	diabetes	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1744	RESULTS: After 4- to 14-month period of therapy with the combination of indapamide (2.5 mg/day) and [s1]fosinopril[e1] (10 mg/day) in three patients and 6-month period of monotherapy with indapamide (2.5 mg/day) in one patient, glucose levels of all patients increased and achieve criteria of [s2]diabetes[e2] diagnoses.
	(16, 78)	indapamide	diabetes	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1745	RESULTS: After 4- to 14-month period of therapy with the combination of [s1]indapamide[e1] (2.5 mg/day) and fosinopril (10 mg/day) in three patients and 6-month period of monotherapy with indapamide (2.5 mg/day) in one patient, glucose levels of all patients increased and achieve criteria of [s2]diabetes[e2] diagnoses.
	(16, 78)	indapamide	diabetes	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1746	RESULTS: After 4- to 14-month period of therapy with the combination of [s1]indapamide[e1] (2.5 mg/day) and fosinopril (10 mg/day) in three patients and 6-month period of monotherapy with indapamide (2.5 mg/day) in one patient, glucose levels of all patients increased and achieve criteria of [s2]diabetes[e2] diagnoses.
	(6, 30)	discrepancies between hematologic, marrow morphologic, and cytogenetic responses	imatinib mesylate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1747	CONTEXT: Previous investigators have reported [s1]discrepancies between hematologic, marrow morphologic, and cytogenetic responses[e1] to [s2]imatinib mesylate[e2] among patients with chronic myeloid leukemia (CML).
	(26, 36)	blast crisis	imatinib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1748	Despite a hematologic response in all 3 patients, none of them achieved cytogenetic remission, and all progressed to [s1]blast crisis[e1] at 7 to 10 months of [s2]imatinib[e2] therapy.
	(18, 23)	blast crisis	imatinib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1749	In addition to disease refractoriness, rare instances of disease progression from chronic phase to [s1]blast crisis[e1] during [s2]imatinib[e2] therapy have recently been anecdotally reported.
	(24, 30)	blast crisis	imatinib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1750	OBJECTIVES: To describe the clinicopathologic features of 3 patients with CML who rapidly progressed from chronic phase to [s1]blast crisis[e1] while taking [s2]imatinib[e2] and to perform a review of the literature.
	(5, 17)	progression of marrow reticulin fibrosis	imatinib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1751	Our findings suggest that significant [s1]progression of marrow reticulin fibrosis[e1] during [s2]imatinib[e2] therapy can be an indicator for a return or progression of CML and, in some patients with CML, imatinib may promote cytogenetic clonal evolution, resulting in a poor response to treatment.
	(8, 15)	blast crisis	imatinib mesylate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1752	Progression of chronic myeloid leukemia to [s1]blast crisis[e1] during treatment with [s2]imatinib mesylate[e2] 
	(9, 18)	hypotension	nimodipine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1753	Easily reversible hypoxemia and [s1]hypotension[e1] induced by [s2]nimodipine[e2] 
	(4, 18)	hypoxemia	nimodipine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1754	Easily reversible [s1]hypoxemia[e1] and hypotension induced by [s2]nimodipine[e2] 
	(8, 26)	nimodipine	hypoxemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1755	In this paper we report a case of [s1]nimodipine[e1] overdosage resulting in prolonged hypotension and [s2]hypoxemia[e2]  which was successfully treated with calcium gluconate.
	(8, 19)	nimodipine	prolonged hypotension	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1756	In this paper we report a case of [s1]nimodipine[e1] overdosage resulting in [s2]prolonged hypotension[e2] and hypoxemia, which was successfully treated with calcium gluconate.
	(0, 12)	Refractory hypoglycemia	ciprofloxacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1757	 [s1]Refractory hypoglycemia[e1] from [s2]ciprofloxacin[e2] and glyburide interaction.
	(0, 19)	Refractory hypoglycemia	glyburide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1758	 [s1]Refractory hypoglycemia[e1] from ciprofloxacin and [s2]glyburide[e2] interaction.
	(18, 28)	ciprofloxacin	prolonged hypoglycemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1759	We present a case of a diabetic patient taking glyburide who was prescribed [s1]ciprofloxacin[e1] and developed [s2]prolonged hypoglycemia[e2]  which persisted for over 24 hours.
	(11, 28)	glyburide	prolonged hypoglycemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1760	We present a case of a diabetic patient taking [s1]glyburide[e1] who was prescribed ciprofloxacin and developed [s2]prolonged hypoglycemia[e2]  which persisted for over 24 hours.
	(0, 18)	Aminophylline hypersensitivity	Aminophylline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1761	 [s1]Aminophylline hypersensitivity[e1] apparently due to ethylenediamine [s2]Aminophylline[e2] hypersensitivity apparently due to ethylenediamine.
	(0, 13)	Aminophylline hypersensitivity	ethylenediamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1762	 [s1]Aminophylline hypersensitivity[e1] apparently due to [s2]ethylenediamine[e2] 
	(12, 32)	delayed hypersensitivity reaction	aminophylline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1763	We present a case of ethylenediamine-induced [s1]delayed hypersensitivity reaction[e1] in a 46-year-old woman who received parenteral [s2]aminophylline[e2] for an acute asthma exacerbation.
	(5, 13)	ethylenediamine	delayed hypersensitivity reaction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1764	We present a case of [s1]ethylenediamine[e1] induced [s2]delayed hypersensitivity reaction[e2] in a 46-year-old woman who received parenteral aminophylline for an acute asthma exacerbation.
	(0, 18)	L-asparaginase	lethal complication	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1765	 [s1]L-asparaginase[e1] induced pancreatitis is an uncommon but potential [s2]lethal complication[e2] of the treatment of leukemia.
	(0, 9)	L-asparaginase	pancreatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1766	 [s1]L-asparaginase[e1] induced [s2]pancreatitis[e2] is an uncommon but potential lethal complication of the treatment of leukemia.
	(0, 9)	L-asparaginase	severe necrotizing pancreatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1767	 [s1]L-asparaginase[e1] induced [s2]severe necrotizing pancreatitis[e2] successfully treated with percutaneous drainage.
	(3, 11)	pancreatitis	L-asparaginase	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1768	Most cases of [s1]pancreatitis[e1] associated with [s2]L-asparaginase[e2] toxicity are self-limiting and respond favorably to nasogastric decompression and intravenous hyperalimentation.
	(0, 24)	Pancreatitis	L-asparaginase	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1769	 [s1]Pancreatitis[e1] has been noted to be a complication in 2-16% of patients undergoing treatment with [s2]L-asparaginase[e2] for a variety of pediatric neoplasms.
	(11, 20)	L-asparaginase	necrotizing pancreatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1770	We present a pediatric patient with leukemia and a severe, [s1]L-asparaginase[e1] induced [s2]necrotizing pancreatitis[e2]  treated successfully with percutaneous drainage used to flush the infected necrotic parts.
	(0, 7)	Disulfiram	fulminant hepatic failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1771	 [s1]Disulfiram[e1] induced [s2]fulminant hepatic failure[e2] in an active duty soldier.
	(0, 16)	Fulminant hepatic failure	disulfiram	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1772	 [s1]Fulminant hepatic failure[e1] is a rare complication of [s2]disulfiram[e2] treatment for alcoholism.
	(3, 17)	fulminant hepatic failure	disulfiram	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1773	This case describes [s1]fulminant hepatic failure[e1] in a patient taking [s2]disulfiram[e2] with no previous liver disease and report of being compliant with alcohol abstinence.
	(0, 8)	Tiagabine	unusual array of neurological symptoms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1774	 [s1]Tiagabine[e1] overdose causes an [s2]unusual array of neurological symptoms[e2]  many similar to reported adverse effects during therapeutic use.
	(3, 31)	sideroblastic anemia	linezolid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1775	A case of [s1]sideroblastic anemia[e1] is presented in a patient with a left ventricular assist device drive-line infection who was receiving [s2]linezolid[e2]  an antibiotic used for serious infections with gram-positive organisms.
	(1, 11)	linezolid	hematologic side effects	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1776	As [s1]linezolid[e1] has been shown to have [s2]hematologic side effects[e2]  blood count monitoring is recommended in patients receiving this drug for long-term therapy.
	(0, 10)	Sideroblastic anemia	linezolid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1777	 [s1]Sideroblastic anemia[e1] due to [s2]linezolid[e2] in a patient with a left ventricular assist device.
	(15, 35)	harlequin color change	prostaglandin E1	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1778	In this report, two newborns with congenital heart anomalies demonstrated the [s1]harlequin color change[e1]  one whose skin findings showed a course related to the dose of systemic [s2]prostaglandin E1[e2]  suggesting a possible association.
	(1, 11)	harlequin color change	prostaglandin E1	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1779	The [s1]harlequin color change[e1] and association with [s2]prostaglandin E1[e2] 
	(0, 17)	Acute renal insufficiency	ciprofloxacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1780	 [s1]Acute renal insufficiency[e1] is known to occur in patients who are taking [s2]ciprofloxacin[e2]  particularly the elderly.
	(0, 9)	Ciprofloxacin	renal insufficiency	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1781	 [s1]Ciprofloxacin[e1] induced [s2]renal insufficiency[e2] in cystic fibrosis.
	(3, 12)	ciprofloxacin	nephrotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1782	Multiple mechanisms for [s1]ciprofloxacin[e1] induced [s2]nephrotoxicity[e2] have been proposed.
	(14, 29)	acute renal insufficiency	ciprofloxacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1783	We report two young patients with cystic fibrosis who presented with [s1]acute renal insufficiency[e1] after 2-3 weeks of oral [s2]ciprofloxacin[e2] therapy.
	(5, 15)	necrotizing vasculitis	infliximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1784	Sensory neuropathy revealing [s1]necrotizing vasculitis[e1] during [s2]infliximab[e2] therapy for rheumatoid arthritis.
	(0, 15)	Sensory neuropathy	infliximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1785	 [s1]Sensory neuropathy[e1] revealing necrotizing vasculitis during [s2]infliximab[e2] therapy for rheumatoid arthritis.
	(30, 47)	infliximab	necrotizing vasculitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1786	We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom [s1]infliximab[e1] therapy was associated with peripheral neuropathy due to [s2]necrotizing vasculitis[e2] in one patient and to progression of preexisting mononeuritis multiplex in the other.
	(30, 41)	infliximab	peripheral neuropathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1787	We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom [s1]infliximab[e1] therapy was associated with [s2]peripheral neuropathy[e2] due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other.
	(30, 59)	infliximab	progression of preexisting mononeuritis multiplex	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1788	We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom [s1]infliximab[e1] therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to [s2]progression of preexisting mononeuritis multiplex[e2] in the other.
	(0, 9)	Progressive anemia	interferon-alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1789	 [s1]Progressive anemia[e1] following combination therapy with [s2]interferon-alpha[e2] and interleukin-2 in a patient with metastatic renal cell carcinoma.
	(0, 15)	Progressive anemia	interleukin-2	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1790	 [s1]Progressive anemia[e1] following combination therapy with interferon-alpha and [s2]interleukin-2[e2] in a patient with metastatic renal cell carcinoma.
	(5, 26)	severe anemia	IFN-alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1791	We report a case of [s1]severe anemia[e1]  which responded well to steroid therapy, in a patient receiving IL-2 plus [s2]IFN-alpha[e2] for metastatic renal cell carcinoma.
	(5, 22)	severe anemia	IL-2	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1792	We report a case of [s1]severe anemia[e1]  which responded well to steroid therapy, in a patient receiving [s2]IL-2[e2] plus IFN-alpha for metastatic renal cell carcinoma.
	(10, 18)	clotting abnormality	warfarin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1793	An objective causality assessment indicated a probable relationship between [s1]clotting abnormality[e1] and [s2]warfarin[e2] administration, although the degree of elevation of the INR was unusual in the light of the daily warfarin dose and duration of its exposure.
	(18, 26)	abnormal hypersensitivity	warfarin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1794	Based on the clinical status of the patient, it was suspected that several conditions contributed to the [s1]abnormal hypersensitivity[e1] to [s2]warfarin[e2] 
	(6, 36)	warfarin	bleeding symptoms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1795	Despite the low dosage of [s1]warfarin[e1]  international normalized ratio (INR) was markedly elevated from 1.15 to 11.28 for only 4 days, and [s2]bleeding symptoms[e2] concurrently developed.
	(32, 42)	fatal haemorrhage	warfarin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1796	In view of our experience in the present case, it should be stressed that close monitoring of coagulation capacity is necessary in critically ill patients in order to avoid [s1]fatal haemorrhage[e1] after initiating [s2]warfarin[e2] therapy regardless of the dosage.
	(1, 8)	hypersensitivity	warfarin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1797	Unusual [s1]hypersensitivity[e1] to [s2]warfarin[e2] in a critically ill patient.
	(13, 36)	CMV infection	cidofovir	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1798	We report an allogeneic bone marrow transplant recipient who developed [s1]CMV infection[e1] refractory to sequential therapy with ganciclovir, foscarnet, and [s2]cidofovir[e2] 
	(13, 30)	CMV infection	foscarnet	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1799	We report an allogeneic bone marrow transplant recipient who developed [s1]CMV infection[e1] refractory to sequential therapy with ganciclovir, [s2]foscarnet[e2]  and cidofovir.
	(13, 25)	CMV infection	ganciclovir	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1800	We report an allogeneic bone marrow transplant recipient who developed [s1]CMV infection[e1] refractory to sequential therapy with [s2]ganciclovir[e2]  foscarnet, and cidofovir.
	(0, 16)	5-fluorouracil	peripheral neuropathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1801	 [s1]5-fluorouracil[e1] (5-FU)-associated [s2]peripheral neuropathy[e2] is an uncommon event.
	(7, 14)	5-FU	peripheral neuropathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1802	5-fluorouracil  [s1]5-FU[e1] -associated [s2]peripheral neuropathy[e2] is an uncommon event.
	(6, 41)	CAP	peripheral neuropathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1803	During analysis of 28 patients receiving [s1]CAP[e1] with concomitant radiation (XRT) for pancreatic cancer (resected or locally advanced), two patients developed signs and symptoms consistent with [s2]peripheral neuropathy[e2] 
	(6, 19)	CAP	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1804	Knowledge regarding potential adverse effects of [s1]CAP[e1] is paramount and dose modification is indicated with development of [s2]neurotoxicity[e2] 
	(0, 9)	Neurologic symptoms	CAP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1805	 [s1]Neurologic symptoms[e1] resolved after stopping [s2]CAP[e2] for 4 weeks in Patient A, with no recurrence after reinitiating CAP alone at 2000 mg/m2.
	(0, 9)	Neurologic symptoms	CAP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1806	 [s1]Neurologic symptoms[e1] resolved after stopping [s2]CAP[e2] for 4 weeks in Patient A, with no recurrence after reinitiating CAP alone at 2000 mg/m2.
	(6, 14)	foot drop	CAP-XRT	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1807	Patient A reported right leg weakness  [s1]foot drop[e1]  during week 4 of [s2]CAP-XRT[e2] (1600 mg/m2).
	(3, 16)	right leg weakness	CAP-XRT	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1808	Patient A reported [s1]right leg weakness[e1] (foot drop) during week 4 of [s2]CAP-XRT[e2] (1600 mg/m2).
	(3, 21)	perioral and upper extremity paresthesias	CAP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1809	Patient B developed [s1]perioral and upper extremity paresthesias[e1] during the fourth cycle of [s2]CAP[e2] alone (2500 mg/m2).
	(0, 8)	Peripheral neuropathy	capecitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1810	 [s1]Peripheral neuropathy[e1] associated with [s2]capecitabine[e2] 
	(2, 9)	peripheral neuropathy	5-FU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1811	We conclude [s1]peripheral neuropathy[e1] with [s2]5-FU[e2] is rare.
	(0, 17)	Severe hypo-alpha-lipoproteinemia	rosiglitazone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1812	 [s1]Severe hypo-alpha-lipoproteinemia[e1] during treatment with [s2]rosiglitazone[e2] 
	(26, 49)	reduction in plasma HDL cholesterol and apolipoprotein AI levels	rosiglitazone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1813	We report three patients, all of whom had preexisting diabetic dyslipidemia, who showed a profound [s1]reduction in plasma HDL cholesterol and apolipoprotein AI levels[e1] soon after the initiation of [s2]rosiglitazone[e2] therapy.
	(7, 22)	mild hepatotoxicity	nevirapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1814	Severe leukopenia associated with [s1]mild hepatotoxicity[e1] in an HIV carrier treated with [s2]nevirapine[e2] 
	(0, 22)	Severe leukopenia	nevirapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1815	 [s1]Severe leukopenia[e1] associated with mild hepatotoxicity in an HIV carrier treated with [s2]nevirapine[e2] 
	(10, 22)	leukopenia	nevirapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1816	We report an HIV-infected woman who developed mild [s1]leukopenia[e1] as the first sign of a [s2]nevirapine[e2] related adverse event, which was followed by skin and hepatic toxicity associated with a more severe leukopenia.
	(10, 22)	leukopenia	nevirapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1817	We report an HIV-infected woman who developed mild [s1]leukopenia[e1] as the first sign of a [s2]nevirapine[e2] related adverse event, which was followed by skin and hepatic toxicity associated with a more severe leukopenia.
	(20, 33)	nevirapine	skin and hepatic toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1818	We report an HIV-infected woman who developed mild leukopenia as the first sign of a [s1]nevirapine[e1] related adverse event, which was followed by [s2]skin and hepatic toxicity[e2] associated with a more severe leukopenia.
	(8, 28)	quetiapine	death	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1819	In all cases, drugs in addition to [s1]quetiapine[e1] were detected, but in cases #1 and #2, the cause of [s2]death[e2] was considered to be a quetiapine overdose and the other drugs were not considered to be contributory.
	(10, 25)	deaths	quetiapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1820	These cases were chosen for study because they were all [s1]deaths[e1] as a result of suicidal ingestion of drugs in which [s2]quetiapine[e2] was considered a significant factor.
	(17, 25)	suicidal overdose deaths	quetiapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1821	We present three cases from the Provincial Toxicology Center of British Columbia, Canada in which [s1]suicidal overdose deaths[e1] were associated with [s2]quetiapine[e2] 
	(5, 14)	sertraline	intense itching sensation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1822	After approximately two weeks of [s1]sertraline[e1] treatment he noted an [s2]intense itching sensation[e2] in his scalp after eating a piece of chocolate cake.
	(0, 10)	Itch	fluoxetine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1823	 [s1]Itch[e1] and skin rash from chocolate during [s2]fluoxetine[e2] and sertraline treatment: case report.
	(0, 15)	Itch	sertraline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1824	 [s1]Itch[e1] and skin rash from chocolate during fluoxetine and [s2]sertraline[e2] treatment: case report.
	(3, 10)	skin rash	fluoxetine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1825	Itch and [s1]skin rash[e1] from chocolate during [s2]fluoxetine[e2] and sertraline treatment: case report.
	(3, 15)	skin rash	sertraline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1826	Itch and [s1]skin rash[e1] from chocolate during fluoxetine and [s2]sertraline[e2] treatment: case report.
	(0, 16)	Pulmonary lymphohistiocytic reactions	etanercept	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1827	 [s1]Pulmonary lymphohistiocytic reactions[e1] temporally related to [s2]etanercept[e2] therapy.
	(25, 44)	pulmonary signs and symptoms with alveolar infiltrates	etanercept	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1828	This report details the pulmonary pathologic findings in four patients with rheumatoid arthritis, who developed new onset of [s1]pulmonary signs and symptoms with alveolar infiltrates[e1] temporally related to the institution of [s2]etanercept[e2] therapy.
	(0, 13)	Paradoxical cerebral cortical hyperexcitability	flupirtine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1829	 [s1]Paradoxical cerebral cortical hyperexcitability[e1] following [s2]flupirtine[e2] overdose.
	(8, 23)	increased cerebral cortical excitability	flupirtine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1830	We report the case of a patient with [s1]increased cerebral cortical excitability[e1] following intoxication with [s2]flupirtine[e2]  a centrally acting analgesic and antispastic drug.
	(12, 18)	celiac disease	pegylated interferon alpha-2a	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1831	AIM: Report of a case of a woman patient who developed [s1]celiac disease[e1] after [s2]pegylated interferon alpha-2a[e2] and ribavirin use for chronic hepatitis C.
	(12, 28)	celiac disease	ribavirin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1832	AIM: Report of a case of a woman patient who developed [s1]celiac disease[e1] after pegylated interferon alpha-2a and [s2]ribavirin[e2] use for chronic hepatitis C.
	(0, 7)	Celiac disease	pegylated interferon	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1833	 [s1]Celiac disease[e1] onset after [s2]pegylated interferon[e2] and ribavirin treatment of chronic hepatitis C.
	(0, 14)	Celiac disease	ribavirin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1834	 [s1]Celiac disease[e1] onset after pegylated interferon and [s2]ribavirin[e2] treatment of chronic hepatitis C.
	(21, 45)	pegylated interferon alpha-2a	anemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1835	PATIENT AND METHOD: A 34-year-old woman with chronic hepatitis C, genotype 3, receiving [s1]pegylated interferon alpha-2a[e1] and ribavirin for 6 months, developed progressive malaise and [s2]anemia[e2] 6 months after the end of treatment.
	(31, 45)	ribavirin	anemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1836	PATIENT AND METHOD: A 34-year-old woman with chronic hepatitis C, genotype 3, receiving pegylated interferon alpha-2a and [s1]ribavirin[e1] for 6 months, developed progressive malaise and [s2]anemia[e2] 6 months after the end of treatment.
	(21, 41)	pegylated interferon alpha-2a	progressive malaise	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1837	PATIENT AND METHOD: A 34-year-old woman with chronic hepatitis C, genotype 3, receiving [s1]pegylated interferon alpha-2a[e1] and ribavirin for 6 months, developed [s2]progressive malaise[e2] and anemia 6 months after the end of treatment.
	(31, 41)	ribavirin	progressive malaise	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1838	PATIENT AND METHOD: A 34-year-old woman with chronic hepatitis C, genotype 3, receiving pegylated interferon alpha-2a and [s1]ribavirin[e1] for 6 months, developed [s2]progressive malaise[e2] and anemia 6 months after the end of treatment.
	(5, 41)	anaphylaxis	metaraminol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1839	We present two cases of [s1]anaphylaxis[e1] under anaesthesia where return of spontaneous circulation was refractory to epinephrine, but occurred following the administration of the alpha-agonist [s2]metaraminol[e2] 
	(15, 27)	glatiramer acetate	localized panniculitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1840	In this article, we describe another case of subcutaneous changes following repeated [s1]glatiramer acetate[e1] injection, presented as [s2]localized panniculitis[e2] in the area around the injection sites, in a 46-year-old female patient who was treated with glatiramer acetate for 18 months.
	(15, 27)	glatiramer acetate	localized panniculitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1841	In this article, we describe another case of subcutaneous changes following repeated [s1]glatiramer acetate[e1] injection, presented as [s2]localized panniculitis[e2] in the area around the injection sites, in a 46-year-old female patient who was treated with glatiramer acetate for 18 months.
	(9, 17)	subcutaneous changes	glatiramer acetate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1842	In this article, we describe another case of [s1]subcutaneous changes[e1] following repeated [s2]glatiramer acetate[e2] injection, presented as localized panniculitis in the area around the injection sites, in a 46-year-old female patient who was treated with glatiramer acetate for 18 months.
	(7, 23)	lipoatrophy	Copaxone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1843	Localized panniculitis and subsequent [s1]lipoatrophy[e1] with subcutaneous glatiramer acetate  [s2]Copaxone[e2]  injection for the treatment of multiple sclerosis.
	(7, 17)	lipoatrophy	glatiramer acetate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1844	Localized panniculitis and subsequent [s1]lipoatrophy[e1] with subcutaneous [s2]glatiramer acetate[e2] (Copaxone) injection for the treatment of multiple sclerosis.
	(0, 23)	Localized panniculitis	Copaxone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1845	 [s1]Localized panniculitis[e1] and subsequent lipoatrophy with subcutaneous glatiramer acetate  [s2]Copaxone[e2]  injection for the treatment of multiple sclerosis.
	(0, 17)	Localized panniculitis	glatiramer acetate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1846	 [s1]Localized panniculitis[e1] and subsequent lipoatrophy with subcutaneous [s2]glatiramer acetate[e2] (Copaxone) injection for the treatment of multiple sclerosis.
	(19, 28)	verapamil	exacerbation in myasthenic weakness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1847	In a postoperative patient with pre-existent myasthenia gravis, oral [s1]verapamil[e1] caused a marked [s2]exacerbation in myasthenic weakness[e2] 
	(15, 38)	hepatic veno-occlusive disease	busulfan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1848	In four patients, thrombosis occurred 2-45 days after severe [s1]hepatic veno-occlusive disease[e1] (HVOD) secondary to intensive chemotherapy containing [s2]busulfan[e2] 
	(26, 36)	HVOD	busulfan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1849	In four patients, thrombosis occurred 2-45 days after severe hepatic veno-occlusive disease  [s1]HVOD[e1]  secondary to intensive chemotherapy containing [s2]busulfan[e2] 
	(4, 38)	thrombosis	busulfan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1850	In four patients, [s1]thrombosis[e1] occurred 2-45 days after severe hepatic veno-occlusive disease (HVOD) secondary to intensive chemotherapy containing [s2]busulfan[e2] 
	(20, 30)	busulfan	HVOD	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1851	PVT during chemotherapy in children is a rare event and appears to be closely related to intensive chemotherapy containing [s1]busulfan[e1] and to be associated with [s2]HVOD[e2] 
	(0, 22)	PVT	busulfan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1852	 [s1]PVT[e1] during chemotherapy in children is a rare event and appears to be closely related to intensive chemotherapy containing [s2]busulfan[e2] and to be associated with HVOD.
	(7, 26)	Vogt-Koyanagi-Harada disease	interferon	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1853	Here, we describe a case of [s1]Vogt-Koyanagi-Harada disease[e1] occurring 4 months after the start of [s2]interferon[e2] alpha treatment, probably induced by the immunomodulatory effects of interferon.
	(7, 26)	Vogt-Koyanagi-Harada disease	interferon alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1854	Here, we describe a case of [s1]Vogt-Koyanagi-Harada disease[e1] occurring 4 months after the start of [s2]interferon alpha[e2] treatment, probably induced by the immunomodulatory effects of interferon.
	(0, 33)	Retinal abnormalities	interferon	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1855	" [s1]Retinal abnormalities[e1]  including retinal hemorrhage and ""cotton-wool"" spots, often occur within the first 8 weeks in the course of [s2]interferon[e2] therapy in patients with chronic hepatitis C."
	(6, 34)	retinal hemorrhage	interferon	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1856	"Retinal abnormalities, including [s1]retinal hemorrhage[e1] and ""cotton-wool"" spots, often occur within the first 8 weeks in the course of [s2]interferon[e2] therapy in patients with chronic hepatitis C."
	(0, 14)	Vogt-Koyanagi-Harada disease	interferon alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1857	 [s1]Vogt-Koyanagi-Harada disease[e1] occurring during [s2]interferon alpha[e2] therapy for chronic hepatitis C.
	(0, 16)	Acute hepatic failure	propylthiouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1858	 [s1]Acute hepatic failure[e1] is a rare and potentially lethal complication of [s2]propylthiouracil[e2] (PTU) use for hyperthyroidism.
	(0, 22)	Acute hepatic failure	PTU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1859	 [s1]Acute hepatic failure[e1] is a rare and potentially lethal complication of propylthiouracil  [s2]PTU[e2]  use for hyperthyroidism.
	(34, 39)	PTU	fulminant hepatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1860	After an extensive review of the literature, we believe that this is the first communication of the successful use of amiodarone to control hyperthyroidism in a patient with [s1]PTU[e1] induced [s2]fulminant hepatitis[e2] 
	(15, 24)	propylthiouracil	acute hepatic failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1861	Successful treatment of hyperthyroidism with amiodarone in a patient with [s1]propylthiouracil[e1] induced [s2]acute hepatic failure[e2] 
	(18, 23)	PTU	fulminant hepatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1862	We present a 20-year-old woman with Basedow-Graves' disease who developed [s1]PTU[e1] induced [s2]fulminant hepatitis[e2]  which progressed to acute hepatic failure with grade III hepatic encephalopathy.
	(0, 27)	Epstein-Barr virus-associated lymphoproliferative disorder	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1863	 [s1]Epstein-Barr virus-associated lymphoproliferative disorder[e1] in a patient with rheumatoid arthritis on [s2]methotrexate[e2] and rofecoxib: idiosyncratic reaction or pharmacogenetics?
	(0, 33)	Epstein-Barr virus-associated lymphoproliferative disorder	rofecoxib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1864	 [s1]Epstein-Barr virus-associated lymphoproliferative disorder[e1] in a patient with rheumatoid arthritis on methotrexate and [s2]rofecoxib[e2]  idiosyncratic reaction or pharmacogenetics?
	(0, 29)	Methotrexate	Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1865	 [s1]Methotrexate[e1] (MTX) is a commonly used second line agent for RA, and there have been several recent reports of [s2]Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder[e2] in MTX-treated RA patients.
	(5, 27)	MTX	Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1866	Methotrexate  [s1]MTX[e1]  is a commonly used second line agent for RA, and there have been several recent reports of [s2]Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder[e2] in MTX-treated RA patients.
	(5, 27)	MTX	Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1867	Methotrexate  [s1]MTX[e1]  is a commonly used second line agent for RA, and there have been several recent reports of [s2]Epstein-Barr virus (EBV)-associated polyclonal B cell lymphoproliferative disorder[e2] in MTX-treated RA patients.
	(7, 35)	MTX	acute renal failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1868	Previous studies have demonstrated the interaction of [s1]MTX[e1] and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including [s2]acute renal failure[e2]  pancytopenia, vomiting, diarrhea, elevated liver transaminases, jaundice, mucosal ulcerations, and pyrexia.
	(7, 46)	MTX	diarrhea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1869	Previous studies have demonstrated the interaction of [s1]MTX[e1] and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, [s2]diarrhea[e2]  elevated liver transaminases, jaundice, mucosal ulcerations, and pyrexia.
	(7, 50)	MTX	elevated liver transaminases	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1870	Previous studies have demonstrated the interaction of [s1]MTX[e1] and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, diarrhea, [s2]elevated liver transaminases[e2]  jaundice, mucosal ulcerations, and pyrexia.
	(7, 56)	MTX	jaundice	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1871	Previous studies have demonstrated the interaction of [s1]MTX[e1] and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, diarrhea, elevated liver transaminases, [s2]jaundice[e2]  mucosal ulcerations, and pyrexia.
	(7, 60)	MTX	mucosal ulcerations	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1872	Previous studies have demonstrated the interaction of [s1]MTX[e1] and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, diarrhea, elevated liver transaminases, jaundice, [s2]mucosal ulcerations[e2]  and pyrexia.
	(7, 39)	MTX	pancytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1873	Previous studies have demonstrated the interaction of [s1]MTX[e1] and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, [s2]pancytopenia[e2]  vomiting, diarrhea, elevated liver transaminases, jaundice, mucosal ulcerations, and pyrexia.
	(7, 68)	MTX	pyrexia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1874	Previous studies have demonstrated the interaction of [s1]MTX[e1] and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, diarrhea, elevated liver transaminases, jaundice, mucosal ulcerations, and [s2]pyrexia[e2] 
	(7, 44)	MTX	vomiting	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1875	Previous studies have demonstrated the interaction of [s1]MTX[e1] and a variety of non-steroidal, anti-inflammatory drugs (NSAIDs) with various clinical manifestations including acute renal failure, pancytopenia, [s2]vomiting[e2]  diarrhea, elevated liver transaminases, jaundice, mucosal ulcerations, and pyrexia.
	(11, 40)	MTX	EBV-associated lymphoproliferative disease	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1876	We hypothesize that decreased renal elimination of [s1]MTX[e1] induced by the COX-2 inhibitor resulted in enhanced hematopoietic toxicity and immunosuppression causing the [s2]EBV-associated lymphoproliferative disease[e2] 
	(11, 25)	MTX	hematopoietic toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1877	We hypothesize that decreased renal elimination of [s1]MTX[e1] induced by the COX-2 inhibitor resulted in enhanced [s2]hematopoietic toxicity[e2] and immunosuppression causing the EBV-associated lymphoproliferative disease.
	(11, 32)	MTX	immunosuppression	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1878	We hypothesize that decreased renal elimination of [s1]MTX[e1] induced by the COX-2 inhibitor resulted in enhanced hematopoietic toxicity and [s2]immunosuppression[e2] causing the EBV-associated lymphoproliferative disease.
	(4, 34)	aggravation and spreading of a psoriatic plaque	imiquimod	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1879	OBSERVATIONS: We observed [s1]aggravation and spreading of a psoriatic plaque[e1] when treated topically with the toll-like receptor (TLR) 7 agonist [s2]imiquimod[e2] 
	(0, 14)	Psoriasis	imiquimod	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1880	 [s1]Psoriasis[e1] triggered by toll-like receptor 7 agonist [s2]imiquimod[e2] in the presence of dermal plasmacytoid dendritic cell precursors.
	(1, 10)	imiquimod	large amounts of type I interferon production	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1881	Since [s1]imiquimod[e1] induces [s2]large amounts of type I interferon production[e2] from TLR7-expressing plasmacytoid dendritic cell precursors (PDCs), the natural interferon-producing cells of the peripheral blood, we asked whether PDCs are present in psoriatic skin.
	(1, 33)	exacerbation of psoriasis	imiquimod	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1882	The [s1]exacerbation of psoriasis[e1] was accompanied by a massive induction of lesional type I interferon activity, detected by MxA expression after [s2]imiquimod[e2] therapy.
	(0, 7)	Vision declined	methylprednisolone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1883	 [s1]Vision declined[e1] after treatment with [s2]methylprednisolone[e2]  after which fundus examination became consistent with progressive outer retinal necrosis.
	(4, 13)	AZA	allergic skin eruptions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1884	Allergic side effects of [s1]AZA[e1] are rare, and reported [s2]allergic skin eruptions[e2] from AZA are very limited in Japan.
	(4, 13)	AZA	allergic skin eruptions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1885	Allergic side effects of [s1]AZA[e1] are rare, and reported [s2]allergic skin eruptions[e2] from AZA are very limited in Japan.
	(8, 12)	AZA	allergy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1886	DLST is a good diagnostic tool for [s1]AZA[e1]  [s2]allergy[e2]  especially for severe drug allergy cases.
	(0, 6)	Drug eruption	azathioprine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1887	 [s1]Drug eruption[e1] caused by [s2]azathioprine[e2]  value of using the drug-induced lymphocytes stimulation test for diagnosis.
	(2, 7)	AZA	drug eruption	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1888	We report [s1]AZA[e1] induced [s2]drug eruption[e2] that developed in two cases of systemic scleroderma with polymyositis.
	(0, 15)	Tardive dyskinesia	ziprasidone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1889	 [s1]Tardive dyskinesia[e1] in 2 patients treated with [s2]ziprasidone[e2] 
	(5, 15)	TD	ziprasidone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1890	Two of our patients developed [s1]TD[e1] after 23 months and 34 months of [s2]ziprasidone[e2] monotherapy, respectively.
	(0, 28)	Ziprasidone	extrapyramidal symptoms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1891	 [s1]Ziprasidone[e1] is an atypical antipsychotic drug that is believed to have a low propensity for inducing [s2]extrapyramidal symptoms[e2]  including tardive dyskinesia (TD).
	(0, 35)	Ziprasidone	tardive dyskinesia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1892	 [s1]Ziprasidone[e1] is an atypical antipsychotic drug that is believed to have a low propensity for inducing extrapyramidal symptoms, including [s2]tardive dyskinesia[e2] (TD).
	(0, 43)	Ziprasidone	TD	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1893	 [s1]Ziprasidone[e1] is an atypical antipsychotic drug that is believed to have a low propensity for inducing extrapyramidal symptoms, including tardive dyskinesia  [s2]TD[e2] .
	(0, 24)	Asthenozoospermia	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1894	 [s1]Asthenozoospermia[e1]  possible association with long-term exposure to an anti-epileptic drug of [s2]carbamazepine[e2] 
	(6, 28)	no motile sperm	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1895	The patient was found to have [s1]no motile sperm[e1] with a normal sperm count, while taking a dose of 400 mg/day of [s2]carbamazepine[e2] 
	(0, 13)	Scrotal ulceration	retinoic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1896	 [s1]Scrotal ulceration[e1] induced by all-trans [s2]retinoic acid[e2] in a patient with acute promyelocytic leukemia.
	(1, 18)	ulcer	ATRA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1897	The [s1]ulcer[e1] did not respond to antibiotic treatment and healed shortly after withholding [s2]ATRA[e2] 
	(5, 32)	scrotal ulcer	ATRA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1898	We report the development of [s1]scrotal ulcer[e1] in a patient with acute promyleocytic leukemia (APL) within 10 days of treatment with [s2]ATRA[e2] at a dose of 40 mg orally twice daily.
	(3, 9)	clozapine	tonic-clonic seizures	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1899	A case of [s1]clozapine[e1] induced [s2]tonic-clonic seizures[e2] managed with valproate: implications for clinical care.
	(6, 23)	clozapine	seizures	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1900	Following discontinuation of [s1]clozapine[e1]  she was rechallenged and again was observed to have [s2]seizures[e2] 
	(4, 10)	clozapine	seizures	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1901	These findings suggest that [s1]clozapine[e1] induced [s2]seizures[e2] can be successfully treated, that gradual dose titration can reduce the likelihood of further episodes of seizures and that concomitant use of a suitable mood stabilizer/anti-epileptic medication can improve the outcome of treatment-resistant schizophrenia.
	(5, 11)	clozapine	seizures	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1902	We describe a case of [s1]clozapine[e1] induced [s2]seizures[e2] in a patient with treatment-resistant schizophrenia.
	(9, 18)	colitis	rofecoxib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1903	CONCLUSIONS: Symptoms and pathologic changes of [s1]colitis[e1] are associated with exposure to [s2]rofecoxib[e2] 
	(15, 26)	lower gastrointestinal symptoms	rofecoxib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1904	OBJECTIVES: To describe clinical and pathologic findings in patients noted to develop [s1]lower gastrointestinal symptoms[e1] when exposed to [s2]rofecoxib[e2] 
	(12, 17)	IBD	rofecoxib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1905	RESULTS: Three patients who developed symptoms of inflammatory bowel disease  [s1]IBD[e1]  during [s2]rofecoxib[e2] exposure are described along with pathology findings.
	(8, 19)	inflammatory bowel disease	rofecoxib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1906	RESULTS: Three patients who developed symptoms of [s1]inflammatory bowel disease[e1] (IBD) during [s2]rofecoxib[e2] exposure are described along with pathology findings.
	(32, 42)	Carbamazepine intoxication	Carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1907	After administration of Oxybutynin concomitantly with an increase in the dose of Dantrolene, she presented the clinical symptoms and laboratory finding of [s1]Carbamazepine intoxication[e1]  [s2]Carbamazepine[e2] intoxication.
	(19, 33)	Dantrolene	Carbamazepine intoxication	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1908	After administration of Oxybutynin concomitantly with an increase in the dose of [s1]Dantrolene[e1]  she presented the clinical symptoms and laboratory finding of [s2]Carbamazepine intoxication[e2] 
	(3, 34)	Oxybutynin	Carbamazepine intoxication	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1909	After administration of [s1]Oxybutynin[e1] concomitantly with an increase in the dose of Dantrolene, she presented the clinical symptoms and laboratory finding of [s2]Carbamazepine intoxication[e2] 
	(0, 23)	Carbamazepine toxicity	Carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1910	 [s1]Carbamazepine toxicity[e1] following Oxybutynin and Dantrolene administration: a case report [s2]Carbamazepine[e2] toxicity following Oxybutynin and Dantrolene administration: a case report.
	(0, 15)	Carbamazepine toxicity	Dantrolene	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1911	 [s1]Carbamazepine toxicity[e1] following Oxybutynin and [s2]Dantrolene[e2] administration: a case report.
	(0, 9)	Carbamazepine toxicity	Oxybutynin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1912	 [s1]Carbamazepine toxicity[e1] following [s2]Oxybutynin[e2] and Dantrolene administration: a case report.
	(7, 15)	Carbamazepine toxicity	Carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1913	OBJECTIVE: To report a case of [s1]Carbamazepine toxicity[e1]  [s2]Carbamazepine[e2] toxicity following the administration of Oxybutynin and Dantrolene.
	(7, 25)	Carbamazepine toxicity	Dantrolene	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1914	OBJECTIVE: To report a case of [s1]Carbamazepine toxicity[e1] following the administration of Oxybutynin and [s2]Dantrolene[e2] 
	(7, 19)	Carbamazepine toxicity	Oxybutynin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1915	OBJECTIVE: To report a case of [s1]Carbamazepine toxicity[e1] following the administration of [s2]Oxybutynin[e2] and Dantrolene.
	(14, 20)	captopril	pemphigus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1916	To the best of our knowledge, this is the first reported patient with [s1]captopril[e1] induced [s2]pemphigus[e2] in whom no new lesions developed after subsequent treatment with enalapril.
	(8, 26)	pemphigus	captopril	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1917	We report a case of drug-induced [s1]pemphigus[e1] caused by an angiotensin-converting enzyme inhibitor, [s2]captopril[e2] 
	(0, 11)	Neuropathy	thalidomide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1918	 [s1]Neuropathy[e1] is a significant side effect of [s2]thalidomide[e2] therapy, which may limit its clinical use.
	(0, 6)	Thalidomide	neuropathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1919	 [s1]Thalidomide[e1]  [s2]neuropathy[e2] in childhood.
	(0, 6)	Thalidomide	neuropathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1920	 [s1]Thalidomide[e1]  [s2]neuropathy[e2] is often associated with proximal weakness and may progress even after discontinuation of treatment, in the phenomenon of 'coasting'.
	(0, 13)	Thalidomide	proximal weakness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1921	 [s1]Thalidomide[e1] neuropathy is often associated with [s2]proximal weakness[e2] and may progress even after discontinuation of treatment, in the phenomenon of 'coasting'.
	(0, 17)	Thalidomide	teratogenic effects	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1922	 [s1]Thalidomide[e1] was withdrawn from world markets in 1961 following recognition of its [s2]teratogenic effects[e2] 
	(5, 25)	sensorimotor axonal neuropathy	thalidomide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1923	We report four cases of [s1]sensorimotor axonal neuropathy[e1] in children aged 10-15 years, treated with [s2]thalidomide[e2] for myxopapillary ependymoma, Crohn's disease and recurrent giant aphthous ulceration.
	(0, 7)	Cerebral edema	Gliadel	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1924	 [s1]Cerebral edema[e1] associated with [s2]Gliadel[e2] wafers: two case studies.
	(8, 18)	cerebral edema	Gliadel	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1925	Following are two clinical case reports demonstrating profound [s1]cerebral edema[e1] associated with implantation of [s2]Gliadel[e2] wafers.
	(4, 46)	carmustine	cerebral edema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1926	While the introduction of [s1]carmustine[e1] wafers (Gliadel wafers) into the tumor resection cavity has been shown to be a beneficial therapy for malignant glioma, it is recognized that clinically significant [s2]cerebral edema[e2] is a potential adverse effect.
	(9, 45)	Gliadel	cerebral edema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1927	While the introduction of carmustine wafers  [s1]Gliadel[e1] wafers) into the tumor resection cavity has been shown to be a beneficial therapy for malignant glioma, it is recognized that clinically significant [s2]cerebral edema[e2] is a potential adverse effect.
	(0, 18)	Cis-retinoic acid	BMTN	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1928	 [s1]Cis-retinoic acid[e1] (RA) may further increase the risk of developing [s2]BMTN[e2] 
	(6, 16)	RA	BMTN	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1929	Cis-retinoic acid  [s1]RA[e1]  may further increase the risk of developing [s2]BMTN[e2] 
	(4, 10)	RA	deterioration in renal function	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1930	It is likely that [s1]RA[e1] contributed to the [s2]deterioration in renal function[e2] in these patients.
	(0, 11)	Retinoic acid	bone marrow transplant nephropathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1931	 [s1]Retinoic acid[e1] may increase the risk of [s2]bone marrow transplant nephropathy[e2] 
	(3, 13)	BMTN	RA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1932	The occurrence of [s1]BMTN[e1] in two children treated with [s2]RA[e2] in our unit is unlikely to be coincidental.
	(4, 13)	secondary infection	imiquimod	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1933	He developed a late [s1]secondary infection[e1] in some sites treated with [s2]imiquimod[e2] 
	(10, 23)	myoclonic jerks	quetiapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1934	A 64-year-old man with schizophrenia developed [s1]myoclonic jerks[e1] when given higher doses of [s2]quetiapine[e2] 
	(0, 6)	Quetiapine	myoclonus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1935	 [s1]Quetiapine[e1] induced [s2]myoclonus[e2] 
	(5, 13)	myoclonus	quetiapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1936	We report a case of [s1]myoclonus[e1] induced by [s2]quetiapine[e2] 
	(3, 12)	myelodysplastic syndrome	temozolomide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1937	Treatment-related [s1]myelodysplastic syndrome[e1] after [s2]temozolomide[e2] for recurrent high-grade glioma.
	(14, 37)	refractory anemia with excess blasts	temozolomide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1938	We report a 44-year-old woman with t-MDS  [s1]refractory anemia with excess blasts[e1]  following treatment of recurrent anaplastic astrocytoma with [s2]temozolomide[e2] (TMZ).
	(14, 42)	refractory anemia with excess blasts	TMZ	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1939	We report a 44-year-old woman with t-MDS  [s1]refractory anemia with excess blasts[e1]  following treatment of recurrent anaplastic astrocytoma with temozolomide  [s2]TMZ[e2] .
	(5, 21)	neutropenia	penicillin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1940	Typically, drug-induced [s1]neutropenia[e1] occurs in a patient receiving a semisynthetic [s2]penicillin[e2] for two weeks or more.
	(0, 10)	Livedo reticularis	interferon alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1941	 [s1]Livedo reticularis[e1] associated with [s2]interferon alpha[e2] therapy in two melanoma patients.
	(6, 21)	livedo reticularis	interferon alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1942	These cases highlight the occurrence of [s1]livedo reticularis[e1] as an uncommon side-effect of [s2]interferon alpha[e2] treatment.
	(7, 21)	livedo reticularis	interferon alpha 2b	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1943	We report two patients who developed intense [s1]livedo reticularis[e1] clearly related to the administration of [s2]interferon alpha 2b[e2] as an adjuvant therapy for melanoma.
	(6, 11)	PTU	ANCA-associated vasculitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1944	CONCLUSION: This rare case of [s1]PTU[e1] induced [s2]ANCA-associated vasculitis[e2] manifested with ototoxicity in combination with systemic involvement.
	(6, 21)	PTU	ototoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1945	CONCLUSION: This rare case of [s1]PTU[e1] induced ANCA-associated vasculitis manifested with [s2]ototoxicity[e2] in combination with systemic involvement.
	(23, 37)	propylthiouracil	antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1946	OBJECTIVE: To report the case of a young woman with Graves' disease in whom ototoxicity developed because of [s1]propylthiouracil[e1] (PTU)-induced [s2]antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis[e2] 
	(29, 35)	PTU	antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1947	OBJECTIVE: To report the case of a young woman with Graves' disease in whom ototoxicity developed because of propylthiouracil  [s1]PTU[e1] -induced [s2]antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis[e2] 
	(16, 25)	ototoxicity	propylthiouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1948	OBJECTIVE: To report the case of a young woman with Graves' disease in whom [s1]ototoxicity[e1] developed because of [s2]propylthiouracil[e2] (PTU)-induced antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
	(16, 31)	ototoxicity	PTU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1949	OBJECTIVE: To report the case of a young woman with Graves' disease in whom [s1]ototoxicity[e1] developed because of propylthiouracil  [s2]PTU[e2] -induced antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
	(0, 16)	Propylthiouracil	antineutrophil cytoplasmic antibodies	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1950	 [s1]Propylthiouracil[e1] induced sensorineural hearing loss associated with [s2]antineutrophil cytoplasmic antibodies[e2] 
	(0, 9)	Propylthiouracil	sensorineural hearing loss	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1951	 [s1]Propylthiouracil[e1] induced [s2]sensorineural hearing loss[e2] associated with antineutrophil cytoplasmic antibodies.
	(20, 45)	hearing impairment in the left ear (with progression to the right ear)	PTU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1952	RESULTS: In a 22-year-old Thai woman with Graves' disease, tinnitus, [s1]hearing impairment in the left ear (with progression to the right ear)[e1]  and vertigo developed after 3 years of therapy with [s2]PTU[e2] 
	(16, 45)	tinnitus	PTU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1953	RESULTS: In a 22-year-old Thai woman with Graves' disease, [s1]tinnitus[e1]  hearing impairment in the left ear (with progression to the right ear), and vertigo developed after 3 years of therapy with [s2]PTU[e2] 
	(36, 46)	vertigo	PTU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1954	RESULTS: In a 22-year-old Thai woman with Graves' disease, tinnitus, hearing impairment in the left ear (with progression to the right ear), and [s1]vertigo[e1] developed after 3 years of therapy with [s2]PTU[e2] 
	(1, 13)	hearing impairment	PTU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1955	The [s1]hearing impairment[e1] and tinnitus were gradually reduced after [s2]PTU[e2] withdrawal and corticosteroid and azathioprine treatment.
	(4, 13)	tinnitus	PTU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1956	The hearing impairment and [s1]tinnitus[e1] were gradually reduced after [s2]PTU[e2] withdrawal and corticosteroid and azathioprine treatment.
	(19, 27)	optic neuritis	ethambutol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1957	Anti-tuberculous drugs had been stopped on the 2nd day of therapy due to development of [s1]optic neuritis[e1] secondary to [s2]ethambutol[e2] administration at another hospital.
	(9, 17)	visual loss	ethambutol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1958	During the anti-tuberculous therapy, [s1]visual loss[e1] can be related to [s2]ethambutol[e2] toxicity or the tuberculosis infection itself.
	(3, 12)	ethambutol	visual loss	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1959	In addition, [s1]ethambutol[e1] rarely causes [s2]visual loss[e2] during the early period or when given at lower doses.
	(0, 9)	Flucloxacillin	aplastic anaemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1960	 [s1]Flucloxacillin[e1] induced [s2]aplastic anaemia[e2] and liver failure.
	(0, 14)	Flucloxacillin	liver failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1961	 [s1]Flucloxacillin[e1] induced aplastic anaemia and [s2]liver failure[e2] 
	(6, 18)	flucloxacillin	fatal hepatic injury	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1962	It is well-recognized that [s1]flucloxacillin[e1] may occasionally result in [s2]fatal hepatic injury[e2] 
	(23, 34)	aplastic anaemia	flucloxacillin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1963	We report the case of a 40-year-old woman who developed fulminant hepatic failure and [s1]aplastic anaemia[e1] following a course of oral [s2]flucloxacillin[e2] 
	(14, 34)	fulminant hepatic failure	flucloxacillin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1964	We report the case of a 40-year-old woman who developed [s1]fulminant hepatic failure[e1] and aplastic anaemia following a course of oral [s2]flucloxacillin[e2] 
	(6, 28)	Zoledronic acid	bronchospasm	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1965	Four days after intravenous [s1]Zoledronic acid[e1]  the patient presented to emergency room with complaints of carpopedal spasm and [s2]bronchospasm[e2] 
	(6, 22)	Zoledronic acid	carpopedal spasm	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1966	Four days after intravenous [s1]Zoledronic acid[e1]  the patient presented to emergency room with complaints of [s2]carpopedal spasm[e2] and bronchospasm.
	(0, 8)	Zoledronic acid	severe hypocalcaemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1967	 [s1]Zoledronic acid[e1] induced [s2]severe hypocalcaemia[e2] in a prostate cancer patient with extensive osteoblastic bone metastases.
	(7, 25)	severe lupus erythematosus	CY	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1968	This case report describes an adolescent with [s1]severe lupus erythematosus[e1] who received cyclophosphamide  [s2]CY[e2]  paired with taste (cod liver oil) and smell (rose perfume) as conditioned stimuli.
	(7, 19)	severe lupus erythematosus	cyclophosphamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1969	This case report describes an adolescent with [s1]severe lupus erythematosus[e1] who received [s2]cyclophosphamide[e2] (CY) paired with taste (cod liver oil) and smell (rose perfume) as conditioned stimuli.
	(0, 16)	Mucosal pigmentation	tacrolimus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1970	 [s1]Mucosal pigmentation[e1] after oral lichen planus treatment with topical [s2]tacrolimus[e2] 
	(3, 19)	tacrolimus	pigmentation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1971	The relation between [s1]tacrolimus[e1] treatment and staining was suggested by the appearance of [s2]pigmentation[e2] during topical tacrolimus treatment and its clinical disappearance when treatment was stopped.
	(3, 19)	tacrolimus	pigmentation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1972	The relation between [s1]tacrolimus[e1] treatment and staining was suggested by the appearance of [s2]pigmentation[e2] during topical tacrolimus treatment and its clinical disappearance when treatment was stopped.
	(12, 26)	oral mucosa pigmentation	tacrolimus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1973	We report the first histopathologically documented case of [s1]oral mucosa pigmentation[e1] after OLP treatment with topical [s2]tacrolimus[e2] 
	(24, 36)	Methotrexate	malignant lymphoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1974	Recently, some studies have also reported association between patients with juvenile rheumatoid arthritis (JRA) treated with [s1]Methotrexate[e1] (MTX) and [s2]malignant lymphoma[e2] developing.
	(29, 34)	MTX	malignant lymphoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1975	Recently, some studies have also reported association between patients with juvenile rheumatoid arthritis (JRA) treated with Methotrexate  [s1]MTX[e1]  and [s2]malignant lymphoma[e2] developing.
	(0, 70)	Risperidone	tardive dyskinesia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1976	 [s1]Risperidone[e1] is a frequently used member of a new class of atypical antipsychotics-the serotonin-dopamine antagonists (SDAs)-due to its comparatively high efficacy and low D2/5HT2 binding ratio, which results in a low incidence of extrapyramidal side effects including [s2]tardive dyskinesia[e2] (TD).
	(0, 78)	Risperidone	TD	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1977	 [s1]Risperidone[e1] is a frequently used member of a new class of atypical antipsychotics-the serotonin-dopamine antagonists (SDAs)-due to its comparatively high efficacy and low D2/5HT2 binding ratio, which results in a low incidence of extrapyramidal side effects including tardive dyskinesia  [s2]TD[e2] .
	(0, 9)	Risperidone	respiratory dyskinesia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1978	 [s1]Risperidone[e1] withdrawal-related [s2]respiratory dyskinesia[e2]  a case diagnosed by spirography and fibroscopy.
	(28, 50)	limb dyskinesia	risperidone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1979	The authors present an elderly patient with mixed dementia who developed TD at multiple sites, (including respiratory dyskinesia [RD], [s1]limb dyskinesia[e1]  and orofacial dyskinesia) following abrupt withdrawal of [s2]risperidone[e2] therapy.
	(36, 50)	orofacial dyskinesia	risperidone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1980	The authors present an elderly patient with mixed dementia who developed TD at multiple sites, (including respiratory dyskinesia [RD], limb dyskinesia, and [s1]orofacial dyskinesia[e1]  following abrupt withdrawal of [s2]risperidone[e2] therapy.
	(24, 49)	RD	risperidone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1981	The authors present an elderly patient with mixed dementia who developed TD at multiple sites, (including respiratory dyskinesia  [s1]RD[e1] , limb dyskinesia, and orofacial dyskinesia) following abrupt withdrawal of [s2]risperidone[e2] therapy.
	(18, 51)	respiratory dyskinesia	risperidone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1982	The authors present an elderly patient with mixed dementia who developed TD at multiple sites, (including [s1]respiratory dyskinesia[e1] [RD], limb dyskinesia, and orofacial dyskinesia) following abrupt withdrawal of [s2]risperidone[e2] therapy.
	(11, 51)	TD	risperidone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1983	The authors present an elderly patient with mixed dementia who developed [s1]TD[e1] at multiple sites, (including respiratory dyskinesia [RD], limb dyskinesia, and orofacial dyskinesia) following abrupt withdrawal of [s2]risperidone[e2] therapy.
	(12, 26)	RD	SDA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1984	Therefore, clinicians should pay close attention to possible onset of [s1]RD[e1] in patients with multiple risk factors for TD, even when [s2]SDA[e2] therapy is used.
	(12, 22)	BTX-B	parasympathetic dysfunction of the visual system	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1985	In this study, we report on three individual patients who received [s1]BTX-B[e1] and who subsequently developed [s2]parasympathetic dysfunction of the visual system[e2] after injections of BTX-B at remote sites.
	(12, 22)	BTX-B	parasympathetic dysfunction of the visual system	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1986	In this study, we report on three individual patients who received [s1]BTX-B[e1] and who subsequently developed [s2]parasympathetic dysfunction of the visual system[e2] after injections of BTX-B at remote sites.
	(9, 15)	visual disturbances	BTX-B	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1987	To date, there have been few reports of [s1]visual disturbances[e1] associated with [s2]BTX-B[e2] use.
	(6, 15)	parasympathetic dysfunction	botulinum toxin type B	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1988	Visual system side effects caused by [s1]parasympathetic dysfunction[e1] after [s2]botulinum toxin type B[e2] injections.
	(0, 15)	Visual system side effects	botulinum toxin type B	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1989	 [s1]Visual system side effects[e1] caused by parasympathetic dysfunction after [s2]botulinum toxin type B[e2] injections.
	(0, 7)	Enalapril	anemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1990	 [s1]Enalapril[e1] induced [s2]anemia[e2] in two kidney transplant recipients.
	(5, 15)	anemia	enalapril	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1991	Two renal transplant patients developed [s1]anemia[e1] during treatment of hypertension with [s2]enalapril[e2] medication.
	(15, 39)	cerivastatin	muscle pain	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1992	A 74-year-old hypercholestrerolaemic woman taking [s1]cerivastatin[e1] (0.15 mg/day) for 22 days complained of general muscle weakness and [s2]muscle pain[e2] 
	(15, 36)	cerivastatin	muscle weakness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1993	A 74-year-old hypercholestrerolaemic woman taking [s1]cerivastatin[e1] (0.15 mg/day) for 22 days complained of general [s2]muscle weakness[e2] and muscle pain.
	(3, 24)	cerivastatin	rhabdomyolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1994	Clearance rates of [s1]cerivastatin[e1] metabolites in a patient with cerivastatin-induced [s2]rhabdomyolysis[e2] 
	(7, 17)	acute rhabdomyolysis	cerivastatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1995	We report on a patient who developed [s1]acute rhabdomyolysis[e1] after taking [s2]cerivastatin[e2] 
	(0, 6)	Carboplatin	hypersensitivity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1996	 [s1]Carboplatin[e1]  [s2]hypersensitivity[e2] induced by low-dose paclitaxel/carboplatin in multiple platinum-treated patients with recurrent ovarian cancer.
	(4, 19)	hypersensitivity	carboplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1997	Carboplatin [s1]hypersensitivity[e1] induced by low-dose paclitaxel [s2]carboplatin[e2] in multiple platinum-treated patients with recurrent ovarian cancer.
	(4, 15)	hypersensitivity	paclitaxel	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1998	Carboplatin [s1]hypersensitivity[e1] induced by low-dose [s2]paclitaxel[e2] carboplatin in multiple platinum-treated patients with recurrent ovarian cancer.
	(15, 41)	apnea	CBDCA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	1999	However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and [s1]apnea[e1]  and another four patients developed eruptions, hypotension, and tachycardia soon after administration of [s2]CBDCA[e2] 
	(12, 42)	cardiac arrest	CBDCA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2000	However, one patient exhibited severe hypersensitivity reactions including [s1]cardiac arrest[e1] and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of [s2]CBDCA[e2] 
	(23, 41)	eruptions	CBDCA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2001	However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed [s1]eruptions[e1]  hypotension, and tachycardia soon after administration of [s2]CBDCA[e2] 
	(25, 41)	hypotension	CBDCA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2002	However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, [s1]hypotension[e1]  and tachycardia soon after administration of [s2]CBDCA[e2] 
	(5, 42)	severe hypersensitivity reactions	CBDCA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2003	However, one patient exhibited [s1]severe hypersensitivity reactions[e1] including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of [s2]CBDCA[e2] 
	(32, 42)	tachycardia	CBDCA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2004	However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and [s1]tachycardia[e1] soon after administration of [s2]CBDCA[e2] 
	(4, 9)	CBDCA	hypersensitivity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2005	Our report suggested that [s1]CBDCA[e1]  [s2]hypersensitivity[e2] was correlated with the total dose of previously administered platinum agents and that CBDCA should be excluded in patients who have received multiple platinum-based chemotherapy, even in platinum-sensitive cases, because CBDCA hypersensitivity can occur even with low-dose CBDCA administration.
	(4, 9)	CBDCA	hypersensitivity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2006	Our report suggested that [s1]CBDCA[e1]  [s2]hypersensitivity[e2] was correlated with the total dose of previously administered platinum agents and that CBDCA should be excluded in patients who have received multiple platinum-based chemotherapy, even in platinum-sensitive cases, because CBDCA hypersensitivity can occur even with low-dose CBDCA administration.
	(4, 9)	CBDCA	hypersensitivity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2007	Our report suggested that [s1]CBDCA[e1]  [s2]hypersensitivity[e2] was correlated with the total dose of previously administered platinum agents and that CBDCA should be excluded in patients who have received multiple platinum-based chemotherapy, even in platinum-sensitive cases, because CBDCA hypersensitivity can occur even with low-dose CBDCA administration.
	(4, 9)	CBDCA	hypersensitivity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2008	Our report suggested that [s1]CBDCA[e1]  [s2]hypersensitivity[e2] was correlated with the total dose of previously administered platinum agents and that CBDCA should be excluded in patients who have received multiple platinum-based chemotherapy, even in platinum-sensitive cases, because CBDCA hypersensitivity can occur even with low-dose CBDCA administration.
	(5, 16)	carboplatin	hypersensitivity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2009	We report five cases of [s1]carboplatin[e1] (CBDCA) [s2]hypersensitivity[e2] after weekly low-dose paclitaxel (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy in patients with recurrent ovarian cancer receiving multiple platinum-based chemotherapy.
	(9, 14)	CBDCA	hypersensitivity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2010	We report five cases of carboplatin  [s1]CBDCA[e1]  [s2]hypersensitivity[e2] after weekly low-dose paclitaxel (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy in patients with recurrent ovarian cancer receiving multiple platinum-based chemotherapy.
	(14, 25)	hypersensitivity	paclitaxel	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2011	We report five cases of carboplatin (CBDCA) [s1]hypersensitivity[e1] after weekly low-dose [s2]paclitaxel[e2] (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy in patients with recurrent ovarian cancer receiving multiple platinum-based chemotherapy.
	(17, 28)	cyclosporine	cholestasis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2012	TREATMENT/OUTCOME: Standard anti-tuberculosis therapy was administered but was complicated by interaction with [s1]cyclosporine[e1] and drug-induced [s2]cholestasis[e2] 
	(1, 9)	fentanyl	adrenocortical insufficiency	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2013	Chronic [s1]fentanyl[e1] application induces [s2]adrenocortical insufficiency[e2] 
	(14, 34)	adrenocortical insufficiency	fentanyl	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2014	We report a case of a 64-year-old man with secondary [s1]adrenocortical insufficiency[e1] who has been on a chronic transdermal [s2]fentanyl[e2] treatment because of sciatic pain syndrome.
	(0, 7)	Fluphenazine	neuroleptic malignant syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2015	 [s1]Fluphenazine[e1] induced [s2]neuroleptic malignant syndrome[e2] in a schizophrenic patient.
	(7, 22)	neuroleptic malignant syndrome	fluphenazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2016	OBJECTIVE: To report a case of [s1]neuroleptic malignant syndrome[e1] (NMS) associated with [s2]fluphenazine[e2] in a schizophrenic patient and review the literature related to this condition.
	(14, 20)	NMS	fluphenazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2017	OBJECTIVE: To report a case of neuroleptic malignant syndrome  [s1]NMS[e1]  associated with [s2]fluphenazine[e2] in a schizophrenic patient and review the literature related to this condition.
	(4, 11)	vancomycin	cerebrospinal fluid eosinophilia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2018	Intraventricular [s1]vancomycin[e1] induced [s2]cerebrospinal fluid eosinophilia[e2]  report of two patients.
	(5, 35)	vancomycin	CSFE	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2019	We propose a mechanism of [s1]vancomycin[e1] induced mast cell degranulation and subsequent release of eosinophil chemotactic factor as a cause of [s2]CSFE[e2] 
	(5, 31)	cerebrospinal fluid eosinophilia	vancomycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2020	We report two cases of [s1]cerebrospinal fluid eosinophilia[e1] (CSFE) secondary to the intraventricular administration of [s2]vancomycin[e2] 
	(16, 29)	CSFE	vancomycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2021	We report two cases of cerebrospinal fluid eosinophilia  [s1]CSFE[e1]  secondary to the intraventricular administration of [s2]vancomycin[e2] 
	(3, 15)	interstitial pneumonitis	bicalutamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2022	Successful recovery from [s1]interstitial pneumonitis[e1]  induced by [s2]bicalutamide[e2] and leuprorelin acetate given as treatment for prostate cancer.
	(3, 20)	interstitial pneumonitis	leuprorelin acetate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2023	Successful recovery from [s1]interstitial pneumonitis[e1]  induced by bicalutamide and [s2]leuprorelin acetate[e2] given as treatment for prostate cancer.
	(5, 17)	interstitial pneumonitis	bicalutamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2024	We report a case of [s1]interstitial pneumonitis[e1] induced by [s2]bicalutamide[e2] and/or leuprorelin acetate given as therapy for prostate cancer, in which the pneumonitis was successfully managed by steroid treatment.
	(5, 24)	interstitial pneumonitis	leuprorelin acetate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2025	We report a case of [s1]interstitial pneumonitis[e1] induced by bicalutamide and/or [s2]leuprorelin acetate[e2] given as therapy for prostate cancer, in which the pneumonitis was successfully managed by steroid treatment.
	(14, 30)	corneal endothelial deposits	rifabutin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2026	CONCLUSIONS: In these 3 cases, the unique positive ocular finding was [s1]corneal endothelial deposits[e1]  which may be related to the use of [s2]rifabutin[e2] 
	(0, 10)	Corneal endothelial deposits	rifabutin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2027	 [s1]Corneal endothelial deposits[e1] associated with [s2]rifabutin[e2] use.
	(15, 28)	corneal endothelial deposits	rifabutin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2028	PURPOSE: The aim of this study was to report on the possible development of [s1]corneal endothelial deposits[e1] resulting from the use of [s2]rifabutin[e2] 
	(5, 17)	corneal endothelial deposits	rifabutin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2029	RESULTS: All cases developed [s1]corneal endothelial deposits[e1] after previous use of [s2]rifabutin[e2] 
	(3, 35)	malignant mixed mesodermal tumor	raloxifene	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2030	CASE: A [s1]malignant mixed mesodermal tumor[e1] was diagnosed in a 64-year-old woman with a bicornuate uterus while she was taking [s2]raloxifene[e2] for osteoporosis prevention.
	(8, 19)	raloxifene	malignant mixed mesodermal tumor	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2031	CONCLUSION: There may be an association between [s1]raloxifene[e1] and the development of [s2]malignant mixed mesodermal tumor[e2] 
	(0, 16)	Malignant mixed mullerian tumor of the uterus	raloxifene	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2032	 [s1]Malignant mixed mullerian tumor of the uterus[e1] in a patient taking [s2]raloxifene[e2] 
	(10, 26)	malignant mixed mesodermal tumor	raloxifene	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2033	We report a case of a women in whom a [s1]malignant mixed mesodermal tumor[e1] was diagnosed while she was taking [s2]raloxifene[e2]  which is also a selective estrogen receptor modulator.
	(13, 21)	neutropenia	MMF	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2034	Herein we report four patients who underwent liver transplantation and developed [s1]neutropenia[e1] while receiving [s2]MMF[e2] 
	(0, 12)	Mycophenolate mofetil	neutropenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2035	 [s1]Mycophenolate mofetil[e1] induced [s2]neutropenia[e2] in liver transplantation.
	(5, 13)	MMF	neutropenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2036	The mean time from starting [s1]MMF[e1] to the development of [s2]neutropenia[e2] was 4 months.
	(4, 10)	MMF	bone marrow toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2037	The side effects of [s1]MMF[e1]  such as [s2]bone marrow toxicity[e2]  have been reported.
	(10, 25)	acute hemoglobinemia	anti-D IGIV	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2038	A previous review described data on 15 patients who experienced [s1]acute hemoglobinemia[e1] or hemoglobinuria following [s2]anti-D IGIV[e2] administration for ITP or secondary thrombocytopenia.
	(17, 25)	hemoglobinuria	anti-D IGIV	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2039	A previous review described data on 15 patients who experienced acute hemoglobinemia or [s1]hemoglobinuria[e1] following [s2]anti-D IGIV[e2] administration for ITP or secondary thrombocytopenia.
	(11, 26)	acute hemoglobinemia	Rh(0)(D) immune globulin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2040	Disseminated intravascular coagulation associated with [s1]acute hemoglobinemia[e1] or hemoglobinuria following [s2]Rh(0)(D) immune globulin[e2] intravenous administration for immune thrombocytopenic purpura.
	(0, 26)	Disseminated intravascular coagulation	Rh(0)(D) immune globulin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2041	 [s1]Disseminated intravascular coagulation[e1] associated with acute hemoglobinemia or hemoglobinuria following [s2]Rh(0)(D) immune globulin[e2] intravenous administration for immune thrombocytopenic purpura.
	(18, 26)	hemoglobinuria	Rh(0)(D) immune globulin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2042	Disseminated intravascular coagulation associated with acute hemoglobinemia or [s1]hemoglobinuria[e1] following [s2]Rh(0)(D) immune globulin[e2] intravenous administration for immune thrombocytopenic purpura.
	(6, 39)	anti-D IGIV	DIC	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2043	That review suggested that patients receiving [s1]anti-D IGIV[e1] be monitored for those and other potential complications of hemoglobinemia, particularly disseminated intravascular coagulation  [s2]DIC[e2] .
	(6, 30)	anti-D IGIV	disseminated intravascular coagulation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2044	That review suggested that patients receiving [s1]anti-D IGIV[e1] be monitored for those and other potential complications of hemoglobinemia, particularly [s2]disseminated intravascular coagulation[e2] (DIC).
	(6, 23)	anti-D IGIV	hemoglobinemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2045	That review suggested that patients receiving [s1]anti-D IGIV[e1] be monitored for those and other potential complications of [s2]hemoglobinemia[e2]  particularly disseminated intravascular coagulation (DIC).
	(17, 31)	DIC	anti-D IGIV	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2046	The purpose of this review is to increase awareness among physicians and other health care professionals that [s1]DIC[e1] may be a rare but potentially severe complication of [s2]anti-D IGIV[e2] treatment.
	(12, 27)	acute hemoglobinemia	anti-D IGIV	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2047	This review presents the first case series of DIC associated with [s1]acute hemoglobinemia[e1] or hemoglobinuria following [s2]anti-D IGIV[e2] administration for ITP.
	(8, 27)	DIC	anti-D IGIV	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2048	This review presents the first case series of [s1]DIC[e1] associated with acute hemoglobinemia or hemoglobinuria following [s2]anti-D IGIV[e2] administration for ITP.
	(19, 27)	hemoglobinuria	anti-D IGIV	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2049	This review presents the first case series of DIC associated with acute hemoglobinemia or [s1]hemoglobinuria[e1] following [s2]anti-D IGIV[e2] administration for ITP.
	(3, 19)	infliximab	severe transient neutropenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2050	After the second [s1]infliximab[e1] infusion, he was found to have a [s2]severe transient neutropenia[e2] (0.5 x 10(9)/L).
	(3, 13)	agranulocytosis	infliximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2051	Drug-induced [s1]agranulocytosis[e1] during treatment with [s2]infliximab[e2] in enteropathic spondyloarthropathy.
	(4, 30)	infliximab	autoimmune agranulocytosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2052	These data indicated that [s1]infliximab[e1] possibly triggered production of granulocyte and neutrophil autoantibodies with resultant [s2]autoimmune agranulocytosis[e2] 
	(4, 13)	infliximab	production of granulocyte and neutrophil autoantibodies	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2053	These data indicated that [s1]infliximab[e1] possibly triggered [s2]production of granulocyte and neutrophil autoantibodies[e2] with resultant autoimmune agranulocytosis.
	(7, 14)	bone marrow depression	linezolid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2054	However, peripheral neuropathy and [s1]bone marrow depression[e1] led to [s2]linezolid[e2] withdrawal in seven patients, and neuropathy may not be fully reversible in all patients.
	(3, 14)	neuropathy	linezolid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2055	However, peripheral [s1]neuropathy[e1] and bone marrow depression led to [s2]linezolid[e2] withdrawal in seven patients, and neuropathy may not be fully reversible in all patients.
	(2, 14)	peripheral neuropathy	linezolid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2056	However, [s1]peripheral neuropathy[e1] and bone marrow depression led to [s2]linezolid[e2] withdrawal in seven patients, and neuropathy may not be fully reversible in all patients.
	(10, 39)	bone marrow depression	linezolid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2057	Six patients developed peripheral neuropathy and five patients [s1]bone marrow depression[e1]  blood transfusions were given to three patients and in all five patients bone marrow function normalized after cessation of [s2]linezolid[e2] 
	(3, 40)	peripheral neuropathy	linezolid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2058	Six patients developed [s1]peripheral neuropathy[e1] and five patients bone marrow depression, blood transfusions were given to three patients and in all five patients bone marrow function normalized after cessation of [s2]linezolid[e2] 
	(3, 45)	high-grade endometrial stromal sarcoma	tamoxifen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2059	A case of [s1]high-grade endometrial stromal sarcoma[e1]  confined into an intrauterine polypoid growth, in a woman with a history of breast cancer who was treated with adjuvant [s2]tamoxifen[e2] 
	(20, 45)	intrauterine polypoid growth	tamoxifen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2060	A case of high-grade endometrial stromal sarcoma, confined into an [s1]intrauterine polypoid growth[e1]  in a woman with a history of breast cancer who was treated with adjuvant [s2]tamoxifen[e2] 
	(0, 16)	High-grade endometrial stromal sarcoma	tamoxifen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2061	 [s1]High-grade endometrial stromal sarcoma[e1] after [s2]tamoxifen[e2] therapy for breast cancer.
	(3, 32)	tamoxifen	endometrial adenocarcinoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2062	In deciding if [s1]tamoxifen[e1] therapy is warranted, all potentially life-threatening adverse events associated with tamoxifen should be considered, including [s2]endometrial adenocarcinoma[e2] or uterine sarcoma.
	(3, 32)	tamoxifen	endometrial adenocarcinoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2063	In deciding if [s1]tamoxifen[e1] therapy is warranted, all potentially life-threatening adverse events associated with tamoxifen should be considered, including [s2]endometrial adenocarcinoma[e2] or uterine sarcoma.
	(3, 42)	tamoxifen	uterine sarcoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2064	In deciding if [s1]tamoxifen[e1] therapy is warranted, all potentially life-threatening adverse events associated with tamoxifen should be considered, including endometrial adenocarcinoma or [s2]uterine sarcoma[e2] 
	(3, 42)	tamoxifen	uterine sarcoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2065	In deciding if [s1]tamoxifen[e1] therapy is warranted, all potentially life-threatening adverse events associated with tamoxifen should be considered, including endometrial adenocarcinoma or [s2]uterine sarcoma[e2] 
	(6, 20)	pentamidine	heart rate had decreased	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2066	After only the third dose of [s1]pentamidine[e1]  it was noted that the patient's [s2]heart rate had decreased[e2] to 48 beats/minute.
	(5, 12)	pentamidine	cardiotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2067	Although various manifestations of [s1]pentamidine[e1] induced [s2]cardiotoxicity[e2] have been reported, to our knowledge, second-degree heart block associated with this agent has not been described.
	(5, 25)	pentamidine	second-degree heart block	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2068	Although various manifestations of [s1]pentamidine[e1] induced cardiotoxicity have been reported, to our knowledge, [s2]second-degree heart block[e2] associated with this agent has not been described.
	(10, 20)	cardiotoxicity	pentamidine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2069	Clinicians should be vigilant when monitoring for [s1]cardiotoxicity[e1] in patients receiving [s2]pentamidine[e2] throughout the duration of therapy.
	(3, 10)	pentamidine	second-degree heart block	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2070	Early-onset [s1]pentamidine[e1] associated [s2]second-degree heart block[e2] and sinus bradycardia: case report and review of the literature.
	(3, 16)	pentamidine	sinus bradycardia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2071	Early-onset [s1]pentamidine[e1] associated second-degree heart block and [s2]sinus bradycardia[e2]  case report and review of the literature.
	(0, 9)	Falling backward	bupropion	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2072	 [s1]Falling backward[e1] in two elderly patients taking [s2]bupropion[e2] 
	(14, 21)	falling backward	bupropion	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2073	RESULTS: Both patients experienced a previously unreported side effect- [s1]falling backward[e1] -associated with [s2]bupropion[e2] use.
	(0, 17)	Ophthalmologic and neurologic findings	vigabatrin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2074	 [s1]Ophthalmologic and neurologic findings[e1] in two children exposed to [s2]vigabatrin[e2] in utero.
	(3, 8)	VGB	visual dysfunction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2075	The knowledge concerning [s1]VGB[e1] associated [s2]visual dysfunction[e2] in pediatric patients, particularly in those who have been exposed to VGB in utero is limited.
	(0, 7)	Vigabatrin	visual field defects	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2076	 [s1]Vigabatrin[e1] induced [s2]visual field defects[e2] are at present the most important safety issue in the use of the drug.
	(2, 24)	ophthalmic and neurologic findings	VGB	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2077	We explored [s1]ophthalmic and neurologic findings[e1] in two children who have been exposed prenatally to [s2]VGB[e2] 
	(5, 26)	IFN	cotton wool spots	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2078	BACKGROUND: Interferon  [s1]IFN[e1] -associated retinopathy is typically characterized by retinal hemorrhages and [s2]cotton wool spots[e2] at the posterior fundus, but visual function is usually maintained.
	(2, 28)	Interferon	cotton wool spots	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2079	BACKGROUND: [s1]Interferon[e1] (IFN)-associated retinopathy is typically characterized by retinal hemorrhages and [s2]cotton wool spots[e2] at the posterior fundus, but visual function is usually maintained.
	(5, 18)	IFN	retinal hemorrhages	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2080	BACKGROUND: Interferon  [s1]IFN[e1] -associated retinopathy is typically characterized by [s2]retinal hemorrhages[e2] and cotton wool spots at the posterior fundus, but visual function is usually maintained.
	(2, 20)	Interferon	retinal hemorrhages	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2081	BACKGROUND: [s1]Interferon[e1] (IFN)-associated retinopathy is typically characterized by [s2]retinal hemorrhages[e2] and cotton wool spots at the posterior fundus, but visual function is usually maintained.
	(5, 11)	IFN	retinopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2082	BACKGROUND: Interferon  [s1]IFN[e1] -associated [s2]retinopathy[e2] is typically characterized by retinal hemorrhages and cotton wool spots at the posterior fundus, but visual function is usually maintained.
	(2, 13)	Interferon	retinopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2083	BACKGROUND: [s1]Interferon[e1] (IFN)-associated [s2]retinopathy[e2] is typically characterized by retinal hemorrhages and cotton wool spots at the posterior fundus, but visual function is usually maintained.
	(3, 13)	macular edema	interferon	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2084	Clinical course of [s1]macular edema[e1] in two cases of [s2]interferon[e2] associated retinopathy observed by optical coherence tomography.
	(11, 17)	interferon	retinopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2085	Clinical course of macular edema in two cases of [s1]interferon[e1] associated [s2]retinopathy[e2] observed by optical coherence tomography.
	(5, 27)	IFN	decreased vision	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2086	CONCLUSION: During and after [s1]IFN[e1] therapy, OCT is a useful examination technique for revealing macular edema in patients who have [s2]decreased vision[e2] 
	(5, 19)	IFN	macular edema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2087	CONCLUSION: During and after [s1]IFN[e1] therapy, OCT is a useful examination technique for revealing [s2]macular edema[e2] in patients who have decreased vision.
	(15, 29)	IFN	hypoalbuminemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2088	Ophthalmologists should be aware of the ocular side effects of [s1]IFN[e1] therapy and carefully monitor patients for the possible occurrence of [s2]hypoalbuminemia[e2] and thrombocytopenia.
	(10, 17)	ocular side effects	IFN	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2089	Ophthalmologists should be aware of the [s1]ocular side effects[e1] of [s2]IFN[e2] therapy and carefully monitor patients for the possible occurrence of hypoalbuminemia and thrombocytopenia.
	(15, 37)	IFN	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2090	Ophthalmologists should be aware of the ocular side effects of [s1]IFN[e1] therapy and carefully monitor patients for the possible occurrence of hypoalbuminemia and [s2]thrombocytopenia[e2] 
	(8, 19)	visual acuity had decreased	IFN	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2091	The former patient had complained once that his [s1]visual acuity had decreased[e1] after the termination of [s2]IFN[e2] therapy, and the latter patient complained twice during IFN therapy that his visual acuity had decreased.
	(8, 19)	visual acuity had decreased	IFN	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2092	The former patient had complained once that his [s1]visual acuity had decreased[e1] after the termination of [s2]IFN[e2] therapy, and the latter patient complained twice during IFN therapy that his visual acuity had decreased.
	(17, 28)	IFN	macular edema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2093	With the use of optical coherence tomography (OCT), two patients with [s1]IFN[e1] associated retinopathy who had developed [s2]macular edema[e2] and reduced visual acuity during the clinical course of IFN therapy were observed.
	(17, 28)	IFN	macular edema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2094	With the use of optical coherence tomography (OCT), two patients with [s1]IFN[e1] associated retinopathy who had developed [s2]macular edema[e2] and reduced visual acuity during the clinical course of IFN therapy were observed.
	(17, 33)	IFN	reduced visual acuity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2095	With the use of optical coherence tomography (OCT), two patients with [s1]IFN[e1] associated retinopathy who had developed macular edema and [s2]reduced visual acuity[e2] during the clinical course of IFN therapy were observed.
	(17, 33)	IFN	reduced visual acuity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2096	With the use of optical coherence tomography (OCT), two patients with [s1]IFN[e1] associated retinopathy who had developed macular edema and [s2]reduced visual acuity[e2] during the clinical course of IFN therapy were observed.
	(17, 22)	IFN	retinopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2097	With the use of optical coherence tomography (OCT), two patients with [s1]IFN[e1] associated [s2]retinopathy[e2] who had developed macular edema and reduced visual acuity during the clinical course of IFN therapy were observed.
	(17, 22)	IFN	retinopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2098	With the use of optical coherence tomography (OCT), two patients with [s1]IFN[e1] associated [s2]retinopathy[e2] who had developed macular edema and reduced visual acuity during the clinical course of IFN therapy were observed.
	(3, 10)	diabetes mellitus	interferon-alfa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2099	Late development of [s1]diabetes mellitus[e1] after [s2]interferon-alfa[e2] and ribavirin therapy for chronic hepatitis C: a case report.
	(3, 16)	diabetes mellitus	ribavirin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2100	Late development of [s1]diabetes mellitus[e1] after interferon-alfa and [s2]ribavirin[e2] therapy for chronic hepatitis C: a case report.
	(8, 20)	immune-mediated diabetes mellitus	alfa-interferon	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2101	OBJECTIVE: To report the late development of [s1]immune-mediated diabetes mellitus[e1] after completion of [s2]alfa-interferon[e2] therapy for hepatitis C in an Asian patient.
	(0, 18)	Cutaneous necrosis	interferon alfa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2102	 [s1]Cutaneous necrosis[e1] after injection of polyethylene glycol-modified [s2]interferon alfa[e2] 
	(0, 10)	Cutaneous necrosis	interferon alfa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2103	 [s1]Cutaneous necrosis[e1] as a result of [s2]interferon alfa[e2] is an infrequent complication with unknown pathogenesis, in which a cutaneous local immune-mediated inflammatory process might be involved.
	(13, 45)	pegylated interferon alfa-2b	local cutaneous reactions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2104	We report 5 patients (3 patients with chronic hepatitis C treated with [s1]pegylated interferon alfa-2b[e1] in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed [s2]local cutaneous reactions[e2] at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.
	(13, 45)	pegylated interferon alfa-2b	local cutaneous reactions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2105	We report 5 patients (3 patients with chronic hepatitis C treated with [s1]pegylated interferon alfa-2b[e1] in association with oral ribavirin and two patients with chronic myelocytic leukemia) who developed [s2]local cutaneous reactions[e2] at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.
	(27, 45)	ribavirin	local cutaneous reactions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2106	We report 5 patients (3 patients with chronic hepatitis C treated with pegylated interferon alfa-2b in association with oral [s1]ribavirin[e1] and two patients with chronic myelocytic leukemia) who developed [s2]local cutaneous reactions[e2] at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa-2b at different doses.
	(9, 19)	cutaneous necrosis	interferon alfa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2107	We review the literature on previously reported cases of [s1]cutaneous necrosis[e1] after injection of standard [s2]interferon alfa[e2] or pegylated interferon alfa-2b and discuss the different pathophysiologic mechanisms that might be involved.
	(9, 24)	cutaneous necrosis	pegylated interferon alfa-2b	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2108	We review the literature on previously reported cases of [s1]cutaneous necrosis[e1] after injection of standard interferon alfa or [s2]pegylated interferon alfa-2b[e2] and discuss the different pathophysiologic mechanisms that might be involved.
	(7, 17)	ischemic colitis	tegaserod	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2109	Potential mechanisms involved in the occurrence of [s1]ischemic colitis[e1] in patients receiving [s2]tegaserod[e2] are also discussed.
	(0, 7)	Tegaserod	ischemic colitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2110	 [s1]Tegaserod[e1] associated [s2]ischemic colitis[e2] 
	(17, 41)	tegaserod	irritable bowel syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2111	We describe the development of ischemic colitis in a woman who was treated with [s1]tegaserod[e1] and review the relationship among ischemic colitis, tegaserod use, and [s2]irritable bowel syndrome[e2] 
	(17, 41)	tegaserod	irritable bowel syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2112	We describe the development of ischemic colitis in a woman who was treated with [s1]tegaserod[e1] and review the relationship among ischemic colitis, tegaserod use, and [s2]irritable bowel syndrome[e2] 
	(5, 19)	ischemic colitis	tegaserod	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2113	We describe the development of [s1]ischemic colitis[e1] in a woman who was treated with [s2]tegaserod[e2] and review the relationship among ischemic colitis, tegaserod use, and irritable bowel syndrome.
	(5, 19)	ischemic colitis	tegaserod	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2114	We describe the development of [s1]ischemic colitis[e1] in a woman who was treated with [s2]tegaserod[e2] and review the relationship among ischemic colitis, tegaserod use, and irritable bowel syndrome.
	(5, 19)	ischemic colitis	tegaserod	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2115	We describe the development of [s1]ischemic colitis[e1] in a woman who was treated with [s2]tegaserod[e2] and review the relationship among ischemic colitis, tegaserod use, and irritable bowel syndrome.
	(5, 19)	ischemic colitis	tegaserod	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2116	We describe the development of [s1]ischemic colitis[e1] in a woman who was treated with [s2]tegaserod[e2] and review the relationship among ischemic colitis, tegaserod use, and irritable bowel syndrome.
	(8, 31)	chronic, watery diarrhea	lansoprazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2117	A 57-year-old man developed [s1]chronic, watery diarrhea[e1] four weeks after Helicobacter pylori eradication therapy including [s2]lansoprazole[e2] followed by lansoprazole monotherapy for gastroesophageal reflux disease.
	(8, 31)	chronic, watery diarrhea	lansoprazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2118	A 57-year-old man developed [s1]chronic, watery diarrhea[e1] four weeks after Helicobacter pylori eradication therapy including [s2]lansoprazole[e2] followed by lansoprazole monotherapy for gastroesophageal reflux disease.
	(0, 7)	Lansoprazole	collagenous colitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2119	 [s1]Lansoprazole[e1] associated [s2]collagenous colitis[e2]  a case report.
	(14, 24)	lansoprazole	collagenous colitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2120	The reported case represents an unusual association between medication with the proton pump inhibitor [s1]lansoprazole[e1] and the development of [s2]collagenous colitis[e2] suggesting the importance of evaluation of drug use in patients with microscopic colitis.
	(7, 31)	painful ulcers	interferon beta-1b	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2121	46-year-old woman developed [s1]painful ulcers[e1] over her lower abdomen in the form of reticulate erythema after injecting [s2]interferon beta-1b[e2] subcutaneously for multiple sclerosis.
	(19, 31)	reticulate erythema	interferon beta-1b	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2122	46-year-old woman developed painful ulcers over her lower abdomen in the form of [s1]reticulate erythema[e1] after injecting [s2]interferon beta-1b[e2] subcutaneously for multiple sclerosis.
	(0, 13)	Abdominal wall ulceration	recombinant human interferon-beta-1b	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2123	 [s1]Abdominal wall ulceration[e1] and mucinosis secondary to [s2]recombinant human interferon-beta-1b[e2] 
	(6, 13)	mucinosis	recombinant human interferon-beta-1b	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2124	Abdominal wall ulceration and [s1]mucinosis[e1] secondary to [s2]recombinant human interferon-beta-1b[e2] 
	(0, 9)	Itraconazole	vincristine neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2125	 [s1]Itraconazole[e1] related increased [s2]vincristine neurotoxicity[e2]  case report and review of literature.
	(8, 19)	vincristine neurotoxicity	vincristine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2126	Itraconazole-related increased [s1]vincristine neurotoxicity[e1]  [s2]vincristine[e2] neurotoxicity: case report and review of literature.
	(9, 18)	neurotoxicity	itraconazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2127	Nineteen cases of unusual enhanced vincristine [s1]neurotoxicity[e1] related to [s2]itraconazole[e2] have been reported in children.
	(5, 11)	vincristine	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2128	Nineteen cases of unusual enhanced [s1]vincristine[e1]  [s2]neurotoxicity[e2] related to itraconazole have been reported in children.
	(3, 32)	itraconazole	absence of deep reflexes	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2129	Ten days after [s1]itraconazole[e1] was started, he developed paralytic ileus, neurogenic bladder, mild left ptosis, and [s2]absence of deep reflexes[e2]  with severe paralysis of the lower extremities and mild weakness of the upper extremities.
	(3, 26)	itraconazole	mild left ptosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2130	Ten days after [s1]itraconazole[e1] was started, he developed paralytic ileus, neurogenic bladder, [s2]mild left ptosis[e2]  and absence of deep reflexes, with severe paralysis of the lower extremities and mild weakness of the upper extremities.
	(3, 49)	itraconazole	mild weakness of the upper extremities	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2131	Ten days after [s1]itraconazole[e1] was started, he developed paralytic ileus, neurogenic bladder, mild left ptosis, and absence of deep reflexes, with severe paralysis of the lower extremities and [s2]mild weakness of the upper extremities[e2] 
	(3, 21)	itraconazole	neurogenic bladder	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2132	Ten days after [s1]itraconazole[e1] was started, he developed paralytic ileus, [s2]neurogenic bladder[e2]  mild left ptosis, and absence of deep reflexes, with severe paralysis of the lower extremities and mild weakness of the upper extremities.
	(3, 15)	itraconazole	paralytic ileus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2133	Ten days after [s1]itraconazole[e1] was started, he developed [s2]paralytic ileus[e2]  neurogenic bladder, mild left ptosis, and absence of deep reflexes, with severe paralysis of the lower extremities and mild weakness of the upper extremities.
	(3, 39)	itraconazole	severe paralysis of the lower extremities	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2134	Ten days after [s1]itraconazole[e1] was started, he developed paralytic ileus, neurogenic bladder, mild left ptosis, and absence of deep reflexes, with [s2]severe paralysis of the lower extremities[e2] and mild weakness of the upper extremities.
	(12, 42)	itraconazole	fatal toxicities	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2135	The authors suggest that in the absence of any proven benefit of [s1]itraconazole[e1] prophylaxis, and given the interaction of this drug with vincristine leading to severe and even potentially [s2]fatal toxicities[e2]  the combination use of these drugs should be avoided.
	(30, 42)	vincristine	fatal toxicities	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2136	The authors suggest that in the absence of any proven benefit of itraconazole prophylaxis, and given the interaction of this drug with [s1]vincristine[e1] leading to severe and even potentially [s2]fatal toxicities[e2]  the combination use of these drugs should be avoided.
	(8, 38)	intracerebral hemorrhage	pseudoephedrine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2137	CASE REPORT: We report a case of [s1]intracerebral hemorrhage[e1] occurring in a middle-aged man who suffered from chronic sinusitis and had been ingesting [s2]pseudoephedrine[e2] daily for one year.
	(4, 16)	phenylpropanolamine	intracerebral hemorrhage	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2138	Only one report links [s1]phenylpropanolamine[e1] consumption to an [s2]intracerebral hemorrhage[e2] in a patient with an AVM.
	(0, 14)	Pseudoephedrine	cerebral vascular malformation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2139	 [s1]Pseudoephedrine[e1] induced hemorrhage associated with a [s2]cerebral vascular malformation[e2] 
	(0, 7)	Pseudoephedrine	hemorrhage	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2140	 [s1]Pseudoephedrine[e1] induced [s2]hemorrhage[e2] associated with a cerebral vascular malformation.
	(13, 23)	phenylpropanolamine	stroke	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2141	Since 1979, over 30 published case reports have documented the relationship between [s1]phenylpropanolamine[e1] and [s2]stroke[e2] 
	(5, 12)	pseudoephedrine	intracerebral hemorrhage	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2142	This is a case of [s1]pseudoephedrine[e1] induced [s2]intracerebral hemorrhage[e2] in a patient with an underlying vascular malformation.
	(3, 9)	quetiapine	diabetic ketoacidosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2143	Rapid onset of [s1]quetiapine[e1] induced [s2]diabetic ketoacidosis[e2] in an elderly patient: a case report.
	(8, 29)	DKA	quetiapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2144	We report a case of reversible [s1]DKA[e1] and new-onset DM that developed in a demented patient who was treated with [s2]quetiapine[e2] for 14 days.
	(14, 29)	DM	quetiapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2145	We report a case of reversible DKA and new-onset [s1]DM[e1] that developed in a demented patient who was treated with [s2]quetiapine[e2] for 14 days.
	(0, 9)	Pulmonary leukostasis	all-trans retinoic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2146	 [s1]Pulmonary leukostasis[e1] secondary to [s2]all-trans retinoic acid[e2] in the treatment of acute promyelocytic leukemia in first relapse.
	(0, 15)	Eruptive epidermoid cysts	imiquimod	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2147	 [s1]Eruptive epidermoid cysts[e1] resulting from treatment with [s2]imiquimod[e2] 
	(12, 31)	imiquimod	verrucous plaque	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2148	METHODS: A 79-year-old woman being treated with [s1]imiquimod[e1] 5 days per week for a nodular basal cell developed a [s2]verrucous plaque[e2] over the treatment area after 7 weeks of therapy.
	(1, 23)	multiple comedones	imiquimod	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2149	The [s1]multiple comedones[e1] and ruptured epidermoid cysts are newly reported adverse effects of [s2]imiquimod[e2] therapy.
	(6, 23)	ruptured epidermoid cysts	imiquimod	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2150	The multiple comedones and [s1]ruptured epidermoid cysts[e1] are newly reported adverse effects of [s2]imiquimod[e2] therapy.
	(7, 24)	fluoxetine	death	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2151	We report an unusual case of massive [s1]fluoxetine[e1] ingestion resulting in neurological and cardiovascular toxicity resulting in [s2]death[e2] 
	(7, 18)	fluoxetine	neurological and cardiovascular toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2152	We report an unusual case of massive [s1]fluoxetine[e1] ingestion resulting in [s2]neurological and cardiovascular toxicity[e2] resulting in death.
	(0, 12)	Hepatocellular damage	iron sucrose	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2153	 [s1]Hepatocellular damage[e1] following therapeutic intravenous [s2]iron sucrose[e2] infusion in a child.
	(16, 37)	iron sucrose	systemic iron toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2154	The case reported here is of a child given a large dose of intravenous [s1]iron sucrose[e1] (16 mg/kg) over 3 hours, who subsequently developed features of [s2]systemic iron toxicity[e2] 
	(5, 18)	acute amnestic episode	clioquinol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2155	Five personal observations of an [s1]acute amnestic episode[e1] in younger individuals after intake of [s2]clioquinol[e2] are described together with three observations from the medical literature.
	(13, 34)	clioquinol	retrograde amnesia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2156	The clinical aspect closely resembled classical transient global amnesia but the episode after [s1]clioquinol[e1] lasted longer (24 hours to three days) and a more or less extensive [s2]retrograde amnesia[e2] persisted permanently.
	(6, 15)	transient global amnesia	clioquinol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2157	The clinical aspect closely resembled classical [s1]transient global amnesia[e1] but the episode after [s2]clioquinol[e2] lasted longer (24 hours to three days) and a more or less extensive retrograde amnesia persisted permanently.
	(0, 6)	Transient global amnesia	clioquinol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2158	 [s1]Transient global amnesia[e1] after [s2]clioquinol[e2]  five personal observations from outside Japan.
	(13, 27)	Neisseria mucosa knee arthritis	sodium hyaluronate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2159	In the other patient, a 78-year-old woman, [s1]Neisseria mucosa knee arthritis[e1] occurred after a single [s2]sodium hyaluronate[e2] injection.
	(14, 39)	Staphylococcus aureus knee arthritis	corticosteroids	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2160	One patient was an 80-year-old woman who was admitted for [s1]Staphylococcus aureus knee arthritis[e1] after several intraarticular injections of sodium hyaluronate and [s2]corticosteroids[e2] 
	(14, 33)	Staphylococcus aureus knee arthritis	sodium hyaluronate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2161	One patient was an 80-year-old woman who was admitted for [s1]Staphylococcus aureus knee arthritis[e1] after several intraarticular injections of [s2]sodium hyaluronate[e2] and corticosteroids.
	(0, 11)	Septic knee arthritis	hyaluronate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2162	 [s1]Septic knee arthritis[e1] after intra-articular [s2]hyaluronate[e2] injection.
	(0, 8)	Acute dystonia	lamivudine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2163	 [s1]Acute dystonia[e1] induced by [s2]lamivudine[e2] 
	(0, 33)	ADR	lamivudine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2164	 [s1]ADR[e1] induced by drug treatment can be a side effect of treatment with antipsychotic drugs and other drugs; however, there have been no reports of [s2]lamivudine[e2] induced ADR in the English literature.
	(6, 22)	acute dystonic reactions	lamivudine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2165	The authors report two cases of [s1]acute dystonic reactions[e1] (ADRs) as a side effect of [s2]lamivudine[e2] 
	(11, 20)	ADRs	lamivudine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2166	The authors report two cases of acute dystonic reactions  [s1]ADRs[e1]  as a side effect of [s2]lamivudine[e2] 
	(5, 21)	lamivudine	ADRs	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2167	The authors think that although [s1]lamivudine[e1] is widely used and well tolerated, it can cause [s2]ADRs[e2]  which are reversible after drug withdrawal.
	(0, 23)	Pleuropulmonary fibrosis	pergolide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2168	 [s1]Pleuropulmonary fibrosis[e1] after long-term treatment with the dopamine agonist [s2]pergolide[e2] for Parkinson Disease.
	(10, 27)	risperidone	psychiatric and physical manifestations	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2169	"CONCLUSIONS: This observation of ""on-off"" [s1]risperidone[e1] treatment suggests that risperidone may have worsened both [s2]psychiatric and physical manifestations[e2] of the mitochondrial disorder in this adolescent."
	(10, 27)	risperidone	psychiatric and physical manifestations	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2170	"CONCLUSIONS: This observation of ""on-off"" [s1]risperidone[e1] treatment suggests that risperidone may have worsened both [s2]psychiatric and physical manifestations[e2] of the mitochondrial disorder in this adolescent."
	(31, 39)	increased mood symptoms	risperidone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2171	OBJECTIVE: To our knowledge, this is the first published case report of an adolescent girl with a mitochondrial disorder and depression who displayed both new-onset psychotic and [s1]increased mood symptoms[e1] during treatment with [s2]risperidone[e2] 
	(0, 10)	Risperidone	depression	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2172	 [s1]Risperidone[e1] induced psychosis and [s2]depression[e2] in a child with a mitochondrial disorder.
	(0, 7)	Risperidone	psychosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2173	 [s1]Risperidone[e1] induced [s2]psychosis[e2] and depression in a child with a mitochondrial disorder.
	(0, 11)	Fatal radiation myelopathy	busulfan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2174	 [s1]Fatal radiation myelopathy[e1] after high-dose [s2]busulfan[e2] and melphalan chemotherapy and radiotherapy for Ewing's sarcoma: a review of the literature and implications for practice.
	(0, 15)	Fatal radiation myelopathy	melphalan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2175	 [s1]Fatal radiation myelopathy[e1] after high-dose busulfan and [s2]melphalan[e2] chemotherapy and radiotherapy for Ewing's sarcoma: a review of the literature and implications for practice.
	(0, 7)	Gemcitabine	pericardial effusion	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2176	 [s1]Gemcitabine[e1] induced [s2]pericardial effusion[e2] and tamponade after unblocked cardiac irradiation.
	(0, 14)	Gemcitabine	tamponade	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2177	 [s1]Gemcitabine[e1] induced pericardial effusion and [s2]tamponade[e2] after unblocked cardiac irradiation.
	(0, 11)	Gemcitabine	radiation recall reactions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2178	 [s1]Gemcitabine[e1] therapy has been associated with [s2]radiation recall reactions[e2] when used in the treatment of carcinoma.
	(10, 28)	gemcitabine	pericardial effusion	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2179	Physicians should be aware of the potential for developing a [s1]gemcitabine[e1] induced radiation recall reaction resulting in hemodynamically significant [s2]pericardial effusion[e2] 
	(10, 17)	gemcitabine	radiation recall reaction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2180	Physicians should be aware of the potential for developing a [s1]gemcitabine[e1] induced [s2]radiation recall reaction[e2] resulting in hemodynamically significant pericardial effusion.
	(11, 32)	pericardial effusion	gemcitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2181	We report four cases of hemodynamically significant [s1]pericardial effusion[e1] in patients with refractory lymphoma who were receiving [s2]gemcitabine[e2]  all of whom had a history of mediastinal radiation without subcarinal blocking.
	(9, 14)	MM	CNS lymphoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2182	A patient with generalized MG was effectively managed with [s1]MM[e1] but developed [s2]CNS lymphoma[e2] after 3 years of treatment.
	(16, 26)	MM	lymphoproliferative disorders	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2183	Despite minimal short-term side effects and apparent efficacy, chronic treatment of MG with [s1]MM[e1] may be associated with increased risk of [s2]lymphoproliferative disorders[e2] 
	(1, 23)	CNS lymphoma	mycophenolate mofetil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2184	Primary [s1]CNS lymphoma[e1] complicating treatment of myasthenia gravis with [s2]mycophenolate mofetil[e2] 
	(1, 14)	CNS lymphoma	MM	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2185	Primary [s1]CNS lymphoma[e1] regressed on withdrawal of [s2]MM[e2] 
	(0, 12)	Baclofen	fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2186	 [s1]Baclofen[e1] withdrawal: a cause of prolonged [s2]fever[e2] in the intensive care unit.
	(0, 6)	Baclofen	withdrawal syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2187	 [s1]Baclofen[e1]  [s2]withdrawal syndrome[e2] resulting from underdosing of oral baclofen should be considered as a potential source of prolonged fever in the intensive care unit.
	(4, 15)	withdrawal syndrome	baclofen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2188	Baclofen [s1]withdrawal syndrome[e1] resulting from underdosing of oral [s2]baclofen[e2] should be considered as a potential source of prolonged fever in the intensive care unit.
	(7, 37)	autonomic instability	baclofen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2189	The patient continued to have fever and [s1]autonomic instability[e1] without evidence of infection which entirely resolved within 24 hours of reinstitution of full preadmission dosing of oral [s2]baclofen[e2] 
	(5, 37)	fever	baclofen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2190	The patient continued to have [s1]fever[e1] and autonomic instability without evidence of infection which entirely resolved within 24 hours of reinstitution of full preadmission dosing of oral [s2]baclofen[e2] 
	(5, 11)	baclofen	withdrawal syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2191	We report a case of [s1]baclofen[e1]  [s2]withdrawal syndrome[e2] resulting from oral baclofen underdosing.
	(5, 11)	baclofen	withdrawal syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2192	We report a case of [s1]baclofen[e1]  [s2]withdrawal syndrome[e2] resulting from oral baclofen underdosing.
	(5, 26)	captopril	eosinophilia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2193	After discontinuing [s1]captopril[e1] and starting systemic steroids, her symptomatology rapidly improved, and her [s2]eosinophilia[e2] and radiographic abnormalities both resolved.
	(5, 32)	captopril	radiographic abnormalities	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2194	After discontinuing [s1]captopril[e1] and starting systemic steroids, her symptomatology rapidly improved, and her eosinophilia and [s2]radiographic abnormalities[e2] both resolved.
	(0, 6)	Captopril	pulmonary infiltrates with eosinophilia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2195	 [s1]Captopril[e1] induced [s2]pulmonary infiltrates with eosinophilia[e2] in an infant with congenital heart disease.
	(16, 31)	captopril	pulmonary infiltrates with eosinophilia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2196	We report a case of an infant with complex congenital heart disease who was placed on [s1]captopril[e1] for afterload reduction following cardiac surgery and subsequently developed [s2]pulmonary infiltrates with eosinophilia[e2] 
	(1, 10)	propofol	pancreatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2197	Can [s1]propofol[e1] precipitate [s2]pancreatitis[e2] in patients with Cushing's syndrome?
	(38, 46)	acute pancreatitis	propofol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2198	Since elevated cortisol levels in Cushing's disease poses a threat for pancreatitis, there is a possibility that patients with Cushing's disease might be more prone to [s1]acute pancreatitis[e1] following [s2]propofol[e2] administration.
	(32, 38)	focal seizure	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2199	Since recent studies have reported no negative interactions with concurrent use, we here report three cases (one case of a prolonged seizure, a serotonin syndrome and a [s1]focal seizure[e1]  of severe [s2]lithium[e2] induced side effects while patients underwent ECT without complications and lithium serum levels were still subtherapeutic.
	(22, 38)	prolonged seizure	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2200	Since recent studies have reported no negative interactions with concurrent use, we here report three cases (one case of a [s1]prolonged seizure[e1]  a serotonin syndrome and a focal seizure) of severe [s2]lithium[e2] induced side effects while patients underwent ECT without complications and lithium serum levels were still subtherapeutic.
	(26, 39)	serotonin syndrome	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2201	Since recent studies have reported no negative interactions with concurrent use, we here report three cases (one case of a prolonged seizure, a [s1]serotonin syndrome[e1] and a focal seizure) of severe [s2]lithium[e2] induced side effects while patients underwent ECT without complications and lithium serum levels were still subtherapeutic.
	(0, 44)	CD20-negative T-cell-rich B-cell lymphoma	rituximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2202	 [s1]CD20-negative T-cell-rich B-cell lymphoma[e1] as a progression of a nodular lymphocyte-predominant Hodgkin's lymphoma treated with [s2]rituximab[e2]  a molecular analysis using laser capture microdissection.
	(2, 13)	CD20-negative tumors	Rituximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2203	Recently, [s1]CD20-negative tumors[e1] have been described after [s2]Rituximab[e2] therapy.
	(9, 25)	angio-oedema	irbesartan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2204	A 51-year old physically fit woman experienced [s1]angio-oedema[e1] and hypotensive shock after [s2]irbesartan[e2] ingestion requiring noradrenaline infusion.
	(16, 25)	hypotensive shock	irbesartan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2205	A 51-year old physically fit woman experienced angio-oedema and [s1]hypotensive shock[e1] after [s2]irbesartan[e2] ingestion requiring noradrenaline infusion.
	(14, 23)	angio-oedema	irbesartan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2206	To our knowledge, our report is one of the first on shock and [s1]angio-oedema[e1] from [s2]irbesartan[e2] 
	(12, 23)	shock	irbesartan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2207	To our knowledge, our report is one of the first on [s1]shock[e1] and angio-oedema from [s2]irbesartan[e2] 
	(7, 29)	congestive heart failure	desferrioxamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2208	She died within six weeks of developing [s1]congestive heart failure[e1] coupled with liver failure due to haemosiderosis despite regular use of [s2]desferrioxamine[e2] 
	(18, 29)	haemosiderosis	desferrioxamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2209	She died within six weeks of developing congestive heart failure coupled with liver failure due to [s1]haemosiderosis[e1] despite regular use of [s2]desferrioxamine[e2] 
	(14, 29)	liver failure	desferrioxamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2210	She died within six weeks of developing congestive heart failure coupled with [s1]liver failure[e1] due to haemosiderosis despite regular use of [s2]desferrioxamine[e2] 
	(0, 16)	Transfusion haemosiderosis	desferrioxamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2211	 [s1]Transfusion haemosiderosis[e1] inspite of regular use of [s2]desferrioxamine[e2]  case report.
	(11, 21)	triamcinolone	cataract	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2212	One of the side-effects of intravitreal [s1]triamcinolone[e1] is the development of [s2]cataract[e2]  and it is known that cataract extraction can exacerbate macular degeneration.
	(7, 18)	cataract	triamcinolone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2213	Severe loss of vision after removal of [s1]cataract[e1] caused by intravitreal [s2]triamcinolone[e2] in combination with photodynamic therapy for exudative age-related macular degeneration.
	(0, 18)	Severe loss of vision	triamcinolone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2214	 [s1]Severe loss of vision[e1] after removal of cataract caused by intravitreal [s2]triamcinolone[e2] in combination with photodynamic therapy for exudative age-related macular degeneration.
	(0, 14)	Rhabdomyolysis	ritodrine hydrochloride	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2215	 [s1]Rhabdomyolysis[e1] caused by tocolysis with oral [s2]ritodrine hydrochloride[e2] in a pregnant patient with myotonic dystrophy.
	(0, 20)	Rhabdomyolysis	ritodrine hydrochloride	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2216	 [s1]Rhabdomyolysis[e1] has been recognized as a complication of tocolytic therapy with [s2]ritodrine hydrochloride[e2] 
	(7, 19)	ritodrine-hydrochloride	rhabdomyolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2217	We report here a rare case of [s1]ritodrine-hydrochloride[e1] induced [s2]rhabdomyolysis[e2] in a pregnant patient with myotonic dystrophy.
	(0, 16)	Acute myocardial ischemia	epinephrine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2218	 [s1]Acute myocardial ischemia[e1] following accidental intravenous administration of [s2]epinephrine[e2] in high concentration.
	(6, 17)	epinephrine	lethal complications	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2219	Inadvertent and accidental [s1]epinephrine[e1] overdose might result in potentially [s2]lethal complications[e2] 
	(6, 15)	epinephrine	acute myocardial ischemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2220	We present a case of acute [s1]epinephrine[e1] toxicity resulting in [s2]acute myocardial ischemia[e2] in a young boy with combined variable immunodeficiency syndrome who developed severe allergic reaction to intravenous immunoglobulin, and was subsequently given epinephrine by mistake intravenously rather than subcutaneously.
	(6, 37)	epinephrine	severe allergic reaction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2221	We present a case of acute [s1]epinephrine[e1] toxicity resulting in acute myocardial ischemia in a young boy with combined variable immunodeficiency syndrome who developed [s2]severe allergic reaction[e2] to intravenous immunoglobulin, and was subsequently given epinephrine by mistake intravenously rather than subcutaneously.
	(6, 37)	epinephrine	severe allergic reaction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2222	We present a case of acute [s1]epinephrine[e1] toxicity resulting in acute myocardial ischemia in a young boy with combined variable immunodeficiency syndrome who developed [s2]severe allergic reaction[e2] to intravenous immunoglobulin, and was subsequently given epinephrine by mistake intravenously rather than subcutaneously.
	(12, 22)	levodopa	restless legs syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2223	Polysomnographic and pharmacokinetic findings in [s1]levodopa[e1] induced augmentation of [s2]restless legs syndrome[e2] 
	(4, 14)	augmentation	levodopa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2224	Symptoms and signs of [s1]augmentation[e1] were related to low plasma [s2]levodopa[e2] levels, abating 75 minutes after oral levodopa administration and reappearing after 3 hours, closely mirroring the rapid rise and fall of plasma levodopa concentration.
	(4, 14)	augmentation	levodopa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2225	Symptoms and signs of [s1]augmentation[e1] were related to low plasma [s2]levodopa[e2] levels, abating 75 minutes after oral levodopa administration and reappearing after 3 hours, closely mirroring the rapid rise and fall of plasma levodopa concentration.
	(17, 35)	levodopa	anarchic discharges of motor unit potentials	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2226	Videopolysomnographic and pharmacokinetic studies with monitoring of plasma [s1]levodopa[e1] levels demonstrated marked motor hyperactivity during augmentation, with [s2]anarchic discharges of motor unit potentials[e2]  tonic grouped discharges and flexor spasms, associated with painful dysesthesia.
	(17, 51)	levodopa	flexor spasms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2227	Videopolysomnographic and pharmacokinetic studies with monitoring of plasma [s1]levodopa[e1] levels demonstrated marked motor hyperactivity during augmentation, with anarchic discharges of motor unit potentials, tonic grouped discharges and [s2]flexor spasms[e2]  associated with painful dysesthesia.
	(17, 24)	levodopa	marked motor hyperactivity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2228	Videopolysomnographic and pharmacokinetic studies with monitoring of plasma [s1]levodopa[e1] levels demonstrated [s2]marked motor hyperactivity[e2] during augmentation, with anarchic discharges of motor unit potentials, tonic grouped discharges and flexor spasms, associated with painful dysesthesia.
	(17, 58)	levodopa	painful dysesthesia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2229	Videopolysomnographic and pharmacokinetic studies with monitoring of plasma [s1]levodopa[e1] levels demonstrated marked motor hyperactivity during augmentation, with anarchic discharges of motor unit potentials, tonic grouped discharges and flexor spasms, associated with [s2]painful dysesthesia[e2] 
	(17, 46)	levodopa	tonic grouped discharges	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2230	Videopolysomnographic and pharmacokinetic studies with monitoring of plasma [s1]levodopa[e1] levels demonstrated marked motor hyperactivity during augmentation, with anarchic discharges of motor unit potentials, [s2]tonic grouped discharges[e2] and flexor spasms, associated with painful dysesthesia.
	(12, 21)	augmentation	levodopa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2231	We describe a patient with idiopathic RLS who developed [s1]augmentation[e1] after 8 months of [s2]levodopa[e2] treatment.
	(5, 13)	infliximab	infection	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2232	The major side effect of [s1]infliximab[e1] is [s2]infection[e2] 
	(7, 15)	infliximab	membranous nephropathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2233	This report describes a probable case of [s1]infliximab[e1] induced [s2]membranous nephropathy[e2] 
	(0, 6)	Linezolid	dyserythropoiesis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2234	 [s1]Linezolid[e1] induced [s2]dyserythropoiesis[e2]  chloramphenicol toxicity revisited.
	(6, 22)	dyserythropoietic anaemia	linezolid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2235	We report here two cases of [s1]dyserythropoietic anaemia[e1] associated with long-term [s2]linezolid[e2] use that share striking similarities to chloramphenicol-associated myelotoxicity.
	(29, 38)	chloramphenicol	myelotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2236	We report here two cases of dyserythropoietic anaemia associated with long-term linezolid use that share striking similarities to [s1]chloramphenicol[e1] associated [s2]myelotoxicity[e2] 
	(4, 14)	fluoxetine	eye movements in nonrapid eye movement (NREM) sleep	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2237	A selective association between [s1]fluoxetine[e1] and extensive, prominent [s2]eye movements in nonrapid eye movement (NREM) sleep[e2] was detected, utilizing Fisher's exact one-tailed statistic (p less than 0.00001 for each comparison).
	(21, 28)	RBD	fluoxetine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2238	In addition, a 31-year-old man with obsessive-compulsive disorder developed [s1]RBD[e1] soon after starting [s2]fluoxetine[e2] therapy, which persisted at PSG study 19 months after fluoxetine discontinuation.
	(21, 28)	RBD	fluoxetine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2239	In addition, a 31-year-old man with obsessive-compulsive disorder developed [s1]RBD[e1] soon after starting [s2]fluoxetine[e2] therapy, which persisted at PSG study 19 months after fluoxetine discontinuation.
	(0, 17)	Prominent eye movements during NREM sleep	fluoxetine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2240	 [s1]Prominent eye movements during NREM sleep[e1] and REM sleep behavior disorder associated with [s2]fluoxetine[e2] treatment of depression and obsessive-compulsive disorder.
	(8, 17)	REM sleep behavior disorder	fluoxetine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2241	Prominent eye movements during NREM sleep and [s1]REM sleep behavior disorder[e1] associated with [s2]fluoxetine[e2] treatment of depression and obsessive-compulsive disorder.
	(7, 23)	increase in the QT interval	dofetilide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2242	Because of serious side effects of an [s1]increase in the QT interval[e1] causing torsades de pointes, [s2]dofetilide[e2] must be initiated with close monitoring of the QT interval in an inpatient setting.
	(14, 22)	torsades de pointes	dofetilide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2243	Because of serious side effects of an increase in the QT interval causing [s1]torsades de pointes[e1]  [s2]dofetilide[e2] must be initiated with close monitoring of the QT interval in an inpatient setting.
	(15, 26)	acute ischemia	dofetilide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2244	Marked QT prolongation and torsades de pointes secondary to [s1]acute ischemia[e1] in an elderly man taking [s2]dofetilide[e2] for atrial fibrillation: a cautionary tale.
	(0, 26)	Marked QT prolongation	dofetilide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2245	 [s1]Marked QT prolongation[e1] and torsades de pointes secondary to acute ischemia in an elderly man taking [s2]dofetilide[e2] for atrial fibrillation: a cautionary tale.
	(7, 26)	torsades de pointes	dofetilide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2246	Marked QT prolongation and [s1]torsades de pointes[e1] secondary to acute ischemia in an elderly man taking [s2]dofetilide[e2] for atrial fibrillation: a cautionary tale.
	(25, 42)	acute myocardial ischemia	dofetilide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2247	We report marked QT prolongation and torsades de pointes in a setting of flash pulmonary edema resulting from [s1]acute myocardial ischemia[e1] in a patient who was being treated with [s2]dofetilide[e2] for atrial fibrillation.
	(19, 42)	flash pulmonary edema	dofetilide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2248	We report marked QT prolongation and torsades de pointes in a setting of [s1]flash pulmonary edema[e1] resulting from acute myocardial ischemia in a patient who was being treated with [s2]dofetilide[e2] for atrial fibrillation.
	(3, 42)	QT prolongation	dofetilide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2249	We report marked [s1]QT prolongation[e1] and torsades de pointes in a setting of flash pulmonary edema resulting from acute myocardial ischemia in a patient who was being treated with [s2]dofetilide[e2] for atrial fibrillation.
	(9, 42)	torsades de pointes	dofetilide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2250	We report marked QT prolongation and [s1]torsades de pointes[e1] in a setting of flash pulmonary edema resulting from acute myocardial ischemia in a patient who was being treated with [s2]dofetilide[e2] for atrial fibrillation.
	(1, 14)	positive U waves	phenylephrine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2251	Prominent [s1]positive U waves[e1] appearing with high-dose intravenous [s2]phenylephrine[e2] 
	(6, 16)	phenylephrine	positive U waves	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2252	While on a maximal dose of [s1]phenylephrine[e1] she developed prominent [s2]positive U waves[e2]  which disappeared with the cessation of the drug.
	(0, 13)	Hepatoxicity	SRL	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2253	 [s1]Hepatoxicity[e1] is a rare complication of [s2]SRL[e2] therapy and may be connected with some diagnostic and/or therapeutic problems.
	(0, 6)	Sirolimus	hepatotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2254	 [s1]Sirolimus[e1] associated [s2]hepatotoxicity[e2] in the kidney graft recipient.
	(8, 17)	hepatotoxicity	sirolimus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2255	The aim of our paper was to describe [s1]hepatotoxicity[e1] of [s2]sirolimus[e2] (SRL) in a kidney graft recipient.
	(22, 54)	nephrotic syndrome	interferon beta 1a	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2256	CASE REPORT: We present a case of a 28-yr-old male who developed a severe case of [s1]nephrotic syndrome[e1] while being treated for relapsing/remitting Multiple Sclerosis (RRMS) with weekly injections of [s2]interferon beta 1a[e2] 
	(0, 16)	Nephrotic syndrome	interferon beta 1a	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2257	 [s1]Nephrotic syndrome[e1] in a multiple sclerosis patient treated with [s2]interferon beta 1a[e2] 
	(4, 14)	nephrosis	interferon	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2258	SUBSEQUENT COURSE: The [s1]nephrosis[e1] resolved almost completely once the [s2]interferon[e2] was stopped and after immunosuppressive treatment.
	(25, 30)	renal toxicity	interferons	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2259	This latest (third) report suggests that the safety profile should be reexamined and at least raises the question of potential [s1]renal toxicity[e1] of [s2]interferons[e2] in MS.
	(0, 7)	Capecitabine	multifocal leukoencephalopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2260	 [s1]Capecitabine[e1] induced [s2]multifocal leukoencephalopathy[e2]  a report of five cases.
	(7, 14)	capecitabine	multifocal leukoencephalopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2261	The authors report five additional cases of [s1]capecitabine[e1] induced [s2]multifocal leukoencephalopathy[e2] 
	(16, 26)	UI	venlafaxine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2262	A 56-year-old white woman with a diagnosis of reactive depression developed severe [s1]UI[e1] after a 30 days' treatment with [s2]venlafaxine[e2] 75 mg/day.
	(13, 24)	UI	venlafaxine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2263	The authors report a case of urinary incontinence  [s1]UI[e1]  that occurred in a woman after administration of [s2]venlafaxine[e2] 
	(6, 26)	urinary incontinence	venlafaxine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2264	The authors report a case of [s1]urinary incontinence[e1] (UI) that occurred in a woman after administration of [s2]venlafaxine[e2] 
	(0, 8)	Venlafaxine	urinary incontinence	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2265	 [s1]Venlafaxine[e1] induced [s2]urinary incontinence[e2] resolved after switching to sertraline.
	(2, 22)	hypothyroidism	alpha interferon	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2266	Diagnosis of [s1]hypothyroidism[e1] during treatment can be difficult because of the common side effects of [s2]alpha interferon[e2] 
	(0, 11)	Sustained hypothyroidism	recombinant alpha interferon	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2267	 [s1]Sustained hypothyroidism[e1] induced by [s2]recombinant alpha interferon[e2] in patients with chronic hepatitis C.
	(0, 15)	Thyroid dysfunction	recombinant alpha interferon	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2268	 [s1]Thyroid dysfunction[e1] has been reported in patients with malignant disease treated with [s2]recombinant alpha interferon[e2] 
	(3, 19)	hypothyroidism	recombinant alpha interferon	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2269	Two cases of [s1]hypothyroidism[e1] in patients with chronic hepatitis C treated with [s2]recombinant alpha interferon[e2] are reported.
	(0, 8)	Atrial fibrillation	vardenafil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2270	 [s1]Atrial fibrillation[e1] after [s2]vardenafil[e2] therapy.
	(11, 35)	symptomatic paroxysmal atrial fibrillation	vardenafil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2271	We report a case admitted with a first-detected, [s1]symptomatic paroxysmal atrial fibrillation[e1] in a healthy patient after self-medication with [s2]vardenafil[e2] 
	(7, 26)	Mycobacterium abscessus	infliximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2272	We describe a case of infection with [s1]Mycobacterium abscessus[e1] in a 67-year-old woman receiving [s2]infliximab[e2] as a component of her therapy for RA.
	(2, 12)	Interferon alpha-2b	cardiomyopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2273	DIAGNOSIS: [s1]Interferon alpha-2b[e1] induced [s2]cardiomyopathy[e2] 
	(0, 13)	Reversible cardiomyopathy	interferon alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2274	 [s1]Reversible cardiomyopathy[e1] caused by administration of [s2]interferon alpha[e2] 
	(3, 32)	senna	liver injury	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2275	In this case [s1]senna[e1] was likely the cause of a subacute cholestatic hepatitis exemplifying again the potential role of herbal related [s2]liver injury[e2] 
	(3, 13)	senna	subacute cholestatic hepatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2276	In this case [s1]senna[e1] was likely the cause of a [s2]subacute cholestatic hepatitis[e2] exemplifying again the potential role of herbal related liver injury.
	(0, 16)	Subacute cholestatic hepatitis	senna	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2277	 [s1]Subacute cholestatic hepatitis[e1] likely related to the use of [s2]senna[e2] for chronic constipation.
	(5, 10)	senna	cholestatic hepatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2278	We report a case of [s1]senna[e1] induced [s2]cholestatic hepatitis[e2] which was not diagnosed at presentation.
	(11, 15)	insulin	lipohypertrophy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2279	Based on the history and clinical features, a diagnosis of [s1]insulin[e1] induced [s2]lipohypertrophy[e2] was made.
	(0, 4)	Insulin	lipohypertrophy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2280	 [s1]Insulin[e1] induced [s2]lipohypertrophy[e2]  report of a case with histopathology.
	(8, 25)	insulin	lipohypertrophy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2281	Thus, the possible in vivo effects of [s1]insulin[e1] on adipocytes were clearly observed in this case of insulin-induced [s2]lipohypertrophy[e2] 
	(10, 14)	insulin	lipohypertrophy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2282	To our knowledge, this is the first report of [s1]insulin[e1] induced [s2]lipohypertrophy[e2] with detailed histological examinations.
	(8, 35)	diabetes mellitus	azathioprine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2283	A 7-year-old girl developed [s1]diabetes mellitus[e1] and exocrine pancreatic insufficiency after 3.5 years of almost continuous treatment with [s2]azathioprine[e2] and/or prednisone for idiopathic auto-immune haemolytic anaemia.
	(8, 42)	diabetes mellitus	prednisone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2284	A 7-year-old girl developed [s1]diabetes mellitus[e1] and exocrine pancreatic insufficiency after 3.5 years of almost continuous treatment with azathioprine and/or [s2]prednisone[e2] for idiopathic auto-immune haemolytic anaemia.
	(13, 35)	exocrine pancreatic insufficiency	azathioprine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2285	A 7-year-old girl developed diabetes mellitus and [s1]exocrine pancreatic insufficiency[e1] after 3.5 years of almost continuous treatment with [s2]azathioprine[e2] and/or prednisone for idiopathic auto-immune haemolytic anaemia.
	(13, 42)	exocrine pancreatic insufficiency	prednisone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2286	A 7-year-old girl developed diabetes mellitus and [s1]exocrine pancreatic insufficiency[e1] after 3.5 years of almost continuous treatment with azathioprine and/or [s2]prednisone[e2] for idiopathic auto-immune haemolytic anaemia.
	(8, 19)	JHR	penicillin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2287	An objective causality assessment suggests that the [s1]JHR[e1] in our patient was probably related to [s2]penicillin[e2] 
	(35, 47)	JHR	penicillin G	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2288	CASE SUMMARY: A 45-year-old HIV-positive man (CD4+ count 450 cells/mm(3) and history of AIDS-defining illness) presented with [s1]JHR[e1] after an initial intravenous dose of [s2]penicillin G[e2] for presumed neurosyphilis.
	(0, 6)	Penicillin	Jarisch-Herxheimer reaction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2289	 [s1]Penicillin[e1] induced [s2]Jarisch-Herxheimer reaction[e2] 
	(10, 25)	chills	penicillin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2290	The patient described feeling cold with worsening headache and [s1]chills[e1] approximately one hour after infusion of the first dose of [s2]penicillin[e2] 
	(3, 25)	feeling cold	penicillin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2291	The patient described [s1]feeling cold[e1] with worsening headache and chills approximately one hour after infusion of the first dose of [s2]penicillin[e2] 
	(6, 25)	worsening headache	penicillin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2292	The patient described feeling cold with [s1]worsening headache[e1] and chills approximately one hour after infusion of the first dose of [s2]penicillin[e2] 
	(0, 7)	Acute respiratory distress syndrome	rituximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2293	 [s1]Acute respiratory distress syndrome[e1] after [s2]rituximab[e2] infusion.
	(0, 25)	ARDS	gemtuzumab ozogamicin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2294	 [s1]ARDS[e1] has been associated with the administration of other monoclonal antibodies, such as infliximab, [s2]gemtuzumab ozogamicin[e2]  and OKT3 and is believed to be directly mediated by release of proinflammatory cytokines.
	(0, 19)	ARDS	infliximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2295	 [s1]ARDS[e1] has been associated with the administration of other monoclonal antibodies, such as [s2]infliximab[e2]  gemtuzumab ozogamicin, and OKT3 and is believed to be directly mediated by release of proinflammatory cytokines.
	(0, 36)	ARDS	OKT3	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2296	 [s1]ARDS[e1] has been associated with the administration of other monoclonal antibodies, such as infliximab, gemtuzumab ozogamicin, and [s2]OKT3[e2] and is believed to be directly mediated by release of proinflammatory cytokines.
	(0, 8)	ARDS	rituximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2297	 [s1]ARDS[e1] is rarely associated with [s2]rituximab[e2] infusion for lympho-proliferative disorders, but it should be considered by those administering rituximab, especially when a patient develops severe pulmonary symptoms soon after infusion.
	(0, 8)	ARDS	rituximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2298	 [s1]ARDS[e1] is rarely associated with [s2]rituximab[e2] infusion for lympho-proliferative disorders, but it should be considered by those administering rituximab, especially when a patient develops severe pulmonary symptoms soon after infusion.
	(6, 45)	rituximab	severe pulmonary symptoms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2299	ARDS is rarely associated with [s1]rituximab[e1] infusion for lympho-proliferative disorders, but it should be considered by those administering rituximab, especially when a patient develops [s2]severe pulmonary symptoms[e2] soon after infusion.
	(0, 22)	Dyspnea	rituximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2300	 [s1]Dyspnea[e1]  hypoxemia, and pleuritic chest pain occurred within 24 hours of [s2]rituximab[e2] administration, and there was no other apparent explanation.
	(5, 22)	hypoxemia	rituximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2301	Dyspnea, [s1]hypoxemia[e1]  and pleuritic chest pain occurred within 24 hours of [s2]rituximab[e2] administration, and there was no other apparent explanation.
	(11, 23)	pleuritic chest pain	rituximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2302	Dyspnea, hypoxemia, and [s1]pleuritic chest pain[e1] occurred within 24 hours of [s2]rituximab[e2] administration, and there was no other apparent explanation.
	(0, 19)	Progressive hypoxemia	rituximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2303	 [s1]Progressive hypoxemia[e1] mandated endotracheal intubation 1 week after [s2]rituximab[e2] administration and led to death 4 weeks after admission.
	(33, 49)	acute respiratory distress syndrome	rituximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2304	We report the case of a 43-year-old man with ITP refractory to steroids and intravenous immunoglobulin who developed [s1]acute respiratory distress syndrome[e1] (ARDS) after a single infusion of [s2]rituximab[e2] 
	(37, 47)	ARDS	rituximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2305	We report the case of a 43-year-old man with ITP refractory to steroids and intravenous immunoglobulin who developed acute respiratory distress syndrome  [s1]ARDS[e1]  after a single infusion of [s2]rituximab[e2] 
	(11, 17)	renal impairment	bisphosphonate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2306	Symptomatic hypocalcaemia and [s1]renal impairment[e1] associated with [s2]bisphosphonate[e2] treatment in patients with multiple myeloma.
	(0, 17)	Symptomatic hypocalcaemia	bisphosphonate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2307	 [s1]Symptomatic hypocalcaemia[e1] and renal impairment associated with [s2]bisphosphonate[e2] treatment in patients with multiple myeloma.
	(5, 20)	severe hypocalcaemia	bisphosphonate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2308	We report three cases of [s1]severe hypocalcaemia[e1] associated with i.v. [s2]bisphosphonate[e2] treatment in patients with multiple myeloma.
	(0, 7)	Gemcitabine	radiation recall	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2309	 [s1]Gemcitabine[e1] related [s2]radiation recall[e2] in a patient with pancreatic cancer.
	(0, 17)	Gemcitabine	radiation recall	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2310	 [s1]Gemcitabine[e1] should be added to the list of drugs known to cause [s2]radiation recall[e2] 
	(0, 5)	Radiation recall	gemcitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2311	 [s1]Radiation recall[e1] from [s2]gemcitabine[e2] is rare, but can potentially arise in any site that has been previously irradiated.
	(0, 6)	Radiation recall	gemcitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2312	 [s1]Radiation recall[e1] related to [s2]gemcitabine[e2] has been reported in lung and breast cancer.
	(14, 28)	gastrointestinal bleeding	gemcitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2313	We report a patient with inoperable pancreatic cancer who developed [s1]gastrointestinal bleeding[e1] secondary to radiation-recall related to [s2]gemcitabine[e2] and review literature.
	(21, 28)	radiation-recall	gemcitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2314	We report a patient with inoperable pancreatic cancer who developed gastrointestinal bleeding secondary to [s1]radiation-recall[e1] related to [s2]gemcitabine[e2] and review literature.
	(6, 13)	gemcitabine	radiation recall	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2315	We suggest discontinuing [s1]gemcitabine[e1] if [s2]radiation recall[e2] is observed.
	(16, 32)	acute renal failure	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2316	A 17-year-old boy with acute lymphoblastic leukemia developed [s1]acute renal failure[e1] within 48 h of an intravenous high-dose [s2]methotrexate[e2] (5 g/m2) infusion.
	(3, 11)	methotrexate	acute renal failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2317	High-dose [s1]methotrexate[e1] associated [s2]acute renal failure[e2] may be an avoidable complication.
	(0, 8)	Methotrexate	nephropathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2318	 [s1]Methotrexate[e1] associated [s2]nephropathy[e2] is a rare complication in pediatric oncology, and a review of the literature suggests that exposure to nephrotoxic agents may be a significant but perhaps underrecognized risk factor for its development.
	(1, 22)	prolapse of the urethral mucosa	calcium hydroxylapatite	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2319	Massive [s1]prolapse of the urethral mucosa[e1] following periurethral injection of [s2]calcium hydroxylapatite[e2] for stress urinary incontinence.
	(8, 34)	granulomatous reaction	calcium hydroxylapatite	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2320	The authors present a case report of a [s1]granulomatous reaction[e1] leading to urethral prolapse, 3 months after the transurethral injection of [s2]calcium hydroxylapatite[e2] 
	(15, 33)	urethral prolapse	calcium hydroxylapatite	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2321	The authors present a case report of a granulomatous reaction leading to [s1]urethral prolapse[e1]  3 months after the transurethral injection of [s2]calcium hydroxylapatite[e2] 
	(8, 17)	granulomatous reaction	calcium hydroxylapatite	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2322	To our knowledge, this is the first [s1]granulomatous reaction[e1] described after [s2]calcium hydroxylapatite[e2] injection.
	(38, 56)	pancreatitis	furosemide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2323	"CASE SUMMARY: A 57-year-old female with cardiomyopathy and ""sulfa"" (trimethoprim/sulfamethoxazole) allergy documented as [s1]pancreatitis[e1] presented with symptoms consistent with pancreatitis after use of [s2]furosemide[e2] "
	(12, 19)	pancreatitis	furosemide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2324	In addition, while cases of loop diuretic-induced [s1]pancreatitis[e1]  including [s2]furosemide[e2]  have been published, the allergic manifestations with both sulfonamide antibiotics and non-antibiotics in our patient suggest possible cross-reactivity between these 2 drug classes.
	(0, 20)	Torsemide	pancreatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2325	 [s1]Torsemide[e1] appears to also be a part of a long list of agents that can cause [s2]pancreatitis[e2] 
	(0, 14)	Heparin	massive thrombosis of the inferior vena cava	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2326	 [s1]Heparin[e1] induced thrombocytopenia complicated with [s2]massive thrombosis of the inferior vena cava[e2] after filter placement.
	(0, 6)	Heparin	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2327	 [s1]Heparin[e1] induced [s2]thrombocytopenia[e2] complicated with massive thrombosis of the inferior vena cava after filter placement.
	(20, 30)	heparin	IVC thrombosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2328	On the 3rd day, an inferior vena cava (IVC) filter was placed with a [s1]heparin[e1] flush, after which massive [s2]IVC thrombosis[e2] developed.
	(9, 29)	heparin	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2329	The patient was positive for antibody against complexes of [s1]heparin[e1] and platelet factor 4, and was diagnosed as heparin-induced [s2]thrombocytopenia[e2] with thrombosis syndrome (HITTS).
	(9, 36)	heparin	thrombosis syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2330	The patient was positive for antibody against complexes of [s1]heparin[e1] and platelet factor 4, and was diagnosed as heparin-induced thrombocytopenia with [s2]thrombosis syndrome[e2] (HITTS).
	(1, 9)	thrombosis	heparin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2331	When [s1]thrombosis[e1] develops during [s2]heparin[e2] treatment, it is important to suspect HITTs and to assay for the associated antibodies, regardless of the actual platelet count.
	(1, 15)	gastric-outlet obstruction	prostaglandin E1	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2332	After [s1]gastric-outlet obstruction[e1] was recognized in several infants who received [s2]prostaglandin E1[e2]  we studied the association between the drug and this complication.
	(5, 26)	prostaglandin E1	antral hyperplasia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2333	CONCLUSIONS: The administration of [s1]prostaglandin E1[e1] to neonates can cause gastric-outlet obstruction due to [s2]antral hyperplasia[e2] 
	(5, 19)	prostaglandin E1	gastric-outlet obstruction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2334	CONCLUSIONS: The administration of [s1]prostaglandin E1[e1] to neonates can cause [s2]gastric-outlet obstruction[e2] due to antral hyperplasia.
	(18, 39)	cisplatin	RPLS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2335	Moreover, treatment with immunosuppressive drugs such as cyclosporine, [s1]cisplatin[e1]  tacrolimus, and interferon-alpha can induce a condition resembling [s2]RPLS[e2] 
	(12, 39)	cyclosporine	RPLS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2336	Moreover, treatment with immunosuppressive drugs such as [s1]cyclosporine[e1]  cisplatin, tacrolimus, and interferon-alpha can induce a condition resembling [s2]RPLS[e2] 
	(28, 40)	interferon-alpha	RPLS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2337	Moreover, treatment with immunosuppressive drugs such as cyclosporine, cisplatin, tacrolimus, and [s1]interferon-alpha[e1] can induce a condition resembling [s2]RPLS[e2] 
	(22, 39)	tacrolimus	RPLS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2338	Moreover, treatment with immunosuppressive drugs such as cyclosporine, cisplatin, [s1]tacrolimus[e1]  and interferon-alpha can induce a condition resembling [s2]RPLS[e2] 
	(0, 32)	Reversible posterior leukoencephalopathy syndrome	cyclosporine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2339	 [s1]Reversible posterior leukoencephalopathy syndrome[e1] in systemic lupus erythematosus with thrombocytopenia treated with [s2]cyclosporine[e2] 
	(27, 34)	headache	cyclosporine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2340	We report a case of a young woman with SLE and thrombocytopenia, who developed severe perspiration, [s1]headache[e1]  and seizure after receiving [s2]cyclosporine[e2] 
	(30, 35)	seizure	cyclosporine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2341	We report a case of a young woman with SLE and thrombocytopenia, who developed severe perspiration, headache, and [s1]seizure[e1] after receiving [s2]cyclosporine[e2] 
	(21, 34)	severe perspiration	cyclosporine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2342	We report a case of a young woman with SLE and thrombocytopenia, who developed [s1]severe perspiration[e1]  headache, and seizure after receiving [s2]cyclosporine[e2] 
	(11, 20)	mania	lopinavir	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2343	OBJECTIVE: To describe a case of exacerbated [s1]mania[e1] potentially related to an interaction between [s2]lopinavir[e2] ritonavir and valproic acid (VPA) and propose a mechanism of action for this interaction.
	(11, 23)	mania	ritonavir	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2344	OBJECTIVE: To describe a case of exacerbated [s1]mania[e1] potentially related to an interaction between lopinavir [s2]ritonavir[e2] and valproic acid (VPA) and propose a mechanism of action for this interaction.
	(11, 29)	mania	valproic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2345	OBJECTIVE: To describe a case of exacerbated [s1]mania[e1] potentially related to an interaction between lopinavir/ritonavir and [s2]valproic acid[e2] (VPA) and propose a mechanism of action for this interaction.
	(11, 33)	mania	VPA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2346	OBJECTIVE: To describe a case of exacerbated [s1]mania[e1] potentially related to an interaction between lopinavir/ritonavir and valproic acid  [s2]VPA[e2]  and propose a mechanism of action for this interaction.
	(3, 21)	lopinavir	bipolar disorder	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2347	Possible interaction between [s1]lopinavir[e1] ritonavir and valproic Acid exacerbates [s2]bipolar disorder[e2] 
	(6, 21)	ritonavir	bipolar disorder	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2348	Possible interaction between lopinavir [s1]ritonavir[e1] and valproic Acid exacerbates [s2]bipolar disorder[e2] 
	(12, 22)	valproic Acid	bipolar disorder	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2349	Possible interaction between lopinavir/ritonavir and [s1]valproic Acid[e1] exacerbates [s2]bipolar disorder[e2] 
	(7, 16)	triamcinolone acetonide	cataract	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2350	After intravitreal injection of [s1]triamcinolone acetonide[e1]  [s2]cataract[e2] may rapidly develop in eyes that have been intensively treated, topically and systemically, by corticosteroids for several years.
	(0, 15)	Arthritis	interferon-beta	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2351	 [s1]Arthritis[e1] and bursitis in multiple sclerosis patients treated with [s2]interferon-beta[e2] 
	(2, 15)	bursitis	interferon-beta	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2352	Arthritis and [s1]bursitis[e1] in multiple sclerosis patients treated with [s2]interferon-beta[e2] 
	(11, 19)	inflammatory arthritis	IFN-beta	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2353	Our literature review revealed an additional six cases of onset of [s1]inflammatory arthritis[e1] in MS patients receiving [s2]IFN-beta[e2] 
	(5, 16)	monoarthritis	IFN-beta	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2354	The first patient developed a [s1]monoarthritis[e1] 2 weeks after initiation of [s2]IFN-beta[e2]  which persisted during the 14 months of therapy and resolved with discontinuation of the medication.
	(2, 16)	IFN-beta	autoimmune disorders	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2355	Therapy with [s1]IFN-beta[e1] has rarely been associated with the development of [s2]autoimmune disorders[e2] 
	(5, 29)	autoimmune thyroid disease	IFN-beta	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2356	The second patient developed both [s1]autoimmune thyroid disease[e1] and a refractory pre-patellar bursitis after 50 months of [s2]IFN-beta[e2] therapy.
	(13, 29)	refractory pre-patellar bursitis	IFN-beta	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2357	The second patient developed both autoimmune thyroid disease and a [s1]refractory pre-patellar bursitis[e1] after 50 months of [s2]IFN-beta[e2] therapy.
	(28, 40)	inflammatory musculoskeletal manifestations	IFN-beta	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2358	We present the cases of two female patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) who developed [s1]inflammatory musculoskeletal manifestations[e1]  following [s2]IFN-beta[e2] therapy.
	(0, 15)	Trimethoprim-sulfamethoxazole	aseptic meningitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2359	 [s1]Trimethoprim-sulfamethoxazole[e1] induced [s2]aseptic meningitis[e2] 
	(29, 51)	meningitis	SMX	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2360	We present a 46-year-old African-American man with AIDS who was admitted on two different occasions within three weeks for signs and symptoms of [s1]meningitis[e1] after using trimethoprim/sulfamethoxazole (TMP [s2]SMX[e2] .
	(29, 40)	meningitis	sulfamethoxazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2361	We present a 46-year-old African-American man with AIDS who was admitted on two different occasions within three weeks for signs and symptoms of [s1]meningitis[e1] after using trimethoprim [s2]sulfamethoxazole[e2] (TMP/SMX).
	(29, 48)	meningitis	TMP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2362	We present a 46-year-old African-American man with AIDS who was admitted on two different occasions within three weeks for signs and symptoms of [s1]meningitis[e1] after using trimethoprim/sulfamethoxazole  [s2]TMP[e2] SMX).
	(29, 36)	meningitis	trimethoprim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2363	We present a 46-year-old African-American man with AIDS who was admitted on two different occasions within three weeks for signs and symptoms of [s1]meningitis[e1] after using [s2]trimethoprim[e2] sulfamethoxazole (TMP/SMX).
	(18, 23)	SMX	aseptic meningitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2364	We reviewed the literature in an attempt to characterize the pattern and predictors of TMP [s1]SMX[e1] induced [s2]aseptic meningitis[e2] 
	(16, 24)	TMP	aseptic meningitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2365	We reviewed the literature in an attempt to characterize the pattern and predictors of [s1]TMP[e1] SMX-induced [s2]aseptic meningitis[e2] 
	(20, 29)	corticosteroid	disseminated nocardiosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2366	In this paper, we report a patient with primary anti-phospholipid syndrome treated by [s1]corticosteroid[e1]  who developed [s2]disseminated nocardiosis[e2] 
	(0, 8)	Chloroquine	bilateral ptosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2367	 [s1]Chloroquine[e1] induced [s2]bilateral ptosis[e2] 
	(0, 8)	Ptosis	chloroquine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2368	 [s1]Ptosis[e1] occurring 24 h after [s2]chloroquine[e2] therapy, with full recovery 48 h after cessation of chloroquine, has not been described previously.
	(0, 8)	Ptosis	chloroquine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2369	 [s1]Ptosis[e1] occurring 24 h after [s2]chloroquine[e2] therapy, with full recovery 48 h after cessation of chloroquine, has not been described previously.
	(6, 13)	bilateral ptosis	chloroquine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2370	This report describes a case of [s1]bilateral ptosis[e1] induced by [s2]chloroquine[e2] 
	(27, 38)	central neurological syndrome	MTX	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2371	DESIGN: We reviewed the medical records of four patients, who were seen by us between July 2000 and February 2004 for sudden onset of a [s1]central neurological syndrome[e1] within days of intrathecal [s2]MTX[e2] 
	(11, 19)	methotrexate	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2372	Diffusion-weighted MRI correlates of subacute [s1]methotrexate[e1] related [s2]neurotoxicity[e2] 
	(4, 22)	stroke-like leukoencephalopathy	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2373	OBJECTIVES: A delayed [s1]stroke-like leukoencephalopathy[e1] has been observed in patients receiving [s2]methotrexate[e2] (MTX) for childhood leukemia.
	(4, 27)	stroke-like leukoencephalopathy	MTX	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2374	OBJECTIVES: A delayed [s1]stroke-like leukoencephalopathy[e1] has been observed in patients receiving methotrexate  [s2]MTX[e2]  for childhood leukemia.
	(18, 32)	subacute neurotoxicity	MTX	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2375	Our objective is to present a retrospective analysis of the DWI findings in four patients who suffered [s1]subacute neurotoxicity[e1] after intrathecal [s2]MTX[e2] 
	(6, 12)	ARDS	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2376	This is a rare case of [s1]ARDS[e1] associated with [s2]lithium[e2] intoxication.
	(52, 65)	dyskinesias	L-dopa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2377	"CONCLUSION: The present findings suggest that: (i) amantadine probably exerts its anti-dyskinetic effect by acting on the ""indirect"" pathway; (ii) the pathophysiological mechanisms of subthalamotomy induced [s1]dyskinesias[e1] may differ from those involved in [s2]L-dopa[e2] induced dyskinesias; (iii) dyskinesias induced by STN surgery resolve spontaneously as compensatory mechanisms develop."
	(4, 10)	levodopa	dyskinesia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2378	Prior to surgery, [s1]levodopa[e1] induced [s2]dyskinesia[e2] had improved (< or = 50%) under treatment with amantadine (400 mg/day, po) in all three patients.
	(19, 26)	triazolam	eating disorder	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2379	A combination of behavioural and cognitive adverse effects is illustrated in this case report of a recurrent [s1]triazolam[e1] induced [s2]eating disorder[e2] 
	(0, 12)	Triazolam	amnesia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2380	 [s1]Triazolam[e1] induced nocturnal bingeing with [s2]amnesia[e2] 
	(0, 7)	Triazolam	nocturnal bingeing	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2381	 [s1]Triazolam[e1] induced [s2]nocturnal bingeing[e2] with amnesia.
	(13, 30)	sarcoidosis	interferon alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2382	Although interferon gamma has been implicated in the pathogenesis of [s1]sarcoidosis[e1]  only a few cases of sarcoidosis associated with [s2]interferon alpha[e2] therapy have been reported.
	(2, 9)	sarcoidosis	interferon alpha 2b	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2383	Development of [s1]sarcoidosis[e1] during [s2]interferon alpha 2b[e2] and ribavirin combination therapy for chronic hepatitis C--a case report and review of the literature.
	(2, 16)	sarcoidosis	ribavirin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2384	Development of [s1]sarcoidosis[e1] during interferon alpha 2b and [s2]ribavirin[e2] combination therapy for chronic hepatitis C--a case report and review of the literature.
	(14, 24)	sarcoidosis	interferon alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2385	We report a case with chronic hepatitis C (CHC) who developed [s1]sarcoidosis[e1] after the treatment by [s2]interferon alpha[e2] and ribavirin.
	(14, 29)	sarcoidosis	ribavirin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2386	We report a case with chronic hepatitis C (CHC) who developed [s1]sarcoidosis[e1] after the treatment by interferon alpha and [s2]ribavirin[e2] 
	(3, 17)	sarcoidosis	interferon alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2387	We suggest that [s1]sarcoidosis[e1] may develop in chronic hepatitis C patients during [s2]interferon alpha[e2] and/or ribavirin treatment, and diagnostic tests for this adverse effect should be performed during the follow-ups.
	(3, 24)	sarcoidosis	ribavirin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2388	We suggest that [s1]sarcoidosis[e1] may develop in chronic hepatitis C patients during interferon alpha and/or [s2]ribavirin[e2] treatment, and diagnostic tests for this adverse effect should be performed during the follow-ups.
	(0, 20)	Neutropenic colitis	irinotecan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2389	 [s1]Neutropenic colitis[e1] during standard dose combination chemotherapy with nedaplatin and [s2]irinotecan[e2] for testicular cancer.
	(0, 15)	Neutropenic colitis	nedaplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2390	 [s1]Neutropenic colitis[e1] during standard dose combination chemotherapy with [s2]nedaplatin[e2] and irinotecan for testicular cancer.
	(9, 36)	severe hypercalcemia	cinacalcet HCl	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2391	In this paper, we report a case of [s1]severe hypercalcemia[e1] of immobilization in a 40-year-old hemodialyzed woman treated by [s2]cinacalcet HCl[e2] for a severe HPTH-II (PTH>1,000 pg/mL).
	(7, 13)	sirolimus	interstitial pneumonitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2392	Here, we present a case of [s1]sirolimus[e1] associated [s2]interstitial pneumonitis[e2] in a cardiac transplant recipient that resolved completely with withdrawal of the drug and treatment with corticosteroids.
	(3, 9)	sirolimus	pneumonitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2393	Reversible [s1]sirolimus[e1] associated [s2]pneumonitis[e2] after heart transplantation.
	(3, 9)	sirolimus	pneumonitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2394	Two cases of [s1]sirolimus[e1] associated [s2]pneumonitis[e2] have been reported after cardiac transplantation.
	(16, 22)	NCSE	ifosfamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2395	An objective causality assessment by use of the Naranjo probability scale revealed that [s1]NCSE[e1] due to [s2]ifosfamide[e2] was probable.
	(9, 18)	ifosfamide	NCSE	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2396	CASE SUMMARIES: Two patients who received [s1]ifosfamide[e1] containing chemotherapy developed [s2]NCSE[e2] 
	(7, 13)	ifosfamide	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2397	CONCLUSIONS: Among the many presentations of [s1]ifosfamide[e1]  [s2]neurotoxicity[e2]  clinicians should consider NCSE as a possible explanation for changes in consciousness in a patient receiving this agent.
	(0, 29)	NCSE	ifosfamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2398	 [s1]NCSE[e1]  an epileptic disorder in which typical convulsive activity is absent, has previously been reported in only 4 patients receiving [s2]ifosfamide[e2] 
	(0, 14)	Nonconvulsive status epilepticus	ifosfamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2399	 [s1]Nonconvulsive status epilepticus[e1] due to [s2]ifosfamide[e2] 
	(17, 25)	NCSE	ifosfamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2400	OBJECTIVE: To report 2 cases of nonconvulsive status epilepticus  [s1]NCSE[e1]  following infusion of [s2]ifosfamide[e2] 
	(7, 27)	nonconvulsive status epilepticus	ifosfamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2401	OBJECTIVE: To report 2 cases of [s1]nonconvulsive status epilepticus[e1] (NCSE) following infusion of [s2]ifosfamide[e2] 
	(8, 14)	gelatine	anaphylaxis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2402	We describe a case of intraoperative [s1]gelatine[e1] induced [s2]anaphylaxis[e2] whose diagnosis was delayed as the use of gelatine during surgical procedures was omitted for two times in patient's medical records.
	(8, 14)	gelatine	anaphylaxis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2403	We describe a case of intraoperative [s1]gelatine[e1] induced [s2]anaphylaxis[e2] whose diagnosis was delayed as the use of gelatine during surgical procedures was omitted for two times in patient's medical records.
	(0, 14)	Cutaneous mycobacterial infection	BCG	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2404	 [s1]Cutaneous mycobacterial infection[e1] post intravesical [s2]BCG[e2] installation.
	(0, 13)	Disseminated tuberculous lesions	BCG	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2405	 [s1]Disseminated tuberculous lesions[e1] post intravesical [s2]BCG[e2] therapy are rare but need to be identified and treated quickly.
	(3, 13)	hypersensitivity rash	HCQ	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2406	Some patients develop [s1]hypersensitivity rash[e1] in response to [s2]HCQ[e2] 
	(2, 36)	sumatriptan	symptomatic cerebral vasospasm	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2407	Administration of [s1]sumatriptan[e1] in subarachnoid haemorrhage (SAH) patients, misdiagnosed as migraine patients, may induce [s2]symptomatic cerebral vasospasm[e2] with potentially dangerous consequences.
	(9, 22)	diabetic ketoacidosis	quetiapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2408	METHOD: We describe two patients who presented with [s1]diabetic ketoacidosis[e1] after treatment with [s2]quetiapine[e2] and risperidone, respectively.
	(9, 26)	diabetic ketoacidosis	risperidone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2409	METHOD: We describe two patients who presented with [s1]diabetic ketoacidosis[e1] after treatment with quetiapine and [s2]risperidone[e2]  respectively.
	(56, 93)	atypical lymphocytosis	SMX	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2410	A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, [s1]atypical lymphocytosis[e1]  and eosinophilia two weeks after receiving trimethoprim (TMP)-sulfamethoxazole  [s2]SMX[e2]  treatment.
	(56, 85)	atypical lymphocytosis	sulfamethoxazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2411	A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, [s1]atypical lymphocytosis[e1]  and eosinophilia two weeks after receiving trimethoprim (TMP) [s2]sulfamethoxazole[e2] (SMX) treatment.
	(56, 81)	atypical lymphocytosis	TMP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2412	A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, [s1]atypical lymphocytosis[e1]  and eosinophilia two weeks after receiving trimethoprim  [s2]TMP[e2] -sulfamethoxazole (SMX) treatment.
	(56, 77)	atypical lymphocytosis	trimethoprim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2413	A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, [s1]atypical lymphocytosis[e1]  and eosinophilia two weeks after receiving [s2]trimethoprim[e2] (TMP)-sulfamethoxazole (SMX) treatment.
	(39, 93)	cervical lymphadenopathy	SMX	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2414	A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, [s1]cervical lymphadenopathy[e1]  hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP)-sulfamethoxazole  [s2]SMX[e2]  treatment.
	(39, 85)	cervical lymphadenopathy	sulfamethoxazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2415	A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, [s1]cervical lymphadenopathy[e1]  hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP) [s2]sulfamethoxazole[e2] (SMX) treatment.
	(39, 81)	cervical lymphadenopathy	TMP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2416	A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, [s1]cervical lymphadenopathy[e1]  hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim  [s2]TMP[e2] -sulfamethoxazole (SMX) treatment.
	(39, 77)	cervical lymphadenopathy	trimethoprim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2417	A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, [s1]cervical lymphadenopathy[e1]  hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving [s2]trimethoprim[e2] (TMP)-sulfamethoxazole (SMX) treatment.
	(67, 94)	eosinophilia	SMX	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2418	A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and [s1]eosinophilia[e1] two weeks after receiving trimethoprim (TMP)-sulfamethoxazole  [s2]SMX[e2]  treatment.
	(67, 86)	eosinophilia	sulfamethoxazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2419	A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and [s1]eosinophilia[e1] two weeks after receiving trimethoprim (TMP) [s2]sulfamethoxazole[e2] (SMX) treatment.
	(67, 82)	eosinophilia	TMP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2420	A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and [s1]eosinophilia[e1] two weeks after receiving trimethoprim  [s2]TMP[e2] -sulfamethoxazole (SMX) treatment.
	(67, 78)	eosinophilia	trimethoprim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2421	A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and [s1]eosinophilia[e1] two weeks after receiving [s2]trimethoprim[e2] (TMP)-sulfamethoxazole (SMX) treatment.
	(34, 93)	fever	SMX	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2422	A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with [s1]fever[e1]  skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP)-sulfamethoxazole  [s2]SMX[e2]  treatment.
	(34, 85)	fever	sulfamethoxazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2423	A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with [s1]fever[e1]  skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP) [s2]sulfamethoxazole[e2] (SMX) treatment.
	(34, 81)	fever	TMP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2424	A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with [s1]fever[e1]  skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim  [s2]TMP[e2] -sulfamethoxazole (SMX) treatment.
	(34, 77)	fever	trimethoprim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2425	A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with [s1]fever[e1]  skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving [s2]trimethoprim[e2] (TMP)-sulfamethoxazole (SMX) treatment.
	(47, 93)	hepatosplenomegaly	SMX	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2426	A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, [s1]hepatosplenomegaly[e1]  atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP)-sulfamethoxazole  [s2]SMX[e2]  treatment.
	(47, 85)	hepatosplenomegaly	sulfamethoxazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2427	A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, [s1]hepatosplenomegaly[e1]  atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP) [s2]sulfamethoxazole[e2] (SMX) treatment.
	(47, 81)	hepatosplenomegaly	TMP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2428	A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, [s1]hepatosplenomegaly[e1]  atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim  [s2]TMP[e2] -sulfamethoxazole (SMX) treatment.
	(47, 77)	hepatosplenomegaly	trimethoprim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2429	A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, [s1]hepatosplenomegaly[e1]  atypical lymphocytosis, and eosinophilia two weeks after receiving [s2]trimethoprim[e2] (TMP)-sulfamethoxazole (SMX) treatment.
	(36, 93)	skin eruptions	SMX	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2430	A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, [s1]skin eruptions[e1]  cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP)-sulfamethoxazole  [s2]SMX[e2]  treatment.
	(36, 85)	skin eruptions	sulfamethoxazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2431	A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, [s1]skin eruptions[e1]  cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim (TMP) [s2]sulfamethoxazole[e2] (SMX) treatment.
	(36, 81)	skin eruptions	TMP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2432	A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, [s1]skin eruptions[e1]  cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim  [s2]TMP[e2] -sulfamethoxazole (SMX) treatment.
	(36, 77)	skin eruptions	trimethoprim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2433	A 27-year-old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, [s1]skin eruptions[e1]  cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving [s2]trimethoprim[e2] (TMP)-sulfamethoxazole (SMX) treatment.
	(6, 14)	TMP-SMX	hypersensitivity syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2434	This is the first case of [s1]TMP-SMX[e1] induced [s2]hypersensitivity syndrome[e2] associated with the reactivation of a latent viral infection.
	(0, 15)	Trimethoprim-sulfamethoxazole	hypersensitivity syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2435	 [s1]Trimethoprim-sulfamethoxazole[e1] induced [s2]hypersensitivity syndrome[e2] associated with reactivation of human herpesvirus-6.
	(8, 16)	corticosteroid	glaucoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2436	PURPOSE: To report a case of severe [s1]corticosteroid[e1] induced [s2]glaucoma[e2] after intravitreal injection of triamcinolone acetate in a 34-year-old man without a history of glaucoma.
	(15, 28)	glaucoma	triamcinolone acetate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2437	PURPOSE: To report a case of severe corticosteroid-induced [s1]glaucoma[e1] after intravitreal injection of [s2]triamcinolone acetate[e2] in a 34-year-old man without a history of glaucoma.
	(14, 29)	severe vision loss	triamcinolone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2438	RESULTS: A 34-year-old man acquired visual field defects and [s1]severe vision loss[e1] in both eyes after intravitreal injection of [s2]triamcinolone[e2] for diabetic macular edema.
	(10, 29)	visual field defects	triamcinolone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2439	RESULTS: A 34-year-old man acquired [s1]visual field defects[e1] and severe vision loss in both eyes after intravitreal injection of [s2]triamcinolone[e2] for diabetic macular edema.
	(1, 6)	steroid	glaucoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2440	Severe [s1]steroid[e1] induced [s2]glaucoma[e2] following intravitreal injection of triamcinolone acetonide.
	(5, 18)	glaucoma	triamcinolone acetonide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2441	Severe steroid-induced [s1]glaucoma[e1] following intravitreal injection of [s2]triamcinolone acetonide[e2] 
	(16, 24)	corticosteroid	glaucoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2442	This treatment has the potential to cause severe vision loss as a result of intractable [s1]corticosteroid[e1] induced [s2]glaucoma[e2] 
	(7, 18)	severe vision loss	corticosteroid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2443	This treatment has the potential to cause [s1]severe vision loss[e1] as a result of intractable [s2]corticosteroid[e2] induced glaucoma.
	(0, 20)	Autoimmune thyroid disease	IFN-alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2444	 [s1]Autoimmune thyroid disease[e1] is a common side-effect of interferon-alpha  [s2]IFN-alpha[e2]  treatment of viral hepatitis C.
	(0, 15)	Autoimmune thyroid disease	interferon-alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2445	 [s1]Autoimmune thyroid disease[e1] is a common side-effect of [s2]interferon-alpha[e2] (IFN-alpha) treatment of viral hepatitis C.
	(13, 21)	IFN-alpha	Graves' hyperthyroidism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2446	Destructive thyrotoxicosis appeared 4-6 months after starting [s1]IFN-alpha[e1]  followed by [s2]Graves' hyperthyroidism[e2] within 8 to 11 months.
	(1, 15)	thyrotoxicosis	IFN-alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2447	Destructive [s1]thyrotoxicosis[e1] appeared 4-6 months after starting [s2]IFN-alpha[e2]  followed by Graves' hyperthyroidism within 8 to 11 months.
	(2, 10)	hyperthyroidism	IFN-alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2448	Hence, [s1]hyperthyroidism[e1] induced by [s2]IFN-alpha[e2] could correspond to the first phase of silent thyroiditis, to Graves' disease or to the succession of both.
	(0, 8)	Interferon-alpha	hyperthyroidism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2449	 [s1]Interferon-alpha[e1] induced [s2]hyperthyroidism[e2]  a three-stage evolution from silent thyroiditis towards Graves' disease.
	(10, 34)	IFN-alpha	hyperthryroidism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2450	We have described three patients with hepatitis C for whom [s1]IFN-alpha[e1] and ribavirin were prescribed and who developed two successive phases of silent thyroiditis followed by [s2]hyperthryroidism[e2] relapse due to Graves' disease.
	(15, 34)	ribavirin	hyperthryroidism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2451	We have described three patients with hepatitis C for whom IFN-alpha and [s1]ribavirin[e1] were prescribed and who developed two successive phases of silent thyroiditis followed by [s2]hyperthryroidism[e2] relapse due to Graves' disease.
	(10, 30)	IFN-alpha	thyroiditis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2452	We have described three patients with hepatitis C for whom [s1]IFN-alpha[e1] and ribavirin were prescribed and who developed two successive phases of silent [s2]thyroiditis[e2] followed by hyperthryroidism relapse due to Graves' disease.
	(15, 30)	ribavirin	thyroiditis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2453	We have described three patients with hepatitis C for whom IFN-alpha and [s1]ribavirin[e1] were prescribed and who developed two successive phases of silent [s2]thyroiditis[e2] followed by hyperthryroidism relapse due to Graves' disease.
	(0, 40)	Dipyrone	agranulocytosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2454	 [s1]Dipyrone[e1]  also known as metamizole, is an analgesic and antipyretic drug that was banned by the United States Food and Drug Administration because of its association with [s2]agranulocytosis[e2] 
	(7, 40)	metamizole	agranulocytosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2455	Dipyrone, also known as [s1]metamizole[e1]  is an analgesic and antipyretic drug that was banned by the United States Food and Drug Administration because of its association with [s2]agranulocytosis[e2] 
	(0, 6)	Dipyrone	granulocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2456	 [s1]Dipyrone[e1] induced [s2]granulocytopenia[e2]  a case for awareness.
	(6, 17)	granulocytopenia	dipyrone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2457	We describe a patient who developed [s1]granulocytopenia[e1] and fever after taking [s2]dipyrone[e2] and discuss the available literature.
	(10, 28)	CD8+ cutaneous lymphoproliferative disorders	efalizumab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2458	Herein, we describe 2 patients who developed unusual [s1]CD8+ cutaneous lymphoproliferative disorders[e1] after treatment with [s2]efalizumab[e2] and infliximab.
	(10, 35)	CD8+ cutaneous lymphoproliferative disorders	infliximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2459	Herein, we describe 2 patients who developed unusual [s1]CD8+ cutaneous lymphoproliferative disorders[e1] after treatment with efalizumab and [s2]infliximab[e2] 
	(16, 45)	pyrimethamine	abdominal pain	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2460	A 7-year-old with congenital toxoplasmosis who took [s1]pyrimethamine[e1] and sulfadiazine for reactivated chorioretinitis developed fever, severe cutaneous involvement, swelling, [s2]abdominal pain[e2] and transaminitis, persisting weeks after withholding medicines.
	(22, 45)	sulfadiazine	abdominal pain	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2461	A 7-year-old with congenital toxoplasmosis who took pyrimethamine and [s1]sulfadiazine[e1] for reactivated chorioretinitis developed fever, severe cutaneous involvement, swelling, [s2]abdominal pain[e2] and transaminitis, persisting weeks after withholding medicines.
	(16, 36)	pyrimethamine	fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2462	A 7-year-old with congenital toxoplasmosis who took [s1]pyrimethamine[e1] and sulfadiazine for reactivated chorioretinitis developed [s2]fever[e2]  severe cutaneous involvement, swelling, abdominal pain and transaminitis, persisting weeks after withholding medicines.
	(22, 36)	sulfadiazine	fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2463	A 7-year-old with congenital toxoplasmosis who took pyrimethamine and [s1]sulfadiazine[e1] for reactivated chorioretinitis developed [s2]fever[e2]  severe cutaneous involvement, swelling, abdominal pain and transaminitis, persisting weeks after withholding medicines.
	(16, 38)	pyrimethamine	severe cutaneous involvement	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2464	A 7-year-old with congenital toxoplasmosis who took [s1]pyrimethamine[e1] and sulfadiazine for reactivated chorioretinitis developed fever, [s2]severe cutaneous involvement[e2]  swelling, abdominal pain and transaminitis, persisting weeks after withholding medicines.
	(22, 38)	sulfadiazine	severe cutaneous involvement	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2465	A 7-year-old with congenital toxoplasmosis who took pyrimethamine and [s1]sulfadiazine[e1] for reactivated chorioretinitis developed fever, [s2]severe cutaneous involvement[e2]  swelling, abdominal pain and transaminitis, persisting weeks after withholding medicines.
	(16, 43)	pyrimethamine	swelling	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2466	A 7-year-old with congenital toxoplasmosis who took [s1]pyrimethamine[e1] and sulfadiazine for reactivated chorioretinitis developed fever, severe cutaneous involvement, [s2]swelling[e2]  abdominal pain and transaminitis, persisting weeks after withholding medicines.
	(22, 43)	sulfadiazine	swelling	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2467	A 7-year-old with congenital toxoplasmosis who took pyrimethamine and [s1]sulfadiazine[e1] for reactivated chorioretinitis developed fever, severe cutaneous involvement, [s2]swelling[e2]  abdominal pain and transaminitis, persisting weeks after withholding medicines.
	(16, 48)	pyrimethamine	transaminitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2468	A 7-year-old with congenital toxoplasmosis who took [s1]pyrimethamine[e1] and sulfadiazine for reactivated chorioretinitis developed fever, severe cutaneous involvement, swelling, abdominal pain and [s2]transaminitis[e2]  persisting weeks after withholding medicines.
	(22, 48)	sulfadiazine	transaminitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2469	A 7-year-old with congenital toxoplasmosis who took pyrimethamine and [s1]sulfadiazine[e1] for reactivated chorioretinitis developed fever, severe cutaneous involvement, swelling, abdominal pain and [s2]transaminitis[e2]  persisting weeks after withholding medicines.
	(1, 7)	sulfadiazine	hypersensitivity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2470	Severe [s1]sulfadiazine[e1]  [s2]hypersensitivity[e2] in a child with reactivated congenital toxoplasmic chorioretinitis.
	(10, 16)	sulfadiazine	hypersensitivity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2471	This case underscores problems in clinical management with [s1]sulfadiazine[e1]  [s2]hypersensitivity[e2]  potential immunosuppression from corticosteroids and selection of medications for recurrences of toxoplasmic chorioretinitis.
	(0, 44)	Fatal lung fibrosis	carboplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2472	 [s1]Fatal lung fibrosis[e1] caused by paclitaxel toxicity has not been reported In this report, we describe the case of a 62-year-old woman who received six cycles of paclitaxel and [s2]carboplatin[e2] as combination chemotherapy for advanced ovarian cancer.
	(0, 9)	Fatal lung fibrosis	paclitaxel	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2473	 [s1]Fatal lung fibrosis[e1] caused by [s2]paclitaxel[e2] toxicity has not been reported In this report, we describe the case of a 62-year-old woman who received six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer.
	(0, 9)	Fatal lung fibrosis	paclitaxel	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2474	 [s1]Fatal lung fibrosis[e1] caused by [s2]paclitaxel[e2] toxicity has not been reported In this report, we describe the case of a 62-year-old woman who received six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer.
	(0, 9)	Fatal pulmonary fibrosis	paclitaxel	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2475	 [s1]Fatal pulmonary fibrosis[e1] induced by [s2]paclitaxel[e2]  a case report and review of the literature.
	(10, 27)	paclitaxel	lung fibrosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2476	Physicians should keep in mind that taxanes such as [s1]paclitaxel[e1] have the potential to cause pneumonitis and [s2]lung fibrosis[e2] 
	(10, 21)	paclitaxel	pneumonitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2477	Physicians should keep in mind that taxanes such as [s1]paclitaxel[e1] have the potential to cause [s2]pneumonitis[e2] and lung fibrosis.
	(0, 11)	Pulmonary fibrosis	paclitaxel	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2478	 [s1]Pulmonary fibrosis[e1] is a complication of [s2]paclitaxel[e2] therapy that may occur despite treatments with corticosteroids.
	(0, 12)	Infections	anti-TNF-alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2479	 [s1]Infections[e1] are a major adverse effect during the treatment with [s2]anti-TNF-alpha[e2] 
	(19, 33)	subfulminant hepatitis B	infliximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2480	In this case report, we have described a patient with Crohn's disease who developed [s1]subfulminant hepatitis B[e1] after the fourth infusion of [s2]infliximab[e2] due to an unrecognized HBs-antigen carrier state.
	(0, 9)	Subfulminant hepatitis B	infliximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2481	 [s1]Subfulminant hepatitis B[e1] after [s2]infliximab[e2] in Crohn's disease: need for HBV-screening?
	(0, 15)	Acute unilateral total visual loss	phenol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2482	 [s1]Acute unilateral total visual loss[e1] after retrogasserian [s2]phenol[e2] injection for the treatment of trigeminal neuralgia: a case report.
	(10, 15)	phenol	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2483	The visual loss in this patient seems to result from [s1]phenol[e1]  [s2]neurotoxicity[e2] rather than mechanical compression of the intraorbital optic nerve.
	(1, 12)	visual loss	phenol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2484	The [s1]visual loss[e1] in this patient seems to result from [s2]phenol[e2] neurotoxicity rather than mechanical compression of the intraorbital optic nerve.
	(11, 26)	acute unilateral total visual loss	phenol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2485	We report a 78-year-old man who had [s1]acute unilateral total visual loss[e1] after retrogasserian [s2]phenol[e2] injection for the treatment of trigeminal neuralgia.
	(2, 13)	liver injury	IFN-beta	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2486	Drug induced [s1]liver injury[e1] secondary to interferon-beta  [s2]IFN-beta[e2]  in multiple sclerosis.
	(2, 8)	liver injury	interferon-beta	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2487	Drug induced [s1]liver injury[e1] secondary to [s2]interferon-beta[e2] (IFN-beta) in multiple sclerosis.
	(0, 40)	Grade 3 hepatotoxicity	IFN beta	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2488	 [s1]Grade 3 hepatotoxicity[e1] (AST and ALT > 5 to 20 upper limit normal) or higher has been observed in as many as 1.4% of MS patients on [s2]IFN beta[e2] 
	(9, 29)	IFN beta	hepatotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2489	Post marketing studies of Interferon-beta  [s1]IFN beta[e1]  therapy in multiple sclerosis (MS) have demonstrated surprisingly high rates of [s2]hepatotoxicity[e2] 
	(4, 31)	Interferon-beta	hepatotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2490	Post marketing studies of [s1]Interferon-beta[e1] (IFN beta) therapy in multiple sclerosis (MS) have demonstrated surprisingly high rates of [s2]hepatotoxicity[e2] 
	(5, 11)	IFN beta	hepatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2491	We report three cases of [s1]IFN beta[e1] induced [s2]hepatitis[e2] in MS and discuss the pathology findings and possible mechanisms of drug-induced liver injury.
	(5, 26)	IFN beta	liver injury	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2492	We report three cases of [s1]IFN beta[e1] induced hepatitis in MS and discuss the pathology findings and possible mechanisms of drug-induced [s2]liver injury[e2] 
	(11, 33)	acute urticaria	cloxacillin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2493	A 55-year-old woman presented an episode of [s1]acute urticaria[e1] and labial angioedema 60 minutes after ingesting 500 mg of [s2]cloxacillin[e2] for a skin abscess.
	(16, 33)	labial angioedema	cloxacillin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2494	A 55-year-old woman presented an episode of acute urticaria and [s1]labial angioedema[e1] 60 minutes after ingesting 500 mg of [s2]cloxacillin[e2] for a skin abscess.
	(0, 5)	Allergy	cloxacillin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2495	 [s1]Allergy[e1] to [s2]cloxacillin[e2] with normal tolerance to amoxicillin and cefuroxime.
	(1, 9)	hypersensitivity	cloxacillin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2496	Several [s1]hypersensitivity[e1] reactions to [s2]cloxacillin[e2] have been reported, although IgE-mediated allergic reactions to the drug are rare and there is little information about possible tolerance to other semisynthetic penicillins or cephalosporins in patients with cloxacillin allergy.
	(7, 19)	cloxacillin	IgE-mediated allergic reactions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2497	Several hypersensitivity reactions to [s1]cloxacillin[e1] have been reported, although [s2]IgE-mediated allergic reactions[e2] to the drug are rare and there is little information about possible tolerance to other semisynthetic penicillins or cephalosporins in patients with cloxacillin allergy.
	(0, 6)	Cardiac toxicity	BCNU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2498	 [s1]Cardiac toxicity[e1] related to [s2]BCNU[e2] has not been described well.
	(0, 13)	Myocardial ischemia	carmustine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2499	 [s1]Myocardial ischemia[e1] associated with high-dose [s2]carmustine[e2] infusion.
	(23, 35)	myocardial ischemia	BCNU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2500	Three patients are reported without a history of angina pectoris who had clinical and electrocardiographic evidence of [s1]myocardial ischemia[e1] during and immediately after [s2]BCNU[e2] infusion.
	(6, 12)	aspirin	asthma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2501	Adverse reaction in a patient with [s1]aspirin[e1] induced [s2]asthma[e2] treated with zafirlukast.
	(5, 15)	hypereosinophilia	zafirlukast	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2502	We present a case of [s1]hypereosinophilia[e1] related to [s2]zafirlukast[e2] therapy.
	(7, 27)	pegfilgrastim	edema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2503	Shortly after chemotherapy and an injection of [s1]pegfilgrastim[e1]  the patient developed poorly defined, rapidly progressive erythema, [s2]edema[e2]  and pain in his right forearm.
	(7, 31)	pegfilgrastim	pain in his right forearm	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2504	Shortly after chemotherapy and an injection of [s1]pegfilgrastim[e1]  the patient developed poorly defined, rapidly progressive erythema, edema, and [s2]pain in his right forearm[e2] 
	(7, 21)	pegfilgrastim	rapidly progressive erythema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2505	Shortly after chemotherapy and an injection of [s1]pegfilgrastim[e1]  the patient developed poorly defined, [s2]rapidly progressive erythema[e2]  edema, and pain in his right forearm.
	(10, 21)	myasthenic syndrome	statin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2506	A few recent individual case reports have suggested that a [s1]myasthenic syndrome[e1] may be associated with [s2]statin[e2] treatment, but this association is not well described.
	(0, 5)	Statin	myasthenia gravis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2507	 [s1]Statin[e1] associated [s2]myasthenia gravis[e2]  report of 4 cases and review of the literature.
	(8, 25)	myasthenia gravis	statin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2508	We report 4 patients who developed symptoms of [s1]myasthenia gravis[e1] within 2 weeks of starting treatment with a [s2]statin[e2] drug.
	(0, 31)	Reactivation of cytomegalovirus	azathioprine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2509	 [s1]Reactivation of cytomegalovirus[e1] probably followed the treatment of Wegener's granulomatosis with corticosteroids and [s2]azathioprine[e2] 
	(11, 22)	HCQ	ventricular tachycardia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2510	After excluding other causes of long QT syndrome, the [s1]HCQ[e1] was suspected as the cause of her [s2]ventricular tachycardia[e2] 
	(1, 13)	hydroxychloroquine	QT prolongation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2511	Chronic [s1]hydroxychloroquine[e1] use associated with [s2]QT prolongation[e2] and refractory ventricular arrhythmia.
	(1, 19)	hydroxychloroquine	refractory ventricular arrhythmia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2512	Chronic [s1]hydroxychloroquine[e1] use associated with QT prolongation and [s2]refractory ventricular arrhythmia[e2] 
	(6, 35)	HCQ	cardiac arrhythmias	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2513	CONCLUSION: The chronic use of [s1]HCQ[e1] for rheumatic diseases, or as an anti-malarial drug, should be balanced against the risk of developing potentially lethal [s2]cardiac arrhythmias[e2] 
	(8, 14)	HCQ	torsade de pointes	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2514	We report a case of chronic use of [s1]HCQ[e1] associated with [s2]torsade de pointes[e2] 
	(13, 24)	metformin	lactic acidosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2515	CONCLUSIONS: The increasing prevalence of Type 2 diabetes and its treatment with [s1]metformin[e1] might result in more cases of [s2]lactic acidosis[e2] 
	(0, 8)	Severe acidosis	metformin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2516	 [s1]Severe acidosis[e1] in patients taking [s2]metformin[e2] -rapid reversal and survival despite high APACHE score.
	(7, 26)	diabetes	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2517	Case report: lack of control of [s1]diabetes[e1] and weight gain in a patient on initiation and rechallenge of therapy with [s2]olanzapine[e2] 
	(9, 26)	weight gain	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2518	Case report: lack of control of diabetes and [s1]weight gain[e1] in a patient on initiation and rechallenge of therapy with [s2]olanzapine[e2] 
	(24, 34)	olanzapine	uncontrolled diabetes mellitus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2519	The following is a case report analysis intended to draw attention to the need for better care coordination by describing the observed relationship of [s1]olanzapine[e1] to metabolic changes manifested as [s2]uncontrolled diabetes mellitus[e2] and weight gain.
	(24, 43)	olanzapine	weight gain	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2520	The following is a case report analysis intended to draw attention to the need for better care coordination by describing the observed relationship of [s1]olanzapine[e1] to metabolic changes manifested as uncontrolled diabetes mellitus and [s2]weight gain[e2] 
	(20, 32)	olanzapine	uncontrolled diabetes	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2521	The patient was enrolled in a weight-loss clinic, and his diabetes medications were adjusted.Subsequently, [s1]olanzapine[e1] was discontinued because of weight gain and [s2]uncontrolled diabetes[e2] 
	(20, 29)	olanzapine	weight gain	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2522	The patient was enrolled in a weight-loss clinic, and his diabetes medications were adjusted.Subsequently, [s1]olanzapine[e1] was discontinued because of [s2]weight gain[e2] and uncontrolled diabetes.
	(13, 25)	Enterobacter keratitis	LASIK	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2523	PURPOSE: To report a case of traumatic flap dehiscence and [s1]Enterobacter keratitis[e1] 34 months after [s2]LASIK[e2] 
	(7, 25)	traumatic flap dehiscence	LASIK	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2524	PURPOSE: To report a case of [s1]traumatic flap dehiscence[e1] and Enterobacter keratitis 34 months after [s2]LASIK[e2] 
	(7, 17)	Enterobacter keratitis	LASIK	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2525	Traumatic late flap dehiscence and [s1]Enterobacter keratitis[e1] following [s2]LASIK[e2] 
	(0, 17)	Traumatic late flap dehiscence	LASIK	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2526	 [s1]Traumatic late flap dehiscence[e1] and Enterobacter keratitis following [s2]LASIK[e2] 
	(26, 33)	BOOP	docetaxel	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2527	We report the case of a lung cancer patient with bronquiloalveolar carcinoma (BAC) presenting with [s1]BOOP[e1] after chemotherapy with [s2]docetaxel[e2] and gemcitabine producing severe respiratory insufficiency, and simulating a progression of the tumor.
	(26, 38)	BOOP	gemcitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2528	We report the case of a lung cancer patient with bronquiloalveolar carcinoma (BAC) presenting with [s1]BOOP[e1] after chemotherapy with docetaxel and [s2]gemcitabine[e2] producing severe respiratory insufficiency, and simulating a progression of the tumor.
	(31, 54)	docetaxel	progression of the tumor	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2529	We report the case of a lung cancer patient with bronquiloalveolar carcinoma (BAC) presenting with BOOP after chemotherapy with [s1]docetaxel[e1] and gemcitabine producing severe respiratory insufficiency, and simulating a [s2]progression of the tumor[e2] 
	(36, 54)	gemcitabine	progression of the tumor	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2530	We report the case of a lung cancer patient with bronquiloalveolar carcinoma (BAC) presenting with BOOP after chemotherapy with docetaxel and [s1]gemcitabine[e1] producing severe respiratory insufficiency, and simulating a [s2]progression of the tumor[e2] 
	(31, 43)	docetaxel	severe respiratory insufficiency	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2531	We report the case of a lung cancer patient with bronquiloalveolar carcinoma (BAC) presenting with BOOP after chemotherapy with [s1]docetaxel[e1] and gemcitabine producing [s2]severe respiratory insufficiency[e2]  and simulating a progression of the tumor.
	(36, 43)	gemcitabine	severe respiratory insufficiency	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2532	We report the case of a lung cancer patient with bronquiloalveolar carcinoma (BAC) presenting with BOOP after chemotherapy with docetaxel and [s1]gemcitabine[e1] producing [s2]severe respiratory insufficiency[e2]  and simulating a progression of the tumor.
	(8, 33)	warfarin	bloody tears	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2533	A 65-year-old man on [s1]warfarin[e1] therapy with a sudden spontaneous onset of sub-conjunctival haematoma associated with [s2]bloody tears[e2] was assessed in the clinic following a referral from an optometrist.
	(8, 20)	warfarin	sub-conjunctival haematoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2534	A 65-year-old man on [s1]warfarin[e1] therapy with a sudden spontaneous onset of [s2]sub-conjunctival haematoma[e2] associated with bloody tears was assessed in the clinic following a referral from an optometrist.
	(5, 22)	sub-conjunctival haematoma	warfarin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2535	An unusual presentation of spontaneous [s1]sub-conjunctival haematoma[e1] in a patient receiving [s2]warfarin[e2] 
	(4, 24)	diplopia	warfarin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2536	Due to discomfort, [s1]diplopia[e1] and lagophthalmos, the haematoma necessitated suspension of [s2]warfarin[e2] therapy and a surgical evacuation.
	(2, 23)	discomfort	warfarin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2537	Due to [s1]discomfort[e1]  diplopia and lagophthalmos, the haematoma necessitated suspension of [s2]warfarin[e2] therapy and a surgical evacuation.
	(15, 24)	haematoma	warfarin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2538	Due to discomfort, diplopia and lagophthalmos, the [s1]haematoma[e1] necessitated suspension of [s2]warfarin[e2] therapy and a surgical evacuation.
	(8, 23)	lagophthalmos	warfarin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2539	Due to discomfort, diplopia and [s1]lagophthalmos[e1]  the haematoma necessitated suspension of [s2]warfarin[e2] therapy and a surgical evacuation.
	(1, 18)	sub-conjunctival haematoma	warfarin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2540	The [s1]sub-conjunctival haematoma[e1] in a patient receiving [s2]warfarin[e2] can pose a significant management challenge.
	(0, 15)	Angioedema	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2541	 [s1]Angioedema[e1] and maculopapular eruptions associated with [s2]carbamazepine[e2] administration.
	(5, 15)	maculopapular eruptions	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2542	Angioedema and [s1]maculopapular eruptions[e1] associated with [s2]carbamazepine[e2] administration.
	(0, 11)	Angioedema	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2543	 [s1]Angioedema[e1]  a rare side effect of [s2]carbamazepine[e2]  involves vascular leakage in dermis and subcutis mediated by immunoglobulin E and/or bradykinins.
	(0, 12)	Cutaneous eruptions	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2544	 [s1]Cutaneous eruptions[e1] occur in 3% of individuals administered [s2]carbamazepine[e2] 
	(0, 16)	Cutaneous rashes	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2545	 [s1]Cutaneous rashes[e1] and eruptions can be caused by many medications, including [s2]carbamazepine[e2] 
	(5, 16)	eruptions	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2546	Cutaneous rashes and [s1]eruptions[e1] can be caused by many medications, including [s2]carbamazepine[e2] 
	(22, 30)	angioedema	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2547	We report the case of a 27-year-old Indian woman who developed maculopapular rash and [s1]angioedema[e1] secondary to [s2]carbamazepine[e2] administration.
	(15, 30)	maculopapular rash	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2548	We report the case of a 27-year-old Indian woman who developed [s1]maculopapular rash[e1] and angioedema secondary to [s2]carbamazepine[e2] administration.
	(5, 10)	AVP	infliximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2549	Severe adenovirus pneumonia  [s1]AVP[e1]  following [s2]infliximab[e2] infusion for the treatment of Crohn's disease.
	(0, 12)	Severe adenovirus pneumonia	infliximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2550	 [s1]Severe adenovirus pneumonia[e1] (AVP) following [s2]infliximab[e2] infusion for the treatment of Crohn's disease.
	(5, 16)	severe AVP	infliximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2551	We report a case of [s1]severe AVP[e1] three weeks following the administration of [s2]infliximab[e2] for the treatment of Crohn's disease (CD).
	(3, 11)	ivermectin	severe hepatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2552	First case of [s1]ivermectin[e1] induced [s2]severe hepatitis[e2] 
	(10, 18)	ivermectin	severe liver disease	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2553	To our knowledge, this is the first case of [s1]ivermectin[e1] induced [s2]severe liver disease[e2] published in the literature.
	(27, 39)	severe hepatitis	ivermectin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2554	We report the case of a 20-year-old woman originally from Cameroon who was infected by the L. loa parasite and developed [s1]severe hepatitis[e1]  identified 1 month after a single dose of [s2]ivermectin[e2] 
	(16, 23)	myositis	gemcitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2555	CASE REPORT: We hereby report a case of radiation recall dermatitis and [s1]myositis[e1] occurring on [s2]gemcitabine[e2] monotherapy, five months after completing chemoradiation for locally advanced pancreatic cancer.
	(10, 23)	radiation recall dermatitis	gemcitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2556	CASE REPORT: We hereby report a case of [s1]radiation recall dermatitis[e1] and myositis occurring on [s2]gemcitabine[e2] monotherapy, five months after completing chemoradiation for locally advanced pancreatic cancer.
	(10, 17)	gemcitabine	radiation recall	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2557	CONCLUSIONS: This is the second case report that describes [s1]gemcitabine[e1] induced [s2]radiation recall[e2] in rectus abdominus muscles after gemcitabine-based radiation therapy.
	(0, 7)	Gemcitabine	rectus abdominus radiation recall	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2558	 [s1]Gemcitabine[e1] induced [s2]rectus abdominus radiation recall[e2] 
	(0, 11)	Sporadic rippling muscle disease	simvastatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2559	 [s1]Sporadic rippling muscle disease[e1] unmasked by [s2]simvastatin[e2] 
	(12, 26)	rippling muscle disease	simvastatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2560	We report a 53-year-old-man who developed [s1]rippling muscle disease[e1] (RMD) 2 months after starting [s2]simvastatin[e2] therapy for hypercholesterolemia.
	(16, 24)	RMD	simvastatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2561	We report a 53-year-old-man who developed rippling muscle disease  [s1]RMD[e1]  2 months after starting [s2]simvastatin[e2] therapy for hypercholesterolemia.
	(0, 8)	Acute coronary syndrome	capecitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2562	 [s1]Acute coronary syndrome[e1] induced by [s2]capecitabine[e2] therapy.
	(7, 18)	acute coronary syndrome	Capecitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2563	This case highlights the possible development of [s1]acute coronary syndrome[e1] as a side effect of [s2]Capecitabine[e2] therapy.
	(6, 18)	carbamazepine	coma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2564	Acute severe intoxication with [s1]carbamazepine[e1] is associated with seizures, [s2]coma[e2] and respiratory depression.
	(6, 20)	carbamazepine	respiratory depression	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2565	Acute severe intoxication with [s1]carbamazepine[e1] is associated with seizures, coma and [s2]respiratory depression[e2] 
	(6, 16)	carbamazepine	seizures	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2566	Acute severe intoxication with [s1]carbamazepine[e1] is associated with [s2]seizures[e2]  coma and respiratory depression.
	(8, 17)	pegvisomant	hepatic enzyme disturbances	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2567	After rechallenge with monotherapy [s1]pegvisomant[e1]  however, the [s2]hepatic enzyme disturbances[e2] reappeared within a few weeks, indicating that most likely pegvisomant alone and not the long-acting somatostatin analog or the combination of these two drugs was responsible for this case of drug-induced hepatitis.
	(8, 17)	pegvisomant	hepatic enzyme disturbances	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2568	After rechallenge with monotherapy [s1]pegvisomant[e1]  however, the [s2]hepatic enzyme disturbances[e2] reappeared within a few weeks, indicating that most likely pegvisomant alone and not the long-acting somatostatin analog or the combination of these two drugs was responsible for this case of drug-induced hepatitis.
	(8, 64)	pegvisomant	hepatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2569	After rechallenge with monotherapy [s1]pegvisomant[e1]  however, the hepatic enzyme disturbances reappeared within a few weeks, indicating that most likely pegvisomant alone and not the long-acting somatostatin analog or the combination of these two drugs was responsible for this case of drug-induced [s2]hepatitis[e2] 
	(3, 22)	hepatitis	octreotide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2570	Drug-induced [s1]hepatitis[e1] in an acromegalic patient during combined treatment with pegvisomant and [s2]octreotide[e2] long-acting repeatable attributed to the use of pegvisomant.
	(3, 17)	hepatitis	pegvisomant	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2571	Drug-induced [s1]hepatitis[e1] in an acromegalic patient during combined treatment with [s2]pegvisomant[e2] and octreotide long-acting repeatable attributed to the use of pegvisomant.
	(3, 17)	hepatitis	pegvisomant	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2572	Drug-induced [s1]hepatitis[e1] in an acromegalic patient during combined treatment with [s2]pegvisomant[e2] and octreotide long-acting repeatable attributed to the use of pegvisomant.
	(1, 16)	hepatic enzyme disturbances	pegvisomant	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2573	The [s1]hepatic enzyme disturbances[e1] normalized after discontinuation of [s2]pegvisomant[e2] 
	(16, 33)	hepatitis	octreotide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2574	We report on a patient with acromegaly who developed severe drug-induced [s1]hepatitis[e1] during combined treatment with the long-acting somatostatin-analog [s2]octreotide[e2] and the GH receptor antagonist pegvisomant.
	(16, 42)	hepatitis	pegvisomant	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2575	We report on a patient with acromegaly who developed severe drug-induced [s1]hepatitis[e1] during combined treatment with the long-acting somatostatin-analog octreotide and the GH receptor antagonist [s2]pegvisomant[e2] 
	(5, 23)	AmB	anaemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2576	Amphotericin B  [s1]AmB[e1]  is effective, but its use is limited by toxicity: renal impairment, [s2]anaemia[e2]  fever, malaise, and hypokalaemia are common.
	(0, 25)	Amphotericin B	anaemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2577	 [s1]Amphotericin B[e1] (AmB) is effective, but its use is limited by toxicity: renal impairment, [s2]anaemia[e2]  fever, malaise, and hypokalaemia are common.
	(5, 26)	AmB	fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2578	Amphotericin B  [s1]AmB[e1]  is effective, but its use is limited by toxicity: renal impairment, anaemia, [s2]fever[e2]  malaise, and hypokalaemia are common.
	(0, 28)	Amphotericin B	fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2579	 [s1]Amphotericin B[e1] (AmB) is effective, but its use is limited by toxicity: renal impairment, anaemia, [s2]fever[e2]  malaise, and hypokalaemia are common.
	(5, 32)	AmB	hypokalaemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2580	Amphotericin B  [s1]AmB[e1]  is effective, but its use is limited by toxicity: renal impairment, anaemia, fever, malaise, and [s2]hypokalaemia[e2] are common.
	(0, 34)	Amphotericin B	hypokalaemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2581	 [s1]Amphotericin B[e1] (AmB) is effective, but its use is limited by toxicity: renal impairment, anaemia, fever, malaise, and [s2]hypokalaemia[e2] are common.
	(5, 28)	AmB	malaise	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2582	Amphotericin B  [s1]AmB[e1]  is effective, but its use is limited by toxicity: renal impairment, anaemia, fever, [s2]malaise[e2]  and hypokalaemia are common.
	(0, 30)	Amphotericin B	malaise	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2583	 [s1]Amphotericin B[e1] (AmB) is effective, but its use is limited by toxicity: renal impairment, anaemia, fever, [s2]malaise[e2]  and hypokalaemia are common.
	(5, 20)	AmB	renal impairment	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2584	Amphotericin B  [s1]AmB[e1]  is effective, but its use is limited by toxicity: [s2]renal impairment[e2]  anaemia, fever, malaise, and hypokalaemia are common.
	(0, 22)	Amphotericin B	renal impairment	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2585	 [s1]Amphotericin B[e1] (AmB) is effective, but its use is limited by toxicity: [s2]renal impairment[e2]  anaemia, fever, malaise, and hypokalaemia are common.
	(3, 60)	temozolomide	brain abscess with Listeria monocytogenes	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2586	DIAGNOSIS: Severe [s1]temozolomide[e1] induced immunosuppression, exacerbated by corticosteroids, with profound T-cell lymphocytopenia and simultaneous opportunistic infections with Pneumocystis jiroveci pneumonia, [s2]brain abscess with Listeria monocytogenes[e2]  and cutaneous Kaposi's sarcoma.
	(3, 74)	temozolomide	cutaneous Kaposi's sarcoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2587	DIAGNOSIS: Severe [s1]temozolomide[e1] induced immunosuppression, exacerbated by corticosteroids, with profound T-cell lymphocytopenia and simultaneous opportunistic infections with Pneumocystis jiroveci pneumonia, brain abscess with Listeria monocytogenes, and [s2]cutaneous Kaposi's sarcoma[e2] 
	(3, 11)	temozolomide	immunosuppression	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2588	DIAGNOSIS: Severe [s1]temozolomide[e1] induced [s2]immunosuppression[e2]  exacerbated by corticosteroids, with profound T-cell lymphocytopenia and simultaneous opportunistic infections with Pneumocystis jiroveci pneumonia, brain abscess with Listeria monocytogenes, and cutaneous Kaposi's sarcoma.
	(3, 47)	temozolomide	infections with Pneumocystis jiroveci pneumonia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2589	DIAGNOSIS: Severe [s1]temozolomide[e1] induced immunosuppression, exacerbated by corticosteroids, with profound T-cell lymphocytopenia and simultaneous opportunistic [s2]infections with Pneumocystis jiroveci pneumonia[e2]  brain abscess with Listeria monocytogenes, and cutaneous Kaposi's sarcoma.
	(3, 31)	temozolomide	T-cell lymphocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2590	DIAGNOSIS: Severe [s1]temozolomide[e1] induced immunosuppression, exacerbated by corticosteroids, with profound [s2]T-cell lymphocytopenia[e2] and simultaneous opportunistic infections with Pneumocystis jiroveci pneumonia, brain abscess with Listeria monocytogenes, and cutaneous Kaposi's sarcoma.
	(15, 26)	Kaposi's sarcoma	temozolomide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2591	Listeria brain abscess, Pneumocystis pneumonia and [s1]Kaposi's sarcoma[e1] after [s2]temozolomide[e2] 
	(0, 25)	Listeria brain abscess	temozolomide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2592	 [s1]Listeria brain abscess[e1]  Pneumocystis pneumonia and Kaposi's sarcoma after [s2]temozolomide[e2] 
	(7, 26)	Pneumocystis pneumonia	temozolomide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2593	Listeria brain abscess, [s1]Pneumocystis pneumonia[e1] and Kaposi's sarcoma after [s2]temozolomide[e2] 
	(2, 8)	Topiramate	angle-closure glaucoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2594	PURPOSE: [s1]Topiramate[e1] induced [s2]angle-closure glaucoma[e2] (TiACG) is believed to be related to its sulfonamide moiety.
	(8, 25)	angle-closure glaucoma	mannitol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2595	Rapid resolution of topiramate-induced [s1]angle-closure glaucoma[e1] with methylprednisolone and [s2]mannitol[e2] 
	(8, 18)	angle-closure glaucoma	methylprednisolone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2596	Rapid resolution of topiramate-induced [s1]angle-closure glaucoma[e1] with [s2]methylprednisolone[e2] and mannitol.
	(3, 9)	topiramate	angle-closure glaucoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2597	Rapid resolution of [s1]topiramate[e1] induced [s2]angle-closure glaucoma[e2] with methylprednisolone and mannitol.
	(0, 11)	Spontaneous splenic infarction	sumatriptan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2598	 [s1]Spontaneous splenic infarction[e1] associated with [s2]sumatriptan[e2] use.
	(14, 26)	myocardial infarction	triptan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2599	Though they are generally considered safe, there have been a few reports of [s1]myocardial infarction[e1] and stroke associated with [s2]triptan[e2] use.
	(21, 26)	stroke	triptan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2600	Though they are generally considered safe, there have been a few reports of myocardial infarction and [s1]stroke[e1] associated with [s2]triptan[e2] use.
	(6, 19)	spontaneous splenic infarction	sumatriptan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2601	We report a patient who developed [s1]spontaneous splenic infarction[e1] after the use of [s2]sumatriptan[e2] for the treatment of migraine headache.
	(0, 13)	Acute myocardial infarction	methylprednisolone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2602	 [s1]Acute myocardial infarction[e1] during high-dose [s2]methylprednisolone[e2] therapy for Graves' ophthalmopathy.
	(1, 10)	hypothyroidism	radioiodine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2603	Except [s1]hypothyroidism[e1] after [s2]radioiodine[e2] treatment (euthyroid under substitutional therapy), she suffered from no other diseases.
	(13, 44)	methylprednisolone	myocardial infarction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2604	Here we present the case of a woman who received high doses of [s1]methylprednisolone[e1] (1 g iv daily) for active Graves' ophthalmopathy, and developed severe hypertension followed by [s2]myocardial infarction[e2] on the fifth day of treatment.
	(13, 39)	methylprednisolone	severe hypertension	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2605	Here we present the case of a woman who received high doses of [s1]methylprednisolone[e1] (1 g iv daily) for active Graves' ophthalmopathy, and developed [s2]severe hypertension[e2] followed by myocardial infarction on the fifth day of treatment.
	(3, 20)	myocardial infarction	glucocorticoids	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2606	We conclude that [s1]myocardial infarction[e1] may develop in patients treated with high-dose [s2]glucocorticoids[e2] for Graves' ophthalmopathy, and increased blood pressure may herald this complication.
	(26, 36)	SASP	psoriasis-like skin reaction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2607	Presented is a case story of a woman with classical rheumatoid arthritis, who during introduction of sulphasalazine  [s1]SASP[e1]  therapy developed a severe and lasting [s2]psoriasis-like skin reaction[e2] 
	(21, 38)	sulphasalazine	psoriasis-like skin reaction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2608	Presented is a case story of a woman with classical rheumatoid arthritis, who during introduction of [s1]sulphasalazine[e1] (SASP) therapy developed a severe and lasting [s2]psoriasis-like skin reaction[e2] 
	(0, 20)	Psoriasis-like skin reaction	sulphasalazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2609	 [s1]Psoriasis-like skin reaction[e1] in a patient with rheumatoid arthritis after [s2]sulphasalazine[e2] therapy.
	(7, 16)	vincristine	bilateral ptosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2610	Five days after the fourth dose of [s1]vincristine[e1]  she presented with [s2]bilateral ptosis[e2] 
	(0, 7)	Vincristine	cranial polyneuropathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2611	 [s1]Vincristine[e1] induced [s2]cranial polyneuropathy[e2] 
	(12, 19)	vincristine	cranial polyneuropathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2612	We describe a 5-year-old girl showed recovery of [s1]vincristine[e1] induced [s2]cranial polyneuropathy[e2] with pyridoxine and pyridostigmine treatment.
	(0, 15)	Acute generalized exanthematous pustulosis	morphine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2613	 [s1]Acute generalized exanthematous pustulosis[e1] caused by [s2]morphine[e2]  confirmed by positive patch test and lymphocyte transformation test.
	(0, 20)	Morphine	facial flushing	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2614	 [s1]Morphine[e1]  an opium alkaloid, frequently causes side effects such as hyperhidrosis and [s2]facial flushing[e2]  but serious cutaneous adverse drug reactions are seldom observed.
	(0, 16)	Morphine	hyperhidrosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2615	 [s1]Morphine[e1]  an opium alkaloid, frequently causes side effects such as [s2]hyperhidrosis[e2] and facial flushing, but serious cutaneous adverse drug reactions are seldom observed.
	(15, 28)	erlotinib	skin manifestations	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2616	We describe a case of a man treated with an EGFR-inhibitor  [s1]erlotinib[e1]  for a cell lung cancer who developed [s2]skin manifestations[e2] localized in an uncommon area and with an atypical evolution.
	(0, 6)	Olanzapine	neuroleptic malignant syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2617	 [s1]Olanzapine[e1] associated [s2]neuroleptic malignant syndrome[e2] 
	(0, 9)	Allergic contact angioedema	benzoyl peroxide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2618	 [s1]Allergic contact angioedema[e1] to [s2]benzoyl peroxide[e2] 
	(7, 17)	severe angioedematous reaction	BP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2619	Factors that suggested an association between the [s1]severe angioedematous reaction[e1] and [s2]BP[e2] topical application include the strong reaction to BP in the patch-test, the temporal relationship, the complete resolution of symptoms after the drug was withdrawn and the absence of other identified explanations.
	(24, 36)	5-fluorouracil	acute confusional state	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2620	A 35-year-old woman presented with neurotoxicity correlated to an i.v. regimen of [s1]5-fluorouracil[e1] as episodes of [s2]acute confusional state[e2] and abnormalities of symmetrically restricted diffusion in the periventricular white matter and corpus callosum.
	(9, 26)	neurotoxicity	5-fluorouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2621	A 35-year-old woman presented with [s1]neurotoxicity[e1] correlated to an i.v. regimen of [s2]5-fluorouracil[e2] as episodes of acute confusional state and abnormalities of symmetrically restricted diffusion in the periventricular white matter and corpus callosum.
	(8, 17)	5-fluorouracil	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2622	Reversible findings of restricted diffusion in [s1]5-fluorouracil[e1]  [s2]neurotoxicity[e2] 
	(20, 27)	caffeine	suicide attempt	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2623	We present the case of a 58-year-old woman who ingested more than 35 g of [s1]caffeine[e1] in a [s2]suicide attempt[e2] 
	(15, 20)	dapsone	hypersensitivity syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2624	It may cause a severe adverse drug reaction with multiorgan involvement known as [s1]dapsone[e1]  [s2]hypersensitivity syndrome[e2] 
	(1, 6)	dapsone	hypersensitivity syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2625	Severe [s1]dapsone[e1]  [s2]hypersensitivity syndrome[e2] 
	(14, 19)	dapsone	hypersensitivity syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2626	We report the case of a 21-year-old female patient with [s1]dapsone[e1]  [s2]hypersensitivity syndrome[e2] 
	(0, 11)	Anaphylaxis	diamorphine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2627	 [s1]Anaphylaxis[e1] to intrathecal [s2]diamorphine[e2] 
	(11, 18)	diamorphine	anaphylaxis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2628	We believe this is the first report of intrathecal [s1]diamorphine[e1] causing [s2]anaphylaxis[e2] 
	(5, 18)	systemic allergic reaction	aprotinin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2629	We highlight two instances of [s1]systemic allergic reaction[e1]  and discuss the potential side effects of local [s2]aprotinin[e2] injections in the orthopaedic setting as well as the evidence base for its use.
	(33, 44)	carbamazepine	NMS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2630	METHOD: Case analysis of a poly-drug overdose (venlafaxine, topiramate, divalproex sodium, risperidone, and [s1]carbamazepine[e1]  presenting with mixed SS [s2]NMS[e2] features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS/NMS in critical care settings.
	(21, 44)	divalproex sodium	NMS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2631	METHOD: Case analysis of a poly-drug overdose (venlafaxine, topiramate, [s1]divalproex sodium[e1]  risperidone, and carbamazepine) presenting with mixed SS [s2]NMS[e2] features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS/NMS in critical care settings.
	(27, 44)	risperidone	NMS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2632	METHOD: Case analysis of a poly-drug overdose (venlafaxine, topiramate, divalproex sodium, [s1]risperidone[e1]  and carbamazepine) presenting with mixed SS [s2]NMS[e2] features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS/NMS in critical care settings.
	(17, 44)	topiramate	NMS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2633	METHOD: Case analysis of a poly-drug overdose (venlafaxine, [s1]topiramate[e1]  divalproex sodium, risperidone, and carbamazepine) presenting with mixed SS [s2]NMS[e2] features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS/NMS in critical care settings.
	(10, 43)	venlafaxine	NMS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2634	METHOD: Case analysis of a poly-drug overdose  [s1]venlafaxine[e1]  topiramate, divalproex sodium, risperidone, and carbamazepine) presenting with mixed SS [s2]NMS[e2] features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS/NMS in critical care settings.
	(33, 43)	carbamazepine	SS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2635	METHOD: Case analysis of a poly-drug overdose (venlafaxine, topiramate, divalproex sodium, risperidone, and [s1]carbamazepine[e1]  presenting with mixed [s2]SS[e2] NMS features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS/NMS in critical care settings.
	(21, 43)	divalproex sodium	SS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2636	METHOD: Case analysis of a poly-drug overdose (venlafaxine, topiramate, [s1]divalproex sodium[e1]  risperidone, and carbamazepine) presenting with mixed [s2]SS[e2] NMS features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS/NMS in critical care settings.
	(27, 43)	risperidone	SS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2637	METHOD: Case analysis of a poly-drug overdose (venlafaxine, topiramate, divalproex sodium, [s1]risperidone[e1]  and carbamazepine) presenting with mixed [s2]SS[e2] NMS features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS/NMS in critical care settings.
	(17, 43)	topiramate	SS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2638	METHOD: Case analysis of a poly-drug overdose (venlafaxine, [s1]topiramate[e1]  divalproex sodium, risperidone, and carbamazepine) presenting with mixed [s2]SS[e2] NMS features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS/NMS in critical care settings.
	(10, 42)	venlafaxine	SS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2639	METHOD: Case analysis of a poly-drug overdose  [s1]venlafaxine[e1]  topiramate, divalproex sodium, risperidone, and carbamazepine) presenting with mixed [s2]SS[e2] NMS features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS/NMS in critical care settings.
	(0, 16)	Fever	phenytoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2640	 [s1]Fever[e1] and maculopapular rashes appeared at 10 days after [s2]phenytoin[e2] initiation, and then the drug was discontinued.
	(2, 16)	maculopapular rashes	phenytoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2641	Fever and [s1]maculopapular rashes[e1] appeared at 10 days after [s2]phenytoin[e2] initiation, and then the drug was discontinued.
	(0, 8)	Localized purpura	lamotrigine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2642	 [s1]Localized purpura[e1] associated with [s2]lamotrigine[e2] 
	(8, 16)	localized purpura	lamotrigine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2643	This case study is the second report of [s1]localized purpura[e1] after prolonged [s2]lamotrigine[e2] treatment suggesting this may be an atypical lamotrigine-induced drug reaction.
	(26, 36)	localized purpura	lamotrigine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2644	This report describes a 13-year-old female with a right frontal high-grade glioma and complex partial seizures who developed [s1]localized purpura[e1] after 23 months of [s2]lamotrigine[e2] monotherapy.
	(0, 6)	Acute renal failure	lisinopril	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2645	 [s1]Acute renal failure[e1] during [s2]lisinopril[e2] and losartan therapy for proteinuria.
	(0, 11)	Acute renal failure	losartan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2646	 [s1]Acute renal failure[e1] during lisinopril and [s2]losartan[e2] therapy for proteinuria.
	(13, 33)	hypotension	lisinopril	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2647	This report describes a case of acute compromise of renal function associated with [s1]hypotension[e1] in a 7-year-old boy treated with the ACE inhibitor [s2]lisinopril[e2] and the ARB losartan.
	(13, 41)	hypotension	losartan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2648	This report describes a case of acute compromise of renal function associated with [s1]hypotension[e1] in a 7-year-old boy treated with the ACE inhibitor lisinopril and the ARB [s2]losartan[e2] 
	(0, 20)	Reversible corneal keratinization	5-fluorouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2649	 [s1]Reversible corneal keratinization[e1] following trabeculectomy and treatment with [s2]5-fluorouracil[e2] 
	(0, 14)	Bronchiolitis obliterans with organizing pneumonia	rituximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2650	 [s1]Bronchiolitis obliterans with organizing pneumonia[e1] after [s2]rituximab[e2] therapy for non-Hodgkin's lymphoma.
	(9, 14)	BOOP	rituximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2651	Moreover, these findings suggest that the incidence of [s1]BOOP[e1] following [s2]rituximab[e2] therapy may be higher than has been previously appreciated.
	(7, 16)	BOOP	rituximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2652	This is the first reported case of [s1]BOOP[e1] associated with single-agent [s2]rituximab[e2]  and along with two other patients we describe, as well as two prior reports of BOOP in NHL patients receiving rituximab-based combinations, strengthens the possibility of a causal relationship.
	(7, 16)	BOOP	rituximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2653	This is the first reported case of [s1]BOOP[e1] associated with single-agent [s2]rituximab[e2]  and along with two other patients we describe, as well as two prior reports of BOOP in NHL patients receiving rituximab-based combinations, strengthens the possibility of a causal relationship.
	(10, 32)	rituximab	bronchiolitis obliterans with organizing pneumonia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2654	We describe a case of an NHL patient who received [s1]rituximab[e1] and developed symptomatic, biopsy-proven multinodular [s2]bronchiolitis obliterans with organizing pneumonia[e2] (BOOP).
	(9, 22)	severe arterial thrombotic events	thrombin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2655	Despite a very low complication rate, several [s1]severe arterial thrombotic events[e1] have been reported following [s2]thrombin[e2] injection of pseudoaneurysms.
	(4, 16)	arterial thrombosis	thrombin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2656	Lower extremity [s1]arterial thrombosis[e1] following sonographically guided [s2]thrombin[e2] injection of a femoral pseudoaneurysm.
	(1, 16)	arterial thrombosis	thrombin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2657	Native [s1]arterial thrombosis[e1]  though recognized as a severe complication of [s2]thrombin[e2] injection, has not been well described in the literature.
	(9, 20)	arterial thrombosis	thrombin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2658	We report a case of successful surgical management of [s1]arterial thrombosis[e1] after percutaneous [s2]thrombin[e2] injection of a femoral artery pseudoaneurysm in a 69-year-old woman.
	(4, 11)	oxaliplatin	hemolytic and/or thrombocytopenic reactions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2659	A small number of [s1]oxaliplatin[e1] related [s2]hemolytic and/or thrombocytopenic reactions[e2] have been reported.
	(0, 14)	Hemolytic uremic syndrome	oxaliplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2660	 [s1]Hemolytic uremic syndrome[e1] following the infusion of [s2]oxaliplatin[e2]  case report.
	(5, 30)	hemolytic-uremic syndrome	5-fluorouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2661	We present a case of [s1]hemolytic-uremic syndrome[e1] that developed during the 4th cycle of combination chemotherapy with oxaliplatin, [s2]5-fluorouracil[e2] and leucovorin.
	(5, 38)	hemolytic-uremic syndrome	leucovorin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2662	We present a case of [s1]hemolytic-uremic syndrome[e1] that developed during the 4th cycle of combination chemotherapy with oxaliplatin, 5-fluorouracil and [s2]leucovorin[e2] 
	(5, 25)	hemolytic-uremic syndrome	oxaliplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2663	We present a case of [s1]hemolytic-uremic syndrome[e1] that developed during the 4th cycle of combination chemotherapy with [s2]oxaliplatin[e2]  5-fluorouracil and leucovorin.
	(20, 30)	agranulocytosis	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2664	First, a review of the literature produced 41 anecdotic cases of neutropenia or [s1]agranulocytosis[e1] during treatment with [s2]olanzapine[e2] (Zyprexa) reported in a total of 24 publications.
	(20, 33)	agranulocytosis	Zyprexa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2665	First, a review of the literature produced 41 anecdotic cases of neutropenia or [s1]agranulocytosis[e1] during treatment with olanzapine  [s2]Zyprexa[e2]  reported in a total of 24 publications.
	(15, 30)	neutropenia	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2666	First, a review of the literature produced 41 anecdotic cases of [s1]neutropenia[e1] or agranulocytosis during treatment with [s2]olanzapine[e2] (Zyprexa) reported in a total of 24 publications.
	(15, 33)	neutropenia	Zyprexa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2667	First, a review of the literature produced 41 anecdotic cases of [s1]neutropenia[e1] or agranulocytosis during treatment with olanzapine  [s2]Zyprexa[e2]  reported in a total of 24 publications.
	(5, 24)	agranulocytosis	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2668	Neutropenia and [s1]agranulocytosis[e1] are risks known to occur with phenothiazines and [s2]clozapine[e2] 
	(5, 18)	agranulocytosis	phenothiazines	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2669	Neutropenia and [s1]agranulocytosis[e1] are risks known to occur with [s2]phenothiazines[e2] and clozapine.
	(0, 24)	Neutropenia	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2670	 [s1]Neutropenia[e1] and agranulocytosis are risks known to occur with phenothiazines and [s2]clozapine[e2] 
	(0, 18)	Neutropenia	phenothiazines	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2671	 [s1]Neutropenia[e1] and agranulocytosis are risks known to occur with [s2]phenothiazines[e2] and clozapine.
	(7, 23)	neutropenia	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2672	Second, we report a case of [s1]neutropenia[e1]  which proved to be fatal in a schizophrenia patient receiving [s2]olanzapine[e2] and thiazide.
	(7, 27)	neutropenia	thiazide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2673	Second, we report a case of [s1]neutropenia[e1]  which proved to be fatal in a schizophrenia patient receiving olanzapine and [s2]thiazide[e2] 
	(4, 16)	severe neutropenia	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2674	Thus any case of [s1]severe neutropenia[e1] occurring in a patient receiving [s2]olanzapine[e2] is alarming to clinicians.
	(13, 23)	camptocormia	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2675	We present a depressive patient who developed mild parkinsonian signs and [s1]camptocormia[e1] after the introduction of [s2]olanzapine[e2] 
	(8, 23)	mild parkinsonian signs	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2676	We present a depressive patient who developed [s1]mild parkinsonian signs[e1] and camptocormia after the introduction of [s2]olanzapine[e2] 
	(4, 14)	mirtazapine	symptomatic hyponatremia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2677	Five months after initiating [s1]mirtazapine[e1] therapy, she developed [s2]symptomatic hyponatremia[e2] 
	(9, 24)	hyponatremia	citalopram	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2678	In this case, unlike those previously reported, [s1]hyponatremia[e1] recurred 5 months after switching from [s2]citalopram[e2] to mirtazapine, which is believed to be a safe antidepressant.
	(9, 29)	hyponatremia	mirtazapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2679	In this case, unlike those previously reported, [s1]hyponatremia[e1] recurred 5 months after switching from citalopram to [s2]mirtazapine[e2]  which is believed to be a safe antidepressant.
	(0, 11)	Recurrent hyponatremia	citalopram	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2680	 [s1]Recurrent hyponatremia[e1] associated with [s2]citalopram[e2] and mirtazapine.
	(0, 16)	Recurrent hyponatremia	mirtazapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2681	 [s1]Recurrent hyponatremia[e1] associated with citalopram and [s2]mirtazapine[e2] 
	(16, 29)	nephrotic syndrome	interferon (IFN)-beta-1b	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2682	A 43-year-old woman with multiple sclerosis (MS) had [s1]nephrotic syndrome[e1] 21 months after starting treatment with [s2]interferon (IFN)-beta-1b[e2] (subcutaneous administration).
	(1, 12)	nephrotic syndrome	IFN	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2683	Because [s1]nephrotic syndrome[e1] may be induced by [s2]IFN[e2] therapy, the IFN was stopped.
	(1, 12)	nephrotic syndrome	IFN	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2684	Because [s1]nephrotic syndrome[e1] may be induced by [s2]IFN[e2] therapy, the IFN was stopped.
	(0, 9)	Nephrotic syndrome	interferon-beta-1b	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2685	 [s1]Nephrotic syndrome[e1] associated with [s2]interferon-beta-1b[e2] therapy for multiple sclerosis.
	(4, 17)	nephrotic syndrome	IFN-beta-1b	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2686	Though proteinuria and [s1]nephrotic syndrome[e1] is a rare adverse effect of [s2]IFN-beta-1b[e2] therapy, physicians treating MS patients with this agent should pay careful attention to new clinical symptoms and laboratory findings.
	(1, 17)	proteinuria	IFN-beta-1b	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2687	Though [s1]proteinuria[e1] and nephrotic syndrome is a rare adverse effect of [s2]IFN-beta-1b[e2] therapy, physicians treating MS patients with this agent should pay careful attention to new clinical symptoms and laboratory findings.
	(14, 29)	dyspnea	homochlorcyclizine hydrochloride	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2688	A 70-year-old man was admitted to our hospital because of [s1]dyspnea[e1] after taking an antihistaminic agent  [s2]homochlorcyclizine hydrochloride[e2]  for itching.
	(0, 11)	Acute eosinophilic pneumonia	calcium stearate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2689	 [s1]Acute eosinophilic pneumonia[e1] caused by [s2]calcium stearate[e2]  an additive agent for an oral antihistaminic medication.
	(9, 16)	pulmonary disease	calcium stearate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2690	Therefore, we concluded that this patient's [s1]pulmonary disease[e1] was caused by [s2]calcium stearate[e2]  an additive for an antihistaminic drug.
	(0, 9)	Scleritis	zoledronic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2691	 [s1]Scleritis[e1] complicating [s2]zoledronic acid[e2] infusion.
	(5, 18)	severe unilateral posterior scleritis	zoledronic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2692	We present a case of [s1]severe unilateral posterior scleritis[e1] associated with [s2]zoledronic acid[e2] administration that was recognized and treated in a timely manner.
	(2, 10)	hepatitis B virus reactivation	rituximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2693	Late lethal [s1]hepatitis B virus reactivation[e1] after [s2]rituximab[e2] treatment of low-grade cutaneous B-cell lymphoma.
	(2, 14)	HBV reactivations	rituximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2694	Several such [s1]HBV reactivations[e1] were reported after combined [s2]rituximab[e2] and multiagent chemotherapy for B-cell lymphomas.
	(6, 18)	HBV reactivation	rituximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2695	This is the first case of [s1]HBV reactivation[e1] occurring during the year following [s2]rituximab[e2] monotherapy in the absence of any other immunosuppressive factor.
	(7, 37)	cryptococcal meningitis	azathioprine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2696	This is a case report of fatal [s1]cryptococcal meningitis[e1] in a child with systemic lupus erythematosus being treated with prednisolone and [s2]azathioprine[e2] 
	(7, 31)	cryptococcal meningitis	prednisolone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2697	This is a case report of fatal [s1]cryptococcal meningitis[e1] in a child with systemic lupus erythematosus being treated with [s2]prednisolone[e2] and azathioprine.
	(1, 15)	intertrigo-like eruption	doxorubicin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2698	An [s1]intertrigo-like eruption[e1] from pegylated liposomal [s2]doxorubicin[e2] 
	(1, 13)	eruption	PLD	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2699	This [s1]eruption[e1] appears to be a distinct cutaneous toxicity of [s2]PLD[e2] 
	(18, 30)	erosions in the axilla and groin	PLD	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2700	We report the case of a 60-year-old woman who developed erythema and [s1]erosions in the axilla and groin[e1] while on [s2]PLD[e2] for breast cancer.
	(14, 30)	erythema	PLD	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2701	We report the case of a 60-year-old woman who developed [s1]erythema[e1] and erosions in the axilla and groin while on [s2]PLD[e2] for breast cancer.
	(12, 18)	warfarin	skin necrosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2702	Herein is reported an unusual case of coexistent [s1]warfarin[e1] induced [s2]skin necrosis[e2] and heparin-induced thrombocytopenia following mitral valve replacement for thromboembolic phenomena associated with marantic endocarditis and bronchial adenocarcinoma.
	(21, 27)	heparin	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2703	Herein is reported an unusual case of coexistent warfarin-induced skin necrosis and [s1]heparin[e1] induced [s2]thrombocytopenia[e2] following mitral valve replacement for thromboembolic phenomena associated with marantic endocarditis and bronchial adenocarcinoma.
	(0, 6)	Warfarin	skin necrosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2704	 [s1]Warfarin[e1] induced [s2]skin necrosis[e2] and heparin-induced thrombocytopenia following mitral valve replacement for marantic endocarditis.
	(9, 15)	heparin	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2705	Warfarin-induced skin necrosis and [s1]heparin[e1] induced [s2]thrombocytopenia[e2] following mitral valve replacement for marantic endocarditis.
	(6, 27)	indomethacin	premature closure of the ductus arteriosus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2706	Exposure of the fetus to [s1]indomethacin[e1] by administration of the drug to the mother may cause many side effects, including [s2]premature closure of the ductus arteriosus[e2] 
	(0, 23)	Hypoxia	indomethacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2707	 [s1]Hypoxia[e1] is a predisposing factor for premature ductal closure and often occurs after maternal [s2]indomethacin[e2] therapy.
	(12, 23)	premature ductal closure	indomethacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2708	Hypoxia is a predisposing factor for [s1]premature ductal closure[e1] and often occurs after maternal [s2]indomethacin[e2] therapy.
	(0, 25)	Premature closure of the ductus arteriosus	indomethacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2709	 [s1]Premature closure of the ductus arteriosus[e1]  variable response among monozygotic twins after in utero exposure to [s2]indomethacin[e2] 
	(30, 38)	ductal closure	indomethacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2710	This selective closure of the ductus arteriosus suggests that the affected twin was predisposed to hypoxia and thus was more susceptible to [s1]ductal closure[e1] in response to [s2]indomethacin[e2] exposure.
	(20, 38)	hypoxia	indomethacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2711	This selective closure of the ductus arteriosus suggests that the affected twin was predisposed to [s1]hypoxia[e1] and thus was more susceptible to ductal closure in response to [s2]indomethacin[e2] exposure.
	(6, 20)	moxifloxacin	corneal ulcers	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2712	CONCLUSION: These cases suggest that [s1]moxifloxacin[e1] may interfere with the healing of [s2]corneal ulcers[e2] 
	(7, 30)	corneal ulcers	moxifloxacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2713	RESULTS: Both cases presented here describe [s1]corneal ulcers[e1] that persisted and showed signs of worsening during weeks of frequent topical dosing with [s2]moxifloxacin[e2] 
	(0, 8)	Severe corneal toxicity	fluoroquinolone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2714	 [s1]Severe corneal toxicity[e1] after topical [s2]fluoroquinolone[e2] therapy: report of two cases.
	(0, 15)	Acute generalized exanthematous pustulosis	nimesulide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2715	 [s1]Acute generalized exanthematous pustulosis[e1] induced by [s2]nimesulide[e2] 
	(5, 39)	acute generalized exanthematous pustulosis	nimesulide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2716	We report a case of [s1]acute generalized exanthematous pustulosis[e1] (AGEP) in a 50-year-old woman that was attributed to the ingestion of [s2]nimesulide[e2] 
	(16, 37)	AGEP	nimesulide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2717	We report a case of acute generalized exanthematous pustulosis  [s1]AGEP[e1]  in a 50-year-old woman that was attributed to the ingestion of [s2]nimesulide[e2] 
	(2, 32)	Amphotericin B deoxycholate	bradycardia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2718	DISCUSSION: [s1]Amphotericin B deoxycholate[e1] has been reported to produce significant cardiac toxicity, with ventricular arrhythmias and [s2]bradycardia[e2] reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates.
	(2, 19)	Amphotericin B deoxycholate	cardiac toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2719	DISCUSSION: [s1]Amphotericin B deoxycholate[e1] has been reported to produce significant [s2]cardiac toxicity[e2]  with ventricular arrhythmias and bradycardia reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates.
	(2, 23)	Amphotericin B deoxycholate	ventricular arrhythmias	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2720	DISCUSSION: [s1]Amphotericin B deoxycholate[e1] has been reported to produce significant cardiac toxicity, with [s2]ventricular arrhythmias[e2] and bradycardia reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates.
	(26, 40)	fatal cardiac arrhythmia	amphotericin B	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2721	OBJECTIVE: To report the clinical course of a woman with cryptococcal meningitis and no previous cardiac disease who developed a [s1]fatal cardiac arrhythmia[e1] after an acute overdose of [s2]amphotericin B[e2] and to review its toxicity.
	(16, 21)	cardiac toxicity	amphotericin B deoxycholate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2722	Use of the Naranjo probability scale indicated a highly probable relationship between the observed [s1]cardiac toxicity[e1] and [s2]amphotericin B deoxycholate[e2] therapy in this patient.
	(6, 22)	valvular heart disease	benfluorex	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2723	The authors describe a case of [s1]valvular heart disease[e1] in a 48-year-old woman receiving [s2]benfluorex[e2] (150 mg t.i.d. for 8 years) and leading to surgical mitral valve replacement.
	(0, 11)	Valvular heart disease	benfluorex	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2724	 [s1]Valvular heart disease[e1] in a patient taking [s2]benfluorex[e2] 
	(6, 29)	Lp-TAE	liver dysfunction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2725	The main side-effects of [s1]Lp-TAE[e1] combined with HT were low-grade fever, localized pain, myelo-suppression and [s2]liver dysfunction[e2]  but these were transient and eventually disappeared.
	(6, 21)	Lp-TAE	localized pain	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2726	The main side-effects of [s1]Lp-TAE[e1] combined with HT were low-grade fever, [s2]localized pain[e2]  myelo-suppression and liver dysfunction, but these were transient and eventually disappeared.
	(6, 16)	Lp-TAE	low-grade fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2727	The main side-effects of [s1]Lp-TAE[e1] combined with HT were [s2]low-grade fever[e2]  localized pain, myelo-suppression and liver dysfunction, but these were transient and eventually disappeared.
	(6, 24)	Lp-TAE	myelo-suppression	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2728	The main side-effects of [s1]Lp-TAE[e1] combined with HT were low-grade fever, localized pain, [s2]myelo-suppression[e2] and liver dysfunction, but these were transient and eventually disappeared.
	(0, 14)	Tacrolimus	acute renal failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2729	 [s1]Tacrolimus[e1] induced HUS: an unusual cause of [s2]acute renal failure[e2] in nephrotic syndrome.
	(0, 7)	Tacrolimus	HUS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2730	 [s1]Tacrolimus[e1] induced [s2]HUS[e2]  an unusual cause of acute renal failure in nephrotic syndrome.
	(2, 16)	tacrolimus	ARF	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2731	Thus, [s1]tacrolimus[e1] induced HUS is a rare cause of [s2]ARF[e2] in nephrotic syndrome.
	(2, 9)	tacrolimus	HUS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2732	Thus, [s1]tacrolimus[e1] induced [s2]HUS[e2] is a rare cause of ARF in nephrotic syndrome.
	(4, 13)	fulminant hepatitis	nevirapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2733	Liver transplantation for [s1]fulminant hepatitis[e1] related to [s2]nevirapine[e2] therapy.
	(6, 15)	fulminant hepatitis	nevirapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2734	We describe a detailed case of [s1]fulminant hepatitis[e1] induced by [s2]nevirapine[e2] (Viramune) and treated by liver transplantation.
	(6, 18)	fulminant hepatitis	Viramune	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2735	We describe a detailed case of [s1]fulminant hepatitis[e1] induced by nevirapine  [s2]Viramune[e2]  and treated by liver transplantation.
	(0, 26)	Cholelithiasis	cyclosporin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2736	 [s1]Cholelithiasis[e1] and thrombosis of the central retinal vein in a renal transplant recipient treated with [s2]cyclosporin[e2] 
	(6, 26)	thrombosis of the central retinal vein	cyclosporin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2737	Cholelithiasis and [s1]thrombosis of the central retinal vein[e1] in a renal transplant recipient treated with [s2]cyclosporin[e2] 
	(45, 52)	azathioprine	thrombosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2738	In this report, a patient who had undergone a renal transplantation as a result of malignant hypertension, and who was on immunosuppressive therapy consisting of cyclosporin, prednisone and [s1]azathioprine[e1]  developed [s2]thrombosis[e2] of the central retinal vein 5 years following the transplantation.
	(34, 52)	cyclosporin	thrombosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2739	In this report, a patient who had undergone a renal transplantation as a result of malignant hypertension, and who was on immunosuppressive therapy consisting of [s1]cyclosporin[e1]  prednisone and azathioprine, developed [s2]thrombosis[e2] of the central retinal vein 5 years following the transplantation.
	(40, 53)	prednisone	thrombosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2740	In this report, a patient who had undergone a renal transplantation as a result of malignant hypertension, and who was on immunosuppressive therapy consisting of cyclosporin, [s1]prednisone[e1] and azathioprine, developed [s2]thrombosis[e2] of the central retinal vein 5 years following the transplantation.
	(3, 17)	cyclosporin	cholelithiasis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2741	The use of [s1]cyclosporin[e1] has been associated with the development of [s2]cholelithiasis[e2] in transplant recipients.
	(0, 10)	Hepatotoxicity	cyproterone acetate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2742	 [s1]Hepatotoxicity[e1] induced by [s2]cyproterone acetate[e2]  a report of three cases.
	(13, 25)	severe hepatotoxic reactions	CPA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2743	Three male patients aged 78-83 years are presented, in whom [s1]severe hepatotoxic reactions[e1] emerged after [s2]CPA[e2] administration.
	(21, 80)	CS	cutaneous leishmaniasis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2744	CASE PRESENTATION: Three cases of Leishmania infantum leishmaniasis in corticosteroid  [s1]CS[e1] -treated patients are reported: an isolated lingual leishmaniasis in a farmer treated with CS for asthma, a severe visceral leishmaniasis associated with cutaneous lesions in a woman with myasthenia gravis, and a visceral involvement after [s2]cutaneous leishmaniasis[e2] in a man receiving CS.
	(6, 18)	Leishmania infantum leishmaniasis	corticosteroid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2745	CASE PRESENTATION: Three cases of [s1]Leishmania infantum leishmaniasis[e1] in [s2]corticosteroid[e2] (CS)-treated patients are reported: an isolated lingual leishmaniasis in a farmer treated with CS for asthma, a severe visceral leishmaniasis associated with cutaneous lesions in a woman with myasthenia gravis, and a visceral involvement after cutaneous leishmaniasis in a man receiving CS.
	(6, 23)	Leishmania infantum leishmaniasis	CS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2746	CASE PRESENTATION: Three cases of [s1]Leishmania infantum leishmaniasis[e1] in corticosteroid  [s2]CS[e2] -treated patients are reported: an isolated lingual leishmaniasis in a farmer treated with CS for asthma, a severe visceral leishmaniasis associated with cutaneous lesions in a woman with myasthenia gravis, and a visceral involvement after cutaneous leishmaniasis in a man receiving CS.
	(16, 34)	corticosteroid	lingual leishmaniasis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2747	CASE PRESENTATION: Three cases of Leishmania infantum leishmaniasis in [s1]corticosteroid[e1] (CS)-treated patients are reported: an isolated [s2]lingual leishmaniasis[e2] in a farmer treated with CS for asthma, a severe visceral leishmaniasis associated with cutaneous lesions in a woman with myasthenia gravis, and a visceral involvement after cutaneous leishmaniasis in a man receiving CS.
	(21, 32)	CS	lingual leishmaniasis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2748	CASE PRESENTATION: Three cases of Leishmania infantum leishmaniasis in corticosteroid  [s1]CS[e1] -treated patients are reported: an isolated [s2]lingual leishmaniasis[e2] in a farmer treated with CS for asthma, a severe visceral leishmaniasis associated with cutaneous lesions in a woman with myasthenia gravis, and a visceral involvement after cutaneous leishmaniasis in a man receiving CS.
	(0, 12)	Leishmania infantum leishmaniasis	corticosteroid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2749	 [s1]Leishmania infantum leishmaniasis[e1] in [s2]corticosteroid[e2] -treated patients.
	(5, 10)	Ritalin	glaucoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2750	However, an association of [s1]Ritalin[e1] with [s2]glaucoma[e2] has been reported.
	(3, 11)	methylphenidate	cataract	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2751	Large dose of [s1]methylphenidate[e1] may cause [s2]cataract[e2] and glaucoma.
	(3, 15)	methylphenidate	glaucoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2752	Large dose of [s1]methylphenidate[e1] may cause cataract and [s2]glaucoma[e2] 
	(0, 12)	Methylphenidate	cataract	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2753	 [s1]Methylphenidate[e1] (Ritalin)-associated [s2]cataract[e2] and glaucoma.
	(4, 10)	Ritalin	cataract	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2754	Methylphenidate  [s1]Ritalin[e1] -associated [s2]cataract[e2] and glaucoma.
	(0, 16)	Methylphenidate	glaucoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2755	 [s1]Methylphenidate[e1] (Ritalin)-associated cataract and [s2]glaucoma[e2] 
	(4, 14)	Ritalin	glaucoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2756	Methylphenidate  [s1]Ritalin[e1] -associated cataract and [s2]glaucoma[e2] 
	(5, 10)	Ritalin	cataract	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2757	We report a case of [s1]Ritalin[e1] associated [s2]cataract[e2] and glaucoma.
	(5, 14)	Ritalin	glaucoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2758	We report a case of [s1]Ritalin[e1] associated cataract and [s2]glaucoma[e2] 
	(12, 26)	CBS	Avastin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2759	CONCLUSIONS: We report a typical symptoms of Charles-Bonnet syndrome  [s1]CBS[e1]  in patients with severe AMD after intravitreal [s2]Avastin[e2] injections.
	(8, 28)	Charles-Bonnet syndrome	Avastin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2760	CONCLUSIONS: We report a typical symptoms of [s1]Charles-Bonnet syndrome[e1] (CBS) in patients with severe AMD after intravitreal [s2]Avastin[e2] injections.
	(4, 36)	transient structured visual hallucinations	Avastin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2761	PURPOSE: To describe [s1]transient structured visual hallucinations[e1] in a patient with vascular age-related macular degeneration (AMD), following an intravitreal [s2]Avastin[e2] injection.
	(0, 13)	Visual hallucinations	bevacizumab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2762	 [s1]Visual hallucinations[e1] after intravitreal injection of [s2]bevacizumab[e2] in vascular age-related macular degeneration.
	(3, 12)	metoclopramide	oculogyric crisis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2763	A case of [s1]metoclopramide[e1] induced [s2]oculogyric crisis[e2] in a 16-year-old girl with cystic fibrosis.
	(3, 12)	oculogyric crisis	metoclopramide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2764	A case of [s1]oculogyric crisis[e1] induced by [s2]metoclopramide[e2] is described in this paper.
	(2, 16)	cyclosporine	nephrotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2765	However, [s1]cyclosporine[e1] dependency is associated with the risk of [s2]nephrotoxicity[e2] 
	(0, 26)	Quinapril	prolonged hypotension	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2766	 [s1]Quinapril[e1] is an angiotensin-converting enzyme inhibitor (ACE-inhibitor) and overdose can lead to [s2]prolonged hypotension[e2] and, less frequently, transient renal impairment.
	(0, 37)	Quinapril	transient renal impairment	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2767	 [s1]Quinapril[e1] is an angiotensin-converting enzyme inhibitor (ACE-inhibitor) and overdose can lead to prolonged hypotension and, less frequently, [s2]transient renal impairment[e2] 
	(0, 20)	Cardiomyopathy	actinomycin-D	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2768	 [s1]Cardiomyopathy[e1] after widely separated courses of adriamycin exacerbated by [s2]actinomycin-D[e2] and mithramycin.
	(0, 11)	Cardiomyopathy	adriamycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2769	 [s1]Cardiomyopathy[e1] after widely separated courses of [s2]adriamycin[e2] exacerbated by actinomycin-D and mithramycin.
	(0, 27)	Cardiomyopathy	mithramycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2770	 [s1]Cardiomyopathy[e1] after widely separated courses of adriamycin exacerbated by actinomycin-D and [s2]mithramycin[e2] 
	(0, 23)	Exacerbations of the heart failure	actinomycin-D	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2771	 [s1]Exacerbations of the heart failure[e1] were temporally related to the administration of the antitumor antibiotics [s2]actinomycin-D[e2] (NSC-3053) and mithramycin (NSC-24559).
	(0, 37)	Exacerbations of the heart failure	mithramycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2772	 [s1]Exacerbations of the heart failure[e1] were temporally related to the administration of the antitumor antibiotics actinomycin-D (NSC-3053) and [s2]mithramycin[e2] (NSC-24559).
	(0, 41)	Exacerbations of the heart failure	NSC-24559	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2773	 [s1]Exacerbations of the heart failure[e1] were temporally related to the administration of the antitumor antibiotics actinomycin-D (NSC-3053) and mithramycin  [s2]NSC-24559[e2] .
	(0, 29)	Exacerbations of the heart failure	NSC-3053	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2774	 [s1]Exacerbations of the heart failure[e1] were temporally related to the administration of the antitumor antibiotics actinomycin-D  [s2]NSC-3053[e2]  and mithramycin (NSC-24559).
	(9, 15)	adriamycin	cardiomyopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2775	The pathogenic mechanisms involved in the development of [s1]adriamycin[e1]  [s2]cardiomyopathy[e2] are reviewed, and the possible synergistic effect of other antitumor antibiotics is discussed.
	(0, 22)	Cardiac hypersensitivity	mesalazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2776	 [s1]Cardiac hypersensitivity[e1] and myopericarditis have been reported during long-term treatment with [s2]mesalazine[e2] 
	(6, 22)	myopericarditis	mesalazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2777	Cardiac hypersensitivity and [s1]myopericarditis[e1] have been reported during long-term treatment with [s2]mesalazine[e2] 
	(10, 27)	mesalazine	pericarditis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2778	We report the case of a man, treated with [s1]mesalazine[e1] for Crohn's disease who developed drug-induced [s2]pericarditis[e2] 
	(3, 8)	hepatitis	erlotinib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2779	Acute drug induced [s1]hepatitis[e1] due to [s2]erlotinib[e2] 
	(8, 15)	acute severe hepatitis	erlotinib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2780	CASE REPORT: We report a case of [s1]acute severe hepatitis[e1] resulting from [s2]erlotinib[e2] monotherapy in a patient with locally advanced pancreatic cancer.
	(2, 22)	Acute severe hepatitis	erlotinib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2781	CONCLUSIONS: [s1]Acute severe hepatitis[e1] though rare is occasionally observed with EGFR inhibitors gefitinib or [s2]erlotinib[e2] 
	(2, 17)	Acute severe hepatitis	gefitinib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2782	CONCLUSIONS: [s1]Acute severe hepatitis[e1] though rare is occasionally observed with EGFR inhibitors [s2]gefitinib[e2] or erlotinib.
	(0, 10)	Hepatotoxicity	erlotinib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2783	 [s1]Hepatotoxicity[e1] resolved once [s2]erlotinib[e2] was discontinued and serum transaminases returned to baseline normal values.
	(0, 6)	Heparin	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2784	 [s1]Heparin[e1] associated [s2]thrombocytopenia[e2] and thrombosis is a severe complication of systemic heparin therapy.
	(5, 25)	thrombocytopenia	heparin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2785	Heparin-associated [s1]thrombocytopenia[e1] and thrombosis is a severe complication of systemic [s2]heparin[e2] therapy.
	(0, 13)	Heparin	thrombosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2786	 [s1]Heparin[e1] associated thrombocytopenia and [s2]thrombosis[e2] is a severe complication of systemic heparin therapy.
	(12, 25)	thrombosis	heparin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2787	Heparin-associated thrombocytopenia and [s1]thrombosis[e1] is a severe complication of systemic [s2]heparin[e2] therapy.
	(6, 25)	heparin	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2788	This experience supports the hypothesis that [s1]heparin[e1] can be readministered early to patients with heparin-associated [s2]thrombocytopenia[e2] and thrombosis, provided antiplatelet therapy is given.
	(6, 32)	heparin	thrombosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2789	This experience supports the hypothesis that [s1]heparin[e1] can be readministered early to patients with heparin-associated thrombocytopenia and [s2]thrombosis[e2]  provided antiplatelet therapy is given.
	(11, 17)	heparin	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2790	Usefulness of antiplatelet drugs in the management of [s1]heparin[e1] associated [s2]thrombocytopenia[e2] and thrombosis.
	(11, 24)	heparin	thrombosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2791	Usefulness of antiplatelet drugs in the management of [s1]heparin[e1] associated thrombocytopenia and [s2]thrombosis[e2] 
	(6, 24)	fixed drug eruption	Cialis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2792	RESULTS: A clinical diagnosis of [s1]fixed drug eruption[e1] owing to use of the PDE5 inhibitor tadalafil  [s2]Cialis[e2]  was made.
	(6, 20)	fixed drug eruption	tadalafil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2793	RESULTS: A clinical diagnosis of [s1]fixed drug eruption[e1] owing to use of the PDE5 inhibitor [s2]tadalafil[e2] (Cialis) was made.
	(18, 25)	docetaxel	pulmonary toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2794	Even though only a few cases of this adverse event have been reported in the literature, severe [s1]docetaxel[e1] induced [s2]pulmonary toxicity[e2] needs to be considered in the differential diagnosis when such patients present with respiratory symptoms.
	(0, 13)	Fatal interstitial pneumonitis	docetaxel	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2795	 [s1]Fatal interstitial pneumonitis[e1] associated with [s2]docetaxel[e2] administration in a patient with hormone-refractory prostate cancer.
	(28, 36)	docetaxel	subacute interstitial pneumonitis-related pulmonary fibrosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2796	The case is presented of a 72-year-old man with hormone-refractory prostate cancer and weekly administration of 30 mg/m2 [s1]docetaxel[e1] who developed [s2]subacute interstitial pneumonitis-related pulmonary fibrosis[e2] after seven doses and died despite mechanical ventilation and high-dose corticosteroid treatment.
	(4, 37)	fulminant microangiopathic hemolytic anemia	sulfamethoxazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2797	The patient presented with [s1]fulminant microangiopathic hemolytic anemia[e1] and thrombocytopenia within 48 hr of initiating therapy with trimethoprim [s2]sulfamethoxazole[e2] 
	(4, 33)	fulminant microangiopathic hemolytic anemia	trimethoprim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2798	The patient presented with [s1]fulminant microangiopathic hemolytic anemia[e1] and thrombocytopenia within 48 hr of initiating therapy with [s2]trimethoprim[e2] sulfamethoxazole.
	(18, 37)	thrombocytopenia	sulfamethoxazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2799	The patient presented with fulminant microangiopathic hemolytic anemia and [s1]thrombocytopenia[e1] within 48 hr of initiating therapy with trimethoprim [s2]sulfamethoxazole[e2] 
	(18, 33)	thrombocytopenia	trimethoprim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2800	The patient presented with fulminant microangiopathic hemolytic anemia and [s1]thrombocytopenia[e1] within 48 hr of initiating therapy with [s2]trimethoprim[e2] sulfamethoxazole.
	(0, 22)	Thrombotic thrombocytopenic purpura	sulfamethoxazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2801	 [s1]Thrombotic thrombocytopenic purpura[e1] induced by trimethoprim [s2]sulfamethoxazole[e2] in a Jehovah's Witness.
	(0, 18)	Thrombotic thrombocytopenic purpura	trimethoprim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2802	 [s1]Thrombotic thrombocytopenic purpura[e1] induced by [s2]trimethoprim[e2] sulfamethoxazole in a Jehovah's Witness.
	(5, 31)	Thrombotic Thrombocytopenic Purpura	sulfamethoxazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2803	We report a case of [s1]Thrombotic Thrombocytopenic Purpura[e1] occurring as an allergic response to trimethoprim [s2]sulfamethoxazole[e2] therapy (Bactrim, Septra) in a Jehovah's Witness patient.
	(5, 27)	Thrombotic Thrombocytopenic Purpura	trimethoprim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2804	We report a case of [s1]Thrombotic Thrombocytopenic Purpura[e1] occurring as an allergic response to [s2]trimethoprim[e2] sulfamethoxazole therapy (Bactrim, Septra) in a Jehovah's Witness patient.
	(0, 12)	Juvenile absence epilepsy	valproic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2805	 [s1]Juvenile absence epilepsy[e1] exacerbated by [s2]valproic acid[e2] 
	(6, 19)	paradoxical	seizure exacerbation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2806	This report describes a case of [s1]paradoxical[e1]  intravenous valproic acid-induced [s2]seizure exacerbation[e2] in a child with juvenile absence epilepsy, documented by video-electroencephalography.
	(12, 19)	valproic acid	seizure exacerbation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2807	This report describes a case of paradoxical, intravenous [s1]valproic acid[e1] induced [s2]seizure exacerbation[e2] in a child with juvenile absence epilepsy, documented by video-electroencephalography.
	(0, 19)	Acute endophthalmitis	Avastin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2808	 [s1]Acute endophthalmitis[e1] following intravitreal bevacizumab  [s2]Avastin[e2]  injection.
	(0, 14)	Acute endophthalmitis	bevacizumab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2809	 [s1]Acute endophthalmitis[e1] following intravitreal [s2]bevacizumab[e2] (Avastin) injection.
	(2, 21)	Infectious endophthalmitis	bevacizumab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2810	CONCLUSIONS: [s1]Infectious endophthalmitis[e1] is a potential complication of intravitreal [s2]bevacizumab[e2] injection.
	(8, 30)	age-related macular degeneration	bevacizumab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2811	METHODS: Two patients with exudative [s1]age-related macular degeneration[e1] were treated sequentially with an intravitreal injection of [s2]bevacizumab[e2] and developed signs of severe but painless infectious endophthalmitis 2 days later.
	(28, 41)	bevacizumab	painless infectious endophthalmitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2812	METHODS: Two patients with exudative age-related macular degeneration were treated sequentially with an intravitreal injection of [s1]bevacizumab[e1] and developed signs of severe but [s2]painless infectious endophthalmitis[e2] 2 days later.
	(7, 21)	acute endophthalmitis	bevacizumab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2813	PURPOSE: To report two cases of [s1]acute endophthalmitis[e1] following intravitreal [s2]bevacizumab[e2] injection.
	(0, 6)	Pulmonary hypertension	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2814	 [s1]Pulmonary hypertension[e1] during [s2]lithium[e2] therapy: clinical case study.
	(6, 12)	pulmonary hypertension	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2815	The authors presented a case of [s1]pulmonary hypertension[e1] during [s2]lithium[e2] therapy, while she has been on lithium for 6 years.
	(6, 16)	pulmonary hypertension	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2816	This is the first report of [s1]pulmonary hypertension[e1] in an adult patient during [s2]lithium[e2] therapy.
	(4, 14)	arthritis	infliximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2817	The patient's [s1]arthritis[e1] flared after the second infusion of [s2]infliximab[e2]  which was discontinued.
	(20, 36)	circulatory collapse	perospirone hydrochloride	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2818	A 32-year-old man with a family history of type 2 diabetes mellitus presented with [s1]circulatory collapse[e1] and deep coma after 9 days of treatment with [s2]perospirone hydrochloride[e2]  a recently developed atypical antipsychotic agent available only in Japan.
	(26, 36)	deep coma	perospirone hydrochloride	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2819	A 32-year-old man with a family history of type 2 diabetes mellitus presented with circulatory collapse and [s1]deep coma[e1] after 9 days of treatment with [s2]perospirone hydrochloride[e2]  a recently developed atypical antipsychotic agent available only in Japan.
	(6, 27)	diabetic ketoacidosis	perospirone hydrochloride	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2820	The risk of new-onset [s1]diabetic ketoacidosis[e1] in patients with diabetic risk factors who are taking [s2]perospirone hydrochloride[e2] or other atypical antipsychotics should be kept in mind.
	(0, 14)	Fatal venous thrombembolism	imatinib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2821	 [s1]Fatal venous thrombembolism[e1] complicating [s2]imatinib[e2] therapy in a patient with metastatic gastrointestinal stromal tumor.
	(3, 45)	deep vein thrombosis	imatinib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2822	The possibility of [s1]deep vein thrombosis[e1] caused by the compression of the veins by necrotic tumor should be considered in patients with abdominal or pelvic metastases of GIST, including patients treated with [s2]imatinib[e2] 
	(22, 32)	status epilepticus	cisplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2823	We describe the case of a 50-year-old woman with advanced non-small cell lung cancer who developed [s1]status epilepticus[e1] shortly after receiving [s2]cisplatin[e2] and gemcitabine chemotherapy.
	(22, 36)	status epilepticus	gemcitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2824	We describe the case of a 50-year-old woman with advanced non-small cell lung cancer who developed [s1]status epilepticus[e1] shortly after receiving cisplatin and [s2]gemcitabine[e2] chemotherapy.
	(8, 23)	fluctuation of the QT interval	methadone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2825	Of particular interest in this patient is the [s1]fluctuation of the QT interval[e1] at a stable dose of [s2]methadone[e2]  suggesting that a single normal electrocardiogram (ECG) does not guarantee that the patient is not at risk of ventricular arrhythmias.
	(11, 21)	prolonged QT	methadone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2826	We present a case report of a patient who developed a [s1]prolonged QT[e1] while being treated with oral [s2]methadone[e2] for a chronic pain syndrome.
	(7, 15)	piloerection	fluvoxamine maleate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2827	AIMS: To present a case of [s1]piloerection[e1] after replacing [s2]fluvoxamine maleate[e2] with milnacipran hydrochloride, and to analyse this effect based on receptor occupancy theory.
	(7, 22)	piloerection	milnacipran hydrochloride	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2828	AIMS: To present a case of [s1]piloerection[e1] after replacing fluvoxamine maleate with [s2]milnacipran hydrochloride[e2]  and to analyse this effect based on receptor occupancy theory.
	(3, 14)	piloerection	fluvoxamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2829	CONCLUSIONS: The [s1]piloerection[e1] observed after the replacement of [s2]fluvoxamine[e2] with milnacipran in this patient appears to have been due to an increase in the alpha(1)-adrenoceptor occupancy by endogenous norepinephrine induced by milnacipran.
	(3, 19)	piloerection	milnacipran	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2830	CONCLUSIONS: The [s1]piloerection[e1] observed after the replacement of fluvoxamine with [s2]milnacipran[e2] in this patient appears to have been due to an increase in the alpha(1)-adrenoceptor occupancy by endogenous norepinephrine induced by milnacipran.
	(0, 9)	Piloerection	fluvoxamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2831	 [s1]Piloerection[e1] induced by replacing [s2]fluvoxamine[e2] with milnacipran.
	(0, 14)	Piloerection	milnacipran	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2832	 [s1]Piloerection[e1] induced by replacing fluvoxamine with [s2]milnacipran[e2] 
	(11, 38)	recurrent eosinophilia	tobramycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2833	CASE PRESENTATION: We report a patient with CF who developed [s1]recurrent eosinophilia[e1] and severe persistent bronchospasm following repeated administration of preservative-free [s2]tobramycin[e2] by inhalation, beginning at 16 months of age.
	(19, 38)	severe persistent bronchospasm	tobramycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2834	CASE PRESENTATION: We report a patient with CF who developed recurrent eosinophilia and [s1]severe persistent bronchospasm[e1] following repeated administration of preservative-free [s2]tobramycin[e2] by inhalation, beginning at 16 months of age.
	(22, 32)	deterioration of pulmonary function	tobramycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2835	CONCLUSION: Hypersensitivity reaction should be considered in patients who develop recurrent eosinophilia and [s1]deterioration of pulmonary function[e1] following the use of [s2]tobramycin[e2] by inhalation or by intravenous administration.
	(14, 32)	recurrent eosinophilia	tobramycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2836	CONCLUSION: Hypersensitivity reaction should be considered in patients who develop [s1]recurrent eosinophilia[e1] and deterioration of pulmonary function following the use of [s2]tobramycin[e2] by inhalation or by intravenous administration.
	(1, 10)	tobramycin	recurrent eosinophilia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2837	Inhaled [s1]tobramycin[e1] solution-associated [s2]recurrent eosinophilia[e2] and severe persistent bronchospasm in a patient with cystic fibrosis: a case report.
	(1, 18)	tobramycin	severe persistent bronchospasm	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2838	Inhaled [s1]tobramycin[e1] solution-associated recurrent eosinophilia and [s2]severe persistent bronchospasm[e2] in a patient with cystic fibrosis: a case report.
	(7, 30)	bisphosphonate	osteonecrosis of the mandible	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2839	The most serious dental side effect of [s1]bisphosphonate[e1] treatment (particularly when it is administered intravenously) is, paradoxically, [s2]osteonecrosis of the mandible[e2] or the maxilla represented by exposed nonhealing bone.
	(3, 19)	amiodarone	aggravation of arrhythmia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2840	Adverse effects of [s1]amiodarone[e1] including pulmonary toxicity, hepatotoxicity, [s2]aggravation of arrhythmia[e2]  and thyroid diseases are well understood.
	(3, 12)	amiodarone	hepatotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2841	Adverse effects of [s1]amiodarone[e1] including pulmonary toxicity, [s2]hepatotoxicity[e2]  aggravation of arrhythmia, and thyroid diseases are well understood.
	(3, 9)	amiodarone	pulmonary toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2842	Adverse effects of [s1]amiodarone[e1] including [s2]pulmonary toxicity[e2]  hepatotoxicity, aggravation of arrhythmia, and thyroid diseases are well understood.
	(3, 30)	amiodarone	thyroid diseases	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2843	Adverse effects of [s1]amiodarone[e1] including pulmonary toxicity, hepatotoxicity, aggravation of arrhythmia, and [s2]thyroid diseases[e2] are well understood.
	(0, 17)	Pancreatitis	amiodarone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2844	 [s1]Pancreatitis[e1] is a very rare adverse effect associated with the use of [s2]amiodarone[e2]  and only four cases of amiodarone-induced pancreatitis have been reported in literature.
	(15, 30)	amiodarone	pancreatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2845	Pancreatitis is a very rare adverse effect associated with the use of [s1]amiodarone[e1]  and only four cases of amiodarone-induced [s2]pancreatitis[e2] have been reported in literature.
	(4, 10)	amiodarone	acute pancreatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2846	Under the suspicion of [s1]amiodarone[e1] induced [s2]acute pancreatitis[e2]  amiodarone was substituted by propafenone.
	(6, 14)	acute pancreatitis	amiodarone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2847	We report a patient who developed [s1]acute pancreatitis[e1] during [s2]amiodarone[e2] therapy.
	(12, 23)	tuberculous uveitis	etanercept	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2848	DISCUSSION: To our knowledge this is the first reported case of [s1]tuberculous uveitis[e1] following treatment with [s2]etanercept[e2] 
	(0, 11)	Tuberculous uveitis	etanercept	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2849	 [s1]Tuberculous uveitis[e1] after treatment with [s2]etanercept[e2] 
	(6, 16)	tuberculous uveitis	etanercept	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2850	We report the first case of [s1]tuberculous uveitis[e1] due to [s2]etanercept[e2] 
	(4, 18)	melanonychia	pemetrexed	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2851	A complex pattern of [s1]melanonychia[e1] and onycholysis after treatment with [s2]pemetrexed[e2] for lung cancer.
	(9, 18)	onycholysis	pemetrexed	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2852	A complex pattern of melanonychia and [s1]onycholysis[e1] after treatment with [s2]pemetrexed[e2] for lung cancer.
	(0, 19)	Infliximab	osteomyelitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2853	 [s1]Infliximab[e1] and its serious adverse effects are discussed, and other cases of [s2]osteomyelitis[e2] with infliximab use are also reviewed.
	(17, 25)	osteomyelitis	infliximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2854	Infliximab and its serious adverse effects are discussed, and other cases of [s1]osteomyelitis[e1] with [s2]infliximab[e2] use are also reviewed.
	(0, 9)	Osteomyelitis	infliximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2855	 [s1]Osteomyelitis[e1] occurring during [s2]infliximab[e2] treatment of severe psoriasis.
	(9, 26)	serotonin syndrome	citalopram	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2856	Based on the Naranjo probability scale, [s1]serotonin syndrome[e1] was a probable adverse reaction associated with co-administration of [s2]citalopram[e2] and fentanyl.
	(9, 31)	serotonin syndrome	fentanyl	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2857	Based on the Naranjo probability scale, [s1]serotonin syndrome[e1] was a probable adverse reaction associated with co-administration of citalopram and [s2]fentanyl[e2] 
	(27, 36)	citalopram	agitation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2858	CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) [s1]citalopram[e1] developed confusion, [s2]agitation[e2]  tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl.
	(34, 68)	agitation	fentanyl	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2859	CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, [s1]agitation[e1]  tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of [s2]fentanyl[e2]  and all symptoms and signs resolved following discontinuation of fentanyl.
	(34, 68)	agitation	fentanyl	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2860	CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, [s1]agitation[e1]  tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of [s2]fentanyl[e2]  and all symptoms and signs resolved following discontinuation of fentanyl.
	(27, 34)	citalopram	confusion	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2861	CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) [s1]citalopram[e1] developed [s2]confusion[e2]  agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl.
	(32, 68)	confusion	fentanyl	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2862	CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed [s1]confusion[e1]  agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of [s2]fentanyl[e2]  and all symptoms and signs resolved following discontinuation of fentanyl.
	(32, 68)	confusion	fentanyl	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2863	CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed [s1]confusion[e1]  agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of [s2]fentanyl[e2]  and all symptoms and signs resolved following discontinuation of fentanyl.
	(27, 46)	citalopram	myoclonic jerks	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2864	CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) [s1]citalopram[e1] developed confusion, agitation, tachycardia, tremors, [s2]myoclonic jerks[e2] and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl.
	(44, 69)	myoclonic jerks	fentanyl	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2865	CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, tremors, [s1]myoclonic jerks[e1] and unsteady gait, consistent with serotonin syndrome, following initiation of [s2]fentanyl[e2]  and all symptoms and signs resolved following discontinuation of fentanyl.
	(44, 69)	myoclonic jerks	fentanyl	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2866	CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, tremors, [s1]myoclonic jerks[e1] and unsteady gait, consistent with serotonin syndrome, following initiation of [s2]fentanyl[e2]  and all symptoms and signs resolved following discontinuation of fentanyl.
	(27, 61)	citalopram	serotonin syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2867	CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) [s1]citalopram[e1] developed confusion, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with [s2]serotonin syndrome[e2]  following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl.
	(59, 68)	serotonin syndrome	fentanyl	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2868	CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with [s1]serotonin syndrome[e1]  following initiation of [s2]fentanyl[e2]  and all symptoms and signs resolved following discontinuation of fentanyl.
	(59, 68)	serotonin syndrome	fentanyl	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2869	CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with [s1]serotonin syndrome[e1]  following initiation of [s2]fentanyl[e2]  and all symptoms and signs resolved following discontinuation of fentanyl.
	(27, 38)	citalopram	tachycardia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2870	CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) [s1]citalopram[e1] developed confusion, agitation, [s2]tachycardia[e2]  tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl.
	(36, 68)	tachycardia	fentanyl	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2871	CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, [s1]tachycardia[e1]  tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of [s2]fentanyl[e2]  and all symptoms and signs resolved following discontinuation of fentanyl.
	(36, 68)	tachycardia	fentanyl	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2872	CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, [s1]tachycardia[e1]  tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of [s2]fentanyl[e2]  and all symptoms and signs resolved following discontinuation of fentanyl.
	(27, 43)	citalopram	tremors	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2873	CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) [s1]citalopram[e1] developed confusion, agitation, tachycardia, [s2]tremors[e2]  myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl.
	(41, 68)	tremors	fentanyl	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2874	CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, [s1]tremors[e1]  myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of [s2]fentanyl[e2]  and all symptoms and signs resolved following discontinuation of fentanyl.
	(41, 68)	tremors	fentanyl	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2875	CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, [s1]tremors[e1]  myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of [s2]fentanyl[e2]  and all symptoms and signs resolved following discontinuation of fentanyl.
	(27, 53)	citalopram	unsteady gait	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2876	CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) [s1]citalopram[e1] developed confusion, agitation, tachycardia, tremors, myoclonic jerks and [s2]unsteady gait[e2]  consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl.
	(51, 68)	unsteady gait	fentanyl	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2877	CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, tremors, myoclonic jerks and [s1]unsteady gait[e1]  consistent with serotonin syndrome, following initiation of [s2]fentanyl[e2]  and all symptoms and signs resolved following discontinuation of fentanyl.
	(51, 68)	unsteady gait	fentanyl	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2878	CASE SUMMARY: A 65-year-old patient chronically treated with the selective serotonin reuptake inhibitor (SSRI) citalopram developed confusion, agitation, tachycardia, tremors, myoclonic jerks and [s1]unsteady gait[e1]  consistent with serotonin syndrome, following initiation of [s2]fentanyl[e2]  and all symptoms and signs resolved following discontinuation of fentanyl.
	(12, 25)	serotonin syndrome	fentanyl	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2879	CONCLUSION: Healthcare professionals should be aware of the possible development of [s1]serotonin syndrome[e1] as a complication of initiation of [s2]fentanyl[e2] and other phenylpiperidine opioids in patients treated with SSRIs.
	(7, 21)	serotonin syndrome	citalopram	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2880	OBJECTIVE: To report a case of [s1]serotonin syndrome[e1] associated with interaction between fentanyl and [s2]citalopram[e2]  as evidenced by medication history, clinical features and reversal following discontinuation of fentanyl.
	(7, 17)	serotonin syndrome	fentanyl	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2881	OBJECTIVE: To report a case of [s1]serotonin syndrome[e1] associated with interaction between [s2]fentanyl[e2] and citalopram, as evidenced by medication history, clinical features and reversal following discontinuation of fentanyl.
	(7, 17)	serotonin syndrome	fentanyl	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2882	OBJECTIVE: To report a case of [s1]serotonin syndrome[e1] associated with interaction between [s2]fentanyl[e2] and citalopram, as evidenced by medication history, clinical features and reversal following discontinuation of fentanyl.
	(0, 10)	Serotonin syndrome	citalopram	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2883	 [s1]Serotonin syndrome[e1] caused by interaction between [s2]citalopram[e2] and fentanyl.
	(0, 15)	Serotonin syndrome	fentanyl	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2884	 [s1]Serotonin syndrome[e1] caused by interaction between citalopram and [s2]fentanyl[e2] 
	(0, 8)	Renal failure	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2885	 [s1]Renal failure[e1] after high-dose [s2]methotrexate[e2] in a child homozygous for MTHFR C677T polymorphism.
	(26, 43)	renal failure	HDMTX	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2886	We report the case of an 11-year-old female treated for mediastinal T-cell lymphoma who presented [s1]renal failure[e1] following the second cycle of high-dose methotrexate  [s2]HDMTX[e2] .
	(26, 38)	renal failure	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2887	We report the case of an 11-year-old female treated for mediastinal T-cell lymphoma who presented [s1]renal failure[e1] following the second cycle of high-dose [s2]methotrexate[e2] (HDMTX).
	(0, 7)	Docetaxel	Meibomian duct inflammation and blockage	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2888	 [s1]Docetaxel[e1] induced [s2]Meibomian duct inflammation and blockage[e2] is the likely cause of this presentation in a patient with no history of eyelid masses in the past.
	(0, 17)	Docetaxel	chalazion	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2889	 [s1]Docetaxel[e1] induced Meibomian duct inflammation and blockage leading to [s2]chalazion[e2] formation.
	(0, 7)	Docetaxel	Meibomian duct inflammation and blockage	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2890	 [s1]Docetaxel[e1] induced [s2]Meibomian duct inflammation and blockage[e2] leading to chalazion formation.
	(21, 33)	docetaxel	eye irritation and dryness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2891	We report a 71-year male with castration-resistant metastatic prostate cancer who was treated with weekly [s1]docetaxel[e1] for 12 weeks and developed significant [s2]eye irritation and dryness[e2] during treatment.
	(3, 13)	recall pneumonitis	gemcitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2892	A case of [s1]recall pneumonitis[e1] induced by [s2]gemcitabine[e2] is reported.
	(3, 20)	gemcitabine	dry cough	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2893	After having received [s1]gemcitabine[e1] on day 1 of the second course, the patient developed [s2]dry cough[e2]  subfebrile temperatures and dyspnea within 48 h.
	(3, 29)	gemcitabine	dyspnea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2894	After having received [s1]gemcitabine[e1] on day 1 of the second course, the patient developed dry cough, subfebrile temperatures and [s2]dyspnea[e2] within 48 h.
	(3, 23)	gemcitabine	subfebrile temperatures	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2895	After having received [s1]gemcitabine[e1] on day 1 of the second course, the patient developed dry cough, [s2]subfebrile temperatures[e2] and dyspnea within 48 h.
	(2, 9)	Gemcitabine	recall pneumonitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2896	CONCLUSION: [s1]Gemcitabine[e1] induced [s2]recall pneumonitis[e2] is a rarely reported phenomenon and should be taken into account even after extended time interval to the previous radiotherapy.
	(0, 11)	Radiation recall pneumonitis	gemcitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2897	 [s1]Radiation recall pneumonitis[e1] induced by [s2]gemcitabine[e2] 
	(6, 13)	vancomycin	neutropenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2898	CONCLUSIONS: For all patients with [s1]vancomycin[e1] induced [s2]neutropenia[e2]  possible cross-reactivity of teicoplanin should be monitored.
	(6, 50)	neutropenia	teicoplanin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2899	However, a new episode of [s1]neutropenia[e1]  with a WBC count of 2.8 x 10(3)/mm3 and ANC of 0.448 x 10(3)/mm3, occurred 11 days after [s2]teicoplanin[e2] initiation.
	(4, 12)	teicoplanin	neutropenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2900	OBJECTIVE: To report [s1]teicoplanin[e1] related [s2]neutropenia[e2] that developed after an episode of neutropenia induced by vancomycin therapy.
	(11, 29)	neutropenia	vancomycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2901	OBJECTIVE: To report teicoplanin-related [s1]neutropenia[e1] that developed after an episode of neutropenia induced by [s2]vancomycin[e2] therapy.
	(0, 8)	Teicoplanin	agranulocytosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2902	 [s1]Teicoplanin[e1] induced [s2]agranulocytosis[e2] that followed vancomycin-induced agranulocytosis suggests a possible cross-reactivity between the 2 drugs.
	(7, 16)	agranulocytosis	vancomycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2903	Teicoplanin-induced [s1]agranulocytosis[e1] that followed [s2]vancomycin[e2] induced agranulocytosis suggests a possible cross-reactivity between the 2 drugs.
	(0, 15)	Cutaneous ulceration	pentamidine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2904	 [s1]Cutaneous ulceration[e1]  an unusual complication of intravenous [s2]pentamidine[e2] therapy.
	(19, 38)	chemical cellulitis	pentamidine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2905	This is a report of a renal transplant patient with Pneumocystis pneumonia who developed [s1]chemical cellulitis[e1] and ulceration following the extravasation of intravenous [s2]pentamidine[e2] into the soft tissues of the left hand and forearm.
	(24, 38)	ulceration	pentamidine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2906	This is a report of a renal transplant patient with Pneumocystis pneumonia who developed chemical cellulitis and [s1]ulceration[e1] following the extravasation of intravenous [s2]pentamidine[e2] into the soft tissues of the left hand and forearm.
	(11, 30)	disfiguring facial edema	peginterferon alfa-2a	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2907	OBSERVATIONS: A 48-year-old woman presented with [s1]disfiguring facial edema[e1] 10 weeks after she began antiviral therapy with [s2]peginterferon alfa-2a[e2] and ribavirin for chronic hepatitis C infection.
	(11, 39)	disfiguring facial edema	ribavirin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2908	OBSERVATIONS: A 48-year-old woman presented with [s1]disfiguring facial edema[e1] 10 weeks after she began antiviral therapy with peginterferon alfa-2a and [s2]ribavirin[e2] for chronic hepatitis C infection.
	(0, 13)	Tumor-volume increase	interferon alpha 2-beta	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2909	 [s1]Tumor-volume increase[e1] at beginning of primary treatment with topical [s2]interferon alpha 2-beta[e2] in a case of conjunctiva-cornea intraepithelial neoplasia.
	(0, 12)	Flecainide	cardiovascular collapse	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2910	 [s1]Flecainide[e1] overdose can rapidly result in profound [s2]cardiovascular collapse[e2]  and is associated with a relatively high mortality.
	(1, 7)	cardiovascular collapse	flecainide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2911	Managing [s1]cardiovascular collapse[e1] in severe [s2]flecainide[e2] overdose without recourse to extracorporeal therapy.
	(0, 8)	Ezetimibe	acute pancreatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2912	 [s1]Ezetimibe[e1] induced [s2]acute pancreatitis[e2] 
	(13, 21)	ezetimibe	pancreatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2913	Since its FDA approval in 2002, there are no known citations of [s1]ezetimibe[e1] induced [s2]pancreatitis[e2] 
	(6, 14)	raloxifene	aggravation of nonalcoholic steatohepatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2914	Selective estrogen receptor modulator [s1]raloxifene[e1] associated [s2]aggravation of nonalcoholic steatohepatitis[e2] 
	(11, 18)	NASH	raloxifene	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2915	This is the first histologically confirmed case of [s1]NASH[e1] that was aggravated by [s2]raloxifene[e2] 
	(3, 10)	liver damage	Danazol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2916	A case of [s1]liver damage[e1] following treatment with [s2]Danazol[e2] for fibrocystic breast disease is reported.
	(0, 7)	Hepatic damage	danazol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2917	 [s1]Hepatic damage[e1] after [s2]danazol[e2] treatment.
	(0, 19)	Hypersensitivity pneumonitis-like syndrome	lenalidomide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2918	 [s1]Hypersensitivity pneumonitis-like syndrome[e1] associated with the use of [s2]lenalidomide[e2] 
	(9, 30)	lenalidomide	diffuse pulmonary infiltrates	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2919	In this report, we describe a patient receiving [s1]lenalidomide[e1] in whom dyspnea, fever, hypoxia, and [s2]diffuse pulmonary infiltrates[e2] developed.
	(9, 17)	lenalidomide	dyspnea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2920	In this report, we describe a patient receiving [s1]lenalidomide[e1] in whom [s2]dyspnea[e2]  fever, hypoxia, and diffuse pulmonary infiltrates developed.
	(9, 22)	lenalidomide	fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2921	In this report, we describe a patient receiving [s1]lenalidomide[e1] in whom dyspnea, [s2]fever[e2]  hypoxia, and diffuse pulmonary infiltrates developed.
	(9, 24)	lenalidomide	hypoxia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2922	In this report, we describe a patient receiving [s1]lenalidomide[e1] in whom dyspnea, fever, [s2]hypoxia[e2]  and diffuse pulmonary infiltrates developed.
	(15, 32)	thalidomide	fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2923	Physicians should be cognizant of this potential complication in patients receiving [s1]thalidomide[e1] or thalidomide-like drugs who present with [s2]fever[e2] and pulmonary infiltrates and fail to improve despite treatment with broad-spectrum antibiotics.
	(15, 34)	thalidomide	pulmonary infiltrates	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2924	Physicians should be cognizant of this potential complication in patients receiving [s1]thalidomide[e1] or thalidomide-like drugs who present with fever and [s2]pulmonary infiltrates[e2] and fail to improve despite treatment with broad-spectrum antibiotics.
	(16, 23)	lenalidomide	hypersensitivity pneumonitis-like syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2925	Thus, the patient's clinical course and workup strongly support a diagnosis of [s1]lenalidomide[e1] induced [s2]hypersensitivity pneumonitis-like syndrome[e2] 
	(4, 17)	triamcinolone	exacerbation of retinochoroiditis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2926	Intravitreal [s1]triamcinolone[e1] may have had an influence on the [s2]exacerbation of retinochoroiditis[e2] in the posterior pole of the patient.
	(22, 30)	rapid cognitive decline	ethambutol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2927	A 40-year-old man with advanced HIV infection and Mycobacterium avium complex infection experienced [s1]rapid cognitive decline[e1] after commencement of [s2]ethambutol[e2]  and symptoms fully resolved with cessation.
	(0, 11)	Ethambutol	acute onset psychosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2928	 [s1]Ethambutol[e1] toxicity manifesting as [s2]acute onset psychosis[e2] 
	(0, 7)	Psoriasis	interferon-alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2929	 [s1]Psoriasis[e1] induced by [s2]interferon-alpha[e2] 
	(0, 31)	Recombinant human interferon-alpha	exacerbate psoriasis or trigger off its onset	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2930	 [s1]Recombinant human interferon-alpha[e1] has been used in the treatment of several cancers, but there have been several reports that it may [s2]exacerbate psoriasis or trigger off its onset[e2] 
	(10, 29)	psoriasis	interferon-alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2931	We report four patients, three of whom first developed [s1]psoriasis[e1] and one who had an aggravation of the condition during treatment with [s2]interferon-alpha[e2] 
	(27, 40)	generalized erythema	sulfamethoxazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2932	A 61-year-old man with early diffuse cutaneous scleroderma with myositis and progressive interstitial pneumonia developed [s1]generalized erythema[e1] with high fever 3 weeks after taking [s2]sulfamethoxazole[e2] trimethoprim.
	(27, 47)	generalized erythema	trimethoprim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2933	A 61-year-old man with early diffuse cutaneous scleroderma with myositis and progressive interstitial pneumonia developed [s1]generalized erythema[e1] with high fever 3 weeks after taking sulfamethoxazole [s2]trimethoprim[e2] 
	(23, 36)	raised intracranial pressure	sodium valproic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2934	INTRODUCTION: We describe the neurointensive care (NIC) management of a patient with severe cerebral swelling and [s1]raised intracranial pressure[e1] (ICP) after severe [s2]sodium valproic acid[e2] (VPA) intoxication.
	(23, 41)	raised intracranial pressure	VPA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2935	INTRODUCTION: We describe the neurointensive care (NIC) management of a patient with severe cerebral swelling and [s1]raised intracranial pressure[e1] (ICP) after severe sodium valproic acid  [s2]VPA[e2]  intoxication.
	(19, 36)	severe cerebral swelling	sodium valproic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2936	INTRODUCTION: We describe the neurointensive care (NIC) management of a patient with [s1]severe cerebral swelling[e1] and raised intracranial pressure (ICP) after severe [s2]sodium valproic acid[e2] (VPA) intoxication.
	(19, 41)	severe cerebral swelling	VPA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2937	INTRODUCTION: We describe the neurointensive care (NIC) management of a patient with [s1]severe cerebral swelling[e1] and raised intracranial pressure (ICP) after severe sodium valproic acid  [s2]VPA[e2]  intoxication.
	(8, 18)	raised intracranial pressure	valproic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2938	Neurointensive care management of [s1]raised intracranial pressure[e1] caused by severe [s2]valproic acid[e2] intoxication.
	(0, 7)	Bleomycin	hyperpigmentation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2939	 [s1]Bleomycin[e1] induced [s2]hyperpigmentation[e2] with yolk sac tumor.
	(26, 31)	skin toxicity	bleomycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2940	The hyperpigmentation was diffuse scattered, flagellate like and linear streaking which was thought to be mainly related to the [s1]skin toxicity[e1] of [s2]bleomycin[e2] 
	(11, 35)	localized pigmentation	bleomycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2941	We report a child with yolk sac tumor who developed [s1]localized pigmentation[e1] after the first course of chemotherapy regimen that included cisplatin, etoposide and [s2]bleomycin[e2] 
	(11, 26)	localized pigmentation	cisplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2942	We report a child with yolk sac tumor who developed [s1]localized pigmentation[e1] after the first course of chemotherapy regimen that included [s2]cisplatin[e2]  etoposide and bleomycin.
	(11, 30)	localized pigmentation	etoposide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2943	We report a child with yolk sac tumor who developed [s1]localized pigmentation[e1] after the first course of chemotherapy regimen that included cisplatin, [s2]etoposide[e2] and bleomycin.
	(6, 18)	capecitabine	headache	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2944	A cause-effect relationship to [s1]capecitabine[e1] was suggested due to resolution of [s2]headache[e2] with capecitabine withdrawal and reappearance with capecitabine rechallenge.
	(2, 15)	Headaches	capecitabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2945	BACKGROUND: [s1]Headaches[e1] have been reported as a potential side effect of [s2]capecitabine[e2] therapy.
	(0, 7)	Capecitabine	headache	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2946	 [s1]Capecitabine[e1] induced [s2]headache[e2] responding to diltiazem.
	(9, 21)	5-FU	headaches	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2947	CCBs should be considered in the treatment of [s1]5-FU[e1] or capecitabine-induced [s2]headaches[e2] 
	(13, 20)	capecitabine	headaches	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2948	CCBs should be considered in the treatment of 5-FU or [s1]capecitabine[e1] induced [s2]headaches[e2] 
	(5, 12)	capecitabine	headache	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2949	The patient developed grade 3 [s1]capecitabine[e1] induced [s2]headache[e2] 
	(7, 14)	capecitabine	headache	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2950	We hypothesize that [s1]capecitabine[e1] induced [s2]headache[e2] is vascular in nature.
	(0, 19)	Brugada type electrocardiographic changes	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2951	 [s1]Brugada type electrocardiographic changes[e1] induced by concomitant use of [s2]lithium[e2] and propafenone in patient with Wolff-Parkinson-White syndrome.
	(0, 21)	Brugada type electrocardiographic changes	propafenone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2952	 [s1]Brugada type electrocardiographic changes[e1] induced by concomitant use of lithium and [s2]propafenone[e2] in patient with Wolff-Parkinson-White syndrome.
	(5, 26)	ST elevation in right precordial leads	propafenone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2953	We report a case of [s1]ST elevation in right precordial leads[e1] compatible with type 1 Brugada syndrome following administration of [s2]propafenone[e2] in a patient with Wolff-Parkinson-White syndrome who was receiving lithium at concentrations within therapeutic levels.
	(15, 26)	type 1 Brugada syndrome	propafenone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2954	We report a case of ST elevation in right precordial leads compatible with [s1]type 1 Brugada syndrome[e1] following administration of [s2]propafenone[e2] in a patient with Wolff-Parkinson-White syndrome who was receiving lithium at concentrations within therapeutic levels.
	(4, 11)	gastritis	dexamethasone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2955	We postulate that [s1]gastritis[e1] caused by [s2]dexamethasone[e2]  mucositis caused by doxorubicin, and the unique anatomic nature of a Meckel diverticulum may have contributed to this extremely unlikely and previously unreported event.
	(15, 22)	mucositis	doxorubicin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2956	We postulate that gastritis caused by dexamethasone, [s1]mucositis[e1] caused by [s2]doxorubicin[e2]  and the unique anatomic nature of a Meckel diverticulum may have contributed to this extremely unlikely and previously unreported event.
	(0, 16)	Bortezomib	gastrointestinal side effect	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2957	 [s1]Bortezomib[e1] induced paralytic ileus is a potential [s2]gastrointestinal side effect[e2] of this first-in-class anticancer proteasome inhibitor.
	(0, 8)	Bortezomib	paralytic ileus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2958	 [s1]Bortezomib[e1] induced [s2]paralytic ileus[e2] is a potential gastrointestinal side effect of this first-in-class anticancer proteasome inhibitor.
	(0, 10)	Paralytic ileus	bortezomib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2959	 [s1]Paralytic ileus[e1] in patients undergoing [s2]bortezomib[e2] treatment has been reported, although a definite attribution to bortezomib administration has not been established.
	(9, 18)	severe paralytic ileus	bortezomib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2960	We report a myeloma patient who developed [s1]severe paralytic ileus[e1] during [s2]bortezomib[e2] therapy, which presented in the context of progressive constipation without other known causes and which regressed promptly with medical management after drug cessation, suggesting a direct causal relationship.
	(3, 13)	delusional parasitosis	phenelzine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2961	A woman developed [s1]delusional parasitosis[e1] when taking [s2]phenelzine[e2] 
	(0, 10)	Delusional parasitosis	phenelzine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2962	 [s1]Delusional parasitosis[e1] associated with [s2]phenelzine[e2] 
	(9, 24)	alveolar hemorrhage	rituximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2963	Interstitial pneumonitis and [s1]alveolar hemorrhage[e1] complicating use of [s2]rituximab[e2]  case report and review of the literature.
	(0, 24)	Interstitial pneumonitis	rituximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2964	 [s1]Interstitial pneumonitis[e1] and alveolar hemorrhage complicating use of [s2]rituximab[e2]  case report and review of the literature.
	(3, 16)	rituximab	delayed pulmonary toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2965	The use of [s1]rituximab[e1] has been uncommonly associated with [s2]delayed pulmonary toxicity[e2] 
	(4, 13)	metoclopramide	neuroleptic malignant syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2966	Fulminant [s1]metoclopramide[e1] induced [s2]neuroleptic malignant syndrome[e2] rapidly responsive to intravenous dantrolene.
	(9, 35)	neuroleptic malignant syndrome	metoclopramide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2967	We report a case of fulminant [s1]neuroleptic malignant syndrome[e1] in a man aged 70 developing within 12 hours of starting six-hourly intravenous [s2]metoclopramide[e2] 
	(4, 22)	gastric mucosa foveolar hyperplasia	PGE1	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2968	The clinical symptoms of [s1]gastric mucosa foveolar hyperplasia[e1] due to long-term [s2]PGE1[e2] therapy simulate hypertrophic pyloric stenosis.
	(16, 32)	gastric mucosa foveolar hyperplasia	PGE1	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2969	The results of the ultrasound examination combined with clinical anamnesis allowed diagnosis of [s1]gastric mucosa foveolar hyperplasia[e1] due to prolonged [s2]PGE1[e2] therapy.
	(40, 56)	fatigue	colchicine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2970	A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of [s1]fatigue[e1]  myalgia, and leg weakness, shortly after starting treatment with [s2]colchicine[e2] 
	(47, 56)	leg weakness	colchicine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2971	A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of fatigue, myalgia, and [s1]leg weakness[e1]  shortly after starting treatment with [s2]colchicine[e2] 
	(42, 56)	myalgia	colchicine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2972	A 79-year-old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of fatigue, [s1]myalgia[e1]  and leg weakness, shortly after starting treatment with [s2]colchicine[e2] 
	(3, 9)	colchicine	rhabdomyolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2973	A case of [s1]colchicine[e1] induced [s2]rhabdomyolysis[e2] is reported.
	(0, 6)	Colchicine	rhabdomyolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2974	 [s1]Colchicine[e1] induced [s2]rhabdomyolysis[e2] is a rare complication, and the postulated mechanisms and risk factors for this severe complication are discussed.
	(0, 6)	Colchicine	rhabdomyolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2975	 [s1]Colchicine[e1] induced [s2]rhabdomyolysis[e2] 
	(17, 32)	colchicine	rhabdomylysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2976	Investigation confirmed the diagnosis of rhabdomyolysis, and discontinuation of [s1]colchicine[e1] resulted in resolution of clinical and biochemical features of [s2]rhabdomylysis[e2] 
	(0, 9)	5-Fluorouracil	cardiotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2977	 [s1]5-Fluorouracil[e1]  [s2]cardiotoxicity[e2] complicating treatment of stage IIB cervical cancer--case report.
	(2, 14)	Acetic acid	vagina bleeding	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2978	CONCLUSION: [s1]Acetic acid[e1] is corrosive and may cause [s2]vagina bleeding[e2] 
	(2, 13)	systemic lupus erythematosus	interferon-gamma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2979	Induction of [s1]systemic lupus erythematosus[e1] by [s2]interferon-gamma[e2] in a patient with rheumatoid arthritis.
	(11, 21)	SLE	recombinant human interferon gamma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2980	The development of systemic lupus erythematosus  [s1]SLE[e1]  after 38 months of therapy with [s2]recombinant human interferon gamma[e2] (rIFN-gamma) was observed in a patient with rheumatoid arthritis.
	(11, 30)	SLE	rIFN-gamma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2981	The development of systemic lupus erythematosus  [s1]SLE[e1]  after 38 months of therapy with recombinant human interferon gamma  [s2]rIFN-gamma[e2]  was observed in a patient with rheumatoid arthritis.
	(3, 23)	systemic lupus erythematosus	recombinant human interferon gamma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2982	The development of [s1]systemic lupus erythematosus[e1] (SLE) after 38 months of therapy with [s2]recombinant human interferon gamma[e2] (rIFN-gamma) was observed in a patient with rheumatoid arthritis.
	(3, 32)	systemic lupus erythematosus	rIFN-gamma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2983	The development of [s1]systemic lupus erythematosus[e1] (SLE) after 38 months of therapy with recombinant human interferon gamma  [s2]rIFN-gamma[e2]  was observed in a patient with rheumatoid arthritis.
	(3, 16)	rIFN-gamma	SLE	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2984	We assume that [s1]rIFN-gamma[e1] induced the de novo development of [s2]SLE[e2] in our patient.
	(0, 8)	Bisphosphonate	osteochemonecrosis of the jaw	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2985	 [s1]Bisphosphonate[e1] induced [s2]osteochemonecrosis of the jaw[e2] mimicking a tumour.
	(0, 6)	Clozapine	eosinophilia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2986	 [s1]Clozapine[e1] induced [s2]eosinophilia[e2] and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies.
	(3, 20)	eosinophilia	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2987	Drug-induced [s1]eosinophilia[e1] is a non-dose-dependent side effect of [s2]clozapine[e2] 
	(7, 22)	clozapine	agranulocytosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2988	Occasionally, despite good therapeutic response, [s1]clozapine[e1] must be stopped due to dangerous side effects such as [s2]agranulocytosis[e2] 
	(5, 24)	lactic acidosis	metformin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2989	Metformin-associated [s1]lactic acidosis[e1] (MALA) is a serious metabolic complication that occurs because of [s2]metformin[e2] accumulation in patients who become dehydrated or developed acute renal failure.
	(0, 6)	Metformin	lactic acidosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2990	 [s1]Metformin[e1] associated [s2]lactic acidosis[e2] (MALA) is a serious metabolic complication that occurs because of metformin accumulation in patients who become dehydrated or developed acute renal failure.
	(0, 6)	Metformin	lactic acidosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2991	 [s1]Metformin[e1] associated [s2]lactic acidosis[e2] precipitated by diarrhea.
	(9, 30)	MMF	red blood cell anemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2992	An apparent link is described between the use of [s1]MMF[e1] with prednisone to treat pemphigus vulgaris and the development of [s2]red blood cell anemia[e2] 
	(12, 30)	prednisone	red blood cell anemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2993	An apparent link is described between the use of MMF with [s1]prednisone[e1] to treat pemphigus vulgaris and the development of [s2]red blood cell anemia[e2] 
	(0, 22)	Red blood cell anemia	mycophenolate mofetil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2994	 [s1]Red blood cell anemia[e1] in a patient with pemphigus vulgaris induced by the use of [s2]mycophenolate mofetil[e2] and prednisone.
	(0, 32)	Red blood cell anemia	prednisone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2995	 [s1]Red blood cell anemia[e1] in a patient with pemphigus vulgaris induced by the use of mycophenolate mofetil and [s2]prednisone[e2] 
	(13, 24)	anemia	MMF	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2996	The dermatology literature heretofore has not noted that [s1]anemia[e1] is a side effect of patients taking [s2]MMF[e2] to treat pemphigus.
	(4, 45)	anemia	cyclosporine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2997	This report suggests that [s1]anemia[e1] can occur due to MMF, in particular when it is given with prednisone, a side effect well documented in the transplantation literature when the triple combination of MMF, [s2]cyclosporine[e2] and prednisone is used.
	(4, 12)	anemia	MMF	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2998	This report suggests that [s1]anemia[e1] can occur due to [s2]MMF[e2]  in particular when it is given with prednisone, a side effect well documented in the transplantation literature when the triple combination of MMF, cyclosporine and prednisone is used.
	(4, 12)	anemia	MMF	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	2999	This report suggests that [s1]anemia[e1] can occur due to [s2]MMF[e2]  in particular when it is given with prednisone, a side effect well documented in the transplantation literature when the triple combination of MMF, cyclosporine and prednisone is used.
	(4, 22)	anemia	prednisone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3000	This report suggests that [s1]anemia[e1] can occur due to MMF, in particular when it is given with [s2]prednisone[e2]  a side effect well documented in the transplantation literature when the triple combination of MMF, cyclosporine and prednisone is used.
	(4, 22)	anemia	prednisone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3001	This report suggests that [s1]anemia[e1] can occur due to MMF, in particular when it is given with [s2]prednisone[e2]  a side effect well documented in the transplantation literature when the triple combination of MMF, cyclosporine and prednisone is used.
	(20, 28)	oxcarbazepine	angioedema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3002	A search of the United States Food and Drug Administration's Adverse Event Reporting System identified nine cases of [s1]oxcarbazepine[e1] associated [s2]angioedema[e2] in pediatric patients aged 16 years and younger.
	(3, 11)	oxcarbazepine	angioneurotic edema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3003	Clinical profile of [s1]oxcarbazepine[e1] related [s2]angioneurotic edema[e2]  case report and review.
	(0, 8)	Oxcarbazepine	angioedema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3004	 [s1]Oxcarbazepine[e1] associated [s2]angioedema[e2] manifested by swelling of the face, eyes, lips, or tongue or difficulty swallowing or breathing (or both) is a rare but potentially life-threatening reaction for which early recognition and management are vital.
	(28, 37)	angioedema	oxcarbazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3005	We describe in detail the first U.S. case report, of a 4(1/2)-year-old boy who experienced [s1]angioedema[e1] during treatment with [s2]oxcarbazepine[e2] 
	(6, 25)	VOD	azathioprine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3006	Here we describe another case of [s1]VOD[e1] occurring after LT, but in which the causative role was played by [s2]azathioprine[e2] 
	(3, 10)	tacrolimus	hepatic VOD	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3007	One case of [s1]tacrolimus[e1] induced [s2]hepatic VOD[e2] developing after lung transplantation (LT) has been recently reported.
	(0, 7)	Carbamazepine	hypersensitivity syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3008	 [s1]Carbamazepine[e1]  [s2]hypersensitivity syndrome[e2] is a rare, life-threatening condition.
	(14, 23)	pulmonary toxicity	etoposide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3009	A patient with chronic myelomonocytic leukemia developed drug-induced [s1]pulmonary toxicity[e1] after using low dose oral [s2]etoposide[e2] 
	(1, 8)	etoposide	pulmonary toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3010	Because [s1]etoposide[e1] induced [s2]pulmonary toxicity[e2] is an uncommon but serious adverse event, clinicians must be vigilant about the possibility of it, so that the optimal treatment can start as soon as possible.
	(5, 12)	etoposide	pulmonary toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3011	PET scintigraphy of [s1]etoposide[e1] induced [s2]pulmonary toxicity[e2] 
	(16, 25)	L-tryptophan	eosinophilia-myalgia syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3012	Detection of antineutrophil cytoplasmic antibody in a patient with [s1]L-tryptophan[e1] induced [s2]eosinophilia-myalgia syndrome[e2] 
	(11, 27)	eosinophilia-myalgia syndrome	L-tryptophan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3013	The Center for Disease Control has received numerous reports of an [s1]eosinophilia-myalgia syndrome[e1] related to products containing [s2]L-tryptophan[e2] 
	(7, 12)	RFP	hypothyroidism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3014	Here, we report a case of [s1]RFP[e1] induced [s2]hypothyroidism[e2] without underlying thyroid disease.
	(0, 7)	Rifampin	hypothyroidism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3015	 [s1]Rifampin[e1] induced [s2]hypothyroidism[e2] without underlying thyroid disease.
	(4, 38)	RFP	Hashimoto's thyroiditis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3016	Rifampin  [s1]RFP[e1]  increases hepatic microsomal enzyme activity, and there are case reports of RFP-induced hypothyroidism, all associated with [s2]Hashimoto's thyroiditis[e2] 
	(0, 40)	Rifampin	Hashimoto's thyroiditis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3017	 [s1]Rifampin[e1] (RFP) increases hepatic microsomal enzyme activity, and there are case reports of RFP-induced hypothyroidism, all associated with [s2]Hashimoto's thyroiditis[e2] 
	(4, 28)	RFP	hypothyroidism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3018	Rifampin  [s1]RFP[e1]  increases hepatic microsomal enzyme activity, and there are case reports of RFP-induced [s2]hypothyroidism[e2]  all associated with Hashimoto's thyroiditis.
	(0, 30)	Rifampin	hypothyroidism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3019	 [s1]Rifampin[e1] (RFP) increases hepatic microsomal enzyme activity, and there are case reports of RFP-induced [s2]hypothyroidism[e2]  all associated with Hashimoto's thyroiditis.
	(10, 31)	pulmonary fibrosis	nabumetone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3020	A patient is described who developed a rapid onset of [s1]pulmonary fibrosis[e1] following treatment with a new non-steroidal anti-inflammatory drug, [s2]nabumetone[e2] 
	(0, 8)	Pulmonary fibrosis	nabumetone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3021	 [s1]Pulmonary fibrosis[e1] associated with [s2]nabumetone[e2] 
	(0, 28)	Cyclosporine	rhabdomyolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3022	 [s1]Cyclosporine[e1] is a potent inhibitor of simvastatin metabolism, and may therefore facilitate simvastatin-induced [s2]rhabdomyolysis[e2] 
	(10, 28)	simvastatin	rhabdomyolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3023	Cyclosporine is a potent inhibitor of [s1]simvastatin[e1] metabolism, and may therefore facilitate simvastatin-induced [s2]rhabdomyolysis[e2] 
	(10, 21)	cyclosporine	rhabdomyolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3024	Discontinuation of simvastatin and [s1]cyclosporine[e1] resulted in resolution of [s2]rhabdomyolysis[e2] and normalization of renal function.
	(5, 21)	simvastatin	rhabdomyolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3025	Discontinuation of [s1]simvastatin[e1] and cyclosporine resulted in resolution of [s2]rhabdomyolysis[e2] and normalization of renal function.
	(6, 14)	rhabdomyolysis	cyclosporine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3026	Simvastatin-induced [s1]rhabdomyolysis[e1] following [s2]cyclosporine[e2] treatment for uveitis.
	(0, 7)	Simvastatin	rhabdomyolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3027	 [s1]Simvastatin[e1] induced [s2]rhabdomyolysis[e2] following cyclosporine treatment for uveitis.
	(0, 14)	Generalized lichen nitidus	interferon alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3028	 [s1]Generalized lichen nitidus[e1] with involvement of the palms following [s2]interferon alpha[e2] treatment.
	(7, 30)	generalized lichen nitidus	interferon alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3029	Here we present the case of a [s1]generalized lichen nitidus[e1] with involvement of the palms in a patient with hepatitis C after systemic treatment with [s2]interferon alpha[e2] and ribavirin.
	(7, 35)	generalized lichen nitidus	ribavirin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3030	Here we present the case of a [s1]generalized lichen nitidus[e1] with involvement of the palms in a patient with hepatitis C after systemic treatment with interferon alpha and [s2]ribavirin[e2] 
	(7, 21)	interferon alpha	lichen nitidus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3031	It is tempting to speculate that [s1]interferon alpha[e1] may be involved in the pathogenesis of [s2]lichen nitidus[e2] 
	(0, 17)	Sirolimus-eluting stent thrombosis	clopidogrel	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3032	 [s1]Sirolimus-eluting stent thrombosis[e1] several years after [s2]clopidogrel[e2] discontinuation.
	(12, 22)	ATRA	teratogenic effect	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3033	Treatment of APL in pregnancy is controversial as the use of [s1]ATRA[e1] has been questioned due to the [s2]teratogenic effect[e2] of retinoids.
	(5, 15)	ILD	gefitinib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3034	Interstitial lung disease  [s1]ILD[e1]  related to therapy with the drug [s2]gefitinib[e2] has been well reported.
	(0, 17)	Interstitial lung disease	gefitinib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3035	 [s1]Interstitial lung disease[e1] (ILD) related to therapy with the drug [s2]gefitinib[e2] has been well reported.
	(0, 6)	Pulmonary toxicity	erlotinib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3036	 [s1]Pulmonary toxicity[e1] associated with [s2]erlotinib[e2] 
	(28, 40)	pulmonary fibrosis	erlotinib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3037	Similar to reports in patients receiving gefitinib, those with pathologic findings of UIP on resected lung specimens or known [s1]pulmonary fibrosis[e1] may be at particular risk for [s2]erlotinib[e2] pulmonary toxicity.
	(38, 44)	erlotinib	pulmonary toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3038	Similar to reports in patients receiving gefitinib, those with pathologic findings of UIP on resected lung specimens or known pulmonary fibrosis may be at particular risk for [s1]erlotinib[e1]  [s2]pulmonary toxicity[e2] 
	(14, 21)	erlotinib	ILD	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3039	This case and other published evidence should alert physicians to the possibility of fatal [s1]erlotinib[e1] induced [s2]ILD[e2] 
	(5, 23)	fatal pulmonary toxicity	erlotinib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3040	We report a case of [s1]fatal pulmonary toxicity[e1] in a patient with advanced non-small cell lung cancer who received [s2]erlotinib[e2] 
	(5, 27)	fluoroquinolone	torsade de pointes	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3041	It has been reported that [s1]fluoroquinolone[e1] antimicrobials prolong the corrected QT interval but rarely cause [s2]torsade de pointes[e2] 
	(0, 10)	Torsade de pointes	moxifloxacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3042	 [s1]Torsade de pointes[e1] associated with [s2]moxifloxacin[e2]  a rare but potentially fatal adverse event.
	(8, 33)	skin necrosis	Glypressin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3043	AIM: To report three cases of extensive [s1]skin necrosis[e1] in cirrhotic patients treated with the vasoconstrictor agent terlipressin  [s2]Glypressin[e2] .
	(8, 29)	skin necrosis	terlipressin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3044	AIM: To report three cases of extensive [s1]skin necrosis[e1] in cirrhotic patients treated with the vasoconstrictor agent [s2]terlipressin[e2] (Glypressin).
	(1, 14)	colchicine	myopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3045	Both [s1]colchicine[e1] and statin therapy may be associated with [s2]myopathy[e2]  which usually occurs after several months of therapy.
	(5, 14)	statin	myopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3046	Both colchicine and [s1]statin[e1] therapy may be associated with [s2]myopathy[e2]  which usually occurs after several months of therapy.
	(3, 25)	muscle weakness	colchicine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3047	Rapid onset of [s1]muscle weakness[e1] (rhabdomyolysis) associated with the combined use of simvastatin and [s2]colchicine[e2] 
	(3, 20)	muscle weakness	simvastatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3048	Rapid onset of [s1]muscle weakness[e1] (rhabdomyolysis) associated with the combined use of [s2]simvastatin[e2] and colchicine.
	(5, 23)	rhabdomyolysis	colchicine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3049	Rapid onset of muscle weakness  [s1]rhabdomyolysis[e1]  associated with the combined use of simvastatin and [s2]colchicine[e2] 
	(5, 18)	rhabdomyolysis	simvastatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3050	Rapid onset of muscle weakness  [s1]rhabdomyolysis[e1]  associated with the combined use of [s2]simvastatin[e2] and colchicine.
	(10, 26)	colchicine	muscle weakness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3051	The concomitant use, however, of [s1]colchicine[e1] and statin has been associated with the rapid onset of [s2]muscle weakness[e2] 
	(14, 26)	statin	muscle weakness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3052	The concomitant use, however, of colchicine and [s1]statin[e1] has been associated with the rapid onset of [s2]muscle weakness[e2] 
	(29, 42)	acute weakness	colchicine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3053	We report a case of a patient with mild chronic renal insufficiency who had been taking simvastatin for over a year and developed [s1]acute weakness[e1] within 3 weeks after the start of treatment with [s2]colchicine[e2] for acute gouty bursitis.
	(19, 31)	simvastatin	acute weakness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3054	We report a case of a patient with mild chronic renal insufficiency who had been taking [s1]simvastatin[e1] for over a year and developed [s2]acute weakness[e2] within 3 weeks after the start of treatment with colchicine for acute gouty bursitis.
	(8, 21)	mild chronic renal insufficiency	simvastatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3055	We report a case of a patient with [s1]mild chronic renal insufficiency[e1] who had been taking [s2]simvastatin[e2] for over a year and developed acute weakness within 3 weeks after the start of treatment with colchicine for acute gouty bursitis.
	(0, 17)	Pneumocystis carinii pneumonia	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3056	 [s1]Pneumocystis carinii pneumonia[e1] as a complication of [s2]methotrexate[e2] treatment of asthma.
	(15, 25)	methotrexate	fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3057	Pneumocystis pneumonia should be considered in asthmatic patients taking [s1]methotrexate[e1] who present with [s2]fever[e2]  pulmonary infiltrates, and hypoxia.
	(15, 32)	methotrexate	hypoxia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3058	Pneumocystis pneumonia should be considered in asthmatic patients taking [s1]methotrexate[e1] who present with fever, pulmonary infiltrates, and [s2]hypoxia[e2] 
	(0, 17)	Pneumocystis pneumonia	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3059	 [s1]Pneumocystis pneumonia[e1] should be considered in asthmatic patients taking [s2]methotrexate[e2] who present with fever, pulmonary infiltrates, and hypoxia.
	(15, 27)	methotrexate	pulmonary infiltrates	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3060	Pneumocystis pneumonia should be considered in asthmatic patients taking [s1]methotrexate[e1] who present with fever, [s2]pulmonary infiltrates[e2]  and hypoxia.
	(23, 34)	unilateral hearing loss	desferrioxamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3061	CASE REPORT: A six-year-old boy with transfusion-dependent beta-thalassaemia developed a [s1]unilateral hearing loss[e1] shortly after commencing [s2]desferrioxamine[e2] therapy.
	(9, 51)	leflunomide	abdominal sepsis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3062	Eleven patients developed infection requiring hospitalization while taking [s1]leflunomide[e1] including: lower respiratory tract infections (3), cellulitis (2), disseminated herpes zoster (2), probable TB liver (1), [s2]abdominal sepsis[e2] (1), mycotic aneurysm (1) and gastroenteritis (1).
	(9, 25)	leflunomide	cellulitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3063	Eleven patients developed infection requiring hospitalization while taking [s1]leflunomide[e1] including: lower respiratory tract infections (3), [s2]cellulitis[e2] (2), disseminated herpes zoster (2), probable TB liver (1), abdominal sepsis (1), mycotic aneurysm (1) and gastroenteritis (1).
	(9, 32)	leflunomide	disseminated herpes zoster	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3064	Eleven patients developed infection requiring hospitalization while taking [s1]leflunomide[e1] including: lower respiratory tract infections (3), cellulitis (2), [s2]disseminated herpes zoster[e2] (2), probable TB liver (1), abdominal sepsis (1), mycotic aneurysm (1) and gastroenteritis (1).
	(9, 69)	leflunomide	gastroenteritis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3065	Eleven patients developed infection requiring hospitalization while taking [s1]leflunomide[e1] including: lower respiratory tract infections (3), cellulitis (2), disseminated herpes zoster (2), probable TB liver (1), abdominal sepsis (1), mycotic aneurysm (1) and [s2]gastroenteritis[e2] (1).
	(3, 11)	infection	leflunomide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3066	Eleven patients developed [s1]infection[e1] requiring hospitalization while taking [s2]leflunomide[e2] including: lower respiratory tract infections (3), cellulitis (2), disseminated herpes zoster (2), probable TB liver (1), abdominal sepsis (1), mycotic aneurysm (1) and gastroenteritis (1).
	(9, 17)	leflunomide	lower respiratory tract infections	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3067	Eleven patients developed infection requiring hospitalization while taking [s1]leflunomide[e1] including: [s2]lower respiratory tract infections[e2] (3), cellulitis (2), disseminated herpes zoster (2), probable TB liver (1), abdominal sepsis (1), mycotic aneurysm (1) and gastroenteritis (1).
	(9, 58)	leflunomide	mycotic aneurysm	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3068	Eleven patients developed infection requiring hospitalization while taking [s1]leflunomide[e1] including: lower respiratory tract infections (3), cellulitis (2), disseminated herpes zoster (2), probable TB liver (1), abdominal sepsis (1), [s2]mycotic aneurysm[e2] (1) and gastroenteritis (1).
	(9, 45)	leflunomide	TB liver	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3069	Eleven patients developed infection requiring hospitalization while taking [s1]leflunomide[e1] including: lower respiratory tract infections (3), cellulitis (2), disseminated herpes zoster (2), probable [s2]TB liver[e2] (1), abdominal sepsis (1), mycotic aneurysm (1) and gastroenteritis (1).
	(0, 7)	Leflunomide	infections	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3070	 [s1]Leflunomide[e1] associated [s2]infections[e2] in rheumatoid arthritis.
	(15, 24)	severe infections	leflunomide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3071	The NZ Pharmacovigilance Centre has received 7 additional reports of [s1]severe infections[e1] in patients with RA taking [s2]leflunomide[e2] 
	(18, 44)	fever	sulfasalazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3072	A 58-year-old woman with rheumatoid arthritis (RA) developed [s1]fever[e1]  skin eruptions, leukocytopenia, and thrombocytopenia, 3 weeks after treatment with [s2]sulfasalazine[e2] 
	(23, 44)	leukocytopenia	sulfasalazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3073	A 58-year-old woman with rheumatoid arthritis (RA) developed fever, skin eruptions, [s1]leukocytopenia[e1]  and thrombocytopenia, 3 weeks after treatment with [s2]sulfasalazine[e2] 
	(20, 44)	skin eruptions	sulfasalazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3074	A 58-year-old woman with rheumatoid arthritis (RA) developed fever, [s1]skin eruptions[e1]  leukocytopenia, and thrombocytopenia, 3 weeks after treatment with [s2]sulfasalazine[e2] 
	(31, 44)	thrombocytopenia	sulfasalazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3075	A 58-year-old woman with rheumatoid arthritis (RA) developed fever, skin eruptions, leukocytopenia, and [s1]thrombocytopenia[e1]  3 weeks after treatment with [s2]sulfasalazine[e2] 
	(0, 14)	Sulfasalazine	hemophagocytic syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3076	 [s1]Sulfasalazine[e1] induced hypersensitivity syndrome and [s2]hemophagocytic syndrome[e2] associated with reactivation of Epstein-Barr virus.
	(0, 8)	Sulfasalazine	hypersensitivity syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3077	 [s1]Sulfasalazine[e1] induced [s2]hypersensitivity syndrome[e2] and hemophagocytic syndrome associated with reactivation of Epstein-Barr virus.
	(5, 37)	hemophagocytic syndrome	sulfasalazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3078	This case illustrates that the [s1]hemophagocytic syndrome[e1] associated with reactivation of EBV can occur as part of drug hypersensitivity reactions in RA patients taking [s2]sulfasalazine[e2] 
	(26, 54)	status migrainosus	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3079	The goal of this study is to describe three patients diagnosed with migraine and epilepsy (both under control) who evolved into [s1]status migrainosus[e1] after the introduction of oxcarbazepine (OXC), as part of a switch off from [s2]carbamazepine[e2] (CBZ).
	(26, 59)	status migrainosus	CBZ	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3080	The goal of this study is to describe three patients diagnosed with migraine and epilepsy (both under control) who evolved into [s1]status migrainosus[e1] after the introduction of oxcarbazepine (OXC), as part of a switch off from carbamazepine  [s2]CBZ[e2] .
	(26, 42)	status migrainosus	OXC	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3081	The goal of this study is to describe three patients diagnosed with migraine and epilepsy (both under control) who evolved into [s1]status migrainosus[e1] after the introduction of oxcarbazepine  [s2]OXC[e2] , as part of a switch off from carbamazepine (CBZ).
	(26, 37)	status migrainosus	oxcarbazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3082	The goal of this study is to describe three patients diagnosed with migraine and epilepsy (both under control) who evolved into [s1]status migrainosus[e1] after the introduction of [s2]oxcarbazepine[e2] (OXC), as part of a switch off from carbamazepine (CBZ).
	(4, 9)	headache	oxcarbazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3083	Uncontrolled [s1]headache[e1] induced by [s2]oxcarbazepine[e2] 
	(11, 22)	myoclonic muscle spasms	dobutamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3084	CONCLUSION: A patient with CHF and ESRD developed [s1]myoclonic muscle spasms[e1] after receiving [s2]dobutamine[e2] by continuous i.v. infusion.
	(0, 9)	Myoclonus	dobutamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3085	 [s1]Myoclonus[e1] associated with continuous [s2]dobutamine[e2] infusion in a patient with end-stage renal disease.
	(5, 21)	myoclonus	dobutamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3086	PURPOSE: The occurrence of [s1]myoclonus[e1] associated with continuous i.v. infusion of [s2]dobutamine[e2] in a patient with end-stage renal disease (ESRD) is described.
	(2, 16)	colonic perforation	calcium polystyrene sulfonate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3087	Reports of [s1]colonic perforation[e1] as a result of the administration of [s2]calcium polystyrene sulfonate[e2] and sorbitol are rare.
	(2, 25)	colonic perforation	sorbitol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3088	Reports of [s1]colonic perforation[e1] as a result of the administration of calcium polystyrene sulfonate and [s2]sorbitol[e2] are rare.
	(4, 27)	colonic ulcer	calcium polystyrene sulfonate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3089	We concluded that the [s1]colonic ulcer[e1] and the sigmoidovesical fistula had been caused by the administration of [s2]calcium polystyrene sulfonate[e2] and sorbitol.
	(4, 36)	colonic ulcer	sorbitol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3090	We concluded that the [s1]colonic ulcer[e1] and the sigmoidovesical fistula had been caused by the administration of calcium polystyrene sulfonate and [s2]sorbitol[e2] 
	(10, 27)	sigmoidovesical fistula	calcium polystyrene sulfonate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3091	We concluded that the colonic ulcer and the [s1]sigmoidovesical fistula[e1] had been caused by the administration of [s2]calcium polystyrene sulfonate[e2] and sorbitol.
	(10, 36)	sigmoidovesical fistula	sorbitol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3092	We concluded that the colonic ulcer and the [s1]sigmoidovesical fistula[e1] had been caused by the administration of calcium polystyrene sulfonate and [s2]sorbitol[e2] 
	(0, 21)	Psychosis	efavirenz	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3093	 [s1]Psychosis[e1] in a 12-year-old HIV-positive girl with an increased serum concentration of [s2]efavirenz[e2] 
	(18, 33)	psychosis	efavirenz	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3094	We report (to our knowledge, for the first time in a child) the emergence of [s1]psychosis[e1] in a 12-year old white girl with an increased [s2]efavirenz[e2] concentration and heterozygous gene polymorphism of the CYP2B6-G516T.
	(0, 23)	Mycobacterium marinum infection	infliximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3095	 [s1]Mycobacterium marinum infection[e1] complicating Crohn's disease, treated with [s2]infliximab[e2] 
	(0, 13)	Sustained monomorphic ventricular tachycardia	adenosine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3096	 [s1]Sustained monomorphic ventricular tachycardia[e1] after [s2]adenosine[e2] infusion.
	(6, 19)	sustained monomorphic ventricular tachycardia	adenosine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3097	We present a case of a [s1]sustained monomorphic ventricular tachycardia[e1] following [s2]adenosine[e2] infusion.
	(10, 19)	tardive OGC	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3098	Surprisingly, we found that three patients appeared to develop [s1]tardive OGC[e1] while taking [s2]clozapine[e2] 
	(0, 13)	Tardive oculogyric crisis	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3099	 [s1]Tardive oculogyric crisis[e1] during treatment with [s2]clozapine[e2]  report of three cases.
	(0, 7)	Metronidazole	neuropathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3100	 [s1]Metronidazole[e1]  [s2]neuropathy[e2] 
	(6, 24)	sensory neuropathy	metronidazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3101	Two patients are described who developed [s1]sensory neuropathy[e1] after the ingestion of 30.6 and 114 g [s2]metronidazole[e2] respectively.
	(19, 34)	methotrexate	infection with both M. tuberculosis and M. chelonae	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3102	We report a case of a patient with rheumatoid arthritis treated with low-dose [s1]methotrexate[e1] (15 mg/week) who developed [s2]infection with both M. tuberculosis and M. chelonae[e2] after the revision of a prosthetic hip.
	(2, 15)	Sustained ventricular tachycardia	thalidomide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3103	DIAGNOSIS: [s1]Sustained ventricular tachycardia[e1] possibly owing to [s2]thalidomide[e2] treatment.
	(0, 11)	Multiple syncopal episodes	thalidomide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3104	 [s1]Multiple syncopal episodes[e1] started to occur during [s2]thalidomide[e2] treatment, and a Holter electrocardiogram showed multiple abnormalities, with an episode of sustained ventricular tachycardia.
	(9, 33)	thalidomide	sustained ventricular tachycardia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3105	Multiple syncopal episodes started to occur during [s1]thalidomide[e1] treatment, and a Holter electrocardiogram showed multiple abnormalities, with an episode of [s2]sustained ventricular tachycardia[e2] 
	(0, 12)	Sustained ventricular tachycardia	thalidomide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3106	 [s1]Sustained ventricular tachycardia[e1] in a [s2]thalidomide[e2] treated patient with primary plasma-cell leukemia.
	(4, 17)	ECM	glatiramer acetate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3107	A patient developed typical [s1]ECM[e1] after subcutaneous selfinjection of [s2]glatiramer acetate[e2] for multiple sclerosis.
	(0, 17)	Embolia cutis medicamentosa	glatiramer acetate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3108	 [s1]Embolia cutis medicamentosa[e1] following subcutaneous injection of [s2]glatiramer acetate[e2] 
	(36, 46)	glatiramer acetate	skin necrosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3109	This case is remarkable since 1) ECM developed after subcutaneous and not after intramuscular injection, 2) the injection was given by the patient himself, and 3) [s1]glatiramer acetate[e1] can induce [s2]skin necrosis[e2] as a side effect.
	(12, 45)	amiodarone	hypothyroidism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3110	Although it is difficult to be certain of the direct link of [s1]amiodarone[e1] on the basis of a single case, it is reasonable to presume that this histopathology is associated with amiodarone-induced [s2]hypothyroidism[e2] and that involution changes represent the hypofunctional status of this drug-induced disorder.
	(0, 30)	Amiodarone	thyroid dysfunction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3111	 [s1]Amiodarone[e1] is well recognized as an anti-arrhythmic drug containing a high dose of iodine with considerable potential to cause [s2]thyroid dysfunction[e2] 
	(8, 14)	amiodarone	hypothyroidism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3112	Histopathology of the thyroid in [s1]amiodarone[e1] induced [s2]hypothyroidism[e2] 
	(19, 25)	amiodarone	hypothyroidism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3113	This is the first report on the histopathological findings of thyroid tissue from a patient with [s1]amiodarone[e1] induced [s2]hypothyroidism[e2] 
	(14, 30)	leucocytopenia	quetiapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3114	Although adverse effects are usually mild, the author reports here a case of [s1]leucocytopenia[e1] and thrombocytopenia with [s2]quetiapine[e2] treatment that required its discontinuation.
	(21, 30)	thrombocytopenia	quetiapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3115	Although adverse effects are usually mild, the author reports here a case of leucocytopenia and [s1]thrombocytopenia[e1] with [s2]quetiapine[e2] treatment that required its discontinuation.
	(0, 6)	Quetiapine	leucopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3116	 [s1]Quetiapine[e1] induced [s2]leucopenia[e2] and thrombocytopenia.
	(0, 11)	Quetiapine	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3117	 [s1]Quetiapine[e1] induced leucopenia and [s2]thrombocytopenia[e2] 
	(0, 8)	Amphotericin B	cutaneous leucocytoclastic vasculitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3118	 [s1]Amphotericin B[e1] induced [s2]cutaneous leucocytoclastic vasculitis[e2]  case report.
	(0, 24)	Palpable purpuric skin lesions	amphotericin B	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3119	 [s1]Palpable purpuric skin lesions[e1] on the anterior surface of both legs appeared on the 55th day of [s2]amphotericin B[e2] treatment.
	(5, 21)	cutaneous leucocytoclastic vasculitis	amphotericin B	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3120	We present a case of [s1]cutaneous leucocytoclastic vasculitis[e1] in which [s2]amphotericin B[e2] might presumably be the aetiological factor.
	(3, 19)	5-fluorouracil	cardiotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3121	The incidence of [s1]5-fluorouracil[e1] (5-FU)-related [s2]cardiotoxicity[e2] seems to be dosage and schedule dependent.
	(10, 17)	5-FU	cardiotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3122	The incidence of 5-fluorouracil  [s1]5-FU[e1] -related [s2]cardiotoxicity[e2] seems to be dosage and schedule dependent.
	(0, 17)	Transient asymptomatic bradycardia	5-fluorouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3123	 [s1]Transient asymptomatic bradycardia[e1] in patients on infusional [s2]5-fluorouracil[e2] 
	(9, 27)	transient asymptomatic bradycardia	5-FU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3124	We report such a series of patients who had [s1]transient asymptomatic bradycardia[e1] after being treated with continuous infusion [s2]5-FU[e2] 
	(10, 20)	papular eruption	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3125	According to the Naranjo probability scale, the [s1]papular eruption[e1] was probably caused by [s2]methotrexate[e2] 
	(6, 14)	methotrexate	papular eruption	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3126	CONCLUSIONS: The pathogenesis of [s1]methotrexate[e1] induced [s2]papular eruption[e2] in collagen vascular diseases may suggest cutaneous small-vessel vasculitis.
	(2, 10)	Methotrexate	papular eruption	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3127	DISCUSSION: [s1]Methotrexate[e1] induced [s2]papular eruption[e2] is rarely reported shortly after beginning methotrexate therapy in patients with acute exacerbation of collagen vascular diseases.
	(0, 8)	Methotrexate	papular eruption	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3128	 [s1]Methotrexate[e1] induced [s2]papular eruption[e2] following treatment of psoriasis has not been previously reported.
	(0, 8)	Methotrexate	papular eruption	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3129	 [s1]Methotrexate[e1] induced [s2]papular eruption[e2] following treatment of psoriasis.
	(8, 22)	diffuse papular eruption	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3130	OBJECTIVE: To report a case of a [s1]diffuse papular eruption[e1] following treatment of psoriasis with [s2]methotrexate[e2] injections.
	(3, 34)	methotrexate	cutaneous vasculitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3131	Pathogenesis of [s1]methotrexate[e1] induced papular eruption in psoriasis may involve immune mechanisms other than those of methotrexate-induced [s2]cutaneous vasculitis[e2] in collagen vascular disease.
	(3, 11)	methotrexate	papular eruption	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3132	Pathogenesis of [s1]methotrexate[e1] induced [s2]papular eruption[e2] in psoriasis may involve immune mechanisms other than those of methotrexate-induced cutaneous vasculitis in collagen vascular disease.
	(5, 18)	methotrexate	diffuse pruritic papular eruption	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3133	Ten hours after the second [s1]methotrexate[e1] injection, the patient experienced a [s2]diffuse pruritic papular eruption[e2] located mainly on the limbs.
	(0, 7)	Metabolic acidosis	acetazolamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3134	 [s1]Metabolic acidosis[e1] induced by [s2]acetazolamide[e2] 
	(0, 11)	Pericardial hemorrhage	acetylsalicylic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3135	 [s1]Pericardial hemorrhage[e1] due to [s2]acetylsalicylic acid[e2] in a patient with essential thrombocythemia.
	(3, 22)	pericardial hemorrhage	acetylsalicylic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3136	The authors describe [s1]pericardial hemorrhage[e1]  which is related to the use of low-dose [s2]acetylsalicylic acid[e2] in a patient with essential thrombocythemia.
	(25, 31)	nelfinavir	cutaneous rash	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3137	From 1996 to 2002 several medications were changed due to their adverse effects: indinavir (renal colic and fever), [s1]nelfinavir[e1]  [s2]cutaneous rash[e2] , and efavirenz (nausea and temporary memory loss).
	(14, 24)	indinavir	fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3138	From 1996 to 2002 several medications were changed due to their adverse effects: [s1]indinavir[e1] (renal colic and [s2]fever[e2] , nelfinavir (cutaneous rash), and efavirenz (nausea and temporary memory loss).
	(36, 43)	efavirenz	nausea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3139	From 1996 to 2002 several medications were changed due to their adverse effects: indinavir (renal colic and fever), nelfinavir (cutaneous rash), and [s1]efavirenz[e1]  [s2]nausea[e2] and temporary memory loss).
	(14, 19)	indinavir	renal colic	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3140	From 1996 to 2002 several medications were changed due to their adverse effects: [s1]indinavir[e1]  [s2]renal colic[e2] and fever), nelfinavir (cutaneous rash), and efavirenz (nausea and temporary memory loss).
	(36, 46)	efavirenz	temporary memory loss	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3141	From 1996 to 2002 several medications were changed due to their adverse effects: indinavir (renal colic and fever), nelfinavir (cutaneous rash), and [s1]efavirenz[e1] (nausea and [s2]temporary memory loss[e2] .
	(8, 16)	methotrexate	sub-acute neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3142	Conventional and diffusion-weighted MRI findings of [s1]methotrexate[e1] related [s2]sub-acute neurotoxicity[e2] 
	(13, 31)	sub-acute toxic leukoencephalopathy	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3143	This case demonstrates the value of DWI in evaluation and diagnosis of [s1]sub-acute toxic leukoencephalopathy[e1] in patients being treated with [s2]methotrexate[e2] 
	(9, 22)	sub-acute leukoencephalopathy	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3144	We describe longitudinal diffusion-weighted MRI findings of [s1]sub-acute leukoencephalopathy[e1] following [s2]methotrexate[e2] therapy in a 24-year-old man diagnosed with pre-B-cell acute lymphoblastic leukemia (ALL), presenting with right-sided paralysis and aphasia after second consolidation with intrathecal triple-drug therapy given intrathecally.
	(3, 17)	CD	etanercept	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3145	New onset of [s1]CD[e1] may be considered as an immune-mediated injury induced by [s2]etanercept[e2] 
	(9, 17)	immune-mediated injury	etanercept	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3146	New onset of CD may be considered as an [s1]immune-mediated injury[e1] induced by [s2]etanercept[e2] 
	(3, 24)	Crohn's disease	etanercept	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3147	New onset of [s1]Crohn's disease[e1] during treatment of active ankylosing spondylitis with [s2]etanercept[e2] 
	(4, 18)	CD	etanercept	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3148	Typical symptoms of active [s1]CD[e1] occurred 11, 12, and 26 months after start of [s2]etanercept[e2] therapy, respectively.
	(7, 21)	etanercept	CD	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3149	We describe 3 AS patients treated with [s1]etanercept[e1] for active AS who developed new onset of [s2]CD[e2] while AS related symptoms responded well to etanercept.
	(0, 18)	Upper gastrointestinal haemorrhage	aspirin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3150	 [s1]Upper gastrointestinal haemorrhage[e1] is a serious complication of [s2]aspirin[e2] and clopidogrel (dual) anti-platelet therapy with a high morbidity and mortality.
	(0, 22)	Upper gastrointestinal haemorrhage	clopidogrel	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3151	 [s1]Upper gastrointestinal haemorrhage[e1] is a serious complication of aspirin and [s2]clopidogrel[e2] (dual) anti-platelet therapy with a high morbidity and mortality.
	(1, 20)	doxorubicin	breathing distress	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3152	While [s1]doxorubicin[e1] was administered, the patient presented thoracic pain and [s2]breathing distress[e2] due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum.
	(1, 15)	doxorubicin	thoracic pain	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3153	While [s1]doxorubicin[e1] was administered, the patient presented [s2]thoracic pain[e2] and breathing distress due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum.
	(0, 9)	Severe hepatocellular dysfunction	cyproterone acetate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3154	 [s1]Severe hepatocellular dysfunction[e1] following [s2]cyproterone acetate[e2] therapy.
	(13, 21)	CPA	fatal fulminant hepatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3155	We report 3 patients with severe hepatocellular damage due to [s1]CPA[e1] therapy, 2 with [s2]fatal fulminant hepatitis[e2] 
	(5, 15)	severe hepatocellular damage	CPA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3156	We report 3 patients with [s1]severe hepatocellular damage[e1] due to [s2]CPA[e2] therapy, 2 with fatal fulminant hepatitis.
	(4, 14)	acyclovir	VZV antigen-positive zoster	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3157	She was treated with [s1]acyclovir[e1] and subsequently developed [s2]VZV antigen-positive zoster[e2] 
	(15, 30)	temozolomide	fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3158	According to the Naranjo adverse drug reaction probability scale, the likelihood that [s1]temozolomide[e1] was responsible for the adverse drug reaction of [s2]fever[e2] was probable (score of 6).
	(12, 22)	exfoliative rash	temozolomide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3159	Clinicians should be aware that an erythematous and [s1]exfoliative rash[e1] may be induced by [s2]temozolomide[e2]  and be familiar with the pharmacologic and supportive measures necessary for its treatment.
	(6, 9)	rash	temozolomide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3160	Due to the severity of the [s1]rash[e1]  [s2]temozolomide[e2] was permanently discontinued.
	(0, 8)	Temozolomide	desquamative skin rash	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3161	 [s1]Temozolomide[e1] induced [s2]desquamative skin rash[e2] in a patient with metastatic melanoma.
	(0, 18)	Temozolomide	fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3162	 [s1]Temozolomide[e1] was restarted 2 months later; the patient again developed a [s2]fever[e2] 
	(0, 10)	Exfoliative dermatitis	tobramycin sulfate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3163	 [s1]Exfoliative dermatitis[e1] secondary to [s2]tobramycin sulfate[e2] 
	(5, 27)	exfoliative dermatitis	tobramycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3164	We report a case of [s1]exfoliative dermatitis[e1] clearly linked to intravenous and intraperitoneal administration of [s2]tobramycin[e2] 
	(0, 10)	Rituximab-CHOP	interstitial pneumonitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3165	 [s1]Rituximab-CHOP[e1] induced [s2]interstitial pneumonitis[e2] in patients with disseminated extranodal marginal zone B cell lymphoma.
	(0, 13)	Phenytoin	cerebellar syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3166	 [s1]Phenytoin[e1] toxicity: an easily missed cause of [s2]cerebellar syndrome[e2] 
	(3, 11)	trastuzumab	pneumonitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3167	A diagnosis of [s1]trastuzumab[e1] induced [s2]pneumonitis[e2] was made.
	(20, 35)	plural effusion dyspnoea	trastuzumab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3168	A female patient with HER2 positive, metastatic breast cancer presented with pulmonary infiltrates, and a [s1]plural effusion dyspnoea[e1] after several months of [s2]trastuzumab[e2] treatment.
	(14, 34)	pulmonary infiltrates	trastuzumab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3169	A female patient with HER2 positive, metastatic breast cancer presented with [s1]pulmonary infiltrates[e1]  and a plural effusion dyspnoea after several months of [s2]trastuzumab[e2] treatment.
	(3, 12)	interstitial lung disease	trastuzumab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3170	Life-threatening [s1]interstitial lung disease[e1] associated with [s2]trastuzumab[e2]  case report.
	(12, 22)	acute allergic contact dermatitis	4-chloro-7-nitrobenzofurazan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3171	A 30-year-old pharmacist suffered from [s1]acute allergic contact dermatitis[e1] due to [s2]4-chloro-7-nitrobenzofurazan[e2] (NBD-Cl).
	(12, 37)	acute allergic contact dermatitis	NBD-Cl	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3172	A 30-year-old pharmacist suffered from [s1]acute allergic contact dermatitis[e1] due to 4-chloro-7-nitrobenzofurazan  [s2]NBD-Cl[e2] .
	(0, 8)	Allergic contact dermatitis	4-chloro-7-nitrobenzofurazan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3173	 [s1]Allergic contact dermatitis[e1] from [s2]4-chloro-7-nitrobenzofurazan[e2] 
	(0, 14)	Photo-onycholysis	aripiprazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3174	 [s1]Photo-onycholysis[e1] caused by olanzapine and [s2]aripiprazole[e2] 
	(0, 10)	Photo-onycholysis	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3175	 [s1]Photo-onycholysis[e1] caused by [s2]olanzapine[e2] and aripiprazole.
	(9, 24)	photo-onycholysis	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3176	We report the case of a woman who developed [s1]photo-onycholysis[e1] on multiple nails after uptake of [s2]olanzapine[e2] 
	(0, 11)	Diffuse alveolar hemorrhage	leflunomide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3177	 [s1]Diffuse alveolar hemorrhage[e1] after [s2]leflunomide[e2] therapy in a patient with rheumatoid arthritis.
	(29, 46)	hemoptysis	leflunomide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3178	We report the case of a young man, affected by rheumatoid arthritis who developed a rapid-onset short-of-breath, [s1]hemoptysis[e1]  and severe weakness, about 2 weeks after the administration of [s2]leflunomide[e2] 
	(35, 46)	severe weakness	leflunomide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3179	We report the case of a young man, affected by rheumatoid arthritis who developed a rapid-onset short-of-breath, hemoptysis, and [s1]severe weakness[e1]  about 2 weeks after the administration of [s2]leflunomide[e2] 
	(23, 46)	short-of-breath	leflunomide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3180	We report the case of a young man, affected by rheumatoid arthritis who developed a rapid-onset [s1]short-of-breath[e1]  hemoptysis, and severe weakness, about 2 weeks after the administration of [s2]leflunomide[e2] 
	(0, 16)	Hyponatraemia	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3181	 [s1]Hyponatraemia[e1] developed after rechallenge with controlled release [s2]carbamazepine[e2] 
	(0, 11)	Hyponatraemia	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3182	 [s1]Hyponatraemia[e1] during low-dose [s2]carbamazepine[e2] therapy.
	(6, 20)	antidiuresis	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3183	We report the syndrome of inappropriate [s1]antidiuresis[e1] as a much earlier side-effect of [s2]carbamazepine[e2] administration in a 29-year Nigerian female patient with generalized tonic-elonic seizures.
	(15, 33)	severe systemic CMV infection	cyclosporine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3184	In the present paper, we describe two patients with active UC who developed a [s1]severe systemic CMV infection[e1] during a treatment with an oral microemulsion form of [s2]cyclosporine[e2] 
	(4, 10)	imatinib	hepatotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3185	A short review on [s1]imatinib[e1] related [s2]hepatotoxicity[e2] is also presented.
	(0, 9)	Imatinib mesylate	fatal acute hepatic failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3186	 [s1]Imatinib mesylate[e1] related [s2]fatal acute hepatic failure[e2] in a patient with chronic myeloid leukaemia and chronic hepatitis B infection.
	(8, 15)	imatinib	hepatotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3187	Up to four percent of patients treated with [s1]imatinib[e1] may develop [s2]hepatotoxicity[e2]  which usually resolves with discontinuation of the drug.
	(21, 35)	imatinib	acute liver failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3188	We report a 45-year-old Chinese man with CML and chronic hepatitis B virus infection, on [s1]imatinib[e1] treatment, presenting with herpetic rash and [s2]acute liver failure[e2] 
	(21, 30)	imatinib	herpetic rash	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3189	We report a 45-year-old Chinese man with CML and chronic hepatitis B virus infection, on [s1]imatinib[e1] treatment, presenting with [s2]herpetic rash[e2] and acute liver failure.
	(8, 22)	olanzapine	hyperglycemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3190	CONCLUSIONS: Clinicians treating elderly patients with [s1]olanzapine[e1] should be aware of the potential for rapidly developing [s2]hyperglycemia[e2] and monitor such patients accordingly.
	(9, 28)	hyperglycemia	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3191	OBJECTIVE: To report a case of rapidly occurring [s1]hyperglycemia[e1] that occurred in a geriatric patient 3 days after treatment with [s2]olanzapine[e2] 
	(2, 11)	hyperglycemia	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3192	Rapidly developing [s1]hyperglycemia[e1] during treatment with [s2]olanzapine[e2] 
	(4, 23)	hyperglycemia	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3193	Subsequently, he developed [s1]hyperglycemia[e1] (fasting blood glucose 138 mg/dL) that resolved when [s2]olanzapine[e2] was stopped and recurred (fasting blood glucose 150 mg/dL) after 2 days of rechallenge with olanzapine 2.5 mg twice daily.
	(7, 14)	hyperglycemia	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3194	There have been numerous case reports of [s1]hyperglycemia[e1] with [s2]olanzapine[e2] in the literature, but none reported hyperglycemia within days of initiation of the medication.
	(0, 9)	Adult respiratory distress syndrome	pegylated interferon alpha-2a	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3195	 [s1]Adult respiratory distress syndrome[e1] after treatment with [s2]pegylated interferon alpha-2a[e2] and ribavirin.
	(0, 19)	Adult respiratory distress syndrome	ribavirin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3196	 [s1]Adult respiratory distress syndrome[e1] after treatment with pegylated interferon alpha-2a and [s2]ribavirin[e2] 
	(10, 31)	adult respiratory distress syndrome	pegIFNalpha-2a	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3197	We report the first case of fulminant [s1]adult respiratory distress syndrome[e1] (ARDS) associated with pegylated interferon alpha-2a  [s2]pegIFNalpha-2a[e2]  and ribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure.
	(10, 22)	adult respiratory distress syndrome	pegylated interferon alpha-2a	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3198	We report the first case of fulminant [s1]adult respiratory distress syndrome[e1] (ARDS) associated with [s2]pegylated interferon alpha-2a[e2] (pegIFNalpha-2a) and ribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure.
	(10, 40)	adult respiratory distress syndrome	ribavirin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3199	We report the first case of fulminant [s1]adult respiratory distress syndrome[e1] (ARDS) associated with pegylated interferon alpha-2a (pegIFNalpha-2a) and [s2]ribavirin[e2] use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure.
	(14, 29)	ARDS	pegIFNalpha-2a	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3200	We report the first case of fulminant adult respiratory distress syndrome  [s1]ARDS[e1]  associated with pegylated interferon alpha-2a  [s2]pegIFNalpha-2a[e2]  and ribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure.
	(14, 20)	ARDS	pegylated interferon alpha-2a	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3201	We report the first case of fulminant adult respiratory distress syndrome  [s1]ARDS[e1]  associated with [s2]pegylated interferon alpha-2a[e2] (pegIFNalpha-2a) and ribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure.
	(14, 38)	ARDS	ribavirin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3202	We report the first case of fulminant adult respiratory distress syndrome  [s1]ARDS[e1]  associated with pegylated interferon alpha-2a (pegIFNalpha-2a) and [s2]ribavirin[e2] use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure.
	(0, 9)	Bilateral anterior uveitis	clomiphene citrate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3203	 [s1]Bilateral anterior uveitis[e1] associated with [s2]clomiphene citrate[e2] 
	(7, 22)	bilateral anterior uveitis	clomiphene citrate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3204	PURPOSE: To report a case of [s1]bilateral anterior uveitis[e1] associated with ovulation induction therapy using [s2]clomiphene citrate[e2] 
	(2, 15)	tics	atomoxetine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3205	Development of [s1]tics[e1] in a thirteen-year-old male following [s2]atomoxetine[e2] use.
	(15, 22)	tics	atomoxetine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3206	There are, however, case studies describing patients experiencing recurrences of [s1]tics[e1] following treatment with [s2]atomoxetine[e2] 
	(8, 26)	type 1 diabetes mellitus	alpha-2b peginterferon	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3207	A 51-year-old man developed [s1]type 1 diabetes mellitus[e1] following 24 weeks of treatment with recombinant [s2]alpha-2b peginterferon[e2] plus ribavirin for chronic hepatitis C.
	(8, 36)	type 1 diabetes mellitus	ribavirin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3208	A 51-year-old man developed [s1]type 1 diabetes mellitus[e1] following 24 weeks of treatment with recombinant alpha-2b peginterferon plus [s2]ribavirin[e2] for chronic hepatitis C.
	(5, 25)	recombinant alpha-2b peginterferon	type 1 diabetes mellitus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3209	The clinical course suggested that [s1]recombinant alpha-2b peginterferon[e1] plus ribavirin provoked [s2]type 1 diabetes mellitus[e2]  therefore, in patients who are candidates for interferon therapy the presence of pancreatic autoantibodies and the fasting plasma glucose level should be investigated before and during treatment.
	(19, 25)	ribavirin	type 1 diabetes mellitus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3210	The clinical course suggested that recombinant alpha-2b peginterferon plus [s1]ribavirin[e1] provoked [s2]type 1 diabetes mellitus[e2]  therefore, in patients who are candidates for interferon therapy the presence of pancreatic autoantibodies and the fasting plasma glucose level should be investigated before and during treatment.
	(0, 10)	Type 1 diabetes mellitus	peginterferon alpha-2b	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3211	 [s1]Type 1 diabetes mellitus[e1] provoked by [s2]peginterferon alpha-2b[e2] plus ribavirin treatment for chronic hepatitis C.
	(0, 20)	Type 1 diabetes mellitus	ribavirin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3212	 [s1]Type 1 diabetes mellitus[e1] provoked by peginterferon alpha-2b plus [s2]ribavirin[e2] treatment for chronic hepatitis C.
	(7, 19)	ocular hypertension	ranibizumab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3213	BACKGROUND: To describe the occurrence of [s1]ocular hypertension[e1] in four patients following injection of [s2]ranibizumab[e2] intravitreally.
	(4, 18)	sustained ocular hypertension	ranibizumab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3214	CONCLUSION: Severe and [s1]sustained ocular hypertension[e1] may occur after intravitreal [s2]ranibizumab[e2] 
	(0, 12)	Ocular hypertension	ranibizumab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3215	 [s1]Ocular hypertension[e1] occurred 1 month after the second [s2]ranibizumab[e2] injection in patients 1 and 3, and 1 month after the first ranibizumab in patient 2.
	(0, 14)	Persisent ocular hypertension	ranibizumab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3216	 [s1]Persisent ocular hypertension[e1] following intravitreal [s2]ranibizumab[e2] 
	(5, 13)	dextroamphetamine	peripheral vasculopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3217	Methylphenidate and [s1]dextroamphetamine[e1] induced [s2]peripheral vasculopathy[e2] 
	(0, 14)	Methylphenidate	peripheral vasculopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3218	 [s1]Methylphenidate[e1] and dextroamphetamine-induced [s2]peripheral vasculopathy[e2] 
	(14, 24)	dextroamphetamine	acral cyanosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3219	We report 4 patients, 2 on methylphenidate and 2 on [s1]dextroamphetamine[e1] who presented with [s2]acral cyanosis[e2]  livedo reticularis, or Raynaud phenomenon.
	(7, 24)	methylphenidate	acral cyanosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3220	We report 4 patients, 2 on [s1]methylphenidate[e1] and 2 on dextroamphetamine who presented with [s2]acral cyanosis[e2]  livedo reticularis, or Raynaud phenomenon.
	(14, 30)	dextroamphetamine	livedo reticularis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3221	We report 4 patients, 2 on methylphenidate and 2 on [s1]dextroamphetamine[e1] who presented with acral cyanosis, [s2]livedo reticularis[e2]  or Raynaud phenomenon.
	(7, 30)	methylphenidate	livedo reticularis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3222	We report 4 patients, 2 on [s1]methylphenidate[e1] and 2 on dextroamphetamine who presented with acral cyanosis, [s2]livedo reticularis[e2]  or Raynaud phenomenon.
	(14, 38)	dextroamphetamine	Raynaud phenomenon	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3223	We report 4 patients, 2 on methylphenidate and 2 on [s1]dextroamphetamine[e1] who presented with acral cyanosis, livedo reticularis, or [s2]Raynaud phenomenon[e2] 
	(7, 38)	methylphenidate	Raynaud phenomenon	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3224	We report 4 patients, 2 on [s1]methylphenidate[e1] and 2 on dextroamphetamine who presented with acral cyanosis, livedo reticularis, or [s2]Raynaud phenomenon[e2] 
	(0, 24)	Disseminated eruptive giant mollusca contagiosa	efalizumab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3225	 [s1]Disseminated eruptive giant mollusca contagiosa[e1] in an adult psoriasis patient during [s2]efalizumab[e2] therapy.
	(14, 34)	eruptive mollusca contagiosa	efalizumab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3226	We report a 45-year-old psoriasis patient who developed [s1]eruptive mollusca contagiosa[e1] during an antipsoriatic treatment with [s2]efalizumab[e2] 
	(12, 27)	cervical adenocarcinoma	tamoxifen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3227	Gastric tumor, endometrial carcinoma and [s1]cervical adenocarcinoma[e1] in situ were detected after treatment with [s2]tamoxifen[e2] for breast cancer.
	(4, 27)	endometrial carcinoma	tamoxifen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3228	Gastric tumor, [s1]endometrial carcinoma[e1] and cervical adenocarcinoma in situ were detected after treatment with [s2]tamoxifen[e2] for breast cancer.
	(0, 26)	Gastric tumor	tamoxifen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3229	 [s1]Gastric tumor[e1]  endometrial carcinoma and cervical adenocarcinoma in situ were detected after treatment with [s2]tamoxifen[e2] for breast cancer.
	(0, 13)	Incomplete posterior hyaloid detachment	pegaptanib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3230	 [s1]Incomplete posterior hyaloid detachment[e1] after intravitreal [s2]pegaptanib[e2] injection in diabetic macular edema.
	(6, 22)	incomplete posterior hyaloid detachment	pegaptanib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3231	The authors report one case of [s1]incomplete posterior hyaloid detachment[e1] (PHD) following intravitreal [s2]pegaptanib[e2] to treat DME.
	(0, 8)	Enalaprilat	acute parotitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3232	 [s1]Enalaprilat[e1] induced [s2]acute parotitis[e2] 
	(8, 22)	acute bilateral parotitis	enalaprilat	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3233	We present here a female patient who developed [s1]acute bilateral parotitis[e1] within minutes of i.v. [s2]enalaprilat[e2] injection and recovered within 24 hours of stopping the drug and with symptomatic treatment.
	(12, 27)	acute bilateral blindness	oxybutynin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3234	We report a 4-year-old girl who presented with [s1]acute bilateral blindness[e1]  a focal seizure and hypertension 10 days after commencing [s2]oxybutynin[e2] to treat enuresis.
	(17, 28)	focal seizure	oxybutynin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3235	We report a 4-year-old girl who presented with acute bilateral blindness, a [s1]focal seizure[e1] and hypertension 10 days after commencing [s2]oxybutynin[e2] to treat enuresis.
	(20, 28)	hypertension	oxybutynin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3236	We report a 4-year-old girl who presented with acute bilateral blindness, a focal seizure and [s1]hypertension[e1] 10 days after commencing [s2]oxybutynin[e2] to treat enuresis.
	(0, 13)	Severe symptomatic hyponatremia	sibutramine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3237	 [s1]Severe symptomatic hyponatremia[e1] during [s2]sibutramine[e2] therapy: a case report.
	(5, 13)	sibutramine	hypertension	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3238	The known side effects of [s1]sibutramine[e1]  ie, [s2]hypertension[e2] and tachycardia, depend on its adrenergic and serotoninergic effects.
	(5, 16)	sibutramine	tachycardia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3239	The known side effects of [s1]sibutramine[e1]  ie, hypertension and [s2]tachycardia[e2]  depend on its adrenergic and serotoninergic effects.
	(8, 17)	hyponatremia	sibutramine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3240	We describe a case of life-threatening [s1]hyponatremia[e1] associated with [s2]sibutramine[e2] use in an obese woman.
	(13, 22)	pregabalin	cortical negative myoclonus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3241	Our findings reveal that even in patients without a history of seizures, [s1]pregabalin[e1] can cause a [s2]cortical negative myoclonus[e2] 
	(0, 7)	Pregabalin	cortical negative myoclonus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3242	 [s1]Pregabalin[e1] induced [s2]cortical negative myoclonus[e2] in a patient with neuropathic pain.
	(12, 28)	pregabalin	negative myoclonus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3243	We describe a patient who, after receiving his first dose of [s1]pregabalin[e1] to relieve neuropathic pain, presented with a [s2]negative myoclonus[e2] 
	(0, 7)	Muzolimine	severe neuromyeloencephalopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3244	 [s1]Muzolimine[e1] induced [s2]severe neuromyeloencephalopathy[e2]  report of seven cases.
	(30, 46)	muzolimine	fatal neuromyeloencephalopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3245	We report on 7 patients (2 women, 5 men) with chronic renal failure, who developed under a high dosage of the new diuretic [s1]muzolimine[e1] (range 240 to 1440 mg per day) [s2]fatal neuromyeloencephalopathy[e2] 
	(0, 9)	L-asparaginase	posterior reversible encephalopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3246	 [s1]L-asparaginase[e1] induced [s2]posterior reversible encephalopathy[e2] syndrome during acute lymphoblastic leukemia treatment in children.
	(14, 32)	posterior reversible encephalopathy syndrome	L-asparaginase	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3247	The purpose of this article is to present the first case-series of [s1]posterior reversible encephalopathy syndrome[e1] (PRES) associated with [s2]L-asparaginase[e2] treatment.
	(24, 30)	PRES	L-asparaginase	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3248	The purpose of this article is to present the first case-series of posterior reversible encephalopathy syndrome  [s1]PRES[e1]  associated with [s2]L-asparaginase[e2] treatment.
	(18, 24)	altered sensorium	L-asparaginase	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3249	We report 3 cases of children with acute lymphoblastic leukemia who developed seizures and [s1]altered sensorium[e1] after [s2]L-asparaginase[e2] therapy.
	(16, 24)	seizures	L-asparaginase	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3250	We report 3 cases of children with acute lymphoblastic leukemia who developed [s1]seizures[e1] and altered sensorium after [s2]L-asparaginase[e2] therapy.
	(0, 8)	Anastrozole	sclerosing glomerulonephritis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3251	 [s1]Anastrozole[e1] associated [s2]sclerosing glomerulonephritis[e2] in a patient with breast cancer.
	(2, 19)	Anastrozole	sclerosing glomerulonephritis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3252	CONCLUSIONS: [s1]Anastrozole[e1] may be the causative factor in patients with [s2]sclerosing glomerulonephritis[e2] 
	(2, 20)	sclerosing glomerulonephritis	anastrozole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3253	Diagnosis of [s1]sclerosing glomerulonephritis[e1] occurred in this patient during [s2]anastrozole[e2] use, suggesting a newly defined side effect of anastrozole.
	(0, 6)	Renal injury	anastrozole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3254	 [s1]Renal injury[e1] due to [s2]anastrozole[e2] has not been published in the English literature.
	(6, 14)	anastrozole	decrease in both lumbar spine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3255	There are major side effects of [s1]anastrozole[e1] including [s2]decrease in both lumbar spine[e2] and total hip bone mineral density, increase in the incidence of all bone fractures (especially fractures of spine, hip and wrist), joint disorders and increase in the cholesterol level.
	(6, 50)	anastrozole	increase in the cholesterol level	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3256	There are major side effects of [s1]anastrozole[e1] including decrease in both lumbar spine and total hip bone mineral density, increase in the incidence of all bone fractures (especially fractures of spine, hip and wrist), joint disorders and [s2]increase in the cholesterol level[e2] 
	(6, 28)	anastrozole	increase in the incidence of all bone fractures	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3257	There are major side effects of [s1]anastrozole[e1] including decrease in both lumbar spine and total hip bone mineral density, [s2]increase in the incidence of all bone fractures[e2] (especially fractures of spine, hip and wrist), joint disorders and increase in the cholesterol level.
	(6, 47)	anastrozole	joint disorders	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3258	There are major side effects of [s1]anastrozole[e1] including decrease in both lumbar spine and total hip bone mineral density, increase in the incidence of all bone fractures (especially fractures of spine, hip and wrist), [s2]joint disorders[e2] and increase in the cholesterol level.
	(4, 15)	acute renal failure	anastrozole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3259	We believe that the [s1]acute renal failure[e1] in our patient was associated with [s2]anastrozole[e2] 
	(19, 37)	acute hepatitis	itraconazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3260	CASE SUMMARY: A 61-year-old woman with no apparent risk factors for liver injury developed [s1]acute hepatitis[e1] one week after the final dose of a long-term course of pulse [s2]itraconazole[e2] therapy (200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk) for onychomycosis.
	(5, 24)	itraconazole	severe and irreversible hepatotoxic events	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3261	CONCLUSIONS: Prolonged exposure to [s1]itraconazole[e1]  administered either continuously or intermittently, may precipitate [s2]severe and irreversible hepatotoxic events[e2] 
	(0, 9)	Fatal hepatitis	itraconazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3262	 [s1]Fatal hepatitis[e1] after long-term pulse [s2]itraconazole[e2] treatment for onychomycosis.
	(7, 21)	acute cytolytic hepatitis	itraconazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3263	OBJECTIVE: To report the occurrence of [s1]acute cytolytic hepatitis[e1] in a patient exposed to pulse [s2]itraconazole[e2] therapy for 24 weeks and provide a concise review of the literature on cases of itraconazole-induced hepatitis.
	(12, 21)	hepatitis	itraconazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3264	OBJECTIVE: To report the occurrence of acute cytolytic [s1]hepatitis[e1] in a patient exposed to pulse [s2]itraconazole[e2] therapy for 24 weeks and provide a concise review of the literature on cases of itraconazole-induced hepatitis.
	(4, 17)	severe symptomatic hepatitis	itraconazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3265	Only one case of [s1]severe symptomatic hepatitis[e1] occurring after pulse therapy with [s2]itraconazole[e2] for onychomycosis and requiring transplantation has been reported previously.
	(5, 12)	baclofen	impair sexual function	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3266	CONCLUSIONS: Intrathecal [s1]baclofen[e1] can [s2]impair sexual function[e2] and ejaculation in some patients.
	(17, 27)	baclofen	sexual dysfunction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3267	RESULTS: A male and a female patient with spasticity treated with intrathecal [s1]baclofen[e1] were recognized to have [s2]sexual dysfunction[e2] side effects from treatment.
	(0, 9)	Sexual dysfunction	baclofen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3268	 [s1]Sexual dysfunction[e1] associated with intrathecal [s2]baclofen[e2] use: a report of two cases.
	(0, 8)	Anaphylactic reaction	recombinant insulin-like growth factor-I	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3269	 [s1]Anaphylactic reaction[e1] to [s2]recombinant insulin-like growth factor-I[e2] 
	(13, 25)	anaphylaxis	Increlex	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3270	We report a 13 year-old male who developed life-threatening [s1]anaphylaxis[e1] early in the course of [s2]Increlex[e2] therapy.
	(2, 14)	olanzapine	RLS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3271	Increasing the [s1]olanzapine[e1] dosage severely aggravated the symptoms of [s2]RLS[e2] 
	(4, 14)	periodic limb movements during sleep	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3272	Restless legs syndrome and [s1]periodic limb movements during sleep[e1] probably associated with [s2]olanzapine[e2] 
	(0, 14)	Restless legs syndrome	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3273	 [s1]Restless legs syndrome[e1] and periodic limb movements during sleep probably associated with [s2]olanzapine[e2] 
	(7, 12)	agitation	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3274	The fifth patient exhibited paraesthesia and [s1]agitation[e1] caused by [s2]olanzapine[e2] that was misdiagnosed as psychotic agitation.
	(4, 12)	paraesthesia	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3275	The fifth patient exhibited [s1]paraesthesia[e1] and agitation caused by [s2]olanzapine[e2] that was misdiagnosed as psychotic agitation.
	(4, 19)	RLS symptoms	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3276	The fourth patient showed [s1]RLS symptoms[e1] that were initially caused by a 20-mg daily [s2]olanzapine[e2] dosage and were later mitigated when olanzapine was reduced and ropinirole was administered.
	(5, 10)	PLMS	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3277	The second patient exhibited sudden [s1]PLMS[e1] following [s2]olanzapine[e2] injection.
	(8, 26)	akathisia	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3278	The third patient had been suffering from serious [s1]akathisia[e1] while on risperidone, and was cured after switching to [s2]olanzapine[e2]  but thereafter the patient suffered from RLS at nighttime.
	(8, 15)	akathisia	risperidone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3279	The third patient had been suffering from serious [s1]akathisia[e1] while on [s2]risperidone[e2]  and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime.
	(24, 35)	olanzapine	RLS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3280	The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to [s1]olanzapine[e1]  but thereafter the patient suffered from [s2]RLS[e2] at nighttime.
	(13, 35)	risperidone	RLS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3281	The third patient had been suffering from serious akathisia while on [s1]risperidone[e1]  and was cured after switching to olanzapine, but thereafter the patient suffered from [s2]RLS[e2] at nighttime.
	(13, 29)	periodic limb movements during sleep	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3282	We report five cases of restless legs syndrome (RLS) and [s1]periodic limb movements during sleep[e1] (PLMS) that were probably associated with [s2]olanzapine[e2] 
	(18, 27)	PLMS	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3283	We report five cases of restless legs syndrome (RLS) and periodic limb movements during sleep  [s1]PLMS[e1]  that were probably associated with [s2]olanzapine[e2] 
	(5, 29)	restless legs syndrome	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3284	We report five cases of [s1]restless legs syndrome[e1] (RLS) and periodic limb movements during sleep (PLMS) that were probably associated with [s2]olanzapine[e2] 
	(8, 27)	RLS	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3285	We report five cases of restless legs syndrome  [s1]RLS[e1]  and periodic limb movements during sleep (PLMS) that were probably associated with [s2]olanzapine[e2] 
	(2, 10)	Alendronate	nodular scleritis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3286	CONCLUSION: [s1]Alendronate[e1] led to [s2]nodular scleritis[e2] and rechallenge caused recurrence of scleritis.
	(2, 12)	Alendronate	scleritis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3287	CONCLUSION: [s1]Alendronate[e1] led to nodular [s2]scleritis[e2] and rechallenge caused recurrence of scleritis.
	(0, 8)	Nodular scleritis	alendronate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3288	 [s1]Nodular scleritis[e1] following [s2]alendronate[e2] therapy.
	(7, 15)	nodular scleritis	alendronate sodium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3289	PURPOSE: To report a case of [s1]nodular scleritis[e1] following [s2]alendronate sodium[e2] 
	(8, 22)	alendronate sodium	scleritis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3290	Two weeks following rechallenge with [s1]alendronate sodium[e1] resulted in recurrence of his [s2]scleritis[e2] 
	(8, 16)	prolonged ECT seizure	ciprofloxacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3291	In addition, there is a report on [s1]prolonged ECT seizure[e1] related to [s2]ciprofloxacin[e2]  which has an epileptogenic property with a similar action to beta-lactam antibiotics.
	(2, 22)	tardive seizures	cefotiam	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3292	Thus, [s1]tardive seizures[e1] in our cases are thought to be related to piperacillin and [s2]cefotiam[e2] 
	(2, 17)	tardive seizures	piperacillin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3293	Thus, [s1]tardive seizures[e1] in our cases are thought to be related to [s2]piperacillin[e2] and cefotiam.
	(0, 8)	Acute delirium	levofloxacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3294	 [s1]Acute delirium[e1] resulting from [s2]levofloxacin[e2] therapy is an exceedingly rare complication that has been thought to occur more commonly in elderly patients.
	(35, 77)	gatifloxacin	dizziness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3295	CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, [s1]gatifloxacin[e1] and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, [s2]dizziness[e2] and insomnia.
	(21, 76)	grepafloxacin	dizziness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3296	CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, [s1]grepafloxacin[e1]  trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, [s2]dizziness[e2] and insomnia.
	(8, 75)	levofloxacin	dizziness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3297	CONCLUSION: The new quinolone derivatives  [s1]levofloxacin[e1]  sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, [s2]dizziness[e2] and insomnia.
	(42, 76)	moxifloxacin	dizziness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3298	CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and [s1]moxifloxacin[e1] , also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, [s2]dizziness[e2] and insomnia.
	(15, 76)	sparfloxacin	dizziness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3299	CONCLUSION: The new quinolone derivatives (levofloxacin, [s1]sparfloxacin[e1]  grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, [s2]dizziness[e2] and insomnia.
	(28, 76)	trovafloxacin	dizziness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3300	CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, [s1]trovafloxacin[e1]  gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, [s2]dizziness[e2] and insomnia.
	(35, 75)	gatifloxacin	headache	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3301	CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, [s1]gatifloxacin[e1] and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including [s2]headache[e2]  dizziness and insomnia.
	(21, 74)	grepafloxacin	headache	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3302	CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, [s1]grepafloxacin[e1]  trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including [s2]headache[e2]  dizziness and insomnia.
	(8, 73)	levofloxacin	headache	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3303	CONCLUSION: The new quinolone derivatives  [s1]levofloxacin[e1]  sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including [s2]headache[e2]  dizziness and insomnia.
	(42, 74)	moxifloxacin	headache	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3304	CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and [s1]moxifloxacin[e1] , also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including [s2]headache[e2]  dizziness and insomnia.
	(15, 74)	sparfloxacin	headache	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3305	CONCLUSION: The new quinolone derivatives (levofloxacin, [s1]sparfloxacin[e1]  grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including [s2]headache[e2]  dizziness and insomnia.
	(28, 74)	trovafloxacin	headache	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3306	CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, [s1]trovafloxacin[e1]  gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including [s2]headache[e2]  dizziness and insomnia.
	(35, 80)	gatifloxacin	insomnia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3307	CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, [s1]gatifloxacin[e1] and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, dizziness and [s2]insomnia[e2] 
	(21, 79)	grepafloxacin	insomnia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3308	CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, [s1]grepafloxacin[e1]  trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, dizziness and [s2]insomnia[e2] 
	(8, 78)	levofloxacin	insomnia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3309	CONCLUSION: The new quinolone derivatives  [s1]levofloxacin[e1]  sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, dizziness and [s2]insomnia[e2] 
	(42, 79)	moxifloxacin	insomnia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3310	CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and [s1]moxifloxacin[e1] , also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, dizziness and [s2]insomnia[e2] 
	(15, 79)	sparfloxacin	insomnia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3311	CONCLUSION: The new quinolone derivatives (levofloxacin, [s1]sparfloxacin[e1]  grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, dizziness and [s2]insomnia[e2] 
	(28, 79)	trovafloxacin	insomnia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3312	CONCLUSION: The new quinolone derivatives (levofloxacin, sparfloxacin, grepafloxacin, [s1]trovafloxacin[e1]  gatifloxacin and moxifloxacin), also called gyrase inhibitors, are known for their potential to cause central nervous system-related adverse effects, including headache, dizziness and [s2]insomnia[e2] 
	(4, 12)	levofloxacin	delirium with psychotic features	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3313	Here, we describe [s1]levofloxacin[e1] induced [s2]delirium with psychotic features[e2] in a relatively young, otherwise healthy female.
	(0, 8)	Levofloxacin	delirium with psychotic features	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3314	 [s1]Levofloxacin[e1] induced [s2]delirium with psychotic features[e2] 
	(13, 28)	acute-onset delirium with psychotic features	levofloxacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3315	RESULTS: A previously healthy 42-year-old woman presented with [s1]acute-onset delirium with psychotic features[e1] as a consequence of [s2]levofloxacin[e2] therapy.
	(8, 24)	Crohn's disease	Copaxone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3316	CONCLUSIONS: Clinicians should be aware that [s1]Crohn's disease[e1] is a potential novel adverse drug effect of [s2]Copaxone[e2] 
	(2, 20)	Crohn's disease	copaxone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3317	Development of [s1]Crohn's disease[e1] in a patient with multiple sclerosis treated with [s2]copaxone[e2] 
	(5, 15)	Crohn's disease	Copaxone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3318	RESULTS: Our patient developed [s1]Crohn's disease[e1] while on [s2]Copaxone[e2] treatment as a consequence of long-term immunosuppression.
	(13, 23)	Copaxone	long-term immunosuppression	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3319	RESULTS: Our patient developed Crohn's disease while on [s1]Copaxone[e1] treatment as a consequence of [s2]long-term immunosuppression[e2] 
	(4, 21)	Copaxone	gastrointestinal symptoms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3320	She had been on [s1]Copaxone[e1] 20 mg/day treatment for 2 years when she first exhibited [s2]gastrointestinal symptoms[e2] 
	(18, 38)	obsessional-like suicidal ideas and images	ketoconazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3321	The authors present a case study of a mentally healthy man who repeatedly experienced short-lived, [s1]obsessional-like suicidal ideas and images[e1] after ingestion of the anti-fungal drug [s2]ketoconazole[e2] 
	(6, 40)	terlipressin	prolonged QT interval	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3322	During intravenous treatment with [s1]terlipressin[e1] for recurrent gastrointestinal (GI) bleeding, a 50-year-old male with no history of heart disease developed a newly [s2]prolonged QT interval[e2] and torsade de pointes.
	(6, 45)	terlipressin	torsade de pointes	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3323	During intravenous treatment with [s1]terlipressin[e1] for recurrent gastrointestinal (GI) bleeding, a 50-year-old male with no history of heart disease developed a newly prolonged QT interval and [s2]torsade de pointes[e2] 
	(0, 7)	Terlipressin	ventricular arrhythmia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3324	 [s1]Terlipressin[e1] induced [s2]ventricular arrhythmia[e2] 
	(0, 14)	Spontaneous nasal septal perforation	bevacizumab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3325	 [s1]Spontaneous nasal septal perforation[e1] with antiangiogenic [s2]bevacizumab[e2] therapy.
	(14, 32)	spontaneous nasal septal perforation	bevacizumab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3326	This case describes a 52-year-old white woman who developed a [s1]spontaneous nasal septal perforation[e1] after given the antiangiogenic drug, [s2]bevacizumab[e2]  for metastatic ovarian cancer treatment.
	(25, 31)	VRC	angio-oedema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3327	A 37-year-old woman with relapsing invasive vertebral aspergillosis received intravenous [s1]VRC[e1] and developed [s2]angio-oedema[e2] 10 days after starting therapy.
	(0, 17)	Angio-oedema	voriconazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3328	 [s1]Angio-oedema[e1] as an unusual tolerable side effect of [s2]voriconazole[e2] therapy.
	(7, 17)	angio-oedema	VRC	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3329	Here, we report a case of [s1]angio-oedema[e1] associated with [s2]VRC[e2] therapy.
	(11, 21)	angio-oedema	VRC	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3330	To our knowledge, this is the first report of an [s1]angio-oedema[e1] associated with [s2]VRC[e2] 
	(0, 18)	Voriconazole	angio-oedema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3331	 [s1]Voriconazole[e1] (VRC) has not previously been reported to cause [s2]angio-oedema[e2] 
	(5, 16)	VRC	angio-oedema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3332	Voriconazole  [s1]VRC[e1]  has not previously been reported to cause [s2]angio-oedema[e2] 
	(0, 5)	Multiple seizures	bupropion	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3333	 [s1]Multiple seizures[e1] after [s2]bupropion[e2] overdose in a small child.
	(7, 35)	agitation	bupropion	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3334	The patient experienced hallucinations, [s1]agitation[e1]  vomiting, tachycardia and seizures after ingestion of 1050 (48 mg/kg) of extended-release [s2]bupropion[e2] 
	(3, 35)	hallucinations	bupropion	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3335	The patient experienced [s1]hallucinations[e1]  agitation, vomiting, tachycardia and seizures after ingestion of 1050 (48 mg/kg) of extended-release [s2]bupropion[e2] 
	(16, 36)	seizures	bupropion	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3336	The patient experienced hallucinations, agitation, vomiting, tachycardia and [s1]seizures[e1] after ingestion of 1050 (48 mg/kg) of extended-release [s2]bupropion[e2] 
	(11, 36)	tachycardia	bupropion	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3337	The patient experienced hallucinations, agitation, vomiting, [s1]tachycardia[e1] and seizures after ingestion of 1050 (48 mg/kg) of extended-release [s2]bupropion[e2] 
	(9, 35)	vomiting	bupropion	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3338	The patient experienced hallucinations, agitation, [s1]vomiting[e1]  tachycardia and seizures after ingestion of 1050 (48 mg/kg) of extended-release [s2]bupropion[e2] 
	(6, 17)	bupropion	multiple seizures	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3339	We report a case of pediatric [s1]bupropion[e1] ingestion resulting in [s2]multiple seizures[e2] 
	(0, 7)	Methylphenidate	enuresis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3340	 [s1]Methylphenidate[e1] associated [s2]enuresis[e2] in attention deficit hyperactivity disorder.
	(9, 16)	methylphenidate	enuresis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3341	This is a case report of possible association of [s1]methylphenidate[e1] and [s2]enuresis[e2] in an 11-year-old boy with attention deficit hyperactivity disorder.
	(0, 8)	Cephalosporin	leukopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3342	 [s1]Cephalosporin[e1] induced [s2]leukopenia[e2] following rechallenge with cefoxitin.
	(2, 17)	Cefazolin	leukopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3343	CONCLUSIONS: [s1]Cefazolin[e1] was a probable cause of this patient's [s2]leukopenia[e2] 
	(7, 14)	cefazolin	leukopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3344	OBJECTIVE: To describe a case of [s1]cefazolin[e1] induced [s2]leukopenia[e2] in a critically ill patient who developed this adverse reaction upon rechallenge with cefoxitin.
	(12, 21)	cephalosporin	leukopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3345	Use of the Naranjo probability scale determined the association between [s1]cephalosporin[e1] use and [s2]leukopenia[e2] to be probable.
	(10, 16)	PRES	cyclosporine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3346	Posterior reversible encephalopathy syndrome  [s1]PRES[e1]  induced by [s2]cyclosporine[e2] use in a patient with collapsing focal glomeruloesclerosis.
	(0, 12)	Posterior reversible encephalopathy syndrome	PRES	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3347	 [s1]Posterior reversible encephalopathy syndrome[e1]  [s2]PRES[e2]  induced by cyclosporine use in a patient with collapsing focal glomeruloesclerosis.
	(5, 38)	PRES	CSA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3348	We describe a case of [s1]PRES[e1] in a patient with collapsing focal glomeruloesclerosis (collapsing FGS) with complete recovery after withdrawal of cyclosporine  [s2]CSA[e2] .
	(5, 33)	PRES	cyclosporine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3349	We describe a case of [s1]PRES[e1] in a patient with collapsing focal glomeruloesclerosis (collapsing FGS) with complete recovery after withdrawal of [s2]cyclosporine[e2] (CSA).
	(0, 11)	Stuttering priapism	warfarin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3350	 [s1]Stuttering priapism[e1] complicating [s2]warfarin[e2] therapy in a patient with protein C deficiency.
	(6, 12)	Warfarin	skin necrosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3351	This therapy was also complicated by [s1]Warfarin[e1] induced [s2]skin necrosis[e2] 
	(12, 27)	priapism	Warfarin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3352	We report a rare case of recurrent (stuttering) [s1]priapism[e1] in a patient with protein C deficiency while maintained on [s2]Warfarin[e2] therapy.
	(8, 25)	stuttering	Warfarin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3353	We report a rare case of recurrent  [s1]stuttering[e1]  priapism in a patient with protein C deficiency while maintained on [s2]Warfarin[e2] therapy.
	(13, 24)	pulmonary fibrosis	bleomycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3354	The patient expired after seven cycles of treatment had been completed because of [s1]pulmonary fibrosis[e1] and the drug toxicity of [s2]bleomycin[e2] 
	(19, 27)	mild cognitive impairment	propafenone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3355	CASE SUMMARY: An 80-year-old white female, followed up at the Memory Clinic for [s1]mild cognitive impairment[e1]  had been taking [s2]propafenone[e2] 900 mg/d for >10 years for paroxysmal atrial fibrillation without adverse effects.
	(17, 43)	citalopram	coronary artery disease	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3356	CONCLUSIONS: This is the first report of a possible interaction between propafenone and [s1]citalopram[e1]  which caused propafenone adverse effects (eg, dizziness, falls) and mimicked [s2]coronary artery disease[e2] 
	(12, 44)	propafenone	coronary artery disease	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3357	CONCLUSIONS: This is the first report of a possible interaction between [s1]propafenone[e1] and citalopram, which caused propafenone adverse effects (eg, dizziness, falls) and mimicked [s2]coronary artery disease[e2] 
	(17, 35)	citalopram	dizziness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3358	CONCLUSIONS: This is the first report of a possible interaction between propafenone and [s1]citalopram[e1]  which caused propafenone adverse effects (eg, [s2]dizziness[e2]  falls) and mimicked coronary artery disease.
	(12, 36)	propafenone	dizziness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3359	CONCLUSIONS: This is the first report of a possible interaction between [s1]propafenone[e1] and citalopram, which caused propafenone adverse effects (eg, [s2]dizziness[e2]  falls) and mimicked coronary artery disease.
	(17, 38)	citalopram	falls	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3360	CONCLUSIONS: This is the first report of a possible interaction between propafenone and [s1]citalopram[e1]  which caused propafenone adverse effects (eg, dizziness, [s2]falls[e2]  and mimicked coronary artery disease.
	(12, 39)	propafenone	falls	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3361	CONCLUSIONS: This is the first report of a possible interaction between [s1]propafenone[e1] and citalopram, which caused propafenone adverse effects (eg, dizziness, [s2]falls[e2]  and mimicked coronary artery disease.
	(4, 14)	citalopram	chest tightness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3362	Three months after starting [s1]citalopram[e1]  she experienced episodes of [s2]chest tightness[e2] and dizziness.
	(4, 18)	citalopram	dizziness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3363	Three months after starting [s1]citalopram[e1]  she experienced episodes of chest tightness and [s2]dizziness[e2] 
	(15, 34)	neurologic symptoms	vancomycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3364	CONCLUSIONS: Clinicians should be aware of this adverse reaction when facing similar complex [s1]neurologic symptoms[e1] in patients who are receiving the antibiotic treatment described here, especially [s2]vancomycin[e2] 
	(13, 38)	neuralgic amyotrophy	piperacillin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3365	DISCUSSION: To our knowledge, this is the first case report illustrating [s1]neuralgic amyotrophy[e1] triggered by exposure to the antibiotics vancomycin, tobramycin, and [s2]piperacillin[e2] tazobactam.
	(13, 42)	neuralgic amyotrophy	tazobactam	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3366	DISCUSSION: To our knowledge, this is the first case report illustrating [s1]neuralgic amyotrophy[e1] triggered by exposure to the antibiotics vancomycin, tobramycin, and piperacillin [s2]tazobactam[e2] 
	(13, 32)	neuralgic amyotrophy	tobramycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3367	DISCUSSION: To our knowledge, this is the first case report illustrating [s1]neuralgic amyotrophy[e1] triggered by exposure to the antibiotics vancomycin, [s2]tobramycin[e2]  and piperacillin/tazobactam.
	(13, 27)	neuralgic amyotrophy	vancomycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3368	DISCUSSION: To our knowledge, this is the first case report illustrating [s1]neuralgic amyotrophy[e1] triggered by exposure to the antibiotics [s2]vancomycin[e2]  tobramycin, and piperacillin/tazobactam.
	(0, 11)	Seizures	methylprednisolone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3369	 [s1]Seizures[e1] and transient blindness following intravenous pulse [s2]methylprednisolone[e2] in children with primary glomerulonephritis.
	(2, 11)	transient blindness	methylprednisolone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3370	Seizures and [s1]transient blindness[e1] following intravenous pulse [s2]methylprednisolone[e2] in children with primary glomerulonephritis.
	(36, 51)	seizures	methylprednisolone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3371	Two children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis, presented an episode of [s1]seizures[e1] and transient blindness at different times after i.v. pulse [s2]methylprednisolone[e2] (IVPMP) treatment.
	(38, 51)	transient blindness	methylprednisolone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3372	Two children, 1 with idiopathic nephrotic syndrome and 1 with endo-extracapillary glomerulonephritis, presented an episode of seizures and [s1]transient blindness[e1] at different times after i.v. pulse [s2]methylprednisolone[e2] (IVPMP) treatment.
	(2, 32)	Hydroxyurea	mucocutaneous adverse events	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3373	BACKGROUND: [s1]Hydroxyurea[e1] is a cytostatic agent used to treat myeloproliferative disorders and long-term treatment is associated with [s2]mucocutaneous adverse events[e2] and nail hyperpigmentation.
	(2, 39)	Hydroxyurea	nail hyperpigmentation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3374	BACKGROUND: [s1]Hydroxyurea[e1] is a cytostatic agent used to treat myeloproliferative disorders and long-term treatment is associated with mucocutaneous adverse events and [s2]nail hyperpigmentation[e2] 
	(17, 45)	hydroxyurea	myeloproliferative disorder	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3375	Based on the Naranjo algorithm, the adverse reaction observed was probably related to the [s1]hydroxyurea[e1] treatment (score = 6); however, the hydroxyurea chemotherapy could not be discontinued because of the [s2]myeloproliferative disorder[e2] 
	(2, 21)	longitudinal melanonychia	hydroxyurea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3376	Both the [s1]longitudinal melanonychia[e1] and the multiple skin cancers first appeared after approximately 6 months of [s2]hydroxyurea[e2] treatment.
	(9, 21)	multiple skin cancers	hydroxyurea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3377	Both the longitudinal melanonychia and the [s1]multiple skin cancers[e1] first appeared after approximately 6 months of [s2]hydroxyurea[e2] treatment.
	(14, 24)	multiple skin cancers	hydroxyurea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3378	CONCLUSIONS: We report this case of the concomitant appearance of [s1]multiple skin cancers[e1] and nail changes associated with [s2]hydroxyurea[e2] use.
	(18, 24)	nail changes	hydroxyurea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3379	CONCLUSIONS: We report this case of the concomitant appearance of multiple skin cancers and [s1]nail changes[e1] associated with [s2]hydroxyurea[e2] use.
	(0, 14)	Hydroxyurea	diffuse longitudinal melanonychia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3380	 [s1]Hydroxyurea[e1] associated with concomitant occurrence of [s2]diffuse longitudinal melanonychia[e2] and multiple squamous cell carcinomas in an elderly subject.
	(0, 21)	Hydroxyurea	multiple squamous cell carcinomas	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3381	 [s1]Hydroxyurea[e1] associated with concomitant occurrence of diffuse longitudinal melanonychia and [s2]multiple squamous cell carcinomas[e2] in an elderly subject.
	(26, 36)	diffuse nail hyperpigmentation	hydroxyurea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3382	OBJECTIVE: The purpose of this study was to report the concomitant occurrence of multiple squamous cell carcinomas and [s1]diffuse nail hyperpigmentation[e1] associated with [s2]hydroxyurea[e2] treatment, and to describe a successful therapeutic approach using imiquimod 5%.
	(17, 36)	multiple squamous cell carcinomas	hydroxyurea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3383	OBJECTIVE: The purpose of this study was to report the concomitant occurrence of [s1]multiple squamous cell carcinomas[e1] and diffuse nail hyperpigmentation associated with [s2]hydroxyurea[e2] treatment, and to describe a successful therapeutic approach using imiquimod 5%.
	(27, 37)	painful hand ulcer	hydroxyurea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3384	The patient completed a 10-month follow-up, maintaining a complete resolution of the treated skin lesions; however, the development of a [s1]painful hand ulcer[e1]  possibly associated with the [s2]hydroxyurea[e2]  and new skin cancers were observed at the last follow-up visit.
	(36, 44)	hydroxyurea	skin cancers	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3385	The patient completed a 10-month follow-up, maintaining a complete resolution of the treated skin lesions; however, the development of a painful hand ulcer, possibly associated with the [s1]hydroxyurea[e1]  and new [s2]skin cancers[e2] were observed at the last follow-up visit.
	(6, 15)	ciprofloxacin	VBDS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3386	It is the first case of [s1]ciprofloxacin[e1] induced [s2]VBDS[e2] successfully treated with tacrolimus.
	(4, 12)	Stevens-Johnson syndrome	ciprofloxacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3387	Vanishing bile duct and [s1]Stevens-Johnson syndrome[e1] associated with [s2]ciprofloxacin[e2] treated with tacrolimus.
	(0, 12)	Vanishing bile duct	ciprofloxacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3388	 [s1]Vanishing bile duct[e1] and Stevens-Johnson syndrome associated with [s2]ciprofloxacin[e2] treated with tacrolimus.
	(8, 17)	ciprofloxacin	SJS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3389	We report a case of a patient with [s1]ciprofloxacin[e1] induced [s2]SJS[e2] and acute onset of VBDS, and reviewed the related literature.
	(8, 23)	ciprofloxacin	VBDS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3390	We report a case of a patient with [s1]ciprofloxacin[e1] induced SJS and acute onset of [s2]VBDS[e2]  and reviewed the related literature.
	(22, 30)	intracranial bleeding	aspirin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3391	A 64 year old woman with previous history of coronary stenting five days before was admitted in our institution for [s1]intracranial bleeding[e1] while receiving [s2]aspirin[e2] and clopidogrel.
	(22, 34)	intracranial bleeding	clopidogrel	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3392	A 64 year old woman with previous history of coronary stenting five days before was admitted in our institution for [s1]intracranial bleeding[e1] while receiving aspirin and [s2]clopidogrel[e2] 
	(0, 13)	Disseminated salmonellosis	temozolomide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3393	 [s1]Disseminated salmonellosis[e1] in a patient treated with [s2]temozolomide[e2] 
	(6, 19)	disseminated salmonellosis	temozolomide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3394	We describe the first case of [s1]disseminated salmonellosis[e1] in a patient treated with [s2]temozolomide[e2] 
	(0, 8)	Ceftriaxone	fixed drug eruption	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3395	 [s1]Ceftriaxone[e1] induced [s2]fixed drug eruption[e2]  first report.
	(0, 5)	FDE	cephalosporins	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3396	 [s1]FDE[e1] from [s2]cephalosporins[e2] has been rarely reported, and to the best of our knowledge there is no published report of ceftriaxone-induced FDE in the literature.
	(0, 28)	FDE	ceftriaxone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3397	 [s1]FDE[e1] from cephalosporins has been rarely reported, and to the best of our knowledge there is no published report of [s2]ceftriaxone[e2] induced FDE in the literature.
	(17, 25)	ceftriaxone	FDE	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3398	We report the first case of a 54-year-old Turkish woman who presented with [s1]ceftriaxone[e1] induced [s2]FDE[e2] 
	(16, 33)	gabapentin	renal impairment	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3399	CONCLUSION: All doctors need to be aware of the need to review the indications for [s1]gabapentin[e1] use during periods of acute illness, especially with regard to [s2]renal impairment[e2] 
	(0, 8)	Gabapentin	renal failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3400	 [s1]Gabapentin[e1] toxicity in [s2]renal failure[e2]  the importance of dose adjustment.
	(18, 28)	gabapentin	acute renal failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3401	OBJECTIVE: This case report outlines a significant type of morbidity due to continued use of [s1]gabapentin[e1] during an episode of [s2]acute renal failure[e2] 
	(0, 21)	Acute syphilitic posterior placoid chorioretinitis	triamcinolone acetonide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3402	 [s1]Acute syphilitic posterior placoid chorioretinitis[e1] following intravitreal [s2]triamcinolone acetonide[e2] injection.
	(17, 52)	acute syphilitic posterior placoid chorioretinitis	IVTA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3403	BACKGROUND: We describe the ophthalmic features and clinical course of two cases of [s1]acute syphilitic posterior placoid chorioretinitis[e1] (ASPPC) that developed after intravitreal triamcinolone acetonide  [s2]IVTA[e2]  injection.
	(17, 45)	acute syphilitic posterior placoid chorioretinitis	triamcinolone acetonide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3404	BACKGROUND: We describe the ophthalmic features and clinical course of two cases of [s1]acute syphilitic posterior placoid chorioretinitis[e1] (ASPPC) that developed after intravitreal [s2]triamcinolone acetonide[e2] (IVTA) injection.
	(31, 50)	ASPPC	IVTA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3405	BACKGROUND: We describe the ophthalmic features and clinical course of two cases of acute syphilitic posterior placoid chorioretinitis  [s1]ASPPC[e1]  that developed after intravitreal triamcinolone acetonide  [s2]IVTA[e2]  injection.
	(31, 43)	ASPPC	triamcinolone acetonide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3406	BACKGROUND: We describe the ophthalmic features and clinical course of two cases of acute syphilitic posterior placoid chorioretinitis  [s1]ASPPC[e1]  that developed after intravitreal [s2]triamcinolone acetonide[e2] (IVTA) injection.
	(14, 20)	ASPPC	IVTA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3407	CONCLUSIONS: The fundus picture shown in these cases may be typical of [s1]ASPPC[e1] after [s2]IVTA[e2] injection.
	(12, 21)	severe chorioretinitis	IVTA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3408	RESULTS: Two patients with ocular inflammation of unknown origin developed [s1]severe chorioretinitis[e1] after [s2]IVTA[e2] injection.
	(7, 18)	intratumoral hemorrhage	aspirin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3409	Although it is difficult to solely attribute [s1]intratumoral hemorrhage[e1] to [s2]aspirin[e2]  we have to be careful when prescribing aspirin for patients who have asymptomatic meningioma.
	(0, 22)	Hemorrhage	aspirin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3410	 [s1]Hemorrhage[e1] from a falx meningioma after internal use of low-dose [s2]aspirin[e2] 
	(5, 14)	aspirin	enlargement of spontaneous hemorrhage	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3411	On the other hand, [s1]aspirin[e1] may have promoted the [s2]enlargement of spontaneous hemorrhage[e2] from meningioma.
	(8, 25)	hemorrhage	aspirin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3412	Our case is the second one in which [s1]hemorrhage[e1] from a meningioma may have been induced by [s2]aspirin[e2] prophylaxis.
	(6, 38)	hemorrhage	aspirin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3413	We report a case in which [s1]hemorrhage[e1] occurred in an asymptomatic falx meningioma known beforehand, after the internal use of low-dose [s2]aspirin[e2] for 16 months.
	(0, 15)	Acute coronary syndromes	rituximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3414	 [s1]Acute coronary syndromes[e1] can be associated with the infusion of [s2]rituximab[e2] 
	(0, 16)	Acute coronary syndromes	rituximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3415	 [s1]Acute coronary syndromes[e1] complicating the first infusion of [s2]rituximab[e2] 
	(11, 22)	acute coronary syndromes	rituximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3416	The aim of this study was to describe the occurrence of [s1]acute coronary syndromes[e1] in 3 cases of [s2]rituximab[e2] infusions.
	(10, 24)	acute coronary syndrome	rituximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3417	The occurrence of symptoms that could be ascribed to an [s1]acute coronary syndrome[e1] should always be taken seriously during the first [s2]rituximab[e2] infusion and investigated aggressively.
	(18, 32)	acute coronary syndromes	rituximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3418	We reviewed the records of 3 patients with lymphoproliferative disorders who experienced [s1]acute coronary syndromes[e1] associated with their initial infusion of [s2]rituximab[e2] 
	(22, 42)	acenocoumarol	laryngeal hematoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3419	CONCLUSION: This report describes a case of a probable interaction between topical econazole lotion 1% and [s1]acenocoumarol[e1] that resulted in overanticoagulation and a life-threatening [s2]laryngeal hematoma[e2] in this elderly patient.
	(13, 42)	econazole	laryngeal hematoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3420	CONCLUSION: This report describes a case of a probable interaction between topical [s1]econazole[e1] lotion 1% and acenocoumarol that resulted in overanticoagulation and a life-threatening [s2]laryngeal hematoma[e2] in this elderly patient.
	(0, 16)	Laryngeal dyspnea	acenocoumarol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3421	 [s1]Laryngeal dyspnea[e1] in relation to an interaction between [s2]acenocoumarol[e2] and topical econazole lotion.
	(0, 23)	Laryngeal dyspnea	econazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3422	 [s1]Laryngeal dyspnea[e1] in relation to an interaction between acenocoumarol and topical [s2]econazole[e2] lotion.
	(0, 14)	Adrenal suppression in a fetus	methylprednisolone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3423	 [s1]Adrenal suppression in a fetus[e1] due to administration of [s2]methylprednisolone[e2] has hitherto been rarely published.
	(5, 38)	adrenal suppression	methylprednisolone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3424	CONCLUSIONS: Life-threatening [s1]adrenal suppression[e1]  requiring hydrocortisone supplementation and intensive therapy, was observed and successfully treated in a newborn, whose mother had received high-dose [s2]methylprednisolone[e2] in late pregnancy.
	(3, 23)	methylprednisolone	adrenal suppression	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3425	High-dose [s1]methylprednisolone[e1] in a pregnant woman with Crohn's disease and [s2]adrenal suppression[e2] in her newborn.
	(18, 33)	moderately severe bronchospasm	disodium cromoglycate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3426	A 10-year-old asthmatic boy began to suffer from urticarial rash and [s1]moderately severe bronchospasm[e1] after 8 weeks' treatment with [s2]disodium cromoglycate[e2] 
	(13, 33)	urticarial rash	disodium cromoglycate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3427	A 10-year-old asthmatic boy began to suffer from [s1]urticarial rash[e1] and moderately severe bronchospasm after 8 weeks' treatment with [s2]disodium cromoglycate[e2] 
	(0, 8)	Asthma	disodium cromoglycate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3428	 [s1]Asthma[e1] and urticaria during [s2]disodium cromoglycate[e2] treatment.
	(2, 8)	urticaria	disodium cromoglycate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3429	Asthma and [s1]urticaria[e1] during [s2]disodium cromoglycate[e2] treatment.
	(1, 9)	DSCG	urticaria	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3430	When [s1]DSCG[e1] was withdrawn, [s2]urticaria[e2] vanished and the child remained symptom-free.
	(6, 17)	propranolol	atrioventricular block	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3431	After the first oral dose of [s1]propranolol[e1]  syncope developed together with [s2]atrioventricular block[e2] 
	(6, 12)	propranolol	syncope	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3432	After the first oral dose of [s1]propranolol[e1]  [s2]syncope[e2] developed together with atrioventricular block.
	(0, 6)	Syncope	propranolol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3433	 [s1]Syncope[e1] induced by [s2]propranolol[e2] in hypertrophic cardiomyopathy.
	(0, 6)	Olanzapine	hyperglycaemic coma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3434	 [s1]Olanzapine[e1] induced [s2]hyperglycaemic coma[e2] and neuroleptic malignant syndrome: case report and review of literature.
	(0, 13)	Olanzapine	neuroleptic malignant syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3435	 [s1]Olanzapine[e1] induced hyperglycaemic coma and [s2]neuroleptic malignant syndrome[e2]  case report and review of literature.
	(7, 33)	leflunomide	allergic skin reactions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3436	DISCUSSION: The main adverse effects of [s1]leflunomide[e1] consist of diarrhea, nausea, liver enzyme elevation, hypertension, alopecia, and [s2]allergic skin reactions[e2] 
	(7, 28)	leflunomide	alopecia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3437	DISCUSSION: The main adverse effects of [s1]leflunomide[e1] consist of diarrhea, nausea, liver enzyme elevation, hypertension, [s2]alopecia[e2]  and allergic skin reactions.
	(7, 15)	leflunomide	diarrhea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3438	DISCUSSION: The main adverse effects of [s1]leflunomide[e1] consist of [s2]diarrhea[e2]  nausea, liver enzyme elevation, hypertension, alopecia, and allergic skin reactions.
	(7, 25)	leflunomide	hypertension	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3439	DISCUSSION: The main adverse effects of [s1]leflunomide[e1] consist of diarrhea, nausea, liver enzyme elevation, [s2]hypertension[e2]  alopecia, and allergic skin reactions.
	(7, 21)	leflunomide	liver enzyme elevation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3440	DISCUSSION: The main adverse effects of [s1]leflunomide[e1] consist of diarrhea, nausea, [s2]liver enzyme elevation[e2]  hypertension, alopecia, and allergic skin reactions.
	(7, 19)	leflunomide	nausea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3441	DISCUSSION: The main adverse effects of [s1]leflunomide[e1] consist of diarrhea, [s2]nausea[e2]  liver enzyme elevation, hypertension, alopecia, and allergic skin reactions.
	(0, 7)	Leflunomide	toxic epidermal necrolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3442	 [s1]Leflunomide[e1] induced [s2]toxic epidermal necrolysis[e2] in a patient with rheumatoid arthritis.
	(30, 51)	mediastinal lymphadenopathy	Etanercept	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3443	In this report we described a case of juvenile idiopathic arthritis patient who developed thymic enlargement (true thymic hyperplasia), [s1]mediastinal lymphadenopathy[e1] and pleurisy associated with systemic symptoms under [s2]Etanercept[e2] treatment.
	(40, 51)	pleurisy	Etanercept	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3444	In this report we described a case of juvenile idiopathic arthritis patient who developed thymic enlargement (true thymic hyperplasia), mediastinal lymphadenopathy and [s1]pleurisy[e1] associated with systemic symptoms under [s2]Etanercept[e2] treatment.
	(16, 51)	thymic enlargement	Etanercept	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3445	In this report we described a case of juvenile idiopathic arthritis patient who developed [s1]thymic enlargement[e1] (true thymic hyperplasia), mediastinal lymphadenopathy and pleurisy associated with systemic symptoms under [s2]Etanercept[e2] treatment.
	(23, 50)	thymic hyperplasia	Etanercept	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3446	In this report we described a case of juvenile idiopathic arthritis patient who developed thymic enlargement (true [s1]thymic hyperplasia[e1] , mediastinal lymphadenopathy and pleurisy associated with systemic symptoms under [s2]Etanercept[e2] treatment.
	(0, 17)	Thymic enlargement	etanercept	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3447	 [s1]Thymic enlargement[e1] in a patient with juvenile idiopathic arthritis during [s2]etanercept[e2] therapy.
	(0, 19)	Oxcarbazepine	DRESS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3448	 [s1]Oxcarbazepine[e1] induced Drug Reaction with Eosinophilia and Systemic Symptoms  [s2]DRESS[e2] .
	(0, 8)	Oxcarbazepine	Drug Reaction with Eosinophilia and Systemic Symptoms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3449	 [s1]Oxcarbazepine[e1] induced [s2]Drug Reaction with Eosinophilia and Systemic Symptoms[e2] (DRESS).
	(19, 28)	severe rash	oxcarbazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3450	This is an image and brief case report of a 13-year-old boy who presented with [s1]severe rash[e1] and systemic symptoms after starting [s2]oxcarbazepine[e2] 
	(13, 23)	Partusisten	supraventricular tachycardia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3451	After treatment with a beta-sympathomimetic drug  [s1]Partusisten[e1]  one fetus developed [s2]supraventricular tachycardia[e2] 
	(0, 8)	Rosaceiform eruption	erlotinib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3452	 [s1]Rosaceiform eruption[e1] induced by [s2]erlotinib[e2] 
	(11, 19)	rosaceiform eruption	erlotinib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3453	The aim of this paper is to report the case of [s1]rosaceiform eruption[e1] induced by [s2]erlotinib[e2] in an 81-year-old-man and to discuss the pathogenetic role of Demodex folliculorum mites, found in the present patient, using skin scraping.
	(3, 11)	methotrexate	anaphylaxis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3454	In patients with [s1]methotrexate[e1] induced [s2]anaphylaxis[e2]  discontinuation of treatment may increase the risk of death due to cancer progression.
	(8, 16)	methotrexate	anaphylaxis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3455	Management and successful desensitization in [s1]methotrexate[e1] induced [s2]anaphylaxis[e2] 
	(20, 28)	methotrexate	anaphylaxis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3456	Thus, we confirm that desensitization may be a safe procedure in patients with cancer who experience [s1]methotrexate[e1] induced [s2]anaphylaxis[e2] 
	(19, 33)	anaphylactic/anaphylactoid reaction	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3457	We report the case of a child with metastatic osteosarcoma, who experienced an [s1]anaphylactic/anaphylactoid reaction[e1] to [s2]methotrexate[e2] 
	(3, 8)	fever	diltiazem	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3458	Drug-induced [s1]fever[e1] due to [s2]diltiazem[e2] 
	(3, 21)	fever	diltiazem	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3459	Drug-induced [s1]fever[e1] should be considered in patients who have unexplained high temperatures during [s2]diltiazem[e2] therapy.
	(7, 18)	fever	diltiazem hydrochloride	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3460	To our knowledge, drug-induced [s1]fever[e1] has not been reported with the use of [s2]diltiazem hydrochloride[e2]  a commonly prescribed calcium channel blocker.
	(3, 19)	congestive heart failure	Adriamycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3461	A case of [s1]congestive heart failure[e1] in a child with Wilms' tumor treated [s2]Adriamycin[e2] is presented and discussed.
	(4, 10)	adriamycin	cardiotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3462	Radiologic recognition of [s1]adriamycin[e1]  [s2]cardiotoxicity[e2] 
	(3, 13)	Adriamycin	cardiotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3463	The role of [s1]Adriamycin[e1] in the production of [s2]cardiotoxicity[e2] is reviewed.
	(0, 8)	Carbamazepine	Diabetes mellitus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3464	 [s1]Carbamazepine[e1] induced [s2]Diabetes mellitus[e2] 
	(0, 12)	Diabetes Mellitus	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3465	 [s1]Diabetes Mellitus[e1] was observed in a patient given [s2]carbamazepine[e2] 
	(8, 32)	unusual weight fluctuation	aripiprazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3466	The present study describes a patient who had [s1]unusual weight fluctuation[e1] under corticosteroid and psychotropic treatment such as mianserin and [s2]aripiprazole[e2] 
	(8, 28)	unusual weight fluctuation	mianserin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3467	The present study describes a patient who had [s1]unusual weight fluctuation[e1] under corticosteroid and psychotropic treatment such as [s2]mianserin[e2] and aripiprazole.
	(1, 15)	heparin	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3468	Although [s1]heparin[e1] dependent antibodies (HDAs) typically manifest with [s2]thrombocytopenia[e2] as in heparin-induced thrombocytopenia (HIT), they may also manifest with preserved platelet counts.
	(22, 31)	thrombosis	heparin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3469	Clinicians should be cognizant of this possibility and consider a diagnosis of HDAs in patients with ongoing [s1]thrombosis[e1] who are receiving [s2]heparin[e2] therapy.
	(12, 18)	heparin	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3470	Heparin-dependent antibodies and thrombosis without [s1]heparin[e1] induced [s2]thrombocytopenia[e2] 
	(13, 31)	venous thromboembolism	heparin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3471	Despite these antithrombotic effects, the patient developed repeated [s1]venous thromboembolism[e1] during treatment with low-molecular-weight [s2]heparin[e2] 
	(22, 40)	progressive liver failure	tacrolimus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3472	Four months after receiving an orthotopic liver transplant, a 51-year-old man was admitted for [s1]progressive liver failure[e1] and severe hepatocellular necrosis thought to be due to [s2]tacrolimus[e2] 
	(26, 40)	severe hepatocellular necrosis	tacrolimus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3473	Four months after receiving an orthotopic liver transplant, a 51-year-old man was admitted for progressive liver failure and [s1]severe hepatocellular necrosis[e1] thought to be due to [s2]tacrolimus[e2] 
	(2, 30)	posaconazole	enterococcal peritonitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3474	Initiation of [s1]posaconazole[e1] led to clinical improvement until the patient's demise from bacteremic vancomycin-resistant [s2]enterococcal peritonitis[e2] 
	(0, 12)	Iatrogenic Cushing syndrome	triamcinolone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3475	 [s1]Iatrogenic Cushing syndrome[e1] after epidural [s2]triamcinolone[e2] injections in an HIV type 1-infected patient receiving therapy with ritonavir-lopinavir.
	(42, 54)	Cushing syndrome	triamcinolone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3476	We report the first case of a human immunodeficiency virus type 1 (HIV-1)-infected individual receiving combination antiretroviral therapy, which included ritonavir, who developed [s1]Cushing syndrome[e1] with profound complications after epidural [s2]triamcinolone[e2] injections.
	(11, 36)	flunitrazepam	acute ischaemia of the left leg	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3477	A 22-year-old drug-abuser injected [s1]flunitrazepam[e1] tablets dissolved in tap water into her left femoral artery and presented with clinical signs of [s2]acute ischaemia of the left leg[e2] 
	(0, 17)	Acute ischaemia of the leg	flunitrazepam	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3478	 [s1]Acute ischaemia of the leg[e1] following accidental intra-arterial injection of dissolved [s2]flunitrazepam[e2] tablets.
	(27, 45)	syringotropic hypersensitivity reaction	infliximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3479	A 17-year-old boy with refractory psoriatic arthritis and alpha-1 antitrypsin deficiency who developed a [s1]syringotropic hypersensitivity reaction[e1] after 9 months of therapy with [s2]infliximab[e2] and leflunomide is described.
	(27, 51)	syringotropic hypersensitivity reaction	leflunomide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3480	A 17-year-old boy with refractory psoriatic arthritis and alpha-1 antitrypsin deficiency who developed a [s1]syringotropic hypersensitivity reaction[e1] after 9 months of therapy with infliximab and [s2]leflunomide[e2] is described.
	(0, 14)	Syringotropic hypersensitivity reaction	infliximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3481	 [s1]Syringotropic hypersensitivity reaction[e1] associated with [s2]infliximab[e2] and leflunomide combination therapy in a child with psoriatic arthritis.
	(0, 20)	Syringotropic hypersensitivity reaction	leflunomide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3482	 [s1]Syringotropic hypersensitivity reaction[e1] associated with infliximab and [s2]leflunomide[e2] combination therapy in a child with psoriatic arthritis.
	(3, 14)	severe aplastic anemia	lenalidomide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3483	A case of [s1]severe aplastic anemia[e1] secondary to treatment with [s2]lenalidomide[e2] for multiple myeloma.
	(17, 23)	lenalidomide	aplastic anemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3484	Although moderate myelosuppression is not uncommonly seen in patients treated with [s1]lenalidomide[e1]  [s2]aplastic anemia[e2] has not previously been reported to be associated with this agent.
	(10, 18)	AA	lenalidomide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3485	We describe a case of severe aplastic anemia  [s1]AA[e1]  that was probably induced by [s2]lenalidomide[e2] 
	(5, 20)	severe aplastic anemia	lenalidomide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3486	We describe a case of [s1]severe aplastic anemia[e1] (AA) that was probably induced by [s2]lenalidomide[e2] 
	(5, 11)	amantadine	edema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3487	After cessation of [s1]amantadine[e1]  the [s2]edema[e2] resolved, and the endothelial cell densities were <or=600/mm.
	(2, 9)	Amantadine	reversible corneal edema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3488	CONCLUSIONS: [s1]Amantadine[e1] can cause [s2]reversible corneal edema[e2] but can irreversibly reduce the density of endothelial cells.
	(0, 13)	Corneal edema	amantadine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3489	 [s1]Corneal edema[e1] recurred when the administration of [s2]amantadine[e2] was resumed.
	(0, 10)	Corneal endothelial dysfunction	amantadine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3490	 [s1]Corneal endothelial dysfunction[e1] associated with [s2]amantadine[e2] toxicity.
	(4, 26)	bilateral corneal endothelial dysfunction	amantadine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3491	PURPOSE: To describe [s1]bilateral corneal endothelial dysfunction[e1] in a patient with Parkinson disease who was treated with long-term [s2]amantadine[e2] 
	(15, 24)	amantadine	bilateral corneal edema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3492	RESULTS: A 52-year-old woman with Parkinson disease who had taken [s1]amantadine[e1] for 6 years had [s2]bilateral corneal edema[e2] for 2 months at baseline.
	(2, 12)	amantadine	cornea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3493	Therefore, [s1]amantadine[e1] was permanently discontinued and the [s2]cornea[e2] cleared again.
	(4, 22)	acute interstitial nephritis	sunitinib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3494	Biopsy-proven [s1]acute interstitial nephritis[e1] associated with the tyrosine kinase inhibitor [s2]sunitinib[e2]  a class effect?
	(9, 25)	acute interstitial nephritis	Sunitinib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3495	We report the first biopsy confirmed occurrence of [s1]acute interstitial nephritis[e1] in a patient receiving treatment with [s2]Sunitinib[e2] for metastatic renal cell cancer.
	(0, 15)	Extrapyramidal symptoms	haloperidol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3496	 [s1]Extrapyramidal symptoms[e1] are well-documented complications of therapy with [s2]haloperidol[e2]  even when small doses are used.
	(9, 19)	dysphagia	haloperidol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3497	This report highlights a case of drug-induced [s1]dysphagia[e1] in a patient receiving [s2]haloperidol[e2] for obsessive nocturnal thoughts and auditory disturbances.
	(20, 33)	iron deficiency anemia	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3498	A 52 year-old male patient diagnosed of ankylosing spondylitis presented with an [s1]iron deficiency anemia[e1] after a ten-month treatment of [s2]methotrexate[e2] 
	(0, 8)	Methotrexate	sprue-like syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3499	 [s1]Methotrexate[e1] induced [s2]sprue-like syndrome[e2] 
	(4, 10)	imatinib	tumor lysis syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3500	Only 3 cases of [s1]imatinib[e1] induced [s2]tumor lysis syndrome[e2] have been reported.
	(28, 40)	tumor lysis syndrome	imatinib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3501	We herein described an additional patient with BCR-ABL (ela2) positive acute lymphoblastic leukemia who developed [s1]tumor lysis syndrome[e1] after 10-day treatment with [s2]imatinib[e2] 
	(0, 10)	IFNalpha	Graves' disease	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3502	 [s1]IFNalpha[e1] induced recurrence of [s2]Graves' disease[e2] ten years after thyroidectomy in chronic viral hepatitis C.
	(11, 21)	Graves' disease	IFN-alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3503	In contrast to chronic or subacute thyroiditis, [s1]Graves' disease[e1] rarely complicates [s2]IFN-alpha[e2] therapy for chronic viral C hepatitis.
	(5, 20)	subacute thyroiditis	IFN-alpha	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3504	In contrast to chronic or [s1]subacute thyroiditis[e1]  Graves' disease rarely complicates [s2]IFN-alpha[e2] therapy for chronic viral C hepatitis.
	(14, 28)	IFN-alpha	Graves' disease	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3505	We report the case of a 51-year-old man in whom [s1]IFN-alpha[e1] treatment was followed by recurrence of [s2]Graves' disease[e2] 10 years after thyroidectomy was performed and the patient was declared cured.
	(0, 14)	Interstitial granulomatous dermatitis	darifenacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3506	 [s1]Interstitial granulomatous dermatitis[e1] associated with [s2]darifenacin[e2] 
	(6, 20)	interstitial granulomatous dermatitis	darifenacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3507	The authors describe a case of [s1]interstitial granulomatous dermatitis[e1] associated with [s2]darifenacin[e2] 
	(0, 12)	Gemcitabine	hemolytic uremic syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3508	 [s1]Gemcitabine[e1] is a known risk factor for [s2]hemolytic uremic syndrome[e2] (HUS), which can often have a rapidly fatal clinical course despite intervention with steroids, plasmapheresis and hemodialysis.
	(0, 19)	Gemcitabine	HUS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3509	 [s1]Gemcitabine[e1] is a known risk factor for hemolytic uremic syndrome  [s2]HUS[e2] , which can often have a rapidly fatal clinical course despite intervention with steroids, plasmapheresis and hemodialysis.
	(10, 17)	gemcitabine	HUS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3510	METHODS: A retrospective report of the first case of [s1]gemcitabine[e1] related [s2]HUS[e2]  in a patient with metastatic pancreatic adenocarcinoma, treated with a variety of standard therapies in addition to rituximab is presented.
	(9, 16)	gemcitabine	hemolytic uremic syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3511	Rituximab-based therapy for [s1]gemcitabine[e1] induced [s2]hemolytic uremic syndrome[e2] in a patient with metastatic pancreatic adenocarcinoma: a case report.
	(0, 14)	Drug rash with eosinophilia and systemic symptoms	chlorambucil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3512	 [s1]Drug rash with eosinophilia and systemic symptoms[e1] after [s2]chlorambucil[e2] treatment in chronic lymphocytic leukaemia.
	(17, 28)	acute renal failure	chlorambucil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3513	He developed recurrent skin rash, fever, hypereosinophilia, and [s1]acute renal failure[e1] after rechallenge with [s2]chlorambucil[e2] 
	(7, 27)	fever	chlorambucil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3514	He developed recurrent skin rash, [s1]fever[e1]  hypereosinophilia, and acute renal failure after rechallenge with [s2]chlorambucil[e2] 
	(9, 27)	hypereosinophilia	chlorambucil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3515	He developed recurrent skin rash, fever, [s1]hypereosinophilia[e1]  and acute renal failure after rechallenge with [s2]chlorambucil[e2] 
	(4, 27)	skin rash	chlorambucil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3516	He developed recurrent [s1]skin rash[e1]  fever, hypereosinophilia, and acute renal failure after rechallenge with [s2]chlorambucil[e2] 
	(6, 15)	chlorambucil	DRESS syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3517	We report the first case of [s1]chlorambucil[e1] induced [s2]DRESS syndrome[e2] in a 70-year-old man recently diagnosed with chronic lymphocytic leukaemia.
	(61, 84)	methotrexate	acute renal failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3518	A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose [s1]methotrexate[e1] (MTX) (12 g/m2), and went on to develop [s2]acute renal failure[e2] with life-threatening hyperkalemia 29 hours later.
	(66, 82)	MTX	acute renal failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3519	A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate  [s1]MTX[e1]  (12 g/m2), and went on to develop [s2]acute renal failure[e2] with life-threatening hyperkalemia 29 hours later.
	(26, 63)	elevation of aspartate aminotrasferase	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3520	A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme [s1]elevation of aspartate aminotrasferase[e1] and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose [s2]methotrexate[e2] (MTX) (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later.
	(26, 68)	elevation of aspartate aminotrasferase	MTX	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3521	A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme [s1]elevation of aspartate aminotrasferase[e1] and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate  [s2]MTX[e2]  (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later.
	(22, 63)	renal toxicity	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3522	A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending [s1]renal toxicity[e1] and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose [s2]methotrexate[e2] (MTX) (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later.
	(22, 68)	renal toxicity	MTX	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3523	A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending [s1]renal toxicity[e1] and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate  [s2]MTX[e2]  (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later.
	(44, 64)	renal toxicity	MTX	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3524	Although his renal function recovered completely with high-dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2, we present this case to emphasize that signs of [s1]renal toxicity[e1] may be present as early as 2 hours after the completion of a 4-hour [s2]MTX[e2] infusion, and to suggest that monitoring for MTX toxicity should perhaps begin within a few hours after the completion of 4-hour MTX infusion.
	(3, 11)	renal toxicity	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3525	Early recognition of [s1]renal toxicity[e1] of high-dose [s2]methotrexate[e2] therapy: a case report.
	(9, 17)	ethambutol	visual loss	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3526	Multifocal electroretinographic abnormalities in [s1]ethambutol[e1] induced [s2]visual loss[e2] 
	(15, 31)	bitemporal visual field defects	ethambutol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3527	These are the first reported patients to show mfERG abnormalities that correspond to [s1]bitemporal visual field defects[e1] and add to the growing evidence that [s2]ethambutol[e2] damages the retina.
	(8, 31)	mfERG abnormalities	ethambutol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3528	These are the first reported patients to show [s1]mfERG abnormalities[e1] that correspond to bitemporal visual field defects and add to the growing evidence that [s2]ethambutol[e2] damages the retina.
	(12, 34)	ethambutol	bitemporal visual field defects	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3529	Two patients who developed decreased visual acuity after several months of [s1]ethambutol[e1] treatment for Mycobacterium avium-intracellulare infection had [s2]bitemporal visual field defects[e2] that suggested optic chiasm damage.
	(4, 14)	decreased visual acuity	ethambutol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3530	Two patients who developed [s1]decreased visual acuity[e1] after several months of [s2]ethambutol[e2] treatment for Mycobacterium avium-intracellulare infection had bitemporal visual field defects that suggested optic chiasm damage.
	(0, 7)	Tenofovir	nephrotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3531	 [s1]Tenofovir[e1] associated [s2]nephrotoxicity[e2] in two HIV-infected adolescent males.
	(11, 16)	TDF	irreversible renal failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3532	To our knowledge, these cases represent the first reports of [s1]TDF[e1] associated [s2]irreversible renal failure[e2] and rickets in pediatric patients.
	(11, 23)	TDF	rickets	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3533	To our knowledge, these cases represent the first reports of [s1]TDF[e1] associated irreversible renal failure and [s2]rickets[e2] in pediatric patients.
	(9, 15)	TDF	nephrotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3534	We report two cases of tenofovir  [s1]TDF[e1] -associated [s2]nephrotoxicity[e2] in perinatally HIV-infected adolescents.
	(5, 17)	tenofovir	nephrotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3535	We report two cases of [s1]tenofovir[e1] (TDF)-associated [s2]nephrotoxicity[e2] in perinatally HIV-infected adolescents.
	(8, 38)	piroxicam	ulcers	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3536	In this case, discontinuing [s1]piroxicam[e1]  a nonsteroidal anti-inflammatory drug, and starting a palliative treatment plan helped resolve a patient's [s2]ulcers[e2] 
	(0, 9)	Acute renal failure	immunoglobulin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3537	 [s1]Acute renal failure[e1] following intravenous [s2]immunoglobulin[e2] therapy in a HIV-infected patient.
	(0, 17)	Acute renal failure	immunoglobulin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3538	 [s1]Acute renal failure[e1] is a rare complication following the administration of intravenous [s2]immunoglobulin[e2] (IVIG).
	(4, 9)	IVIG	acute renal failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3539	The exact mechanism of [s1]IVIG[e1] associated [s2]acute renal failure[e2] remains unclear.
	(17, 44)	proteinuria	temsirolimus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3540	A 58-year-old man with advanced renal cell carcinoma developed grade 3 [s1]proteinuria[e1] (8.5 g/24 h) without microscopic hematuria or renal insufficiency five days after [s2]temsirolimus[e2] infusion.
	(0, 8)	Temsirolimus	glomerulopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3541	 [s1]Temsirolimus[e1] induced [s2]glomerulopathy[e2] 
	(0, 15)	Hypoglycemia	etanercept	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3542	 [s1]Hypoglycemia[e1] can be a serious side effect of [s2]etanercept[e2] in patients already on antidiabetic medications known to cause hypoglycemia, such as sulfonylureas, meglitinides, and insulin.
	(13, 31)	etanercept	hypoglycemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3543	Hypoglycemia can be a serious side effect of [s1]etanercept[e1] in patients already on antidiabetic medications known to cause [s2]hypoglycemia[e2]  such as sulfonylureas, meglitinides, and insulin.
	(29, 52)	hypoglycemia	insulin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3544	Hypoglycemia can be a serious side effect of etanercept in patients already on antidiabetic medications known to cause [s1]hypoglycemia[e1]  such as sulfonylureas, meglitinides, and [s2]insulin[e2] 
	(29, 46)	hypoglycemia	meglitinides	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3545	Hypoglycemia can be a serious side effect of etanercept in patients already on antidiabetic medications known to cause [s1]hypoglycemia[e1]  such as sulfonylureas, [s2]meglitinides[e2]  and insulin.
	(29, 39)	hypoglycemia	sulfonylureas	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3546	Hypoglycemia can be a serious side effect of etanercept in patients already on antidiabetic medications known to cause [s1]hypoglycemia[e1]  such as [s2]sulfonylureas[e2]  meglitinides, and insulin.
	(0, 15)	Persistent hypoglycemia	etanercept	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3547	 [s1]Persistent hypoglycemia[e1] in a patient with diabetes taking [s2]etanercept[e2] for the treatment of psoriasis.
	(27, 41)	etanercept	persistent hypoglycemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3548	We report a patient with type 2 diabetes mellitus who, while treated with the antitumor necrosis factor-alpha blocking agent [s1]etanercept[e1] for severe plaque psoriasis, experienced [s2]persistent hypoglycemia[e2] requiring the lowering and eventual elimination of his previous insulin regimen.
	(8, 16)	dexmedetomidine	bradycardia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3549	We report on three cases wherein treatment of [s1]dexmedetomidine[e1] induced [s2]bradycardia[e2] with i.v. glycopyrrolate (5.0 microg/kg) not only resulting in resolution of bradycardia but also resulting in an exaggerated increase of arterial blood pressure.
	(23, 54)	glycopyrrolate	exaggerated increase of arterial blood pressure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3550	We report on three cases wherein treatment of dexmedetomidine-induced bradycardia with i.v. [s1]glycopyrrolate[e1] (5.0 microg/kg) not only resulting in resolution of bradycardia but also resulting in an [s2]exaggerated increase of arterial blood pressure[e2] 
	(0, 8)	Bisphosphonate	osteonecrosis of the jaw	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3551	 [s1]Bisphosphonate[e1] related [s2]osteonecrosis of the jaw[e2] (BRONJ) is reported in up to 18.6% of patients treated with intravenous bisphosphonates and can result in significant morbidity.
	(0, 8)	Bisphosphonate	osteonecrosis of the skull base	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3552	 [s1]Bisphosphonate[e1] related [s2]osteonecrosis of the skull base[e2] 
	(6, 11)	quinine	TTP/HUS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3553	A previous study of patients with  [s1]quinine[e1] associated [s2]TTP/HUS[e2]  found that ADAMTS13 activities were not abnormal in 12/12 patients.
	(8, 13)	quinine	thrombotic microangiopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3554	A retrospective review of TTP patients with [s1]quinine[e1] associated [s2]thrombotic microangiopathy[e2] (TMA) for whom ADAMTS13 was measured before plasma exchange was performed.
	(8, 21)	quinine	TMA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3555	A retrospective review of TTP patients with [s1]quinine[e1] associated thrombotic microangiopathy  [s2]TMA[e2]  for whom ADAMTS13 was measured before plasma exchange was performed.
	(0, 16)	Thrombocytopenia	quinine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3556	" [s1]Thrombocytopenia[e1] with or without microangiopathy following [s2]quinine[e2] is often referred to as quinine ""hypersensitivity."" When schistocytes are present it is frequently termed ""quinine-associated TTP/HUS."" A severe deficiency of the vWF-cleaving protease, ADAMTS13, is associated with idiopathic TTP."
	(14, 48)	quinine	TTP/HUS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3557	"Thrombocytopenia with or without microangiopathy following [s1]quinine[e1] is often referred to as quinine ""hypersensitivity."" When schistocytes are present it is frequently termed ""quinine-associated [s2]TTP/HUS[e2] "" A severe deficiency of the vWF-cleaving protease, ADAMTS13, is associated with idiopathic TTP."
	(11, 22)	schistocytosis	quinine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3558	We conclude that while thrombocytopenia and [s1]schistocytosis[e1] can be seen in [s2]quinine[e2] associated TTP/HUS, the pathophysiology seems to be distinct from that seen in most cases of idiopathic TTP (i.e., severely decreased ADAMTS13 with an inhibitor).
	(4, 22)	thrombocytopenia	quinine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3559	We conclude that while [s1]thrombocytopenia[e1] and schistocytosis can be seen in [s2]quinine[e2] associated TTP/HUS, the pathophysiology seems to be distinct from that seen in most cases of idiopathic TTP (i.e., severely decreased ADAMTS13 with an inhibitor).
	(20, 25)	quinine	TTP/HUS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3560	We conclude that while thrombocytopenia and schistocytosis can be seen in [s1]quinine[e1] associated [s2]TTP/HUS[e2]  the pathophysiology seems to be distinct from that seen in most cases of idiopathic TTP (i.e., severely decreased ADAMTS13 with an inhibitor).
	(9, 22)	quinine	thrombotic microangiopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3561	We recommend that a TMA in association with [s1]quinine[e1] be consistently referred to as quinine-associated [s2]thrombotic microangiopathy[e2] (quinine-TMA) to better distinguish this entity from idiopathic TTP.
	(3, 20)	primary and secondary perforation of the bladder	epirubicin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3562	Complications associated with [s1]primary and secondary perforation of the bladder[e1] following immediate instillations of [s2]epirubicin[e2] after transurethral resection of superficial urothelial tumours.
	(15, 32)	primary and secondary perforation of the bladder	epirubicin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3563	MATERIALS AND METHODS: We present two cases of significant morbidity related to [s1]primary and secondary perforation of the bladder[e1] following two instillations of [s2]epirubicin[e2] 
	(0, 6)	Aliskiren	acute renal failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3564	 [s1]Aliskiren[e1] associated [s2]acute renal failure[e2] with hyperkalemia.
	(6, 24)	acute renal failure	aliskiren	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3565	We report the first case of [s1]acute renal failure[e1] with hyperkalemia associated with the recently marketed direct renin inhibitor [s2]aliskiren[e2] 
	(10, 24)	hyperkalemia	aliskiren	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3566	We report the first case of acute renal failure with [s1]hyperkalemia[e1] associated with the recently marketed direct renin inhibitor [s2]aliskiren[e2] 
	(3, 17)	acute cardiomyopathy	methylphenidate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3567	A case of [s1]acute cardiomyopathy[e1] and pericarditis associated with [s2]methylphenidate[e2] 
	(9, 17)	pericarditis	methylphenidate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3568	A case of acute cardiomyopathy and [s1]pericarditis[e1] associated with [s2]methylphenidate[e2] 
	(2, 16)	acute cardiomyopathy	methylphenidate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3569	However, [s1]acute cardiomyopathy[e1] and pericarditis secondary to [s2]methylphenidate[e2] use has been rarely reported.
	(8, 16)	pericarditis	methylphenidate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3570	However, acute cardiomyopathy and [s1]pericarditis[e1] secondary to [s2]methylphenidate[e2] use has been rarely reported.
	(24, 37)	acute left ventricular dysfunction	methylphenidate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3571	We report the case of a 17-year-old male who developed chest pain, elevated cardiac biomarkers, and [s1]acute left ventricular dysfunction[e1] following a single dose of [s2]methylphenidate[e2] 
	(14, 36)	chest pain	methylphenidate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3572	We report the case of a 17-year-old male who developed [s1]chest pain[e1]  elevated cardiac biomarkers, and acute left ventricular dysfunction following a single dose of [s2]methylphenidate[e2] 
	(17, 36)	elevated cardiac biomarkers	methylphenidate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3573	We report the case of a 17-year-old male who developed chest pain, [s1]elevated cardiac biomarkers[e1]  and acute left ventricular dysfunction following a single dose of [s2]methylphenidate[e2] 
	(15, 26)	enoxaparin	hepatotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3574	According to the Naranjo et al. adverse-reaction probability scale, [s1]enoxaparin[e1] was the probable cause of [s2]hepatotoxicity[e2] in this patient.
	(5, 19)	enoxaparin	hepatotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3575	CONCLUSION: A woman receiving [s1]enoxaparin[e1] every 12 hours developed signs and symptoms of [s2]hepatotoxicity[e2] after the second dose.
	(1, 8)	enoxaparin	hepatotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3576	Probable [s1]enoxaparin[e1] induced [s2]hepatotoxicity[e2] 
	(6, 13)	enoxaparin	hepatotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3577	PURPOSE: A case of probable [s1]enoxaparin[e1] induced [s2]hepatotoxicity[e2] is described.
	(0, 14)	Posterior reversible encephalopathy syndrome	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3578	 [s1]Posterior reversible encephalopathy syndrome[e1] associated with [s2]methotrexate[e2] neurotoxicity: conventional magnetic resonance and diffusion-weighted imaging findings.
	(6, 38)	methotrexate	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3579	The addition of intrathecal [s1]methotrexate[e1] to treatment protocols has increased survival rates in children with acute lymphoblastic leukemia but is also associated with varying degrees of [s2]neurotoxicity[e2] 
	(12, 33)	acute lymphoblastic leukemia	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3580	We describe a 15-year-old female patient diagnosed with [s1]acute lymphoblastic leukemia[e1] presenting with status epilepticus after receiving intrathecal [s2]methotrexate[e2] 
	(0, 8)	Cyclosporine	pain syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3581	 [s1]Cyclosporine[e1] induced [s2]pain syndrome[e2] in a child undergoing hematopoietic stem cell transplant.
	(4, 15)	CIPS	cyclosporine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3582	In this case, [s1]CIPS[e1] was considered to be probably associated with [s2]cyclosporine[e2] according to the Naranjo probability scale.
	(7, 14)	calcineurin	pain syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3583	OBJECTIVE: To report a case of [s1]calcineurin[e1] induced [s2]pain syndrome[e2] (CIPS) in a child undergoing his second hematopoietic stem cell transplant (HSCT).
	(3, 16)	cyclosporine	leg pain	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3584	With the first [s1]cyclosporine[e1] dose, the patient complained of [s2]leg pain[e2] that was most severe during the cyclosporine infusion.
	(3, 16)	cyclosporine	leg pain	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3585	With the first [s1]cyclosporine[e1] dose, the patient complained of [s2]leg pain[e2] that was most severe during the cyclosporine infusion.
	(0, 11)	Neuroleptic malignant syndrome	risperidone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3586	 [s1]Neuroleptic malignant syndrome[e1] due to [s2]risperidone[e2] treatment in a child with Joubert syndrome.
	(6, 17)	neuroleptic malignant syndrome	risperidone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3587	This report describes a case of [s1]neuroleptic malignant syndrome[e1] due to [s2]risperidone[e2] in a child with Joubert syndrome.
	(3, 10)	tuberculosis	Efalizumab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3588	A case of [s1]tuberculosis[e1] in a patient on [s2]Efalizumab[e2] and Etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis.
	(3, 17)	tuberculosis	Etanercept	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3589	A case of [s1]tuberculosis[e1] in a patient on Efalizumab and [s2]Etanercept[e2] for treatment of refractory palmopustular psoriasis and psoriatic arthritis.
	(6, 14)	warfarin	bleeding	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3590	The most common complication of [s1]warfarin[e1] use is adverse [s2]bleeding[e2] 
	(21, 36)	symptomatic hyperlactatemia	stavudine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3591	CASE REPORT: We describe here a case of a 60 year old female that experienced a relapse of [s1]symptomatic hyperlactatemia[e1] after being switched from [s2]stavudine[e2] to zidovudine and how the case was managed at the Infectious Diseases Institute, Kampala, Uganda.
	(21, 41)	symptomatic hyperlactatemia	zidovudine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3592	CASE REPORT: We describe here a case of a 60 year old female that experienced a relapse of [s1]symptomatic hyperlactatemia[e1] after being switched from stavudine to [s2]zidovudine[e2] and how the case was managed at the Infectious Diseases Institute, Kampala, Uganda.
	(8, 19)	zidovudine	hyperlactatemia relapse	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3593	DISCUSSION: This case shows that switching to [s1]zidovudine[e1] potentially can lead to a [s2]hyperlactatemia relapse[e2] 
	(16, 23)	stavudine	hyperlactatemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3594	INTRODUCTION: In resource limited settings patients on antiretroviral treatment who develop [s1]stavudine[e1] induced [s2]hyperlactatemia[e2] are often switched to zidovudine on the basis of published studies that demonstrate that this agent can be a safe alternative.
	(0, 8)	Anaphylactic reaction	bacitracin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3595	 [s1]Anaphylactic reaction[e1] to [s2]bacitracin[e2] ointment.
	(15, 25)	anaphylactic reaction	bacitracin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3596	We report a case of an 11-year-old boy who experienced an [s1]anaphylactic reaction[e1] after administration of [s2]bacitracin[e2] ointment.
	(10, 23)	prolonged hypoglycemia	octreotide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3597	Herein, we present a patient with severe and [s1]prolonged hypoglycemia[e1] after long-acting [s2]octreotide[e2] treatment.
	(0, 13)	Hypoglycemia	somatostatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3598	 [s1]Hypoglycemia[e1] induced by long-acting [s2]somatostatin[e2] analogues in a patient with nonfunctional neuroendocrine tumor.
	(7, 14)	octreotide	serious hypoglycemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3599	In these patients, long-acting [s1]octreotide[e1] may trigger [s2]serious hypoglycemia[e2] 
	(0, 23)	Leukopenia	azathioprine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3600	 [s1]Leukopenia[e1] due to parvovirus B19 in a Crohn's disease patient using [s2]azathioprine[e2] 
	(14, 40)	AZA	leukopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3601	The uncomplicated long-term use of adequately-dosed [s1]AZA[e1] and stable non-toxic metabolite levels could not acknowledge TPMT deficiency as a primary cause of the [s2]leukopenia[e2] 
	(23, 33)	leukopenia	AZA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3602	We present the case of an adult Crohn's disease patient with a parvovirus B19 infection and [s1]leukopenia[e1] during long-term [s2]AZA[e2] therapy.
	(0, 7)	Isoniazid	breast tissue enlargement	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3603	 [s1]Isoniazid[e1] causing [s2]breast tissue enlargement[e2] has been very rarely reported.
	(0, 7)	Isoniazid	gynaecomastia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3604	 [s1]Isoniazid[e1] induced [s2]gynaecomastia[e2]  a case report.
	(0, 23)	Cryptococcus neoformans fatal sepsis	alemtuzumab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3605	 [s1]Cryptococcus neoformans fatal sepsis[e1] in a chronic lymphocytic leukemia patient treated with [s2]alemtuzumab[e2]  case report and review of the literature.
	(17, 28)	alemtuzumab	fungal infections	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3606	The international literature regarding opportunistic infections after immunosuppressive therapy with [s1]alemtuzumab[e1] with particular attention on [s2]fungal infections[e2] has also been reviewed.
	(4, 19)	opportunistic infections	alemtuzumab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3607	The international literature regarding [s1]opportunistic infections[e1] after immunosuppressive therapy with [s2]alemtuzumab[e2] with particular attention on fungal infections has also been reviewed.
	(1, 9)	acute myeloid leukemia	etoposide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3608	Secondary [s1]acute myeloid leukemia[e1] after [s2]etoposide[e2] therapy for haemophagocytic lymphohistiocytosis.
	(4, 26)	sAML	etoposide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3609	The risk of developing [s1]sAML[e1] is estimated to be between 1% and 5%, 2-20 years after exposure to [s2]etoposide[e2] but may also be related to cumulative drug doses, treatment schedules, host factors and co-administration of other antineoplastic agents.
	(7, 20)	etoposide	sAML	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3610	Two patients with HLH developed [s1]etoposide[e1] related secondary acute myeloid leukemia  [s2]sAML[e2]  following therapy for HLH.
	(7, 14)	etoposide	secondary acute myeloid leukemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3611	Two patients with HLH developed [s1]etoposide[e1] related [s2]secondary acute myeloid leukemia[e2] (sAML) following therapy for HLH.
	(0, 13)	Polymyoclonus seizure	tranexamic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3612	 [s1]Polymyoclonus seizure[e1] resulting from accidental injection of [s2]tranexamic acid[e2] in spinal anesthesia.
	(0, 8)	Rhabdomyolysis	clarithromycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3613	 [s1]Rhabdomyolysis[e1] following [s2]clarithromycin[e2] monotherapy.
	(6, 18)	rhabdomyolysis	clarithromycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3614	We report the first case of [s1]rhabdomyolysis[e1] related to the administration of [s2]clarithromycin[e2] without concurrent use of other medications.
	(8, 21)	sunitinib	development of abnormally large mammary glands	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3615	At the end of his fifth cycle of [s1]sunitinib[e1] therapy, the patient complained of the [s2]development of abnormally large mammary glands[e2] associated with pain and peri-areolar erythema.
	(8, 32)	sunitinib	pain	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3616	At the end of his fifth cycle of [s1]sunitinib[e1] therapy, the patient complained of the development of abnormally large mammary glands associated with [s2]pain[e2] and peri-areolar erythema.
	(8, 34)	sunitinib	peri-areolar erythema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3617	At the end of his fifth cycle of [s1]sunitinib[e1] therapy, the patient complained of the development of abnormally large mammary glands associated with pain and [s2]peri-areolar erythema[e2] 
	(6, 16)	sunitinib	bilateral breast enlargement	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3618	However, re-initiation of [s1]sunitinib[e1] treatment was followed by [s2]bilateral breast enlargement[e2] again.
	(3, 16)	gynaecomastia	sunitinib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3619	Onset of male [s1]gynaecomastia[e1] in a patient treated with [s2]sunitinib[e2] for metastatic renal cell carcinoma.
	(4, 12)	sunitinib	gynaecomastia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3620	The mechanism by which [s1]sunitinib[e1] induces [s2]gynaecomastia[e2] is thought to be associated with an unknown direct action on breast hormonal receptors.
	(10, 27)	sunitinib	elevated lipase	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3621	The more common grade 3 or 4 adverse effects of [s1]sunitinib[e1] include hypertension, fatigue, hand-foot syndrome, [s2]elevated lipase[e2] and lymphopenia.
	(10, 20)	sunitinib	fatigue	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3622	The more common grade 3 or 4 adverse effects of [s1]sunitinib[e1] include hypertension, [s2]fatigue[e2]  hand-foot syndrome, elevated lipase and lymphopenia.
	(10, 22)	sunitinib	hand-foot syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3623	The more common grade 3 or 4 adverse effects of [s1]sunitinib[e1] include hypertension, fatigue, [s2]hand-foot syndrome[e2]  elevated lipase and lymphopenia.
	(10, 17)	sunitinib	hypertension	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3624	The more common grade 3 or 4 adverse effects of [s1]sunitinib[e1] include [s2]hypertension[e2]  fatigue, hand-foot syndrome, elevated lipase and lymphopenia.
	(10, 31)	sunitinib	lymphopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3625	The more common grade 3 or 4 adverse effects of [s1]sunitinib[e1] include hypertension, fatigue, hand-foot syndrome, elevated lipase and [s2]lymphopenia[e2] 
	(0, 8)	Divalproex sodium	eosinophilic pleural effusion	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3626	 [s1]Divalproex sodium[e1] induced [s2]eosinophilic pleural effusion[e2] 
	(20, 29)	Depakote	dyspnea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3627	We report a case of 48-year-old woman with seizure disorder on divalproex sodium  [s1]Depakote[e1]  who presented with [s2]dyspnea[e2] 
	(15, 31)	divalproex sodium	dyspnea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3628	We report a case of 48-year-old woman with seizure disorder on [s1]divalproex sodium[e1] (Depakote) who presented with [s2]dyspnea[e2] 
	(2, 13)	Depakote	effusion	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3629	Withdrawal of [s1]Depakote[e1] resulted in resolution of the [s2]effusion[e2] 
	(0, 8)	Flurbiprofen	acute tubulointerstitial nephritis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3630	 [s1]Flurbiprofen[e1] associated [s2]acute tubulointerstitial nephritis[e2] 
	(9, 28)	acute tubulointerstitial nephritis	flurbiprofen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3631	We report a case of biopsy-proven [s1]acute tubulointerstitial nephritis[e1] associated with a second course of [s2]flurbiprofen[e2]  a nonsteroidal anti-inflammatory drug of the propionic acid class.
	(0, 18)	Stupor	valproate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3632	 [s1]Stupor[e1] and fast activity on electroencephalography in a child treated with [s2]valproate[e2] 
	(11, 17)	valproate	stupor	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3633	The case of a 4-year-old girl with [s1]valproate[e1] induced [s2]stupor[e2] and electroencephalographic pattern of increased fast activity is reported.
	(0, 14)	Localized dyskeratotic plaque	sorafenib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3634	 [s1]Localized dyskeratotic plaque[e1] with milia associated with [s2]sorafenib[e2] 
	(8, 14)	milia	sorafenib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3635	Localized dyskeratotic plaque with [s1]milia[e1] associated with [s2]sorafenib[e2] 
	(7, 27)	atypical localized cutaneous eruption	sorafenib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3636	This article presents a case of an [s1]atypical localized cutaneous eruption[e1] with an unusual course and protracted resolution time associated with [s2]sorafenib[e2] therapy.
	(12, 25)	tigecycline	acute pancreatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3637	According to the Naranjo adverse drug reaction probability scale, [s1]tigecycline[e1] was the probable cause of her [s2]acute pancreatitis[e2] 
	(4, 23)	tigecycline	acute pancreatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3638	Following 7 days of [s1]tigecycline[e1] she developed severe abdominal pain and elevated pancreatic enzymes suggesting [s2]acute pancreatitis[e2] 
	(4, 17)	tigecycline	elevated pancreatic enzymes	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3639	Following 7 days of [s1]tigecycline[e1] she developed severe abdominal pain and [s2]elevated pancreatic enzymes[e2] suggesting acute pancreatitis.
	(4, 13)	tigecycline	severe abdominal pain	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3640	Following 7 days of [s1]tigecycline[e1] she developed [s2]severe abdominal pain[e2] and elevated pancreatic enzymes suggesting acute pancreatitis.
	(20, 28)	tigecycline	acute pancreatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3641	Pancreatitis has been associated with the tetracycline class of antibiotics and concerns about [s1]tigecycline[e1] induced [s2]acute pancreatitis[e2] have recently been raised.
	(0, 8)	Tigecycline	acute pancreatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3642	 [s1]Tigecycline[e1] induced [s2]acute pancreatitis[e2]  case report and literature review.
	(18, 25)	abdominal pain	tigecycline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3643	We recommend that clinicians monitor patients for signs and symptoms of pancreatitis, including [s1]abdominal pain[e1]  during treatment with [s2]tigecycline[e2] 
	(12, 25)	pancreatitis	tigecycline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3644	We recommend that clinicians monitor patients for signs and symptoms of [s1]pancreatitis[e1]  including abdominal pain, during treatment with [s2]tigecycline[e2] 
	(2, 10)	polymyositis	leuprolide acetate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3645	Drug induced [s1]polymyositis[e1] secondary to [s2]leuprolide acetate[e2] (Lupron) therapy for prostate carcinoma.
	(2, 16)	polymyositis	Lupron	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3646	Drug induced [s1]polymyositis[e1] secondary to leuprolide acetate  [s2]Lupron[e2]  therapy for prostate carcinoma.
	(8, 21)	myositis	leuprolide acetate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3647	We report a case of biopsy proven [s1]myositis[e1] whose symptoms began within 10 days of receiving [s2]leuprolide acetate[e2] therapy for prostate cancer.
	(0, 8)	Aripiprazole	hiccups	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3648	 [s1]Aripiprazole[e1] induced [s2]hiccups[e2]  a case report.
	(12, 26)	hiccups	aripiprazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3649	We report a patient of organic bipolar affective disorder who developed [s1]hiccups[e1] with the atypical antipsychotic [s2]aripiprazole[e2] 
	(6, 17)	rhabdomyolysis	sertraline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3650	CONCLUSIONS: This patient's [s1]rhabdomyolysis[e1] was probably induced by [s2]sertraline[e2] therapy.
	(13, 23)	sertraline	rhabdomyolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3651	DISCUSSION: The Naranjo probability scale indicated a probable relationship between [s1]sertraline[e1] treatment and the onset of [s2]rhabdomyolysis[e2] 
	(7, 13)	sertraline	rhabdomyolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3652	OBJECTIVE: To describe a case of [s1]sertraline[e1] induced [s2]rhabdomyolysis[e2] in an elderly patient with dementia and comorbidities.
	(0, 6)	Sertraline	rhabdomyolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3653	 [s1]Sertraline[e1] induced [s2]rhabdomyolysis[e2] in an elderly patient with dementia and comorbidities.
	(19, 27)	sertraline	rhabdomyolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3654	The patient's other comorbidities and medications have not been suggested as possible interactions with [s1]sertraline[e1] that can cause [s2]rhabdomyolysis[e2] 
	(0, 15)	Tumor lysis syndrome	cisplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3655	 [s1]Tumor lysis syndrome[e1] after transcatheter arterial infusion of [s2]cisplatin[e2] and embolization therapy for liver metastases of melanoma.
	(2, 11)	priapism	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3656	He had [s1]priapism[e1] following the use of [s2]olanzapine[e2] 
	(0, 7)	Priapism	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3657	 [s1]Priapism[e1] associated with [s2]olanzapine[e2] 
	(1, 10)	ketamine	damage to the urinary tract	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3658	Can [s1]ketamine[e1] prescribed for pain cause [s2]damage to the urinary tract[e2] 
	(3, 13)	damage to the urothelium	ketamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3659	Possible mechanisms for [s1]damage to the urothelium[e1] by [s2]ketamine[e2] are suggested.
	(11, 29)	ketamine	urological symptoms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3660	Presentation of three palliative care patients who were given [s1]ketamine[e1] as an analgesic and subsequently developed significant and debilitating [s2]urological symptoms[e2] 
	(8, 18)	lopinavir	arrhythmias	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3661	These two cases highlight the importance of considering [s1]lopinavir[e1] ritonavir induced [s2]arrhythmias[e2] when dealing with HIV-positive individuals.
	(11, 18)	ritonavir	arrhythmias	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3662	These two cases highlight the importance of considering lopinavir [s1]ritonavir[e1] induced [s2]arrhythmias[e2] when dealing with HIV-positive individuals.
	(0, 11)	Transient cardiac arrhythmias	lopinavir	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3663	 [s1]Transient cardiac arrhythmias[e1] related to [s2]lopinavir[e2] ritonavir in two patients with HIV infection.
	(0, 14)	Transient cardiac arrhythmias	ritonavir	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3664	 [s1]Transient cardiac arrhythmias[e1] related to lopinavir [s2]ritonavir[e2] in two patients with HIV infection.
	(0, 8)	Colitis	infliximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3665	 [s1]Colitis[e1] as a manifestation of [s2]infliximab[e2] associated disseminated cryptococcosis.
	(6, 14)	infliximab	disseminated cryptococcosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3666	Colitis as a manifestation of [s1]infliximab[e1] associated [s2]disseminated cryptococcosis[e2] 
	(4, 27)	carbamazepine	aggressive behavior	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3667	After three weeks of [s1]carbamazepine[e1] therapy, the patient arrived at the emergency department (ED) with severe agitation and [s2]aggressive behavior[e2] 
	(4, 24)	carbamazepine	severe agitation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3668	After three weeks of [s1]carbamazepine[e1] therapy, the patient arrived at the emergency department (ED) with [s2]severe agitation[e2] and aggressive behavior.
	(0, 8)	Carbamazepine	hyperammonemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3669	 [s1]Carbamazepine[e1] induced [s2]hyperammonemia[e2] 
	(13, 23)	hyperammonemia	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3670	CONCLUSION: A 26-year-old man with bipolar disorder developed [s1]hyperammonemia[e1] three weeks after initiating [s2]carbamazepine[e2] therapy.
	(4, 12)	elevated serum ammonia levels	valproic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3671	He had also developed [s1]elevated serum ammonia levels[e1] while on [s2]valproic acid[e2] 
	(5, 13)	carbamazepine	hyperammonemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3672	PURPOSE: A case of [s1]carbamazepine[e1] induced [s2]hyperammonemia[e2] is presented.
	(0, 7)	Adriamycin	cardiomyopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3673	 [s1]Adriamycin[e1] induced [s2]cardiomyopathy[e2] aggravated by cis-platinum nephrotoxicity requiring dialysis.
	(12, 17)	cis-platinum	nephrotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3674	Adriamycin-induced cardiomyopathy aggravated by [s1]cis-platinum[e1]  [s2]nephrotoxicity[e2] requiring dialysis.
	(30, 36)	adriamycin	cardiotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3675	Complications of chemotherapy for a synovial sarcoma in an eight-year old boy included cisplatinum nephrotoxicity and [s1]adriamycin[e1]  [s2]cardiotoxicity[e2] 
	(19, 25)	cisplatinum	nephrotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3676	Complications of chemotherapy for a synovial sarcoma in an eight-year old boy included [s1]cisplatinum[e1]  [s2]nephrotoxicity[e2] and adriamycin cardiotoxicity.
	(10, 45)	jaundice	adalimumab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3677	A 65-year-old female patient presented with [s1]jaundice[e1] followed 2 days later by severe dyspnea and tachypnea which worsened when patient was lying flat, 1 week after the fourth dose of [s2]adalimumab[e2] 
	(18, 45)	severe dyspnea	adalimumab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3678	A 65-year-old female patient presented with jaundice followed 2 days later by [s1]severe dyspnea[e1] and tachypnea which worsened when patient was lying flat, 1 week after the fourth dose of [s2]adalimumab[e2] 
	(24, 45)	tachypnea	adalimumab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3679	A 65-year-old female patient presented with jaundice followed 2 days later by severe dyspnea and [s1]tachypnea[e1] which worsened when patient was lying flat, 1 week after the fourth dose of [s2]adalimumab[e2] 
	(3, 16)	acute respiratory failure	adalimumab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3680	A case of [s1]acute respiratory failure[e1] due to diaphragmatic weakness following [s2]adalimumab[e2] therapy for psoriasis is described.
	(0, 13)	Acute bilateral phrenic neuropathy	adalimumab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3681	 [s1]Acute bilateral phrenic neuropathy[e1] following treatment with [s2]adalimumab[e2] 
	(4, 26)	SJS	TMP-Sx	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3682	The potential development of [s1]SJS[e1] TEN, a severe life-threatening illness, emphasizes the need for judicious use of [s2]TMP-Sx[e2] and close monitoring and follow-up for patients who were given TMP-Sx for SSTIs.
	(6, 25)	TEN	TMP-Sx	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3683	The potential development of SJS [s1]TEN[e1]  a severe life-threatening illness, emphasizes the need for judicious use of [s2]TMP-Sx[e2] and close monitoring and follow-up for patients who were given TMP-Sx for SSTIs.
	(17, 37)	SJS	TMP-Sx	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3684	We report a case of Stevens-Johnson syndrome/toxic epidermal necrolysis  [s1]SJS[e1] TEN) secondary to trimethoprim-sulfamethoxazole  [s2]TMP-Sx[e2]  therapy for presumed community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infection.
	(17, 25)	SJS	trimethoprim-sulfamethoxazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3685	We report a case of Stevens-Johnson syndrome/toxic epidermal necrolysis  [s1]SJS[e1] TEN) secondary to [s2]trimethoprim-sulfamethoxazole[e2] (TMP-Sx) therapy for presumed community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infection.
	(5, 38)	Stevens-Johnson syndrome	TMP-Sx	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3686	We report a case of [s1]Stevens-Johnson syndrome[e1] toxic epidermal necrolysis (SJS/TEN) secondary to trimethoprim-sulfamethoxazole  [s2]TMP-Sx[e2]  therapy for presumed community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infection.
	(5, 26)	Stevens-Johnson syndrome	trimethoprim-sulfamethoxazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3687	We report a case of [s1]Stevens-Johnson syndrome[e1] toxic epidermal necrolysis (SJS/TEN) secondary to [s2]trimethoprim-sulfamethoxazole[e2] (TMP-Sx) therapy for presumed community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infection.
	(20, 37)	TEN	TMP-Sx	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3688	We report a case of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS [s1]TEN[e1]  secondary to trimethoprim-sulfamethoxazole  [s2]TMP-Sx[e2]  therapy for presumed community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infection.
	(20, 25)	TEN	trimethoprim-sulfamethoxazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3689	We report a case of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS [s1]TEN[e1]  secondary to [s2]trimethoprim-sulfamethoxazole[e2] (TMP-Sx) therapy for presumed community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infection.
	(9, 38)	toxic epidermal necrolysis	TMP-Sx	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3690	We report a case of Stevens-Johnson syndrome [s1]toxic epidermal necrolysis[e1] (SJS/TEN) secondary to trimethoprim-sulfamethoxazole  [s2]TMP-Sx[e2]  therapy for presumed community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infection.
	(9, 26)	toxic epidermal necrolysis	trimethoprim-sulfamethoxazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3691	We report a case of Stevens-Johnson syndrome [s1]toxic epidermal necrolysis[e1] (SJS/TEN) secondary to [s2]trimethoprim-sulfamethoxazole[e2] (TMP-Sx) therapy for presumed community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infection.
	(2, 16)	Spontaneous hemothorax	LMWH	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3692	CONCLUSIONS: [s1]Spontaneous hemothorax[e1] is a rare phenomenon in conjunction with [s2]LMWH[e2] but should be considered in cases of acute respiratory distress following commencement of LMWH.
	(8, 17)	dalteparin	acute respiratory distress	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3693	On day 4, following 3 doses of [s1]dalteparin[e1]  the patient developed [s2]acute respiratory distress[e2] attributable to a massive right hemothorax confirmed by computed tomography pulmonary angiography (CTPA) and intercostal drainage of 1500 mL of frank blood.
	(0, 18)	Spontaneous hemothorax	heparin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3694	 [s1]Spontaneous hemothorax[e1] following anticoagulation with low-molecular-weight [s2]heparin[e2] 
	(0, 19)	Acute ocular ischemic change	bevacizumab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3695	 [s1]Acute ocular ischemic change[e1] may be associated with intravitreal injection of [s2]bevacizumab[e2] in patients with vascular compromised diabetic retinopathy and/or underlying stenosis of the carotid artery.
	(0, 17)	Acute vision loss	avastin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3696	 [s1]Acute vision loss[e1] after intravitreal injection of bevacizumab  [s2]avastin[e2]  associated with ocular ischemic syndrome.
	(0, 12)	Acute vision loss	bevacizumab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3697	 [s1]Acute vision loss[e1] after intravitreal injection of [s2]bevacizumab[e2] (avastin) associated with ocular ischemic syndrome.
	(15, 22)	avastin	ocular ischemic syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3698	Acute vision loss after intravitreal injection of bevacizumab  [s1]avastin[e1]  associated with [s2]ocular ischemic syndrome[e2] 
	(10, 24)	bevacizumab	ocular ischemic syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3699	Acute vision loss after intravitreal injection of [s1]bevacizumab[e1] (avastin) associated with [s2]ocular ischemic syndrome[e2] 
	(16, 35)	acute retinal ischemic change	bevacizumab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3700	AIM: To report a patient with diabetic rubeosis who suffered from [s1]acute retinal ischemic change[e1] and stroke after intravitreal injection of [s2]bevacizumab[e2] 
	(25, 35)	stroke	bevacizumab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3701	AIM: To report a patient with diabetic rubeosis who suffered from acute retinal ischemic change and [s1]stroke[e1] after intravitreal injection of [s2]bevacizumab[e2] 
	(11, 28)	bevacizumab	carotid insufficiency	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3702	CONCLUSIONS: Patients receiving intravitreal injections of [s1]bevacizumab[e1] should be evaluated for potential systemic risk factors such as [s2]carotid insufficiency[e2]  coagulopathy and poorly controlled diabetes mellitus.
	(11, 36)	bevacizumab	coagulopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3703	CONCLUSIONS: Patients receiving intravitreal injections of [s1]bevacizumab[e1] should be evaluated for potential systemic risk factors such as carotid insufficiency, [s2]coagulopathy[e2] and poorly controlled diabetes mellitus.
	(11, 41)	bevacizumab	poorly controlled diabetes mellitus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3704	CONCLUSIONS: Patients receiving intravitreal injections of [s1]bevacizumab[e1] should be evaluated for potential systemic risk factors such as carotid insufficiency, coagulopathy and [s2]poorly controlled diabetes mellitus[e2] 
	(9, 16)	bevacizumab	acute ocular ischemic syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3705	Three days after intravitreal injection of [s1]bevacizumab[e1]  [s2]acute ocular ischemic syndrome[e2] occurred.
	(10, 31)	bevacizumab	acute vision loss	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3706	Three days after receiving intravitreal injection of [s1]bevacizumab[e1] (1.25 mg in 0.1 ml), he developed [s2]acute vision loss[e2] and change of consciousness.
	(10, 35)	bevacizumab	change of consciousness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3707	Three days after receiving intravitreal injection of [s1]bevacizumab[e1] (1.25 mg in 0.1 ml), he developed acute vision loss and [s2]change of consciousness[e2] 
	(15, 45)	pancytopenia	cyclophosphamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3708	Herein, we describe a patient with AIDS who presented to medical attention with [s1]pancytopenia[e1] 48 months postchemotherapy with etoposide, prednisone, vincristine, [s2]cyclophosphamide[e2]  doxorubicin, and rituximab (R-EPOCH) for diffuse large B-cell lymphoma.
	(15, 52)	pancytopenia	doxorubicin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3709	Herein, we describe a patient with AIDS who presented to medical attention with [s1]pancytopenia[e1] 48 months postchemotherapy with etoposide, prednisone, vincristine, cyclophosphamide, [s2]doxorubicin[e2]  and rituximab (R-EPOCH) for diffuse large B-cell lymphoma.
	(15, 30)	pancytopenia	etoposide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3710	Herein, we describe a patient with AIDS who presented to medical attention with [s1]pancytopenia[e1] 48 months postchemotherapy with [s2]etoposide[e2]  prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (R-EPOCH) for diffuse large B-cell lymphoma.
	(15, 35)	pancytopenia	prednisone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3711	Herein, we describe a patient with AIDS who presented to medical attention with [s1]pancytopenia[e1] 48 months postchemotherapy with etoposide, [s2]prednisone[e2]  vincristine, cyclophosphamide, doxorubicin, and rituximab (R-EPOCH) for diffuse large B-cell lymphoma.
	(15, 60)	pancytopenia	rituximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3712	Herein, we describe a patient with AIDS who presented to medical attention with [s1]pancytopenia[e1] 48 months postchemotherapy with etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and [s2]rituximab[e2] (R-EPOCH) for diffuse large B-cell lymphoma.
	(15, 40)	pancytopenia	vincristine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3713	Herein, we describe a patient with AIDS who presented to medical attention with [s1]pancytopenia[e1] 48 months postchemotherapy with etoposide, prednisone, [s2]vincristine[e2]  cyclophosphamide, doxorubicin, and rituximab (R-EPOCH) for diffuse large B-cell lymphoma.
	(5, 20)	hepatitis B infection	adefovir	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3714	Favorable outcome of de novo [s1]hepatitis B infection[e1] after liver transplantation with lamivudine and [s2]adefovir[e2] therapy.
	(5, 15)	hepatitis B infection	lamivudine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3715	Favorable outcome of de novo [s1]hepatitis B infection[e1] after liver transplantation with [s2]lamivudine[e2] and adefovir therapy.
	(0, 6)	Linezolid	acute interstitial nephritis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3716	 [s1]Linezolid[e1] associated [s2]acute interstitial nephritis[e2] and drug rash with eosinophilia and systemic symptoms (DRESS) syndrome.
	(0, 26)	Linezolid	DRESS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3717	 [s1]Linezolid[e1] associated acute interstitial nephritis and drug rash with eosinophilia and systemic symptoms  [s2]DRESS[e2]  syndrome.
	(0, 15)	Linezolid	drug rash with eosinophilia and systemic symptoms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3718	 [s1]Linezolid[e1] associated acute interstitial nephritis and [s2]drug rash with eosinophilia and systemic symptoms[e2] (DRESS) syndrome.
	(4, 27)	linezolid	eosinophilia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3719	On day 7 of [s1]linezolid[e1] treatment, the patient developed severe pruritus, macular rash, facial edema, [s2]eosinophilia[e2]  marked increase in serum creatinine level, and mild hepatitis.
	(4, 23)	linezolid	facial edema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3720	On day 7 of [s1]linezolid[e1] treatment, the patient developed severe pruritus, macular rash, [s2]facial edema[e2]  eosinophilia, marked increase in serum creatinine level, and mild hepatitis.
	(4, 19)	linezolid	macular rash	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3721	On day 7 of [s1]linezolid[e1] treatment, the patient developed severe pruritus, [s2]macular rash[e2]  facial edema, eosinophilia, marked increase in serum creatinine level, and mild hepatitis.
	(4, 33)	linezolid	marked increase in serum creatinine level	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3722	On day 7 of [s1]linezolid[e1] treatment, the patient developed severe pruritus, macular rash, facial edema, eosinophilia, [s2]marked increase in serum creatinine level[e2]  and mild hepatitis.
	(4, 44)	linezolid	mild hepatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3723	On day 7 of [s1]linezolid[e1] treatment, the patient developed severe pruritus, macular rash, facial edema, eosinophilia, marked increase in serum creatinine level, and [s2]mild hepatitis[e2] 
	(4, 14)	linezolid	severe pruritus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3724	On day 7 of [s1]linezolid[e1] treatment, the patient developed [s2]severe pruritus[e2]  macular rash, facial edema, eosinophilia, marked increase in serum creatinine level, and mild hepatitis.
	(3, 9)	linezolid	acute interstitial nephritis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3725	This case of [s1]linezolid[e1] associated [s2]acute interstitial nephritis[e2] within the context of a drug rash with eosinophilia and systemic symptoms (DRESS) syndrome in a patient treated with linezolid raises concerns about the presumed renal safety of this drug.
	(3, 9)	linezolid	acute interstitial nephritis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3726	This case of [s1]linezolid[e1] associated [s2]acute interstitial nephritis[e2] within the context of a drug rash with eosinophilia and systemic symptoms (DRESS) syndrome in a patient treated with linezolid raises concerns about the presumed renal safety of this drug.
	(3, 33)	linezolid	DRESS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3727	This case of [s1]linezolid[e1] associated acute interstitial nephritis within the context of a drug rash with eosinophilia and systemic symptoms  [s2]DRESS[e2]  syndrome in a patient treated with linezolid raises concerns about the presumed renal safety of this drug.
	(3, 33)	linezolid	DRESS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3728	This case of [s1]linezolid[e1] associated acute interstitial nephritis within the context of a drug rash with eosinophilia and systemic symptoms  [s2]DRESS[e2]  syndrome in a patient treated with linezolid raises concerns about the presumed renal safety of this drug.
	(3, 22)	linezolid	drug rash with eosinophilia and systemic symptoms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3729	This case of [s1]linezolid[e1] associated acute interstitial nephritis within the context of a [s2]drug rash with eosinophilia and systemic symptoms[e2] (DRESS) syndrome in a patient treated with linezolid raises concerns about the presumed renal safety of this drug.
	(3, 22)	linezolid	drug rash with eosinophilia and systemic symptoms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3730	This case of [s1]linezolid[e1] associated acute interstitial nephritis within the context of a [s2]drug rash with eosinophilia and systemic symptoms[e2] (DRESS) syndrome in a patient treated with linezolid raises concerns about the presumed renal safety of this drug.
	(9, 27)	LPD	MTX	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3731	Increased awareness is needed on the possible occurrence of [s1]LPD[e1] resembling gastric cancer in rheumatoid arthritis patients treated with [s2]MTX[e2] 
	(3, 11)	methotrexate	lymphoproliferative disorder	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3732	Reversible [s1]methotrexate[e1] associated [s2]lymphoproliferative disorder[e2] resembling advanced gastric cancer in a patient with rheumatoid arthritis.
	(4, 35)	Epstein-Barr virus-associated polymorphic lymphoproliferative disorder	MTX	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3733	She was diagnosed with [s1]Epstein-Barr virus-associated polymorphic lymphoproliferative disorder[e1] (LPD) due to immunodeficiency caused by [s2]MTX[e2] administration.
	(26, 35)	immunodeficiency	MTX	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3734	She was diagnosed with Epstein-Barr virus-associated polymorphic lymphoproliferative disorder (LPD) due to [s1]immunodeficiency[e1] caused by [s2]MTX[e2] administration.
	(20, 33)	LPD	MTX	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3735	She was diagnosed with Epstein-Barr virus-associated polymorphic lymphoproliferative disorder  [s1]LPD[e1]  due to immunodeficiency caused by [s2]MTX[e2] administration.
	(14, 19)	MTX	gastric LPD	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3736	To our knowledge, this is the first case of spontaneous remission of [s1]MTX[e1] associated [s2]gastric LPD[e2] after discontinuation of MTX therapy.
	(4, 23)	acute renal failure	sorafenib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3737	However, he developed [s1]acute renal failure[e1]  hyperkalemia, and hyperuricemia 30 d after receiving the [s2]sorafenib[e2] treatment.
	(8, 23)	hyperkalemia	sorafenib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3738	However, he developed acute renal failure, [s1]hyperkalemia[e1]  and hyperuricemia 30 d after receiving the [s2]sorafenib[e2] treatment.
	(13, 24)	hyperuricemia	sorafenib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3739	However, he developed acute renal failure, hyperkalemia, and [s1]hyperuricemia[e1] 30 d after receiving the [s2]sorafenib[e2] treatment.
	(0, 7)	Sorafenib	tumor lysis syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3740	 [s1]Sorafenib[e1] induced [s2]tumor lysis syndrome[e2] in an advanced hepatocellular carcinoma patient.
	(15, 23)	oxymetazoline	syncope	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3741	Are nasal decongestants safer than rhinitis? A case of [s1]oxymetazoline[e1] induced [s2]syncope[e2] 
	(8, 14)	neurological depression	oxymetalzoline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3742	We report here a case of cardiovascular and [s1]neurological depression[e1] induced by [s2]oxymetalzoline[e2] in a toddler.
	(7, 46)	nitrofurantoin	toxic liver damage	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3743	Given that discontinuation of [s1]nitrofurantoin[e1] and introduction of methylprednisolon therapy significantly lowered liver enzyme levels, restoring most of them to normal, we concluded that this was probably the case of [s2]toxic liver damage[e2] caused by nitrofurantoin.
	(0, 8)	Nitrofurantoin	acute liver damage	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3744	 [s1]Nitrofurantoin[e1] induced [s2]acute liver damage[e2] in pregnancy.
	(32, 43)	PCNSL	natalizumab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3745	A 40-year-old man with relapsing-remitting multiple sclerosis (MS) developed primary central nervous system lymphoma  [s1]PCNSL[e1]  after having received 21 doses of [s2]natalizumab[e2] monotherapy.
	(24, 45)	primary central nervous system lymphoma	natalizumab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3746	A 40-year-old man with relapsing-remitting multiple sclerosis (MS) developed [s1]primary central nervous system lymphoma[e1] (PCNSL) after having received 21 doses of [s2]natalizumab[e2] monotherapy.
	(0, 15)	Primary central nervous system lymphoma	natalizumab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3747	 [s1]Primary central nervous system lymphoma[e1] in a patient treated with [s2]natalizumab[e2] 
	(14, 23)	sunitinib	fatigue	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3748	The first patient is undergoing hemodialysis and, though responding to [s1]sunitinib[e1]  is having significant [s2]fatigue[e2] and hypertension.
	(14, 25)	sunitinib	hypertension	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3749	The first patient is undergoing hemodialysis and, though responding to [s1]sunitinib[e1]  is having significant fatigue and [s2]hypertension[e2] 
	(7, 17)	severe apnea	lamotrigine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3750	OBJECTIVE: To report a case of [s1]severe apnea[e1] in an infant exposed to [s2]lamotrigine[e2] through breast-feeding.
	(0, 10)	Severe apnea	lamotrigine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3751	 [s1]Severe apnea[e1] in an infant exposed to [s2]lamotrigine[e2] in breast milk.
	(11, 18)	apnea	lamotrigine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3752	The Naranjo probability scale indicated a probable relationship between [s1]apnea[e1] and exposure to [s2]lamotrigine[e2] through breast-feeding in this infant.
	(28, 34)	dasatinib	pleural effusion	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3753	Although there have been numerous reports of effusions, none have provided complete pleural fluid analysis; therefore, we report 2 patients with [s1]dasatinib[e1] induced [s2]pleural effusion[e2] with complete pleural fluid analysis.
	(0, 6)	Dasatinib	pleural effusions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3754	 [s1]Dasatinib[e1] induced [s2]pleural effusions[e2]  a lymphatic network disorder?
	(19, 31)	carboplatin	platinum hypersensitivity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3755	RESULTS: One case of recurrent primary peritoneal carcinoma previously treated with a [s1]carboplatin[e1] based regimen, developed a [s2]platinum hypersensitivity[e2] 
	(8, 42)	adalimumab	fulminant cardiomyopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3756	One week after the initial-dose of [s1]adalimumab[e1] (160 mg), which was initiated due to an acute exacerbation of Crohn's disease, the patient developed a [s2]fulminant cardiomyopathy[e2] 
	(0, 19)	Severe cardiomyopathy	adalimumab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3757	 [s1]Severe cardiomyopathy[e1] following treatment with the tumour necrosis factor-alpha inhibitor [s2]adalimumab[e2] for Crohn's disease.
	(0, 14)	Amikacin	severe hypocalcemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3758	 [s1]Amikacin[e1] induced type 5 Bartter-like syndrome with [s2]severe hypocalcemia[e2] 
	(0, 6)	Amikacin	type 5 Bartter-like syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3759	 [s1]Amikacin[e1] induced [s2]type 5 Bartter-like syndrome[e2] with severe hypocalcemia.
	(3, 20)	tubular dysfunction	Amikacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3760	Recovery of the [s1]tubular dysfunction[e1] took 15 days following cessation of the offending drug, [s2]Amikacin[e2] 
	(17, 33)	Amikacin	hypocalcemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3761	We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with [s1]Amikacin[e1]  resulting in refractory hypokalemia, [s2]hypocalcemia[e2]  hypomagnesemia, metabolic alkalosis, and polyuria.
	(17, 39)	Amikacin	hypomagnesemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3762	We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with [s1]Amikacin[e1]  resulting in refractory hypokalemia, hypocalcemia, [s2]hypomagnesemia[e2]  metabolic alkalosis, and polyuria.
	(17, 46)	Amikacin	metabolic alkalosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3763	We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with [s1]Amikacin[e1]  resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, [s2]metabolic alkalosis[e2]  and polyuria.
	(17, 52)	Amikacin	polyuria	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3764	We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with [s1]Amikacin[e1]  resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, metabolic alkalosis, and [s2]polyuria[e2] 
	(17, 24)	Amikacin	refractory hypokalemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3765	We discuss a patient who developed severe renal tubular dysfunction secondary to short-term therapy with [s1]Amikacin[e1]  resulting in [s2]refractory hypokalemia[e2]  hypocalcemia, hypomagnesemia, metabolic alkalosis, and polyuria.
	(6, 19)	severe renal tubular dysfunction	Amikacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3766	We discuss a patient who developed [s1]severe renal tubular dysfunction[e1] secondary to short-term therapy with [s2]Amikacin[e2]  resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, metabolic alkalosis, and polyuria.
	(16, 45)	thrombin	multiple infarcts	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3767	Postoperatively, the first two patients treated with 1 to 2 cc of [s1]thrombin[e1] were slow to awaken; one had evidence of vasospasm by transcranial Doppler ultrasound studies and [s2]multiple infarcts[e2] on cranial computerized tomography, while the other had a moderate-sized frontal hematoma with intracranial hypertension.
	(16, 22)	thrombin	slow to awaken	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3768	Postoperatively, the first two patients treated with 1 to 2 cc of [s1]thrombin[e1] were [s2]slow to awaken[e2]  one had evidence of vasospasm by transcranial Doppler ultrasound studies and multiple infarcts on cranial computerized tomography, while the other had a moderate-sized frontal hematoma with intracranial hypertension.
	(16, 31)	thrombin	vasospasm	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3769	Postoperatively, the first two patients treated with 1 to 2 cc of [s1]thrombin[e1] were slow to awaken; one had evidence of [s2]vasospasm[e2] by transcranial Doppler ultrasound studies and multiple infarcts on cranial computerized tomography, while the other had a moderate-sized frontal hematoma with intracranial hypertension.
	(0, 42)	Thrombin	cerebral infarctions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3770	 [s1]Thrombin[e1] is highly effective for stopping intractable arterial hemorrhage during stereotactic brain biopsy; however, it is a vasospastic agent and may have been responsible for the [s2]cerebral infarctions[e2] in one patient.
	(0, 9)	Ciprofloxacin	hemorrhagic vasculitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3771	 [s1]Ciprofloxacin[e1] induced [s2]hemorrhagic vasculitis[e2] 
	(0, 9)	Ciprofloxacin	hemorrhagic vasculitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3772	 [s1]Ciprofloxacin[e1] induced [s2]hemorrhagic vasculitis[e2] is a rare side effect.
	(25, 34)	ciprofloxacin	hemorrhagic vasculitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3773	Ciprofloxacin is among the standard treatments for infected ischemic ulcers; in the rare case of [s1]ciprofloxacin[e1] induced [s2]hemorrhagic vasculitis[e2]  it might be interpreted as progression of infection, instead of a complication of the treatment, thus leading to faulty diagnosis and treatment.
	(13, 64)	ciprofloxacin	below-knee amputation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3774	In one patient the vasculitis resolved after termination of the [s1]ciprofloxacin[e1] therapy; in the other patient the ciprofloxacin-induced hemorrhagic vasculitis was superimposed on a severe forefoot infection, leading to progressive gangrene and a [s2]below-knee amputation[e2] 
	(13, 36)	ciprofloxacin	hemorrhagic vasculitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3775	In one patient the vasculitis resolved after termination of the [s1]ciprofloxacin[e1] therapy; in the other patient the ciprofloxacin-induced [s2]hemorrhagic vasculitis[e2] was superimposed on a severe forefoot infection, leading to progressive gangrene and a below-knee amputation.
	(13, 58)	ciprofloxacin	progressive gangrene	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3776	In one patient the vasculitis resolved after termination of the [s1]ciprofloxacin[e1] therapy; in the other patient the ciprofloxacin-induced hemorrhagic vasculitis was superimposed on a severe forefoot infection, leading to [s2]progressive gangrene[e2] and a below-knee amputation.
	(13, 51)	ciprofloxacin	severe forefoot infection	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3777	In one patient the vasculitis resolved after termination of the [s1]ciprofloxacin[e1] therapy; in the other patient the ciprofloxacin-induced hemorrhagic vasculitis was superimposed on a [s2]severe forefoot infection[e2]  leading to progressive gangrene and a below-knee amputation.
	(4, 15)	vasculitis	ciprofloxacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3778	In one patient the [s1]vasculitis[e1] resolved after termination of the [s2]ciprofloxacin[e2] therapy; in the other patient the ciprofloxacin-induced hemorrhagic vasculitis was superimposed on a severe forefoot infection, leading to progressive gangrene and a below-knee amputation.
	(12, 29)	interstitial pneumonia	sorafenib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3779	However, a recent post-marketing survey in Japan revealed that [s1]interstitial pneumonia[e1] occurred in 4 among approximately 2 000 Japanese patients treated with [s2]sorafenib[e2] 
	(0, 9)	Interstitial pneumonia	sorafenib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3780	 [s1]Interstitial pneumonia[e1] probably associated with [s2]sorafenib[e2] treatment: An alert of an adverse event.
	(10, 20)	severe interstitial pneumonia	sorafenib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3781	In this article, we describe a Japanese patient with [s1]severe interstitial pneumonia[e1] probably caused by [s2]sorafenib[e2] treatment for metastatic renal cell carcinoma.
	(18, 28)	sorafenib	interstitial lung disease	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3782	Oncologists supervising future clinical trials for lung cancer should be alert to the fact that [s1]sorafenib[e1] can potentially induce serious [s2]interstitial lung disease[e2]  although this might depend on racial differences.
	(1, 8)	gemcitabine	pulmonary toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3783	Fatal [s1]gemcitabine[e1] induced [s2]pulmonary toxicity[e2] in metastatic   gallbladder adenocarcinoma.
	(0, 7)	Gemcitabine	pulmonary toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3784	 [s1]Gemcitabine[e1] induced [s2]pulmonary toxicity[e2] is usually a dramatic condition.
	(8, 15)	gemcitabine	pulmonary toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3785	In this report, we describe a fatal [s1]gemcitabine[e1] induced [s2]pulmonary toxicity[e2] in a patient with gallbladder metastatic adenocarcinoma.
	(2, 21)	hypokalemia	licorice	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3786	He had [s1]hypokalemia[e1] (K 2.3 mmol/L) induced by [s2]licorice[e2] and also had received disopyramide for arrhythmia, bicalutamide for prostate cancer, and silodosin for prostate hypertrophy.
	(3, 16)	garenoxacin	cardiac rhythms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3787	Therefore, although [s1]garenoxacin[e1] reportedly causes fewer adverse reactions for [s2]cardiac rhythms[e2] than third-generation quinolone antibiotics, one must be cautious of the interference of other drugs during hypokalemia in order to prevent TdP.
	(3, 38)	garenoxacin	hypokalemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3788	Therefore, although [s1]garenoxacin[e1] reportedly causes fewer adverse reactions for cardiac rhythms than third-generation quinolone antibiotics, one must be cautious of the interference of other drugs during [s2]hypokalemia[e2] in order to prevent TdP.
	(0, 19)	Torsades de Pointes	disopyramide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3789	 [s1]Torsades de Pointes[e1] induced by a combination of garenoxacin and [s2]disopyramide[e2] and other cytochrome P450, family 3, subfamily A polypeptide-4-influencing drugs during hypokalemia due to licorice.
	(0, 13)	Torsades de Pointes	garenoxacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3790	 [s1]Torsades de Pointes[e1] induced by a combination of [s2]garenoxacin[e2] and disopyramide and other cytochrome P450, family 3, subfamily A polypeptide-4-influencing drugs during hypokalemia due to licorice.
	(25, 33)	TdP	garenoxacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3791	We report an 82-year-old man who developed ventricular tachycardia and Torsades de Pointes  [s1]TdP[e1]  after oral administration of [s2]garenoxacin[e2]  a novel quinolone antibiotic agent that differs from the third-generation quinolones, for pneumonia.
	(19, 35)	Torsades de Pointes	garenoxacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3792	We report an 82-year-old man who developed ventricular tachycardia and [s1]Torsades de Pointes[e1] (TdP) after oral administration of [s2]garenoxacin[e2]  a novel quinolone antibiotic agent that differs from the third-generation quinolones, for pneumonia.
	(11, 35)	ventricular tachycardia	garenoxacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3793	We report an 82-year-old man who developed [s1]ventricular tachycardia[e1] and Torsades de Pointes (TdP) after oral administration of [s2]garenoxacin[e2]  a novel quinolone antibiotic agent that differs from the third-generation quinolones, for pneumonia.
	(6, 20)	8MOP	acute dermatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3794	Of 371 patients treated with [s1]8MOP[e1]  three (0.8%) developed an [s2]acute dermatitis[e2] in the PUVA-treated areas.
	(0, 12)	Hepatotoxicity	methylprednisolone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3795	 [s1]Hepatotoxicity[e1] after high-dose [s2]methylprednisolone[e2] for demyelinating disease.
	(5, 18)	hepatotoxicity	methylprednisolone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3796	We observed 2 cases of [s1]hepatotoxicity[e1] after a high-dose [s2]methylprednisolone[e2] treatment of a demyelinating disease and evaluated the potential relationship in the light of available evidence.
	(0, 12)	Colonic mucosal necrosis	calcium polystryrene sulfonate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3797	 [s1]Colonic mucosal necrosis[e1] following administration of [s2]calcium polystryrene sulfonate[e2] (Kalimate) in a uremic patient.
	(0, 21)	Colonic mucosal necrosis	Kalimate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3798	 [s1]Colonic mucosal necrosis[e1] following administration of calcium polystryrene sulfonate  [s2]Kalimate[e2]  in a uremic patient.
	(0, 17)	Colonic necrosis	Kayexalate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3799	 [s1]Colonic necrosis[e1] is known as a rare complication following the administration of [s2]Kayexalate[e2] (sodium polystryrene sulfonate) in sorbitol.
	(0, 20)	Colonic necrosis	sodium polystryrene sulfonate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3800	 [s1]Colonic necrosis[e1] is known as a rare complication following the administration of Kayexalate  [s2]sodium polystryrene sulfonate[e2]  in sorbitol.
	(5, 31)	Kalimate	colonic mucosal necrosis in the rectum	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3801	Two days after administration of [s1]Kalimate[e1] enema, he had profuse hematochezia, and a sigmoidoscopy showed diffuse [s2]colonic mucosal necrosis in the rectum[e2] and sigmoid colon.
	(5, 14)	Kalimate	profuse hematochezia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3802	Two days after administration of [s1]Kalimate[e1] enema, he had [s2]profuse hematochezia[e2]  and a sigmoidoscopy showed diffuse colonic mucosal necrosis in the rectum and sigmoid colon.
	(6, 18)	colonic mucosal necrosis	calcium polystryrene sulfonate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3803	We report a rare case of [s1]colonic mucosal necrosis[e1] following Kalimate  [s2]calcium polystryrene sulfonate[e2] , an analogue of Kayexalate without sorbitol in a 34-yr-old man.
	(6, 16)	colonic mucosal necrosis	Kalimate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3804	We report a rare case of [s1]colonic mucosal necrosis[e1] following [s2]Kalimate[e2] (calcium polystryrene sulfonate), an analogue of Kayexalate without sorbitol in a 34-yr-old man.
	(6, 33)	colonic mucosal necrosis	Kayexalate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3805	We report a rare case of [s1]colonic mucosal necrosis[e1] following Kalimate (calcium polystryrene sulfonate), an analogue of [s2]Kayexalate[e2] without sorbitol in a 34-yr-old man.
	(0, 6)	Clozapine	tardive dyskinesia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3806	 [s1]Clozapine[e1] induced [s2]tardive dyskinesia[e2] in schizophrenic patients taking clozapine as a first-line antipsychotic drug.
	(6, 35)	clozapine	discomfort	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3807	CONCLUSIONS: These results suggest that [s1]clozapine[e1] may cause TD; however, the prevalence is low and the severity is relatively mild, with no or mild self-reported [s2]discomfort[e2] 
	(6, 13)	clozapine	TD	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3808	CONCLUSIONS: These results suggest that [s1]clozapine[e1] may cause [s2]TD[e2]  however, the prevalence is low and the severity is relatively mild, with no or mild self-reported discomfort.
	(8, 16)	clozapine	TD	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3809	However, several case reports have suggested that [s1]clozapine[e1] could also cause [s2]TD[e2] 
	(2, 9)	Clozapine	extrapyramidal symptoms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3810	OBJECTIVE: [s1]Clozapine[e1] causes few [s2]extrapyramidal symptoms[e2] and is recommended as a treatment drug for severe tardive dyskinesia (TD).
	(0, 10)	All-trans retinoic acid	focal myositis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3811	 [s1]All-trans retinoic acid[e1] induced [s2]focal myositis[e2]  synovitis, and mononeuritis.
	(0, 20)	All-trans retinoic acid	mononeuritis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3812	 [s1]All-trans retinoic acid[e1] induced focal myositis, synovitis, and [s2]mononeuritis[e2] 
	(0, 15)	All-trans retinoic acid	synovitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3813	 [s1]All-trans retinoic acid[e1] induced focal myositis, [s2]synovitis[e2]  and mononeuritis.
	(17, 37)	acute focal myositis	all-trans retinoic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3814	Here we report a patient with newly diagnosed acute promyelocytic leukemia who developed [s1]acute focal myositis[e1]  synovitis, and possible vasculitis, after receiving [s2]all-trans retinoic acid[e2] therapy.
	(28, 37)	possible vasculitis	all-trans retinoic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3815	Here we report a patient with newly diagnosed acute promyelocytic leukemia who developed acute focal myositis, synovitis, and [s1]possible vasculitis[e1]  after receiving [s2]all-trans retinoic acid[e2] therapy.
	(23, 37)	synovitis	all-trans retinoic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3816	Here we report a patient with newly diagnosed acute promyelocytic leukemia who developed acute focal myositis, [s1]synovitis[e1]  and possible vasculitis, after receiving [s2]all-trans retinoic acid[e2] therapy.
	(13, 20)	retinopathy	pegylated interferon	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3817	BACKGROUND: To assess the nature, incidence, and risk factors of [s1]retinopathy[e1] associated with [s2]pegylated interferon[e2] and ribavirin combination therapy in chronic hepatitis C patients.
	(13, 27)	retinopathy	ribavirin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3818	BACKGROUND: To assess the nature, incidence, and risk factors of [s1]retinopathy[e1] associated with pegylated interferon and [s2]ribavirin[e2] combination therapy in chronic hepatitis C patients.
	(9, 26)	irreversible decrease of visual acuity	pegylated interferon	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3819	CONCLUSION: Significant ocular complications such as an [s1]irreversible decrease of visual acuity[e1] may develop in patients treated with [s2]pegylated interferon[e2] 
	(3, 26)	ocular complications	pegylated interferon	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3820	CONCLUSION: Significant [s1]ocular complications[e1] such as an irreversible decrease of visual acuity may develop in patients treated with [s2]pegylated interferon[e2] 
	(0, 14)	Retinopathy	pegylated interferon	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3821	 [s1]Retinopathy[e1] in hepatitis C patients due to combination therapy with [s2]pegylated interferon[e2] and ribavirin.
	(0, 21)	Retinopathy	ribavirin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3822	 [s1]Retinopathy[e1] in hepatitis C patients due to combination therapy with pegylated interferon and [s2]ribavirin[e2] 
	(9, 15)	carboplatin	hypersensitivity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3823	Administration of cisplatin in three patients with [s1]carboplatin[e1]  [s2]hypersensitivity[e2]  is skin testing useful?
	(0, 7)	Hypersensitivity	carboplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3824	 [s1]Hypersensitivity[e1] to [s2]carboplatin[e2] has been reported in up to 44% of patients receiving this antineoplastic agent, usually occurring after several courses of treatment.
	(15, 35)	carboplatin	severe hypersensitivity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3825	Prick tests and intradermal tests with a series of dilutions of [s1]carboplatin[e1] and cisplatin were performed on three patients who had exhibited medium and [s2]severe hypersensitivity[e2] reactions to carboplatin.
	(0, 35)	Aseptic meningitis	sulfamethoxazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3826	 [s1]Aseptic meningitis[e1]  hemolytic anemia, hepatitis, and orthostatic hypotension in a patient treated with trimethoprim [s2]sulfamethoxazole[e2] 
	(0, 31)	Aseptic meningitis	trimethoprim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3827	 [s1]Aseptic meningitis[e1]  hemolytic anemia, hepatitis, and orthostatic hypotension in a patient treated with [s2]trimethoprim[e2] sulfamethoxazole.
	(7, 35)	hemolytic anemia	sulfamethoxazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3828	Aseptic meningitis, [s1]hemolytic anemia[e1]  hepatitis, and orthostatic hypotension in a patient treated with trimethoprim [s2]sulfamethoxazole[e2] 
	(7, 31)	hemolytic anemia	trimethoprim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3829	Aseptic meningitis, [s1]hemolytic anemia[e1]  hepatitis, and orthostatic hypotension in a patient treated with [s2]trimethoprim[e2] sulfamethoxazole.
	(13, 35)	hepatitis	sulfamethoxazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3830	Aseptic meningitis, hemolytic anemia, [s1]hepatitis[e1]  and orthostatic hypotension in a patient treated with trimethoprim [s2]sulfamethoxazole[e2] 
	(13, 31)	hepatitis	trimethoprim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3831	Aseptic meningitis, hemolytic anemia, [s1]hepatitis[e1]  and orthostatic hypotension in a patient treated with [s2]trimethoprim[e2] sulfamethoxazole.
	(16, 36)	orthostatic hypotension	sulfamethoxazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3832	Aseptic meningitis, hemolytic anemia, hepatitis, and [s1]orthostatic hypotension[e1] in a patient treated with trimethoprim [s2]sulfamethoxazole[e2] 
	(16, 32)	orthostatic hypotension	trimethoprim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3833	Aseptic meningitis, hemolytic anemia, hepatitis, and [s1]orthostatic hypotension[e1] in a patient treated with [s2]trimethoprim[e2] sulfamethoxazole.
	(37, 52)	aseptic meningitis	sulfamethoxazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3834	CONCLUSION: A 37-year-old African- American man with G6PD deficiency developed hemolytic anemia, hepatitis, orthostatic hypotension, and [s1]aseptic meningitis[e1] simultaneously after using trimethoprim [s2]sulfamethoxazole[e2] 
	(37, 48)	aseptic meningitis	trimethoprim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3835	CONCLUSION: A 37-year-old African- American man with G6PD deficiency developed hemolytic anemia, hepatitis, orthostatic hypotension, and [s1]aseptic meningitis[e1] simultaneously after using [s2]trimethoprim[e2] sulfamethoxazole.
	(18, 51)	hemolytic anemia	sulfamethoxazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3836	CONCLUSION: A 37-year-old African- American man with G6PD deficiency developed [s1]hemolytic anemia[e1]  hepatitis, orthostatic hypotension, and aseptic meningitis simultaneously after using trimethoprim [s2]sulfamethoxazole[e2] 
	(18, 47)	hemolytic anemia	trimethoprim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3837	CONCLUSION: A 37-year-old African- American man with G6PD deficiency developed [s1]hemolytic anemia[e1]  hepatitis, orthostatic hypotension, and aseptic meningitis simultaneously after using [s2]trimethoprim[e2] sulfamethoxazole.
	(24, 51)	hepatitis	sulfamethoxazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3838	CONCLUSION: A 37-year-old African- American man with G6PD deficiency developed hemolytic anemia, [s1]hepatitis[e1]  orthostatic hypotension, and aseptic meningitis simultaneously after using trimethoprim [s2]sulfamethoxazole[e2] 
	(24, 47)	hepatitis	trimethoprim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3839	CONCLUSION: A 37-year-old African- American man with G6PD deficiency developed hemolytic anemia, [s1]hepatitis[e1]  orthostatic hypotension, and aseptic meningitis simultaneously after using [s2]trimethoprim[e2] sulfamethoxazole.
	(26, 51)	orthostatic hypotension	sulfamethoxazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3840	CONCLUSION: A 37-year-old African- American man with G6PD deficiency developed hemolytic anemia, hepatitis, [s1]orthostatic hypotension[e1]  and aseptic meningitis simultaneously after using trimethoprim [s2]sulfamethoxazole[e2] 
	(26, 47)	orthostatic hypotension	trimethoprim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3841	CONCLUSION: A 37-year-old African- American man with G6PD deficiency developed hemolytic anemia, hepatitis, [s1]orthostatic hypotension[e1]  and aseptic meningitis simultaneously after using [s2]trimethoprim[e2] sulfamethoxazole.
	(8, 36)	sulfamethoxazole	difficulty with speech	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3842	He had been taking trimethoprim [s1]sulfamethoxazole[e1] for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, [s2]difficulty with speech[e2]  weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted.
	(4, 36)	trimethoprim	difficulty with speech	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3843	He had been taking [s1]trimethoprim[e1] sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, [s2]difficulty with speech[e2]  weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted.
	(8, 33)	sulfamethoxazole	dizziness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3844	He had been taking trimethoprim [s1]sulfamethoxazole[e1] for approximately eight days when he revisited his family physician, complaining of headaches, [s2]dizziness[e2]  difficulty with speech, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted.
	(4, 33)	trimethoprim	dizziness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3845	He had been taking [s1]trimethoprim[e1] sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, [s2]dizziness[e2]  difficulty with speech, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted.
	(8, 30)	sulfamethoxazole	headaches	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3846	He had been taking trimethoprim [s1]sulfamethoxazole[e1] for approximately eight days when he revisited his family physician, complaining of [s2]headaches[e2]  dizziness, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted.
	(4, 30)	trimethoprim	headaches	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3847	He had been taking [s1]trimethoprim[e1] sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of [s2]headaches[e2]  dizziness, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted.
	(8, 43)	sulfamethoxazole	itching on the trunk	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3848	He had been taking trimethoprim [s1]sulfamethoxazole[e1] for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and [s2]itching on the trunk[e2] of his body and legs, where a maculopapular rash was noted.
	(4, 43)	trimethoprim	itching on the trunk	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3849	He had been taking [s1]trimethoprim[e1] sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and [s2]itching on the trunk[e2] of his body and legs, where a maculopapular rash was noted.
	(8, 56)	sulfamethoxazole	maculopapular rash	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3850	He had been taking trimethoprim [s1]sulfamethoxazole[e1] for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a [s2]maculopapular rash[e2] was noted.
	(4, 56)	trimethoprim	maculopapular rash	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3851	He had been taking [s1]trimethoprim[e1] sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a [s2]maculopapular rash[e2] was noted.
	(8, 40)	sulfamethoxazole	weakness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3852	He had been taking trimethoprim [s1]sulfamethoxazole[e1] for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, [s2]weakness[e2]  and itching on the trunk of his body and legs, where a maculopapular rash was noted.
	(4, 40)	trimethoprim	weakness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3853	He had been taking [s1]trimethoprim[e1] sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, [s2]weakness[e2]  and itching on the trunk of his body and legs, where a maculopapular rash was noted.
	(9, 43)	aseptic meningitis	sulfamethoxazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3854	PURPOSE: The case of a patient who developed [s1]aseptic meningitis[e1]  hemolytic anemia, hepatitis, and orthostatic hypotension simultaneously during treatment with trimethoprim [s2]sulfamethoxazole[e2] is described.
	(9, 39)	aseptic meningitis	trimethoprim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3855	PURPOSE: The case of a patient who developed [s1]aseptic meningitis[e1]  hemolytic anemia, hepatitis, and orthostatic hypotension simultaneously during treatment with [s2]trimethoprim[e2] sulfamethoxazole is described.
	(16, 43)	hemolytic anemia	sulfamethoxazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3856	PURPOSE: The case of a patient who developed aseptic meningitis, [s1]hemolytic anemia[e1]  hepatitis, and orthostatic hypotension simultaneously during treatment with trimethoprim [s2]sulfamethoxazole[e2] is described.
	(16, 39)	hemolytic anemia	trimethoprim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3857	PURPOSE: The case of a patient who developed aseptic meningitis, [s1]hemolytic anemia[e1]  hepatitis, and orthostatic hypotension simultaneously during treatment with [s2]trimethoprim[e2] sulfamethoxazole is described.
	(22, 43)	hepatitis	sulfamethoxazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3858	PURPOSE: The case of a patient who developed aseptic meningitis, hemolytic anemia, [s1]hepatitis[e1]  and orthostatic hypotension simultaneously during treatment with trimethoprim [s2]sulfamethoxazole[e2] is described.
	(22, 39)	hepatitis	trimethoprim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3859	PURPOSE: The case of a patient who developed aseptic meningitis, hemolytic anemia, [s1]hepatitis[e1]  and orthostatic hypotension simultaneously during treatment with [s2]trimethoprim[e2] sulfamethoxazole is described.
	(25, 44)	orthostatic hypotension	sulfamethoxazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3860	PURPOSE: The case of a patient who developed aseptic meningitis, hemolytic anemia, hepatitis, and [s1]orthostatic hypotension[e1] simultaneously during treatment with trimethoprim [s2]sulfamethoxazole[e2] is described.
	(25, 40)	orthostatic hypotension	trimethoprim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3861	PURPOSE: The case of a patient who developed aseptic meningitis, hemolytic anemia, hepatitis, and [s1]orthostatic hypotension[e1] simultaneously during treatment with [s2]trimethoprim[e2] sulfamethoxazole is described.
	(8, 25)	ritodrine	acute chest pain	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3862	A patient, while on intravenous [s1]ritodrine[e1] therapy for preterm labor, experienced an episode of [s2]acute chest pain[e2] 
	(17, 28)	ritodrine	type I second-degree AV block	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3863	The electrocardiogram (ECG), which was read as normal prior to [s1]ritodrine[e1] infusion, demonstrated a [s2]type I second-degree AV block[e2] which disappeared upon discontinuation of ritodrine therapy.
	(17, 28)	ritodrine	type I second-degree AV block	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3864	The electrocardiogram (ECG), which was read as normal prior to [s1]ritodrine[e1] infusion, demonstrated a [s2]type I second-degree AV block[e2] which disappeared upon discontinuation of ritodrine therapy.
	(7, 20)	Mobitz type I	ritodrine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3865	Type I second-degree AV block  [s1]Mobitz type I[e1]  Wenckebach AV block) during [s2]ritodrine[e2] therapy for preterm labor.
	(0, 22)	Type I second-degree AV block	ritodrine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3866	 [s1]Type I second-degree AV block[e1] (Mobitz type I, Wenckebach AV block) during [s2]ritodrine[e2] therapy for preterm labor.
	(13, 21)	Wenckebach AV block	ritodrine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3867	Type I second-degree AV block (Mobitz type I, [s1]Wenckebach AV block[e1]  during [s2]ritodrine[e2] therapy for preterm labor.
	(5, 13)	anthracycline	early chronic cardiomyopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3868	Exacerbation of [s1]anthracycline[e1] induced [s2]early chronic cardiomyopathy[e2] with ATRA: role of B-type natriuretic peptide as an indicator of cardiac dysfunction.
	(22, 46)	symptomatic cardiomyopathy	all-trans retinoic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3869	We report the case of a 14-year-old female with acute promyelocytic leukemia who developed [s1]symptomatic cardiomyopathy[e1] only 4 months into treatment with a combination of daunomycin and [s2]all-trans retinoic acid[e2] (ATRA).
	(22, 53)	symptomatic cardiomyopathy	ATRA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3870	We report the case of a 14-year-old female with acute promyelocytic leukemia who developed [s1]symptomatic cardiomyopathy[e1] only 4 months into treatment with a combination of daunomycin and all-trans retinoic acid  [s2]ATRA[e2] .
	(22, 41)	symptomatic cardiomyopathy	daunomycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3871	We report the case of a 14-year-old female with acute promyelocytic leukemia who developed [s1]symptomatic cardiomyopathy[e1] only 4 months into treatment with a combination of [s2]daunomycin[e2] and all-trans retinoic acid (ATRA).
	(14, 23)	KS	imatinib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3872	CONCLUSIONS: We present a case of a patient with CML who developed [s1]KS[e1] 12 months after starting treatment with [s2]imatinib[e2] 400 mg/d.
	(2, 33)	Kaposi's sarcoma	rituximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3873	Flare of [s1]Kaposi's sarcoma[e1] (KS) is well described in immunosuppressed patients treated with corticosteroids and [s2]rituximab[e2]  but has not yet been reported during treatment with imatinib.
	(10, 31)	KS	rituximab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3874	Flare of Kaposi's sarcoma  [s1]KS[e1]  is well described in immunosuppressed patients treated with corticosteroids and [s2]rituximab[e2]  but has not yet been reported during treatment with imatinib.
	(0, 15)	Kaposi's sarcoma	imatinib mesylate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3875	 [s1]Kaposi's sarcoma[e1] in a patient treated with [s2]imatinib mesylate[e2] for chronic myeloid leukemia.
	(7, 22)	cutaneous KS lesions	imatinib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3876	OBJECTIVE: We report a case of [s1]cutaneous KS lesions[e1] in a patient affected by CML treated with [s2]imatinib[e2] 
	(0, 20)	Bulbar	cytosine arabinoside	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3877	 [s1]Bulbar[e1] and pseudobulbar palsy complicating therapy with high-dose [s2]cytosine arabinoside[e2] in children with leukemia.
	(3, 20)	pseudobulbar palsy	cytosine arabinoside	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3878	Bulbar and [s1]pseudobulbar palsy[e1] complicating therapy with high-dose [s2]cytosine arabinoside[e2] in children with leukemia.
	(0, 25)	Interferon	neuropsychiatric symptoms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3879	 [s1]Interferon[e1] based treatments have the potential to decrease the burden of disease, but are complicated by side effects, including [s2]neuropsychiatric symptoms[e2] 
	(0, 6)	Interferon	psychosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3880	" [s1]Interferon[e1] induced [s2]psychosis[e2] as a ""psychiatric contraindication"" to hepatitis C treatment: a review and case-based discussion."
	(13, 25)	interferon	hallucinations	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3881	METHOD: The authors followed a patient with chronic HCV who received [s1]interferon[e1] and ribavirin and who developed [s2]hallucinations[e2] ultimately requiring psychiatric hospitalization.
	(17, 25)	ribavirin	hallucinations	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3882	METHOD: The authors followed a patient with chronic HCV who received interferon and [s1]ribavirin[e1] and who developed [s2]hallucinations[e2] ultimately requiring psychiatric hospitalization.
	(8, 14)	interferon	psychosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3883	OBJECTIVE: The authors described a case of [s1]interferon[e1] induced [s2]psychosis[e2] as a framework to review the literature and discuss the decision to pursue antiviral treatment in psychiatrically ill patients with hepatitis C.
	(2, 14)	Zidovudine	anaemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3884	CONCLUSION: [s1]Zidovudine[e1] is well a known cause of [s2]anaemia[e2] and thus should be used with caution in the initiation of antiretroviral therapy.
	(5, 12)	Zidovudine	anaemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3885	We report a case of [s1]Zidovudine[e1] induced [s2]anaemia[e2] and bone marrow aplasia in a patient infected with HIV.
	(5, 15)	Zidovudine	bone marrow aplasia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3886	We report a case of [s1]Zidovudine[e1] induced anaemia and [s2]bone marrow aplasia[e2] in a patient infected with HIV.
	(0, 7)	Zidovudine	pure red cell aplasia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3887	 [s1]Zidovudine[e1] induced [s2]pure red cell aplasia[e2]  a case report.
	(20, 57)	hydroxychloroquine	objective visual field loss	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3888	CONCLUSIONS: SD-OCT and AO detected abnormalities that correlate topographically with visual field loss from [s1]hydroxychloroquine[e1] toxicity as demonstrated by HVF 10-2 and may be useful in the detection of subclinical abnormalities that precede symptoms or [s2]objective visual field loss[e2] 
	(16, 22)	visual field loss	hydroxychloroquine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3889	CONCLUSIONS: SD-OCT and AO detected abnormalities that correlate topographically with [s1]visual field loss[e1] from [s2]hydroxychloroquine[e2] toxicity as demonstrated by HVF 10-2 and may be useful in the detection of subclinical abnormalities that precede symptoms or objective visual field loss.
	(26, 35)	hydroxychloroquine	retinal toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3890	PURPOSE: To describe spectral-domain optical coherence tomography (SD-OCT) and adaptive optics (AO) imaging in [s1]hydroxychloroquine[e1]  [s2]retinal toxicity[e2] 
	(14, 23)	hydroxychloroquine	retinal toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3891	Spectral-domain optical coherence tomography and adaptive optics may detect [s1]hydroxychloroquine[e1]  [s2]retinal toxicity[e2] before symptomatic vision loss.
	(1, 8)	trazodone	hypomanic symptoms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3892	Transient [s1]trazodone[e1] induced [s2]hypomanic symptoms[e2] occurred in three depressed patients.
	(0, 7)	Trazodone	transient hypomanic symptoms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3893	 [s1]Trazodone[e1] induced [s2]transient hypomanic symptoms[e2] and their management.
	(2, 18)	etanercept	severe heart failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3894	Introduction of [s1]etanercept[e1] was also clinically effective but followed by development of [s2]severe heart failure[e2] 
	(0, 11)	Reversible heart failure	etanercept	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3895	 [s1]Reversible heart failure[e1] in a patient receiving [s2]etanercept[e2] for ankylosing spondylitis.
	(1, 16)	methylephedrine	stroke	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3896	Combining [s1]methylephedrine[e1] and Chinese herbal drugs might carry a risk of [s2]stroke[e2] 
	(6, 25)	chronic nausea	morphine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3897	We describe a patient who experienced [s1]chronic nausea[e1] and an episode of confusion while treated with a small, stable dose of oral [s2]morphine[e2] in the setting of mild renal insufficiency.
	(12, 25)	confusion	morphine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3898	We describe a patient who experienced chronic nausea and an episode of [s1]confusion[e1] while treated with a small, stable dose of oral [s2]morphine[e2] in the setting of mild renal insufficiency.
	(9, 39)	lacosamide	ataxia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3899	Common adverse events (frequency 10%) of [s1]lacosamide[e1] doses up to 600 mg/day include nonspecific central nervous system effects (e.g., dizziness, [s2]ataxia[e2]  diplopia, and somnolence).
	(9, 42)	lacosamide	diplopia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3900	Common adverse events (frequency 10%) of [s1]lacosamide[e1] doses up to 600 mg/day include nonspecific central nervous system effects (e.g., dizziness, ataxia, [s2]diplopia[e2]  and somnolence).
	(9, 36)	lacosamide	dizziness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3901	Common adverse events (frequency 10%) of [s1]lacosamide[e1] doses up to 600 mg/day include nonspecific central nervous system effects (e.g., [s2]dizziness[e2]  ataxia, diplopia, and somnolence).
	(9, 47)	lacosamide	somnolence	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3902	Common adverse events (frequency 10%) of [s1]lacosamide[e1] doses up to 600 mg/day include nonspecific central nervous system effects (e.g., dizziness, ataxia, diplopia, and [s2]somnolence[e2] .
	(3, 24)	aseptic pleuropericarditis	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3903	A case of [s1]aseptic pleuropericarditis[e1] in a patient with chronic plaque psoriasis under [s2]methotrexate[e2] therapy.
	(0, 10)	Methotrexate	serositis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3904	 [s1]Methotrexate[e1] may rarely provoke [s2]serositis[e2]  even with low doses and after just a few weeks of therapy.
	(7, 17)	pleuropericarditis	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3905	We report here a rare case of [s1]pleuropericarditis[e1] due to [s2]methotrexate[e2] 
	(6, 11)	tremor	itraconazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3906	The authors report five cases of [s1]tremor[e1] related to [s2]itraconazole[e2] therapy, which occurred within 1-12 months of initiating treatment and resolved gradually following itraconazole withdrawal.
	(6, 11)	tremor	itraconazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3907	The authors report five cases of [s1]tremor[e1] related to [s2]itraconazole[e2] therapy, which occurred within 1-12 months of initiating treatment and resolved gradually following itraconazole withdrawal.
	(0, 12)	Tremor	itraconazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3908	 [s1]Tremor[e1]  a newly described adverse event with long-term [s2]itraconazole[e2] therapy.
	(0, 7)	Acute kidney injury	zonisamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3909	 [s1]Acute kidney injury[e1] caused by [s2]zonisamide[e2] induced hypersensitivity syndrome.
	(5, 12)	zonisamide	hypersensitivity syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3910	Acute kidney injury caused by [s1]zonisamide[e1] induced [s2]hypersensitivity syndrome[e2] 
	(0, 7)	Hypersensitivity	zonisamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3911	 [s1]Hypersensitivity[e1] to [s2]zonisamide[e2] was confirmed by the skin patch test.
	(9, 26)	zonisamide	acute kidney injury	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3912	The current report describes a man who was prescribed [s1]zonisamide[e1] for epilepsy and subsequently developed widespread skin rash, [s2]acute kidney injury[e2]  high-grade fever, eosinophilia, liver dysfunction, lymphadenopathy and an increase in antihuman herpesvirus-6 immunoglobulin G titer.
	(9, 51)	zonisamide	an increase in antihuman herpesvirus-6 immunoglobulin G titer	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3913	The current report describes a man who was prescribed [s1]zonisamide[e1] for epilepsy and subsequently developed widespread skin rash, acute kidney injury, high-grade fever, eosinophilia, liver dysfunction, lymphadenopathy and [s2]an increase in antihuman herpesvirus-6 immunoglobulin G titer[e2] 
	(9, 35)	zonisamide	eosinophilia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3914	The current report describes a man who was prescribed [s1]zonisamide[e1] for epilepsy and subsequently developed widespread skin rash, acute kidney injury, high-grade fever, [s2]eosinophilia[e2]  liver dysfunction, lymphadenopathy and an increase in antihuman herpesvirus-6 immunoglobulin G titer.
	(9, 30)	zonisamide	high-grade fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3915	The current report describes a man who was prescribed [s1]zonisamide[e1] for epilepsy and subsequently developed widespread skin rash, acute kidney injury, [s2]high-grade fever[e2]  eosinophilia, liver dysfunction, lymphadenopathy and an increase in antihuman herpesvirus-6 immunoglobulin G titer.
	(9, 41)	zonisamide	liver dysfunction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3916	The current report describes a man who was prescribed [s1]zonisamide[e1] for epilepsy and subsequently developed widespread skin rash, acute kidney injury, high-grade fever, eosinophilia, [s2]liver dysfunction[e2]  lymphadenopathy and an increase in antihuman herpesvirus-6 immunoglobulin G titer.
	(9, 44)	zonisamide	lymphadenopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3917	The current report describes a man who was prescribed [s1]zonisamide[e1] for epilepsy and subsequently developed widespread skin rash, acute kidney injury, high-grade fever, eosinophilia, liver dysfunction, [s2]lymphadenopathy[e2] and an increase in antihuman herpesvirus-6 immunoglobulin G titer.
	(9, 23)	zonisamide	skin rash	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3918	The current report describes a man who was prescribed [s1]zonisamide[e1] for epilepsy and subsequently developed widespread [s2]skin rash[e2]  acute kidney injury, high-grade fever, eosinophilia, liver dysfunction, lymphadenopathy and an increase in antihuman herpesvirus-6 immunoglobulin G titer.
	(6, 13)	acute kidney injury	zonisamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3919	This is the first report of [s1]acute kidney injury[e1] due to [s2]zonisamide[e2] induced DRESS/DIHS.
	(11, 19)	zonisamide	DIHS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3920	This is the first report of acute kidney injury due to [s1]zonisamide[e1] induced DRESS [s2]DIHS[e2] 
	(11, 18)	zonisamide	DRESS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3921	This is the first report of acute kidney injury due to [s1]zonisamide[e1] induced [s2]DRESS[e2] DIHS.
	(7, 50)	allergic contact dermatitis	bisabolol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3922	Only two case reports of adults with [s1]allergic contact dermatitis[e1] to this chemical exist in the literature, and we describe three more cases of children with recalcitrant atopic dermatitis found to have potential allergic contact dermatitis to [s2]bisabolol[e2]  a component of the Aquaphor emollient they were using to treat their atopic dermatitis.
	(3, 13)	acute renal failure	immunoglobulin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3923	Case report: [s1]acute renal failure[e1] after administering intravenous [s2]immunoglobulin[e2] 
	(5, 25)	acute renal failure	IVIG	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3924	The hospital course of the [s1]acute renal failure[e1] is presented with a review of the literature on cases of acute renal failure after [s2]IVIG[e2] 
	(31, 49)	azotemia	immunoglobulin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3925	We report the case of an 87-year-old white woman with myasthenia gravis who presented with nausea, shortness of breath, [s1]azotemia[e1]  and hyperkalemia shortly after completing a course of intravenous [s2]immunoglobulin[e2] (IVIG).
	(31, 55)	azotemia	IVIG	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3926	We report the case of an 87-year-old white woman with myasthenia gravis who presented with nausea, shortness of breath, [s1]azotemia[e1]  and hyperkalemia shortly after completing a course of intravenous immunoglobulin  [s2]IVIG[e2] .
	(36, 50)	hyperkalemia	immunoglobulin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3927	We report the case of an 87-year-old white woman with myasthenia gravis who presented with nausea, shortness of breath, azotemia, and [s1]hyperkalemia[e1] shortly after completing a course of intravenous [s2]immunoglobulin[e2] (IVIG).
	(36, 56)	hyperkalemia	IVIG	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3928	We report the case of an 87-year-old white woman with myasthenia gravis who presented with nausea, shortness of breath, azotemia, and [s1]hyperkalemia[e1] shortly after completing a course of intravenous immunoglobulin  [s2]IVIG[e2] .
	(24, 49)	nausea	immunoglobulin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3929	We report the case of an 87-year-old white woman with myasthenia gravis who presented with [s1]nausea[e1]  shortness of breath, azotemia, and hyperkalemia shortly after completing a course of intravenous [s2]immunoglobulin[e2] (IVIG).
	(24, 55)	nausea	IVIG	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3930	We report the case of an 87-year-old white woman with myasthenia gravis who presented with [s1]nausea[e1]  shortness of breath, azotemia, and hyperkalemia shortly after completing a course of intravenous immunoglobulin  [s2]IVIG[e2] .
	(26, 49)	shortness of breath	immunoglobulin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3931	We report the case of an 87-year-old white woman with myasthenia gravis who presented with nausea, [s1]shortness of breath[e1]  azotemia, and hyperkalemia shortly after completing a course of intravenous [s2]immunoglobulin[e2] (IVIG).
	(26, 55)	shortness of breath	IVIG	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3932	We report the case of an 87-year-old white woman with myasthenia gravis who presented with nausea, [s1]shortness of breath[e1]  azotemia, and hyperkalemia shortly after completing a course of intravenous immunoglobulin  [s2]IVIG[e2] .
	(5, 39)	lithium	cardiac toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3933	However, the use of [s1]lithium[e1] should be avoided with any patient who is purging, since it may exacerbate the loss of intracellular potassium, thereby increasing the risk of [s2]cardiac toxicity[e2] 
	(5, 28)	lithium	loss of intracellular potassium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3934	However, the use of [s1]lithium[e1] should be avoided with any patient who is purging, since it may exacerbate the [s2]loss of intracellular potassium[e2]  thereby increasing the risk of cardiac toxicity.
	(1, 8)	vancomycin	anaphylactic reaction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3935	Severe [s1]vancomycin[e1] induced [s2]anaphylactic reaction[e2] 
	(0, 67)	Vancomycin	anaphylactoid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3936	" [s1]Vancomycin[e1] is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an [s2]anaphylactoid[e2] reaction known as ""red man syndrome"" and anaphylaxis."
	(0, 81)	Vancomycin	anaphylaxis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3937	" [s1]Vancomycin[e1] is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as ""red man syndrome"" and [s2]anaphylaxis[e2] "
	(0, 53)	Vancomycin	blood disorders	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3938	" [s1]Vancomycin[e1] is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, [s2]blood disorders[e2]  and two types of hypersensitivity reactions - an anaphylactoid reaction known as ""red man syndrome"" and anaphylaxis."
	(0, 47)	Vancomycin	gastrointestinal disturbances	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3939	" [s1]Vancomycin[e1] is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, [s2]gastrointestinal disturbances[e2]  blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as ""red man syndrome"" and anaphylaxis."
	(0, 60)	Vancomycin	hypersensitivity reactions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3940	" [s1]Vancomycin[e1] is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of [s2]hypersensitivity reactions[e2] - an anaphylactoid reaction known as ""red man syndrome"" and anaphylaxis."
	(0, 35)	Vancomycin	nephrotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3941	" [s1]Vancomycin[e1] is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as [s2]nephrotoxicity[e2]  ototoxicity, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as ""red man syndrome"" and anaphylaxis."
	(0, 42)	Vancomycin	ototoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3942	" [s1]Vancomycin[e1] is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, [s2]ototoxicity[e2]  gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as ""red man syndrome"" and anaphylaxis."
	(0, 75)	Vancomycin	red man syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3943	 [s1]Vancomycin[e1] is widely used against methicillin-resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as  [s2]red man syndrome[e2]  and anaphylaxis.
	(15, 22)	vancomycin	anaphylactic reaction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3944	We report a case of a 23-year-old man who developed a [s1]vancomycin[e1] induced [s2]anaphylactic reaction[e2] in the treatment of methicillin-resistant Staphylococcus aureus infection.
	(4, 16)	pulmonary oedema	hexoprenaline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3945	Four patients in whom [s1]pulmonary oedema[e1] developed during tocolysis with [s2]hexoprenaline[e2] are described and the aetiological factors and pathogenesis of this potentially lethal complication discussed.
	(0, 7)	Pulmonary oedema	hexoprenaline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3946	 [s1]Pulmonary oedema[e1] after [s2]hexoprenaline[e2] administration in preterm labour.
	(0, 9)	Fatal interstitial lung disease	erlotinib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3947	 [s1]Fatal interstitial lung disease[e1] after [s2]erlotinib[e2] administration in a patient with radiation fibrosis.
	(11, 23)	ILD	erlotinib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3948	High-resolution computed tomography scan findings were consistent with [s1]ILD[e1]  which was sufficient to diagnose as [s2]erlotinib[e2] induced ILD.
	(3, 33)	gefitinib	ILD	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3949	INTRODUCTION: Although [s1]gefitinib[e1] used for the treatment of non-small-cell lung cancer is a well-known cause of interstitial lung disease  [s2]ILD[e2] , few case reports on erlotinib-induced ILD have been issued.
	(31, 40)	ILD	erlotinib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3950	INTRODUCTION: Although gefitinib used for the treatment of non-small-cell lung cancer is a well-known cause of interstitial lung disease  [s1]ILD[e1] , few case reports on [s2]erlotinib[e2] induced ILD have been issued.
	(3, 28)	gefitinib	interstitial lung disease	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3951	INTRODUCTION: Although [s1]gefitinib[e1] used for the treatment of non-small-cell lung cancer is a well-known cause of [s2]interstitial lung disease[e2] (ILD), few case reports on erlotinib-induced ILD have been issued.
	(9, 16)	erlotinib	ILD	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3952	RESULTS: We recently experienced a case of fatal [s1]erlotinib[e1] induced [s2]ILD[e2]  diagnosed based on clinical and radiologic findings, which occurred in a patient with radiation fibrosis.
	(24, 31)	ILD	erlotinib	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3953	This case had radiation fibrosis, so we suggest that radiation fibrosis may be another contributor of the occurrence of [s1]ILD[e1] in patients taking [s2]erlotinib[e2] 
	(3, 21)	coronary artery vasospasm	epinephrine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3954	One patient suffered [s1]coronary artery vasospasm[e1]  attributed to the use of topical 1:1000 [s2]epinephrine[e2] during surgery.
	(4, 25)	transient intraoperative hypertension	epinephrine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3955	The other patient developed [s1]transient intraoperative hypertension[e1] immediately after inadvertent submucosal injection of concentrated [s2]epinephrine[e2] 
	(0, 14)	Cisplatin	SIADH	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3956	 [s1]Cisplatin[e1] induced syndrome of inappropriate antidiuretic hormone  [s2]SIADH[e2]  in a patient with neuroendocrine tumor of the cervix: a case report and review of the literature.
	(0, 6)	Cisplatin	syndrome of inappropriate antidiuretic hormone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3957	 [s1]Cisplatin[e1] induced [s2]syndrome of inappropriate antidiuretic hormone[e2] (SIADH) in a patient with neuroendocrine tumor of the cervix: a case report and review of the literature.
	(14, 21)	SIADH	cisplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3958	We present a case of the syndrome of inappropriate antidiuretic hormone  [s1]SIADH[e1]  secondary to [s2]cisplatin[e2] therapy in a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix.
	(6, 23)	syndrome of inappropriate antidiuretic hormone	cisplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3959	We present a case of the [s1]syndrome of inappropriate antidiuretic hormone[e1] (SIADH) secondary to [s2]cisplatin[e2] therapy in a patient with advanced-stage large cell neuroendocrine carcinoma of the cervix.
	(18, 27)	thrombocytosis	enoxaparin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3960	However, to our knowledge, in newborns there have been no reported cases to date of [s1]thrombocytosis[e1] induced by [s2]enoxaparin[e2] 
	(0, 9)	Thrombocytosis	enoxaparin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3961	 [s1]Thrombocytosis[e1] associated with [s2]enoxaparin[e2]  A very rare cause in newborns.
	(0, 9)	Thrombocytosis	enoxaparin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3962	 [s1]Thrombocytosis[e1] induced by [s2]enoxaparin[e2] has been reported as a rare adverse effect of this medication in adults.
	(16, 38)	adalimumab	extreme hyperferritinemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3963	OBJECTIVE: 1) To describe a patient with rheumatoid arthritis receiving [s1]adalimumab[e1] who developed fever, pancytopenia, splenomegaly, and [s2]extreme hyperferritinemia[e2] 
	(16, 24)	adalimumab	fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3964	OBJECTIVE: 1) To describe a patient with rheumatoid arthritis receiving [s1]adalimumab[e1] who developed [s2]fever[e2]  pancytopenia, splenomegaly, and extreme hyperferritinemia.
	(16, 26)	adalimumab	pancytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3965	OBJECTIVE: 1) To describe a patient with rheumatoid arthritis receiving [s1]adalimumab[e1] who developed fever, [s2]pancytopenia[e2]  splenomegaly, and extreme hyperferritinemia.
	(16, 31)	adalimumab	splenomegaly	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3966	OBJECTIVE: 1) To describe a patient with rheumatoid arthritis receiving [s1]adalimumab[e1] who developed fever, pancytopenia, [s2]splenomegaly[e2]  and extreme hyperferritinemia.
	(8, 28)	macrophagic activation syndrome	adalimumab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3967	Visceral leishmaniasis and [s1]macrophagic activation syndrome[e1] in a patient with rheumatoid arthritis under treatment with [s2]adalimumab[e2] 
	(0, 28)	Visceral leishmaniasis	adalimumab	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3968	 [s1]Visceral leishmaniasis[e1] and macrophagic activation syndrome in a patient with rheumatoid arthritis under treatment with [s2]adalimumab[e2] 
	(13, 35)	epiglottitis	prochlorperazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3969	This case presentation is of a patient who had the clinical appearance of [s1]epiglottitis[e1]  but actually had an oro-pharyngeal dystonic reaction to [s2]prochlorperazine[e2] 
	(23, 36)	oro-pharyngeal dystonic reaction	prochlorperazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3970	This case presentation is of a patient who had the clinical appearance of epiglottitis, but actually had an [s1]oro-pharyngeal dystonic reaction[e1] to [s2]prochlorperazine[e2] 
	(25, 34)	hydroxychloroquine	retinopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3971	Normalization of generalized retinal function and progression of maculopathy after cessation of therapy in a case of severe [s1]hydroxychloroquine[e1]  [s2]retinopathy[e2] with 19 years follow-up.
	(10, 25)	TMP-SMX	acute liver toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3972	After other potential causes of liver toxicity were excluded, [s1]TMP-SMX[e1] was determined to be the cause of his [s2]acute liver toxicity[e2] 
	(5, 12)	liver toxicity	TMP-SMX	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3973	After other potential causes of [s1]liver toxicity[e1] were excluded, [s2]TMP-SMX[e2] was determined to be the cause of his acute liver toxicity.
	(15, 24)	cutaneous skin eruptions	TMP-SMX	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3974	Although this combination agent has been associated with a hypersensitivity syndrome involving [s1]cutaneous skin eruptions[e1]  pediatric cases of [s2]TMP-SMX[e2] induced hepatotoxicity are rare.
	(23, 31)	TMP-SMX	hepatotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3975	Although this combination agent has been associated with a hypersensitivity syndrome involving cutaneous skin eruptions, pediatric cases of [s1]TMP-SMX[e1] induced [s2]hepatotoxicity[e2] are rare.
	(9, 25)	hypersensitivity syndrome	TMP-SMX	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3976	Although this combination agent has been associated with a [s1]hypersensitivity syndrome[e1] involving cutaneous skin eruptions, pediatric cases of [s2]TMP-SMX[e2] induced hepatotoxicity are rare.
	(6, 28)	TMP-SMX	immunemediated hypersensitivity reaction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3977	Due to the increasing use of [s1]TMP-SMX[e1] in children, clinicians should be aware of this potentially life-threatening, [s2]immunemediated hypersensitivity reaction[e2] 
	(0, 15)	Trimethoprim-sulfamethoxazole	hepatotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3978	 [s1]Trimethoprim-sulfamethoxazole[e1] induced [s2]hepatotoxicity[e2] in a pediatric patient.
	(27, 37)	hepatotoxicity	TMP-SMX	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3979	Use of the Naranjo adverse drug reaction probability scale indicated a probable relationship (score of 5) between the patient's development of [s1]hepatotoxicity[e1] and the [s2]TMP-SMX[e2] therapy.
	(21, 30)	soft tissue infection	TMP-SMX	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3980	We describe a relatively healthy, 9-year-old boy who developed a CA-MRSA skin and [s1]soft tissue infection[e1] and was treated with [s2]TMP-SMX[e2] 
	(0, 9)	Amiodarone	thyrotoxicosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3981	 [s1]Amiodarone[e1] was discontinued, and [s2]thyrotoxicosis[e2] gradually abated.
	(0, 16)	Goiter	amiodarone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3982	 [s1]Goiter[e1] and hypothyroidism during re-treatment with [s2]amiodarone[e2] in a patient who previously experienced amiodarone-induced thyrotoxicosis.
	(3, 16)	hypothyroidism	amiodarone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3983	Goiter and [s1]hypothyroidism[e1] during re-treatment with [s2]amiodarone[e2] in a patient who previously experienced amiodarone-induced thyrotoxicosis.
	(14, 30)	amiodarone	thyrotoxicosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3984	Goiter and hypothyroidism during re-treatment with [s1]amiodarone[e1] in a patient who previously experienced amiodarone-induced [s2]thyrotoxicosis[e2] 
	(2, 27)	Aphthous stomatitis	sirolimus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3985	BACKGROUND: [s1]Aphthous stomatitis[e1]  a common mucocutaneous disorder, is a well accepted complication of [s2]sirolimus[e2] therapy.
	(20, 48)	worsening of chronic aphthous ulcers	sirolimus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3986	CASE: We present an 11-year old male with Budd-Chiari syndrome who experienced profound [s1]worsening of chronic aphthous ulcers[e1] after immunosuppressive therapy was changed from tacrolimus to [s2]sirolimus[e2] 
	(20, 43)	worsening of chronic aphthous ulcers	tacrolimus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3987	CASE: We present an 11-year old male with Budd-Chiari syndrome who experienced profound [s1]worsening of chronic aphthous ulcers[e1] after immunosuppressive therapy was changed from [s2]tacrolimus[e2] to sirolimus.
	(0, 14)	Severe aphthous stomatitis	calcineurin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3988	 [s1]Severe aphthous stomatitis[e1] associated with oral [s2]calcineurin[e2] and mTOR inhibitors.
	(8, 104)	MP	transient renal failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3989	These findings mean that the effect of the [s1]MP[e1] pulse therapy on renal function depends on the clinical state of the patient and that renal deterioration after the pulse therapy may be more marked in patients who are more nephrotic and more impaired in renal function and suggest that increasing sodium and water retention during an MP therapy and the associated renal interstitial edema, proposed as one of the mechanisms of acute renal failure occurring in patients with minimal-change nephrotic syndrome, may be responsible for the MP-induced [s2]transient renal failure[e2] 
	(26, 30)	MP	transient renal failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3990	Three nephrotic patients who had reduced renal function and active renal disease with progressive deterioration of renal function prior to the use of [s1]MP[e1] developed [s2]transient renal failure[e2] following an MP pulse therapy.
	(26, 30)	MP	transient renal failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3991	Three nephrotic patients who had reduced renal function and active renal disease with progressive deterioration of renal function prior to the use of [s1]MP[e1] developed [s2]transient renal failure[e2] following an MP pulse therapy.
	(29, 41)	severe cholestasis	azathioprine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3992	A 67-year-old patient, with primary polymyositis and without previous evidence of liver disease, developed clinical and biochemical features of [s1]severe cholestasis[e1] 3 months after initiation of [s2]azathioprine[e2] therapy.
	(14, 21)	azathioprine	cholestasis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3993	It is believed that this is the first reported case of reversible [s1]azathioprine[e1] induced [s2]cholestasis[e2] associated with histological evidence of bile duct injury.
	(8, 14)	bile duct injury	azathioprine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3994	Reversible cholestasis with [s1]bile duct injury[e1] following [s2]azathioprine[e2] therapy.
	(3, 14)	cholestasis	azathioprine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3995	Reversible [s1]cholestasis[e1] with bile duct injury following [s2]azathioprine[e2] therapy.
	(8, 18)	acute encephalopathy	calcium hopantenate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3996	A case of the Rett syndrome with [s1]acute encephalopathy[e1] induced during [s2]calcium hopantenate[e2] treatment.
	(11, 22)	acute encephalopathy	calcium hopantenate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3997	We report a girl with the Rett syndrome who had [s1]acute encephalopathy[e1] probably induced by [s2]calcium hopantenate[e2] (HOPA).
	(11, 26)	acute encephalopathy	HOPA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3998	We report a girl with the Rett syndrome who had [s1]acute encephalopathy[e1] probably induced by calcium hopantenate  [s2]HOPA[e2] .
	(0, 8)	Persistent light reactivity	quinine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	3999	 [s1]Persistent light reactivity[e1] from systemic [s2]quinine[e2] 
	(1, 16)	photosensitivity	quinine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4000	The [s1]photosensitivity[e1] is still present 3 years after the withdrawal of [s2]quinine[e2] 
	(9, 35)	hematologic malignancy	doxorubicin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4001	Two cases are reported of patients who developed a [s1]hematologic malignancy[e1] several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, [s2]doxorubicin[e2]  and mitomycin C.
	(9, 29)	hematologic malignancy	etoglucid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4002	Two cases are reported of patients who developed a [s1]hematologic malignancy[e1] several years after intravesical chemotherapy of superficial bladder cancer with [s2]etoglucid[e2]  doxorubicin, and mitomycin C.
	(9, 43)	hematologic malignancy	mitomycin C	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4003	Two cases are reported of patients who developed a [s1]hematologic malignancy[e1] several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and [s2]mitomycin C[e2] 
	(15, 31)	circumferential subglottic stenosis	cyclophosphamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4004	A patient with Wegener's granulomatosis rapidly developed a [s1]circumferential subglottic stenosis[e1] while on a [s2]cyclophosphamide[e2] regimen that had caused resolution of systemic symptoms and pulmonary infiltrates.
	(0, 21)	Subglottic stenosis	cyclophosphamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4005	 [s1]Subglottic stenosis[e1] in Wegener's granulomatosis: development during [s2]cyclophosphamide[e2] treatment with response to carbon dioxide laser therapy.
	(5, 26)	severe splenic hemorrhage and rupture	tPA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4006	A case is described of [s1]severe splenic hemorrhage and rupture[e1] which developed 3 h after completion of [s2]tPA[e2] infusion for suspected acute myocardial infarction.
	(0, 13)	Splenic hemorrhage	tissue plasminogen activator	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4007	 [s1]Splenic hemorrhage[e1]  a complication of [s2]tissue plasminogen activator[e2] treatment.
	(6, 36)	tissue plasminogen activator	gastrointestinal or intracranial bleeding	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4008	Thrombolytic therapy with [s1]tissue plasminogen activator[e1] (tPA) for acute myocardial infarction may result in major bleeding complications such as [s2]gastrointestinal or intracranial bleeding[e2] 
	(14, 34)	tPA	gastrointestinal or intracranial bleeding	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4009	Thrombolytic therapy with tissue plasminogen activator  [s1]tPA[e1]  for acute myocardial infarction may result in major bleeding complications such as [s2]gastrointestinal or intracranial bleeding[e2] 
	(3, 10)	severe acute hepatitis	cyproterone acetate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4010	A case of [s1]severe acute hepatitis[e1] caused by [s2]cyproterone acetate[e2] in a 71 year old man with prostatic carcinoma is reported with a review of the literature on hepatic reactions to this drug.
	(14, 29)	cyproterone acetate	abnormal liver function tests	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4011	Monitoring of liver function tests should be mandatory in patients receiving high doses of [s1]cyproterone acetate[e1]  the drug should be withdrawn immediately if [s2]abnormal liver function tests[e2] are found.
	(0, 6)	Severe hepatitis	cyproterone acetate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4012	 [s1]Severe hepatitis[e1] caused by [s2]cyproterone acetate[e2] 
	(11, 24)	fixed drug eruption	iothalamate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4013	A unique case of a transient, nonpigmenting [s1]fixed drug eruption[e1] caused by the radiopaque contrast medium [s2]iothalamate[e2] is reported.
	(12, 22)	erythema multiforme	griseofulvin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4014	One patient with systemic lupus erythematosus developed [s1]erythema multiforme[e1] after taking [s2]griseofulvin[e2] 
	(0, 17)	Aminoglutethimide	rash	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4015	 [s1]Aminoglutethimide[e1] was discontinued until completion of radiotherapy, and the [s2]rash[e2] resolved.
	(10, 15)	skin toxicity	aminoglutethimide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4016	Concomitant irradiation apparently enhanced the [s1]skin toxicity[e1] of [s2]aminoglutethimide[e2] or possibly aminoglutethimide had a radiosensitizing role in this patient.
	(9, 16)	aminoglutethimide	skin toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4017	We report a case of radiotherapy-enhanced [s1]aminoglutethimide[e1]  [s2]skin toxicity[e2] in a patient with metastatic breast cancer.
	(8, 22)	tamoxifen	carcinoma of the corpus uteri	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4018	Data have been published regarding the possibility that [s1]tamoxifen[e1] may be responsible for the subsequent development of [s2]carcinoma of the corpus uteri[e2] in these patients.
	(15, 32)	tamoxifen	endometrial carcinoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4019	The authors intend to carry out a case-control study on patients treated with [s1]tamoxifen[e1] for breast carcinoma to reveal the possible presence of [s2]endometrial carcinoma[e2] 
	(0, 7)	Disulfiram	hepatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4020	 [s1]Disulfiram[e1] induced [s2]hepatitis[e2] 
	(15, 26)	eosinophilia	disulfiram	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4021	Our patient had headache, mild fever, nausea, vomiting, rash, and [s1]eosinophilia[e1] after 3 weeks of [s2]disulfiram[e2] therapy.
	(3, 25)	headache	disulfiram	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4022	Our patient had [s1]headache[e1]  mild fever, nausea, vomiting, rash, and eosinophilia after 3 weeks of [s2]disulfiram[e2] therapy.
	(5, 25)	mild fever	disulfiram	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4023	Our patient had headache, [s1]mild fever[e1]  nausea, vomiting, rash, and eosinophilia after 3 weeks of [s2]disulfiram[e2] therapy.
	(8, 25)	nausea	disulfiram	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4024	Our patient had headache, mild fever, [s1]nausea[e1]  vomiting, rash, and eosinophilia after 3 weeks of [s2]disulfiram[e2] therapy.
	(12, 25)	rash	disulfiram	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4025	Our patient had headache, mild fever, nausea, vomiting, [s1]rash[e1]  and eosinophilia after 3 weeks of [s2]disulfiram[e2] therapy.
	(10, 25)	vomiting	disulfiram	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4026	Our patient had headache, mild fever, nausea, [s1]vomiting[e1]  rash, and eosinophilia after 3 weeks of [s2]disulfiram[e2] therapy.
	(5, 12)	disulfiram	hepatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4027	We reported a case of [s1]disulfiram[e1] induced [s2]hepatitis[e2] with unique clinical features and compared our case with others in the literature.
	(3, 58)	leukoencephalopathy	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4028	An episode of [s1]leukoencephalopathy[e1] is reported in a 13-year-old girl who, after standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4-hour infusion of 500 mg/m2 [s2]methotrexate[e2] and 12 mg intrathecal methotrexate.
	(3, 58)	leukoencephalopathy	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4029	An episode of [s1]leukoencephalopathy[e1] is reported in a 13-year-old girl who, after standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4-hour infusion of 500 mg/m2 [s2]methotrexate[e2] and 12 mg intrathecal methotrexate.
	(0, 8)	Methotrexate	leukoencephalopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4030	 [s1]Methotrexate[e1] induced [s2]leukoencephalopathy[e2] is treatable with high-dose folinic acid: a case report and analysis of the literature.
	(1, 7)	heparin	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4031	Severe [s1]heparin[e1] associated [s2]thrombocytopenia[e2] is a rare complication of heparin therapy.
	(1, 7)	heparin	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4032	Severe [s1]heparin[e1] associated [s2]thrombocytopenia[e2] is a rare complication of heparin therapy.
	(6, 12)	heparin	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4033	We report a patient who developed [s1]heparin[e1] associated [s2]thrombocytopenia[e2] during continuous arteriovenous haemofiltration and discuss its implications and alternative anticoagulant treatment.
	(1, 5)	aluminum toxicity	alum	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4034	Acute [s1]aluminum toxicity[e1]  [s2]alum[e2] num toxicity after continuous intravesical alum irrigation for hemorrhagic cystitis.
	(7, 34)	cardiomyopathy	aluminum	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4035	An encephalopathy and [s1]cardiomyopathy[e1] developed in a seventeen-year-old girl with chemotherapy-induced renal failure while receiving an intravesical [s2]aluminum[e2] infusion for hemorrhagic cystitis.
	(1, 34)	encephalopathy	aluminum	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4036	An [s1]encephalopathy[e1] and cardiomyopathy developed in a seventeen-year-old girl with chemotherapy-induced renal failure while receiving an intravesical [s2]aluminum[e2] infusion for hemorrhagic cystitis.
	(29, 55)	hemolytic-uremic syndrome	bleomycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4037	A 62-year-old woman who was being treated for squamous cell carcinoma of the head and neck developed a chemotherapy-related [s1]hemolytic-uremic syndrome[e1] during the second cycle of neoadjuvant chemotherapy consisting of cisplatin, [s2]bleomycin[e2]  and methotrexate.
	(29, 51)	hemolytic-uremic syndrome	cisplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4038	A 62-year-old woman who was being treated for squamous cell carcinoma of the head and neck developed a chemotherapy-related [s1]hemolytic-uremic syndrome[e1] during the second cycle of neoadjuvant chemotherapy consisting of [s2]cisplatin[e2]  bleomycin, and methotrexate.
	(29, 61)	hemolytic-uremic syndrome	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4039	A 62-year-old woman who was being treated for squamous cell carcinoma of the head and neck developed a chemotherapy-related [s1]hemolytic-uremic syndrome[e1] during the second cycle of neoadjuvant chemotherapy consisting of cisplatin, bleomycin, and [s2]methotrexate[e2] 
	(19, 28)	psychiatric symptoms	lidocaine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4040	Awareness of this route of intoxication might be important in patients in whom neurologic or [s1]psychiatric symptoms[e1] develop while large amounts of [s2]lidocaine[e2] cream are being used.
	(0, 7)	Nitrendipine	gingival hyperplasia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4041	 [s1]Nitrendipine[e1] induced [s2]gingival hyperplasia[e2] 
	(0, 25)	Nitrendipine	gingival hyperplasia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4042	 [s1]Nitrendipine[e1] is an experimental calcium channel blocking agent that also appears to cause the side effect of drug-induced [s2]gingival hyperplasia[e2] 
	(15, 22)	sulfonamide	injury to the urinary tract	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4043	"Physicians using this ""new"" drug must be aware of the potential danger of [s1]sulfonamide[e1] induced [s2]injury to the urinary tract[e2] "
	(0, 6)	Sulfadiazine	crystalluria	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4044	 [s1]Sulfadiazine[e1]  [s2]crystalluria[e2] revisited.
	(5, 12)	sulfadiazine	crystalluria	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4045	We describe two cases of [s1]sulfadiazine[e1] induced [s2]crystalluria[e2] and renal failure in patients with acquired immunodeficiency syndrome, review the pertinent literature, and discuss the pathogenesis.
	(5, 16)	sulfadiazine	renal failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4046	We describe two cases of [s1]sulfadiazine[e1] induced crystalluria and [s2]renal failure[e2] in patients with acquired immunodeficiency syndrome, review the pertinent literature, and discuss the pathogenesis.
	(0, 14)	Glaucoma	5-fluorouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4047	 [s1]Glaucoma[e1] secondary to epithelial downgrowth and [s2]5-fluorouracil[e2] 
	(6, 38)	glaucoma	5-fluorouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4048	We report a case of secondary [s1]glaucoma[e1] caused by epithelial downgrowth in which filtration surgery was performed with adjunctive use of subconjunctival [s2]5-fluorouracil[e2] 
	(4, 12)	sucralfate	hypophosphatemic osteomalacia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4049	Antacid and [s1]sucralfate[e1] induced [s2]hypophosphatemic osteomalacia[e2]  a case report and review of the literature.
	(3, 18)	hypersensitivity reaction	gentamicin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4050	Because of a [s1]hypersensitivity reaction[e1]  initial therapy with penicillin G and [s2]gentamicin[e2] was stopped and substituted with cefazolin.
	(3, 13)	hypersensitivity reaction	penicillin G	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4051	Because of a [s1]hypersensitivity reaction[e1]  initial therapy with [s2]penicillin G[e2] and gentamicin was stopped and substituted with cefazolin.
	(16, 37)	brain damage	azathioprine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4052	Prenatal cytomegalovirus (CMV) infection associated with severe [s1]brain damage[e1] was detected in an infant whose mother had been treated with prednisolone and [s2]azathioprine[e2] for systemic lupus erythematosus (SLE).
	(16, 31)	brain damage	prednisolone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4053	Prenatal cytomegalovirus (CMV) infection associated with severe [s1]brain damage[e1] was detected in an infant whose mother had been treated with [s2]prednisolone[e2] and azathioprine for systemic lupus erythematosus (SLE).
	(0, 37)	Prenatal cytomegalovirus (CMV) infection	azathioprine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4054	 [s1]Prenatal cytomegalovirus (CMV) infection[e1] associated with severe brain damage was detected in an infant whose mother had been treated with prednisolone and [s2]azathioprine[e2] for systemic lupus erythematosus (SLE).
	(0, 31)	Prenatal cytomegalovirus (CMV) infection	prednisolone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4055	 [s1]Prenatal cytomegalovirus (CMV) infection[e1] associated with severe brain damage was detected in an infant whose mother had been treated with [s2]prednisolone[e2] and azathioprine for systemic lupus erythematosus (SLE).
	(0, 7)	Acute coronary events	cisplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4056	 [s1]Acute coronary events[e1] following [s2]cisplatin[e2] based chemotherapy.
	(16, 29)	acute coronary ischemia	cis-diamine-dichloroplatinum II	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4057	Six patients with no previous signs or symptoms suggestive of coronary artery disease developed [s1]acute coronary ischemia[e1] infarction shortly after [s2]cis-diamine-dichloroplatinum II[e2] (cisplatin) -based chemotherapy.
	(16, 42)	acute coronary ischemia	cisplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4058	Six patients with no previous signs or symptoms suggestive of coronary artery disease developed [s1]acute coronary ischemia[e1] infarction shortly after cis-diamine-dichloroplatinum II  [s2]cisplatin[e2]  -based chemotherapy.
	(22, 29)	infarction	cis-diamine-dichloroplatinum II	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4059	Six patients with no previous signs or symptoms suggestive of coronary artery disease developed acute coronary ischemia [s1]infarction[e1] shortly after [s2]cis-diamine-dichloroplatinum II[e2] (cisplatin) -based chemotherapy.
	(22, 42)	infarction	cisplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4060	Six patients with no previous signs or symptoms suggestive of coronary artery disease developed acute coronary ischemia [s1]infarction[e1] shortly after cis-diamine-dichloroplatinum II  [s2]cisplatin[e2]  -based chemotherapy.
	(0, 14)	Bowel perforation	chromic phosphate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4061	 [s1]Bowel perforation[e1] associated with intraperitoneal [s2]chromic phosphate[e2] instillation.
	(1, 17)	bowel injury	chromic phosphate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4062	Delayed [s1]bowel injury[e1] is an infrequently observed complication of [s2]chromic phosphate[e2] administration.
	(6, 24)	colon perforation	chromic phosphate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4063	This report presents a case of [s1]colon perforation[e1] which occurred 4 months after treatment with intraperitoneal [s2]chromic phosphate[e2] for stage IB ovarian papillary serous cystadenocarcinoma.
	(32, 41)	Ara-C	death	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4064	Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a progressive visual loss and loss of consciousness which worsened during subsequent [s1]Ara-C[e1] treatment and led to [s2]death[e2] within 3 weeks.
	(17, 41)	MTX	death	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4065	Despite a response of the meningeal tumor the patient developed in the third week of [s1]MTX[e1] treatment a progressive visual loss and loss of consciousness which worsened during subsequent Ara-C treatment and led to [s2]death[e2] within 3 weeks.
	(25, 34)	loss of consciousness	Ara-C	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4066	Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a progressive visual loss and [s1]loss of consciousness[e1] which worsened during subsequent [s2]Ara-C[e2] treatment and led to death within 3 weeks.
	(17, 27)	MTX	loss of consciousness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4067	Despite a response of the meningeal tumor the patient developed in the third week of [s1]MTX[e1] treatment a progressive visual loss and [s2]loss of consciousness[e2] which worsened during subsequent Ara-C treatment and led to death within 3 weeks.
	(21, 34)	progressive visual loss	Ara-C	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4068	Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a [s1]progressive visual loss[e1] and loss of consciousness which worsened during subsequent [s2]Ara-C[e2] treatment and led to death within 3 weeks.
	(17, 23)	MTX	progressive visual loss	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4069	Despite a response of the meningeal tumor the patient developed in the third week of [s1]MTX[e1] treatment a [s2]progressive visual loss[e2] and loss of consciousness which worsened during subsequent Ara-C treatment and led to death within 3 weeks.
	(21, 42)	pyridostigmine bromide	bromide intoxication	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4070	A 59-year-old woman with myasthenia gravis who received a large dose of [s1]pyridostigmine bromide[e1] developed postoperative psychosis and was diagnosed as having [s2]bromide intoxication[e2] 
	(21, 32)	pyridostigmine bromide	postoperative psychosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4071	A 59-year-old woman with myasthenia gravis who received a large dose of [s1]pyridostigmine bromide[e1] developed [s2]postoperative psychosis[e2] and was diagnosed as having bromide intoxication.
	(0, 9)	Bromide intoxication	pyridostigmine bromide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4072	 [s1]Bromide intoxication[e1] secondary to [s2]pyridostigmine bromide[e2] therapy.
	(11, 20)	bromide intoxication	pyridostigmine bromide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4073	To our knowledge , this is the first reported case of [s1]bromide intoxication[e1] due to [s2]pyridostigmine bromide[e2] administration.
	(0, 17)	Diazepam	withdrawal symptoms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4074	 [s1]Diazepam[e1] use by pregnant women can be associated with a later presentation of [s2]withdrawal symptoms[e2] in the neonate than that induced by the use of other drugs.
	(21, 29)	ileus	nimodipine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4075	We conclude that neurosurgeons and neurologists should be aware of calcium antagonist--related [s1]ileus[e1] in patients treated with [s2]nimodipine[e2] 
	(33, 47)	adynamic ileus	nimodipine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4076	We report on a patient with subarachnoid haemorrhage who developed an acute life-threatening pseudo-obstruction of the colon, a variant of [s1]adynamic ileus[e1]  while being treated with intravenous [s2]nimodipine[e2] 
	(23, 47)	pseudo-obstruction of the colon	nimodipine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4077	We report on a patient with subarachnoid haemorrhage who developed an acute life-threatening [s1]pseudo-obstruction of the colon[e1]  a variant of adynamic ileus, while being treated with intravenous [s2]nimodipine[e2] 
	(6, 12)	danazol	diabetes	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4078	After discontinuation of [s1]danazol[e1] the [s2]diabetes[e2] completely resolved.
	(0, 11)	Insulin-dependent diabetes mellitus	danazol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4079	 [s1]Insulin-dependent diabetes mellitus[e1] associated with [s2]danazol[e2] 
	(0, 20)	Insulin-dependent diabetes mellitus	danazol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4080	 [s1]Insulin-dependent diabetes mellitus[e1] developed in a young woman 8 weeks after the initiation of [s2]danazol[e2] for treatment of pelvic endometriosis.
	(8, 18)	glipizide	symptomatic hypoglycemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4081	An 83-year-old man receiving [s1]glipizide[e1] 10 mg bid developed [s2]symptomatic hypoglycemia[e2] within three days of adding trimethoprim/sulfamethoxazole (TMP/SMX) to his regimen.
	(16, 48)	symptomatic hypoglycemia	SMX	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4082	An 83-year-old man receiving glipizide 10 mg bid developed [s1]symptomatic hypoglycemia[e1] within three days of adding trimethoprim/sulfamethoxazole (TMP [s2]SMX[e2]  to his regimen.
	(16, 37)	symptomatic hypoglycemia	sulfamethoxazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4083	An 83-year-old man receiving glipizide 10 mg bid developed [s1]symptomatic hypoglycemia[e1] within three days of adding trimethoprim [s2]sulfamethoxazole[e2] (TMP/SMX) to his regimen.
	(16, 45)	symptomatic hypoglycemia	TMP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4084	An 83-year-old man receiving glipizide 10 mg bid developed [s1]symptomatic hypoglycemia[e1] within three days of adding trimethoprim/sulfamethoxazole  [s2]TMP[e2] SMX) to his regimen.
	(16, 33)	symptomatic hypoglycemia	trimethoprim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4085	An 83-year-old man receiving glipizide 10 mg bid developed [s1]symptomatic hypoglycemia[e1] within three days of adding [s2]trimethoprim[e2] sulfamethoxazole (TMP/SMX) to his regimen.
	(0, 15)	Symptomatic hypoglycemia	glipizide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4086	 [s1]Symptomatic hypoglycemia[e1] secondary to a [s2]glipizide[e2] trimethoprim/sulfamethoxazole drug interaction.
	(0, 24)	Symptomatic hypoglycemia	sulfamethoxazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4087	 [s1]Symptomatic hypoglycemia[e1] secondary to a glipizide-trimethoprim [s2]sulfamethoxazole[e2] drug interaction.
	(0, 19)	Symptomatic hypoglycemia	trimethoprim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4088	 [s1]Symptomatic hypoglycemia[e1] secondary to a glipizide [s2]trimethoprim[e2] sulfamethoxazole drug interaction.
	(29, 42)	anuria	ifosfamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4089	A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with [s1]anuria[e1]  the day after 5 g/m2 bolus [s2]ifosfamide[e2] 
	(21, 43)	irreversible lethal renal failure	ifosfamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4090	A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an [s1]irreversible lethal renal failure[e1] with anuria, the day after 5 g/m2 bolus [s2]ifosfamide[e2] 
	(0, 17)	Ifosfamide	tubulopathies	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4091	 [s1]Ifosfamide[e1] is a known nephrotoxic drug with demonstrated [s2]tubulopathies[e2] 
	(0, 11)	Lethal anuria	ifosfamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4092	 [s1]Lethal anuria[e1] complicating high dose [s2]ifosfamide[e2] chemotherapy in a breast cancer patient with an impaired renal function.
	(5, 14)	lethal anuria	ifosfamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4093	We strongly suspect that this [s1]lethal anuria[e1] was mainly due to [s2]ifosfamide[e2]  occurring in a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient hypotension.
	(0, 17)	Ciprofloxacin	interstitial nephritis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4094	 [s1]Ciprofloxacin[e1] is one drug that has been reported to cause [s2]interstitial nephritis[e2] 
	(0, 17)	Renal toxicities	ciprofloxacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4095	 [s1]Renal toxicities[e1] have been reported in less than one percent of the patients receiving [s2]ciprofloxacin[e2] therapy.
	(1, 10)	ciprofloxacin	interstitial nephritis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4096	Suspected [s1]ciprofloxacin[e1] induced [s2]interstitial nephritis[e2] 
	(7, 16)	ciprofloxacin	interstitial nephritis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4097	This article describes a patient with suspected [s1]ciprofloxacin[e1] induced [s2]interstitial nephritis[e2] 
	(16, 36)	doxorubicin	acute encephalopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4098	In a female with acute lymphoblastic leukemia, inadvertent [s1]doxorubicin[e1] administration intrathecally caused severe, life-threatening, [s2]acute encephalopathy[e2] with high-pressure hydrocephalus.
	(16, 43)	doxorubicin	high-pressure hydrocephalus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4099	In a female with acute lymphoblastic leukemia, inadvertent [s1]doxorubicin[e1] administration intrathecally caused severe, life-threatening, acute encephalopathy with [s2]high-pressure hydrocephalus[e2] 
	(0, 17)	Severe acute encephalopathy	doxorubicin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4100	 [s1]Severe acute encephalopathy[e1] following inadvertent intrathecal [s2]doxorubicin[e2] administration.
	(0, 7)	Phenobarbital	hepatotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4101	 [s1]Phenobarbital[e1]  [s2]hepatotoxicity[e2] in an 8-month-old infant.
	(0, 10)	Severe hepatotoxicity	phenobarbital	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4102	 [s1]Severe hepatotoxicity[e1] from [s2]phenobarbital[e2] occurred in an infant boy who had a complicated illness with chronic bilateral subdural hematomas and sepsis.
	(12, 23)	hepatocellular failure	phenobarbital	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4103	Skin rash began after 2 weeks of treatment, and signs of [s1]hepatocellular failure[e1] developed 3 weeks after [s2]phenobarbital[e2] had been started.
	(0, 23)	Skin rash	phenobarbital	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4104	 [s1]Skin rash[e1] began after 2 weeks of treatment, and signs of hepatocellular failure developed 3 weeks after [s2]phenobarbital[e2] had been started.
	(0, 7)	Atenolol	pseudolymphoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4105	 [s1]Atenolol[e1] induced [s2]pseudolymphoma[e2] 
	(1, 35)	tardive dyskinesia	sulpiride	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4106	Although [s1]tardive dyskinesia[e1] is a known adverse reaction of sustained treatment with traditional neuroleptic agents, it was only rarely reported in association with [s2]sulpiride[e2]  a selective D2-receptor antagonist.
	(0, 12)	Tardive dyskinesia	sulpiride	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4107	 [s1]Tardive dyskinesia[e1] induced by [s2]sulpiride[e2] 
	(4, 11)	sulpiride	tardive dyskinesia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4108	These cases indicate that [s1]sulpiride[e1] can cause [s2]tardive dyskinesia[e2] and that this drug should be administered with caution.
	(6, 19)	tardive dyskinesia	sulpiride	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4109	We describe six patients who developed [s1]tardive dyskinesia[e1] after treatment with [s2]sulpiride[e2] for depression or gastrointestinal symptoms.
	(14, 24)	ascites	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4110	A patient with seropositive rheumatoid arthritis developed [s1]ascites[e1] while taking weekly doses of [s2]methotrexate[e2] (MTX).
	(14, 29)	ascites	MTX	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4111	A patient with seropositive rheumatoid arthritis developed [s1]ascites[e1] while taking weekly doses of methotrexate  [s2]MTX[e2] .
	(2, 32)	bridging fibrosis	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4112	Hepatitis with [s1]bridging fibrosis[e1] and reversible hepatic insufficiency in a woman with rheumatoid arthritis taking [s2]methotrexate[e2] 
	(0, 32)	Hepatitis	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4113	 [s1]Hepatitis[e1] with bridging fibrosis and reversible hepatic insufficiency in a woman with rheumatoid arthritis taking [s2]methotrexate[e2] 
	(9, 32)	reversible hepatic insufficiency	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4114	Hepatitis with bridging fibrosis and [s1]reversible hepatic insufficiency[e1] in a woman with rheumatoid arthritis taking [s2]methotrexate[e2] 
	(9, 21)	hepatic decompensation	MTX	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4115	This is the third report of reversible [s1]hepatic decompensation[e1] associated with prolonged [s2]MTX[e2] therapy in patients with rheumatoid arthritis.
	(6, 11)	MTX	ascites	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4116	Upon discontinuation of [s1]MTX[e1]  her [s2]ascites[e2] resolved, and her arthritis became more active.
	(4, 41)	methotrexate	fatal rise in intracranial pressure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4117	Although high-dose [s1]methotrexate[e1] has been shown to be useful in the treatment of primary osteogenic sarcoma, the tumoricidal effects of therapy appear to have caused a [s2]fatal rise in intracranial pressure[e2] 
	(31, 48)	brainstem herniation	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4118	A patient with intracranial osteosarcoma that arose 16 years after radiation therapy for hereditary retinoblastoma developed fatal cerebral edema and [s1]brainstem herniation[e1] after she received a single dose of intravenous [s2]methotrexate[e2] 
	(26, 48)	fatal cerebral edema	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4119	A patient with intracranial osteosarcoma that arose 16 years after radiation therapy for hereditary retinoblastoma developed [s1]fatal cerebral edema[e1] and brainstem herniation after she received a single dose of intravenous [s2]methotrexate[e2] 
	(10, 22)	intracranial mass lesion	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4120	Transtentorial herniation caused by an [s1]intracranial mass lesion[e1] following high-dose [s2]methotrexate[e2] 
	(0, 22)	Transtentorial herniation	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4121	 [s1]Transtentorial herniation[e1] caused by an intracranial mass lesion following high-dose [s2]methotrexate[e2] 
	(0, 15)	Fever	acyclovir	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4122	 [s1]Fever[e1]  pulmonary infiltrates, and pleural effusion following [s2]acyclovir[e2] therapy for herpes zoster ophthalmicus.
	(7, 16)	pleural effusion	acyclovir	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4123	Fever, pulmonary infiltrates, and [s1]pleural effusion[e1] following [s2]acyclovir[e2] therapy for herpes zoster ophthalmicus.
	(2, 15)	pulmonary infiltrates	acyclovir	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4124	Fever, [s1]pulmonary infiltrates[e1]  and pleural effusion following [s2]acyclovir[e2] therapy for herpes zoster ophthalmicus.
	(9, 19)	acyclovir	fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4125	Following the institution of intravenous therapy with [s1]acyclovir[e1]  the patient developed [s2]fever[e2]  hemoptysis, and a pleural friction rub.
	(9, 21)	acyclovir	hemoptysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4126	Following the institution of intravenous therapy with [s1]acyclovir[e1]  the patient developed fever, [s2]hemoptysis[e2]  and a pleural friction rub.
	(9, 28)	acyclovir	pleural friction rub	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4127	Following the institution of intravenous therapy with [s1]acyclovir[e1]  the patient developed fever, hemoptysis, and a [s2]pleural friction rub[e2] 
	(1, 13)	fever	acyclovir	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4128	The [s1]fever[e1] abated promptly following discontinuation of [s2]acyclovir[e2]  and radiographic abnormalities resolved over ten days.
	(7, 24)	fever	acyclovir	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4129	To our knowledge, the syndrome of [s1]fever[e1]  pulmonary infiltrates, and pleural effusion following use of [s2]acyclovir[e2] has not been previously reported.
	(14, 25)	pleural effusion	acyclovir	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4130	To our knowledge, the syndrome of fever, pulmonary infiltrates, and [s1]pleural effusion[e1] following use of [s2]acyclovir[e2] has not been previously reported.
	(9, 24)	pulmonary infiltrates	acyclovir	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4131	To our knowledge, the syndrome of fever, [s1]pulmonary infiltrates[e1]  and pleural effusion following use of [s2]acyclovir[e2] has not been previously reported.
	(0, 5)	Quinine	hearing loss	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4132	 [s1]Quinine[e1] induced [s2]hearing loss[e2] 
	(0, 9)	Sensorineural hearing loss	quinine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4133	 [s1]Sensorineural hearing loss[e1] due to [s2]quinine[e2] therapy for malaria has frequently been mentioned in the literature but has not been a subject of research during the last decades.
	(22, 30)	reversible hearing loss	quinine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4134	The case of a 29-year-old man suffering from falciparum malaria disease who got a [s1]reversible hearing loss[e1] from [s2]quinine[e2] therapy is presented.
	(1, 8)	ototoxicity	quinine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4135	The [s1]ototoxicity[e1] of [s2]quinine[e2] can accurately be studied with ultrahigh frequency audiometry (up to 20 kHz).
	(0, 22)	Hemolytic uremic syndrome	bleomycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4136	 [s1]Hemolytic uremic syndrome[e1] in a patient on cis-platinum, vinblastine and [s2]bleomycin[e2] 
	(0, 13)	Hemolytic uremic syndrome	cis-platinum	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4137	 [s1]Hemolytic uremic syndrome[e1] in a patient on [s2]cis-platinum[e2]  vinblastine and bleomycin.
	(0, 17)	Hemolytic uremic syndrome	vinblastine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4138	 [s1]Hemolytic uremic syndrome[e1] in a patient on cis-platinum, [s2]vinblastine[e2] and bleomycin.
	(12, 21)	acute pneumonitis	bleomycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4139	A case of a 53-year-old man who developed [s1]acute pneumonitis[e1] after [s2]bleomycin[e2] and moderate oxygen administration is presented.
	(12, 27)	acute pneumonitis	oxygen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4140	A case of a 53-year-old man who developed [s1]acute pneumonitis[e1] after bleomycin and moderate [s2]oxygen[e2] administration is presented.
	(5, 15)	bleomycin	pulmonary damage	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4141	Autopsy findings were consistent with [s1]bleomycin[e1] and oxygen-induced [s2]pulmonary damage[e2] 
	(10, 14)	oxygen	pulmonary damage	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4142	Autopsy findings were consistent with bleomycin and [s1]oxygen[e1] induced [s2]pulmonary damage[e2] 
	(0, 6)	Bleomycin	pneumonitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4143	 [s1]Bleomycin[e1]  [s2]pneumonitis[e2] potentiated by oxygen administration.
	(4, 11)	bleomycin	pulmonary toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4144	Oxygen potentiation of [s1]bleomycin[e1] induced [s2]pulmonary toxicity[e2] is discussed.
	(0, 12)	Oxygen	pulmonary toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4145	 [s1]Oxygen[e1] potentiation of bleomycin-induced [s2]pulmonary toxicity[e2] is discussed.
	(12, 34)	incessant orthodromic atrioventricular tachycardia	procainamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4146	A patient with the Wolff-Parkinson-White syndrome presented with [s1]incessant orthodromic atrioventricular tachycardia[e1] following initiation of [s2]procainamide[e2] therapy.
	(16, 42)	tachycardia	procainamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4147	Escape atrial complexes, which occurred following junctional premature complexes, failed to initiate [s1]tachycardia[e1] in the control state but tachycardia was always reinitiated by an identical escape sequence after [s2]procainamide[e2] 
	(4, 22)	tachycardia	procainamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4148	In addition, the [s1]tachycardia[e1] persisted and was repeatedly spontaneously reinitiated for prolonged periods after [s2]procainamide[e2] 
	(0, 7)	Procainamide	incessant supraventricular tachycardia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4149	 [s1]Procainamide[e1] induced [s2]incessant supraventricular tachycardia[e2] in the Wolff-Parkinson-White syndrome.
	(1, 12)	pro-arrhythmic effects	procainamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4150	The [s1]pro-arrhythmic effects[e1] of [s2]procainamide[e2] may be explained on the basis of both its vagolytic action on the atrioventricular node as well as by prolongation of refractoriness in the accessory pathway.
	(0, 12)	Multicentric hepatocellular carcinoma	phosphate diethylstilbestrol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4151	 [s1]Multicentric hepatocellular carcinoma[e1] following [s2]phosphate diethylstilbestrol[e2] therapy for prostatic cancer.
	(7, 25)	hepatocellular carcinoma	DES	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4152	This is a unique autopsy case of [s1]hepatocellular carcinoma[e1] closely related to diethylstilbestrol  [s2]DES[e2]  therapy for prostatic cancer.
	(7, 19)	hepatocellular carcinoma	diethylstilbestrol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4153	This is a unique autopsy case of [s1]hepatocellular carcinoma[e1] closely related to [s2]diethylstilbestrol[e2] (DES) therapy for prostatic cancer.
	(15, 37)	multiple nodules in the liver	PDES	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4154	This paper reports an autopsy case of a 78-year-old male with [s1]multiple nodules in the liver[e1] developed after long-termed administration of phosphate diethylstilbestrol  [s2]PDES[e2]  for prostatic cancer.
	(15, 30)	multiple nodules in the liver	phosphate diethylstilbestrol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4155	This paper reports an autopsy case of a 78-year-old male with [s1]multiple nodules in the liver[e1] developed after long-termed administration of [s2]phosphate diethylstilbestrol[e2] (PDES) for prostatic cancer.
	(17, 28)	cerebellar syndrome	amiodarone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4156	A 52-year-old woman developed symmetric sensorimotor polyneuropathy and [s1]cerebellar syndrome[e1] after 24 months of [s2]amiodarone[e2] treatment.
	(8, 28)	symmetric sensorimotor polyneuropathy	amiodarone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4157	A 52-year-old woman developed [s1]symmetric sensorimotor polyneuropathy[e1] and cerebellar syndrome after 24 months of [s2]amiodarone[e2] treatment.
	(5, 14)	cerebellar syndrome	amiodarone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4158	Peripheral neuropathy and [s1]cerebellar syndrome[e1] associated with [s2]amiodarone[e2] therapy.
	(0, 14)	Peripheral neuropathy	amiodarone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4159	 [s1]Peripheral neuropathy[e1] and cerebellar syndrome associated with [s2]amiodarone[e2] therapy.
	(3, 12)	hyponatremia	vinblastine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4160	Life-threatening [s1]hyponatremia[e1] caused by [s2]vinblastine[e2] 
	(6, 15)	hyponatremic episode	vinblastine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4161	The most likely cause of such [s1]hyponatremic episode[e1] is [s2]vinblastine[e2] 
	(4, 21)	hyperpigmentation	bleomycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4162	Although this type of [s1]hyperpigmentation[e1] has been previously seen in patients with cancer who are receiving [s2]bleomycin[e2]  this is, to our knowledge, the first reported case of bleomycin-induced hyperpigmentation in an AIDS patient and should be added to the growing list of cutaneous eruptions seen in these patients.
	(4, 21)	hyperpigmentation	bleomycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4163	Although this type of [s1]hyperpigmentation[e1] has been previously seen in patients with cancer who are receiving [s2]bleomycin[e2]  this is, to our knowledge, the first reported case of bleomycin-induced hyperpigmentation in an AIDS patient and should be added to the growing list of cutaneous eruptions seen in these patients.
	(5, 13)	hyperpigmentation	bleomycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4164	We report a case of [s1]hyperpigmentation[e1] due to [s2]bleomycin[e2] treatment in a patient with acquired immune deficiency syndrome (AIDS).
	(4, 12)	dextran-40	acute renal failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4165	A typical case of [s1]dextran-40[e1] associated [s2]acute renal failure[e2] is presented.
	(0, 9)	Renal failure	dextran-40	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4166	 [s1]Renal failure[e1] associated with the use of [s2]dextran-40[e2] 
	(7, 16)	renal failure	dextran-40	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4167	Several possible explanations of the mechanism of [s1]renal failure[e1] associated with the use of [s2]dextran-40[e2] are discussed.
	(4, 10)	dextran	renal failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4168	While the mechanism of [s1]dextran[e1] associated [s2]renal failure[e2] remains unsolved, plasma exchange seems to be effective therapy.
	(3, 11)	methotrexate	CNS abnormalities	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4169	MR findings in [s1]methotrexate[e1] induced [s2]CNS abnormalities[e2] 
	(8, 15)	morphea	bromocriptine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4170	A 57-year-old man developed [s1]morphea[e1] while taking [s2]bromocriptine[e2] 
	(0, 6)	Morphea	bromocriptine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4171	 [s1]Morphea[e1] after [s2]bromocriptine[e2] therapy.
	(24, 30)	dapsone	erythroderma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4172	A 35-year-old female with borderline lepromatous (BL) leprosy who suffered from [s1]dapsone[e1] induced [s2]erythroderma[e2] is reported.
	(0, 6)	Dapsone	erythroderma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4173	 [s1]Dapsone[e1] induced [s2]erythroderma[e2] with Beau's lines.
	(0, 13)	Akathisia	fluoxetine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4174	 [s1]Akathisia[e1] appeared to be a common side effect of [s2]fluoxetine[e2] and generally responded well to treatment with the beta-adrenergic antagonist propranolol, dose reduction, or both.
	(3, 25)	fluoxetine	akathisia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4175	Five patients receiving [s1]fluoxetine[e1] for the treatment of obsessive compulsive disorder or major depression developed [s2]akathisia[e2] 
	(0, 7)	Fluoxetine	akathisia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4176	 [s1]Fluoxetine[e1] induced [s2]akathisia[e2]  clinical and theoretical implications.
	(4, 11)	fluoxetine	akathisia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4177	"The authors suggest that [s1]fluoxetine[e1] induced [s2]akathisia[e2] may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic antidepressant-induced ""jitteriness"" may be identical."
	(4, 11)	fluoxetine	akathisia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4178	"The authors suggest that [s1]fluoxetine[e1] induced [s2]akathisia[e2] may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic antidepressant-induced ""jitteriness"" may be identical."
	(2, 14)	fluoxetine	constant pacing	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4179	The typical [s1]fluoxetine[e1] induced symptoms of restlessness, [s2]constant pacing[e2]  purposeless movements of the feet and legs, and marked anxiety were indistinguishable from those of neuroleptic-induced akathisia.
	(2, 27)	fluoxetine	marked anxiety	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4180	The typical [s1]fluoxetine[e1] induced symptoms of restlessness, constant pacing, purposeless movements of the feet and legs, and [s2]marked anxiety[e2] were indistinguishable from those of neuroleptic-induced akathisia.
	(2, 17)	fluoxetine	purposeless movements of the feet and legs	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4181	The typical [s1]fluoxetine[e1] induced symptoms of restlessness, constant pacing, [s2]purposeless movements of the feet and legs[e2]  and marked anxiety were indistinguishable from those of neuroleptic-induced akathisia.
	(2, 11)	fluoxetine	restlessness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4182	The typical [s1]fluoxetine[e1] induced symptoms of [s2]restlessness[e2]  constant pacing, purposeless movements of the feet and legs, and marked anxiety were indistinguishable from those of neuroleptic-induced akathisia.
	(11, 24)	akathisia	fluoxetine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4183	Three patients who had experienced neuroleptic-induced [s1]akathisia[e1] in the past reported that the symptoms of [s2]fluoxetine[e2] induced akathisia were identical, although somewhat milder.
	(6, 21)	demyelinating peripheral neuropathy	cytosine arabinoside	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4184	Horner's syndrome and [s1]demyelinating peripheral neuropathy[e1] caused by high-dose [s2]cytosine arabinoside[e2] 
	(0, 21)	Horner's syndrome	cytosine arabinoside	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4185	 [s1]Horner's syndrome[e1] and demyelinating peripheral neuropathy caused by high-dose [s2]cytosine arabinoside[e2] 
	(0, 15)	Peripheral nerve dysfunction	cytosine arabinoside	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4186	 [s1]Peripheral nerve dysfunction[e1] is a potentially serious complication of high-dose [s2]cytosine arabinoside[e2] 
	(0, 8)	Peripheral nervous system disturbances	cytosine arabinoside	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4187	 [s1]Peripheral nervous system disturbances[e1] caused by [s2]cytosine arabinoside[e2] have rarely been reported.
	(27, 35)	death	cytosine arabinoside	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4188	We describe a patient with acute leukemia who developed Horner's syndrome and a severe demyelinating peripheral neuropathy leading to [s1]death[e1] after receiving high-dose [s2]cytosine arabinoside[e2] 
	(9, 35)	Horner's syndrome	cytosine arabinoside	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4189	We describe a patient with acute leukemia who developed [s1]Horner's syndrome[e1] and a severe demyelinating peripheral neuropathy leading to death after receiving high-dose [s2]cytosine arabinoside[e2] 
	(16, 35)	severe demyelinating peripheral neuropathy	cytosine arabinoside	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4190	We describe a patient with acute leukemia who developed Horner's syndrome and a [s1]severe demyelinating peripheral neuropathy[e1] leading to death after receiving high-dose [s2]cytosine arabinoside[e2] 
	(0, 7)	Nail-changes	penicillamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4191	 [s1]Nail-changes[e1] induced by [s2]penicillamine[e2] 
	(1, 27)	nail-changes	penicillamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4192	Peculiar [s1]nail-changes[e1] in a 70-year-old woman with rheumatoid arthritis occurring after approximately 1 year of [s2]penicillamine[e2] treatment are described.
	(5, 30)	penicillamine	nail-changes	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4193	Reinstitution of [s1]penicillamine[e1] treatment caused a recurrence thus proving a causal relationship between penicillamine and the described [s2]nail-changes[e2] 
	(0, 7)	Ibuprofen	meningitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4194	 [s1]Ibuprofen[e1] induced [s2]meningitis[e2]  detection of intrathecal IgG synthesis and immune complexes.
	(5, 12)	ibuprofen	meningitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4195	We report a case of [s1]ibuprofen[e1] induced [s2]meningitis[e2] in an otherwise healthy individual.
	(0, 9)	Metoclopramide	parkinsonism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4196	 [s1]Metoclopramide[e1] induced [s2]parkinsonism[e2] is not rare, and appropriate dose reduction in patients with renal failure will help reduce the incidence of this morbidity.
	(0, 9)	Metoclopramide	parkinsonism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4197	 [s1]Metoclopramide[e1] induced [s2]parkinsonism[e2] 
	(1, 12)	parkinsonism	metoclopramide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4198	Their [s1]parkinsonism[e1] improved on discontinuation of [s2]metoclopramide[e2] therapy.
	(6, 15)	metoclopramide	parkinsonism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4199	We have reported six cases of [s1]metoclopramide[e1] induced [s2]parkinsonism[e2] seen in consultation over a two-year period.
	(11, 18)	arterial spasm	ergotamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4200	It is suggested that the fatal stroke may have resulted from [s1]arterial spasm[e1] caused by [s2]ergotamine[e2] overdosage and possibly complicated by thrombosis.
	(5, 18)	fatal stroke	ergotamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4201	It is suggested that the [s1]fatal stroke[e1] may have resulted from arterial spasm caused by [s2]ergotamine[e2] overdosage and possibly complicated by thrombosis.
	(3, 15)	acute hyponatraemia	cyclophosphamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4202	Life-threatening [s1]acute hyponatraemia[e1] induced by low dose [s2]cyclophosphamide[e2] and indomethacin.
	(3, 22)	acute hyponatraemia	indomethacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4203	Life-threatening [s1]acute hyponatraemia[e1] induced by low dose cyclophosphamide and [s2]indomethacin[e2] 
	(15, 38)	life-threatening water intoxication	cyclophosphamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4204	We report the case of a patient with multiple myeloma who developed acute [s1]life-threatening water intoxication[e1] following treatment with oral indomethacin and low dose intravenous [s2]cyclophosphamide[e2] 
	(15, 28)	life-threatening water intoxication	indomethacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4205	We report the case of a patient with multiple myeloma who developed acute [s1]life-threatening water intoxication[e1] following treatment with oral [s2]indomethacin[e2] and low dose intravenous cyclophosphamide.
	(0, 7)	Clofazimine	nail changes	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4206	 [s1]Clofazimine[e1] induced [s2]nail changes[e2] 
	(1, 11)	nail changes	clofazimine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4207	These [s1]nail changes[e1] gradually disappeared when the dose of [s2]clofazimine[e2] was reduced.
	(26, 33)	clofazimine	discoloration of nail plate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4208	Two cases of lepromatous leprosy with erythema nodosum leprosum who were on high doses of [s1]clofazimine[e1]  showed [s2]discoloration of nail plate[e2]  subungual hyperkeratosis and onycholysis.
	(26, 48)	clofazimine	onycholysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4209	Two cases of lepromatous leprosy with erythema nodosum leprosum who were on high doses of [s1]clofazimine[e1]  showed discoloration of nail plate, subungual hyperkeratosis and [s2]onycholysis[e2] 
	(26, 40)	clofazimine	subungual hyperkeratosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4210	Two cases of lepromatous leprosy with erythema nodosum leprosum who were on high doses of [s1]clofazimine[e1]  showed discoloration of nail plate, [s2]subungual hyperkeratosis[e2] and onycholysis.
	(4, 11)	asparaginase	hyperglycemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4211	Attenuation of [s1]asparaginase[e1] induced [s2]hyperglycemia[e2] after substitution of the Erwinia carotovora for the Escherichia coli enzyme preparation.
	(2, 11)	persistent late onset asthma	captopril	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4212	Development of [s1]persistent late onset asthma[e1] following treatment with [s2]captopril[e2] 
	(8, 25)	asthma	captopril	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4213	We describe the first case of de novo [s1]asthma[e1] following treatment with the angiotensin converting enzyme (ACE) inhibitor [s2]captopril[e2] 
	(12, 19)	bleomycin	TMA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4214	A case report of a patient with probable cisplatin and [s1]bleomycin[e1] induced [s2]TMA[e2] is presented.
	(8, 20)	cisplatin	TMA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4215	A case report of a patient with probable [s1]cisplatin[e1] and bleomycin-induced [s2]TMA[e2] is presented.
	(12, 37)	busulphan	ascites	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4216	A patient with chronic myeloid leukaemia treated with [s1]busulphan[e1] for 4-5 years, developed signs of busulphan toxicity and portal hypertension with [s2]ascites[e2]  oesophageal varices and jaundice.
	(12, 50)	busulphan	jaundice	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4217	A patient with chronic myeloid leukaemia treated with [s1]busulphan[e1] for 4-5 years, developed signs of busulphan toxicity and portal hypertension with ascites, oesophageal varices and [s2]jaundice[e2] 
	(12, 41)	busulphan	oesophageal varices	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4218	A patient with chronic myeloid leukaemia treated with [s1]busulphan[e1] for 4-5 years, developed signs of busulphan toxicity and portal hypertension with ascites, [s2]oesophageal varices[e2] and jaundice.
	(12, 33)	busulphan	portal hypertension	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4219	A patient with chronic myeloid leukaemia treated with [s1]busulphan[e1] for 4-5 years, developed signs of busulphan toxicity and [s2]portal hypertension[e2] with ascites, oesophageal varices and jaundice.
	(4, 10)	amiodarone	torsades de pointe	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4220	Although a lot of [s1]amiodarone[e1] induced [s2]torsades de pointe[e2] have been published, a review of all these cases and the underlying risk-factors has never been made.
	(0, 6)	Amiodarone	torsades de pointe	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4221	 [s1]Amiodarone[e1] induced [s2]torsades de pointe[e2] 
	(5, 11)	amiodarone	torsades de pointe	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4222	We report three cases of [s1]amiodarone[e1] induced [s2]torsades de pointe[e2] 
	(7, 12)	lithium	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4223	The syndrome of irreversible [s1]lithium[e1] effectuated [s2]neurotoxicity[e2] (SILENT).
	(2, 8)	respiratory depression	morphine-6-glucuronide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4224	Long lasting [s1]respiratory depression[e1] induced by [s2]morphine-6-glucuronide[e2] 
	(7, 17)	respiratory depression	morphine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4225	We report a case of long lasting [s1]respiratory depression[e1] after intravenous administration of [s2]morphine[e2] to a 7 year old girl with haemolytic uraemic syndrome.
	(0, 7)	Rifampin	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4226	 [s1]Rifampin[e1] associated [s2]thrombocytopenia[e2] secondary to poor compliance.
	(0, 17)	Rifampin	acute renal failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4227	 [s1]Rifampin[e1] can be associated with severe adverse effects such as hepatitis, [s2]acute renal failure[e2]  hemolytic anemia, and thrombocytopenia.
	(0, 21)	Rifampin	hemolytic anemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4228	 [s1]Rifampin[e1] can be associated with severe adverse effects such as hepatitis, acute renal failure, [s2]hemolytic anemia[e2]  and thrombocytopenia.
	(0, 15)	Rifampin	hepatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4229	 [s1]Rifampin[e1] can be associated with severe adverse effects such as [s2]hepatitis[e2]  acute renal failure, hemolytic anemia, and thrombocytopenia.
	(0, 28)	Rifampin	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4230	 [s1]Rifampin[e1] can be associated with severe adverse effects such as hepatitis, acute renal failure, hemolytic anemia, and [s2]thrombocytopenia[e2] 
	(6, 13)	rifampin	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4231	This article reports the occurrence of [s1]rifampin[e1] associated [s2]thrombocytopenia[e2] in an indigent patient after a four-month lapse in therapy for pulmonary tuberculosis.
	(6, 17)	WES	haloperidol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4232	We present the first case of [s1]WES[e1] in an infant born to a mother taking [s2]haloperidol[e2] during her pregnancy.
	(0, 12)	Withdrawal emergent syndrome	haloperidol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4233	 [s1]Withdrawal emergent syndrome[e1] in an infant associated with maternal [s2]haloperidol[e2] therapy.
	(7, 33)	acute myelocytic leukemia	5-fluorouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4234	This report describes two patients who developed [s1]acute myelocytic leukemia[e1] only after exposure to cyclophosphamide, methotrexate, and [s2]5-fluorouracil[e2] adjuvant therapy.
	(7, 19)	acute myelocytic leukemia	cyclophosphamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4235	This report describes two patients who developed [s1]acute myelocytic leukemia[e1] only after exposure to [s2]cyclophosphamide[e2]  methotrexate, and 5-fluorouracil adjuvant therapy.
	(7, 26)	acute myelocytic leukemia	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4236	This report describes two patients who developed [s1]acute myelocytic leukemia[e1] only after exposure to cyclophosphamide, [s2]methotrexate[e2]  and 5-fluorouracil adjuvant therapy.
	(0, 9)	Ibuprofen	gastrointestinal adverse reactions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4237	 [s1]Ibuprofen[e1] rarely causes lower [s2]gastrointestinal adverse reactions[e2] but has been implicated in systemic and local side effects in patients with lupus.
	(0, 19)	Ulcerative proctitis	ibuprofen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4238	 [s1]Ulcerative proctitis[e1] in juvenile systemic lupus erythematosus after [s2]ibuprofen[e2] treatment.
	(5, 14)	ulcerative proctitis	ibuprofen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4239	We describe a case of [s1]ulcerative proctitis[e1] after [s2]ibuprofen[e2] treatment in a girl with juvenile systemic lupus erythematosus.
	(3, 26)	cytarabine	central nervous system toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4240	Intravenous [s1]cytarabine[e1] and methotrexate appear to act synergistically to enhance the potential for [s2]central nervous system toxicity[e2] 
	(7, 26)	methotrexate	central nervous system toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4241	Intravenous cytarabine and [s1]methotrexate[e1] appear to act synergistically to enhance the potential for [s2]central nervous system toxicity[e2] 
	(14, 32)	leukoencephalopathy	ara = C	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4242	We present two children with acute lymphocytic leukemia who developed [s1]leukoencephalopathy[e1] following administration of a combination of intravenous [s2]ara = C[e2] and methotrexate during the consolidation phase of chemotherapy.
	(14, 36)	leukoencephalopathy	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4243	We present two children with acute lymphocytic leukemia who developed [s1]leukoencephalopathy[e1] following administration of a combination of intravenous ara = C and [s2]methotrexate[e2] during the consolidation phase of chemotherapy.
	(7, 13)	amiodarone	thyrotoxicosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4244	Dexamethasone treatment of [s1]amiodarone[e1] induced [s2]thyrotoxicosis[e2] (AIT) with or without persistent administration of the drug.
	(2, 8)	amiodarone	thyrotoxicosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4245	Treatment of [s1]amiodarone[e1] induced [s2]thyrotoxicosis[e2] (AIT) with thionamide, lithium or radioactive iodine is ineffective.
	(0, 11)	Acute myelogenous leukemia	chlorambucil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4246	 [s1]Acute myelogenous leukemia[e1] in patients receiving [s2]chlorambucil[e2] as long-term adjuvant chemotherapy for stage II breast cancer.
	(2, 26)	chlorambucil	AML	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4247	After the [s1]chlorambucil[e1] was discontinued, the wbc count began to slowly rise and the patient developed clinical [s2]AML[e2] 
	(0, 11)	Panic anxiety	mianserin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4248	 [s1]Panic anxiety[e1] after abrupt discontinuation of [s2]mianserin[e2] 
	(1, 32)	panic anxiety	mianserin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4249	This [s1]panic anxiety[e1] was not relieved by taking etizolam and flunitrazepam again, but subsided rapidly by the re-administration of [s2]mianserin[e2] 30 mg/day, and because of that the depressive symptom also disappeared.
	(13, 18)	lithium	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4250	Prior neurologic illness and the syndrome of irreversible [s1]lithium[e1] effectuated [s2]neurotoxicity[e2] (SILENT).
	(19, 27)	neurotoxicity	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4251	Prior neurologic illness or CNS insult of any kind is known to increase the vulnerability to [s1]neurotoxicity[e1] of [s2]lithium[e2] 
	(19, 24)	lithium	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4252	The authors describe a patient with hemiparesis who developed the syndrome of irreversible [s1]lithium[e1] effectuated [s2]neurotoxicity[e2] (SILENT) while being treated with lithium for a manic episode.
	(5, 37)	trihexyphenidyl	acute respiratory difficulties	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4253	Abrupt, accidental withdrawal of [s1]trihexyphenidyl[e1] triggered severe exacerbation of the cranial dystonia associated with inspiratory stridor and [s2]acute respiratory difficulties[e2]  prompting emergency admission.
	(5, 22)	trihexyphenidyl	cranial dystonia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4254	Abrupt, accidental withdrawal of [s1]trihexyphenidyl[e1] triggered severe exacerbation of the [s2]cranial dystonia[e2] associated with inspiratory stridor and acute respiratory difficulties, prompting emergency admission.
	(5, 29)	trihexyphenidyl	inspiratory stridor	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4255	Abrupt, accidental withdrawal of [s1]trihexyphenidyl[e1] triggered severe exacerbation of the cranial dystonia associated with [s2]inspiratory stridor[e2] and acute respiratory difficulties, prompting emergency admission.
	(3, 11)	cranial dystonia	trihexyphenidyl	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4256	Life-threatening [s1]cranial dystonia[e1] following [s2]trihexyphenidyl[e2] withdrawal.
	(3, 11)	methotrexate	CNS abnormalities	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4257	MR findings in [s1]methotrexate[e1] induced [s2]CNS abnormalities[e2] 
	(5, 32)	Ara-C	paresthesias	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4258	Administration of intrathecal [s1]Ara-C[e1] in the same dose over longer intervals within 3-5 days between consecutive doses resulted in mild, transient neurological symptoms  [s2]paresthesias[e2]  in only one of 30 patients so treated.
	(0, 9)	Paraplegia	cytosine arabinoside	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4259	 [s1]Paraplegia[e1] following intrathecal [s2]cytosine arabinoside[e2] 
	(0, 18)	Paraplegia	Ara-C	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4260	 [s1]Paraplegia[e1] following prophylactic intrathecal cytosine arabinoside  [s2]Ara-C[e2]  is described in a patient with acute myelogenous leukemia in remission who received doses of 100 mg/m2/d for 5 consecutive days.
	(0, 12)	Paraplegia	cytosine arabinoside	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4261	 [s1]Paraplegia[e1] following prophylactic intrathecal [s2]cytosine arabinoside[e2] (Ara-C) is described in a patient with acute myelogenous leukemia in remission who received doses of 100 mg/m2/d for 5 consecutive days.
	(3, 13)	hypoadrenalism	o,p'-DDD	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4262	Both patients developed [s1]hypoadrenalism[e1] while on [s2]o,p'-DDD[e2] and apparently adequate dexamethasone replacement therapy.
	(0, 8)	Alprazolam	mania	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4263	 [s1]Alprazolam[e1] induced [s2]mania[e2]  two clinical cases.
	(6, 20)	alprazolam	mania	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4264	The authors caution that treatment with [s1]alprazolam[e1] may be complicated by the induction of [s2]mania[e2] 
	(4, 24)	alprazolam	manic episodes	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4265	Two patients treated with [s1]alprazolam[e1] had histories suggestive of a bipolar disorder and developed lithium-responsive [s2]manic episodes[e2] 
	(14, 28)	delirious	alprazolam	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4266	A case is presented in which a 68-year-old man became [s1]delirious[e1] after being withdrawn from a low dosage of [s2]alprazolam[e2] 
	(0, 8)	Alprazolam	delirium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4267	 [s1]Alprazolam[e1] withdrawal [s2]delirium[e2] unresponsive to diazepam: case report.
	(0, 11)	Sulfasalazine	bronchopulmonary complications of inflammatory bowel disease	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4268	 [s1]Sulfasalazine[e1] has been associated with [s2]bronchopulmonary complications of inflammatory bowel disease[e2] (IBD) in adults.
	(0, 23)	Sulfasalazine	IBD	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4269	 [s1]Sulfasalazine[e1] has been associated with bronchopulmonary complications of inflammatory bowel disease  [s2]IBD[e2]  in adults.
	(13, 21)	IBD	sulfasalazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4270	We discuss a variety of bronchopulmonary complications of [s1]IBD[e1] and their association with [s2]sulfasalazine[e2] 
	(2, 10)	amantadine	psychotic decompensations	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4271	Administration of [s1]amantadine[e1] was associated with [s2]psychotic decompensations[e2] in two schizophrenic patients being maintained on concomitant neuroleptic medication.
	(21, 27)	amantadine	precipitating psychosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4272	Despite a postulated dopaminergic mechanism, there seems to have been only one previous report of [s1]amantadine[e1] s [s2]precipitating psychosis[e2] in a schizophrenic patient.
	(5, 10)	schizophrenia	amantadine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4273	Exacerbation of [s1]schizophrenia[e1] associated with [s2]amantadine[e2] 
	(7, 18)	chlorpromazine	symptoms resembling Parkinson's disease	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4274	Soon after its introduction in 1952, [s1]chlorpromazine[e1] was noted to induce [s2]symptoms resembling Parkinson's disease[e2] 
	(7, 15)	sulfasalazine	lupus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4275	It is suggested that the patient had [s1]sulfasalazine[e1] induced [s2]lupus[e2]  which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms.
	(7, 25)	sulfasalazine	pulmonary parenchymal involvement	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4276	It is suggested that the patient had [s1]sulfasalazine[e1] induced lupus, which manifested with serositis and [s2]pulmonary parenchymal involvement[e2] in the absence of joint symptoms.
	(7, 21)	sulfasalazine	serositis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4277	It is suggested that the patient had [s1]sulfasalazine[e1] induced lupus, which manifested with [s2]serositis[e2] and pulmonary parenchymal involvement in the absence of joint symptoms.
	(3, 32)	sulfasalazine	lupus syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4278	Physicians who use [s1]sulfasalazine[e1] to treat patients with inflammatory bowel disease should be aware of the signs of sulfasalazine-induced [s2]lupus syndrome[e2] 
	(6, 48)	bilateral pleural effusions	sulfasalazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4279	Pneumonitis, [s1]bilateral pleural effusions[e1]  echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term [s2]sulfasalazine[e2] therapy for chronic ulcerative colitis.
	(20, 48)	cardiac tamponade	sulfasalazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4280	Pneumonitis, bilateral pleural effusions, echocardiographic evidence of [s1]cardiac tamponade[e1]  and positive autoantibodies developed in a 43-year-old man, who was receiving long-term [s2]sulfasalazine[e2] therapy for chronic ulcerative colitis.
	(0, 48)	Pneumonitis	sulfasalazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4281	 [s1]Pneumonitis[e1]  bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term [s2]sulfasalazine[e2] therapy for chronic ulcerative colitis.
	(26, 49)	positive autoantibodies	sulfasalazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4282	Pneumonitis, bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and [s1]positive autoantibodies[e1] developed in a 43-year-old man, who was receiving long-term [s2]sulfasalazine[e2] therapy for chronic ulcerative colitis.
	(0, 8)	Sulfasalazine	lupus erythematosus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4283	 [s1]Sulfasalazine[e1] induced [s2]lupus erythematosus[e2] 
	(0, 17)	Acute myocardial infarction	L-thyroxine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4284	 [s1]Acute myocardial infarction[e1] due to coronary spasm associated with [s2]L-thyroxine[e2] therapy.
	(9, 17)	coronary spasm	L-thyroxine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4285	Acute myocardial infarction due to [s1]coronary spasm[e1] associated with [s2]L-thyroxine[e2] therapy.
	(12, 24)	acute myocardial infarction	L-thyroxine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4286	Electrocardiographic findings and laboratory data indicated a diagnosis of [s1]acute myocardial infarction[e1] due to the [s2]L-thyroxine[e2] therapy.
	(16, 28)	coronary spasm	L-thyroxine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4287	We believe this is the first report of myocardial infarction due to [s1]coronary spasm[e1]  demonstrated by angiography associated with [s2]L-thyroxine[e2] therapy.
	(8, 29)	myocardial infarction	L-thyroxine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4288	We believe this is the first report of [s1]myocardial infarction[e1] due to coronary spasm, demonstrated by angiography associated with [s2]L-thyroxine[e2] therapy.
	(8, 41)	L-T4	leukopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4289	A study of in vitro reactivity to [s1]L-T4[e1]  as assessed by peripheral blood lymphocyte transformation, was carried out in a patient with Hashimoto's disease who developed [s2]leukopenia[e2] during treatment with L-T4.
	(0, 9)	L-Thyroxine	leukopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4290	 [s1]L-Thyroxine[e1] induced [s2]leukopenia[e2] in a patient with Hashimoto's disease: involvement of suppressor-cytotoxic T cells.
	(0, 14)	Ampicillin	generalised exfoliative dermatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4291	 [s1]Ampicillin[e1] induced interstitial nephritis with [s2]generalised exfoliative dermatitis[e2] 
	(0, 6)	Ampicillin	interstitial nephritis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4292	 [s1]Ampicillin[e1] induced [s2]interstitial nephritis[e2] with generalised exfoliative dermatitis.
	(10, 19)	ampicillin	acute interstitial nephritis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4293	However, there are few reports in the literature of [s1]ampicillin[e1] as a cause of [s2]acute interstitial nephritis[e2] 
	(9, 30)	acute interstitial nephritis	ampicillin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4294	In the following case report, a patient developed [s1]acute interstitial nephritis[e1] with renal failure and exfoliative dermatitis following [s2]ampicillin[e2] therapy.
	(21, 30)	exfoliative dermatitis	ampicillin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4295	In the following case report, a patient developed acute interstitial nephritis with renal failure and [s1]exfoliative dermatitis[e1] following [s2]ampicillin[e2] therapy.
	(18, 30)	renal failure	ampicillin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4296	In the following case report, a patient developed acute interstitial nephritis with [s1]renal failure[e1] and exfoliative dermatitis following [s2]ampicillin[e2] therapy.
	(14, 35)	eosinophilia	ampicillin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4297	The diagnosis was based on the rapid onset of renal failure, presence of [s1]eosinophilia[e1]  skin rash, and characteristic renal biopsy finding, following the administration of [s2]ampicillin[e2] 
	(9, 35)	renal failure	ampicillin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4298	The diagnosis was based on the rapid onset of [s1]renal failure[e1]  presence of eosinophilia, skin rash, and characteristic renal biopsy finding, following the administration of [s2]ampicillin[e2] 
	(20, 35)	skin rash	ampicillin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4299	The diagnosis was based on the rapid onset of renal failure, presence of eosinophilia, [s1]skin rash[e1]  and characteristic renal biopsy finding, following the administration of [s2]ampicillin[e2] 
	(3, 35)	vancomycin	erythema of the cartilage of both ears	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4300	A patient receiving [s1]vancomycin[e1] for a serious staphylococcal infection had a lupus-like syndrome characterized by a malar rash, pain and [s2]erythema of the cartilage of both ears[e2]  and tender erythematous and hemorrhagic lesions of the finger tips.
	(3, 54)	vancomycin	hemorrhagic lesions of the finger tips	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4301	A patient receiving [s1]vancomycin[e1] for a serious staphylococcal infection had a lupus-like syndrome characterized by a malar rash, pain and erythema of the cartilage of both ears, and tender erythematous and [s2]hemorrhagic lesions of the finger tips[e2] 
	(3, 21)	vancomycin	lupus-like syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4302	A patient receiving [s1]vancomycin[e1] for a serious staphylococcal infection had a [s2]lupus-like syndrome[e2] characterized by a malar rash, pain and erythema of the cartilage of both ears, and tender erythematous and hemorrhagic lesions of the finger tips.
	(3, 29)	vancomycin	malar rash	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4303	A patient receiving [s1]vancomycin[e1] for a serious staphylococcal infection had a lupus-like syndrome characterized by a [s2]malar rash[e2]  pain and erythema of the cartilage of both ears, and tender erythematous and hemorrhagic lesions of the finger tips.
	(3, 33)	vancomycin	pain	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4304	A patient receiving [s1]vancomycin[e1] for a serious staphylococcal infection had a lupus-like syndrome characterized by a malar rash, [s2]pain[e2] and erythema of the cartilage of both ears, and tender erythematous and hemorrhagic lesions of the finger tips.
	(3, 48)	vancomycin	tender erythematous	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4305	A patient receiving [s1]vancomycin[e1] for a serious staphylococcal infection had a lupus-like syndrome characterized by a malar rash, pain and erythema of the cartilage of both ears, and [s2]tender erythematous[e2] and hemorrhagic lesions of the finger tips.
	(13, 31)	lupus-like syndrome	vancomycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4306	The possible development of a drug-induced vasculitis or [s1]lupus-like syndrome[e1] should be added to the list of rare toxic effects of [s2]vancomycin[e2] 
	(8, 31)	vasculitis	vancomycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4307	The possible development of a drug-induced [s1]vasculitis[e1] or lupus-like syndrome should be added to the list of rare toxic effects of [s2]vancomycin[e2] 
	(0, 7)	Vancomycin	vasculitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4308	 [s1]Vancomycin[e1] induced [s2]vasculitis[e2] 
	(0, 9)	Abnormal retinal function	isotretinoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4309	 [s1]Abnormal retinal function[e1] associated with [s2]isotretinoin[e2] therapy for acne.
	(6, 33)	isotretinoin	excessive glare sensitivity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4310	Three of 50 patients treated with [s1]isotretinoin[e1] (1 mg/kg/day) for cystic acne complained of poor night vision and/or [s2]excessive glare sensitivity[e2] 
	(6, 27)	isotretinoin	poor night vision	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4311	Three of 50 patients treated with [s1]isotretinoin[e1] (1 mg/kg/day) for cystic acne complained of [s2]poor night vision[e2] and/or excessive glare sensitivity.
	(0, 16)	Neurologic toxicity	FUdR	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4312	 [s1]Neurologic toxicity[e1] associated with hepatic artery infusion HAI of [s2]FUdR[e2] 
	(0, 19)	Ethambutol	optic neuropathies	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4313	 [s1]Ethambutol[e1] is frequently used in the treatment of tuberculosis, and, although [s2]optic neuropathies[e2] have been reported with the use of ethambutol, this adverse side effect has been considered to be rare and generally reversible with discontinuation of the medication.
	(12, 24)	ethambutol	toxic optic neuropathies	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4314	However, we recently saw two patients with renal tuberculosis treated with [s1]ethambutol[e1] in whom visual loss from [s2]toxic optic neuropathies[e2] was severe and irreversible despite careful ophthalmological monitoring and prompt discontinuation of the agent at the first sign of impaired visual function.
	(12, 21)	ethambutol	visual loss	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4315	However, we recently saw two patients with renal tuberculosis treated with [s1]ethambutol[e1] in whom [s2]visual loss[e2] from toxic optic neuropathies was severe and irreversible despite careful ophthalmological monitoring and prompt discontinuation of the agent at the first sign of impaired visual function.
	(0, 7)	Optic neuropathy	ethambutol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4316	 [s1]Optic neuropathy[e1] in [s2]ethambutol[e2] treated renal tuberculosis.
	(1, 43)	ethambutol	optic neuropathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4317	Since [s1]ethambutol[e1] is actively excreted via the renal system, compromise of renal function such as due to renal tuberculosis may lead to serum concentration elevations of ethambutol sufficient to produce [s2]optic neuropathy[e2] 
	(15, 29)	dysphagia for solids	nifedipine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4318	A 57-year-old woman presented with a 3-week history of [s1]dysphagia for solids[e1]  6 months after starting treatment with [s2]nifedipine[e2] 
	(0, 15)	Gastro-oesophageal reflux	nifedipine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4319	 [s1]Gastro-oesophageal reflux[e1] associated with [s2]nifedipine[e2] 
	(0, 18)	Nifedipine	gastro-oesophageal reflux	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4320	 [s1]Nifedipine[e1] may induce, or aggravate, pre-existing, [s2]gastro-oesophageal reflux[e2] 
	(9, 26)	bilateral posterior subcapsular cataracts	Decadron	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4321	A young diamond dealer developed visual impairment attributed to [s1]bilateral posterior subcapsular cataracts[e1] following only four courses of intermittent [s2]Decadron[e2] used as part of a five-drug antiemetic regimen for cisplatin-associated nausea.
	(41, 47)	cisplatin	nausea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4322	A young diamond dealer developed visual impairment attributed to bilateral posterior subcapsular cataracts following only four courses of intermittent Decadron used as part of a five-drug antiemetic regimen for [s1]cisplatin[e1] associated [s2]nausea[e2] 
	(5, 26)	visual impairment	Decadron	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4323	A young diamond dealer developed [s1]visual impairment[e1] attributed to bilateral posterior subcapsular cataracts following only four courses of intermittent [s2]Decadron[e2] used as part of a five-drug antiemetic regimen for cisplatin-associated nausea.
	(0, 8)	Cataracts	Decadron	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4324	 [s1]Cataracts[e1] induced by intermittent [s2]Decadron[e2] used as an antiemetic.
	(36, 42)	cisplatin	vomiting	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4325	Recent reports have shown that Decadron (dexamethasone; Merck Sharp & Dohme, West Point, Pa) has a significant antiemetic effect on [s1]cisplatin[e1] induced [s2]vomiting[e2] 
	(1, 8)	phenytoin	IgA deficiency	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4326	Transient [s1]phenytoin[e1] induced [s2]IgA deficiency[e2] and permanent IgE increase.
	(1, 13)	phenytoin	IgE increase	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4327	Transient [s1]phenytoin[e1] induced IgA deficiency and permanent [s2]IgE increase[e2] 
	(9, 23)	chloral hydrate	cardiac arrhythmias	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4328	The pharmacology and toxicology of [s1]chloral hydrate[e1] are discussed with particular reference to the [s2]cardiac arrhythmias[e2] that are seen with overdosage.
	(0, 3)	Adrenaline	dacryolith	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4329	 [s1]Adrenaline[e1]  [s2]dacryolith[e2]  detection by ultrasound examination of the nasolacrimal duct.
	(6, 20)	dacryolith	adrenaline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4330	Histological examination of the [s1]dacryolith[e1] suggested its derivation from breakdown products of [s2]adrenaline[e2] 
	(29, 63)	valproic acid	hyperammonemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4331	Possible pathophysiological mechanisms which may have been operative in this case include: a direct central nervous system (CNS) toxic effect of [s1]valproic acid[e1]  a paradoxical epileptogenic effect secondary to the drug; and an indirect CNS toxic effect mediated through valproic acid-induced [s2]hyperammonemia[e2] 
	(3, 10)	valproic acid	dementia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4332	Reversible [s1]valproic acid[e1] induced [s2]dementia[e2]  a case report.
	(3, 10)	valproic acid	dementia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4333	Reversible [s1]valproic acid[e1] induced [s2]dementia[e2] was documented in a 21-year-old man with epilepsy who had a 3-year history of insidious progressive decline in global cognitive abilities documented by serial neuropsychological studies.
	(0, 8)	Co-trimoxazole	red cell aplasia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4334	 [s1]Co-trimoxazole[e1]  [s2]red cell aplasia[e2] in leukaemia.
	(1, 12)	co-trimoxazole	red cell aplasia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4335	When [s1]co-trimoxazole[e1] was stopped the [s2]red cell aplasia[e2] resolved.
	(3, 18)	optic neuropathy	ethambutol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4336	A patient developed [s1]optic neuropathy[e1] while being treated with isoniazid and [s2]ethambutol[e2] 
	(3, 13)	optic neuropathy	isoniazid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4337	A patient developed [s1]optic neuropathy[e1] while being treated with [s2]isoniazid[e2] and ethambutol.
	(22, 28)	ocular toxicity	isoniazid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4338	A well-recognized complication of ethambutol use is optic neuropathy, but the potential [s1]ocular toxicity[e1] of [s2]isoniazid[e2] is often overlooked.
	(7, 16)	ethambutol	optic neuropathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4339	A well-recognized complication of [s1]ethambutol[e1] use is [s2]optic neuropathy[e2]  but the potential ocular toxicity of isoniazid is often overlooked.
	(5, 16)	ethambutol	optic neuropathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4340	Isoniazid and [s1]ethambutol[e1] as a cause of [s2]optic neuropathy[e2] 
	(0, 16)	Isoniazid	optic neuropathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4341	 [s1]Isoniazid[e1] and ethambutol as a cause of [s2]optic neuropathy[e2] 
	(28, 37)	Depo-Medrol	spastic paraparesis at the lower limbs	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4342	A woman 38-year-old, suffering for about ten years from multiple sclerosis and treated with repeated therapy cycles of intrathecal [s1]Depo-Medrol[e1]  developed a [s2]spastic paraparesis at the lower limbs[e2] 
	(0, 22)	Calcification	Depo-Medrol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4343	 [s1]Calcification[e1] and ossification of the spinal arachnoid after intrathecal administration of [s2]Depo-Medrol[e2] 
	(4, 22)	ossification of the spinal arachnoid	Depo-Medrol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4344	Calcification and [s1]ossification of the spinal arachnoid[e1] after intrathecal administration of [s2]Depo-Medrol[e2] 
	(8, 22)	tonic-clonic seizures	adriamycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4345	A young woman with epilepsy had [s1]tonic-clonic seizures[e1] during antineoplastic therapy with [s2]adriamycin[e2] and cisplatin.
	(8, 27)	tonic-clonic seizures	cisplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4346	A young woman with epilepsy had [s1]tonic-clonic seizures[e1] during antineoplastic therapy with adriamycin and [s2]cisplatin[e2] 
	(0, 12)	Hyperkalemia	adrenocorticotropic hormone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4347	 [s1]Hyperkalemia[e1] as a late side effect of prolonged [s2]adrenocorticotropic hormone[e2] therapy for infantile spasms.
	(3, 15)	hyperkalemia	ACTH	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4348	Two infants developed [s1]hyperkalemia[e1] shortly after cessation of prolonged [s2]ACTH[e2] therapy for infantile spasms.
	(15, 33)	ACTH	hyperkalemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4349	We wish to call for cautious approach at time of cessation of prolonged [s1]ACTH[e1] therapy because of possible unexpected and only partially understood hazardous side effects such as [s2]hyperkalemia[e2] 
	(26, 76)	folinic acid	acute renal impairment	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4350	Three patients, in whom tumour overkill by cytotoxic treatment, including high dose methotrexate with [s1]folinic acid[e1] rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany, with metabolic acidosis and [s2]acute renal impairment[e2]  are described.
	(20, 76)	methotrexate	acute renal impairment	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4351	Three patients, in whom tumour overkill by cytotoxic treatment, including high dose [s1]methotrexate[e1] with folinic acid rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany, with metabolic acidosis and [s2]acute renal impairment[e2]  are described.
	(26, 49)	folinic acid	hyperkalaemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4352	Three patients, in whom tumour overkill by cytotoxic treatment, including high dose methotrexate with [s1]folinic acid[e1] rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, [s2]hyperkalaemia[e2] and hyperphosphataemia with hypocalcaemia and tetany, with metabolic acidosis and acute renal impairment) are described.
	(20, 49)	methotrexate	hyperkalaemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4353	Three patients, in whom tumour overkill by cytotoxic treatment, including high dose [s1]methotrexate[e1] with folinic acid rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, [s2]hyperkalaemia[e2] and hyperphosphataemia with hypocalcaemia and tetany, with metabolic acidosis and acute renal impairment) are described.
	(26, 53)	folinic acid	hyperphosphataemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4354	Three patients, in whom tumour overkill by cytotoxic treatment, including high dose methotrexate with [s1]folinic acid[e1] rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and [s2]hyperphosphataemia[e2] with hypocalcaemia and tetany, with metabolic acidosis and acute renal impairment) are described.
	(20, 53)	methotrexate	hyperphosphataemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4355	Three patients, in whom tumour overkill by cytotoxic treatment, including high dose [s1]methotrexate[e1] with folinic acid rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and [s2]hyperphosphataemia[e2] with hypocalcaemia and tetany, with metabolic acidosis and acute renal impairment) are described.
	(26, 42)	folinic acid	hyper-uricaemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4356	Three patients, in whom tumour overkill by cytotoxic treatment, including high dose methotrexate with [s1]folinic acid[e1] rescue, resulted in the 'phosphate shower syndrome'  [s2]hyper-uricaemia[e2]  hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany, with metabolic acidosis and acute renal impairment) are described.
	(20, 42)	methotrexate	hyper-uricaemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4357	Three patients, in whom tumour overkill by cytotoxic treatment, including high dose [s1]methotrexate[e1] with folinic acid rescue, resulted in the 'phosphate shower syndrome'  [s2]hyper-uricaemia[e2]  hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany, with metabolic acidosis and acute renal impairment) are described.
	(26, 60)	folinic acid	hypocalcaemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4358	Three patients, in whom tumour overkill by cytotoxic treatment, including high dose methotrexate with [s1]folinic acid[e1] rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with [s2]hypocalcaemia[e2] and tetany, with metabolic acidosis and acute renal impairment) are described.
	(20, 60)	methotrexate	hypocalcaemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4359	Three patients, in whom tumour overkill by cytotoxic treatment, including high dose [s1]methotrexate[e1] with folinic acid rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with [s2]hypocalcaemia[e2] and tetany, with metabolic acidosis and acute renal impairment) are described.
	(26, 72)	folinic acid	metabolic acidosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4360	Three patients, in whom tumour overkill by cytotoxic treatment, including high dose methotrexate with [s1]folinic acid[e1] rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany, with [s2]metabolic acidosis[e2] and acute renal impairment) are described.
	(20, 72)	methotrexate	metabolic acidosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4361	Three patients, in whom tumour overkill by cytotoxic treatment, including high dose [s1]methotrexate[e1] with folinic acid rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany, with [s2]metabolic acidosis[e2] and acute renal impairment) are described.
	(26, 37)	folinic acid	phosphate shower syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4362	Three patients, in whom tumour overkill by cytotoxic treatment, including high dose methotrexate with [s1]folinic acid[e1] rescue, resulted in the  [s2]phosphate shower syndrome[e2]  (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany, with metabolic acidosis and acute renal impairment) are described.
	(20, 37)	methotrexate	phosphate shower syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4363	Three patients, in whom tumour overkill by cytotoxic treatment, including high dose [s1]methotrexate[e1] with folinic acid rescue, resulted in the  [s2]phosphate shower syndrome[e2]  (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with hypocalcaemia and tetany, with metabolic acidosis and acute renal impairment) are described.
	(26, 67)	folinic acid	tetany	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4364	Three patients, in whom tumour overkill by cytotoxic treatment, including high dose methotrexate with [s1]folinic acid[e1] rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with hypocalcaemia and [s2]tetany[e2]  with metabolic acidosis and acute renal impairment) are described.
	(20, 67)	methotrexate	tetany	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4365	Three patients, in whom tumour overkill by cytotoxic treatment, including high dose [s1]methotrexate[e1] with folinic acid rescue, resulted in the 'phosphate shower syndrome' (hyper-uricaemia, hyperkalaemia and hyperphosphataemia with hypocalcaemia and [s2]tetany[e2]  with metabolic acidosis and acute renal impairment) are described.
	(2, 16)	camptocormia	valproate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4366	Accordingly, [s1]camptocormia[e1] is a dose-dependent side effect of [s2]valproate[e2] 
	(24, 40)	abnormal posture of extreme forward flexion	valproate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4367	A mentally retarded 23-year-old woman with myoclonic astatic epilepsy developed an [s1]abnormal posture of extreme forward flexion[e1]  called camptocormia, during [s2]valproate[e2] monotherapy.
	(33, 40)	camptocormia	valproate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4368	A mentally retarded 23-year-old woman with myoclonic astatic epilepsy developed an abnormal posture of extreme forward flexion, called [s1]camptocormia[e1]  during [s2]valproate[e2] monotherapy.
	(0, 11)	Camptocormia	sodium valproate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4369	 [s1]Camptocormia[e1]  a new side effect of [s2]sodium valproate[e2] 
	(6, 17)	hepatopathy	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4370	Four weeks earlier she had developed [s1]hepatopathy[e1] during a regimen of [s2]carbamazepine[e2]  lynestrenol and sodium valproate.
	(6, 23)	hepatopathy	lynestrenol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4371	Four weeks earlier she had developed [s1]hepatopathy[e1] during a regimen of carbamazepine, [s2]lynestrenol[e2] and sodium valproate.
	(6, 29)	hepatopathy	sodium valproate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4372	Four weeks earlier she had developed [s1]hepatopathy[e1] during a regimen of carbamazepine, lynestrenol and [s2]sodium valproate[e2] 
	(0, 13)	Hepatopathy	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4373	 [s1]Hepatopathy[e1] subsided after the cessation of [s2]carbamazepine[e2] and lynestrenol.
	(0, 19)	Hepatopathy	lynestrenol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4374	 [s1]Hepatopathy[e1] subsided after the cessation of carbamazepine and [s2]lynestrenol[e2] 
	(19, 31)	lorazepam	seizures	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4375	A 10-year-old girl with Lennox-Gastaut syndrome who received intravenous [s1]lorazepam[e1] for atypical absence status [s2]seizures[e2] is reported.
	(0, 9)	Paradoxical precipitation of tonic seizures	lorazepam	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4376	 [s1]Paradoxical precipitation of tonic seizures[e1] by [s2]lorazepam[e2] in a child with atypical absence seizures.
	(0, 8)	Atrial fibrillation	methylprednisolone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4377	 [s1]Atrial fibrillation[e1] following [s2]methylprednisolone[e2] pulse therapy.
	(0, 21)	Isotretinoin	teratogenic effects	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4378	 [s1]Isotretinoin[e1]  a drug used for the treatment of acne, has been shown to have [s2]teratogenic effects[e2] 
	(0, 6)	Isotretinoin	teratogenicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4379	 [s1]Isotretinoin[e1]  [s2]teratogenicity[e2] 
	(6, 55)	isotretinoin	abnormalities of the corticospinal tracts	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4380	We report an additional case of [s1]isotretinoin[e1] teratogenicity in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and [s2]abnormalities of the corticospinal tracts[e2] 
	(6, 21)	isotretinoin	agenesis of the cerebellar vermis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4381	We report an additional case of [s1]isotretinoin[e1] teratogenicity in which the patient had [s2]agenesis of the cerebellar vermis[e2]  multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and abnormalities of the corticospinal tracts.
	(6, 49)	isotretinoin	hydrocephalus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4382	We report an additional case of [s1]isotretinoin[e1] teratogenicity in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, [s2]hydrocephalus[e2]  and abnormalities of the corticospinal tracts.
	(6, 34)	isotretinoin	multiple leptomeningeal neuroglial heterotopias	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4383	We report an additional case of [s1]isotretinoin[e1] teratogenicity in which the patient had agenesis of the cerebellar vermis, [s2]multiple leptomeningeal neuroglial heterotopias[e2]  hydrocephalus, and abnormalities of the corticospinal tracts.
	(6, 12)	isotretinoin	teratogenicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4384	We report an additional case of [s1]isotretinoin[e1]  [s2]teratogenicity[e2] in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and abnormalities of the corticospinal tracts.
	(3, 10)	allopurinol	hypersensitivity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4385	A case of [s1]allopurinol[e1]  [s2]hypersensitivity[e2]  possibly the first in a black African, is reported.
	(0, 7)	Allopurinol	hypersensitivity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4386	 [s1]Allopurinol[e1]  [s2]hypersensitivity[e2] 
	(1, 8)	allopurinol	hypersensitivity syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4387	The [s1]allopurinol[e1]  [s2]hypersensitivity syndrome[e2] is a rare adverse drug reaction.
	(0, 10)	Bone formation	prostaglandin-E2	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4388	 [s1]Bone formation[e1] induced in an infant by systemic [s2]prostaglandin-E2[e2] administration.
	(3, 13)	severe visual loss	vincristine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4389	A case of [s1]severe visual loss[e1] following a single dose of [s2]vincristine[e2] is described.
	(16, 24)	vincristine	severe visual loss	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4390	Although differential diagnostic alternatives can be considered in all described cases it is very likely that [s1]vincristine[e1] does cause [s2]severe visual loss[e2] in a small number of patients.
	(0, 10)	Severe visual loss	vincristine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4391	 [s1]Severe visual loss[e1] after a single dose of [s2]vincristine[e2] in a patient with spinal cord astrocytoma.
	(3, 9)	vincristine	optic nerve toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4392	The literature of [s1]vincristine[e1]  [s2]optic nerve toxicity[e2] is reviewed.
	(0, 10)	Visual loss	vincristine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4393	 [s1]Visual loss[e1] after a single small dose of [s2]vincristine[e2] has never been reported.
	(0, 7)	Niacin	reversible toxic cystoid maculopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4394	 [s1]Niacin[e1] causes a [s2]reversible toxic cystoid maculopathy[e2] that occurs in approximately 0.67% of patients taking high doses of the drug.
	(0, 5)	Niacin	maculopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4395	 [s1]Niacin[e1]  [s2]maculopathy[e2] 
	(11, 20)	niacin	visual symptoms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4396	The authors conclude that among patients taking high doses of oral [s1]niacin[e1] only those who experience [s2]visual symptoms[e2] need to be ophthalmologically evaluated.
	(3, 12)	niacin	cystoid maculopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4397	Three patients with [s1]niacin[e1] induced visual symptoms had [s2]cystoid maculopathy[e2] without leakage on fluorescein angiography, and a fourth patient with no fundus abnormality experienced cessation of visual symptoms upon discontinuation of niacin.
	(3, 9)	niacin	visual symptoms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4398	Three patients with [s1]niacin[e1] induced [s2]visual symptoms[e2] had cystoid maculopathy without leakage on fluorescein angiography, and a fourth patient with no fundus abnormality experienced cessation of visual symptoms upon discontinuation of niacin.
	(3, 9)	niacin	visual symptoms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4399	Three patients with [s1]niacin[e1] induced [s2]visual symptoms[e2] had cystoid maculopathy without leakage on fluorescein angiography, and a fourth patient with no fundus abnormality experienced cessation of visual symptoms upon discontinuation of niacin.
	(5, 19)	hypersensitivity syndrome	dapsone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4400	A case report of the [s1]hypersensitivity syndrome[e1] occurring in a patient being treated with [s2]dapsone[e2] for a brown recluse spider bite is presented.
	(1, 14)	dapsone	fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4401	A [s1]dapsone[e1] hypersensitivity syndrome, consisting of [s2]fever[e2]  headache, nausea, vomiting, lymphadenopathy, hepatitis, hemolysis, leukopenia, and mononucleosis, has been described in patients treated with the drug for leprosy.
	(1, 16)	dapsone	headache	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4402	A [s1]dapsone[e1] hypersensitivity syndrome, consisting of fever, [s2]headache[e2]  nausea, vomiting, lymphadenopathy, hepatitis, hemolysis, leukopenia, and mononucleosis, has been described in patients treated with the drug for leprosy.
	(1, 31)	dapsone	hemolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4403	A [s1]dapsone[e1] hypersensitivity syndrome, consisting of fever, headache, nausea, vomiting, lymphadenopathy, hepatitis, [s2]hemolysis[e2]  leukopenia, and mononucleosis, has been described in patients treated with the drug for leprosy.
	(1, 29)	dapsone	hepatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4404	A [s1]dapsone[e1] hypersensitivity syndrome, consisting of fever, headache, nausea, vomiting, lymphadenopathy, [s2]hepatitis[e2]  hemolysis, leukopenia, and mononucleosis, has been described in patients treated with the drug for leprosy.
	(1, 6)	dapsone	hypersensitivity syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4405	A [s1]dapsone[e1]  [s2]hypersensitivity syndrome[e2]  consisting of fever, headache, nausea, vomiting, lymphadenopathy, hepatitis, hemolysis, leukopenia, and mononucleosis, has been described in patients treated with the drug for leprosy.
	(1, 35)	dapsone	leukopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4406	A [s1]dapsone[e1] hypersensitivity syndrome, consisting of fever, headache, nausea, vomiting, lymphadenopathy, hepatitis, hemolysis, [s2]leukopenia[e2]  and mononucleosis, has been described in patients treated with the drug for leprosy.
	(1, 22)	dapsone	lymphadenopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4407	A [s1]dapsone[e1] hypersensitivity syndrome, consisting of fever, headache, nausea, vomiting, [s2]lymphadenopathy[e2]  hepatitis, hemolysis, leukopenia, and mononucleosis, has been described in patients treated with the drug for leprosy.
	(1, 41)	dapsone	mononucleosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4408	A [s1]dapsone[e1] hypersensitivity syndrome, consisting of fever, headache, nausea, vomiting, lymphadenopathy, hepatitis, hemolysis, leukopenia, and [s2]mononucleosis[e2]  has been described in patients treated with the drug for leprosy.
	(1, 18)	dapsone	nausea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4409	A [s1]dapsone[e1] hypersensitivity syndrome, consisting of fever, headache, [s2]nausea[e2]  vomiting, lymphadenopathy, hepatitis, hemolysis, leukopenia, and mononucleosis, has been described in patients treated with the drug for leprosy.
	(1, 20)	dapsone	vomiting	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4410	A [s1]dapsone[e1] hypersensitivity syndrome, consisting of fever, headache, nausea, [s2]vomiting[e2]  lymphadenopathy, hepatitis, hemolysis, leukopenia, and mononucleosis, has been described in patients treated with the drug for leprosy.
	(3, 8)	dapsone	hypersensitivity syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4411	Case report: [s1]dapsone[e1]  [s2]hypersensitivity syndrome[e2] associated with treatment of the bite of a brown recluse spider.
	(0, 8)	Rifampicin	adrenal insufficiency	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4412	 [s1]Rifampicin[e1] induced [s2]adrenal insufficiency[e2] in the acquired immunodeficiency syndrome: difficulties in diagnosis and treatment.
	(18, 47)	rifampicin	adrenal failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4413	We report the case of a patient with the acquired immunodeficiency syndrome treated with [s1]rifampicin[e1] who had a 'normal' screening test for adrenal insufficiency, yet had clinical evidence of [s2]adrenal failure[e2] 
	(4, 17)	cutaneous vasculitis	diltiazem	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4414	Two cases of widespread [s1]cutaneous vasculitis[e1] are described in association with [s2]diltiazem[e2]  a recently introduced calcium antagonist.
	(1, 11)	cutaneous vasculitis	diltiazem	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4415	Widespread [s1]cutaneous vasculitis[e1] associated with [s2]diltiazem[e2] 
	(4, 11)	nafcillin	seizures	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4416	Intraventricular [s1]nafcillin[e1] induced [s2]seizures[e2] in a neonate.
	(7, 18)	seizures	nafcillin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4417	We report a premature infant who developed [s1]seizures[e1] associated with intraventricular administration of [s2]nafcillin[e2] and discuss the need for electroencephalographic monitoring of patients receiving intraventricular antibiotics.
	(11, 32)	ischaemic cerebrovascular accident	streptokinase	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4418	A 58-year old patient is reported who developed an [s1]ischaemic cerebrovascular accident[e1] 22 hours after successful thrombolysis with [s2]streptokinase[e2] for life-threatening pulmonary emboli.
	(0, 11)	Thrombo-embolic complication	streptokinase	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4419	 [s1]Thrombo-embolic complication[e1] after [s2]streptokinase[e2] therapy of pulmonary emboli.
	(0, 23)	Renal hypophosphatemia	doxycycline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4420	 [s1]Renal hypophosphatemia[e1] in this patient was caused by the erroneous intake of 1 g [s2]doxycycline[e2] 
	(15, 61)	Creutzfeldt-Jakob disease	human growth hormone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4421	A clinically atypical, neuropathologically verified case of [s1]Creutzfeldt-Jakob disease[e1] is described in a 32-year-old New Zealand woman with idiopathic hypopituitarism who had been treated in late adolescence (1970 to 1973) with [s2]human growth hormone[e2] processed from pooled cadaveric pituitary glands.
	(4, 16)	Creutzfeldt-Jakob disease	human growth hormone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4422	A new case of [s1]Creutzfeldt-Jakob disease[e1] associated with [s2]human growth hormone[e2] therapy in New Zealand.
	(14, 24)	hepatotoxicity	choline magnesium trisalicylate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4423	A case of a 21-year-old woman who had developed mild [s1]hepatotoxicity[e1] while receiving [s2]choline magnesium trisalicylate[e2] therapy is described.
	(12, 29)	salicylate	hepatotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4424	Hepatotoxicity associated with choline magnesium tr [s1]salicylate[e1]  case report and review of salicylate-induced [s2]hepatotoxicity[e2] 
	(0, 10)	Hepatotoxicity	choline magnesium trisalicylate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4425	 [s1]Hepatotoxicity[e1] associated with [s2]choline magnesium trisalicylate[e2]  case report and review of salicylate-induced hepatotoxicity.
	(0, 7)	Salicylate	hepatotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4426	 [s1]Salicylate[e1] induced [s2]hepatotoxicity[e2] is reviewed.
	(9, 15)	salicylate	hepatotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4427	They continued to rise for five more days before [s1]salicylate[e1]  [s2]hepatotoxicity[e2] was suspected.
	(31, 37)	attacks of asthma	captopril	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4428	A 51-yr-old nonsmoking male patient without any history of previous allergies, asthma, hay fever, or urticaria developed [s1]attacks of asthma[e1] when [s2]captopril[e2] was added to the nadolol and dyazide treatment for his high blood pressure.
	(31, 48)	attacks of asthma	dyazide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4429	A 51-yr-old nonsmoking male patient without any history of previous allergies, asthma, hay fever, or urticaria developed [s1]attacks of asthma[e1] when captopril was added to the nadolol and [s2]dyazide[e2] treatment for his high blood pressure.
	(31, 44)	attacks of asthma	nadolol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4430	A 51-yr-old nonsmoking male patient without any history of previous allergies, asthma, hay fever, or urticaria developed [s1]attacks of asthma[e1] when captopril was added to the [s2]nadolol[e2] and dyazide treatment for his high blood pressure.
	(0, 12)	Captopril	asthma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4431	 [s1]Captopril[e1] related (and -induced?) [s2]asthma[e2] 
	(5, 11)	captopril	asthma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4432	This confirmed the history of [s1]captopril[e1] related [s2]asthma[e2] 
	(6, 12)	timolol	ocular pemphigoid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4433	We also describe a case of [s1]timolol[e1] induced [s2]ocular pemphigoid[e2] 
	(0, 12)	Deposits of plasma proteins in the skin	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4434	 [s1]Deposits of plasma proteins in the skin[e1] during treatment with [s2]carbamazepine[e2] and diphenylhydantoin.
	(0, 18)	Deposits of plasma proteins in the skin	diphenylhydantoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4435	 [s1]Deposits of plasma proteins in the skin[e1] during treatment with carbamazepine and [s2]diphenylhydantoin[e2] 
	(8, 15)	pain	desipramine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4436	The observations suggest that testicular swelling and [s1]pain[e1] are side effects of [s2]desipramine[e2] 
	(4, 15)	testicular swelling	desipramine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4437	The observations suggest that [s1]testicular swelling[e1] and pain are side effects of [s2]desipramine[e2] 
	(10, 16)	pain	desipramine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4438	Two patients are described who developed testicular swelling and [s1]pain[e1] during treatment with [s2]desipramine[e2] 
	(6, 16)	testicular swelling	desipramine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4439	Two patients are described who developed [s1]testicular swelling[e1] and pain during treatment with [s2]desipramine[e2] 
	(0, 20)	Benzocaine	methemoglobinemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4440	 [s1]Benzocaine[e1]  an ester-type local anesthetic, was believed responsible for apparent [s2]methemoglobinemia[e2] in a cat.
	(0, 6)	Benzocaine	methemoglobinemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4441	 [s1]Benzocaine[e1] induced [s2]methemoglobinemia[e2] has been reported in man, dogs, and cats.
	(0, 14)	Methemoglobinemia	benzocaine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4442	 [s1]Methemoglobinemia[e1] associated with dermal application of [s2]benzocaine[e2] cream in a cat.
	(11, 24)	erosion of a psoriatic plaque	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4443	A 43-year-old white man developed a shallow [s1]erosion of a psoriatic plaque[e1] after chronic administration of [s2]methotrexate[e2] 
	(0, 10)	Erosion of psoriatic plaques	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4444	 [s1]Erosion of psoriatic plaques[e1] after chronic [s2]methotrexate[e2] administration.
	(10, 37)	cyclosporine A	effective renal plasma flow	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4445	After a six-week course of low-dose [s1]cyclosporine A[e1]  she developed a severe but reversible loss of glomerular filtration rate and [s2]effective renal plasma flow[e2] despite of low cyclosporine A plasma levels.
	(10, 26)	cyclosporine A	loss of glomerular filtration rate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4446	After a six-week course of low-dose [s1]cyclosporine A[e1]  she developed a severe but reversible [s2]loss of glomerular filtration rate[e2] and effective renal plasma flow despite of low cyclosporine A plasma levels.
	(4, 57)	fall of the filtration fraction	cyclosporine A	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4447	Based upon the observed [s1]fall of the filtration fraction[e1]  the rise in the relative clearance of 99Tc-dimercaptosuccinic acid and the increase in proteinuria, we suggest that in this case the tubules and/or interstitium are the main targets for [s2]cyclosporine A[e2] nephrotoxicity.
	(31, 57)	increase in proteinuria	cyclosporine A	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4448	Based upon the observed fall of the filtration fraction, the rise in the relative clearance of 99Tc-dimercaptosuccinic acid and the [s1]increase in proteinuria[e1]  we suggest that in this case the tubules and/or interstitium are the main targets for [s2]cyclosporine A[e2] nephrotoxicity.
	(56, 64)	cyclosporine A	nephrotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4449	Based upon the observed fall of the filtration fraction, the rise in the relative clearance of 99Tc-dimercaptosuccinic acid and the increase in proteinuria, we suggest that in this case the tubules and/or interstitium are the main targets for [s1]cyclosporine A[e1]  [s2]nephrotoxicity[e2] 
	(13, 58)	rise in the relative clearance of 99Tc-dimercaptosuccinic acid	cyclosporine A	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4450	Based upon the observed fall of the filtration fraction, the [s1]rise in the relative clearance of 99Tc-dimercaptosuccinic acid[e1] and the increase in proteinuria, we suggest that in this case the tubules and/or interstitium are the main targets for [s2]cyclosporine A[e2] nephrotoxicity.
	(5, 14)	cyclosporine A	nephrotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4451	Unexpected severe reversible [s1]cyclosporine A[e1] induced [s2]nephrotoxicity[e2] in a patient with systemic lupus erythematosus and tubulointerstitial renal disease.
	(6, 41)	hyperthyroidism	propylthiouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4452	A patient is presented with typical [s1]hyperthyroidism[e1]  who developed a severe proximal muscle weakness and a raised creatine phosphokinase after treatment for hyperthyroidism with [s2]propylthiouracil[e2] (100 mg orally, three times a day).
	(22, 42)	raised creatine phosphokinase	propylthiouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4453	A patient is presented with typical hyperthyroidism, who developed a severe proximal muscle weakness and a [s1]raised creatine phosphokinase[e1] after treatment for hyperthyroidism with [s2]propylthiouracil[e2] (100 mg orally, three times a day).
	(14, 42)	severe proximal muscle weakness	propylthiouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4454	A patient is presented with typical hyperthyroidism, who developed a [s1]severe proximal muscle weakness[e1] and a raised creatine phosphokinase after treatment for hyperthyroidism with [s2]propylthiouracil[e2] (100 mg orally, three times a day).
	(0, 7)	Polymyositis	propylthiouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4455	 [s1]Polymyositis[e1] after [s2]propylthiouracil[e2] treatment for hyperthyroidism.
	(0, 13)	Cardiopulmonary arrest	phenytoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4456	 [s1]Cardiopulmonary arrest[e1] following intravenous [s2]phenytoin[e2] loading.
	(14, 26)	calcium hopantenate	pantothenic acid deficiency	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4457	Evidence obtained indicated that the Reye-like syndrome might be caused by [s1]calcium hopantenate[e1] possibly due to the induction of [s2]pantothenic acid deficiency[e2] 
	(5, 16)	Reye-like syndrome	calcium hopantenate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4458	Evidence obtained indicated that the [s1]Reye-like syndrome[e1] might be caused by [s2]calcium hopantenate[e2] possibly due to the induction of pantothenic acid deficiency.
	(0, 18)	Reye-like syndrome	calcium hopantenate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4459	 [s1]Reye-like syndrome[e1] following treatment with the pantothenic acid antagonist, [s2]calcium hopantenate[e2] 
	(5, 16)	fatal acute encephalopathy	calcium hopantenate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4460	Three senile patients developed [s1]fatal acute encephalopathy[e1] while receiving [s2]calcium hopantenate[e2] 
	(0, 12)	Dyspnea	morphine sulfate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4461	 [s1]Dyspnea[e1] possibly associated with controlled-release [s2]morphine sulfate[e2] tablets.
	(0, 10)	Anhedonic ejaculation	desipramine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4462	 [s1]Anhedonic ejaculation[e1] with [s2]desipramine[e2] 
	(5, 28)	anhedonic ejaculation	desipramine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4463	We report two patients with [s1]anhedonic ejaculation[e1] (ejaculation without orgasm) associated with initiation of treatment with [s2]desipramine[e2] 
	(12, 26)	ejaculation without orgasm	desipramine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4464	We report two patients with anhedonic ejaculation  [s1]ejaculation without orgasm[e1]  associated with initiation of treatment with [s2]desipramine[e2] 
	(0, 12)	Myoclonic spasms	morphine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4465	 [s1]Myoclonic spasms[e1] following intrathecal [s2]morphine[e2] 
	(3, 9)	halothane	hepatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4466	A case of [s1]halothane[e1] induced [s2]hepatitis[e2] is reported in a middle aged woman who underwent gastric surgery for morbid obesity.
	(0, 5)	Halothane	hepatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4467	 [s1]Halothane[e1]  [s2]hepatitis[e2] and prompt resolution with methionine therapy: case report.
	(2, 15)	porphyria cutanea tarda	cyclophosphamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4468	Development of [s1]porphyria cutanea tarda[e1] after treatment with [s2]cyclophosphamide[e2] 
	(19, 33)	porphyria cutanea tarda	cisplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4469	We report a 46-yr-old woman with ovarian carcinoma who developed [s1]porphyria cutanea tarda[e1] while undergoing treatment with [s2]cisplatin[e2] and cyclophosphamide.
	(19, 37)	porphyria cutanea tarda	cyclophosphamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4470	We report a 46-yr-old woman with ovarian carcinoma who developed [s1]porphyria cutanea tarda[e1] while undergoing treatment with cisplatin and [s2]cyclophosphamide[e2] 
	(0, 14)	Acute renal failure	iodine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4471	 [s1]Acute renal failure[e1] in a patient treated by continuous povidone [s2]iodine[e2] mediastinal irrigation.
	(0, 11)	Acute renal failure	povidone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4472	 [s1]Acute renal failure[e1] in a patient treated by continuous [s2]povidone[e2] iodine mediastinal irrigation.
	(21, 28)	PI	acute oliguric renal failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4473	We describe a 63 year old woman with a suppurative mediastinitis, treated with continuous [s1]PI[e1] irrigation who developed an [s2]acute oliguric renal failure[e2] 
	(24, 41)	epithelial crescents	D-penicillamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4474	A 56-year-old woman with scleroderma developed rapidly progressive glomerulonephritis with [s1]epithelial crescents[e1] associated with hemoptysis after 27 months of [s2]D-penicillamine[e2] therapy and a cumulative dose of 1,200 g.
	(31, 41)	hemoptysis	D-penicillamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4475	A 56-year-old woman with scleroderma developed rapidly progressive glomerulonephritis with epithelial crescents associated with [s1]hemoptysis[e1] after 27 months of [s2]D-penicillamine[e2] therapy and a cumulative dose of 1,200 g.
	(13, 41)	rapidly progressive glomerulonephritis	D-penicillamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4476	A 56-year-old woman with scleroderma developed [s1]rapidly progressive glomerulonephritis[e1] with epithelial crescents associated with hemoptysis after 27 months of [s2]D-penicillamine[e2] therapy and a cumulative dose of 1,200 g.
	(0, 9)	D-penicillamine	crescentic glomerulonephritis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4477	 [s1]D-penicillamine[e1] induced [s2]crescentic glomerulonephritis[e2]  report and review of the literature.
	(6, 15)	D-penicillamine	rapidly progressive glomerulonephritis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4478	The 9 other reported cases of [s1]D-penicillamine[e1] induced [s2]rapidly progressive glomerulonephritis[e2] have been reviewed.
	(0, 4)	Gold	pneumonitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4479	 [s1]Gold[e1] induced [s2]pneumonitis[e2] is a rare complication of gold salt therapy.
	(0, 4)	Gold	pneumonitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4480	 [s1]Gold[e1] induced [s2]pneumonitis[e2] 
	(7, 11)	gold	pneumonitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4481	This case supports the view that in [s1]gold[e1] induced [s2]pneumonitis[e2] a prolonged treatment with corticosteroids may be necessary, as lung function continued to improve.
	(13, 20)	gold	bilateral interstitial pulmonary abnormalities	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4482	We describe a patient with rheumatoid arthritis treated with [s1]gold[e1] salts, who developed [s2]bilateral interstitial pulmonary abnormalities[e2] and showed a dramatic response on corticosteroid therapy.
	(0, 4)	Gold	aplastic anemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4483	 [s1]Gold[e1] induced [s2]aplastic anemia[e2] 
	(3, 17)	gold	aplastic anemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4484	Three patients receiving [s1]gold[e1] salt treatment for rheumatoid arthritis developed severe [s2]aplastic anemia[e2] 
	(9, 18)	6-mercaptopurine	myelotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4485	Pharmacokinetic determinants of [s1]6-mercaptopurine[e1]  [s2]myelotoxicity[e2] and therapeutic failure in children with acute lymphoblastic leukemia.
	(2, 25)	cerebellar toxicity	HDARAC	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4486	Because the [s1]cerebellar toxicity[e1] may be worsened by continuation of therapy after initial onset of symptoms, prompt termination of [s2]HDARAC[e2] is recommended.
	(0, 6)	Cytarabine	cerebellar syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4487	 [s1]Cytarabine[e1] induced [s2]cerebellar syndrome[e2]  case report and literature review.
	(10, 28)	ataxia	HDARAC	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4488	During the first treatment, dysarthria and [s1]ataxia[e1] were seen after completion of the patient's eighth and final dose of [s2]HDARAC[e2] 
	(5, 28)	dysarthria	HDARAC	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4489	During the first treatment, [s1]dysarthria[e1] and ataxia were seen after completion of the patient's eighth and final dose of [s2]HDARAC[e2] 
	(1, 10)	neurotoxicity	HDARAC	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4490	The [s1]neurotoxicity[e1] seen with [s2]HDARAC[e2] is dose-related and has occurred in up to 60 percent of treated patients.
	(5, 14)	neurotoxicity	HDARAC	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4491	This case report illustrates the [s1]neurotoxicity[e1] unique to [s2]HDARAC[e2] 
	(0, 25)	Macular infarction	gentamicin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4492	 [s1]Macular infarction[e1] after endophthalmitis treated with vitrectomy and intravitreal [s2]gentamicin[e2] 
	(5, 19)	macular lesion	gentamicin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4493	We are concerned that the [s1]macular lesion[e1] was a retinal toxic effect of [s2]gentamicin[e2] because of the recent description of similar lesions occurring after the inadvertent intraocular injection of massive doses of this drug.
	(37, 58)	B-cell lymphoma	razoxane	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4494	A woman with a 20-year history of acral pustular psoriasis of Hallopeau and recurrent pustular lesions of the forearms and lower legs, developed a [s1]B-cell lymphoma[e1] of the lip following 4 1/2 years of treatment with [s2]razoxane[e2] 
	(23, 37)	hypogammaglobulinemia	gold	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4495	Extensive immunological investigations were performed in a patient with definite seronegative rheumatoid arthritis who developed [s1]hypogammaglobulinemia[e1] in the course of [s2]gold[e2] therapy.
	(0, 12)	Hypogammaglobulinemia	gold	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4496	 [s1]Hypogammaglobulinemia[e1] associated with [s2]gold[e2] therapy: evidence for a partial maturation blockade of B cells.
	(1, 16)	leucopenia	sodium nitroprusside	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4497	Transient [s1]leucopenia[e1] and thrombocytopenia associated with [s2]sodium nitroprusside[e2] infusion.
	(6, 16)	thrombocytopenia	sodium nitroprusside	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4498	Transient leucopenia and [s1]thrombocytopenia[e1] associated with [s2]sodium nitroprusside[e2] infusion.
	(0, 18)	Herpes simplex esophagitis	cyclosporine A	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4499	 [s1]Herpes simplex esophagitis[e1] in a renal transplant patient treated with [s2]cyclosporine A[e2]  a case report.
	(6, 22)	herpes esophagitis	Cyclosporine A	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4500	We report the first case of [s1]herpes esophagitis[e1] in a renal transplant patient treated with [s2]Cyclosporine A[e2] while on chronic steroid therapy.
	(5, 20)	Cyclosporine A	herpes esophagitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4501	With the increasing use of [s1]Cyclosporine A[e1] in transplant patients, the incidence of [s2]herpes esophagitis[e2] may increase.
	(3, 7)	insulin	hypoglycemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4502	Administration of excessive [s1]insulin[e1] induced [s2]hypoglycemia[e2] within 4 to 8 hours, followed by rebound hyperglycemia.
	(3, 21)	insulin	rebound hyperglycemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4503	Administration of excessive [s1]insulin[e1] induced hypoglycemia within 4 to 8 hours, followed by [s2]rebound hyperglycemia[e2] 
	(0, 24)	Posthypoglycemic hyperglycemia	insulin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4504	 [s1]Posthypoglycemic hyperglycemia[e1] (rebound hyperglycemia) after overdosing of [s2]insulin[e2] was diagnosed in 6 cats with diabetes mellitus.
	(10, 22)	rebound hyperglycemia	insulin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4505	Posthypoglycemic hyperglycemia  [s1]rebound hyperglycemia[e1]  after overdosing of [s2]insulin[e2] was diagnosed in 6 cats with diabetes mellitus.
	(1, 12)	hyperglycemia	insulin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4506	Rebound [s1]hyperglycemia[e1] following overdosing of [s2]insulin[e2] in cats with diabetes mellitus.
	(0, 14)	Rebound hyperglycemia	protamine hagedorn	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4507	 [s1]Rebound hyperglycemia[e1] was observed with both intermediate (neutral [s2]protamine hagedorn[e2]  and long-acting (protamine zinc iletin) insulins, and the range of insulin doses at which the disorder developed overlapped previously determined therapeutic doses for these insulins in the cat.
	(0, 25)	Rebound hyperglycemia	protamine zinc iletin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4508	 [s1]Rebound hyperglycemia[e1] was observed with both intermediate (neutral protamine hagedorn) and long-acting  [s2]protamine zinc iletin[e2]  insulins, and the range of insulin doses at which the disorder developed overlapped previously determined therapeutic doses for these insulins in the cat.
	(0, 6)	Captopril	lichen planus pemphigoides	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4509	 [s1]Captopril[e1] induced [s2]lichen planus pemphigoides[e2] with pemphigus-like features.
	(6, 19)	bullous lichenoid eruption	captopril	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4510	We report a case of a [s1]bullous lichenoid eruption[e1] due to the intake of [s2]captopril[e2] 
	(15, 25)	BCG	osteomyelitis in the left calcaneus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4511	An 8-year-old girl, who had been vaccinated with [s1]BCG[e1] without subsequent regional reactions, developed [s2]osteomyelitis in the left calcaneus[e2] 7 months later.
	(0, 10)	Metastatic osteomyelitis	BCG	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4512	 [s1]Metastatic osteomyelitis[e1] following [s2]BCG[e2] vaccination.
	(12, 22)	minoxidil	arteriosclerotic disease	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4513	One of the subjects who was using extemporaneous topical [s1]minoxidil[e1] had hypertension and [s2]arteriosclerotic disease[e2] and the other died of a myocardial infarction.
	(12, 19)	minoxidil	hypertension	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4514	One of the subjects who was using extemporaneous topical [s1]minoxidil[e1] had [s2]hypertension[e2] and arteriosclerotic disease and the other died of a myocardial infarction.
	(12, 34)	minoxidil	myocardial infarction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4515	One of the subjects who was using extemporaneous topical [s1]minoxidil[e1] had hypertension and arteriosclerotic disease and the other died of a [s2]myocardial infarction[e2] 
	(0, 7)	Amoxapine	cognitive impairment	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4516	 [s1]Amoxapine[e1] induced [s2]cognitive impairment[e2] in two patients.
	(7, 18)	cognitive impairments	amoxapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4517	Two patients are described in whom subtle [s1]cognitive impairments[e1] are associated with therapeutic doses of [s2]amoxapine[e2] 
	(18, 29)	severe hypersensitivity reaction	ibuprofen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4518	A 23-year-old woman with systemic lupus erythematosus had a [s1]severe hypersensitivity reaction[e1] to the drug [s2]ibuprofen[e2] 
	(0, 10)	Severe systemic hypersensitivity reaction	ibuprofen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4519	 [s1]Severe systemic hypersensitivity reaction[e1] to [s2]ibuprofen[e2] occurring after prolonged therapy.
	(7, 15)	chloramphenicol	hypersensitivity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4520	A brief review of reported cases of [s1]chloramphenicol[e1]  [s2]hypersensitivity[e2] in the English-language literature, as well as possible alternative explanations in this case, are provided.
	(0, 8)	Hypersensitivity reaction	chloramphenicol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4521	 [s1]Hypersensitivity reaction[e1] following [s2]chloramphenicol[e2] administration in a patient with typhoid fever.
	(0, 9)	Hypersensitivity reactions	chloramphenicol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4522	 [s1]Hypersensitivity reactions[e1] due to [s2]chloramphenicol[e2] are rarely reported in the literature.
	(16, 29)	hypersensitivity reaction	chloramphenicol sodium succinate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4523	We present a case report of a patient with typhoid fever who experienced a [s1]hypersensitivity reaction[e1] subsequent to the infusion of [s2]chloramphenicol sodium succinate[e2] 
	(13, 25)	penicillamine	brain lesions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4524	Replicate brain magnetic resonance imaging examinations after six weeks and 11 months of [s1]penicillamine[e1] therapy documented the development of new [s2]brain lesions[e2] during this period, while liver biopsy specimen data disclosed that excellent hepatic decoppering had occurred.
	(20, 49)	penicillamine	neurologic disease	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4525	To develop information on the relative rarity or frequency of neurologic worsening with the initiation of [s1]penicillamine[e1] therapy, we conducted a retrospective survey of 25 additional patients with Wilson's disease who met the criteria of presenting with [s2]neurologic disease[e2] and having been treated with penicillamine.
	(11, 22)	neurologic worsening	penicillamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4526	To develop information on the relative rarity or frequency of [s1]neurologic worsening[e1] with the initiation of [s2]penicillamine[e2] therapy, we conducted a retrospective survey of 25 additional patients with Wilson's disease who met the criteria of presenting with neurologic disease and having been treated with penicillamine.
	(20, 31)	D-penicillamine	neurologic deterioration	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4527	We describe a patient with Wilson's disease who presented with neurologic disease, was treated with [s1]D-penicillamine[e1]  and suffered sudden [s2]neurologic deterioration[e2] coincident with therapy.
	(0, 18)	Worsening of neurologic syndrome	penicillamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4528	 [s1]Worsening of neurologic syndrome[e1] in patients with Wilson's disease with initial [s2]penicillamine[e2] therapy.
	(1, 10)	upper tract neoplasms	cyclophosphamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4529	Other [s1]upper tract neoplasms[e1] after [s2]cyclophosphamide[e2] are reviewed.
	(0, 11)	Upper tract urothelial malignancy	cyclophosphamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4530	 [s1]Upper tract urothelial malignancy[e1] after [s2]cyclophosphamide[e2] therapy: a case report and literature review.
	(18, 35)	distal ureter without transitional cell carcinoma of the bladder	cyclophosphamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4531	We report an unusual case of simultaneous transitional cell carcinoma of the renal pelvis and [s1]distal ureter without transitional cell carcinoma of the bladder[e1] occurring after chronic [s2]cyclophosphamide[e2] therapy for nonHodgkin's lymphoma.
	(7, 35)	transitional cell carcinoma of the renal pelvis	cyclophosphamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4532	We report an unusual case of simultaneous [s1]transitional cell carcinoma of the renal pelvis[e1] and distal ureter without transitional cell carcinoma of the bladder occurring after chronic [s2]cyclophosphamide[e2] therapy for nonHodgkin's lymphoma.
	(0, 11)	Progressive pulmonary fibrosis	cyclophosphamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4533	 [s1]Progressive pulmonary fibrosis[e1] complicating [s2]cyclophosphamide[e2] therapy.
	(11, 22)	cyclophosphamide	severe restrictive ventilatory defect	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4534	The changes were progressive regardless of discontinuation of [s1]cyclophosphamide[e1] and led to [s2]severe restrictive ventilatory defect[e2] 
	(0, 11)	Torsade de pointes	amiodarone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4535	 [s1]Torsade de pointes[e1] during loading with [s2]amiodarone[e2] 
	(0, 15)	Torsade de pointes	amiodarone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4536	 [s1]Torsade de pointes[e1] represents a potential complication of chronic [s2]amiodarone[e2] therapy.
	(5, 19)	torsade de pointes	amiodarone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4537	We report a case of [s1]torsade de pointes[e1] following a single oral dose of [s2]amiodarone[e2] (1400 mg or 30 mg kg-1) administered after short intravenous loading for prevention of paroxysmal atrial flutter.
	(0, 11)	Pulmonary edema	ritodrine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4538	 [s1]Pulmonary edema[e1] as a delayed complication of [s2]ritodrine[e2] therapy.
	(0, 12)	Pulmonary edema	ritodrine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4539	 [s1]Pulmonary edema[e1] occurred 24 hours after intravenous [s2]ritodrine[e2] therapy and 10 hours after subcutaneous terbutaline therapy.
	(0, 24)	Pulmonary edema	terbutaline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4540	 [s1]Pulmonary edema[e1] occurred 24 hours after intravenous ritodrine therapy and 10 hours after subcutaneous [s2]terbutaline[e2] therapy.
	(0, 31)	Cyclosporin	abnormalities in liver function tests	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4541	 [s1]Cyclosporin[e1] side effects included hirsutism, hypertension, increased blood levels of urea and creatinine, and [s2]abnormalities in liver function tests[e2] 
	(0, 10)	Cyclosporin	hirsutism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4542	 [s1]Cyclosporin[e1] side effects included [s2]hirsutism[e2]  hypertension, increased blood levels of urea and creatinine, and abnormalities in liver function tests.
	(0, 15)	Cyclosporin	hypertension	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4543	 [s1]Cyclosporin[e1] side effects included hirsutism, [s2]hypertension[e2]  increased blood levels of urea and creatinine, and abnormalities in liver function tests.
	(0, 18)	Cyclosporin	increased blood levels of urea and creatinine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4544	 [s1]Cyclosporin[e1] side effects included hirsutism, hypertension, [s2]increased blood levels of urea and creatinine[e2]  and abnormalities in liver function tests.
	(0, 14)	Rupture of a cerebral aneurysm	nifedipine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4545	 [s1]Rupture of a cerebral aneurysm[e1] associated with [s2]nifedipine[e2] treatment.
	(2, 28)	rupture of a cerebral arterial aneurysm	nifedipine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4546	We describe [s1]rupture of a cerebral arterial aneurysm[e1] in a 32 year old hypertensive woman following the introduction of [s2]nifedipine[e2] treatment.
	(5, 34)	prazosin	severe drop in blood pressure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4547	A small initial dose of [s1]prazosin[e1] ranging from 0.5 to 1 mg has been recommended to avoid the first-dose phenomenon characterized by a sudden and [s2]severe drop in blood pressure[e2] after the administration of the first dose of prazosin.
	(5, 34)	prazosin	severe drop in blood pressure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4548	A small initial dose of [s1]prazosin[e1] ranging from 0.5 to 1 mg has been recommended to avoid the first-dose phenomenon characterized by a sudden and [s2]severe drop in blood pressure[e2] after the administration of the first dose of prazosin.
	(0, 14)	Prazosin	hemorrhagic stroke	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4549	 [s1]Prazosin[e1] induced first-dose phenomenon possibly associated with [s2]hemorrhagic stroke[e2]  a report of three cases.
	(1, 15)	fatal massive pulmonary embolus	streptokinase	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4550	A [s1]fatal massive pulmonary embolus[e1] developed in a patient treated with [s2]streptokinase[e2] for acute deep vein thrombosis.
	(0, 11)	Massive pulmonary embolism	streptokinase	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4551	 [s1]Massive pulmonary embolism[e1] complicating [s2]streptokinase[e2] treatment for deep vein thrombosis.
	(0, 7)	Fatal digoxin poisoning	digoxin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4552	 [s1]Fatal digoxin poisoning[e1]  [s2]digoxin[e2] poisoning: an unsuccessful resuscitation with use of digoxin-immune Fab.
	(3, 10)	phenytoin	hepatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4553	A case of [s1]phenytoin[e1] induced [s2]hepatitis[e2] with mononucleosis is reported, and syndromes associated with phenytoin hypersensitivity reactions are discussed.
	(3, 28)	phenytoin	hypersensitivity reactions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4554	A case of [s1]phenytoin[e1] induced hepatitis with mononucleosis is reported, and syndromes associated with phenytoin [s2]hypersensitivity reactions[e2] are discussed.
	(3, 12)	phenytoin	mononucleosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4555	A case of [s1]phenytoin[e1] induced hepatitis with [s2]mononucleosis[e2] is reported, and syndromes associated with phenytoin hypersensitivity reactions are discussed.
	(0, 7)	Phenytoin	hypersensitivity reactions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4556	 [s1]Phenytoin[e1] induced [s2]hypersensitivity reactions[e2] 
	(11, 46)	phenytoin	pruritus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4557	Phenytoin was discontinued after admission; however, [s1]phenytoin[e1] 1 g i.v. was given for a tonic-clonic seizure two days after admission, after which swelling of the face and legs and [s2]pruritus[e2] developed.
	(11, 39)	phenytoin	swelling of the face and legs	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4558	Phenytoin was discontinued after admission; however, [s1]phenytoin[e1] 1 g i.v. was given for a tonic-clonic seizure two days after admission, after which [s2]swelling of the face and legs[e2] and pruritus developed.
	(1, 15)	phenytoin	dermatologic, lymphoid, or hepatic syndromes	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4559	Serious [s1]phenytoin[e1] hypersensitivity reactions may appear as [s2]dermatologic, lymphoid, or hepatic syndromes[e2] 
	(1, 7)	phenytoin	hypersensitivity reactions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4560	Serious [s1]phenytoin[e1]  [s2]hypersensitivity reactions[e2] may appear as dermatologic, lymphoid, or hepatic syndromes.
	(13, 34)	carbamazepine	leukopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4561	She was receiving phenytoin sodium 300 mg/day; [s1]carbamazepine[e1] 200 mg four times daily had been discontinued four days before admission because of [s2]leukopenia[e2] 
	(3, 34)	phenytoin sodium	leukopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4562	She was receiving [s1]phenytoin sodium[e1] 300 mg/day; carbamazepine 200 mg four times daily had been discontinued four days before admission because of [s2]leukopenia[e2] 
	(3, 29)	phenytoin	fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4563	The possibility of [s1]phenytoin[e1] hypersensitivity reactions should be considered when patients receiving phenytoin have unusual symptoms, particularly [s2]fever[e2]  rash, and lymphadenopathy.
	(3, 29)	phenytoin	fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4564	The possibility of [s1]phenytoin[e1] hypersensitivity reactions should be considered when patients receiving phenytoin have unusual symptoms, particularly [s2]fever[e2]  rash, and lymphadenopathy.
	(3, 9)	phenytoin	hypersensitivity reactions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4565	The possibility of [s1]phenytoin[e1]  [s2]hypersensitivity reactions[e2] should be considered when patients receiving phenytoin have unusual symptoms, particularly fever, rash, and lymphadenopathy.
	(3, 9)	phenytoin	hypersensitivity reactions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4566	The possibility of [s1]phenytoin[e1]  [s2]hypersensitivity reactions[e2] should be considered when patients receiving phenytoin have unusual symptoms, particularly fever, rash, and lymphadenopathy.
	(3, 34)	phenytoin	lymphadenopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4567	The possibility of [s1]phenytoin[e1] hypersensitivity reactions should be considered when patients receiving phenytoin have unusual symptoms, particularly fever, rash, and [s2]lymphadenopathy[e2] 
	(3, 34)	phenytoin	lymphadenopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4568	The possibility of [s1]phenytoin[e1] hypersensitivity reactions should be considered when patients receiving phenytoin have unusual symptoms, particularly fever, rash, and [s2]lymphadenopathy[e2] 
	(3, 31)	phenytoin	rash	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4569	The possibility of [s1]phenytoin[e1] hypersensitivity reactions should be considered when patients receiving phenytoin have unusual symptoms, particularly fever, [s2]rash[e2]  and lymphadenopathy.
	(3, 31)	phenytoin	rash	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4570	The possibility of [s1]phenytoin[e1] hypersensitivity reactions should be considered when patients receiving phenytoin have unusual symptoms, particularly fever, [s2]rash[e2]  and lymphadenopathy.
	(17, 35)	fulminant hepatic failure	nicotinic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4571	It was restarted 6 weeks later, and 10 weeks after that, the patient presented with [s1]fulminant hepatic failure[e1]  which resolved rapidly after cessation of [s2]nicotinic acid[e2] therapy.
	(0, 7)	Nicotinic acid	fulminant hepatic failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4572	 [s1]Nicotinic acid[e1] induced [s2]fulminant hepatic failure[e2] 
	(3, 81)	nicotinic acid	hepatotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4573	We suggest that [s1]nicotinic acid[e1] was the cause of his liver disease, that this case is of particular note because of the rather short period of therapy before the onset of liver injury and the severity of the hepatic failure, and that the probable increased use of nicotinic acid for serum cholesterol control makes it especially important for physicians and their patients to be alert to the signs of [s2]hepatotoxicity[e2] 
	(3, 14)	nicotinic acid	liver disease	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4574	We suggest that [s1]nicotinic acid[e1] was the cause of his [s2]liver disease[e2]  that this case is of particular note because of the rather short period of therapy before the onset of liver injury and the severity of the hepatic failure, and that the probable increased use of nicotinic acid for serum cholesterol control makes it especially important for physicians and their patients to be alert to the signs of hepatotoxicity.
	(3, 14)	nicotinic acid	liver disease	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4575	We suggest that [s1]nicotinic acid[e1] was the cause of his [s2]liver disease[e2]  that this case is of particular note because of the rather short period of therapy before the onset of liver injury and the severity of the hepatic failure, and that the probable increased use of nicotinic acid for serum cholesterol control makes it especially important for physicians and their patients to be alert to the signs of hepatotoxicity.
	(10, 42)	athelia	methimazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4576	An infant girl with choanal atresia, [s1]athelia[e1]  minor anomalies, and mild to moderate mental retardation was born to a woman treated for hyperthyroidism throughout pregnancy with [s2]methimazole[e2] and propranolol.
	(10, 47)	athelia	propranolol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4577	An infant girl with choanal atresia, [s1]athelia[e1]  minor anomalies, and mild to moderate mental retardation was born to a woman treated for hyperthyroidism throughout pregnancy with methimazole and [s2]propranolol[e2] 
	(4, 42)	choanal atresia	methimazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4578	An infant girl with [s1]choanal atresia[e1]  athelia, minor anomalies, and mild to moderate mental retardation was born to a woman treated for hyperthyroidism throughout pregnancy with [s2]methimazole[e2] and propranolol.
	(4, 47)	choanal atresia	propranolol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4579	An infant girl with [s1]choanal atresia[e1]  athelia, minor anomalies, and mild to moderate mental retardation was born to a woman treated for hyperthyroidism throughout pregnancy with methimazole and [s2]propranolol[e2] 
	(23, 43)	mental retardation	methimazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4580	An infant girl with choanal atresia, athelia, minor anomalies, and mild to moderate [s1]mental retardation[e1] was born to a woman treated for hyperthyroidism throughout pregnancy with [s2]methimazole[e2] and propranolol.
	(23, 48)	mental retardation	propranolol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4581	An infant girl with choanal atresia, athelia, minor anomalies, and mild to moderate [s1]mental retardation[e1] was born to a woman treated for hyperthyroidism throughout pregnancy with methimazole and [s2]propranolol[e2] 
	(6, 11)	athelia	methimazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4582	Choanal atresia and [s1]athelia[e1]  [s2]methimazole[e2] teratogenicity or a new syndrome?
	(0, 12)	Choanal atresia	methimazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4583	 [s1]Choanal atresia[e1] and athelia: [s2]methimazole[e2] teratogenicity or a new syndrome?
	(10, 16)	methimazole	teratogenicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4584	Choanal atresia and athelia: [s1]methimazole[e1]  [s2]teratogenicity[e2] or a new syndrome?
	(9, 15)	methimazole	teratogenicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4585	The patient's defects may be due to [s1]methimazole[e1]  [s2]teratogenicity[e2] or could represent a previously undescribed syndrome affecting ectodermal structures.
	(0, 16)	Toxic epidermal necrolysis	5-fluorocytosine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4586	 [s1]Toxic epidermal necrolysis[e1] resulted after 19 days of treatment with [s2]5-fluorocytosine[e2] and amphotericin B.
	(0, 24)	Toxic epidermal necrolysis	amphotericin B	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4587	 [s1]Toxic epidermal necrolysis[e1] resulted after 19 days of treatment with 5-fluorocytosine and [s2]amphotericin B[e2] 
	(19, 33)	cyclophosphamide	abdominal right lower quadrant pain	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4588	Five and one-half years after the diagnosis of myeloma, while in remission on [s1]cyclophosphamide[e1] therapy, the patient experienced severe [s2]abdominal right lower quadrant pain[e2] due to a large cecal lymphoma.
	(19, 42)	cyclophosphamide	cecal lymphoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4589	Five and one-half years after the diagnosis of myeloma, while in remission on [s1]cyclophosphamide[e1] therapy, the patient experienced severe abdominal right lower quadrant pain due to a large [s2]cecal lymphoma[e2] 
	(5, 48)	amiodarone	fall in prothrombin time	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4590	After therapy with parenteral [s1]amiodarone[e1] (2300 mg in 3 days) and other measures, signs of congestive heart failure disappeared; subsequently the patient developed jaundice, marked increase in serum transaminase levels and [s2]fall in prothrombin time[e2]  and histologic changes of severe centrilobular necrosis were observed in hepatic biopsy.
	(5, 35)	amiodarone	jaundice	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4591	After therapy with parenteral [s1]amiodarone[e1] (2300 mg in 3 days) and other measures, signs of congestive heart failure disappeared; subsequently the patient developed [s2]jaundice[e2]  marked increase in serum transaminase levels and fall in prothrombin time, and histologic changes of severe centrilobular necrosis were observed in hepatic biopsy.
	(5, 39)	amiodarone	marked increase in serum transaminase levels	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4592	After therapy with parenteral [s1]amiodarone[e1] (2300 mg in 3 days) and other measures, signs of congestive heart failure disappeared; subsequently the patient developed jaundice, [s2]marked increase in serum transaminase levels[e2] and fall in prothrombin time, and histologic changes of severe centrilobular necrosis were observed in hepatic biopsy.
	(5, 62)	amiodarone	severe centrilobular necrosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4593	After therapy with parenteral [s1]amiodarone[e1] (2300 mg in 3 days) and other measures, signs of congestive heart failure disappeared; subsequently the patient developed jaundice, marked increase in serum transaminase levels and fall in prothrombin time, and histologic changes of [s2]severe centrilobular necrosis[e2] were observed in hepatic biopsy.
	(6, 13)	acute hepatitis	amiodarone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4594	A patient with acute changes suggesting [s1]acute hepatitis[e1] after parenteral [s2]amiodarone[e2] administration is described.
	(2, 9)	acute hepatitis	amiodarone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4595	Probable early [s1]acute hepatitis[e1] with parenteral [s2]amiodarone[e2] 
	(4, 15)	amiodarone	acute hepatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4596	Therefore, parenteral [s1]amiodarone[e1] was implicated as the cause of [s2]acute hepatitis[e2] in this patient.
	(2, 14)	hyperkalemic	timolol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4597	He became [s1]hyperkalemic[e1] on rechallenge with [s2]timolol[e2] and normokalemic following its withdrawal.
	(0, 11)	Severe hyperkalemia	timolol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4598	 [s1]Severe hyperkalemia[e1] as a complication of [s2]timolol[e2]  a topically applied beta-adrenergic antagonist.
	(0, 25)	Severe hyperkalemia	prednisone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4599	 [s1]Severe hyperkalemia[e1] occurred in a patient with radiation pneumonitis and glaucoma shortly after beginning [s2]prednisone[e2] therapy.
	(0, 16)	Noncardiogenic pulmonary edema	mono-octanoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4600	 [s1]Noncardiogenic pulmonary edema[e1] during intrabiliary infusion of [s2]mono-octanoin[e2] 
	(6, 23)	noncardiogenic pulmonary edema	monooctanoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4601	We describe a patient in whom [s1]noncardiogenic pulmonary edema[e1] developed during intrabiliary infusion of [s2]monooctanoin[e2] 
	(0, 19)	Paroxysmal supraventricular tachycardia	cisplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4602	 [s1]Paroxysmal supraventricular tachycardia[e1] during treatment with [s2]cisplatin[e2] and etoposide combination.
	(0, 23)	Paroxysmal supraventricular tachycardia	etoposide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4603	 [s1]Paroxysmal supraventricular tachycardia[e1] during treatment with cisplatin and [s2]etoposide[e2] combination.
	(24, 41)	paroxysmal supraventricular tachycardia	cisplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4604	We report a case of a 60-year-old woman affected by squamous lung carcinoma, who developed [s1]paroxysmal supraventricular tachycardia[e1] during [s2]cisplatin[e2] and etoposide combination chemotherapy.
	(24, 45)	paroxysmal supraventricular tachycardia	etoposide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4605	We report a case of a 60-year-old woman affected by squamous lung carcinoma, who developed [s1]paroxysmal supraventricular tachycardia[e1] during cisplatin and [s2]etoposide[e2] combination chemotherapy.
	(16, 32)	decrease in theophylline clearance	viloxazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4606	A case is reported of theophylline intoxication due to a dramatic [s1]decrease in theophylline clearance[e1] following concomitant administration of [s2]viloxazine[e2] 
	(5, 14)	theophylline intoxication	theophylline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4607	A case is reported of [s1]theophylline intoxication[e1]  [s2]theophylline[e2] intoxication due to a dramatic decrease in theophylline clearance following concomitant administration of viloxazine.
	(5, 32)	theophylline intoxication	viloxazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4608	A case is reported of [s1]theophylline intoxication[e1] due to a dramatic decrease in theophylline clearance following concomitant administration of [s2]viloxazine[e2] 
	(8, 15)	viloxazine	decrease in clearance	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4609	Theophylline intoxication following [s1]viloxazine[e1] induced [s2]decrease in clearance[e2] 
	(0, 18)	Theophylline intoxication	Theophylline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4610	 [s1]Theophylline intoxication[e1] following viloxazine induced decrease in clearance [s2]Theophylline[e2] intoxication following viloxazine induced decrease in clearance.
	(0, 10)	Theophylline intoxication	viloxazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4611	 [s1]Theophylline intoxication[e1] following [s2]viloxazine[e2] induced decrease in clearance.
	(7, 21)	nitrofurantoin	eosinophilic pneumonia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4612	Idiosyncratic pulmonary reactions to [s1]nitrofurantoin[e1] are not unusual, often presenting as [s2]eosinophilic pneumonia[e2] 
	(0, 9)	Idiosyncratic pulmonary reactions	nitrofurantoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4613	 [s1]Idiosyncratic pulmonary reactions[e1] to [s2]nitrofurantoin[e2] are not unusual, often presenting as eosinophilic pneumonia.
	(0, 11)	Acute myocardial necrosis	amsacrine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4614	 [s1]Acute myocardial necrosis[e1] during administration of [s2]amsacrine[e2] 
	(26, 33)	amsacrine	cardiotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4615	In addition to the recognized arrhythmic complications, the authors emphasize myocardial necrosis as a possible further manifestation of [s1]amsacrine[e1] related [s2]cardiotoxicity[e2] 
	(15, 28)	myocardial necrosis	amsacrine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4616	In addition to the recognized arrhythmic complications, the authors emphasize [s1]myocardial necrosis[e1] as a possible further manifestation of [s2]amsacrine[e2] related cardiotoxicity.
	(18, 38)	acute myocardial infarction	amsacrine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4617	The authors report a case of focal myocardial necrosis, presenting clinically as an [s1]acute myocardial infarction[e1] during the administration of the antineoplastic drug, [s2]amsacrine[e2]  in a patient without coronary artery disease.
	(6, 37)	focal myocardial necrosis	amsacrine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4618	The authors report a case of [s1]focal myocardial necrosis[e1]  presenting clinically as an acute myocardial infarction during the administration of the antineoplastic drug, [s2]amsacrine[e2]  in a patient without coronary artery disease.
	(5, 39)	phenobarbital	alopecia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4619	A child in whom a [s1]phenobarbital[e1] hypersensitivity drug reaction developed which consisted of fever, a pruritic desquamating erythrodermic rash, [s2]alopecia[e2]  icterus, protein-losing enteropathy, myositis, and nephritis, is described.
	(5, 24)	phenobarbital	a pruritic desquamating erythrodermic rash	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4620	A child in whom a [s1]phenobarbital[e1] hypersensitivity drug reaction developed which consisted of fever, [s2]a pruritic desquamating erythrodermic rash[e2]  alopecia, icterus, protein-losing enteropathy, myositis, and nephritis, is described.
	(5, 22)	phenobarbital	fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4621	A child in whom a [s1]phenobarbital[e1] hypersensitivity drug reaction developed which consisted of [s2]fever[e2]  a pruritic desquamating erythrodermic rash, alopecia, icterus, protein-losing enteropathy, myositis, and nephritis, is described.
	(5, 12)	phenobarbital	hypersensitivity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4622	A child in whom a [s1]phenobarbital[e1]  [s2]hypersensitivity[e2] drug reaction developed which consisted of fever, a pruritic desquamating erythrodermic rash, alopecia, icterus, protein-losing enteropathy, myositis, and nephritis, is described.
	(5, 43)	phenobarbital	icterus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4623	A child in whom a [s1]phenobarbital[e1] hypersensitivity drug reaction developed which consisted of fever, a pruritic desquamating erythrodermic rash, alopecia, [s2]icterus[e2]  protein-losing enteropathy, myositis, and nephritis, is described.
	(5, 53)	phenobarbital	myositis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4624	A child in whom a [s1]phenobarbital[e1] hypersensitivity drug reaction developed which consisted of fever, a pruritic desquamating erythrodermic rash, alopecia, icterus, protein-losing enteropathy, [s2]myositis[e2]  and nephritis, is described.
	(5, 58)	phenobarbital	nephritis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4625	A child in whom a [s1]phenobarbital[e1] hypersensitivity drug reaction developed which consisted of fever, a pruritic desquamating erythrodermic rash, alopecia, icterus, protein-losing enteropathy, myositis, and [s2]nephritis[e2]  is described.
	(5, 46)	phenobarbital	protein-losing enteropathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4626	A child in whom a [s1]phenobarbital[e1] hypersensitivity drug reaction developed which consisted of fever, a pruritic desquamating erythrodermic rash, alopecia, icterus, [s2]protein-losing enteropathy[e2]  myositis, and nephritis, is described.
	(0, 13)	Graft versus host-like illness	phenobarbital	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4627	 [s1]Graft versus host-like illness[e1] in a child with [s2]phenobarbital[e2] hypersensitivity.
	(11, 18)	phenobarbital	hypersensitivity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4628	Graft versus host-like illness in a child with [s1]phenobarbital[e1]  [s2]hypersensitivity[e2] 
	(8, 24)	autoimmune cell-mediated hypersensitivity	phenobarbital	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4629	The clinical findings and laboratory studies suggested an [s1]autoimmune cell-mediated hypersensitivity[e1] reaction triggered by [s2]phenobarbital[e2] 
	(0, 12)	Duodenal ulceration	tolazoline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4630	 [s1]Duodenal ulceration[e1]  a complication of [s2]tolazoline[e2] therapy.
	(5, 15)	Tolazoline	duodenal ulceration	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4631	Two patients who were receiving [s1]Tolazoline[e1] by infusion developed [s2]duodenal ulceration[e2] and subsequent intestinal perforation.
	(5, 23)	Tolazoline	intestinal perforation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4632	Two patients who were receiving [s1]Tolazoline[e1] by infusion developed duodenal ulceration and subsequent [s2]intestinal perforation[e2] 
	(3, 39)	Macrodantin	acute and chronic pulmonary reactions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4633	The latter form  [s1]Macrodantin[e1]  is reported to engender less gastrointestinal intolerance but it can produce the same adverse effects as the conventional form--liver damage, [s2]acute and chronic pulmonary reactions[e2]  peripheral neuropathy, blood dyscrasias and allergic reactions--and does so just as rapidly and floridly; one such case is reported here.
	(3, 57)	Macrodantin	allergic reactions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4634	The latter form  [s1]Macrodantin[e1]  is reported to engender less gastrointestinal intolerance but it can produce the same adverse effects as the conventional form--liver damage, acute and chronic pulmonary reactions, peripheral neuropathy, blood dyscrasias and [s2]allergic reactions[e2] -and does so just as rapidly and floridly; one such case is reported here.
	(3, 50)	Macrodantin	blood dyscrasias	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4635	The latter form  [s1]Macrodantin[e1]  is reported to engender less gastrointestinal intolerance but it can produce the same adverse effects as the conventional form--liver damage, acute and chronic pulmonary reactions, peripheral neuropathy, [s2]blood dyscrasias[e2] and allergic reactions--and does so just as rapidly and floridly; one such case is reported here.
	(3, 35)	Macrodantin	liver damage	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4636	The latter form  [s1]Macrodantin[e1]  is reported to engender less gastrointestinal intolerance but it can produce the same adverse effects as the conventional form- [s2]liver damage[e2]  acute and chronic pulmonary reactions, peripheral neuropathy, blood dyscrasias and allergic reactions--and does so just as rapidly and floridly; one such case is reported here.
	(3, 45)	Macrodantin	peripheral neuropathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4637	The latter form  [s1]Macrodantin[e1]  is reported to engender less gastrointestinal intolerance but it can produce the same adverse effects as the conventional form--liver damage, acute and chronic pulmonary reactions, [s2]peripheral neuropathy[e2]  blood dyscrasias and allergic reactions--and does so just as rapidly and floridly; one such case is reported here.
	(0, 14)	Generalized pustular psoriasis	trazodone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4638	 [s1]Generalized pustular psoriasis[e1] precipitated by [s2]trazodone[e2] in the treatment of depression.
	(20, 38)	Molipaxin	generalized pustular psoriasis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4639	We report a patient in whom the anti-depressant trazodone hydrochloride  [s1]Molipaxin[e1]  Roussel), a serotonin antagonist, provoked [s2]generalized pustular psoriasis[e2] (GPP).
	(12, 40)	trazodone hydrochloride	generalized pustular psoriasis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4640	We report a patient in whom the anti-depressant [s1]trazodone hydrochloride[e1] (Molipaxin, Roussel), a serotonin antagonist, provoked [s2]generalized pustular psoriasis[e2] (GPP).
	(20, 45)	Molipaxin	GPP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4641	We report a patient in whom the anti-depressant trazodone hydrochloride  [s1]Molipaxin[e1]  Roussel), a serotonin antagonist, provoked generalized pustular psoriasis  [s2]GPP[e2] .
	(12, 47)	trazodone hydrochloride	GPP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4642	We report a patient in whom the anti-depressant [s1]trazodone hydrochloride[e1] (Molipaxin, Roussel), a serotonin antagonist, provoked generalized pustular psoriasis  [s2]GPP[e2] .
	(12, 41)	apnea	quinidine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4643	"Intravenous verapamil therapy in babies may cause [s1]apnea[e1]  hypotension, and bradycardia; continued episodes of atrial flutter in a child may cause sudden death; [s2]quinidine[e2] may be related to the death; children with ""familial seizure disorders"" may in fact have the long QT interval syndrome."
	(3, 14)	verapamil	apnea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4644	"Intravenous [s1]verapamil[e1] therapy in babies may cause [s2]apnea[e2]  hypotension, and bradycardia; continued episodes of atrial flutter in a child may cause sudden death; quinidine may be related to the death; children with ""familial seizure disorders"" may in fact have the long QT interval syndrome."
	(3, 31)	verapamil	atrial flutter	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4645	"Intravenous [s1]verapamil[e1] therapy in babies may cause apnea, hypotension, and bradycardia; continued episodes of [s2]atrial flutter[e2] in a child may cause sudden death; quinidine may be related to the death; children with ""familial seizure disorders"" may in fact have the long QT interval syndrome."
	(3, 24)	verapamil	bradycardia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4646	"Intravenous [s1]verapamil[e1] therapy in babies may cause apnea, hypotension, and [s2]bradycardia[e2]  continued episodes of atrial flutter in a child may cause sudden death; quinidine may be related to the death; children with ""familial seizure disorders"" may in fact have the long QT interval syndrome."
	(38, 41)	death	quinidine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4647	"Intravenous verapamil therapy in babies may cause apnea, hypotension, and bradycardia; continued episodes of atrial flutter in a child may cause sudden [s1]death[e1]  [s2]quinidine[e2] may be related to the death; children with ""familial seizure disorders"" may in fact have the long QT interval syndrome."
	(3, 17)	verapamil	hypotension	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4648	"Intravenous [s1]verapamil[e1] therapy in babies may cause apnea, [s2]hypotension[e2]  and bradycardia; continued episodes of atrial flutter in a child may cause sudden death; quinidine may be related to the death; children with ""familial seizure disorders"" may in fact have the long QT interval syndrome."
	(40, 67)	quinidine	long QT interval syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4649	"Intravenous verapamil therapy in babies may cause apnea, hypotension, and bradycardia; continued episodes of atrial flutter in a child may cause sudden death; [s1]quinidine[e1] may be related to the death; children with ""familial seizure disorders"" may in fact have the [s2]long QT interval syndrome[e2] "
	(3, 39)	verapamil	sudden death	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4650	"Intravenous [s1]verapamil[e1] therapy in babies may cause apnea, hypotension, and bradycardia; continued episodes of atrial flutter in a child may cause [s2]sudden death[e2]  quinidine may be related to the death; children with ""familial seizure disorders"" may in fact have the long QT interval syndrome."
	(0, 7)	Methimazole	cholestatic liver injury	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4651	 [s1]Methimazole[e1] associated [s2]cholestatic liver injury[e2]  case report and brief literature review.
	(7, 14)	methimazole	liver damage	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4652	The authors report a further case of [s1]methimazole[e1] associated [s2]liver damage[e2] and present a brief review of eleven previous cases found in the literature.
	(50, 70)	bile stasis	methimazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4653	The main clinical features of this 58-year-old female patient were laboratory evidence of leucopenia and cholestasis, and biopsy features of fatty liver parenchyma degeneration with granulocytic portal infiltration and [s1]bile stasis[e1]  demonstrated 20 days after the initiation of antithyroid therapy with 20 mg [s2]methimazole[e2] daily.
	(22, 70)	cholestasis	methimazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4654	The main clinical features of this 58-year-old female patient were laboratory evidence of leucopenia and [s1]cholestasis[e1]  and biopsy features of fatty liver parenchyma degeneration with granulocytic portal infiltration and bile stasis, demonstrated 20 days after the initiation of antithyroid therapy with 20 mg [s2]methimazole[e2] daily.
	(32, 71)	fatty liver parenchyma degeneration	methimazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4655	The main clinical features of this 58-year-old female patient were laboratory evidence of leucopenia and cholestasis, and biopsy features of [s1]fatty liver parenchyma degeneration[e1] with granulocytic portal infiltration and bile stasis, demonstrated 20 days after the initiation of antithyroid therapy with 20 mg [s2]methimazole[e2] daily.
	(42, 71)	granulocytic portal infiltration	methimazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4656	The main clinical features of this 58-year-old female patient were laboratory evidence of leucopenia and cholestasis, and biopsy features of fatty liver parenchyma degeneration with [s1]granulocytic portal infiltration[e1] and bile stasis, demonstrated 20 days after the initiation of antithyroid therapy with 20 mg [s2]methimazole[e2] daily.
	(17, 71)	leucopenia	methimazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4657	The main clinical features of this 58-year-old female patient were laboratory evidence of [s1]leucopenia[e1] and cholestasis, and biopsy features of fatty liver parenchyma degeneration with granulocytic portal infiltration and bile stasis, demonstrated 20 days after the initiation of antithyroid therapy with 20 mg [s2]methimazole[e2] daily.
	(0, 21)	Fibrosis of corpus cavernosum	papaverine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4658	 [s1]Fibrosis of corpus cavernosum[e1] after intracavernous injection of phentolamine [s2]papaverine[e2] 
	(0, 17)	Fibrosis of corpus cavernosum	phentolamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4659	 [s1]Fibrosis of corpus cavernosum[e1] after intracavernous injection of [s2]phentolamine[e2] papaverine.
	(5, 29)	penile fibrosis	papaverine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4660	We report a case of [s1]penile fibrosis[e1] after intracavernous self-injection of a combination of phentolamine and [s2]papaverine[e2] 
	(5, 24)	penile fibrosis	phentolamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4661	We report a case of [s1]penile fibrosis[e1] after intracavernous self-injection of a combination of [s2]phentolamine[e2] and papaverine.
	(8, 18)	pulmonary sarcoidosis	interferon beta	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4662	A 57-year-old woman developed [s1]pulmonary sarcoidosis[e1] during therapy with [s2]interferon beta[e2] for advanced renal cell carcinoma metastatic to mediastinal lymph nodes.
	(4, 15)	interferon beta	sarcoidosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4663	The possible role of [s1]interferon beta[e1] in the pathogenesis of [s2]sarcoidosis[e2] in this patient is discussed.
	(0, 8)	Fatal outcome	formalin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4664	 [s1]Fatal outcome[e1] of intravesical [s2]formalin[e2] instillation, with changes mimicking renal tuberculosis.
	(21, 35)	mebendazole	alopecia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4665	We present a case report of a patient with alveolar hydatid disease, whose treatment with [s1]mebendazole[e1] was brief due to side effects of [s2]alopecia[e2] and granulocytopenia; and review the features of this disease which, with increasing international migration, may be encountered more frequently in Australia.
	(21, 39)	mebendazole	granulocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4666	We present a case report of a patient with alveolar hydatid disease, whose treatment with [s1]mebendazole[e1] was brief due to side effects of alopecia and [s2]granulocytopenia[e2]  and review the features of this disease which, with increasing international migration, may be encountered more frequently in Australia.
	(4, 32)	colitis	sulfamethoxazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4667	Antibiotic-associated [s1]colitis[e1] (pseudomembranous colitis) developed in four patients with spinal cord injury and taking oral trimethoprim [s2]sulfamethoxazole[e2] 
	(4, 28)	colitis	trimethoprim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4668	Antibiotic-associated [s1]colitis[e1] (pseudomembranous colitis) developed in four patients with spinal cord injury and taking oral [s2]trimethoprim[e2] sulfamethoxazole.
	(6, 30)	pseudomembranous colitis	sulfamethoxazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4669	Antibiotic-associated colitis  [s1]pseudomembranous colitis[e1]  developed in four patients with spinal cord injury and taking oral trimethoprim [s2]sulfamethoxazole[e2] 
	(6, 26)	pseudomembranous colitis	trimethoprim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4670	Antibiotic-associated colitis  [s1]pseudomembranous colitis[e1]  developed in four patients with spinal cord injury and taking oral [s2]trimethoprim[e2] sulfamethoxazole.
	(0, 22)	Pseudomembranous colitis	sulfamethoxazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4671	 [s1]Pseudomembranous colitis[e1] readily occurs in at least certain population groups receiving trimethoprim [s2]sulfamethoxazole[e2] 
	(0, 18)	Pseudomembranous colitis	trimethoprim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4672	 [s1]Pseudomembranous colitis[e1] readily occurs in at least certain population groups receiving [s2]trimethoprim[e2] sulfamethoxazole.
	(1, 9)	lethal complication	vasopressin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4673	A [s1]lethal complication[e1] of peripheral vein [s2]vasopressin[e2] infusion.
	(14, 21)	abdominal pain	vasopressin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4674	The condition should be suspected in patients who develop unexplained [s1]abdominal pain[e1] or collapse following [s2]vasopressin[e2] treatment.
	(17, 21)	collapse	vasopressin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4675	The condition should be suspected in patients who develop unexplained abdominal pain or [s1]collapse[e1] following [s2]vasopressin[e2] treatment.
	(4, 29)	protamine	type I anaphylaxis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4676	Although adverse reactions to [s1]protamine[e1] are reported infrequently and are usually mild, we recently observed the first fatal case of [s2]type I anaphylaxis[e2] resulting from protamine.
	(0, 6)	Protamine	fatal anaphylaxis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4677	 [s1]Protamine[e1] induced [s2]fatal anaphylaxis[e2] 
	(0, 10)	Ototoxicity	cis-platinum	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4678	 [s1]Ototoxicity[e1] as a result of [s2]cis-platinum[e2] administration is well documented.
	(3, 12)	nephrotoxicity	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4679	Controversy concerning the [s1]nephrotoxicity[e1] of [s2]lithium[e2] is discussed, and recommendations for the evaluation of renal failure during lithium therapy are provided.
	(10, 22)	lithium	renal failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4680	Controversy concerning the nephrotoxicity of [s1]lithium[e1] is discussed, and recommendations for the evaluation of [s2]renal failure[e2] during lithium therapy are provided.
	(10, 22)	lithium	renal failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4681	Controversy concerning the nephrotoxicity of [s1]lithium[e1] is discussed, and recommendations for the evaluation of [s2]renal failure[e2] during lithium therapy are provided.
	(5, 33)	nitroglycerin	decrease in blood flow	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4682	Administration of intravenous [s1]nitroglycerin[e1] in a patient with idiopathic pulmonary hypertension resulted in an increase in pulmonary artery pressure associated with a [s2]decrease in blood flow[e2] that is best explained by an increase in pulmonary vascular resistance.
	(5, 25)	nitroglycerin	increase in pulmonary artery pressure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4683	Administration of intravenous [s1]nitroglycerin[e1] in a patient with idiopathic pulmonary hypertension resulted in an [s2]increase in pulmonary artery pressure[e2] associated with a decrease in blood flow that is best explained by an increase in pulmonary vascular resistance.
	(5, 43)	nitroglycerin	increase in pulmonary vascular resistance	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4684	Administration of intravenous [s1]nitroglycerin[e1] in a patient with idiopathic pulmonary hypertension resulted in an increase in pulmonary artery pressure associated with a decrease in blood flow that is best explained by an [s2]increase in pulmonary vascular resistance[e2] 
	(0, 13)	Paradoxical pulmonary vasoconstriction	nitroglycerin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4685	 [s1]Paradoxical pulmonary vasoconstriction[e1] induced by [s2]nitroglycerin[e2] in idiopathic pulmonary hypertension.
	(0, 12)	Atrioventricular block	amiodarone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4686	 [s1]Atrioventricular block[e1] complicating [s2]amiodarone[e2] induced hypothyroidism in a patient with pre-excitation and rate-dependent bilateral bundle branch block.
	(10, 16)	amiodarone	hypothyroidism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4687	Atrioventricular block complicating [s1]amiodarone[e1] induced [s2]hypothyroidism[e2] in a patient with pre-excitation and rate-dependent bilateral bundle branch block.
	(5, 22)	hypothyroidism	amiodarone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4688	Such a case induced by [s1]hypothyroidism[e1] complicating long-term therapy with [s2]amiodarone[e2] in a 45 year old woman with pre-excitation is presented.
	(0, 11)	Ampicillin	electrical decrement	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4689	 [s1]Ampicillin[e1] increased the preexisting [s2]electrical decrement[e2] in three rabbits with experimental autoimmune myasthenia gravis while the drug had no deleterious effects in less affected or normal animals.
	(0, 12)	Ampicillin	myasthenia gravis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4690	 [s1]Ampicillin[e1] may aggravate clinical and experimental [s2]myasthenia gravis[e2] 
	(6, 17)	ampicillin	acute exacerbations	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4691	Myasthenic patients receiving [s1]ampicillin[e1] should be closely monitored for possible [s2]acute exacerbations[e2] 
	(3, 10)	severe temporary weakness	ampicillin sodium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4692	One patient had [s1]severe temporary weakness[e1] after an [s2]ampicillin sodium[e2] challenge.
	(7, 29)	theophylline	ulcer	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4693	A study following large patient groups on [s1]theophylline[e1] and a combination of theophylline and steroids might clarify the risk of [s2]ulcer[e2] formation in patients being treated with these medications for asthma.
	(7, 29)	theophylline	ulcer	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4694	A study following large patient groups on [s1]theophylline[e1] and a combination of theophylline and steroids might clarify the risk of [s2]ulcer[e2] formation in patients being treated with these medications for asthma.
	(18, 27)	prednisone	perforated gastric ulcer	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4695	We presented a patient with status asthmaticus treated with a combination of theophylline and [s1]prednisone[e1] who developed a [s2]perforated gastric ulcer[e2] 
	(13, 27)	theophylline	perforated gastric ulcer	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4696	We presented a patient with status asthmaticus treated with a combination of [s1]theophylline[e1] and prednisone who developed a [s2]perforated gastric ulcer[e2] 
	(3, 12)	propranolol	esophageal spasm	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4697	A case of [s1]propranolol[e1] overdose complicated by [s2]esophageal spasm[e2] preventing extrication of an orogastric lavage tube and relieved by intravenous glucagon is presented.
	(0, 10)	Esophageal spasm	propranolol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4698	 [s1]Esophageal spasm[e1] following [s2]propranolol[e2] overdose relieved by glucagon.
	(0, 12)	Hypotension	nifedipine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4699	 [s1]Hypotension[e1] and sinus arrest with [s2]nifedipine[e2] in pulmonary hypertension.
	(6, 12)	sinus arrest	nifedipine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4700	Hypotension and [s1]sinus arrest[e1] with [s2]nifedipine[e2] in pulmonary hypertension.
	(5, 23)	painful, oedematous, cyanosed hand	diamorphine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4701	A patient presented with a [s1]painful, oedematous, cyanosed hand[e1] having injected a solution of [s2]diamorphine[e2] and methylphenidate into his radial artery.
	(5, 28)	painful, oedematous, cyanosed hand	methylphenidate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4702	A patient presented with a [s1]painful, oedematous, cyanosed hand[e1] having injected a solution of diamorphine and [s2]methylphenidate[e2] into his radial artery.
	(0, 20)	Ischaemia	diamorphine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4703	 [s1]Ischaemia[e1] following selfadministered intra-arterial injection of methylphenidate and [s2]diamorphine[e2] 
	(0, 15)	Ischaemia	methylphenidate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4704	 [s1]Ischaemia[e1] following selfadministered intra-arterial injection of [s2]methylphenidate[e2] and diamorphine.
	(0, 9)	Chronic photosensitivity	hydrochlorothiazide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4705	 [s1]Chronic photosensitivity[e1] associated with [s2]hydrochlorothiazide[e2] ingestion occurred in four patients.
	(0, 8)	Cardiac decompensation	verapamil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4706	 [s1]Cardiac decompensation[e1] following [s2]verapamil[e2] therapy in infants with supraventricular tachycardia.
	(5, 17)	hemodynamic decompensation	verapamil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4707	However, each infant demonstrated [s1]hemodynamic decompensation[e1] shortly after [s2]verapamil[e2] administration and required cardiopulmonary resuscitation.
	(3, 38)	cardiac decompensation	verapamil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4708	The risk of [s1]cardiac decompensation[e1] in infants with supraventricular tachycardia and congestive cardiac failure should be kept in mind prior to administration of [s2]verapamil[e2] 
	(17, 23)	neuropathy	amiodarone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4709	Pneumonitis with pleural and pericardial effusion and [s1]neuropathy[e1] during [s2]amiodarone[e2] therapy.
	(6, 23)	pleural and pericardial effusion	amiodarone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4710	Pneumonitis with [s1]pleural and pericardial effusion[e1] and neuropathy during [s2]amiodarone[e2] therapy.
	(0, 23)	Pneumonitis	amiodarone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4711	 [s1]Pneumonitis[e1] with pleural and pericardial effusion and neuropathy during [s2]amiodarone[e2] therapy.
	(14, 19)	amiodarone	pneumonitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4712	Review of this and previously reported cases indicates the need for early diagnosis of [s1]amiodarone[e1]  [s2]pneumonitis[e2]  immediate withdrawal of amiodarone, and prompt but continued steroid therapy to ensure full recovery.
	(0, 6)	Heparin	hyperkalemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4713	 [s1]Heparin[e1] induced [s2]hyperkalemia[e2] 
	(4, 18)	hyperkalemia	heparin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4714	Our findings suggest that [s1]hyperkalemia[e1] can develop with the use of low-dose [s2]heparin[e2]  within seven days of initiating heparin therapy, and that patients with diabetes mellitus or chronic renal insufficiency are especially predisposed to this complication.
	(4, 18)	hyperkalemia	heparin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4715	Our findings suggest that [s1]hyperkalemia[e1] can develop with the use of low-dose [s2]heparin[e2]  within seven days of initiating heparin therapy, and that patients with diabetes mellitus or chronic renal insufficiency are especially predisposed to this complication.
	(9, 17)	heparin	hyperkalemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4716	We present four cases in which the use of [s1]heparin[e1] was associated with [s2]hyperkalemia[e2] and discuss the pathophysiology.
	(6, 30)	heparin	hyperkalemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4717	While most physicians are aware of [s1]heparin[e1] induced thrombocytopenia and skin necrosis, the association of heparin and [s2]hyperkalemia[e2] is less well recognized.
	(6, 19)	heparin	skin necrosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4718	While most physicians are aware of [s1]heparin[e1] induced thrombocytopenia and [s2]skin necrosis[e2]  the association of heparin and hyperkalemia is less well recognized.
	(6, 12)	heparin	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4719	While most physicians are aware of [s1]heparin[e1] induced [s2]thrombocytopenia[e2] and skin necrosis, the association of heparin and hyperkalemia is less well recognized.
	(13, 16)	insulin	edema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4720	"Careful follow-up of so-called ""self-limited"" [s1]insulin[e1]  [s2]edema[e2] is encouraged, and the early institution of diuretic therapy is advocated in elderly patients to prevent the development of overt cardiac failure."
	(0, 4)	Insulin	cardiac failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4721	 [s1]Insulin[e1] induced [s2]cardiac failure[e2] 
	(0, 15)	Self-limited edema	insulin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4722	 [s1]Self-limited edema[e1] is a well-recognized complication of [s2]insulin[e2] therapy.
	(7, 11)	insulin	cardiac failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4723	This report describes the first case of [s1]insulin[e1] induced [s2]cardiac failure[e2] in a patient without underlying heart disease.
	(3, 11)	pyridoxine	seizures	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4724	A case of [s1]pyridoxine[e1] dependent [s2]seizures[e2] is reported.
	(2, 24)	pyridoxine	acute hypotonia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4725	Administration of [s1]pyridoxine[e1] to an infant after a long period of convulsions was followed by [s2]acute hypotonia[e2] 
	(1, 10)	severe cholestasis	oxacillin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4726	Prolonged [s1]severe cholestasis[e1] induced by [s2]oxacillin[e2] derivatives.
	(10, 25)	reversible cholestatic jaundice	oxacillin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4727	Two patients with osteomyelitis who developed [s1]reversible cholestatic jaundice[e1] during treatment with [s2]oxacillin[e2] derivatives are described.
	(5, 13)	pellagra	isoniazid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4728	In all the patients, [s1]pellagra[e1] symptoms appeared during [s2]isoniazid[e2] therapy.
	(0, 22)	Isoniazid	pellagra	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4729	 [s1]Isoniazid[e1] inhibits the conversion of tryptophan to niacin and may induce [s2]pellagra[e2]  particularly in poorly nourished patients.
	(0, 19)	Pellagra encephalopathy	isoniazid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4730	 [s1]Pellagra encephalopathy[e1] among tuberculous patients: its relation to [s2]isoniazid[e2] therapy.
	(14, 21)	isoniazid	mental, neurological or gastrointestinal symptoms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4731	Pellagra should be suspected whenever tuberculous patients under treatment with [s1]isoniazid[e1] develop [s2]mental, neurological or gastrointestinal symptoms[e2]  even in the absence of typical pellagra dermatitis.
	(11, 22)	RS	aspirin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4732	Physicians should be aware of the potential for the development of [s1]RS[e1] among children who are receiving long-term [s2]aspirin[e2] therapy for the treatment of systemic inflammatory illnesses.
	(0, 23)	Reye syndrome	aspirin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4733	 [s1]Reye syndrome[e1] (RS) is believed to occur infrequently among children receiving long-term [s2]aspirin[e2] therapy.
	(3, 21)	RS	aspirin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4734	Reye syndrome  [s1]RS[e1]  is believed to occur infrequently among children receiving long-term [s2]aspirin[e2] therapy.
	(11, 31)	aspirin	RS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4735	These findings support previous studies that showed that the use of [s1]aspirin[e1] during the antecedent illness may be a risk factor for the development of [s2]RS[e2] 
	(0, 10)	Atrial fibrillation	diltiazem	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4736	 [s1]Atrial fibrillation[e1] was induced by [s2]diltiazem[e2] in two patients and verapamil induced syncope in one patient.
	(16, 23)	verapamil	syncope	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4737	Atrial fibrillation was induced by diltiazem in two patients and [s1]verapamil[e1] induced [s2]syncope[e2] in one patient.
	(10, 16)	amiodarone	thyrotoxicosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4738	A 54-year-old man, treated with [s1]amiodarone[e1]  developed [s2]thyrotoxicosis[e2] 
	(0, 6)	Amiodarone	dysthyroidism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4739	 [s1]Amiodarone[e1] induced [s2]dysthyroidism[e2] 
	(1, 25)	propranolol	decrease in heart rate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4740	IV [s1]propranolol[e1] was used as the initial treatment for his hyperadrenergic state, resulting in a [s2]decrease in heart rate[e2] but a paroxsymal increase in blood pressure.
	(1, 31)	propranolol	paroxsymal increase in blood pressure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4741	IV [s1]propranolol[e1] was used as the initial treatment for his hyperadrenergic state, resulting in a decrease in heart rate but a [s2]paroxsymal increase in blood pressure[e2] 
	(0, 7)	Propranolol	hypertension	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4742	 [s1]Propranolol[e1] induced [s2]hypertension[e2] in treatment of cocaine intoxication.
	(5, 13)	chlorambucil	central nervous toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4743	According to the literature, [s1]chlorambucil[e1]  [s2]central nervous toxicity[e2] is found almost exclusively in childhood nephrotic syndrome.
	(0, 8)	Chlorambucil	central nervous toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4744	 [s1]Chlorambucil[e1]  [s2]central nervous toxicity[e2]  a significant side effect of chlorambucil therapy in childhood nephrotic syndrome.
	(0, 14)	EEG abnormalities	chlorambucil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4745	 [s1]EEG abnormalities[e1] were observed in two of the nine children during [s2]chlorambucil[e2] therapy.
	(20, 28)	IgA deficiency	fenclofenac	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4746	A 35-year-old man with seropositive rheumatoid arthritis developed selective [s1]IgA deficiency[e1] during treatment with [s2]fenclofenac[e2] 
	(0, 9)	Fenclofenac	IgA deficiency	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4747	 [s1]Fenclofenac[e1] induced selective [s2]IgA deficiency[e2] in rheumatoid arthritis.
	(7, 32)	IgA deficiency	aurothiomalate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4748	This case demonstrates the association of selective [s1]IgA deficiency[e1] with remission in rheumatoid arthritis induced by fenclofenac as well as [s2]aurothiomalate[e2] and sulphasalazine.
	(7, 24)	IgA deficiency	fenclofenac	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4749	This case demonstrates the association of selective [s1]IgA deficiency[e1] with remission in rheumatoid arthritis induced by [s2]fenclofenac[e2] as well as aurothiomalate and sulphasalazine.
	(7, 38)	IgA deficiency	sulphasalazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4750	This case demonstrates the association of selective [s1]IgA deficiency[e1] with remission in rheumatoid arthritis induced by fenclofenac as well as aurothiomalate and [s2]sulphasalazine[e2] 
	(18, 24)	lithium	movement disorder	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4751	A 65-year-old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance [s1]lithium[e1] therapy developed a [s2]movement disorder[e2] following high doses of trazodone for treatment of an acute depression.
	(22, 30)	movement disorder	trazodone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4752	A 65-year-old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance lithium therapy developed a [s1]movement disorder[e1] following high doses of [s2]trazodone[e2] for treatment of an acute depression.
	(2, 13)	movement disorder	trazodone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4753	Although the [s1]movement disorder[e1] could not with certainty be attributed to [s2]trazodone[e2] alone, the drug at least acted as an eliciting agent.
	(6, 11)	movement disorder	trazodone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4754	The elicitation of a [s1]movement disorder[e1] by [s2]trazodone[e2]  case report.
	(2, 12)	trazodone	involuntary movements	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4755	When the [s1]trazodone[e1] was reduced, the [s2]involuntary movements[e2] promptly ceased.
	(13, 20)	benzodiazepine	coma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4756	A review of the literature showed no previous description of this pattern in [s1]benzodiazepine[e1]  [s2]coma[e2] 
	(0, 6)	Spindle coma	benzodiazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4757	 [s1]Spindle coma[e1] in [s2]benzodiazepine[e2] toxicity: case report.
	(3, 13)	spindle coma	imipramine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4758	Two reports of [s1]spindle coma[e1] are noted with alcohol and [s2]imipramine[e2] 
	(9, 17)	rifampicin	renal insufficiency	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4759	A literature review revealed 83 other reported cases of [s1]rifampicin[e1] induced [s2]renal insufficiency[e2] 
	(0, 14)	Renal failure	rifampicin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4760	 [s1]Renal failure[e1] is a rare complication associated with the use of [s2]rifampicin[e2] for the treatment of tuberculosis, usually occurring well into the course of therapy.
	(0, 8)	Rifampicin	renal failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4761	 [s1]Rifampicin[e1] induced [s2]renal failure[e2] 
	(9, 17)	rifampicin	renal insufficiency	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4762	The following is a report of 2 cases of [s1]rifampicin[e1] induced [s2]renal insufficiency[e2] 
	(0, 9)	Cerebral and ocular toxicity	desferrioxamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4763	 [s1]Cerebral and ocular toxicity[e1] induced by [s2]desferrioxamine[e2] 
	(10, 24)	neurological effects	desferrioxamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4764	Subsequent in vivo/vitro studies clearly demonstrated that the [s1]neurological effects[e1] were due to a synergistic action of [s2]desferrioxamine[e2] and prochlorperazine, probably resulting in exceptional fluxes of intra/extra cellular iron/copper disturbing noradrenergic and serotonergic systems.
	(10, 30)	neurological effects	prochlorperazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4765	Subsequent in vivo/vitro studies clearly demonstrated that the [s1]neurological effects[e1] were due to a synergistic action of desferrioxamine and [s2]prochlorperazine[e2]  probably resulting in exceptional fluxes of intra/extra cellular iron/copper disturbing noradrenergic and serotonergic systems.
	(13, 21)	prochlorperazine	lost consciousness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4766	Two of these patients, who also received the anti-emetic [s1]prochlorperazine[e1]  [s2]lost consciousness[e2] for 48-72 h and then fully recovered.
	(15, 31)	retinal problems	desferrioxamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4767	Two other patients who did not receive prochlorperazine, developed [s1]retinal problems[e1] which later improved, one after only 15 g of [s2]desferrioxamine[e2] 
	(0, 3)	Gold	nephropathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4768	 [s1]Gold[e1]  [s2]nephropathy[e2]  tissue analysis by X-ray fluorescent spectroscopy.
	(18, 65)	gold	renal disease	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4769	These findings are consistent with an immune-complex form of glomerulopathy in which [s1]gold[e1] is neither the antigen nor a hapten in the glomerular deposits, and they suggest the hypothesis that antibodies to tubular epithelial antigens induced by gold therapy may be a causative factor in the [s2]renal disease[e2] associated with gold therapy in rheumatoid arthritis.
	(18, 65)	gold	renal disease	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4770	These findings are consistent with an immune-complex form of glomerulopathy in which [s1]gold[e1] is neither the antigen nor a hapten in the glomerular deposits, and they suggest the hypothesis that antibodies to tubular epithelial antigens induced by gold therapy may be a causative factor in the [s2]renal disease[e2] associated with gold therapy in rheumatoid arthritis.
	(3, 8)	proteinuria	gold	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4771	Three patients developed [s1]proteinuria[e1] following [s2]gold[e2] therapy for rheumatoid arthritis.
	(3, 22)	fat embolism	Intralipid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4772	Four cases of [s1]fat embolism[e1] are described in infants receiving prolonged intravenous infusion of fat  [s2]Intralipid[e2] 20%).
	(20, 29)	methotrexate	bilateral pulmonary infiltrates	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4773	Conversely, diffuse interstitial pulmonary fibrosis should be considered in the differential diagnosis of patients receiving [s1]methotrexate[e1] who develop [s2]bilateral pulmonary infiltrates[e2] seen on chest roentgenograms.
	(2, 22)	diffuse interstitial pulmonary fibrosis	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4774	Conversely, [s1]diffuse interstitial pulmonary fibrosis[e1] should be considered in the differential diagnosis of patients receiving [s2]methotrexate[e2] who develop bilateral pulmonary infiltrates seen on chest roentgenograms.
	(29, 36)	methotrexate	hepatotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4775	In all three cases, autopsy revealed gross and microscopic features indistinguishable from those seen in the Hamman-Rich syndrome, and [s1]methotrexate[e1]  [s2]hepatotoxicity[e2] was present in one.
	(5, 22)	methotrexate	diffuse interstitial pulmonary fibrosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4776	It is suggested therefore that [s1]methotrexate[e1] be added to the list of agents capable of inducing [s2]diffuse interstitial pulmonary fibrosis[e2] 
	(0, 8)	Methotrexate	diffuse interstitial pulmonary fibrosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4777	 [s1]Methotrexate[e1] induced [s2]diffuse interstitial pulmonary fibrosis[e2] 
	(7, 20)	granulomas	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4778	Pulmonary eosinophilia or [s1]granulomas[e1]  classically seen in previously reported cases of [s2]methotrexate[e2] pneumonitis, were not observed.
	(19, 26)	methotrexate	pneumonitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4779	Pulmonary eosinophilia or granulomas, classically seen in previously reported cases of [s1]methotrexate[e1]  [s2]pneumonitis[e2]  were not observed.
	(0, 21)	Pulmonary eosinophilia	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4780	 [s1]Pulmonary eosinophilia[e1] or granulomas, classically seen in previously reported cases of [s2]methotrexate[e2] pneumonitis, were not observed.
	(14, 23)	methotrexate	bilateral pulmonary infiltrates	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4781	Three patients received respectively 190 mg, 175 mg, and 196 mg of [s1]methotrexate[e1] and developed [s2]bilateral pulmonary infiltrates[e2] without evidence of peripheral blood eosinophilia.
	(23, 35)	hyponatremia	adenine arabinoside	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4782	A patient with disseminated herpes zoster developed a syndrome of inappropriate antidiuretic hormone and profound [s1]hyponatremia[e1] secondary to the administration of [s2]adenine arabinoside[e2] 
	(13, 35)	syndrome of inappropriate antidiuretic hormone	adenine arabinoside	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4783	A patient with disseminated herpes zoster developed a [s1]syndrome of inappropriate antidiuretic hormone[e1] and profound hyponatremia secondary to the administration of [s2]adenine arabinoside[e2] 
	(0, 9)	Inappropriate antidiuretic hormone	adenine arabinoside	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4784	 [s1]Inappropriate antidiuretic hormone[e1] following [s2]adenine arabinoside[e2] administration.
	(4, 30)	methotrexate	abdominal pain	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4785	The toxic effects of [s1]methotrexate[e1] included elevated liver transaminases (3/4), nausea (2/4), [s2]abdominal pain[e2] (2/4), bone pain (2/4), mild neutropenia (1/4), and mild pruritus (1/4).
	(4, 38)	methotrexate	bone pain	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4786	The toxic effects of [s1]methotrexate[e1] included elevated liver transaminases (3/4), nausea (2/4), abdominal pain (2/4), [s2]bone pain[e2] (2/4), mild neutropenia (1/4), and mild pruritus (1/4).
	(4, 12)	methotrexate	elevated liver transaminases	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4787	The toxic effects of [s1]methotrexate[e1] included [s2]elevated liver transaminases[e2] (3/4), nausea (2/4), abdominal pain (2/4), bone pain (2/4), mild neutropenia (1/4), and mild pruritus (1/4).
	(4, 46)	methotrexate	mild neutropenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4788	The toxic effects of [s1]methotrexate[e1] included elevated liver transaminases (3/4), nausea (2/4), abdominal pain (2/4), bone pain (2/4), [s2]mild neutropenia[e2] (1/4), and mild pruritus (1/4).
	(4, 58)	methotrexate	mild pruritus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4789	The toxic effects of [s1]methotrexate[e1] included elevated liver transaminases (3/4), nausea (2/4), abdominal pain (2/4), bone pain (2/4), mild neutropenia (1/4), and [s2]mild pruritus[e2] (1/4).
	(4, 23)	methotrexate	nausea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4790	The toxic effects of [s1]methotrexate[e1] included elevated liver transaminases (3/4), [s2]nausea[e2] (2/4), abdominal pain (2/4), bone pain (2/4), mild neutropenia (1/4), and mild pruritus (1/4).
	(0, 7)	Dystonia	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4791	 [s1]Dystonia[e1] associated with [s2]carbamazepine[e2] administration: experience in brain-damaged children.
	(8, 21)	carbamazepine	dystonia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4792	In one child, a second course of [s1]carbamazepine[e1] resulted in a return of the [s2]dystonia[e2] 
	(15, 40)	carbamazepine	dystonia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4793	The currently available clinical and neuropharmacologic data suggest that [s1]carbamazepine[e1] may be an antagonist of dopamine and that this property is responsible for the production of [s2]dystonia[e2] 
	(11, 26)	dystonia	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4794	We have cared for three children in whom four episodes of [s1]dystonia[e1] proceeding to opisthotonus occurred in association with [s2]carbamazepine[e2] use.
	(16, 26)	opisthotonus	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4795	We have cared for three children in whom four episodes of dystonia proceeding to [s1]opisthotonus[e1] occurred in association with [s2]carbamazepine[e2] use.
	(5, 15)	agranulocytosis	methazolamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4796	Aplastic anemia and [s1]agranulocytosis[e1] in patients using [s2]methazolamide[e2] for glaucoma.
	(0, 15)	Aplastic anemia	methazolamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4797	 [s1]Aplastic anemia[e1] and agranulocytosis in patients using [s2]methazolamide[e2] for glaucoma.
	(4, 13)	aplastic anemia	acetazolamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4798	Several case reports of [s1]aplastic anemia[e1] with use of [s2]acetazolamide[e2]  and two cases with use of methazolamide, have appeared in the literature.
	(4, 25)	aplastic anemia	methazolamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4799	Several case reports of [s1]aplastic anemia[e1] with use of acetazolamide, and two cases with use of [s2]methazolamide[e2]  have appeared in the literature.
	(24, 35)	methazolamide	agranulocytosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4800	This article describes two cases of aplastic anemia, at least one of which was almost certainly induced by the use of [s1]methazolamide[e1]  and one case of [s2]agranulocytosis[e2] related to the use of methazolamide.
	(6, 25)	aplastic anemia	methazolamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4801	This article describes two cases of [s1]aplastic anemia[e1]  at least one of which was almost certainly induced by the use of [s2]methazolamide[e2]  and one case of agranulocytosis related to the use of methazolamide.
	(0, 22)	Squamous-cell carcinoma	5-fluorouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4802	 [s1]Squamous-cell carcinoma[e1] arising in a basal-cell epithelioma treated with [s2]5-fluorouracil[e2] 
	(5, 34)	squamous-cell carcinoma	5-FU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4803	We report the development of [s1]squamous-cell carcinoma[e1] within a basal-cell epithelioma that was treated with intralesional injections of [s2]5-FU[e2] 
	(4, 15)	arterial insufficiency	methysergide maleate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4804	Lower extremity [s1]arterial insufficiency[e1] after long-term [s2]methysergide maleate[e2] therapy.
	(7, 15)	migraine headaches	methysergide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4805	The patient whose case is reviewed had [s1]migraine headaches[e1] and received [s2]methysergide[e2] maleate for 13 years.
	(3, 29)	Erythema Multiforme Bullosum	Rifampicin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4806	A case of [s1]Erythema Multiforme Bullosum[e1] in patient of lepromatous leprosy with pulmonary tuberculosis due to [s2]Rifampicin[e2] is described.
	(0, 13)	Erythema multiforme bullosum	rifampicin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4807	 [s1]Erythema multiforme bullosum[e1] due to [s2]rifampicin[e2] 
	(0, 10)	Renal damage	lithium carbonate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4808	 [s1]Renal damage[e1] associated with long term use of [s2]lithium carbonate[e2] 
	(6, 12)	renal damage	lithium carbonate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4809	The authors report 2 cases of [s1]renal damage[e1] associated with [s2]lithium carbonate[e2] treatment.
	(12, 25)	squamous cell carcinoma	psoralens	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4810	In two patients with mycosis fungoides, a [s1]squamous cell carcinoma[e1] developed during therapy with [s2]psoralens[e2] plus long-wave ultraviolet radiation (PUVA).
	(5, 17)	diabetic coma	propranolol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4811	Hyperglycemia and [s1]diabetic coma[e1]  possible relationship to diuretic [s2]propranolol[e2] therapy.
	(0, 18)	Hyperglycemia	propranolol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4812	 [s1]Hyperglycemia[e1] and diabetic coma: possible relationship to diuretic [s2]propranolol[e2] therapy.
	(3, 23)	diabetic coma	propranolol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4813	Two patients developed [s1]diabetic coma[e1] when taking a combination of a thiazide diuretic and [s2]propranolol[e2] 
	(3, 15)	diabetic coma	thiazide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4814	Two patients developed [s1]diabetic coma[e1] when taking a combination of a [s2]thiazide[e2] diuretic and propranolol.
	(14, 22)	severe acidosis	acetazolamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4815	An insulin-dependent diabetic patient with nephropathy developed [s1]severe acidosis[e1] after treatment with [s2]acetazolamide[e2] for glaucoma.
	(0, 6)	Severe acidosis	acetazolamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4816	 [s1]Severe acidosis[e1] from [s2]acetazolamide[e2] in a diabetic patient.
	(3, 18)	tracheal compression	aspirin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4817	This progressed to [s1]tracheal compression[e1] with stridor after he had taken some [s2]aspirin[e2] for relief of the neck pain.
	(3, 10)	clindamycin	pseudomembranous colitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4818	Five cases of [s1]clindamycin[e1] associated [s2]pseudomembranous colitis[e2] in leukaemic patients are reported.
	(16, 25)	lost vision	Bromocryptine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4819	An infertile patient with amenorrhea-galactorrhea syndrome [s1]lost vision[e1] during a pregnancy occurring after [s2]Bromocryptine[e2] treatment.
	(0, 16)	Fatal acute tubular necrosis	formalin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4820	 [s1]Fatal acute tubular necrosis[e1] occurred in 1 patient in whom intravesical [s2]formalin[e2] was used to control massive persistent hemorrhage from radiation cystitis.
	(0, 9)	Fatal complication	formalin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4821	 [s1]Fatal complication[e1] of intravesical [s2]formalin[e2] during control of intractable hemorrhage from radiation cystitis.
	(20, 28)	metabolic acidosis	formic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4822	Intravenous sodium bicarbonate appears to be indicated prophylactically in combating the associated [s1]metabolic acidosis[e1] due to absorbed [s2]formic acid[e2] 
	(4, 26)	galactorrhea	amoxapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4823	A young woman developed [s1]galactorrhea[e1] during treatment with a new dibenzoxazepine antidepressant, [s2]amoxapine[e2] 
	(4, 15)	galactorrhea	dibenzoxazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4824	A young woman developed [s1]galactorrhea[e1] during treatment with a new [s2]dibenzoxazepine[e2] antidepressant, amoxapine.
	(1, 17)	15-kg weight gain	ibuprofen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4825	A [s1]15-kg weight gain[e1] developed in a patient during the third week of [s2]ibuprofen[e2] therapy.
	(0, 6)	Edema	ibuprofen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4826	 [s1]Edema[e1] associated with [s2]ibuprofen[e2] therapy.
	(5, 15)	ibuprofen	salt and water retention	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4827	It should be recognized that [s1]ibuprofen[e1] may be associated with [s2]salt and water retention[e2] in the same fashion as previously described with phenylbutazone and indomethacin.
	(13, 34)	salt and water retention	indomethacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4828	It should be recognized that ibuprofen may be associated with [s1]salt and water retention[e1] in the same fashion as previously described with phenylbutazone and [s2]indomethacin[e2] 
	(13, 27)	salt and water retention	phenylbutazone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4829	It should be recognized that ibuprofen may be associated with [s1]salt and water retention[e1] in the same fashion as previously described with [s2]phenylbutazone[e2] and indomethacin.
	(0, 8)	Allopurinol	hand and foot deformities	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4830	 [s1]Allopurinol[e1] associated [s2]hand and foot deformities[e2] in chronic tophaceous gout.
	(0, 29)	Telescoped digits of the hands and feet	allopurinol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4831	 [s1]Telescoped digits of the hands and feet[e1] developed in a 69-year-old male with severe chronic tophaceous gout during [s2]allopurinol[e2] treatment.
	(18, 27)	amphotericin B	acute toxic delirium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4832	A patient with coccidioidal meningitis was treated with intrathecally administered [s1]amphotericin B[e1]  and an [s2]acute toxic delirium[e2] with EEG abnormalities developed.
	(18, 33)	amphotericin B	EEG abnormalities	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4833	A patient with coccidioidal meningitis was treated with intrathecally administered [s1]amphotericin B[e1]  and an acute toxic delirium with [s2]EEG abnormalities[e2] developed.
	(0, 13)	Neurotoxicity	amphotericin B	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4834	 [s1]Neurotoxicity[e1] of intrathecal administration of [s2]amphotericin B[e2] 
	(9, 28)	aortic wall in this case was damaged	Bleomycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4835	In keeping with findings in the literature, the [s1]aortic wall in this case was damaged[e1] by secondary changes following irradiation and [s2]Bleomycin[e2] treatment.
	(9, 17)	doxorubicin	cardiomyopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4836	Cardiac glycosides are thought to prevent [s1]doxorubicin[e1]  [s2]cardiomyopathy[e2] by competitively inhibiting doxorubicin at its receptor sites, but ouabain has a much shorter half life than doxorubicin and its metabolites and so is less effective than digoxin.
	(0, 8)	Doxorubicin	cardiotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4837	 [s1]Doxorubicin[e1]  [s2]cardiotoxicity[e2]  possible role of digoxin in its prevention.
	(0, 35)	Minor electrocardiographical changes	ouabain	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4838	 [s1]Minor electrocardiographical changes[e1] were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving [s2]ouabain[e2]  and none of the 16 who were receiving digoxin.
	(4, 14)	digoxin	cardiomyopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4839	One other patient on [s1]digoxin[e1] stopped taking it and developed [s2]cardiomyopathy[e2] 
	(3, 10)	ouabain	cardiomyopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4840	One patient on [s1]ouabain[e1] also developed [s2]cardiomyopathy[e2] 
	(12, 27)	sulindac	isolated idential sensory neuropathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4841	A healthy, 30-year-old man, exposed to [s1]sulindac[e1] on two separate occasions, had an incapacitating [s2]isolated idential sensory neuropathy[e2] 
	(3, 22)	Clinoril	neurologic toxic effects	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4842	Sulindac  [s1]Clinoril[e1] , a nonsteroidal anti-inflammatory agent, has few reported [s2]neurologic toxic effects[e2]  all of which have been associated with systemic disease.
	(0, 24)	Sulindac	neurologic toxic effects	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4843	 [s1]Sulindac[e1] (Clinoril), a nonsteroidal anti-inflammatory agent, has few reported [s2]neurologic toxic effects[e2]  all of which have been associated with systemic disease.
	(11, 28)	isolated paresthesia	sulindac	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4844	To our knowledge, we describe the first reported case of [s1]isolated paresthesia[e1] and peripheral neuropathy, without systemic involvement, secondary to [s2]sulindac[e2] administration.
	(15, 27)	peripheral neuropathy	sulindac	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4845	To our knowledge, we describe the first reported case of isolated paresthesia and [s1]peripheral neuropathy[e1]  without systemic involvement, secondary to [s2]sulindac[e2] administration.
	(10, 15)	serine	psychotic symptoms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4846	In addition, loading with one low oral dose of [s1]serine[e1] produced [s2]psychotic symptoms[e2] 5 h later which lasted 3-6 h.
	(2, 9)	ergotamine	arteriospasm	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4847	Reversal of [s1]ergotamine[e1] induced [s2]arteriospasm[e2] by mechanical intra-arterial dilatation.
	(15, 21)	ergot	arteriospasm	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4848	Two patients with imminent gangrene of the extremities caused by [s1]ergot[e1] induced [s2]arteriospasm[e2] underwent mechanical dilatation of the arteries when conventional measures such as anticoagulation, vasodilation, and sympathetic blockade produced no improvement.
	(4, 17)	gangrene of the extremities	ergot	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4849	Two patients with imminent [s1]gangrene of the extremities[e1] caused by [s2]ergot[e2] induced arteriospasm underwent mechanical dilatation of the arteries when conventional measures such as anticoagulation, vasodilation, and sympathetic blockade produced no improvement.
	(9, 18)	haloperidol	hyperpyrexia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4850	The authors describe a case of combined lithium and [s1]haloperidol[e1] toxicity characterized by [s2]hyperpyrexia[e2]  severe rigidity, mutism, and development of irreversible tardive dyskinesia.
	(7, 18)	lithium	hyperpyrexia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4851	The authors describe a case of combined [s1]lithium[e1] and haloperidol toxicity characterized by [s2]hyperpyrexia[e2]  severe rigidity, mutism, and development of irreversible tardive dyskinesia.
	(9, 33)	haloperidol	irreversible tardive dyskinesia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4852	The authors describe a case of combined lithium and [s1]haloperidol[e1] toxicity characterized by hyperpyrexia, severe rigidity, mutism, and development of [s2]irreversible tardive dyskinesia[e2] 
	(7, 33)	lithium	irreversible tardive dyskinesia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4853	The authors describe a case of combined [s1]lithium[e1] and haloperidol toxicity characterized by hyperpyrexia, severe rigidity, mutism, and development of [s2]irreversible tardive dyskinesia[e2] 
	(9, 27)	haloperidol	mutism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4854	The authors describe a case of combined lithium and [s1]haloperidol[e1] toxicity characterized by hyperpyrexia, severe rigidity, [s2]mutism[e2]  and development of irreversible tardive dyskinesia.
	(7, 27)	lithium	mutism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4855	The authors describe a case of combined [s1]lithium[e1] and haloperidol toxicity characterized by hyperpyrexia, severe rigidity, [s2]mutism[e2]  and development of irreversible tardive dyskinesia.
	(9, 23)	haloperidol	severe rigidity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4856	The authors describe a case of combined lithium and [s1]haloperidol[e1] toxicity characterized by hyperpyrexia, [s2]severe rigidity[e2]  mutism, and development of irreversible tardive dyskinesia.
	(7, 23)	lithium	severe rigidity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4857	The authors describe a case of combined [s1]lithium[e1] and haloperidol toxicity characterized by hyperpyrexia, [s2]severe rigidity[e2]  mutism, and development of irreversible tardive dyskinesia.
	(9, 33)	lithium	lithium toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4858	The authors postulate that two types of combined [s1]lithium[e1] neuroleptic toxicity occur: a neuroleptic malignant extrapyramidal syndrome and a [s2]lithium toxicity[e2] that occurs in combination with phenothiazines, primarily thioridazine.
	(32, 48)	lithium toxicity	thioridazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4859	The authors postulate that two types of combined lithium-neuroleptic toxicity occur: a neuroleptic malignant extrapyramidal syndrome and a [s1]lithium toxicity[e1] that occurs in combination with phenothiazines, primarily [s2]thioridazine[e2] 
	(9, 20)	lithium	neuroleptic malignant extrapyramidal syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4860	The authors postulate that two types of combined [s1]lithium[e1] neuroleptic toxicity occur: a [s2]neuroleptic malignant extrapyramidal syndrome[e2] and a lithium toxicity that occurs in combination with phenothiazines, primarily thioridazine.
	(19, 48)	neuroleptic malignant extrapyramidal syndrome	thioridazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4861	The authors postulate that two types of combined lithium-neuroleptic toxicity occur: a [s1]neuroleptic malignant extrapyramidal syndrome[e1] and a lithium toxicity that occurs in combination with phenothiazines, primarily [s2]thioridazine[e2] 
	(0, 9)	Chlorambucil	chromosome damage	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4862	 [s1]Chlorambucil[e1] induced [s2]chromosome damage[e2] to human lymphocytes is dose-dependent and cumulative.
	(0, 13)	Anaphylactoid reaction	dextrose	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4863	 [s1]Anaphylactoid reaction[e1] to 50% solution of [s2]dextrose[e2] 
	(8, 14)	dextrose	increased histamine release	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4864	Preliminary results suggest that the higher concentrations of [s1]dextrose[e1] induce [s2]increased histamine release[e2] from blood cells, and that this phenomenon is more marked in diabetic, and particularly diabetic-allergic, individuals.
	(22, 41)	anaphylactoid reaction	dextrose	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4865	Two patients with extrinsic asthma and coexistent insulin-dependent diabetes mellitus sustained an [s1]anaphylactoid reaction[e1] after the intravenous administration of 50% solution of [s2]dextrose[e2] 
	(0, 6)	Salicylate	hepato toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4866	 [s1]Salicylate[e1]  [s2]hepato toxicity[e2] in rheumatic fever.
	(8, 20)	anicteric hepatitis	aspirin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4867	Two children with rheumatic fever developed [s1]anicteric hepatitis[e1] while on high-dose [s2]aspirin[e2] therapy.
	(21, 45)	bleomycin	encephalopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4868	A 36-year-old man being treated with cisplatinum, vinblastine, and [s1]bleomycin[e1] for testicular carcinoma developed a dense left homonymous hemianopsia, [s2]encephalopathy[e2]  and a partial nondominant parietal lobe syndrome.
	(10, 44)	cisplatinum	encephalopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4869	A 36-year-old man being treated with [s1]cisplatinum[e1]  vinblastine, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, [s2]encephalopathy[e2]  and a partial nondominant parietal lobe syndrome.
	(15, 44)	vinblastine	encephalopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4870	A 36-year-old man being treated with cisplatinum, [s1]vinblastine[e1]  and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, [s2]encephalopathy[e2]  and a partial nondominant parietal lobe syndrome.
	(21, 36)	bleomycin	left homonymous hemianopsia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4871	A 36-year-old man being treated with cisplatinum, vinblastine, and [s1]bleomycin[e1] for testicular carcinoma developed a dense [s2]left homonymous hemianopsia[e2]  encephalopathy, and a partial nondominant parietal lobe syndrome.
	(10, 35)	cisplatinum	left homonymous hemianopsia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4872	A 36-year-old man being treated with [s1]cisplatinum[e1]  vinblastine, and bleomycin for testicular carcinoma developed a dense [s2]left homonymous hemianopsia[e2]  encephalopathy, and a partial nondominant parietal lobe syndrome.
	(15, 35)	vinblastine	left homonymous hemianopsia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4873	A 36-year-old man being treated with cisplatinum, [s1]vinblastine[e1]  and bleomycin for testicular carcinoma developed a dense [s2]left homonymous hemianopsia[e2]  encephalopathy, and a partial nondominant parietal lobe syndrome.
	(21, 53)	bleomycin	partial nondominant parietal lobe syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4874	A 36-year-old man being treated with cisplatinum, vinblastine, and [s1]bleomycin[e1] for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a [s2]partial nondominant parietal lobe syndrome[e2] 
	(10, 52)	cisplatinum	partial nondominant parietal lobe syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4875	A 36-year-old man being treated with [s1]cisplatinum[e1]  vinblastine, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a [s2]partial nondominant parietal lobe syndrome[e2] 
	(15, 52)	vinblastine	partial nondominant parietal lobe syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4876	A 36-year-old man being treated with cisplatinum, [s1]vinblastine[e1]  and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a [s2]partial nondominant parietal lobe syndrome[e2] 
	(10, 37)	encephalopathy	bleomycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4877	Transient left homonymous hemianopsia and [s1]encephalopathy[e1] following treatment of testicular carcinoma with cisplatinum, vinblastine, and [s2]bleomycin[e2] 
	(10, 26)	encephalopathy	cisplatinum	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4878	Transient left homonymous hemianopsia and [s1]encephalopathy[e1] following treatment of testicular carcinoma with [s2]cisplatinum[e2]  vinblastine, and bleomycin.
	(10, 31)	encephalopathy	vinblastine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4879	Transient left homonymous hemianopsia and [s1]encephalopathy[e1] following treatment of testicular carcinoma with cisplatinum, [s2]vinblastine[e2]  and bleomycin.
	(0, 37)	Transient left homonymous hemianopsia	bleomycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4880	 [s1]Transient left homonymous hemianopsia[e1] and encephalopathy following treatment of testicular carcinoma with cisplatinum, vinblastine, and [s2]bleomycin[e2] 
	(0, 26)	Transient left homonymous hemianopsia	cisplatinum	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4881	 [s1]Transient left homonymous hemianopsia[e1] and encephalopathy following treatment of testicular carcinoma with [s2]cisplatinum[e2]  vinblastine, and bleomycin.
	(0, 31)	Transient left homonymous hemianopsia	vinblastine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4882	 [s1]Transient left homonymous hemianopsia[e1] and encephalopathy following treatment of testicular carcinoma with cisplatinum, [s2]vinblastine[e2]  and bleomycin.
	(9, 21)	eosinophilia	propylthiouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4883	An association of granulocytopenia, [s1]eosinophilia[e1]  skin reaction and hepatitis during [s2]propylthiouracil[e2] (PTU) therapy for thyrotoxicosis in a 47 year old black female is reported.
	(9, 27)	eosinophilia	PTU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4884	An association of granulocytopenia, [s1]eosinophilia[e1]  skin reaction and hepatitis during propylthiouracil  [s2]PTU[e2]  therapy for thyrotoxicosis in a 47 year old black female is reported.
	(3, 21)	granulocytopenia	propylthiouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4885	An association of [s1]granulocytopenia[e1]  eosinophilia, skin reaction and hepatitis during [s2]propylthiouracil[e2] (PTU) therapy for thyrotoxicosis in a 47 year old black female is reported.
	(3, 27)	granulocytopenia	PTU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4886	An association of [s1]granulocytopenia[e1]  eosinophilia, skin reaction and hepatitis during propylthiouracil  [s2]PTU[e2]  therapy for thyrotoxicosis in a 47 year old black female is reported.
	(18, 22)	hepatitis	propylthiouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4887	An association of granulocytopenia, eosinophilia, skin reaction and [s1]hepatitis[e1] during [s2]propylthiouracil[e2] (PTU) therapy for thyrotoxicosis in a 47 year old black female is reported.
	(18, 28)	hepatitis	PTU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4888	An association of granulocytopenia, eosinophilia, skin reaction and [s1]hepatitis[e1] during propylthiouracil  [s2]PTU[e2]  therapy for thyrotoxicosis in a 47 year old black female is reported.
	(15, 22)	skin reaction	propylthiouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4889	An association of granulocytopenia, eosinophilia, [s1]skin reaction[e1] and hepatitis during [s2]propylthiouracil[e2] (PTU) therapy for thyrotoxicosis in a 47 year old black female is reported.
	(15, 28)	skin reaction	PTU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4890	An association of granulocytopenia, eosinophilia, [s1]skin reaction[e1] and hepatitis during propylthiouracil  [s2]PTU[e2]  therapy for thyrotoxicosis in a 47 year old black female is reported.
	(3, 19)	propylthiouracil	eosinophilia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4891	Multiple complications of [s1]propylthiouracil[e1] treatment: granulocytopenia, [s2]eosinophilia[e2]  skin reaction and hepatitis with lymphocyte sensitization.
	(3, 13)	propylthiouracil	granulocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4892	Multiple complications of [s1]propylthiouracil[e1] treatment: [s2]granulocytopenia[e2]  eosinophilia, skin reaction and hepatitis with lymphocyte sensitization.
	(3, 28)	propylthiouracil	hepatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4893	Multiple complications of [s1]propylthiouracil[e1] treatment: granulocytopenia, eosinophilia, skin reaction and [s2]hepatitis[e2] with lymphocyte sensitization.
	(3, 30)	propylthiouracil	lymphocyte sensitization	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4894	Multiple complications of [s1]propylthiouracil[e1] treatment: granulocytopenia, eosinophilia, skin reaction and hepatitis with [s2]lymphocyte sensitization[e2] 
	(3, 25)	propylthiouracil	skin reaction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4895	Multiple complications of [s1]propylthiouracil[e1] treatment: granulocytopenia, eosinophilia, [s2]skin reaction[e2] and hepatitis with lymphocyte sensitization.
	(20, 45)	ataxia	pentobarbital	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4896	A toxic encephalopathy characterized by depressed level of consciousness, marked irritability, and [s1]ataxia[e1] developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of [s2]pentobarbital[e2] and pyrilamine maleate.
	(20, 51)	ataxia	pyrilamine maleate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4897	A toxic encephalopathy characterized by depressed level of consciousness, marked irritability, and [s1]ataxia[e1] developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and [s2]pyrilamine maleate[e2] 
	(9, 44)	depressed level of consciousness	pentobarbital	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4898	A toxic encephalopathy characterized by [s1]depressed level of consciousness[e1]  marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of [s2]pentobarbital[e2] and pyrilamine maleate.
	(9, 50)	depressed level of consciousness	pyrilamine maleate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4899	A toxic encephalopathy characterized by [s1]depressed level of consciousness[e1]  marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and [s2]pyrilamine maleate[e2] 
	(14, 44)	marked irritability	pentobarbital	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4900	A toxic encephalopathy characterized by depressed level of consciousness, [s1]marked irritability[e1]  and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of [s2]pentobarbital[e2] and pyrilamine maleate.
	(14, 50)	marked irritability	pyrilamine maleate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4901	A toxic encephalopathy characterized by depressed level of consciousness, [s1]marked irritability[e1]  and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and [s2]pyrilamine maleate[e2] 
	(1, 45)	toxic encephalopathy	pentobarbital	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4902	A [s1]toxic encephalopathy[e1] characterized by depressed level of consciousness, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of [s2]pentobarbital[e2] and pyrilamine maleate.
	(1, 51)	toxic encephalopathy	pyrilamine maleate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4903	A [s1]toxic encephalopathy[e1] characterized by depressed level of consciousness, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and [s2]pyrilamine maleate[e2] 
	(0, 8)	Optic neuropathy	penicillamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4904	 [s1]Optic neuropathy[e1] associated with [s2]penicillamine[e2] therapy in a patient with rheumatoid arthritis.
	(0, 21)	Optic neuropathy	D-penicillamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4905	 [s1]Optic neuropathy[e1] developed in a patient with rheumatoid arthritis who had been receiving [s2]D-penicillamine[e2] for about 1 year.
	(8, 26)	optic neuropathy	penicillamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4906	The case resembles two previously reported cases of [s1]optic neuropathy[e1] which occurred in patients with Wilson's disease who were receiving [s2]penicillamine[e2] 
	(5, 17)	acute myopia	Accutane	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4907	A patient developed transient, [s1]acute myopia[e1] while on isotretinoin  [s2]Accutane[e2]  therapy for acne.
	(5, 13)	acute myopia	isotretinoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4908	A patient developed transient, [s1]acute myopia[e1] while on [s2]isotretinoin[e2] (Accutane) therapy for acne.
	(9, 20)	Accutane	transient myopia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4909	There was a clear relationship between restarting the [s1]Accutane[e1] and recurrence of the [s2]transient myopia[e2] 
	(0, 13)	Transient acute myopia	accutane	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4910	 [s1]Transient acute myopia[e1] resulting from isotretinoin  [s2]accutane[e2]  therapy.
	(0, 9)	Transient acute myopia	isotretinoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4911	 [s1]Transient acute myopia[e1] resulting from [s2]isotretinoin[e2] (accutane) therapy.
	(0, 12)	Allergic contact dermatitis	benzoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4912	 [s1]Allergic contact dermatitis[e1] to compound tincture of [s2]benzoin[e2] 
	(3, 15)	allergic contact dermatitis	benzoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4913	Nineteen cases of [s1]allergic contact dermatitis[e1] to compound tincture of [s2]benzoin[e2] are described.
	(3, 39)	herpesvirus infection	Ara-C	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4914	Autopsy evidence of [s1]herpesvirus infection[e1] was found in visceral organs of four leukemic patients who had received large doses of cytarabine (cytosine arabinoside; [s2]Ara-C[e2]  shortly before their death.
	(3, 28)	herpesvirus infection	cytarabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4915	Autopsy evidence of [s1]herpesvirus infection[e1] was found in visceral organs of four leukemic patients who had received large doses of [s2]cytarabine[e2] (cytosine arabinoside; Ara-C) shortly before their death.
	(3, 31)	herpesvirus infection	cytosine arabinoside	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4916	Autopsy evidence of [s1]herpesvirus infection[e1] was found in visceral organs of four leukemic patients who had received large doses of cytarabine  [s2]cytosine arabinoside[e2]  Ara-C) shortly before their death.
	(19, 35)	cutaneous herpes zoster	cytarabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4917	In three of these patients the infection was clinically unsuspected; in the fourth, [s1]cutaneous herpes zoster[e1] developed after administration of 300 mg of [s2]cytarabine[e2] daily for the preceding five days.
	(0, 15)	Visceral herpesvirus infections	cytarabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4918	 [s1]Visceral herpesvirus infections[e1] in leukemic patients receiving [s2]cytarabine[e2] 
	(5, 8)	gold	neuropathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4919	Clinical and morphological features of [s1]gold[e1]  [s2]neuropathy[e2] 
	(3, 7)	gold	neuropathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4920	Three cases of [s1]gold[e1] related [s2]neuropathy[e2] are reported.
	(0, 26)	Intra-neural ceroid-like pigment	B663	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4921	 [s1]Intra-neural ceroid-like pigment[e1] following the treatment of lepromatous leprosy with clofazimine  [s2]B663[e2]  Lamprene).
	(0, 22)	Intra-neural ceroid-like pigment	clofazimine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4922	 [s1]Intra-neural ceroid-like pigment[e1] following the treatment of lepromatous leprosy with [s2]clofazimine[e2] (B663; Lamprene).
	(0, 31)	Intra-neural ceroid-like pigment	Lamprene	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4923	 [s1]Intra-neural ceroid-like pigment[e1] following the treatment of lepromatous leprosy with clofazimine (B663; [s2]Lamprene[e2] .
	(4, 23)	clofazimine	ceroid-like pigment	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4924	One of these was [s1]clofazimine[e1]  an aniline aposafranine derivative known to produce a [s2]ceroid-like pigment[e2] in the tissues of patients treated with this drug or lepromatous leprosy.
	(0, 9)	Severe neurotoxicity	methyl G: CALGB	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4925	 [s1]Severe neurotoxicity[e1] with [s2]methyl G: CALGB[e2] experience.
	(5, 21)	sinus tachycardia	nortriptyline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4926	A young patient experienced marked [s1]sinus tachycardia[e1] while smoking marijuana and receiving therapeutic doses of [s2]nortriptyline[e2] 
	(1, 20)	sinus tachycardia	nortriptyline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4927	Marked [s1]sinus tachycardia[e1] resulting from the synergistic effects of marijuana and [s2]nortriptyline[e2] 
	(4, 22)	cerebral atrophy	ACTH	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4928	It is concluded that  [s1]cerebral atrophy[e1]  on CT scans may represent an accumulative effect of [s2]ACTH[e2] and that ACTH should be given with the utmost discretion, and in as low a dose as possible.
	(0, 17)	Disulfiram-like reactions	cefmenoxime	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4929	 [s1]Disulfiram-like reactions[e1] with newer cephalosporins: [s2]cefmenoxime[e2] 
	(7, 17)	disulfiram-like reaction	cefmenoxime	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4930	This is the first report of a [s1]disulfiram-like reaction[e1] with [s2]cefmenoxime[e2] 
	(12, 20)	lithium	akathisia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4931	k bipolar manic-depressive patient, developed while on [s1]lithium[e1] prophylaxis, [s2]akathisia[e2] at therapeutic serum lithium levels and subsequently bucco-linguo-masticatory dyskinesia.
	(12, 30)	lithium	bucco-linguo-masticatory dyskinesia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4932	k bipolar manic-depressive patient, developed while on [s1]lithium[e1] prophylaxis, akathisia at therapeutic serum lithium levels and subsequently [s2]bucco-linguo-masticatory dyskinesia[e2] 
	(0, 9)	Acute leukopenia	silver sulfadiazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4933	 [s1]Acute leukopenia[e1] associated with [s2]silver sulfadiazine[e2] therapy.
	(14, 30)	disseminated histoplasmosis	prednisone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4934	Patients from endemic areas referred to transplant centers may be at high risk for [s1]disseminated histoplasmosis[e1] when treated with long-term [s2]prednisone[e2] for graft-versus-host disease.
	(0, 18)	Acute renal failure	captopril	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4935	 [s1]Acute renal failure[e1] most likely was secondary to the nephrotoxic effect of [s2]captopril[e2] on chronically hypoperfused kidneys.
	(11, 24)	nonoliguric acute renal failure	captopril	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4936	In a patient with severe renovascular hypertension, [s1]nonoliguric acute renal failure[e1] developed after she received [s2]captopril[e2] treatment.
	(0, 10)	Nonoliguric acute renal failure	captopril	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4937	 [s1]Nonoliguric acute renal failure[e1] after [s2]captopril[e2] therapy.
	(0, 6)	Captopril	acute reversible renal failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4938	 [s1]Captopril[e1] induced [s2]acute reversible renal failure[e2] 
	(21, 27)	captopril	acute renal failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4939	The 5 patients had severe renovascular disease which might thus represent a significant risk factor in the development of [s1]captopril[e1] induced [s2]acute renal failure[e2] 
	(5, 22)	acute reversible renal failure	captopril	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4940	We report 5 cases of [s1]acute reversible renal failure[e1] coinciding with the onset of treatment with [s2]captopril[e2] in patients with severe drug-resistant hypertension.
	(3, 8)	mania	fluoxetine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4941	A case of [s1]mania[e1] associated with [s2]fluoxetine[e2] 
	(11, 19)	manic episode	fluoxetine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4942	A depressed woman with no history of bipolar illness developed a [s1]manic episode[e1] during treatment with [s2]fluoxetine[e2] 
	(0, 13)	Alopecia	cyclophosphamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4943	 [s1]Alopecia[e1]  nausea, and vomiting were attributed to the [s2]cyclophosphamide[e2] component of the therapy.
	(4, 13)	nausea	cyclophosphamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4944	Alopecia, [s1]nausea[e1]  and vomiting were attributed to the [s2]cyclophosphamide[e2] component of the therapy.
	(7, 14)	vomiting	cyclophosphamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4945	Alopecia, nausea, and [s1]vomiting[e1] were attributed to the [s2]cyclophosphamide[e2] component of the therapy.
	(0, 23)	Haemolytic-uraemic syndrome	5-fluorouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4946	 [s1]Haemolytic-uraemic syndrome[e1] complicating long-term mitomycin C and [s2]5-fluorouracil[e2] therapy for gastric carcinoma.
	(0, 18)	Haemolytic-uraemic syndrome	mitomycin C	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4947	 [s1]Haemolytic-uraemic syndrome[e1] complicating long-term [s2]mitomycin C[e2] and 5-fluorouracil therapy for gastric carcinoma.
	(3, 21)	acute renal toxicity	5-fluorouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4948	Three cases of [s1]acute renal toxicity[e1] in patients receiving long-term therapy with mitomycin C and [s2]5-fluorouracil[e2] are reported.
	(3, 16)	acute renal toxicity	mitomycin C	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4949	Three cases of [s1]acute renal toxicity[e1] in patients receiving long-term therapy with [s2]mitomycin C[e2] and 5-fluorouracil are reported.
	(1, 21)	25-hydroxyvitain D3	ileal resection	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4950	Oral [s1]25-hydroxyvitain D3[e1] in treatment of osteomalacia associated with [s2]ileal resection[e2] and cholestyramine therapy.
	(4, 33)	osteomalacia	cholestyramine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4951	Severe histological [s1]osteomalacia[e1] developed in a woman with Crohn's disease 2 years after ileal resection and the start of [s2]cholestyramine[e2] therapy.
	(2, 5)	lithium	tremor	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4952	Treatment of [s1]lithium[e1]  [s2]tremor[e2] with metoprolol.
	(18, 22)	tremor	lithium carbonate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4953	Two patients with bipolar affective disorder and a history of bronchospastic phenomena experienced [s1]tremor[e1] during [s2]lithium carbonate[e2] therapy.
	(3, 13)	diazepam	seizures	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4954	Intravenous [s1]diazepam[e1] exacerbated the [s2]seizures[e2] 
	(9, 24)	phenytoin	transient hemiparesis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4955	A 52-year-old Black woman on [s1]phenytoin[e1] therapy for post-traumatic epilepsy developed [s2]transient hemiparesis[e2] contralateral to the injury.
	(4, 15)	focal neurological deficit	phenytoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4956	A possible mechanism for [s1]focal neurological deficit[e1] in brain-damaged patients on [s2]phenytoin[e2] therapy is discussed.
	(0, 9)	Transient hemiparesis	phenytoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4957	 [s1]Transient hemiparesis[e1] caused by [s2]phenytoin[e2] toxicity.
	(9, 42)	severe unilateral grand mal seizure	2-propylpentanoic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4958	A 7-year-old boy developed a [s1]severe unilateral grand mal seizure[e1] at the age of 5 years (phenobarbitone therapy); 1.5 years later valproate  [s2]2-propylpentanoic acid[e2]  VPA) was added to the therapy.
	(9, 25)	severe unilateral grand mal seizure	phenobarbitone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4959	A 7-year-old boy developed a [s1]severe unilateral grand mal seizure[e1] at the age of 5 years  [s2]phenobarbitone[e2] therapy); 1.5 years later valproate (2-propylpentanoic acid, VPA) was added to the therapy.
	(9, 39)	severe unilateral grand mal seizure	valproate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4960	A 7-year-old boy developed a [s1]severe unilateral grand mal seizure[e1] at the age of 5 years (phenobarbitone therapy); 1.5 years later [s2]valproate[e2] (2-propylpentanoic acid, VPA) was added to the therapy.
	(9, 52)	severe unilateral grand mal seizure	VPA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4961	A 7-year-old boy developed a [s1]severe unilateral grand mal seizure[e1] at the age of 5 years (phenobarbitone therapy); 1.5 years later valproate (2-propylpentanoic acid, [s2]VPA[e2]  was added to the therapy.
	(0, 21)	Cefoxitin	granulomatous hepatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4962	 [s1]Cefoxitin[e1] therapy for Mycobacterium fortuitum bacteremia with associated [s2]granulomatous hepatitis[e2] 
	(0, 7)	Stroke-like syndrome	gold sodium thiomalate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4963	 [s1]Stroke-like syndrome[e1] after [s2]gold sodium thiomalate[e2] induced vasomotor reaction.
	(5, 14)	gold sodium thiomalate	vasomotor reaction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4964	Stroke-like syndrome after [s1]gold sodium thiomalate[e1] induced [s2]vasomotor reaction[e2] 
	(0, 8)	Vasomotor reactions	gold sodium thiomalate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4965	 [s1]Vasomotor reactions[e1] after [s2]gold sodium thiomalate[e2] are well recognized.
	(0, 9)	Gold nephropathy	auranofin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4966	 [s1]Gold nephropathy[e1] due to [s2]auranofin[e2] obscured by tolmetin pseudoproteinuria.
	(0, 22)	Gold nephropathy	Gold	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4967	 [s1]Gold nephropathy[e1] due to auranofin obscured by tolmetin pseudoproteinuria [s2]Gold[e2] nephropathy due to auranofin obscured by tolmetin pseudoproteinuria.
	(0, 14)	Gold nephropathy	tolmetin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4968	 [s1]Gold nephropathy[e1] due to auranofin obscured by [s2]tolmetin[e2] pseudoproteinuria.
	(12, 18)	tolmetin	pseudoproteinuria	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4969	Gold nephropathy due to auranofin obscured by [s1]tolmetin[e1]  [s2]pseudoproteinuria[e2] 
	(15, 28)	cough	sodium aurothiomalate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4970	A 52-year-old, white female developed low-grade fever, [s1]cough[e1]  and dyspnea after 8 weeks treatment with [s2]sodium aurothiomalate[e2] for rheumatoid arthritis.
	(18, 29)	dyspnea	sodium aurothiomalate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4971	A 52-year-old, white female developed low-grade fever, cough, and [s1]dyspnea[e1] after 8 weeks treatment with [s2]sodium aurothiomalate[e2] for rheumatoid arthritis.
	(10, 28)	low-grade fever	sodium aurothiomalate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4972	A 52-year-old, white female developed [s1]low-grade fever[e1]  cough, and dyspnea after 8 weeks treatment with [s2]sodium aurothiomalate[e2] for rheumatoid arthritis.
	(0, 5)	Pulmonary gold toxicity	gold	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4973	 [s1]Pulmonary gold toxicity[e1]  [s2]gold[e2] toxicity.
	(0, 20)	Cyclophosphamide	fibrosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4974	 [s1]Cyclophosphamide[e1] can rarely cause interstitial pneumonitis and [s2]fibrosis[e2] 
	(0, 11)	Cyclophosphamide	interstitial pneumonitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4975	 [s1]Cyclophosphamide[e1] can rarely cause [s2]interstitial pneumonitis[e2] and fibrosis.
	(0, 8)	Cyclophosphamide	pneumonitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4976	 [s1]Cyclophosphamide[e1]  [s2]pneumonitis[e2] 
	(29, 45)	cyclophosphamide	lung disease	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4977	The temporal sequence of the respiratory insufficiency and the histopathology, when compared to the previous examples in the literature, suggest that [s1]cyclophosphamide[e1] was aetiologically responsible for the [s2]lung disease[e2] 
	(5, 31)	respiratory insufficiency	cyclophosphamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4978	The temporal sequence of the [s1]respiratory insufficiency[e1] and the histopathology, when compared to the previous examples in the literature, suggest that [s2]cyclophosphamide[e2] was aetiologically responsible for the lung disease.
	(1, 19)	reversible toxic liver damage	disulfiram	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4979	A [s1]reversible toxic liver damage[e1] was observed in a non-alcoholic woman treated with [s2]disulfiram[e2] 
	(0, 6)	Toxic hepatitis	disulfiram	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4980	 [s1]Toxic hepatitis[e1] induced by [s2]disulfiram[e2] in a non-alcoholic.
	(8, 32)	acrodermatitis enteropathica	clioquinol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4981	One type of SMON is associated with [s1]acrodermatitis enteropathica[e1] which has a very high frequency of occurrence in association with administration of [s2]clioquinol[e2] 
	(3, 32)	SMON	clioquinol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4982	One type of [s1]SMON[e1] is associated with acrodermatitis enteropathica which has a very high frequency of occurrence in association with administration of [s2]clioquinol[e2] 
	(6, 20)	tamoxifen	retinal changes	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4983	Four patients receiving high-dose [s1]tamoxifen[e1] for greater than 1 year have demonstrated similar [s2]retinal changes[e2] 
	(0, 6)	Tamoxifen	retinopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4984	 [s1]Tamoxifen[e1]  [s2]retinopathy[e2] 
	(5, 22)	corneal and retinal changes	tamoxifen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4985	These findings suggest that the [s1]corneal and retinal changes[e1] are the result of a toxic effect of [s2]tamoxifen[e2] when used in the doses and duration described.
	(0, 14)	Mammary gigantism	D-penicillamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4986	 [s1]Mammary gigantism[e1] is a rare complication of [s2]D-penicillamine[e2] treatment.
	(12, 21)	ampicillin	seizures	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4987	Although they had complex medical problems, the high serum concentrations of [s1]ampicillin[e1] at the time of [s2]seizures[e2] without their recurrence after discontinuing the antibiotic suggest that the seizures were related to the ampicillin therapy.
	(12, 21)	ampicillin	seizures	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4988	Although they had complex medical problems, the high serum concentrations of [s1]ampicillin[e1] at the time of [s2]seizures[e2] without their recurrence after discontinuing the antibiotic suggest that the seizures were related to the ampicillin therapy.
	(0, 6)	Ampicillin	seizures	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4989	 [s1]Ampicillin[e1] associated [s2]seizures[e2] 
	(3, 9)	ampicillin	seizures	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4990	Two patients had [s1]ampicillin[e1] associated [s2]seizures[e2] 
	(4, 12)	rifampicin	skin lesions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4991	After the patient discontinued [s1]rifampicin[e1]  the [s2]skin lesions[e2] cleared completely within 5 weeks without any systemic medication.
	(0, 12)	Pemphigus foliaceus	rifampicin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4992	 [s1]Pemphigus foliaceus[e1] induced by [s2]rifampicin[e2] 
	(0, 19)	Pemphigus foliaceus	rifampicin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4993	 [s1]Pemphigus foliaceus[e1] was seen in a patient with pulmonary tuberculosis during [s2]rifampicin[e2] therapy.
	(0, 11)	Hyponatremia	lorcainide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4994	 [s1]Hyponatremia[e1] in patients treated with [s2]lorcainide[e2]  a new antiarrhythmic drug.
	(6, 39)	decrease in serum Na+	lorcainide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4995	In eight patients, a mean [s1]decrease in serum Na+[e1] of 8.25 +/- 3.2 mEq/L was observed after a single 200 mg intravenous dose of [s2]lorcainide[e2] 
	(4, 15)	SIADH	lorcainide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4996	It is concluded that [s1]SIADH[e1] is an important side effect of [s2]lorcainide[e2] therapy.
	(3, 22)	severe hyponatremia	hydrochlorothiazide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4997	One patient developed [s1]severe hyponatremia[e1] with serum Na+ of 108 mEq/L when [s2]hydrochlorothiazide[e2] was given to control hypertension.
	(6, 24)	hyponatremia	lorcainide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4998	Sixteen of 33 patients developed significant [s1]hyponatremia[e1] and hypoosmolality during oral treatment with [s2]lorcainide[e2] 
	(12, 24)	hypoosmolality	lorcainide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	4999	Sixteen of 33 patients developed significant hyponatremia and [s1]hypoosmolality[e1] during oral treatment with [s2]lorcainide[e2] 
	(0, 37)	Acute intravascular hemolysis	chlorpropamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5000	 [s1]Acute intravascular hemolysis[e1] developed when a diabetic patient, previously treated with glyburide, was started on another oral sulfonylurea drug, [s2]chlorpropamide[e2] 
	(0, 20)	Acute intravascular hemolysis	glyburide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5001	 [s1]Acute intravascular hemolysis[e1] developed when a diabetic patient, previously treated with [s2]glyburide[e2]  was started on another oral sulfonylurea drug, chlorpropamide.
	(0, 8)	Chlorpropamide	hemolytic anemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5002	 [s1]Chlorpropamide[e1] induced [s2]hemolytic anemia[e2] 
	(14, 20)	amiodarone	interstitial pneumopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5003	In a 61-year-old man receiving chronic low-dosage [s1]amiodarone[e1] an [s2]interstitial pneumopathy[e2] was observed.
	(0, 15)	Interstitial pneumopathy	amiodarone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5004	 [s1]Interstitial pneumopathy[e1] and low-dosage [s2]amiodarone[e2] 
	(0, 14)	Alternating sinus rhythm	propranolol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5005	 [s1]Alternating sinus rhythm[e1] and intermittent sinoatrial block induced by [s2]propranolol[e2] 
	(5, 14)	intermittent sinoatrial block	propranolol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5006	Alternating sinus rhythm and [s1]intermittent sinoatrial block[e1] induced by [s2]propranolol[e2] 
	(0, 36)	Alternating sinus rhythm	propranolol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5007	 [s1]Alternating sinus rhythm[e1] and intermittent sinoatrial (S-A) block was observed in a 57-year-old woman, under treatment for angina with 80 mg [s2]propranolol[e2] daily.
	(5, 36)	intermittent sinoatrial (S-A) block	propranolol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5008	Alternating sinus rhythm and [s1]intermittent sinoatrial (S-A) block[e1] was observed in a 57-year-old woman, under treatment for angina with 80 mg [s2]propranolol[e2] daily.
	(1, 10)	abnormal rhythm	propranolol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5009	The [s1]abnormal rhythm[e1] disappeared with the withdrawal of [s2]propranolol[e2] and when the drug was restarted a 2/1 S-A block was seen.
	(6, 17)	propranolol	conduction disorder	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5010	This was accepted as evidence for [s1]propranolol[e1] being the cause of this [s2]conduction disorder[e2] 
	(4, 13)	anaphylactoid reaction	methylprednisolone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5011	A further case of [s1]anaphylactoid reaction[e1] to [s2]methylprednisolone[e2] is reported.
	(0, 9)	Anaphylactoid reaction	methylprednisolone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5012	 [s1]Anaphylactoid reaction[e1] to [s2]methylprednisolone[e2] pulsed therapy for multiple sclerosis.
	(15, 20)	pulmonary toxicity	CCNU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5013	Although lung specimens were lacking from these three patients, it is suggested that the [s1]pulmonary toxicity[e1] of [s2]CCNU[e2] may be dose-related.
	(0, 11)	Pulmonary fibrosis	CCNU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5014	 [s1]Pulmonary fibrosis[e1] subsequent to high doses of [s2]CCNU[e2] for chronic myeloid leukemia.
	(3, 12)	CCNU	pulmonary fibrosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5015	The responsibility of [s1]CCNU[e1] in the pathogenesis of [s2]pulmonary fibrosis[e2] seems very likely.
	(13, 33)	CCNU	fatal pulmonary fibrosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5016	Two patients treated for chronic myeloid leukemia with high doses of [s1]CCNU[e1] (1100 mg/m2 and 1240 mg/m2, respectively) developed a [s2]fatal pulmonary fibrosis[e2] 
	(0, 10)	Additive pulmonary toxicity	busulfan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5017	 [s1]Additive pulmonary toxicity[e1] with melphalan and [s2]busulfan[e2] therapy.
	(0, 6)	Additive pulmonary toxicity	melphalan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5018	 [s1]Additive pulmonary toxicity[e1] with [s2]melphalan[e2] and busulfan therapy.
	(18, 39)	severe interstitial lung fibrosis	busulfan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5019	We report a 59-year-old patient with chronic myeloid leukemia, who developed [s1]severe interstitial lung fibrosis[e1] after short term and sequential treatment with melphalan and [s2]busulfan[e2] 
	(18, 35)	severe interstitial lung fibrosis	melphalan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5020	We report a 59-year-old patient with chronic myeloid leukemia, who developed [s1]severe interstitial lung fibrosis[e1] after short term and sequential treatment with [s2]melphalan[e2] and busulfan.
	(2, 25)	cholestyramine II	confusion	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5021	After taking [s1]cholestyramine II[e1] sachets twice daily for two months she presented with lethargy, [s2]confusion[e2] and drowsiness.
	(2, 27)	cholestyramine II	drowsiness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5022	After taking [s1]cholestyramine II[e1] sachets twice daily for two months she presented with lethargy, confusion and [s2]drowsiness[e2] 
	(2, 21)	cholestyramine II	lethargy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5023	After taking [s1]cholestyramine II[e1] sachets twice daily for two months she presented with [s2]lethargy[e2]  confusion and drowsiness.
	(0, 8)	Cholestyramine	hyperchloremic metabolic acidosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5024	 [s1]Cholestyramine[e1] induced [s2]hyperchloremic metabolic acidosis[e2] 
	(5, 17)	hyperchloremic metabolic acidosis	cholestyramine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5025	It is presumed that her [s1]hyperchloremic metabolic acidosis[e1] was secondary to [s2]cholestyramine[e2] because of the similarity to pediatric reports; the rapid and lasting response to intravenous sodium bicarbonate; the absence of another etiology; normal serum potassium, chloride and bicarbonate despite continued spironolactone therapy after recovery.
	(10, 18)	cholestyramine	hyperchloremic metabolic acidosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5026	The first reported case, in an adult, of [s1]cholestyramine[e1] induced [s2]hyperchloremic metabolic acidosis[e2] is a 70 year old female with a two year history of primary biliary cirrhosis confirmed by histologic and immunologic criteria.
	(10, 29)	immunosuppression	DCF	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5027	Although myelosuppression is mild, [s1]immunosuppression[e1] and superinfection are potential hazards of treatment with [s2]DCF[e2] 
	(17, 29)	superinfection	DCF	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5028	Although myelosuppression is mild, immunosuppression and [s1]superinfection[e1] are potential hazards of treatment with [s2]DCF[e2] 
	(5, 12)	DCF	conjunctivitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5029	The ocular toxicity of [s1]DCF[e1]  previously described as [s2]conjunctivitis[e2]  appears to be a keratitis of moderate severity which requires further study.
	(5, 22)	DCF	keratitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5030	The ocular toxicity of [s1]DCF[e1]  previously described as conjunctivitis, appears to be a [s2]keratitis[e2] of moderate severity which requires further study.
	(1, 7)	ocular toxicity	DCF	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5031	The [s1]ocular toxicity[e1] of [s2]DCF[e2]  previously described as conjunctivitis, appears to be a keratitis of moderate severity which requires further study.
	(24, 42)	vasopressin	renal damage	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5032	Because there were no other obvious causes of renal failure in either patient, we propose that skeletal muscle ischemia developed during [s1]vasopressin[e1] infusion, followed by release of myoglobin and [s2]renal damage[e2] 
	(17, 26)	skeletal muscle ischemia	vasopressin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5033	Because there were no other obvious causes of renal failure in either patient, we propose that [s1]skeletal muscle ischemia[e1] developed during [s2]vasopressin[e2] infusion, followed by release of myoglobin and renal damage.
	(6, 16)	acute renal failure	vasopressin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5034	Myoglobinuria and [s1]acute renal failure[e1] associated with intravenous [s2]vasopressin[e2] infusion.
	(0, 16)	Myoglobinuria	vasopressin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5035	 [s1]Myoglobinuria[e1] and acute renal failure associated with intravenous [s2]vasopressin[e2] infusion.
	(6, 17)	acute renal failure	vasopressin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5036	Myoglobinuria and [s1]acute renal failure[e1] were observed in two patients with [s2]vasopressin[e2] treated gastrointestinal hemorrhage.
	(0, 17)	Myoglobinuria	vasopressin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5037	 [s1]Myoglobinuria[e1] and acute renal failure were observed in two patients with [s2]vasopressin[e2] treated gastrointestinal hemorrhage.
	(7, 19)	amphotericin B	nephrotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5038	A major limitation in the use of [s1]amphotericin B[e1] is its potential to cause [s2]nephrotoxicity[e2] 
	(0, 7)	Amphotericin B	nephrotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5039	 [s1]Amphotericin B[e1]  [s2]nephrotoxicity[e2] in humans decreased by salt repletion.
	(6, 14)	impaired renal function	amphotericin B	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5040	Experience with five patients in whom [s1]impaired renal function[e1] developed early during [s2]amphotericin B[e2] therapy is reported.
	(0, 21)	Gynecomastia	fluoresone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5041	 [s1]Gynecomastia[e1] developed in two epileptic patients some months after the addition of oral [s2]fluoresone[e2] 750 mg daily to the phenobarbital and phenytoin already being administered.
	(0, 29)	Gynecomastia	phenobarbital	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5042	 [s1]Gynecomastia[e1] developed in two epileptic patients some months after the addition of oral fluoresone 750 mg daily to the [s2]phenobarbital[e2] and phenytoin already being administered.
	(0, 35)	Gynecomastia	phenytoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5043	 [s1]Gynecomastia[e1] developed in two epileptic patients some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and [s2]phenytoin[e2] already being administered.
	(0, 25)	Gynecomastia	fluoresone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5044	 [s1]Gynecomastia[e1] in epileptics treated with phenobarbital, phenytoin and [s2]fluoresone[e2]  two case reports.
	(0, 14)	Gynecomastia	phenobarbital	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5045	 [s1]Gynecomastia[e1] in epileptics treated with [s2]phenobarbital[e2]  phenytoin and fluoresone: two case reports.
	(0, 20)	Gynecomastia	phenytoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5046	 [s1]Gynecomastia[e1] in epileptics treated with phenobarbital, [s2]phenytoin[e2] and fluoresone: two case reports.
	(4, 13)	dyskinesia	amoxapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5047	Case report of withdrawal [s1]dyskinesia[e1] associated with [s2]amoxapine[e2] 
	(3, 19)	dyskinesia	amoxapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5048	Occurrence of withdrawal [s1]dyskinesia[e1] indicates that the neuroleptic effects of [s2]amoxapine[e2] may be clinically significant.
	(6, 24)	oral-facial dyskinesia	amoxapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5049	The authors describe a case of [s1]oral-facial dyskinesia[e1] that occurred after discontinuation of [s2]amoxapine[e2]  and antidepressant which may also have neuroleptic effects.
	(3, 18)	toxic hepatitis	etretinate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5050	A case of [s1]toxic hepatitis[e1] caused by combination therapy with methotrexate and [s2]etretinate[e2] in the treatment of severe psoriasis is presented in a 47-year-old woman.
	(3, 12)	toxic hepatitis	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5051	A case of [s1]toxic hepatitis[e1] caused by combination therapy with [s2]methotrexate[e2] and etretinate in the treatment of severe psoriasis is presented in a 47-year-old woman.
	(0, 15)	Toxic hepatitis	etretinate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5052	 [s1]Toxic hepatitis[e1] due to combination therapy with methotrexate and [s2]etretinate[e2] in psoriasis.
	(0, 9)	Toxic hepatitis	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5053	 [s1]Toxic hepatitis[e1] due to combination therapy with [s2]methotrexate[e2] and etretinate in psoriasis.
	(9, 32)	hydrochlorothiazide	hyponatremia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5054	Metabolic balance studies and rechallenge with [s1]hydrochlorothiazide[e1] were undertaken to investigate the mechanism of the thiazide-induced [s2]hyponatremia[e2] 
	(8, 34)	unilateral acute angle-closure glaucoma	scopolamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5055	A 58-year-old woman developed [s1]unilateral acute angle-closure glaucoma[e1] four days after the application of a patch of transdermal [s2]scopolamine[e2] delivery system (TRANSDERM-V).
	(16, 31)	tardive dyskinesia	deanol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5056	A case history of a 15-year-old boy who developed incapacitating [s1]tardive dyskinesia[e1] that resolved during treatment with [s2]deanol[e2] is presented.
	(0, 12)	Cephalosporins	Vitamin K deficiency	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5057	 [s1]Cephalosporins[e1] are most likely associated with [s2]Vitamin K deficiency[e2] 
	(0, 11)	Coagulopathy	cephalosporin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5058	 [s1]Coagulopathy[e1] associated with the use of [s2]cephalosporin[e2] or moxalactam antibiotics in acute and chronic renal failure.
	(0, 17)	Coagulopathy	moxalactam	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5059	 [s1]Coagulopathy[e1] associated with the use of cephalosporin or [s2]moxalactam[e2] antibiotics in acute and chronic renal failure.
	(0, 14)	Moxalactam	platelet dysfunction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5060	 [s1]Moxalactam[e1] is more likely to be associated with [s2]platelet dysfunction[e2] 
	(3, 20)	coagulopathy	cephalosporin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5061	Nevertheless, the [s1]coagulopathy[e1] seemed to be most closely associated with the administration of the [s2]cephalosporin[e2] 
	(8, 20)	coagulopathy	cephalosporin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5062	Nine azotemic patients who developed a [s1]coagulopathy[e1] associated with the use of either [s2]cephalosporin[e2] or moxalactam antibiotics are reported.
	(8, 26)	coagulopathy	moxalactam	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5063	Nine azotemic patients who developed a [s1]coagulopathy[e1] associated with the use of either cephalosporin or [s2]moxalactam[e2] antibiotics are reported.
	(8, 16)	fatal pulmonary fibrosis	BCNU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5064	A case is reported of a child with [s1]fatal pulmonary fibrosis[e1] following [s2]BCNU[e2] therapy.
	(0, 8)	Fatal pulmonary fibrosis	1,3-bis(2-chloroethyl)-1-nitrosourea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5065	 [s1]Fatal pulmonary fibrosis[e1] following [s2]1,3-bis(2-chloroethyl)-1-nitrosourea[e2] (BCNU) therapy.
	(0, 30)	Fatal pulmonary fibrosis	BCNU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5066	 [s1]Fatal pulmonary fibrosis[e1] following 1,3-bis(2-chloroethyl)-1-nitrosourea  [s2]BCNU[e2]  therapy.
	(0, 17)	Thrombotic thrombocytopenic purpura	penicillamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5067	 [s1]Thrombotic thrombocytopenic purpura[e1] during [s2]penicillamine[e2] therapy in rheumatoid arthritis.
	(0, 47)	Thrombotic thrombocytopenic purpura	penicillamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5068	 [s1]Thrombotic thrombocytopenic purpura[e1] (TTP) developed in a patient with seropositive rheumatoid arthritis (RA) after 2 1/2 months of treatment with [s2]penicillamine[e2] 
	(14, 45)	TTP	penicillamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5069	Thrombotic thrombocytopenic purpura  [s1]TTP[e1]  developed in a patient with seropositive rheumatoid arthritis (RA) after 2 1/2 months of treatment with [s2]penicillamine[e2] 
	(8, 15)	penicillamine	TTP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5070	To our knowledge, no prior cases of [s1]penicillamine[e1] induced [s2]TTP[e2] in RA have been reported.
	(0, 27)	Amiodarone hydrochloride	cough	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5071	 [s1]Amiodarone hydrochloride[e1]  a new antiarrhythmic agent, has been associated with pulmonary toxicity characterized by [s2]cough[e2]  dyspnea and diffuse pulmonary infiltrates.
	(0, 34)	Amiodarone hydrochloride	diffuse pulmonary infiltrates	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5072	 [s1]Amiodarone hydrochloride[e1]  a new antiarrhythmic agent, has been associated with pulmonary toxicity characterized by cough, dyspnea and [s2]diffuse pulmonary infiltrates[e2] 
	(0, 29)	Amiodarone hydrochloride	dyspnea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5073	 [s1]Amiodarone hydrochloride[e1]  a new antiarrhythmic agent, has been associated with pulmonary toxicity characterized by cough, [s2]dyspnea[e2] and diffuse pulmonary infiltrates.
	(0, 23)	Amiodarone hydrochloride	pulmonary toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5074	 [s1]Amiodarone hydrochloride[e1]  a new antiarrhythmic agent, has been associated with [s2]pulmonary toxicity[e2] characterized by cough, dyspnea and diffuse pulmonary infiltrates.
	(5, 10)	amiodarone	pulmonary toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5075	Possible recurrence of [s1]amiodarone[e1]  [s2]pulmonary toxicity[e2] following corticosteroid therapy.
	(9, 14)	amiodarone	pulmonary toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5076	To our knowledge, this recurrence of [s1]amiodarone[e1]  [s2]pulmonary toxicity[e2] has not been reported previously.
	(5, 24)	fibrosing alveolitis	amiodarone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5077	We describe a case of [s1]fibrosing alveolitis[e1]  diagnosed by lung biopsy, in a patient receiving [s2]amiodarone[e2] which responded to corticosteroid therapy.
	(8, 17)	gynecomastia	theophylline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5078	A 61 year-old male patient developed [s1]gynecomastia[e1] after starting [s2]theophylline[e2] 
	(0, 9)	Gynecomastia	theophylline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5079	 [s1]Gynecomastia[e1] associated with [s2]theophylline[e2] 
	(12, 25)	gynecomastia	theophylline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5080	No other endogenous or exogenous cause for the [s1]gynecomastia[e1] could be found except for the [s2]theophylline[e2] 
	(1, 12)	gynecomastia	theophylline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5081	The [s1]gynecomastia[e1] regressed when the [s2]theophylline[e2] was discontinued.
	(2, 9)	verapamil	sustained hypotension	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5082	Parenteral [s1]verapamil[e1] induced [s2]sustained hypotension[e2] 
	(4, 11)	verapamil	hypotension	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5083	The incidence of oral [s1]verapamil[e1] induced [s2]hypotension[e2] in the presence of concomitant beta-adrenergic blockade by the oral route is quite rare.
	(5, 18)	sustained hypotension	verapamil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5084	We report a case of [s1]sustained hypotension[e1] after administration of parenteral [s2]verapamil[e2] 
	(8, 18)	pure red cell aplasia	fenoprofen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5085	A 69-year-old man developed [s1]pure red cell aplasia[e1] after taking [s2]fenoprofen[e2] for ten months.
	(0, 10)	Pure red cell aplasia	fenoprofen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5086	 [s1]Pure red cell aplasia[e1] associated with [s2]fenoprofen[e2] 
	(7, 29)	erythroid aplasia	fenoprofen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5087	This case represents the third example of [s1]erythroid aplasia[e1] associated with an anti-inflammatory agent and the first instance due to [s2]fenoprofen[e2] 
	(3, 12)	psychosis	quinacrine hydrochloride	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5088	Drug-induced [s1]psychosis[e1] resulted from the administration of [s2]quinacrine hydrochloride[e2] at a dosage of 100 mg twice daily for the treatment of discoid lupus.
	(3, 10)	priapism	trazodone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5089	A case of [s1]priapism[e1] associated with [s2]trazodone[e2] is described.
	(0, 7)	Priapism	trazodone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5090	 [s1]Priapism[e1] associated with [s2]trazodone[e2] therapy: case report.
	(17, 32)	paracetamol	severe hepatic necrosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5091	Charcoal haemoperfusion and cysteamine therapy led to the rapid removal of the [s1]paracetamol[e1] from the body and consequently prevented the development of [s2]severe hepatic necrosis[e2] 
	(0, 32)	Anaphylactoid shock	zomepirac	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5092	 [s1]Anaphylactoid shock[e1]  disseminated intravascular coagulation, and anuric renal failure requiring dialysis occurred in a patient receiving [s2]zomepirac[e2] sodium for toothache.
	(18, 33)	anuric renal failure	zomepirac	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5093	Anaphylactoid shock, disseminated intravascular coagulation, and [s1]anuric renal failure[e1] requiring dialysis occurred in a patient receiving [s2]zomepirac[e2] sodium for toothache.
	(7, 32)	disseminated intravascular coagulation	zomepirac	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5094	Anaphylactoid shock, [s1]disseminated intravascular coagulation[e1]  and anuric renal failure requiring dialysis occurred in a patient receiving [s2]zomepirac[e2] sodium for toothache.
	(0, 11)	Focal renal cortical necrosis	zomepirac	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5095	 [s1]Focal renal cortical necrosis[e1] associated with [s2]zomepirac[e2] 
	(3, 12)	anaphylactoid reaction	zomepirac	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5096	The mechanism of [s1]anaphylactoid reaction[e1] to [s2]zomepirac[e2] in this case, therefore, remains unclear.
	(0, 7)	Cimetidine	fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5097	 [s1]Cimetidine[e1] induced [s2]fever[e2] 
	(0, 14)	Cimetidine	fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5098	 [s1]Cimetidine[e1] is a rare cause of drug-induced [s2]fever[e2] 
	(13, 22)	behavioral change	cinepazide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5099	A 56-year-old male parkinsonian patient developed a unique [s1]behavioral change[e1] following the oral administration of [s2]cinepazide[e2]  a cerebral vasodilator.
	(1, 6)	behavioral change	cinepazide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5100	Unique [s1]behavioral change[e1] with [s2]cinepazide[e2] in parkinsonism.
	(25, 34)	small-bowel obstruction	Amphojel	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5101	A 65-year-old woman, in the intensive care unit because of septic shock and acute renal failure, had a [s1]small-bowel obstruction[e1] due to [s2]Amphojel[e2] concretions.
	(12, 24)	periodic alternating nystagmus	phenytoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5102	A patient with alcoholic cerebellar degeneration had [s1]periodic alternating nystagmus[e1] during a period of [s2]phenytoin[e2] intoxication.
	(10, 15)	gold-salt	nephropathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5103	Although the data indicate an immune-complex cause for [s1]gold-salt[e1]  [s2]nephropathy[e2]  the incident antigen (or antigens) and mechanism of action remain unidentified.
	(0, 3)	Gold	nephropathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5104	 [s1]Gold[e1]  [s2]nephropathy[e2] 
	(0, 9)	Gold-salt	damage to proximal tubules	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5105	 [s1]Gold-salt[e1] therapy may result in [s2]damage to proximal tubules[e2] that leak renal tubular antigens, which in turn complex with autoantibody and produce an autoimmune membranous nephropathy.
	(1, 15)	nephrotic syndrome	gold	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5106	The [s1]nephrotic syndrome[e1] developed in a patient receiving therapy with [s2]gold[e2] for rheumatoid arthritis.
	(9, 17)	cutaneous bullae	glibenclamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5107	Intrahepatic cholestasis and [s1]cutaneous bullae[e1] associated with [s2]glibenclamide[e2] therapy are described in a 61-year-old diabetic patient who presented wit hypoglycaemic coma.
	(0, 17)	Intrahepatic cholestasis	glibenclamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5108	 [s1]Intrahepatic cholestasis[e1] and cutaneous bullae associated with [s2]glibenclamide[e2] therapy are described in a 61-year-old diabetic patient who presented wit hypoglycaemic coma.
	(9, 17)	cutaneous bullae	glibenclamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5109	Intrahepatic cholestasis and [s1]cutaneous bullae[e1] associated with [s2]glibenclamide[e2] therapy.
	(0, 17)	Intrahepatic cholestasis	glibenclamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5110	 [s1]Intrahepatic cholestasis[e1] and cutaneous bullae associated with [s2]glibenclamide[e2] therapy.
	(20, 33)	intrahepatic cholestasis	chlorpropamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5111	These features have not previously been reported as side effects of glibenclamide therapy, but [s1]intrahepatic cholestasis[e1] may occur with [s2]chlorpropamide[e2]  a similar sulphonylurea agent.
	(4, 20)	spasm	ergonovine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5112	In four patients, [s1]spasm[e1] occurred spontaneous and in one patient after 0.05 mg of [s2]ergonovine[e2] 
	(10, 28)	delirium	propranolol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5113	The authors describe a woman with chronic schizophrenia who experienced [s1]delirium[e1]  grand mal seizure, and photosensitivity after the addition of [s2]propranolol[e2] to her neuroleptic regimen.
	(14, 28)	grand mal seizure	propranolol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5114	The authors describe a woman with chronic schizophrenia who experienced delirium, [s1]grand mal seizure[e1]  and photosensitivity after the addition of [s2]propranolol[e2] to her neuroleptic regimen.
	(19, 29)	photosensitivity	propranolol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5115	The authors describe a woman with chronic schizophrenia who experienced delirium, grand mal seizure, and [s1]photosensitivity[e1] after the addition of [s2]propranolol[e2] to her neuroleptic regimen.
	(0, 7)	Catatonia	disulfiram	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5116	 [s1]Catatonia[e1] associated with [s2]disulfiram[e2] therapy.
	(16, 27)	disulfiram	catatonia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5117	Neurophysiological mechanisms which aid in elucidating the role of [s1]disulfiram[e1] in the etiology of [s2]catatonia[e2] are discussed.
	(7, 18)	catatonic syndrome	disulfiram	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5118	This is the first report of a [s1]catatonic syndrome[e1] occurring in a patient receiving [s2]disulfiram[e2] treatment.
	(0, 7)	Hepatic reactions	cyclofenil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5119	 [s1]Hepatic reactions[e1] to [s2]cyclofenil[e2] 
	(3, 10)	hepatic reactions	cyclofenil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5120	Thirty patients with [s1]hepatic reactions[e1] to [s2]cyclofenil[e2]  a non-steroidal drug with a stimulating effect on ovulation, are reviewed.
	(8, 16)	theophylline	peptic ulcer disease	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5121	Since early symptoms of the toxic effects of [s1]theophylline[e1] can mimic [s2]peptic ulcer disease[e2]  cimetidine might be prescribed for the gastrointestinal symptoms with subsequent worsening of theophylline poisoning.
	(3, 10)	SIADH	desipramine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5122	A case of [s1]SIADH[e1] associated with [s2]desipramine[e2] treatment in an elderly depressed woman is described.
	(0, 7)	Desipramine	SIADH	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5123	 [s1]Desipramine[e1] associated [s2]SIADH[e2] in an elderly woman: case report.
	(5, 21)	tubular and interstitial lesions	rifampin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5124	Prior reports have emphasized the [s1]tubular and interstitial lesions[e1] associated with intermittent or discontinuous [s2]rifampin[e2] therapy for tuberculosis.
	(3, 20)	renal lesions	rifampin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5125	The spectrum of [s1]renal lesions[e1] occurring during antituberculous therapy, particularly in association with [s2]rifampin[e2]  may be wider than previously suspected.
	(7, 26)	isoniazid	acute renal failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5126	Within 3 weeks of beginning continuous daily [s1]isoniazid[e1] and rifampin therapy for pulmonary tuberculosis, a patient developed [s2]acute renal failure[e2] 
	(12, 26)	rifampin	acute renal failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5127	Within 3 weeks of beginning continuous daily isoniazid and [s1]rifampin[e1] therapy for pulmonary tuberculosis, a patient developed [s2]acute renal failure[e2] 
	(0, 13)	Nephrotic range pseudoproteinuria	tolmetin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5128	 [s1]Nephrotic range pseudoproteinuria[e1] in a [s2]tolmetin[e2] treated patient.
	(4, 19)	isoniazid	histamine reaction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5129	When tuberculosis patients on [s1]isoniazid[e1] eat certain varieties of fish they may develop a [s2]histamine reaction[e2] 
	(0, 9)	Fulminant hepatitis	disulfiram	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5130	 [s1]Fulminant hepatitis[e1] associated with [s2]disulfiram[e2] 
	(5, 18)	fatal fulminant hepatitis	disulfiram	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5131	We report a case of [s1]fatal fulminant hepatitis[e1] caused by the use of [s2]disulfiram[e2] in a man with previously normal hepatocellular function.
	(14, 24)	agranulocytosis	propylthiouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5132	A 45-year-old woman with thyrotoxicosis developed [s1]agranulocytosis[e1] after treatment with [s2]propylthiouracil[e2] 
	(4, 24)	methimazole	agranulocytosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5133	The patient was given [s1]methimazole[e1] instead of propylthiouracil but, 10 weeks later, [s2]agranulocytosis[e2] again occurred.
	(18, 36)	agranulocytosis	methimazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5134	This is, to the best of our knowledge, the first report of a case in which [s1]agranulocytosis[e1] followed treatment with both propylthiouracil and [s2]methimazole[e2] in the same patient.
	(18, 29)	agranulocytosis	propylthiouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5135	This is, to the best of our knowledge, the first report of a case in which [s1]agranulocytosis[e1] followed treatment with both [s2]propylthiouracil[e2] and methimazole in the same patient.
	(9, 23)	prolonged jaundice	thiabendazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5136	A 55-yr-old man developed [s1]prolonged jaundice[e1] and sicca complex after a course of [s2]thiabendazole[e2] therapy.
	(14, 23)	sicca complex	thiabendazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5137	A 55-yr-old man developed prolonged jaundice and [s1]sicca complex[e1] after a course of [s2]thiabendazole[e2] therapy.
	(0, 15)	Intrahepatic cholestasis	thiabendazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5138	 [s1]Intrahepatic cholestasis[e1] and sicca complex after [s2]thiabendazole[e2] 
	(9, 15)	sicca complex	thiabendazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5139	Intrahepatic cholestasis and [s1]sicca complex[e1] after [s2]thiabendazole[e2] 
	(3, 12)	thiabendazole	cholestasis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5140	The literature on [s1]thiabendazole[e1] induced [s2]cholestasis[e2] and its association with sicca complex is reviewed.
	(3, 20)	thiabendazole	sicca complex	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5141	The literature on [s1]thiabendazole[e1] induced cholestasis and its association with [s2]sicca complex[e2] is reviewed.
	(7, 29)	Adriamycin	Adriamycin toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5142	She was placed on adjuvant [s1]Adriamycin[e1] (doxorubicin) chemotherapy, but 6 months later died of [s2]Adriamycin toxicity[e2] 
	(7, 29)	Adriamycin	Adriamycin toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5143	She was placed on adjuvant [s1]Adriamycin[e1] (doxorubicin) chemotherapy, but 6 months later died of [s2]Adriamycin toxicity[e2] 
	(11, 27)	doxorubicin	Adriamycin toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5144	She was placed on adjuvant Adriamycin  [s1]doxorubicin[e1]  chemotherapy, but 6 months later died of [s2]Adriamycin toxicity[e2] 
	(7, 27)	Adriamycin	died	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5145	She was placed on adjuvant [s1]Adriamycin[e1] (doxorubicin) chemotherapy, but 6 months later [s2]died[e2] of Adriamycin toxicity.
	(7, 27)	Adriamycin	died	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5146	She was placed on adjuvant [s1]Adriamycin[e1] (doxorubicin) chemotherapy, but 6 months later [s2]died[e2] of Adriamycin toxicity.
	(11, 25)	doxorubicin	died	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5147	She was placed on adjuvant Adriamycin  [s1]doxorubicin[e1]  chemotherapy, but 6 months later [s2]died[e2] of Adriamycin toxicity.
	(8, 16)	focal seizures	L-asparaginase	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5148	Intracranial hemorrhage and [s1]focal seizures[e1] secondary to use of [s2]L-asparaginase[e2] during induction therapy of acute lymphocytic leukemia.
	(0, 16)	Intracranial hemorrhage	L-asparaginase	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5149	 [s1]Intracranial hemorrhage[e1] and focal seizures secondary to use of [s2]L-asparaginase[e2] during induction therapy of acute lymphocytic leukemia.
	(0, 38)	Dural sinus thrombosis	asparaginase	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5150	 [s1]Dural sinus thrombosis[e1] developed in two children with acute lymphoblastic leukemia during induction treatment with vincristine sulfate, prednisone, and [s2]asparaginase[e2] 
	(0, 32)	Dural sinus thrombosis	prednisone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5151	 [s1]Dural sinus thrombosis[e1] developed in two children with acute lymphoblastic leukemia during induction treatment with vincristine sulfate, [s2]prednisone[e2]  and asparaginase.
	(0, 26)	Dural sinus thrombosis	vincristine sulfate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5152	 [s1]Dural sinus thrombosis[e1] developed in two children with acute lymphoblastic leukemia during induction treatment with [s2]vincristine sulfate[e2]  prednisone, and asparaginase.
	(15, 22)	asparaginase	antithrombin III deficiency	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5153	The cause is presumed to be secondary to hypercoagulability due to [s1]asparaginase[e1] induced [s2]antithrombin III deficiency[e2] 
	(13, 26)	lupus erythematosus	penicillamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5154	Six patients with rheumatoid arthritis developed a syndrome resembling [s1]lupus erythematosus[e1] while being treated with [s2]penicillamine[e2] 
	(0, 11)	Systemic lupus erythematosus	penicillamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5155	 [s1]Systemic lupus erythematosus[e1] during [s2]penicillamine[e2] therapy for rheumatoid arthritis.
	(5, 20)	prednisone	Cushingoid features	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5156	However, the amount of [s1]prednisone[e1] required to maintain normotension resulted in [s2]Cushingoid features[e2] and has been discontinued.
	(6, 25)	fasting hypoglycemia	disopyramide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5157	Clinicians should be aware of [s1]fasting hypoglycemia[e1] as an unusual but potentially serious complication of [s2]disopyramide[e2] therapy.
	(0, 12)	Disopyramide	hypoglycemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5158	 [s1]Disopyramide[e1] (Norpace)-induced [s2]hypoglycemia[e2] 
	(4, 10)	Norpace	hypoglycemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5159	Disopyramide  [s1]Norpace[e1] -induced [s2]hypoglycemia[e2] 
	(0, 7)	Cefoxitin	renal failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5160	 [s1]Cefoxitin[e1] associated [s2]renal failure[e2] 
	(12, 26)	acute tubular necrosis	cefoxitin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5161	The other woman had rheumatoid arthritis and developed [s1]acute tubular necrosis[e1] after treatment with gentamicin and [s2]cefoxitin[e2] 
	(12, 21)	acute tubular necrosis	gentamicin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5162	The other woman had rheumatoid arthritis and developed [s1]acute tubular necrosis[e1] after treatment with [s2]gentamicin[e2] and cefoxitin.
	(5, 15)	acute deterioration of renal function	cefoxitin sodium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5163	Two elderly women suffered an [s1]acute deterioration of renal function[e1] after treatment with [s2]cefoxitin sodium[e2] 
	(0, 17)	Transient anuria	SQ 14225	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5164	 [s1]Transient anuria[e1] following administration of angiotensin I-converting enzyme inhibitor  [s2]SQ 14225[e2]  in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation.
	(18, 32)	acute renal impairment	captopril	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5165	We report on a patient with renal artery stenosis who had only 1 kidney and in whom [s1]acute renal impairment[e1] developed with transient anuria after the administration of [s2]captopril[e2] 
	(23, 32)	transient anuria	captopril	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5166	We report on a patient with renal artery stenosis who had only 1 kidney and in whom acute renal impairment developed with [s1]transient anuria[e1] after the administration of [s2]captopril[e2] 
	(11, 31)	amiodarone	atypical ventricular tachycardia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5167	A 44-year-old woman is described in whom [s1]amiodarone[e1]  disopyramide, and quinidine, administered alone separately, induced [s2]atypical ventricular tachycardia[e2] (AVT, torsade de pointes).
	(15, 31)	disopyramide	atypical ventricular tachycardia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5168	A 44-year-old woman is described in whom amiodarone, [s1]disopyramide[e1]  and quinidine, administered alone separately, induced [s2]atypical ventricular tachycardia[e2] (AVT, torsade de pointes).
	(21, 31)	quinidine	atypical ventricular tachycardia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5169	A 44-year-old woman is described in whom amiodarone, disopyramide, and [s1]quinidine[e1]  administered alone separately, induced [s2]atypical ventricular tachycardia[e2] (AVT, torsade de pointes).
	(11, 41)	amiodarone	AVT	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5170	A 44-year-old woman is described in whom [s1]amiodarone[e1]  disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia  [s2]AVT[e2]  torsade de pointes).
	(15, 41)	disopyramide	AVT	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5171	A 44-year-old woman is described in whom amiodarone, [s1]disopyramide[e1]  and quinidine, administered alone separately, induced atypical ventricular tachycardia  [s2]AVT[e2]  torsade de pointes).
	(21, 41)	quinidine	AVT	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5172	A 44-year-old woman is described in whom amiodarone, disopyramide, and [s1]quinidine[e1]  administered alone separately, induced atypical ventricular tachycardia  [s2]AVT[e2]  torsade de pointes).
	(11, 45)	amiodarone	torsade de pointes	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5173	A 44-year-old woman is described in whom [s1]amiodarone[e1]  disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia (AVT, [s2]torsade de pointes[e2] .
	(15, 45)	disopyramide	torsade de pointes	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5174	A 44-year-old woman is described in whom amiodarone, [s1]disopyramide[e1]  and quinidine, administered alone separately, induced atypical ventricular tachycardia (AVT, [s2]torsade de pointes[e2] .
	(21, 45)	quinidine	torsade de pointes	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5175	A 44-year-old woman is described in whom amiodarone, disopyramide, and [s1]quinidine[e1]  administered alone separately, induced atypical ventricular tachycardia (AVT, [s2]torsade de pointes[e2] .
	(0, 11)	Amiodarone	AVT	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5176	 [s1]Amiodarone[e1] was the third drug to induce [s2]AVT[e2] in this patient; she received 200 mg/day six days per week for six months.
	(24, 38)	arrhythmia	disopyramide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5177	Atypical ventricular tachycardia (torsade de pointes) induced by amiodarone: [s1]arrhythmia[e1] previously induced by quinidine and [s2]disopyramide[e2] 
	(24, 34)	arrhythmia	quinidine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5178	Atypical ventricular tachycardia (torsade de pointes) induced by amiodarone: [s1]arrhythmia[e1] previously induced by [s2]quinidine[e2] and disopyramide.
	(0, 22)	Atypical ventricular tachycardia	amiodarone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5179	 [s1]Atypical ventricular tachycardia[e1] (torsade de pointes) induced by [s2]amiodarone[e2]  arrhythmia previously induced by quinidine and disopyramide.
	(10, 20)	torsade de pointes	amiodarone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5180	Atypical ventricular tachycardia  [s1]torsade de pointes[e1]  induced by [s2]amiodarone[e2]  arrhythmia previously induced by quinidine and disopyramide.
	(13, 27)	disopyramide	AVT	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5181	Two years later, 24 hours following an increase in the dose of [s1]disopyramide[e1] from 300 to 600 mg/day, [s2]AVT[e2] with syncope occurred; isoproterenol abolished the arrhythmia instantly.
	(13, 30)	disopyramide	syncope	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5182	Two years later, 24 hours following an increase in the dose of [s1]disopyramide[e1] from 300 to 600 mg/day, AVT with [s2]syncope[e2] occurred; isoproterenol abolished the arrhythmia instantly.
	(61, 74)	coronary vasoconstriction	dopamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5183	Although the existence of an acute pericarditis or an acute myocarditis as possible causes of the ST elevation cannot be fully ruled out, the sudden onset, prominent magnitude, and brief duration of the ST elevation are perhaps more indicative of an acute ischemic event, possibly related to a transient [s1]coronary vasoconstriction[e1] induced by the [s2]dopamine[e2] infusion.
	(5, 17)	nephrosis	hydroxychloroquine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5184	Complete remission of the [s1]nephrosis[e1] occurred after discontinuation of [s2]hydroxychloroquine[e2] therapy.
	(0, 4)	Hepatitis	cimetidine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5185	 [s1]Hepatitis[e1] following [s2]cimetidine[e2] administration.
	(8, 24)	hepatic dysfunction	cimetidine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5186	The case of an adult who developed both [s1]hepatic dysfunction[e1] and an impaired macrophage migration after exposure to [s2]cimetidine[e2] is discussed.
	(14, 24)	impaired macrophage migration	cimetidine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5187	The case of an adult who developed both hepatic dysfunction and an [s1]impaired macrophage migration[e1] after exposure to [s2]cimetidine[e2] is discussed.
	(7, 14)	cimetidine	hepatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5188	There have been only two reports of [s1]cimetidine[e1] induced [s2]hepatitis[e2] 
	(16, 30)	digoxin	complete atrioventricular block	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5189	A 66-year-old mand suffering from severe coronary heart disease took [s1]digoxin[e1] with suicidal intent an was treated for the ensuing [s2]complete atrioventricular block[e2] with digoxin-specific antibody fragments.
	(0, 10)	Verapamil	angina pectoris	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5190	 [s1]Verapamil[e1] in effort-induced [s2]angina pectoris[e2] in patients with normal coronary arteries.
	(0, 7)	Flucytosine	diarrhea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5191	 [s1]Flucytosine[e1] associated [s2]diarrhea[e2] has been previously described in 6%-10% of patients receiving the drug.
	(6, 39)	flucytosine	marked separation of loops of bowel	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5192	This report describes a case of [s1]flucytosine[e1] associated ulcerating enteritis in which the small bowel x-ray demonstrated severe luminal narrowing, ulceration, and [s2]marked separation of loops of bowel[e2] 
	(6, 28)	flucytosine	severe luminal narrowing	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5193	This report describes a case of [s1]flucytosine[e1] associated ulcerating enteritis in which the small bowel x-ray demonstrated [s2]severe luminal narrowing[e2]  ulceration, and marked separation of loops of bowel.
	(6, 13)	flucytosine	ulcerating enteritis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5194	This report describes a case of [s1]flucytosine[e1] associated [s2]ulcerating enteritis[e2] in which the small bowel x-ray demonstrated severe luminal narrowing, ulceration, and marked separation of loops of bowel.
	(6, 34)	flucytosine	ulceration	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5195	This report describes a case of [s1]flucytosine[e1] associated ulcerating enteritis in which the small bowel x-ray demonstrated severe luminal narrowing, [s2]ulceration[e2]  and marked separation of loops of bowel.
	(0, 9)	Ulcerating enteritis	flucytosine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5196	 [s1]Ulcerating enteritis[e1] associated with [s2]flucytosine[e2] therapy.
	(0, 15)	Papilledema	perhexiline maleate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5197	 [s1]Papilledema[e1] without peripheral neuropathy in a patient taking [s2]perhexiline maleate[e2] 
	(4, 30)	acute pancreatitis	L-asparaginase	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5198	An adolescent male developed [s1]acute pancreatitis[e1] and pseudocyst of the pancreas 16 weeks after cessation of intramuscular [s2]L-asparaginase[e2] 
	(10, 30)	pseudocyst of the pancreas	L-asparaginase	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5199	An adolescent male developed acute pancreatitis and [s1]pseudocyst of the pancreas[e1] 16 weeks after cessation of intramuscular [s2]L-asparaginase[e2] 
	(0, 20)	Delayed pseudocyst of the pancreas	L-asparaginase	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5200	 [s1]Delayed pseudocyst of the pancreas[e1] can be a complication of intramuscular [s2]L-asparaginase[e2] 
	(0, 9)	L-asparaginase	pancreatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5201	 [s1]L-asparaginase[e1] induced [s2]pancreatitis[e2] has been reported during or closely following administration of the drug.
	(3, 30)	pseudocyst of the pancreas	L-asparaginase	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5202	Three cases of [s1]pseudocyst of the pancreas[e1] in two women and one man have previously been reported with the use of intravenous [s2]L-asparaginase[e2] 
	(6, 14)	DCA	decrease in blood lactate levels	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5203	In one patient, treatment with [s1]DCA[e1] was associated with a [s2]decrease in blood lactate levels[e2] from 11.2 mM before treatment to 0.8 mM 16 h later.
	(1, 9)	delirious	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5204	Nine [s1]delirious[e1] patients suffering from [s2]lithium[e2] intoxication were examined with the Mini-Mental State Exam (MMS) to describe the clinical course of the disorder.
	(3, 10)	delirium	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5205	The course of [s1]delirium[e1] due to [s2]lithium[e2] intoxication.
	(3, 10)	hyperkalemia	arginine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5206	Life-threatening [s1]hyperkalemia[e1] induced by [s2]arginine[e2] 
	(0, 16)	Marked hyperkalemia	arginine monohydrochloride	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5207	 [s1]Marked hyperkalemia[e1] was observed during and immediately after an infusion of [s2]arginine monohydrochloride[e2] in two patients with severe hepatic disease and moderate renal insufficiency.
	(15, 24)	lichen planus	gold	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5208	A 58-year-old man with rheumatoid arthritis developed [s1]lichen planus[e1] during treatment with [s2]gold[e2] 
	(0, 6)	Acne	gold	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5209	 [s1]Acne[e1] provoked by [s2]gold[e2] seems not to have been described elsewhere.
	(5, 11)	acne	gold	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5210	Lichen planus and [s1]acne[e1] provoked by [s2]gold[e2] 
	(0, 11)	Lichen planus	gold	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5211	 [s1]Lichen planus[e1] and acne provoked by [s2]gold[e2] 
	(5, 24)	gold	skin disturbances	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5212	The case history confirms that [s1]gold[e1] treatment, even in the same patient, can give rise to a wide range of [s2]skin disturbances[e2]  which in many cases do not break out until long after the drug has been withdrawn.
	(10, 13)	lithium	nephrotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5213	Secondary hyperparathyroidism in certain patients with [s1]lithium[e1]  [s2]nephrotoxicity[e2] is also possible.
	(0, 12)	Secondary hyperparathyroidism	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5214	 [s1]Secondary hyperparathyroidism[e1] in certain patients with [s2]lithium[e2] nephrotoxicity is also possible.
	(4, 9)	lithium	biochemical hyperparathyroidism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5215	These results indicate that [s1]lithium[e1] may cause [s2]biochemical hyperparathyroidism[e2] 
	(26, 33)	CHB	disopyramide phosphate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5216	A 57-year-old woman with right bundle branch block +LPH and ventricular premature contractions developed complete heart block  [s1]CHB[e1]  following administration of [s2]disopyramide phosphate[e2] (Norpace).
	(26, 38)	CHB	Norpace	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5217	A 57-year-old woman with right bundle branch block +LPH and ventricular premature contractions developed complete heart block  [s1]CHB[e1]  following administration of disopyramide phosphate  [s2]Norpace[e2] .
	(23, 35)	complete heart block	disopyramide phosphate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5218	A 57-year-old woman with right bundle branch block +LPH and ventricular premature contractions developed [s1]complete heart block[e1] (CHB) following administration of [s2]disopyramide phosphate[e2] (Norpace).
	(23, 40)	complete heart block	Norpace	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5219	A 57-year-old woman with right bundle branch block +LPH and ventricular premature contractions developed [s1]complete heart block[e1] (CHB) following administration of disopyramide phosphate  [s2]Norpace[e2] .
	(0, 7)	Disopyramide	heart block	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5220	 [s1]Disopyramide[e1] induced [s2]heart block[e2] 
	(8, 43)	bretylium	cardiac arrest	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5221	Although transient increases in ectopy after [s1]bretylium[e1] therapy have been described, presumably due to catecholamine release, the occurrence of life-threatening ventricular arrhythmia leading to [s2]cardiac arrest[e2] has not previously been emphasized.
	(8, 33)	bretylium	ventricular arrhythmia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5222	Although transient increases in ectopy after [s1]bretylium[e1] therapy have been described, presumably due to catecholamine release, the occurrence of life-threatening [s2]ventricular arrhythmia[e2] leading to cardiac arrest has not previously been emphasized.
	(8, 28)	ventricular tachycardia	bretylium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5223	In the first patient, two episodes of [s1]ventricular tachycardia[e1] requiring cardioversion occurred in close temporal sequence with administering [s2]bretylium[e2] 
	(6, 32)	cardiac arrests	bretylium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5224	In the second case, five [s1]cardiac arrests[e1] due to ventricular tachycardia and fibrillation occurred during several hours after beginning a trial of [s2]bretylium[e2] maintenance therapy for complex ventricular ectopy.
	(18, 32)	fibrillation	bretylium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5225	In the second case, five cardiac arrests due to ventricular tachycardia and [s1]fibrillation[e1] occurred during several hours after beginning a trial of [s2]bretylium[e2] maintenance therapy for complex ventricular ectopy.
	(10, 32)	ventricular tachycardia	bretylium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5226	In the second case, five cardiac arrests due to [s1]ventricular tachycardia[e1] and fibrillation occurred during several hours after beginning a trial of [s2]bretylium[e2] maintenance therapy for complex ventricular ectopy.
	(10, 19)	fibrillation	bretylium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5227	Paradoxical ventricular tachycardia and [s1]fibrillation[e1] after intravenous [s2]bretylium[e2] therapy.
	(0, 19)	Paradoxical ventricular tachycardia	bretylium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5228	 [s1]Paradoxical ventricular tachycardia[e1] and fibrillation after intravenous [s2]bretylium[e2] therapy.
	(0, 7)	Lithium	acute renal failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5229	 [s1]Lithium[e1] is known to cause [s2]acute renal failure[e2] and tubulo-interstitial disease, but the recently described association with proteinuria or nephrotic syndrome is little recognized.
	(0, 28)	Lithium	nephrotic syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5230	 [s1]Lithium[e1] is known to cause acute renal failure and tubulo-interstitial disease, but the recently described association with proteinuria or [s2]nephrotic syndrome[e2] is little recognized.
	(0, 25)	Lithium	proteinuria	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5231	 [s1]Lithium[e1] is known to cause acute renal failure and tubulo-interstitial disease, but the recently described association with [s2]proteinuria[e2] or nephrotic syndrome is little recognized.
	(0, 11)	Lithium	tubulo-interstitial disease	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5232	 [s1]Lithium[e1] is known to cause acute renal failure and [s2]tubulo-interstitial disease[e2]  but the recently described association with proteinuria or nephrotic syndrome is little recognized.
	(0, 9)	Nephrotic syndrome	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5233	 [s1]Nephrotic syndrome[e1] associated with [s2]lithium[e2] therapy.
	(6, 12)	lithium	nephrotic syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5234	Two patients on long-term [s1]lithium[e1] therapy developed the [s2]nephrotic syndrome[e2] 
	(8, 22)	diarrhea	ampicillin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5235	A 67-year-old man developed [s1]diarrhea[e1] shortly after a 10-day course of oral [s2]ampicillin[e2] 
	(28, 37)	sensori-neural hearing loss	vincristine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5236	A 73-year-old woman with non-Hodgkin's lymphoma had two episodes of severe, bilateral, [s1]sensori-neural hearing loss[e1] after [s2]vincristine[e2] therapy.
	(0, 9)	Acute acoustic nerve palsy	vincristine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5237	 [s1]Acute acoustic nerve palsy[e1] associated with [s2]vincristine[e2] therapy.
	(0, 19)	Bilateral acoustic (VIII) nerve palsy	vincristine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5238	 [s1]Bilateral acoustic (VIII) nerve palsy[e1] in this patient was most likely a manifestation of [s2]vincristine[e2] neurotoxicity.
	(17, 23)	vincristine	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5239	Bilateral acoustic (VIII) nerve palsy in this patient was most likely a manifestation of [s1]vincristine[e1]  [s2]neurotoxicity[e2] 
	(3, 9)	timolol	heart failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5240	A case of [s1]timolol[e1] associated [s2]heart failure[e2] in a 73-year old white man is reported.
	(0, 15)	Bradycardia	timolol maleate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5241	 [s1]Bradycardia[e1] and congestive heart failure associated with ocular [s2]timolol maleate[e2] 
	(4, 15)	congestive heart failure	timolol maleate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5242	Bradycardia and [s1]congestive heart failure[e1] associated with ocular [s2]timolol maleate[e2] 
	(16, 37)	dyspnea	timolol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5243	On the second day of hospitalization, it was noted that the patient's [s1]dyspnea[e1] and sinus bradycardia could be related to a recent increase in his [s2]timolol[e2] dosage.
	(21, 37)	sinus bradycardia	timolol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5244	On the second day of hospitalization, it was noted that the patient's dyspnea and [s1]sinus bradycardia[e1] could be related to a recent increase in his [s2]timolol[e2] dosage.
	(0, 12)	Fatal ventricular fibrillation	digoxin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5245	 [s1]Fatal ventricular fibrillation[e1] after treatment with [s2]digoxin[e2] in a 27-year-old man with mitral leaflet prolapse syndrome.
	(4, 31)	digoxin	functional impairment	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5246	He was started on [s1]digoxin[e1]  0.25 mg daily, because of echocardiographically demonstrated left ventricular dilatation and [s2]functional impairment[e2]  he died of ventricular fibrillation 15 days later.
	(4, 23)	digoxin	left ventricular dilatation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5247	He was started on [s1]digoxin[e1]  0.25 mg daily, because of echocardiographically demonstrated [s2]left ventricular dilatation[e2] and functional impairment; he died of ventricular fibrillation 15 days later.
	(4, 37)	digoxin	ventricular fibrillation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5248	He was started on [s1]digoxin[e1]  0.25 mg daily, because of echocardiographically demonstrated left ventricular dilatation and functional impairment; he died of [s2]ventricular fibrillation[e2] 15 days later.
	(2, 8)	rapid mood cycling	L-dopa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5249	Induction of [s1]rapid mood cycling[e1] during [s2]L-dopa[e2] treatment in a bipolar patient.
	(20, 26)	L-dopa	shortened the manic-depressive cycle	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5250	The authors report a longitudinal case study of a woman with a history of bipolar affective disorder in which [s1]L-dopa[e1]  [s2]shortened the manic-depressive cycle[e2] length when administered in a double-blind trial.
	(0, 6)	Liver disease	perhexiline maleate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5251	 [s1]Liver disease[e1] induced by [s2]perhexiline maleate[e2] 
	(6, 17)	fatal perhexiline maleate liver injury	perhexiline maleate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5252	This paper reports a case of [s1]fatal perhexiline maleate liver injury[e1]  [s2]perhexiline maleate[e2] liver injury.
	(0, 32)	Acute non-lymphocytic leukemia	dihydroxybusulfan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5253	 [s1]Acute non-lymphocytic leukemia[e1] in patients with ovarian carcinoma following long-term treatment with Treosulfan (= [s2]dihydroxybusulfan[e2] .
	(0, 26)	Acute non-lymphocytic leukemia	Treosulfan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5254	 [s1]Acute non-lymphocytic leukemia[e1] in patients with ovarian carcinoma following long-term treatment with [s2]Treosulfan[e2] (= dihydroxybusulfan).
	(0, 27)	Acute non-lymphocytic leukemia	dihydroxybusulfan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5255	 [s1]Acute non-lymphocytic leukemia[e1] occurred in eight women following long-term treatment with Treosulfan (= [s2]dihydroxybusulfan[e2]  for ovarian carcinoma.
	(0, 21)	Acute non-lymphocytic leukemia	Treosulfan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5256	 [s1]Acute non-lymphocytic leukemia[e1] occurred in eight women following long-term treatment with [s2]Treosulfan[e2] (= dihydroxybusulfan) for ovarian carcinoma.
	(6, 20)	acute leukemia	Treosulfan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5257	Seven of the eight cases of [s1]acute leukemia[e1] occurred in a series of 553 patients treated with [s2]Treosulfan[e2] for ovarian cancer in the period from 1970 to 1977 and followed closely for a total of 1159 patient-years up to February 1978.
	(4, 22)	acute leukemia	Treosulfan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5258	The probability of developing [s1]acute leukemia[e1] in this study was not significantly correlated to the total cumulative dosage of [s2]Treosulfan[e2] 
	(0, 7)	Propranolol	bronchospasm	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5259	 [s1]Propranolol[e1] related [s2]bronchospasm[e2] in patients without history of asthma.
	(13, 28)	bronchospasm	propranolol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5260	Regardless of a negative history of asthma, therefore, life-threatening [s1]bronchospasm[e1] must be considered a possible complication of [s2]propranolol[e2] therapy.
	(2, 17)	bronchospasm	propranolol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5261	Since the [s1]bronchospasm[e1] was relieved with discontinuation of [s2]propranolol[e2] and supportive bronchodilator therapy, the bronchospasm was believed to be caused by propranolol.
	(2, 17)	bronchospasm	propranolol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5262	Since the [s1]bronchospasm[e1] was relieved with discontinuation of [s2]propranolol[e2] and supportive bronchodilator therapy, the bronchospasm was believed to be caused by propranolol.
	(11, 20)	bronchospasm	propranolol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5263	Three patients with no history of asthma or allergy developed [s1]bronchospasm[e1] while taking [s2]propranolol[e2] for hypertension.
	(0, 14)	Propranolol	central nervous system dysfunction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5264	 [s1]Propranolol[e1]  an unrecognized cause of [s2]central nervous system dysfunction[e2] in patients undergoing cardiopulmonary bypass.
	(4, 12)	propranolol	central nervous system disturbances	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5265	The potential role of [s1]propranolol[e1] in inducing [s2]central nervous system disturbances[e2] is emphasized, and the literature on the subject is reviewed.
	(0, 17)	Interstitial fibrosis of the lung	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5266	 [s1]Interstitial fibrosis of the lung[e1] is a potential complication of [s2]methotrexate[e2] therapy for psoriasis.
	(0, 35)	Progressive interstitial fibrosis	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5267	 [s1]Progressive interstitial fibrosis[e1] with roentgenographic honeycombing developed in the case of a psoriatic patient who had been on a regimen of [s2]methotrexate[e2] for 18 years.
	(0, 10)	Progressive interstitial lung disease	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5268	 [s1]Progressive interstitial lung disease[e1] from prolonged [s2]methotrexate[e2] therapy.
	(0, 13)	Abnormalities of the pupil	quinine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5269	 [s1]Abnormalities of the pupil[e1] and visual-evoked potential in [s2]quinine[e2] amblyopia.
	(11, 15)	quinine	amblyopia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5270	Abnormalities of the pupil and visual-evoked potential in [s1]quinine[e1]  [s2]amblyopia[e2] 
	(16, 26)	abnormal visual-evoked potentials	quinine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5271	A transient tonic pupillary response, denervation supersensitivity, and [s1]abnormal visual-evoked potentials[e1] in [s2]quinine[e2] toxicity, to our knowledge, have not been previously reported.
	(7, 25)	denervation supersensitivity	quinine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5272	A transient tonic pupillary response, [s1]denervation supersensitivity[e1]  and abnormal visual-evoked potentials in [s2]quinine[e2] toxicity, to our knowledge, have not been previously reported.
	(1, 25)	transient tonic pupillary response	quinine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5273	A [s1]transient tonic pupillary response[e1]  denervation supersensitivity, and abnormal visual-evoked potentials in [s2]quinine[e2] toxicity, to our knowledge, have not been previously reported.
	(19, 41)	abnormal visual-evoked potentials	quinine sulfate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5274	Total blindness with a transient tonic pupillary response, denervation supersensitivity, and [s1]abnormal visual-evoked potentials[e1] developed in a 54-year-old man after the use of [s2]quinine sulfate[e2] for leg cramps.
	(10, 40)	denervation supersensitivity	quinine sulfate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5275	Total blindness with a transient tonic pupillary response, [s1]denervation supersensitivity[e1]  and abnormal visual-evoked potentials developed in a 54-year-old man after the use of [s2]quinine sulfate[e2] for leg cramps.
	(0, 40)	Total blindness with a transient tonic pupillary response	quinine sulfate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5276	 [s1]Total blindness with a transient tonic pupillary response[e1]  denervation supersensitivity, and abnormal visual-evoked potentials developed in a 54-year-old man after the use of [s2]quinine sulfate[e2] for leg cramps.
	(2, 9)	practolol	sclerosing peritonitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5277	Diagnosis: [s1]practolol[e1] induced [s2]sclerosing peritonitis[e2] 
	(3, 14)	skeletal fluorosis	niflumic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5278	A case of [s1]skeletal fluorosis[e1] induced by prolonged treatment with [s2]niflumic acid[e2]  a fast-acting non-steroid antiinflammatory agent, is reported in a 35-year-old woman suffering from rheumatoid arthritis and treated, in addition, with corticosteroids.
	(18, 29)	fluorosis	niflumic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5279	After ruling out a hydrotelluric source of fluorine, the patient's [s1]fluorosis[e1] was linked to chronic use of [s2]niflumic acid[e2]  following the publication in 1978 of the 2 previously reported cases affected by this drug.
	(0, 8)	Niflumic acid	skeletal fluorosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5280	 [s1]Niflumic acid[e1] induced [s2]skeletal fluorosis[e2]  iatrogenic disease or therapeutic perspective for osteoporosis?
	(6, 16)	niflumic acid	densification of trabecular bone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5281	The fluorine contained in [s1]niflumic acid[e1] induced a marked [s2]densification of trabecular bone[e2] in all 3 cases.
	(0, 12)	Hepatotoxicity	D-penicillamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5282	 [s1]Hepatotoxicity[e1] associated with use of [s2]D-penicillamine[e2] in rheumatoid arthritis.
	(10, 31)	hepatotoxicity	D-penicillamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5283	These cases and a review of the literature suggested that [s1]hepatotoxicity[e1]  though rare, should be added to the list of adverse reactions to [s2]D-penicillamine[e2] 
	(12, 22)	hepatotoxicity	D-penicillamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5284	Two patients with rheumatoid arthritis developed evidence of [s1]hepatotoxicity[e1] while receiving [s2]D-penicillamine[e2] 
	(17, 23)	metformin	miliary tuberculosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5285	A 62-year-old Indian with diabetic nephropathy controlled with [s1]metformin[e1]  developed [s2]miliary tuberculosis[e2] for which he was treated with rifampicin, isoniazid and ethambutol.
	(0, 11)	Para-aminosalicylic acid	hypoglycaemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5286	 [s1]Para-aminosalicylic acid[e1] induced [s2]hypoglycaemia[e2] in a patient with diabetic nephropathy.
	(3, 12)	hypoglycaemia	PAS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5287	The induction of [s1]hypoglycaemia[e1] with [s2]PAS[e2] in this patient suggests a potential role for PAS in the treatment of diabetes mellitus.
	(3, 18)	para-aminosalicylic acid	hypoglycaemic coma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5288	The introduction of [s1]para-aminosalicylic acid[e1] (PAS) led to [s2]hypoglycaemic coma[e2] 
	(11, 16)	PAS	hypoglycaemic coma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5289	The introduction of para-aminosalicylic acid  [s1]PAS[e1]  led to [s2]hypoglycaemic coma[e2] 
	(9, 19)	hepatic dysfunction	perhexiline maleate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5290	A patient developed papilloedema and [s1]hepatic dysfunction[e1] while being treated with [s2]perhexiline maleate[e2] 
	(3, 19)	papilloedema	perhexiline maleate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5291	A patient developed [s1]papilloedema[e1] and hepatic dysfunction while being treated with [s2]perhexiline maleate[e2] 
	(6, 15)	hepatic dysfunction	perhexiline maleate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5292	Papilloedema and [s1]hepatic dysfunction[e1] apparently induced by [s2]perhexiline maleate[e2] (Pexid).
	(6, 21)	hepatic dysfunction	Pexid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5293	Papilloedema and [s1]hepatic dysfunction[e1] apparently induced by perhexiline maleate  [s2]Pexid[e2] .
	(0, 15)	Papilloedema	perhexiline maleate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5294	 [s1]Papilloedema[e1] and hepatic dysfunction apparently induced by [s2]perhexiline maleate[e2] (Pexid).
	(0, 21)	Papilloedema	Pexid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5295	 [s1]Papilloedema[e1] and hepatic dysfunction apparently induced by perhexiline maleate  [s2]Pexid[e2] .
	(1, 17)	increased pigmementation of skin	5-fluorouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5296	Markedly [s1]increased pigmementation of skin[e1] immediately overlying veins used for multiple [s2]5-fluorouracil[e2] infusions was noted.
	(1, 8)	pigmentary changes	5-fluorouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5297	Unusual [s1]pigmentary changes[e1] associated with [s2]5-fluorouracil[e2] therapy.
	(9, 36)	disulfiram	catatonia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5298	Although useful in the management of chronic alcoholism, [s1]disulfiram[e1] is being increasingly associated with a wide spectrum of side effects and untoward medical sequelae, which now include [s2]catatonia[e2] 
	(0, 16)	Disulfiram	catatonia syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5299	 [s1]Disulfiram[e1] encephalopathy as a cause of the [s2]catatonia syndrome[e2] 
	(0, 6)	Disulfiram	encephalopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5300	 [s1]Disulfiram[e1]  [s2]encephalopathy[e2] as a cause of the catatonia syndrome.
	(7, 15)	catatonia syndrome	disulfiram	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5301	The authors describe a case of the [s1]catatonia syndrome[e1] associated with [s2]disulfiram[e2] therapy.
	(0, 13)	Inappropriate antidiuretic hormone secretion	vinblastine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5302	 [s1]Inappropriate antidiuretic hormone secretion[e1] after high dose [s2]vinblastine[e2] 
	(23, 40)	inappropriate secretion of antidiuretic hormone	vinblastine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5303	We report on a patient with an embryonal teratocarcinoma of the testicle who had the syndrome of [s1]inappropriate secretion of antidiuretic hormone[e1] after receiving a high dose of [s2]vinblastine[e2] 
	(3, 28)	oesophageal damage	emepronium bromide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5304	Four cases of [s1]oesophageal damage[e1] associated with ingestion of the urinary anti-spasmodic agent [s2]emepronium bromide[e2] are described.
	(0, 13)	Oesophageal ulceration	emepronium bromide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5305	 [s1]Oesophageal ulceration[e1] due to [s2]emepronium bromide[e2] 
	(0, 11)	Cardiorespiratory toxicity	miconazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5306	 [s1]Cardiorespiratory toxicity[e1] due to [s2]miconazole[e2] 
	(19, 27)	cardiac arrest	doxorubicin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5307	None of them had a history of cardiac disease, and with the possible exception of one case of [s1]cardiac arrest[e1]  where the patient received [s2]doxorubicin[e2]  no predisposing factors could be found.
	(13, 32)	miconazole	cardiorespiratory and anaphylactic reactions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5308	Seven patients with hematologic malignancies who were treated with [s1]miconazole[e1] for either suspected or proven fungal infections developed eight episodes of major adverse [s2]cardiorespiratory and anaphylactic reactions[e2] 
	(0, 7)	Clofibrate	myopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5309	 [s1]Clofibrate[e1] induced [s2]myopathy[e2] in patients with diabetes insipidus.
	(9, 16)	clofibrate	myopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5310	However, we have recently had four cases of [s1]clofibrate[e1] induced [s2]myopathy[e2] in patients with diabetes insipidus due to hypothalamic lesions.
	(31, 61)	clofibrate	myopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5311	Physicians should therefore be aware of its occurrence and carefully monitor serum levels of CPK, GOT and GPT during the treatment of diabetes insipidus with [s1]clofibrate[e1]  especially in patients with associated hypothyroidism, latent or overt, which possibly favors the development of [s2]myopathy[e2] 
	(0, 9)	Hepatotoxicity	hycanthone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5312	 [s1]Hepatotoxicity[e1] of [s2]hycanthone[e2] in patients with metastatic breast cancer.
	(6, 22)	hycanthone	severe hepatotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5313	In a phase II study of [s1]hycanthone[e1] in patients with breast cancer we have recently observed [s2]severe hepatotoxicity[e2]  even at lower doses, which resulted in two drug-related deaths.
	(0, 16)	Fatal interstitial pneumonitis	chlorambucil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5314	 [s1]Fatal interstitial pneumonitis[e1] following high-dose intermittent [s2]chlorambucil[e2] therapy for chronic lymphocyte leukemia.
	(8, 19)	respiratory distress	chlorambucil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5315	Following several of these courses of therapy, [s1]respiratory distress[e1] occurred 9 to 12 days after the [s2]chlorambucil[e2] was given.
	(3, 10)	barbiturate	submassive hepatic necrosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5316	A case of [s1]barbiturate[e1] induced [s2]submassive hepatic necrosis[e2] is presented and the literature is reviewed.
	(0, 7)	Barbiturate	submassive hepatic necrosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5317	 [s1]Barbiturate[e1] induced [s2]submassive hepatic necrosis[e2] 
	(24, 41)	barbiturates	submassive hepatic necrosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5318	The patient's clinical presentation, histologic features on liver biopsy and favorable course after stopping the drug suggest that [s1]barbiturates[e1] can be added to the list of agents which can cause [s2]submassive hepatic necrosis[e2] 
	(29, 46)	granulocytopenia	procainamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5319	A 71-year-old man with paroxysmal atrial fibrillation who had a previous anterior myocardial infarction exhibited [s1]granulocytopenia[e1] 8 days following the administration of oral sustained-release [s2]procainamide[e2] (750 mg/day).
	(3, 10)	procainamide	reversible granulocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5320	Sustained-release [s1]procainamide[e1] induced [s2]reversible granulocytopenia[e2] after myocardial infarction.
	(5, 17)	granulocytopenia	procainamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5321	The frequency and relationship of [s1]granulocytopenia[e1] caused by sustained-release [s2]procainamide[e2] in patients with tachyarrhythmias are briefly discussed, and prior reported cases are reviewed.
	(0, 20)	Monoclonal gammopathy	diphenylhydantoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5322	 [s1]Monoclonal gammopathy[e1] and subsequent multiple myeloma in a patient on chronic [s2]diphenylhydantoin[e2] therapy.
	(9, 20)	multiple myeloma	diphenylhydantoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5323	Monoclonal gammopathy and subsequent [s1]multiple myeloma[e1] in a patient on chronic [s2]diphenylhydantoin[e2] therapy.
	(4, 37)	IgG lambda-type monoclonal gammopathy	DILANTIN	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5324	The development of an [s1]IgG lambda-type monoclonal gammopathy[e1] and subsequent multiple myeloma in an epilepsy patient on diphenylhydantoin  [s2]DILANTIN[e2]  therapy for 20 years is reported.
	(4, 31)	IgG lambda-type monoclonal gammopathy	diphenylhydantoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5325	The development of an [s1]IgG lambda-type monoclonal gammopathy[e1] and subsequent multiple myeloma in an epilepsy patient on [s2]diphenylhydantoin[e2] (DILANTIN) therapy for 20 years is reported.
	(18, 37)	multiple myeloma	DILANTIN	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5326	The development of an IgG lambda-type monoclonal gammopathy and subsequent [s1]multiple myeloma[e1] in an epilepsy patient on diphenylhydantoin  [s2]DILANTIN[e2]  therapy for 20 years is reported.
	(18, 31)	multiple myeloma	diphenylhydantoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5327	The development of an IgG lambda-type monoclonal gammopathy and subsequent [s1]multiple myeloma[e1] in an epilepsy patient on [s2]diphenylhydantoin[e2] (DILANTIN) therapy for 20 years is reported.
	(11, 25)	diphenylhydantoin	monoclonal gammopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5328	We recommended periodic examination of the serum proteins in patients receiving [s1]diphenylhydantoin[e1] in order to detect development of [s2]monoclonal gammopathy[e2] 
	(2, 17)	Atovaquone	vortex keratopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5329	CONCLUSION: [s1]Atovaquone[e1] should be added to the list of agents causing [s2]vortex keratopathy[e2] involving the corneal epithelium.
	(7, 21)	vortex keratopathy	atovaquone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5330	PURPOSE: We studied a case of [s1]vortex keratopathy[e1] that was associated with the use of [s2]atovaquone[e2] 
	(10, 17)	vortex keratopathy	atovaquone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5331	RESULTS: Similar to previous findings of drug-induced [s1]vortex keratopathy[e1]  [s2]atovaquone[e2] vortex keratopathy is presumably caused by its lipophilic properties.
	(10, 17)	vortex keratopathy	atovaquone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5332	RESULTS: Similar to previous findings of drug-induced [s1]vortex keratopathy[e1]  [s2]atovaquone[e2] vortex keratopathy is presumably caused by its lipophilic properties.
	(0, 9)	Vortex keratopathy	atovaquone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5333	 [s1]Vortex keratopathy[e1] associated with [s2]atovaquone[e2] 
	(6, 20)	naloxone	severe pain	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5334	Used injudiciously, [s1]naloxone[e1] can lead to withdrawal syndrome, return of [s2]severe pain[e2]  and other adverse effects.
	(6, 15)	naloxone	withdrawal syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5335	Used injudiciously, [s1]naloxone[e1] can lead to [s2]withdrawal syndrome[e2]  return of severe pain, and other adverse effects.
	(11, 34)	methimazole	ACC	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5336	However, there remain questions concerning whether these drugs, especially [s1]methimazole[e1] (MMI), may be associated with aplasia cutis congenita  [s2]ACC[e2]  and how best to avoid impairment of fetal thyroid function during their use.
	(15, 32)	MMI	ACC	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5337	However, there remain questions concerning whether these drugs, especially methimazole  [s1]MMI[e1] , may be associated with aplasia cutis congenita  [s2]ACC[e2]  and how best to avoid impairment of fetal thyroid function during their use.
	(11, 26)	methimazole	aplasia cutis congenita	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5338	However, there remain questions concerning whether these drugs, especially [s1]methimazole[e1] (MMI), may be associated with [s2]aplasia cutis congenita[e2] (ACC) and how best to avoid impairment of fetal thyroid function during their use.
	(15, 24)	MMI	aplasia cutis congenita	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5339	However, there remain questions concerning whether these drugs, especially methimazole  [s1]MMI[e1] , may be associated with [s2]aplasia cutis congenita[e2] (ACC) and how best to avoid impairment of fetal thyroid function during their use.
	(30, 47)	acute reversible encephalopathy	flecainide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5340	A 73 year-old patient with Wolff-Parkinson-White syndrome and paroxysmic supraventricular tachycardia developed an [s1]acute reversible encephalopathy[e1] within 15 days of initiation of [s2]flecainide[e2] 
	(0, 20)	Acute reversible ataxo-myoclonic encephalopathy	flecainide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5341	 [s1]Acute reversible ataxo-myoclonic encephalopathy[e1] with [s2]flecainide[e2] therapy.
	(27, 50)	bone marrow aplasia	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5342	A 64 year old man with recurrent metastatic squamous cell carcinoma of the head and neck developed severe skin rash and [s1]bone marrow aplasia[e1] 4 and 7 days, respectively, following a single dose of 40 mg/m2 [s2]methotrexate[e2] (MTX).
	(27, 55)	bone marrow aplasia	MTX	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5343	A 64 year old man with recurrent metastatic squamous cell carcinoma of the head and neck developed severe skin rash and [s1]bone marrow aplasia[e1] 4 and 7 days, respectively, following a single dose of 40 mg/m2 methotrexate  [s2]MTX[e2] .
	(23, 50)	severe skin rash	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5344	A 64 year old man with recurrent metastatic squamous cell carcinoma of the head and neck developed [s1]severe skin rash[e1] and bone marrow aplasia 4 and 7 days, respectively, following a single dose of 40 mg/m2 [s2]methotrexate[e2] (MTX).
	(23, 55)	severe skin rash	MTX	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5345	A 64 year old man with recurrent metastatic squamous cell carcinoma of the head and neck developed [s1]severe skin rash[e1] and bone marrow aplasia 4 and 7 days, respectively, following a single dose of 40 mg/m2 methotrexate  [s2]MTX[e2] .
	(0, 17)	Bone marrow aplasia	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5346	 [s1]Bone marrow aplasia[e1] and severe skin rash after a single low dose of [s2]methotrexate[e2] 
	(6, 17)	severe skin rash	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5347	Bone marrow aplasia and [s1]severe skin rash[e1] after a single low dose of [s2]methotrexate[e2] 
	(3, 13)	extensive skin rash	MTX	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5348	Development of an [s1]extensive skin rash[e1] following a single dose of [s2]MTX[e2] may be an early warning sign for life-threatening bone marrow aplasia.
	(32, 41)	acute hypersensitivity reaction	MTX	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5349	In the absence of mucositis or diarrhea, severe dermatologic toxicity following a single low dose of the drug suggests an 'allergic' or [s1]acute hypersensitivity reaction[e1] to [s2]MTX[e2] in this patient.
	(12, 41)	severe dermatologic toxicity	MTX	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5350	In the absence of mucositis or diarrhea, [s1]severe dermatologic toxicity[e1] following a single low dose of the drug suggests an 'allergic' or acute hypersensitivity reaction to [s2]MTX[e2] in this patient.
	(0, 9)	Chlormadinone acetate	withdrawal syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5351	 [s1]Chlormadinone acetate[e1]  [s2]withdrawal syndrome[e2] under combined androgen blockade for advanced prostate cancer.
	(19, 27)	myopia	metronidazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5352	The second had acute cystitis and was treated by sulphonamide and the third developed [s1]myopia[e1] coincident with [s2]metronidazole[e2] treatment for trichomonas vaginalis.
	(11, 21)	sulphonamide	myopia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5353	The second had acute cystitis and was treated by [s1]sulphonamide[e1] and the third developed [s2]myopia[e2] coincident with metronidazole treatment for trichomonas vaginalis.
	(0, 18)	Nephrotic syndrome	griseofulvin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5354	 [s1]Nephrotic syndrome[e1] related to systemic lupus erythematosus after [s2]griseofulvin[e2] therapy.
	(7, 18)	systemic lupus erythematosus	griseofulvin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5355	Nephrotic syndrome related to [s1]systemic lupus erythematosus[e1] after [s2]griseofulvin[e2] therapy.
	(10, 21)	griseofulvin	lupus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5356	To our knowledge, this is the first case of [s1]griseofulvin[e1] exacerbated [s2]lupus[e2] in which nephrotic syndrome has been observed.
	(10, 25)	griseofulvin	nephrotic syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5357	To our knowledge, this is the first case of [s1]griseofulvin[e1] exacerbated lupus in which [s2]nephrotic syndrome[e2] has been observed.
	(11, 47)	nephrotic syndrome	griseofulvin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5358	We report a 16-year-old male who developed [s1]nephrotic syndrome[e1] related to membranous glomerulopathy with clinical and serological evidence of systemic lupus erythematosus after treatment with [s2]griseofulvin[e2] 
	(34, 47)	systemic lupus erythematosus	griseofulvin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5359	We report a 16-year-old male who developed nephrotic syndrome related to membranous glomerulopathy with clinical and serological evidence of [s1]systemic lupus erythematosus[e1] after treatment with [s2]griseofulvin[e2] 
	(0, 9)	Neurological side effects	gold	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5360	 [s1]Neurological side effects[e1] in two patients receiving [s2]gold[e2] injections for rheumatoid arthritis.
	(4, 35)	mild nitritoid symptoms	gold sodium thiomalate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5361	The first patient developed [s1]mild nitritoid symptoms[e1] and pain in a band-like distribution, corresponding to T10-T12 dermatomes, shortly after [s2]gold sodium thiomalate[e2] (GSTM) injection.
	(4, 41)	mild nitritoid symptoms	GSTM	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5362	The first patient developed [s1]mild nitritoid symptoms[e1] and pain in a band-like distribution, corresponding to T10-T12 dermatomes, shortly after gold sodium thiomalate  [s2]GSTM[e2]  injection.
	(11, 35)	pain	gold sodium thiomalate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5363	The first patient developed mild nitritoid symptoms and [s1]pain[e1] in a band-like distribution, corresponding to T10-T12 dermatomes, shortly after [s2]gold sodium thiomalate[e2] (GSTM) injection.
	(11, 41)	pain	GSTM	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5364	The first patient developed mild nitritoid symptoms and [s1]pain[e1] in a band-like distribution, corresponding to T10-T12 dermatomes, shortly after gold sodium thiomalate  [s2]GSTM[e2]  injection.
	(21, 34)	T10-T12 dermatomes	gold sodium thiomalate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5365	The first patient developed mild nitritoid symptoms and pain in a band-like distribution, corresponding to [s1]T10-T12 dermatomes[e1]  shortly after [s2]gold sodium thiomalate[e2] (GSTM) injection.
	(21, 40)	T10-T12 dermatomes	GSTM	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5366	The first patient developed mild nitritoid symptoms and pain in a band-like distribution, corresponding to [s1]T10-T12 dermatomes[e1]  shortly after gold sodium thiomalate  [s2]GSTM[e2]  injection.
	(4, 14)	mild nitritoid symptoms	GSTM	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5367	The second patient experienced [s1]mild nitritoid symptoms[e1] following several [s2]GSTM[e2] injections prior experiencing a cerebrovascular accident within several hours of her next injection.
	(0, 12)	Acute sensorineural hearing loss	ketoralac	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5368	 [s1]Acute sensorineural hearing loss[e1] following intravenous [s2]ketoralac[e2] administration.
	(3, 16)	methotrexate	sensorineural hearing loss	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5369	Both PAN and [s1]methotrexate[e1] have been independently demonstrated to cause [s2]sensorineural hearing loss[e2] 
	(1, 16)	PAN	sensorineural hearing loss	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5370	Both [s1]PAN[e1] and methotrexate have been independently demonstrated to cause [s2]sensorineural hearing loss[e2] 
	(6, 22)	ketorolac	ototoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5371	We recommend the cautious use of [s1]ketorolac[e1] in patients with underlying illnesses where NSAID-induced [s2]ototoxicity[e2] could result in adverse otologic consequences.
	(24, 42)	bilateral sensorineural hearing loss	ketoralac	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5372	We report the case of a 20-year-old female with polyarteritis nodosa (PAN) who developed [s1]bilateral sensorineural hearing loss[e1] 25 minutes after receiving 30 mg of intravenous [s2]ketoralac[e2] 
	(0, 14)	Anaphylactoid reactions	cisplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5373	 [s1]Anaphylactoid reactions[e1] with intraperitoneal [s2]cisplatin[e2] 
	(18, 44)	cisplatin	anaphylactoid reactions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5374	CASE SUMMARIES: While conducting a protocol evaluating the efficacy of intraperitoneal [s1]cisplatin[e1] and hyperthermia in the treatment of recurrent ovarian cancer, 3 patients were noted to exhibit [s2]anaphylactoid reactions[e2] 
	(19, 36)	anaphylactoid reactions	cisplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5375	CONCLUSIONS: We conclude that a high dose combined with a short infusion time increases the risk of [s1]anaphylactoid reactions[e1] with the administration of intraperitoneal [s2]cisplatin[e2] 
	(2, 15)	Anaphylactoid reactions	cisplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5376	DISCUSSION: [s1]Anaphylactoid reactions[e1] have been described previously with [s2]cisplatin[e2] administration.
	(8, 13)	cisplatin	100 mg/m2	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5377	During her third cycle, she again received [s1]cisplatin[e1]  [s2]100 mg/m2[e2] over 30 minutes and developed palmar pruritus, urticaria, and edema.
	(8, 33)	cisplatin	edema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5378	During her third cycle, she again received [s1]cisplatin[e1] 100 mg/m2 over 30 minutes and developed palmar pruritus, urticaria, and [s2]edema[e2] 
	(8, 22)	cisplatin	palmar pruritus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5379	During her third cycle, she again received [s1]cisplatin[e1] 100 mg/m2 over 30 minutes and developed [s2]palmar pruritus[e2]  urticaria, and edema.
	(8, 28)	cisplatin	urticaria	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5380	During her third cycle, she again received [s1]cisplatin[e1] 100 mg/m2 over 30 minutes and developed palmar pruritus, [s2]urticaria[e2]  and edema.
	(7, 21)	anaphylactoid reactions	cisplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5381	OBJECTIVE: To report the occurrence of [s1]anaphylactoid reactions[e1] to intraperitoneal [s2]cisplatin[e2] in 3 patients.
	(39, 48)	anaphylactoid reactions	cisplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5382	We observed 5 reactions in 3 patients that appear to be related to a high dose-infusion time ratio, indicating that dose and rate of infusion may be important factors in precipitating [s1]anaphylactoid reactions[e1] with [s2]cisplatin[e2] 
	(0, 7)	Etoposide	myocardial infarction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5383	 [s1]Etoposide[e1] related [s2]myocardial infarction[e2] 
	(4, 17)	myocardial infarction	etoposide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5384	The occurrence of a [s1]myocardial infarction[e1] is reported after chemotherapy containing [s2]etoposide[e2]  in a man with no risk factors for coronary heart disease.
	(8, 17)	acute renal failure	acyclovir	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5385	A 9-year-old boy developed [s1]acute renal failure[e1] following intravenous [s2]acyclovir[e2] (30 mg/kg per day) administered for 6 days to treat herpetic encephalitis.
	(0, 10)	Acute renal failure	acyclovir	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5386	 [s1]Acute renal failure[e1] in a child associated with [s2]acyclovir[e2] 
	(0, 12)	Anterior ischemic optic neuropathy	interferon alfa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5387	 [s1]Anterior ischemic optic neuropathy[e1] secondary to [s2]interferon alfa[e2] 
	(2, 18)	Anterior ischemic optic neuropathy	interferon alfa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5388	CONCLUSION: [s1]Anterior ischemic optic neuropathy[e1] may complicate treatment with [s2]interferon alfa[e2] 
	(7, 24)	anterior ischemic optic neuropathy	interferon alfa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5389	OBJECTIVE: To report the occurrence of [s1]anterior ischemic optic neuropathy[e1] as a complication of treatment with [s2]interferon alfa[e2] and to consider the possible underlying mechanisms for this association.
	(14, 28)	interferon alfa	sudden bilateral, sequential visual loss	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5390	PATIENTS: Two patients, ages 40 and 51 years, undergoing treatment with [s1]interferon alfa[e1] for malignant neoplasms experienced [s2]sudden bilateral, sequential visual loss[e2] with disc-related field defects and segmental optic disc edema.
	(6, 15)	interferon alfa	anterior ischemic optic neuropathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5391	The interval between initiating treatment with [s1]interferon alfa[e1] and onset of [s2]anterior ischemic optic neuropathy[e2] was similar to that of interferon-associated vascular retinopathy.
	(6, 33)	interferon	vascular retinopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5392	The interval between initiating treatment with [s1]interferon[e1] alfa and onset of anterior ischemic optic neuropathy was similar to that of interferon-associated [s2]vascular retinopathy[e2] 
	(6, 21)	neuroleptic malignant syndrome	amitriptyline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5393	The authors describe a case of [s1]neuroleptic malignant syndrome[e1] that occurred in a patient on [s2]amitriptyline[e2] and lithium carbonate.
	(6, 26)	neuroleptic malignant syndrome	lithium carbonate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5394	The authors describe a case of [s1]neuroleptic malignant syndrome[e1] that occurred in a patient on amitriptyline and [s2]lithium carbonate[e2] 
	(25, 42)	increased serum thyroid-stimulating hormone	levothyroxine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5395	CASE SUMMARIES: Two patients with stable hypothyroidism experienced symptoms of hypothyroidism with [s1]increased serum thyroid-stimulating hormone[e1] (TSH) concentrations after switching from 1 [s2]levothyroxine[e2] product to another.
	(7, 19)	adenosine	arrhythmia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5396	Evidence is shown in this report that [s1]adenosine[e1] was associated with dangerous worsening of [s2]arrhythmia[e2] in patients with atrial flutter.
	(3, 13)	alterations in heart rate	adenosine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5397	Life-threatening [s1]alterations in heart rate[e1] after the use of [s2]adenosine[e2] in atrial flutter.
	(6, 26)	disorientation	propranolol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5398	Comparable adverse effects, such as [s1]disorientation[e1] and temporary amnesia, have been reported in patients in the analogous agent, [s2]propranolol[e2] 
	(11, 25)	temporary amnesia	propranolol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5399	Comparable adverse effects, such as disorientation and [s1]temporary amnesia[e1]  have been reported in patients in the analogous agent, [s2]propranolol[e2] 
	(8, 15)	transient global amnesia	propafenone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5400	OBJECTIVE: To describe a probable case of [s1]transient global amnesia[e1] caused by [s2]propafenone[e2] 
	(1, 8)	propafenone	transient global amnesia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5401	Probable [s1]propafenone[e1] induced [s2]transient global amnesia[e2] 
	(3, 32)	acute subdural haematoma	aspirin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5402	A case of [s1]acute subdural haematoma[e1] originating spontaneously from an angiomatous meningioma in a patient receiving prophylactic [s2]aspirin[e2] therapy is presented.
	(0, 20)	Intracranial haemorrhage	aspirin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5403	 [s1]Intracranial haemorrhage[e1] from a meningioma in a patient receiving [s2]aspirin[e2] prophylaxis: a case report.
	(10, 17)	fluvoxamine	akathisia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5404	Beneficial effect of low-dose mianserin on [s1]fluvoxamine[e1] induced [s2]akathisia[e2] in an obsessive-compulsive patient.
	(0, 28)	Extrapyramidal side effects	fluoxetine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5405	 [s1]Extrapyramidal side effects[e1] induced by some selective serotonin reuptake inhibitors (SSRIs), i.e. [s2]fluoxetine[e2] and sertraline, have been previously reported in patients with depression and obsessive-compulsive disorder (OCD).
	(0, 33)	Extrapyramidal side effects	sertraline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5406	 [s1]Extrapyramidal side effects[e1] induced by some selective serotonin reuptake inhibitors (SSRIs), i.e. fluoxetine and [s2]sertraline[e2]  have been previously reported in patients with depression and obsessive-compulsive disorder (OCD).
	(7, 14)	akathisia	fluvoxamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5407	However, the occurrence and management of [s1]akathisia[e1] induced by [s2]fluvoxamine[e2] have not been described.
	(4, 11)	fluvoxamine	akathisia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5408	In the presented case [s1]fluvoxamine[e1] induced [s2]akathisia[e2] in an OCD patient was partially resistant to the anticholinergic agent biperiden, and was successfully treated with the 5-HT2A/5-HT2C antagonist mianserin.
	(18, 27)	bleomycin	interstitial pneumonitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5409	A 42 year old man, treated for testicular carcinoma with combination chemotherapy that included [s1]bleomycin[e1]  developed life threatening [s2]interstitial pneumonitis[e2] 
	(1, 7)	bleomycin	lung toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5410	Severe [s1]bleomycin[e1]  [s2]lung toxicity[e2]  reversal with high dose corticosteroids.
	(4, 10)	bleomycin	lung toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5411	This report suggests that [s1]bleomycin[e1]  [s2]lung toxicity[e2] may be reversible if treated aggressively.
	(2, 6)	gold	neutropenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5412	Reversal of [s1]gold[e1] induced [s2]neutropenia[e2] with granulocyte colony-stimulating factor (G-CSF).
	(4, 17)	severe neutropenia	gold	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5413	We have successfully overcome [s1]severe neutropenia[e1] in an RA patient treated with [s2]gold[e2] salts, using granulocyte colony-stimulating factor (G-CSF), reducing the duration of neutropenia and risk of infection.
	(0, 14)	Arrhythmias	amphotericin B	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5414	 [s1]Arrhythmias[e1] and cardiac arrest have been reported during [s2]amphotericin B[e2] administration but no effective technique has been described to prevent them.
	(6, 14)	cardiac arrest	amphotericin B	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5415	Arrhythmias and [s1]cardiac arrest[e1] have been reported during [s2]amphotericin B[e2] administration but no effective technique has been described to prevent them.
	(9, 18)	cardiac arrhythmia	amphotericin B	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5416	Correction of serum electrolyte imbalance prevents [s1]cardiac arrhythmia[e1] during [s2]amphotericin B[e2] administration.
	(20, 25)	cardiac arrest	amphotericin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5417	I saw two patients with kala-azar resistant to sodium stibogluconate who developed [s1]cardiac arrest[e1] after [s2]amphotericin[e2] infusion (in spite of tolerating a test dose).
	(9, 30)	lithium	angry outbursts	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5418	We describe two cases that illustrate the use of [s1]lithium[e1] in the treatment of veterans with PTSD who complained of serious problems with irritability or [s2]angry outbursts[e2] 
	(9, 26)	lithium	irritability	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5419	We describe two cases that illustrate the use of [s1]lithium[e1] in the treatment of veterans with PTSD who complained of serious problems with [s2]irritability[e2] or angry outbursts.
	(0, 16)	Graves' hyperthyroidism	interferon	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5420	 [s1]Graves' hyperthyroidism[e1] following transient thyrotoxicosis during [s2]interferon[e2] therapy for chronic hepatitis type C.
	(7, 16)	transient thyrotoxicosis	interferon	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5421	Graves' hyperthyroidism following [s1]transient thyrotoxicosis[e1] during [s2]interferon[e2] therapy for chronic hepatitis type C.
	(30, 39)	Graves' hyperthyroidism	IFN	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5422	This case showed sequential manifestation from transient thyrotoxicosis to the appearance of TSH-receptor autoantibodies, and then the occurrence of [s1]Graves' hyperthyroidism[e1] during [s2]IFN[e2] therapy.
	(5, 21)	Graves' hyperthyroidism	IFN	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5423	We report a case of [s1]Graves' hyperthyroidism[e1] induced by long-term interferon  [s2]IFN[e2]  therapy.
	(5, 18)	Graves' hyperthyroidism	interferon	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5424	We report a case of [s1]Graves' hyperthyroidism[e1] induced by long-term [s2]interferon[e2] (IFN) therapy.
	(1, 5)	INH	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5425	Acute [s1]INH[e1]  [s2]neurotoxicity[e2] was not suspected on the first admission; however, when readmitted 4 weeks later with another seizure, the diagnosis of acute INH neurotoxicity was made.
	(1, 5)	INH	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5426	Acute [s1]INH[e1]  [s2]neurotoxicity[e2] was not suspected on the first admission; however, when readmitted 4 weeks later with another seizure, the diagnosis of acute INH neurotoxicity was made.
	(1, 7)	isoniazid	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5427	Acute [s1]isoniazid[e1]  [s2]neurotoxicity[e2] in an urban hospital.
	(10, 14)	INH	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5428	CONCLUSIONS: We have seen an increased incidence of acute [s1]INH[e1]  [s2]neurotoxicity[e2] because of the resurgence of TB in New York City.
	(7, 11)	INH	seizures	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5429	In patients with a known access to [s1]INH[e1]  [s2]seizures[e2] should be considered to be caused by INH toxicity unless proved otherwise.
	(14, 18)	INH	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5430	OBJECTIVES: To describe the presentation and treatment of acute isoniazid  [s1]INH[e1]  [s2]neurotoxicity[e2] appearing at an inner-city municipal hospital.
	(10, 20)	isoniazid	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5431	OBJECTIVES: To describe the presentation and treatment of acute [s1]isoniazid[e1] (INH) [s2]neurotoxicity[e2] appearing at an inner-city municipal hospital.
	(13, 18)	INH	refractory seizures	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5432	Parenteral pyridoxine, the specific antidote for [s1]INH[e1] induced [s2]refractory seizures[e2]  should be readily available in every emergency department in the areas similarly experiencing increasing trends of TB.
	(11, 15)	INH	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5433	RESULTS: At our institution, no children appeared with acute [s1]INH[e1]  [s2]neurotoxicity[e2] in the period 1985 through 1990, whereas seven patients were treated from 1991 through 1993.
	(0, 12)	Arterial hypertension	phenylephrine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5434	 [s1]Arterial hypertension[e1] associated with topical ocular use of [s2]phenylephrine[e2] in dogs.
	(2, 19)	Squamous metaplasia	progestin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5435	CONCLUSION: [s1]Squamous metaplasia[e1] in these cases appears to be a consequence of [s2]progestin[e2] therapy.
	(7, 26)	squamous metaplasia within endometrial glands	progestin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5436	OBJECTIVE: To report the finding of [s1]squamous metaplasia within endometrial glands[e1] occurring as a result of [s2]progestin[e2] therapy of hyperplasia.
	(3, 20)	squamous metaplasia	progestin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5437	RESULTS: Extensive [s1]squamous metaplasia[e1] was found in endometrial glands following [s2]progestin[e2] therapy.
	(0, 8)	Fever	furosemide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5438	 [s1]Fever[e1] caused by the use of [s2]furosemide[e2] was proved; the fever resolved after discontinuation of this medication and recurred after its reintroduction.
	(0, 6)	Furosemide	fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5439	 [s1]Furosemide[e1] associated [s2]fever[e2] 
	(6, 13)	KW-2149	pulmonary toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5440	The dose-limiting toxicity of [s1]KW-2149[e1] is [s2]pulmonary toxicity[e2] 
	(0, 41)	Musculoskeletal complaints	cyclophosphamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5441	 [s1]Musculoskeletal complaints[e1] were the presenting symptoms in four of 44 children (9%) treated for relapsed Wilms' tumors with ifosfamide, a derivative of [s2]cyclophosphamide[e2] 
	(0, 33)	Musculoskeletal complaints	ifosfamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5442	 [s1]Musculoskeletal complaints[e1] were the presenting symptoms in four of 44 children (9%) treated for relapsed Wilms' tumors with [s2]ifosfamide[e2]  a derivative of cyclophosphamide.
	(7, 24)	Fanconi syndrome	ifosfamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5443	Recognition of a potential drug-induced [s1]Fanconi syndrome[e1] is important when managing pediatric oncology patients previously treated with [s2]ifosfamide[e2] 
	(8, 38)	benzarone	cirrhosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5444	Our cases constitute the most severe cases of [s1]benzarone[e1] hepatotoxicity reported so far, and comprise the first cases of (sub)fulminant hepatitis and [s2]cirrhosis[e2] related to benzarone.
	(8, 38)	benzarone	cirrhosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5445	Our cases constitute the most severe cases of [s1]benzarone[e1] hepatotoxicity reported so far, and comprise the first cases of (sub)fulminant hepatitis and [s2]cirrhosis[e2] related to benzarone.
	(8, 13)	benzarone	hepatotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5446	Our cases constitute the most severe cases of [s1]benzarone[e1]  [s2]hepatotoxicity[e2] reported so far, and comprise the first cases of (sub)fulminant hepatitis and cirrhosis related to benzarone.
	(8, 29)	benzarone	(sub)fulminant hepatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5447	Our cases constitute the most severe cases of [s1]benzarone[e1] hepatotoxicity reported so far, and comprise the first cases of [s2](sub)fulminant hepatitis[e2] and cirrhosis related to benzarone.
	(8, 29)	benzarone	(sub)fulminant hepatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5448	Our cases constitute the most severe cases of [s1]benzarone[e1] hepatotoxicity reported so far, and comprise the first cases of [s2](sub)fulminant hepatitis[e2] and cirrhosis related to benzarone.
	(0, 11)	Severe hepatotoxicity	benzarone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5449	 [s1]Severe hepatotoxicity[e1] related to [s2]benzarone[e2]  a report of three cases with two fatalities.
	(5, 16)	severe hepatotoxicity	benzarone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5450	We report three cases of [s1]severe hepatotoxicity[e1] related to [s2]benzarone[e2]  a benzofuran derivative.
	(5, 12)	benzarone	hepatotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5451	We stress the potential of [s1]benzarone[e1] to cause [s2]hepatotoxicity[e2]  which usually resembles severe chronic active hepatitis.
	(5, 22)	benzarone	severe chronic active hepatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5452	We stress the potential of [s1]benzarone[e1] to cause hepatotoxicity, which usually resembles [s2]severe chronic active hepatitis[e2] 
	(11, 17)	warfarin	necrotizing fasciitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5453	Case study: a modified topical treatment regimen for sodium [s1]warfarin[e1] induced [s2]necrotizing fasciitis[e2] 
	(14, 29)	sodium warfarin	myonecrosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5454	This case study describes an atypical case of refractory, [s1]sodium warfarin[e1] induced necrotizing fasciitis and [s2]myonecrosis[e2] 
	(14, 21)	sodium warfarin	necrotizing fasciitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5455	This case study describes an atypical case of refractory, [s1]sodium warfarin[e1] induced [s2]necrotizing fasciitis[e2] and myonecrosis.
	(27, 41)	mefloquine	severe hypoglycaemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5456	Clinicians who manage cachectic patients, particularly those with protracted diarrhoea and/or receiving anti-malarial drugs including [s1]mefloquine[e1]  should be aware of the risk of [s2]severe hypoglycaemia[e2] 
	(5, 15)	hypoglycaemia	mefloquine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5457	Mechanisms and triggering factors of [s1]hypoglycaemia[e1] induced by [s2]mefloquine[e2] and some other anti-malarial quinine analogues are discussed.
	(0, 8)	Mefloquine	hypoglycaemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5458	 [s1]Mefloquine[e1] associated [s2]hypoglycaemia[e2] in a cachectic AIDS patient.
	(6, 17)	quinidine	iatrogenic hypoglycaemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5459	Quinine and its isomer [s1]quinidine[e1] are well-known causes of [s2]iatrogenic hypoglycaemia[e2]  due to excessive insulin secretion.
	(0, 17)	Quinine	iatrogenic hypoglycaemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5460	 [s1]Quinine[e1] and its isomer quinidine are well-known causes of [s2]iatrogenic hypoglycaemia[e2]  due to excessive insulin secretion.
	(5, 14)	hypoglycaemia	mefloquine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5461	We report a case of [s1]hypoglycaemia[e1] after [s2]mefloquine[e2] therapy (1,500 mg over two days) for severe gastrointestinal cryptosporidiasis in a cachectic AIDS patient with protracted diarrhoea.
	(1, 9)	sumatriptan	coronary artery vasospasm	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5462	Because [s1]sumatriptan[e1] can cause [s2]coronary artery vasospasm[e2]  patients with significant risk factors for coronary artery disease should be carefully evaluated for cardiovascular disease prior to the use of sumatriptan.
	(0, 7)	Cardiac arrest	sumatriptan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5463	 [s1]Cardiac arrest[e1] following use of [s2]sumatriptan[e2] 
	(17, 34)	cardiac arrest	sumatriptan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5464	I report a 35-year-old woman with occult coronary artery disease who experienced [s1]cardiac arrest[e1] within minutes after receiving a first-time dose of subcutaneous [s2]sumatriptan[e2] for migraine.
	(0, 6)	Sotalol	bradycardia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5465	 [s1]Sotalol[e1] induced [s2]bradycardia[e2] reversed by glucagon.
	(5, 11)	sotalol	bradycardia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5466	We present a case of [s1]sotalol[e1] induced [s2]bradycardia[e2] reversed by glucagon.
	(0, 17)	Secretory endometrial adenocarcinoma	tamoxifen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5467	 [s1]Secretory endometrial adenocarcinoma[e1] in a patient on [s2]tamoxifen[e2] for breast cancer: a report of a case.
	(4, 28)	low-grade endometrial carcinoma	tamoxifen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5468	This unusual pattern of [s1]low-grade endometrial carcinoma[e1] adds to the spectrum of uterine neoplasia associated with [s2]tamoxifen[e2] therapy.
	(19, 28)	uterine neoplasia	tamoxifen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5469	This unusual pattern of low-grade endometrial carcinoma adds to the spectrum of [s1]uterine neoplasia[e1] associated with [s2]tamoxifen[e2] therapy.
	(9, 24)	secretory carcinoma of the endometrium	tamoxifen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5470	We believe that this is the first report of [s1]secretory carcinoma of the endometrium[e1] associated with [s2]tamoxifen[e2] use.
	(3, 42)	endometrial adenocarcinoma of the secretory type	tamoxifen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5471	Well-differentiated [s1]endometrial adenocarcinoma of the secretory type[e1] (FIGO Grade 1) with minimal myometrial invasion occurred in a postmenopausal patient on [s2]tamoxifen[e2] therapy 5 years after mastectomy for breast carcinoma.
	(0, 11)	Esophageal candidiasis	omeprazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5472	 [s1]Esophageal candidiasis[e1] following [s2]omeprazole[e2] therapy: a report of two cases.
	(0, 21)	Esophageal candidiasis	omeprazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5473	 [s1]Esophageal candidiasis[e1] was diagnosed at endoscopy in two patients receiving [s2]omeprazole[e2] therapy.
	(0, 12)	High-grade atrioventricular block	dipyridamole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5474	 [s1]High-grade atrioventricular block[e1] during [s2]dipyridamole[e2] stress testing.
	(6, 14)	dipyridamole	high-grade atrioventricular (AV) block	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5475	We present a case in which [s1]dipyridamole[e1] induced [s2]high-grade atrioventricular (AV) block[e2] that responded promptly to intravenous aminophylline but not to atropine.
	(3, 12)	doxorubicin	cardiomyopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5476	Aggressive management of [s1]doxorubicin[e1] induced [s2]cardiomyopathy[e2] associated with 'low' doses of doxorubicin.
	(3, 12)	doxorubicin	cardiomyopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5477	Aggressive management of [s1]doxorubicin[e1] induced [s2]cardiomyopathy[e2] associated with 'low' doses of doxorubicin.
	(8, 20)	doxorubicin	symptomatic cardiac failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5478	There is a dose-effect relationship between [s1]doxorubicin[e1] and the incidence of [s2]symptomatic cardiac failure[e2] 
	(11, 29)	endometriosis	tamoxifen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5479	Ovarian endometrioid carcinoma and [s1]endometriosis[e1] developing in a postmenopausal breast cancer patient during [s2]tamoxifen[e2] therapy: a case report and review of the literature.
	(0, 29)	Ovarian endometrioid carcinoma	tamoxifen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5480	 [s1]Ovarian endometrioid carcinoma[e1] and endometriosis developing in a postmenopausal breast cancer patient during [s2]tamoxifen[e2] therapy: a case report and review of the literature.
	(11, 25)	tamoxifen	ovarian endometrioid carcinoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5481	The association with prolonged unopposed estrogen-like stimulation with [s1]tamoxifen[e1] as a possible factor in the development of [s2]ovarian endometrioid carcinoma[e2] is discussed.
	(17, 35)	endometriosis	tamoxifen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5482	We present the first case of ovarian endometrioid carcinoma and [s1]endometriosis[e1] in a postmenopausal patient who was treated with [s2]tamoxifen[e2] for breast cancer.
	(6, 35)	ovarian endometrioid carcinoma	tamoxifen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5483	We present the first case of [s1]ovarian endometrioid carcinoma[e1] and endometriosis in a postmenopausal patient who was treated with [s2]tamoxifen[e2] for breast cancer.
	(0, 18)	Cerebral demyelinating disease	levamisole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5484	 [s1]Cerebral demyelinating disease[e1] developed in a patient during adjuvant therapy with [s2]levamisole[e2] for malignant melanoma.
	(0, 15)	Multifocal inflammatory leukoencephalopathy	levamisole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5485	 [s1]Multifocal inflammatory leukoencephalopathy[e1] associated with [s2]levamisole[e2] therapy.
	(7, 24)	leukoencephalopathy	5-fluorouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5486	Observations in our patient suggest that the [s1]leukoencephalopathy[e1] that developed in previously reported patients who received [s2]5-fluorouracil[e2] and levamisole may have been caused at least partly by levamisole.
	(7, 32)	leukoencephalopathy	levamisole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5487	Observations in our patient suggest that the [s1]leukoencephalopathy[e1] that developed in previously reported patients who received 5-fluorouracil and [s2]levamisole[e2] may have been caused at least partly by levamisole.
	(7, 32)	leukoencephalopathy	levamisole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5488	Observations in our patient suggest that the [s1]leukoencephalopathy[e1] that developed in previously reported patients who received 5-fluorouracil and [s2]levamisole[e2] may have been caused at least partly by levamisole.
	(3, 13)	noncardiogenic pulmonary edema	ethanolamine oleate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5489	A case of [s1]noncardiogenic pulmonary edema[e1] by [s2]ethanolamine oleate[e2] 
	(2, 7)	EO	noncardiogenic pulmonary edema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5490	However, [s1]EO[e1] induced [s2]noncardiogenic pulmonary edema[e2] has not been reported in human.
	(5, 19)	noncardiogenic pulmonary edema	EO	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5491	We report a case of [s1]noncardiogenic pulmonary edema[e1] developed after therapeutic trial of [s2]EO[e2] as sclerosing agent for esophageal varix.
	(7, 17)	gentamicin sulfate	acute renal failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5492	Five patients are described in whom only [s1]gentamicin sulfate[e1] appeared responsible for [s2]acute renal failure[e2] 
	(0, 7)	Gentamicin	acute renal failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5493	 [s1]Gentamicin[e1] associated [s2]acute renal failure[e2] 
	(0, 11)	Renal failure	gentamicin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5494	 [s1]Renal failure[e1] appeared 8 to 17 days after beginning [s2]gentamicin[e2] therapy and was characterized by creatinine clearances 4 to 10 ml/min, urine to plasma creatinine ratios less than 20, urinary sodium concentrations 16 to 60 mEq/liter, proteinuria, and cylindruria.
	(8, 15)	phenytoin	unilateral gingival hyperplasia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5495	A 15-year follow-up of [s1]phenytoin[e1] induced [s2]unilateral gingival hyperplasia[e2]  a case report.
	(22, 36)	phenytoin	unilateral gingival hyperplasia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5496	INTRODUCTION-The aim of this case report is to present a 15-year follow-up of a patient with [s1]phenytoin[e1] (PHT) intoxication with [s2]unilateral gingival hyperplasia[e2] (GH).
	(26, 34)	PHT	unilateral gingival hyperplasia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5497	INTRODUCTION-The aim of this case report is to present a 15-year follow-up of a patient with phenytoin  [s1]PHT[e1]  intoxication with [s2]unilateral gingival hyperplasia[e2] (GH).
	(5, 40)	generalized cutaneous sclerosis	aminotriazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5498	We report a case of [s1]generalized cutaneous sclerosis[e1] associated with muscle and oesophageal involvement in a patient exposed to herbicides containing bromocil, diuron and [s2]aminotriazole[e2] 
	(5, 32)	generalized cutaneous sclerosis	bromocil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5499	We report a case of [s1]generalized cutaneous sclerosis[e1] associated with muscle and oesophageal involvement in a patient exposed to herbicides containing [s2]bromocil[e2]  diuron and aminotriazole.
	(5, 37)	generalized cutaneous sclerosis	diuron	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5500	We report a case of [s1]generalized cutaneous sclerosis[e1] associated with muscle and oesophageal involvement in a patient exposed to herbicides containing bromocil, [s2]diuron[e2] and aminotriazole.
	(0, 14)	Albuterol	cardiac toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5501	 [s1]Albuterol[e1] induced hypokalemia and its potential [s2]cardiac toxicity[e2] are discussed briefly.
	(0, 6)	Albuterol	hypokalemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5502	 [s1]Albuterol[e1] induced [s2]hypokalemia[e2] and its potential cardiac toxicity are discussed briefly.
	(0, 15)	Hypokalemia	albuterol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5503	 [s1]Hypokalemia[e1] after normal doses of neubulized [s2]albuterol[e2] (salbutamol).
	(0, 18)	Hypokalemia	salbutamol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5504	 [s1]Hypokalemia[e1] after normal doses of neubulized albuterol  [s2]salbutamol[e2] .
	(9, 24)	hypokalemic	albuterol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5505	The cases of two asthmatic patients who became [s1]hypokalemic[e1] after inhalation of normal doses of [s2]albuterol[e2] are presented.
	(0, 8)	Propoxyphene	wide complex dysrhythmia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5506	 [s1]Propoxyphene[e1] induced [s2]wide complex dysrhythmia[e2] responsive to sodium bicarbonate therapy has not been previously reported in the literature.
	(0, 8)	Propoxyphene	wide QRS complex dysrhythmia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5507	 [s1]Propoxyphene[e1] induced [s2]wide QRS complex dysrhythmia[e2] responsive to sodium bicarbonate--a case report.
	(3, 8)	mannitol	nephrotoxicity syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5508	Case report: [s1]mannitol[e1]  [s2]nephrotoxicity syndrome[e2]  role of hemodialysis and postulate of mechanisms.
	(11, 17)	mannitol	ARF	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5509	Hemodialysis should be performed for rapid reversal of [s1]mannitol[e1] induced [s2]ARF[e2] 
	(6, 20)	mannitol	acute renal failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5510	High-dose intravenous [s1]mannitol[e1] infusion in various clinical settings may result in [s2]acute renal failure[e2] (ARF).
	(6, 23)	mannitol	ARF	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5511	High-dose intravenous [s1]mannitol[e1] infusion in various clinical settings may result in acute renal failure  [s2]ARF[e2] .
	(0, 6)	Mannitol	ARF	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5512	 [s1]Mannitol[e1] induced [s2]ARF[e2] responds promptly to hemodialysis with rapid resolution of anuria and recovery of renal failure.
	(6, 12)	ARF	mannitol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5513	The literature is also reviewed for [s1]ARF[e1] associated with [s2]mannitol[e2] infusion in patients who received dialysis and those who did not receive dialysis; and the possible mechanism(s) of mannitol nephrotoxicity are discussed.
	(10, 43)	mannitol	nephrotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5514	The literature is also reviewed for ARF associated with [s1]mannitol[e1] infusion in patients who received dialysis and those who did not receive dialysis; and the possible mechanism(s) of mannitol [s2]nephrotoxicity[e2] are discussed.
	(8, 19)	anuric ARF	mannitol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5515	This is a report of a case of [s1]anuric ARF[e1] after high-dose [s2]mannitol[e2] infusion for treatment of narrow-angle glaucoma that readily responded to acute hemodialysis.
	(3, 15)	extrapyramidal side effects	fluphenazine decanoate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5516	Two patients with [s1]extrapyramidal side effects[e1] after the use of [s2]fluphenazine decanoate[e2] were evaluated by means of IBZM-SPECT.
	(6, 14)	benzodiazepine	sedation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5517	Flumazenil reversal of [s1]benzodiazepine[e1] induced [s2]sedation[e2] for a patient with severe pre-ECT anxiety.
	(14, 23)	irritating cough	quinapril	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5518	CASE SUMMARY: A 68-year-old woman developed a dry, [s1]irritating cough[e1] within one month of starting [s2]quinapril[e2] therapy for the treatment of essential hypertension.
	(0, 5)	Cough	quinapril	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5519	 [s1]Cough[e1] induced by [s2]quinapril[e2] with resolution after changing to fosinopril.
	(12, 29)	cough	quinapril	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5520	OBJECTIVE: To report a case of chronic, nonproductive [s1]cough[e1] secondary to the angiotensin-converting enzyme (ACE) inhibitor [s2]quinapril[e2]  with complete resolution after switching to another ACE inhibitor, fosinopril.
	(1, 11)	cough	quinapril	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5521	The [s1]cough[e1] continued for the duration of therapy with [s2]quinapril[e2] 
	(5, 12)	cough	quinapril	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5522	We report a case of [s1]cough[e1] following the administration of [s2]quinapril[e2]  with complete resolution after changing to the alternative ACE inhibitor fosinopril in a patient with essential hypertension.
	(0, 13)	Fracture of the femoral neck	PSL	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5523	 [s1]Fracture of the femoral neck[e1] occurred in one patient during [s2]PSL[e2] therapy, although the relationship between the fracture and PSL therapy was uncertain.
	(0, 7)	Cefuroxime	acute renal failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5524	 [s1]Cefuroxime[e1] induced [s2]acute renal failure[e2] 
	(4, 12)	DIAN	cefuroxime	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5525	In our patient, [s1]DIAN[e1] possibly was related to [s2]cefuroxime[e2]  but the patient did not experience associated allergic symptoms.
	(9, 16)	renal deterioration	cefuroxime	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5526	The diagnosis was supported by the temporal course of [s1]renal deterioration[e1] during exposure to [s2]cefuroxime[e2] and improvement on its discontinuation; the pattern repeated with rechallenge.
	(8, 14)	DIAN	cefuroxime	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5527	This is the first reported case of suspected [s1]DIAN[e1] due to [s2]cefuroxime[e2] 
	(3, 28)	basilar invagination	phenytoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5528	A case of [s1]basilar invagination[e1] which is thought to have arisen from the patient's intrauterine exposure to [s2]phenytoin[e2] is presented.
	(0, 21)	Basilar invagination	phenytoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5529	 [s1]Basilar invagination[e1] and mid-line skeletal abnormalities due to in utero exposure to [s2]phenytoin[e2] 
	(7, 21)	mid-line skeletal abnormalities	phenytoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5530	Basilar invagination and [s1]mid-line skeletal abnormalities[e1] due to in utero exposure to [s2]phenytoin[e2] 
	(13, 24)	phenytoin	craniocervical abnormality	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5531	His symptoms of brain stem compression were alleviated and the role of [s1]phenytoin[e1] in the production of his [s2]craniocervical abnormality[e2] is discussed.
	(0, 21)	Temporary neurologic abnormalities	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5532	 [s1]Temporary neurologic abnormalities[e1] were observed in one out of 23 patients undergoing chemotherapy with high-dose [s2]methotrexate[e2] (HD-MTX) for osteogenic sarcoma.
	(17, 28)	altered consciousness	HD-MTX	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5533	This patient developed sequential symptoms including alternative hemiparesis, dysarthria and [s1]altered consciousness[e1] 5 days after the second course of [s2]HD-MTX[e2] (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue.
	(12, 28)	dysarthria	HD-MTX	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5534	This patient developed sequential symptoms including alternative hemiparesis, [s1]dysarthria[e1] and altered consciousness 5 days after the second course of [s2]HD-MTX[e2] (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue.
	(7, 27)	hemiparesis	HD-MTX	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5535	This patient developed sequential symptoms including alternative [s1]hemiparesis[e1]  dysarthria and altered consciousness 5 days after the second course of [s2]HD-MTX[e2] (8 gm/m2 by 6 h continuous infusion) with leucovorin rescue.
	(0, 13)	Transient neurological disturbances	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5536	 [s1]Transient neurological disturbances[e1] induced by the chemotherapy of high-dose [s2]methotrexate[e2] for osteogenic sarcoma.
	(14, 45)	stricture of the hepatic flexure region with associated narrowing	high-lipase pancreatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5537	We report a 5-year-old boy with CF who had a [s1]stricture of the hepatic flexure region with associated narrowing[e1] due to submucosal fibrosis of the transverse colon, secondary to [s2]high-lipase pancreatin[e2] therapy.
	(29, 44)	submucosal fibrosis of the transverse colon	high-lipase pancreatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5538	We report a 5-year-old boy with CF who had a stricture of the hepatic flexure region with associated narrowing due to [s1]submucosal fibrosis of the transverse colon[e1]  secondary to [s2]high-lipase pancreatin[e2] therapy.
	(0, 9)	Acute pancreatitis	danazol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5539	 [s1]Acute pancreatitis[e1] associated with [s2]danazol[e2] treatment for endometriosis.
	(2, 8)	danazol	hepatocellular damage	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5540	Additionally, [s1]danazol[e1] produces [s2]hepatocellular damage[e2] in approximately 10% of women.
	(0, 21)	Hypo-oestrogenic and anabolic/androgenic side-effects	danazol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5541	 [s1]Hypo-oestrogenic and anabolic/androgenic side-effects[e1] of [s2]danazol[e2] are well known by the gynaecologist and some of them are present in > 50% of patients being treated for endometriosis.
	(8, 17)	acute pancreatitis	danazol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5542	The present report describes the first case of [s1]acute pancreatitis[e1] associated with [s2]danazol[e2] treatment of endometriosis.
	(0, 7)	Acyclovir	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5543	 [s1]Acyclovir[e1]  [s2]neurotoxicity[e2]  clinical experience and review of the literature.
	(0, 8)	Acyclovir	neurologic symptoms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5544	 [s1]Acyclovir[e1] produces [s2]neurologic symptoms[e2] that resemble extension of viral infection into the central nervous system.
	(14, 21)	acyclovir	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5545	Systemic disease, most commonly renal dysfunction, preceded all 30 reported cases of [s1]acyclovir[e1]  [s2]neurotoxicity[e2] 
	(11, 18)	acyclovir	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5546	We discuss our observations in the cases of two patients with [s1]acyclovir[e1]  [s2]neurotoxicity[e2] and review the findings of all previous reports in the English language literature.
	(3, 10)	promethazine	coma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5547	Response of a [s1]promethazine[e1] induced [s2]coma[e2] to flumazenil.
	(10, 17)	promethazine	coma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5548	We report the first case of a patient in a [s1]promethazine[e1] induced [s2]coma[e2] responding to treatment with flumazenil.
	(0, 14)	Amebic abscess of the spleen	metronidazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5549	 [s1]Amebic abscess of the spleen[e1] complicated by [s2]metronidazole[e2] induced neurotoxicity: case report.
	(12, 20)	metronidazole	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5550	Amebic abscess of the spleen complicated by [s1]metronidazole[e1] induced [s2]neurotoxicity[e2]  case report.
	(23, 55)	metronidazole	ataxia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5551	We describe a patient with a liver abscess due to Entamoeba histolytica, in whom [s1]metronidazole[e1] therapy (total dose, 21 g over 14 days) was complicated by reversible deafness, tinnitus, and [s2]ataxia[e2] and who relapsed 5 months later with a splenic abscess.
	(6, 25)	liver abscess	metronidazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5552	We describe a patient with a [s1]liver abscess[e1] due to Entamoeba histolytica, in whom [s2]metronidazole[e2] therapy (total dose, 21 g over 14 days) was complicated by reversible deafness, tinnitus, and ataxia and who relapsed 5 months later with a splenic abscess.
	(23, 44)	metronidazole	reversible deafness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5553	We describe a patient with a liver abscess due to Entamoeba histolytica, in whom [s1]metronidazole[e1] therapy (total dose, 21 g over 14 days) was complicated by [s2]reversible deafness[e2]  tinnitus, and ataxia and who relapsed 5 months later with a splenic abscess.
	(23, 68)	metronidazole	splenic abscess	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5554	We describe a patient with a liver abscess due to Entamoeba histolytica, in whom [s1]metronidazole[e1] therapy (total dose, 21 g over 14 days) was complicated by reversible deafness, tinnitus, and ataxia and who relapsed 5 months later with a [s2]splenic abscess[e2] 
	(23, 50)	metronidazole	tinnitus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5555	We describe a patient with a liver abscess due to Entamoeba histolytica, in whom [s1]metronidazole[e1] therapy (total dose, 21 g over 14 days) was complicated by reversible deafness, [s2]tinnitus[e2]  and ataxia and who relapsed 5 months later with a splenic abscess.
	(0, 8)	Actinomycin D	hepatic veno-occlusive disease	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5556	 [s1]Actinomycin D[e1] associated [s2]hepatic veno-occlusive disease[e2] -a report of 2 cases.
	(5, 15)	liver failure	AMD	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5557	There are now reports of [s1]liver failure[e1] following treatment of childhood cancers with [s2]AMD[e2] 
	(0, 10)	Phenylpropanolamine	psychosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5558	 [s1]Phenylpropanolamine[e1] induced [s2]psychosis[e2] 
	(6, 20)	paranoid psychosis	PPA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5559	We report a cae of [s1]paranoid psychosis[e1] following use of a decongestant containing [s2]PPA[e2] and summarize the case report literature of psychiatric adverse effects to PPA in which doses were known and stated to be within recommended guidelines.
	(18, 31)	PPA	psychiatric adverse effects	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5560	We report a cae of paranoid psychosis following use of a decongestant containing [s1]PPA[e1] and summarize the case report literature of [s2]psychiatric adverse effects[e2] to PPA in which doses were known and stated to be within recommended guidelines.
	(3, 29)	budesonide	contact dermatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5561	CONCLUSIONS: Although [s1]budesonide[e1] may be beneficial because of its anti-inflammatory effects, clinicians should be alert to its potential for causing [s2]contact dermatitis[e2] 
	(0, 8)	Contact dermatitis	budesonide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5562	 [s1]Contact dermatitis[e1] due to [s2]budesonide[e2]  report of five cases and review of the Japanese literature.
	(5, 13)	contact dermatitis	budesonide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5563	METHODS: Five cases of [s1]contact dermatitis[e1] due to [s2]budesonide[e2]  a nonhalogenated steroid, are described.
	(2, 10)	Budesonide	contact dermatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5564	RESULTS: [s1]Budesonide[e1] use can cause [s2]contact dermatitis[e2] 
	(6, 16)	methemoglobinemia	methyl nitrite	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5565	Although other nitrites induce [s1]methemoglobinemia[e1]  exposure to [s2]methyl nitrite[e2] during phenylpropanolamine production appears to be a new cause of occupational methemoglobinemia.
	(6, 16)	methemoglobinemia	methyl nitrite	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5566	Although other nitrites induce [s1]methemoglobinemia[e1]  exposure to [s2]methyl nitrite[e2] during phenylpropanolamine production appears to be a new cause of occupational methemoglobinemia.
	(0, 12)	Methemoglobinemia	phenylpropanolamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5567	 [s1]Methemoglobinemia[e1]  an occupational hazard of [s2]phenylpropanolamine[e2] production.
	(3, 16)	IFN	IDDM	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5568	During and after [s1]IFN[e1] therapy we should consider the possibility of occurrence of [s2]IDDM[e2] as well as other autoimmune diseases and observe the clinical course carefully.
	(6, 16)	IFN	moderate hyperglycemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5569	Four years after the beginning of [s1]IFN[e1] therapy, he acutely developed [s2]moderate hyperglycemia[e2] and severe ketonuria with positive islet cell antibody, and then 28 units/day of insulin injection was started.
	(6, 22)	IFN	severe ketonuria	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5570	Four years after the beginning of [s1]IFN[e1] therapy, he acutely developed moderate hyperglycemia and [s2]severe ketonuria[e2] with positive islet cell antibody, and then 28 units/day of insulin injection was started.
	(2, 7)	IDDM	interferon	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5571	Occurrence of [s1]IDDM[e1] during [s2]interferon[e2] therapy for chronic viral hepatitis.
	(5, 12)	IDDM	interferon	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5572	We report a case of [s1]IDDM[e1] which occurred during [s2]interferon[e2] therapy for chronic hepatitis.
	(16, 26)	hypersensitivity syndrome	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5573	Four patients who manifested symptoms of the antiepileptic drug (AED) [s1]hypersensitivity syndrome[e1] during therapy with [s2]carbamazepine[e2] are reported.
	(0, 13)	Recurrent hypotension	nortriptyline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5574	 [s1]Recurrent hypotension[e1] immediately after seizures in [s2]nortriptyline[e2] overdose.
	(9, 13)	seizures	nortriptyline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5575	Recurrent hypotension immediately after [s1]seizures[e1] in [s2]nortriptyline[e2] overdose.
	(3, 51)	methotrexate	accelerate HIV disease	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5576	The use of [s1]methotrexate[e1] (MTX) has been contraindicated for treatment of severe psoriasis in HIV infection on the basis of six previously reported cases in which MTX appeared to potentiate opportunistic infections and [s2]accelerate HIV disease[e2] 
	(8, 49)	MTX	accelerate HIV disease	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5577	The use of methotrexate  [s1]MTX[e1]  has been contraindicated for treatment of severe psoriasis in HIV infection on the basis of six previously reported cases in which MTX appeared to potentiate opportunistic infections and [s2]accelerate HIV disease[e2] 
	(8, 49)	MTX	accelerate HIV disease	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5578	The use of methotrexate  [s1]MTX[e1]  has been contraindicated for treatment of severe psoriasis in HIV infection on the basis of six previously reported cases in which MTX appeared to potentiate opportunistic infections and [s2]accelerate HIV disease[e2] 
	(9, 31)	increase of INR	5-FU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5579	CONCLUSIONS: This case describes the clinically significant [s1]increase of INR[e1] in an elderly patient after adding a chemotherapy regimen of levamisole and [s2]5-FU[e2] to a previous regimen of warfarin alone.
	(9, 26)	increase of INR	levamisole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5580	CONCLUSIONS: This case describes the clinically significant [s1]increase of INR[e1] in an elderly patient after adding a chemotherapy regimen of [s2]levamisole[e2] and 5-FU to a previous regimen of warfarin alone.
	(9, 40)	increase of INR	warfarin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5581	CONCLUSIONS: This case describes the clinically significant [s1]increase of INR[e1] in an elderly patient after adding a chemotherapy regimen of levamisole and 5-FU to a previous regimen of [s2]warfarin[e2] alone.
	(6, 16)	5-FU	increase in INR	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5582	However, prolongation of [s1]5-FU[e1] half-life and an [s2]increase in INR[e2] have been reported with the concurrent use of 5-FU and warfarin.
	(14, 32)	increase in INR	warfarin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5583	However, prolongation of 5-FU half-life and an [s1]increase in INR[e1] have been reported with the concurrent use of 5-FU and [s2]warfarin[e2] 
	(0, 21)	Cholestatic liver disease	clindamycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5584	 [s1]Cholestatic liver disease[e1] with ductopenia (vanishing bile duct syndrome) after administration of [s2]clindamycin[e2] and trimethoprim-sulfamethoxazole.
	(0, 26)	Cholestatic liver disease	trimethoprim-sulfamethoxazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5585	 [s1]Cholestatic liver disease[e1] with ductopenia (vanishing bile duct syndrome) after administration of clindamycin and [s2]trimethoprim-sulfamethoxazole[e2] 
	(7, 21)	ductopenia	clindamycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5586	Cholestatic liver disease with [s1]ductopenia[e1] (vanishing bile duct syndrome) after administration of [s2]clindamycin[e2] and trimethoprim-sulfamethoxazole.
	(7, 26)	ductopenia	trimethoprim-sulfamethoxazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5587	Cholestatic liver disease with [s1]ductopenia[e1] (vanishing bile duct syndrome) after administration of clindamycin and [s2]trimethoprim-sulfamethoxazole[e2] 
	(10, 19)	vanishing bile duct syndrome	clindamycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5588	Cholestatic liver disease with ductopenia  [s1]vanishing bile duct syndrome[e1]  after administration of [s2]clindamycin[e2] and trimethoprim-sulfamethoxazole.
	(10, 24)	vanishing bile duct syndrome	trimethoprim-sulfamethoxazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5589	Cholestatic liver disease with ductopenia  [s1]vanishing bile duct syndrome[e1]  after administration of clindamycin and [s2]trimethoprim-sulfamethoxazole[e2] 
	(4, 25)	clindamycin	bile duct injury	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5590	One patient who received [s1]clindamycin[e1] had liver biopsy findings of marked cholestasis, portal inflammation, [s2]bile duct injury[e2] and bile duct paucity (ductopenia).
	(4, 29)	clindamycin	bile duct paucity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5591	One patient who received [s1]clindamycin[e1] had liver biopsy findings of marked cholestasis, portal inflammation, bile duct injury and [s2]bile duct paucity[e2] (ductopenia).
	(4, 33)	clindamycin	ductopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5592	One patient who received [s1]clindamycin[e1] had liver biopsy findings of marked cholestasis, portal inflammation, bile duct injury and bile duct paucity  [s2]ductopenia[e2] .
	(4, 16)	clindamycin	marked cholestasis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5593	One patient who received [s1]clindamycin[e1] had liver biopsy findings of [s2]marked cholestasis[e2]  portal inflammation, bile duct injury and bile duct paucity (ductopenia).
	(4, 22)	clindamycin	portal inflammation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5594	One patient who received [s1]clindamycin[e1] had liver biopsy findings of marked cholestasis, [s2]portal inflammation[e2]  bile duct injury and bile duct paucity (ductopenia).
	(6, 14)	cholestasis	trimethoprim-sulfamethoxazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5595	The second patient, who developed [s1]cholestasis[e1] after receiving [s2]trimethoprim-sulfamethoxazole[e2]  had marked duct paucity in the liver biopsy.
	(12, 28)	trimethoprim-sulfamethoxazole	duct paucity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5596	The second patient, who developed cholestasis after receiving [s1]trimethoprim-sulfamethoxazole[e1]  had marked [s2]duct paucity[e2] in the liver biopsy.
	(11, 19)	ductopenia	clindamycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5597	This is the first description, to our knowledge, of [s1]ductopenia[e1] apparently caused by [s2]clindamycin[e2] 
	(6, 21)	ampicillin	cholestasis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5598	Three years later, treatment with [s1]ampicillin[e1] caused another episode of cholestatic hepatitis with [s2]cholestasis[e2] and duct paucity on rebiopsy.
	(6, 15)	ampicillin	cholestatic hepatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5599	Three years later, treatment with [s1]ampicillin[e1] caused another episode of [s2]cholestatic hepatitis[e2] with cholestasis and duct paucity on rebiopsy.
	(6, 26)	ampicillin	duct paucity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5600	Three years later, treatment with [s1]ampicillin[e1] caused another episode of cholestatic hepatitis with cholestasis and [s2]duct paucity[e2] on rebiopsy.
	(9, 22)	vision loss	ethambutol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5601	METHODS: A patient who developed dramatic, permanent [s1]vision loss[e1] after a 9-month course of treatment with [s2]ethambutol[e2] and isoniazid for pulmonary tuberculosis is presented.
	(9, 28)	vision loss	isoniazid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5602	METHODS: A patient who developed dramatic, permanent [s1]vision loss[e1] after a 9-month course of treatment with ethambutol and [s2]isoniazid[e2] for pulmonary tuberculosis is presented.
	(2, 24)	Ethambutol	development of visually related side effects	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5603	RESULTS: [s1]Ethambutol[e1]  and to a lesser extent isoniazid, are both implicated in the [s2]development of visually related side effects[e2] 
	(13, 24)	isoniazid	development of visually related side effects	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5604	RESULTS: Ethambutol, and to a lesser extent [s1]isoniazid[e1]  are both implicated in the [s2]development of visually related side effects[e2] 
	(4, 10)	ocular toxicity	ethambutol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5605	There is documentation of [s1]ocular toxicity[e1] with [s2]ethambutol[e2] when administered at dosages generally pronounced as being safe.
	(0, 9)	Toxic optic neuropathy	ethambutol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5606	 [s1]Toxic optic neuropathy[e1] associated with [s2]ethambutol[e2]  implications for current therapy.
	(4, 45)	zidovudine	fetal damage	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5607	Currently the use of [s1]zidovudine[e1] is one of the few specific measures available, and as a potentially teratogenic and fetotoxic agent, any decision for its use requires evaluation of the potential for [s2]fetal damage[e2] 
	(4, 27)	zidovudine	fetotoxic	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5608	Currently the use of [s1]zidovudine[e1] is one of the few specific measures available, and as a potentially teratogenic and [s2]fetotoxic[e2] agent, any decision for its use requires evaluation of the potential for fetal damage.
	(4, 23)	zidovudine	teratogenic	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5609	Currently the use of [s1]zidovudine[e1] is one of the few specific measures available, and as a potentially [s2]teratogenic[e2] and fetotoxic agent, any decision for its use requires evaluation of the potential for fetal damage.
	(15, 48)	zidovudine	fetal abnormality	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5610	In a series of 104 cases of intentional or inadvertent use of [s1]zidovudine[e1] at differing gestations in pregnancy, there were eight spontaneous first trimester abortions, eight therapeutic terminations, and eight cases of [s2]fetal abnormality[e2] occurring among a total of 88 cases where the pregnancy progressed.
	(15, 33)	zidovudine	first trimester abortions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5611	In a series of 104 cases of intentional or inadvertent use of [s1]zidovudine[e1] at differing gestations in pregnancy, there were eight spontaneous [s2]first trimester abortions[e2]  eight therapeutic terminations, and eight cases of fetal abnormality occurring among a total of 88 cases where the pregnancy progressed.
	(0, 19)	Zidovudine	birth defects	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5612	 [s1]Zidovudine[e1] use in pregnancy: a report on 104 cases and the occurrence of [s2]birth defects[e2] 
	(0, 6)	Celiprolol	pneumonitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5613	 [s1]Celiprolol[e1]  [s2]pneumonitis[e2] 
	(10, 23)	celiprolol	pneumonitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5614	Inadvertent subsequent rechallenge with [s1]celiprolol[e1] led to recurrence of the [s2]pneumonitis[e2]  10 weeks after drug readministration.
	(7, 27)	hypersensitivity pneumonitis	celiprolol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5615	We report on a patient who developed [s1]hypersensitivity pneumonitis[e1] during treatment with the beta-blocker, [s2]celiprolol[e2] 
	(0, 9)	Ibopamine	leukopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5616	 [s1]Ibopamine[e1] induced reversible [s2]leukopenia[e2] during treatment for congestive heart failure.
	(0, 23)	Reversible leukopenia	ibopamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5617	 [s1]Reversible leukopenia[e1] was documented in an 81-year-old woman treated with adjunctive [s2]ibopamine[e2] 100 mg t.i.d. for chronic congestive heart failure.
	(0, 21)	Diphenylhydantoin	acute intermittent porphyria	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5618	 [s1]Diphenylhydantoin[e1] apparently adversely affected both the clinical and biochemical parameters of the [s2]acute intermittent porphyria[e2] 
	(5, 14)	porphyria	diphenylhydantoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5619	Significant clinical improvement of the [s1]porphyria[e1] followed withdrawal of the [s2]diphenylhydantoin[e2] 
	(17, 27)	schizophrenia	bromocriptine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5620	A 53-year-old male, without any prior history of psychosis, developed [s1]schizophrenia[e1] 4 days after starting low-dose [s2]bromocriptine[e2] therapy for a macroprolactinoma.
	(0, 7)	Bromocriptine	schizophrenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5621	 [s1]Bromocriptine[e1] induced [s2]schizophrenia[e2] 
	(0, 26)	Concurrent acute megaloblastic anaemia	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5622	 [s1]Concurrent acute megaloblastic anaemia[e1] and pneumonitis: a severe side-effect of low-dose [s2]methotrexate[e2] therapy during rheumatoid arthritis.
	(9, 25)	pneumonitis	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5623	Concurrent acute megaloblastic anaemia and [s1]pneumonitis[e1]  a severe side-effect of low-dose [s2]methotrexate[e2] therapy during rheumatoid arthritis.
	(26, 34)	methotrexate	acute megaloblastic anaemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5624	In a patient suffering from rheumatoid arthritis, we report the first simultaneous occurrence of two side effects of low-dose [s1]methotrexate[e1]  an [s2]acute megaloblastic anaemia[e2] and a pneumonitis.
	(26, 43)	methotrexate	pneumonitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5625	In a patient suffering from rheumatoid arthritis, we report the first simultaneous occurrence of two side effects of low-dose [s1]methotrexate[e1]  an acute megaloblastic anaemia and a [s2]pneumonitis[e2] 
	(25, 54)	Levemepromazine	respiratory distress syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5626	An 11-year-old boy who was treated with a relatively high dose of methotrimeprazine meleate  [s1]Levemepromazine[e1]  a phenothiazine antipsychotic drug, was admitted to the pediatric intensive care unit suffering from [s2]respiratory distress syndrome[e2] 
	(16, 56)	methotrimeprazine meleate	respiratory distress syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5627	An 11-year-old boy who was treated with a relatively high dose of [s1]methotrimeprazine meleate[e1] (Levemepromazine) a phenothiazine antipsychotic drug, was admitted to the pediatric intensive care unit suffering from [s2]respiratory distress syndrome[e2] 
	(3, 12)	phenothiazine	respiratory distress syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5628	The association of [s1]phenothiazine[e1] overdose and [s2]respiratory distress syndrome[e2] merits consideration.
	(4, 22)	apomorphine	dyskinesias	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5629	In two patients, [s1]apomorphine[e1] remained effective in the morning, but increased the intensity of the [s2]dyskinesias[e2] in the afternoon.
	(10, 18)	levo-dopa	diphasic dyskinesias	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5630	We report on three observations of parkinsonian patients with [s1]levo-dopa[e1] induced [s2]diphasic dyskinesias[e2]  who received subcutaneous apomorphine to reduce the duration of abnormal movements.
	(0, 19)	Fulminant hepatitis	didanosine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5631	 [s1]Fulminant hepatitis[e1] with severe lactate acidosis in HIV-infected patients on [s2]didanosine[e2] therapy.
	(6, 19)	severe lactate acidosis	didanosine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5632	Fulminant hepatitis with [s1]severe lactate acidosis[e1] in HIV-infected patients on [s2]didanosine[e2] therapy.
	(6, 14)	ddI	fulminant hepatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5633	This prompted us to suspect that [s1]ddI[e1] might be responsible for [s2]fulminant hepatitis[e2] in all three AIDS patients.
	(5, 28)	fulminant hepatic failure	ddI	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5634	We report two cases of [s1]fulminant hepatic failure[e1] in HIV-1-infected patients treated with didanosine  [s2]ddI[e2] .
	(5, 24)	fulminant hepatic failure	didanosine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5635	We report two cases of [s1]fulminant hepatic failure[e1] in HIV-1-infected patients treated with [s2]didanosine[e2] (ddI).
	(0, 11)	Generalized argyria	AgNO3	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5636	 [s1]Generalized argyria[e1] after habitual use of [s2]AgNO3[e2] 
	(3, 10)	fluoxetine	seizures	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5637	A case of [s1]fluoxetine[e1] induced [s2]seizures[e2]  in a person with Down syndrome, is described.
	(0, 5)	Seizures	fluoxetine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5638	 [s1]Seizures[e1] associated with [s2]fluoxetine[e2] therapy are uncommon.
	(0, 5)	Seizures	fluoxetine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5639	 [s1]Seizures[e1] associated with [s2]fluoxetine[e2] therapy.
	(1, 8)	fluoxetine	headache	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5640	Although [s1]fluoxetine[e1] induced [s2]headache[e2] occurred in one patient, the other five reported no side effects at the doses used.
	(5, 42)	carbamazepine	psoriasiform eruptions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5641	Sodium valproate and [s1]carbamazepine[e1]  antiepileptic drugs that are associated with a relatively low rate of adverse cutaneous reactions, should be added to the growing list of drugs that produce [s2]psoriasiform eruptions[e2] 
	(0, 43)	Sodium valproate	psoriasiform eruptions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5642	 [s1]Sodium valproate[e1] and carbamazepine, antiepileptic drugs that are associated with a relatively low rate of adverse cutaneous reactions, should be added to the growing list of drugs that produce [s2]psoriasiform eruptions[e2] 
	(9, 30)	psoriasiform eruption	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5643	We present findings from three patients who experienced a [s1]psoriasiform eruption[e1] apparently due to the antiepileptic agents sodium valproate and [s2]carbamazepine[e2] 
	(9, 25)	psoriasiform eruption	sodium valproate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5644	We present findings from three patients who experienced a [s1]psoriasiform eruption[e1] apparently due to the antiepileptic agents [s2]sodium valproate[e2] and carbamazepine.
	(0, 17)	Severe diffuse interstitial pneumonitis	BCNU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5645	 [s1]Severe diffuse interstitial pneumonitis[e1] induced by carmustine  [s2]BCNU[e2] .
	(0, 14)	Severe diffuse interstitial pneumonitis	carmustine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5646	 [s1]Severe diffuse interstitial pneumonitis[e1] induced by [s2]carmustine[e2] (BCNU).
	(3, 25)	fatal case of acute interstitial pneumonitis	BCNU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5647	We report a [s1]fatal case of acute interstitial pneumonitis[e1] in a patient treated with carmustine  [s2]BCNU[e2]  for a brain tumor.
	(3, 22)	fatal case of acute interstitial pneumonitis	carmustine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5648	We report a [s1]fatal case of acute interstitial pneumonitis[e1] in a patient treated with [s2]carmustine[e2] (BCNU) for a brain tumor.
	(23, 28)	shocks	procainamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5649	A 78-year-old man with a transvenous cardioverter defibrillator system developed frequent [s1]shocks[e1] during oral [s2]procainamide[e2] therapy.
	(0, 10)	Electrical proarrhythmia	procainamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5650	 [s1]Electrical proarrhythmia[e1] with [s2]procainamide[e2]  a new ICD-drug interaction.
	(26, 43)	electrophysiologic effect	procainamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5651	The failure of therapy with disopyramide and mexiletine to reproduce this observation suggests either a previously unreported [s1]electrophysiologic effect[e1] of, or idiosyncratic response to, [s2]procainamide[e2] 
	(22, 32)	valproic acid	altered mental status	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5652	Based on our experience and on previously published data, serum ammonia levels appear to be indicated in all ED patients on [s1]valproic acid[e1] therapy who present with [s2]altered mental status[e2] 
	(0, 14)	Hyperammonemia	valproic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5653	 [s1]Hyperammonemia[e1] has been described as a complication of [s2]valproic acid[e2] therapy but may often be overlooked as a cause of lethargy in the postictal patient who presents to the emergency department.
	(12, 28)	valproic acid	lethargy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5654	Hyperammonemia has been described as a complication of [s1]valproic acid[e1] therapy but may often be overlooked as a cause of [s2]lethargy[e2] in the postictal patient who presents to the emergency department.
	(0, 8)	Hyperammonemia	valproic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5655	 [s1]Hyperammonemia[e1] secondary to [s2]valproic acid[e2] as a cause of lethargy in a postictal patient.
	(6, 16)	valproic acid	lethargy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5656	Hyperammonemia secondary to [s1]valproic acid[e1] as a cause of [s2]lethargy[e2] in a postictal patient.
	(15, 30)	hyperammonemia	valproic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5657	We present the case of a postictal patient with lethargy, [s1]hyperammonemia[e1]  otherwise normal liver function tests, and a therapeutic [s2]valproic acid[e2] level.
	(11, 30)	lethargy	valproic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5658	We present the case of a postictal patient with [s1]lethargy[e1]  hyperammonemia, otherwise normal liver function tests, and a therapeutic [s2]valproic acid[e2] level.
	(0, 8)	Central nervous system toxicity	meperidine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5659	 [s1]Central nervous system toxicity[e1] associated with [s2]meperidine[e2] use in hepatic disease.
	(10, 21)	meperidine	accumulation of the parent drug	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5660	In patients with cirrhosis, the metabolism of [s1]meperidine[e1] is decreased, leading to [s2]accumulation of the parent drug[e2] and possible CNS depressive effects similar to hepatic encephalopathy.
	(10, 28)	meperidine	CNS depressive effects	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5661	In patients with cirrhosis, the metabolism of [s1]meperidine[e1] is decreased, leading to accumulation of the parent drug and possible [s2]CNS depressive effects[e2] similar to hepatic encephalopathy.
	(0, 25)	Meperidine	accumulation of the active metabolite normeperidine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5662	 [s1]Meperidine[e1] associated central nervous system (CNS) excitatory toxicities are believed to be caused by [s2]accumulation of the active metabolite normeperidine[e2] 
	(0, 7)	Meperidine	central nervous system (CNS) excitatory toxicities	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5663	 [s1]Meperidine[e1] associated [s2]central nervous system (CNS) excitatory toxicities[e2] are believed to be caused by accumulation of the active metabolite normeperidine.
	(11, 21)	morphine	hypertension	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5664	She received an accidental 450-mg bolus injection of [s1]morphine[e1] intrathecally and developed [s2]hypertension[e2]  status epilepticus, intracerebral hemorrhage, and respiratory failure.
	(11, 30)	morphine	intracerebral hemorrhage	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5665	She received an accidental 450-mg bolus injection of [s1]morphine[e1] intrathecally and developed hypertension, status epilepticus, [s2]intracerebral hemorrhage[e2]  and respiratory failure.
	(11, 40)	morphine	respiratory failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5666	She received an accidental 450-mg bolus injection of [s1]morphine[e1] intrathecally and developed hypertension, status epilepticus, intracerebral hemorrhage, and [s2]respiratory failure[e2] 
	(11, 24)	morphine	status epilepticus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5667	She received an accidental 450-mg bolus injection of [s1]morphine[e1] intrathecally and developed hypertension, [s2]status epilepticus[e2]  intracerebral hemorrhage, and respiratory failure.
	(0, 23)	Mitomycin C	hemolytic-uremic syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5668	 [s1]Mitomycin C[e1] (MMC) is an alkylating agent that has been recently associated with the [s2]hemolytic-uremic syndrome[e2] (HUS).
	(4, 21)	MMC	hemolytic-uremic syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5669	Mitomycin C  [s1]MMC[e1]  is an alkylating agent that has been recently associated with the [s2]hemolytic-uremic syndrome[e2] (HUS).
	(0, 31)	Mitomycin C	HUS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5670	 [s1]Mitomycin C[e1] (MMC) is an alkylating agent that has been recently associated with the hemolytic-uremic syndrome  [s2]HUS[e2] .
	(4, 29)	MMC	HUS	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5671	Mitomycin C  [s1]MMC[e1]  is an alkylating agent that has been recently associated with the hemolytic-uremic syndrome  [s2]HUS[e2] .
	(10, 22)	hemolytic-uremic syndrome	mitomycin C	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5672	Pulmonary hemorrhage as a clinical manifestation of [s1]hemolytic-uremic syndrome[e1] associated with [s2]mitomycin C[e2] therapy.
	(0, 22)	Pulmonary hemorrhage	mitomycin C	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5673	 [s1]Pulmonary hemorrhage[e1] as a clinical manifestation of hemolytic-uremic syndrome associated with [s2]mitomycin C[e2] therapy.
	(11, 26)	HUS	MMC	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5674	Pulmonary hemorrhage is an uncommon feature in the [s1]HUS[e1]  and seems to appear especially in the HUS associated with [s2]MMC[e2] therapy.
	(11, 26)	HUS	MMC	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5675	Pulmonary hemorrhage is an uncommon feature in the [s1]HUS[e1]  and seems to appear especially in the HUS associated with [s2]MMC[e2] therapy.
	(0, 27)	Pulmonary hemorrhage	MMC	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5676	 [s1]Pulmonary hemorrhage[e1] is an uncommon feature in the HUS, and seems to appear especially in the HUS associated with [s2]MMC[e2] therapy.
	(6, 11)	HUS	MMC	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5677	We describe two women who developed [s1]HUS[e1] after [s2]MMC[e2] therapy and presented massive pulmonary bleeding.
	(9, 16)	MMC	massive pulmonary bleeding	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5678	We describe two women who developed HUS after [s1]MMC[e1] therapy and presented [s2]massive pulmonary bleeding[e2] 
	(0, 6)	Clonidine	bradycardia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5679	 [s1]Clonidine[e1] induced [s2]bradycardia[e2] in patients with spinal cord injury.
	(4, 20)	clonidine	bradycardia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5680	Possible mechanisms by which [s1]clonidine[e1] decreases spasticity are described, probable mechanisms of induced [s2]bradycardia[e2] are reviewed, and specific treatment recommendations for the use of clonidine in spinal cord injured patients are presented.
	(4, 20)	clonidine	bradycardia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5681	Possible mechanisms by which [s1]clonidine[e1] decreases spasticity are described, probable mechanisms of induced [s2]bradycardia[e2] are reviewed, and specific treatment recommendations for the use of clonidine in spinal cord injured patients are presented.
	(26, 32)	clonidine	bradycardia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5682	Though hypotension, dry mouth, and constipation are well-documented possible adverse effects, the possibility of [s1]clonidine[e1] induced [s2]bradycardia[e2] is less well recognized and is rare.
	(11, 28)	constipation	clonidine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5683	Though hypotension, dry mouth, and [s1]constipation[e1] are well-documented possible adverse effects, the possibility of [s2]clonidine[e2] induced bradycardia is less well recognized and is rare.
	(7, 27)	dry mouth	clonidine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5684	Though hypotension, [s1]dry mouth[e1]  and constipation are well-documented possible adverse effects, the possibility of [s2]clonidine[e2] induced bradycardia is less well recognized and is rare.
	(1, 27)	hypotension	clonidine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5685	Though [s1]hypotension[e1]  dry mouth, and constipation are well-documented possible adverse effects, the possibility of [s2]clonidine[e2] induced bradycardia is less well recognized and is rare.
	(4, 17)	cotrimoxazole	elevation of serum creatinine and blood urea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5686	A high dose of [s1]cotrimoxazole[e1] induced hyperkalaemia with the [s2]elevation of serum creatinine and blood urea[e2]  and increased urinary N-acetyl glucosaminase after several days of the drug administration in these patients; one patient became unconscious.
	(4, 12)	cotrimoxazole	hyperkalaemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5687	A high dose of [s1]cotrimoxazole[e1] induced [s2]hyperkalaemia[e2] with the elevation of serum creatinine and blood urea, and increased urinary N-acetyl glucosaminase after several days of the drug administration in these patients; one patient became unconscious.
	(4, 30)	cotrimoxazole	increased urinary N-acetyl glucosaminase	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5688	A high dose of [s1]cotrimoxazole[e1] induced hyperkalaemia with the elevation of serum creatinine and blood urea, and [s2]increased urinary N-acetyl glucosaminase[e2] after several days of the drug administration in these patients; one patient became unconscious.
	(4, 55)	cotrimoxazole	one patient became unconscious	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5689	A high dose of [s1]cotrimoxazole[e1] induced hyperkalaemia with the elevation of serum creatinine and blood urea, and increased urinary N-acetyl glucosaminase after several days of the drug administration in these patients; [s2]one patient became unconscious[e2] 
	(0, 25)	Hyperkalaemia	co-trimoxazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5690	 [s1]Hyperkalaemia[e1] with renal tubular dysfunction by oral therapy of sulfamethoxazole-trimethoprim  [s2]co-trimoxazole[e2]  is described in 2 elderly Japanese patients with lymphoid malignancy, who developed Pneumocystis carinii pneumonia and improved.
	(0, 13)	Hyperkalaemia	sulfamethoxazole-trimethoprim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5691	 [s1]Hyperkalaemia[e1] with renal tubular dysfunction by oral therapy of [s2]sulfamethoxazole-trimethoprim[e2] (co-trimoxazole) is described in 2 elderly Japanese patients with lymphoid malignancy, who developed Pneumocystis carinii pneumonia and improved.
	(4, 25)	renal tubular dysfunction	co-trimoxazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5692	Hyperkalaemia with [s1]renal tubular dysfunction[e1] by oral therapy of sulfamethoxazole-trimethoprim  [s2]co-trimoxazole[e2]  is described in 2 elderly Japanese patients with lymphoid malignancy, who developed Pneumocystis carinii pneumonia and improved.
	(4, 13)	renal tubular dysfunction	sulfamethoxazole-trimethoprim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5693	Hyperkalaemia with [s1]renal tubular dysfunction[e1] by oral therapy of [s2]sulfamethoxazole-trimethoprim[e2] (co-trimoxazole) is described in 2 elderly Japanese patients with lymphoid malignancy, who developed Pneumocystis carinii pneumonia and improved.
	(0, 10)	Hyperkalaemia	sulfamethoxazole-trimethoprim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5694	 [s1]Hyperkalaemia[e1] with renal tubular dysfunction by [s2]sulfamethoxazole-trimethoprim[e2] for Pneumocystis carinii pneumonia in patients with lymphoid malignancy.
	(4, 10)	renal tubular dysfunction	sulfamethoxazole-trimethoprim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5695	Hyperkalaemia with [s1]renal tubular dysfunction[e1] by [s2]sulfamethoxazole-trimethoprim[e2] for Pneumocystis carinii pneumonia in patients with lymphoid malignancy.
	(28, 42)	subacute combined degeneration of the spinal cord	nitrous oxide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5696	Five cases (four from the literature and one new case) are presented in which patients unsuspected of having vitamin B12 deficiency developed [s1]subacute combined degeneration of the spinal cord[e1] following [s2]nitrous oxide[e2] anesthesia.
	(0, 10)	Neurologic degeneration	nitrous oxide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5697	 [s1]Neurologic degeneration[e1] associated with [s2]nitrous oxide[e2] anesthesia in patients with vitamin B12 deficiency.
	(11, 18)	neurologic deterioration	nitrous oxide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5698	Patients with vitamin B12 deficiency are exceedingly sensitive to [s1]neurologic deterioration[e1] following [s2]nitrous oxide[e2] anesthesia.
	(2, 24)	Fluoxetine	sexual dysfunction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5699	BACKGROUND: [s1]Fluoxetine[e1]  a highly specific serotonin reuptake inhibitor, has been reported to cause [s2]sexual dysfunction[e2] in a minority of patients.
	(0, 6)	Captopril	bone marrow suppression	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5700	 [s1]Captopril[e1] induced [s2]bone marrow suppression[e2] in two cardiac patients with trisomy 21.
	(0, 30)	Neutropenia	captopril	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5701	 [s1]Neutropenia[e1] is an infrequent complication following administration of the angiotensin-converting enzyme (ACE) inhibitor, [s2]captopril[e2] 
	(5, 12)	neutropenia	captopril	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5702	We report two cases of [s1]neutropenia[e1] following [s2]captopril[e2] use in cardiac patients with trisomy 21.
	(1, 7)	magnesium sulfate	lactogenesis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5703	Can [s1]magnesium sulfate[e1] therapy impact [s2]lactogenesis[e2] 
	(13, 18)	magnesium sulfate	impeded lactogenesis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5704	No explanation for this delay was found, other than the possibility that [s1]magnesium sulfate[e1] treatment [s2]impeded lactogenesis[e2] 
	(12, 42)	goserelin acetate	flare-up	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5705	Four days after the initial injection of 3.6 mg of [s1]goserelin acetate[e1]  severe dyspnea developed due to worsening pleuritis carcinomatosa, which was considered as a [s2]flare-up[e2] 
	(12, 19)	goserelin acetate	severe dyspnea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5706	Four days after the initial injection of 3.6 mg of [s1]goserelin acetate[e1]  [s2]severe dyspnea[e2] developed due to worsening pleuritis carcinomatosa, which was considered as a flare-up.
	(12, 27)	goserelin acetate	worsening pleuritis carcinomatosa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5707	Four days after the initial injection of 3.6 mg of [s1]goserelin acetate[e1]  severe dyspnea developed due to [s2]worsening pleuritis carcinomatosa[e2]  which was considered as a flare-up.
	(0, 27)	Imidazoline intoxication	Imidazoline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5708	 [s1]Imidazoline intoxication[e1] due to overdose or accidental ingestion but also after normal therapeutic usage is frequent in children [s2]Imidazoline[e2] intoxication due to overdose or accidental ingestion but also after normal therapeutic usage is frequent in children.
	(0, 11)	Imidazoline intoxication	Imidazoline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5709	 [s1]Imidazoline intoxication[e1] in children [s2]Imidazoline[e2] intoxication in children.
	(7, 21)	L-asparaginase	aphasia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5710	Cerebrovascular complications of [s1]L-asparaginase[e1] therapy in children with leukemia: [s2]aphasia[e2] and other neuropsychological deficits.
	(0, 9)	Cerebrovascular complications	L-asparaginase	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5711	 [s1]Cerebrovascular complications[e1] of [s2]L-asparaginase[e2] therapy in children with leukemia: aphasia and other neuropsychological deficits.
	(7, 26)	L-asparaginase	neuropsychological deficits	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5712	Cerebrovascular complications of [s1]L-asparaginase[e1] therapy in children with leukemia: aphasia and other [s2]neuropsychological deficits[e2] 
	(15, 27)	L-asparaginase	cerebral thrombosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5713	Children with acute lymphoblastic leukemia (ALL), treated with [s1]L-asparaginase[e1] are at risk for [s2]cerebral thrombosis[e2] or hemorrhage because of coagulation protein deficiencies.
	(15, 39)	L-asparaginase	coagulation protein deficiencies	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5714	Children with acute lymphoblastic leukemia (ALL), treated with [s1]L-asparaginase[e1] are at risk for cerebral thrombosis or hemorrhage because of [s2]coagulation protein deficiencies[e2] 
	(15, 33)	L-asparaginase	hemorrhage	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5715	Children with acute lymphoblastic leukemia (ALL), treated with [s1]L-asparaginase[e1] are at risk for cerebral thrombosis or [s2]hemorrhage[e2] because of coagulation protein deficiencies.
	(0, 15)	Myoclonus	L-dopa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5716	 [s1]Myoclonus[e1] and seizures disappeared after discontinuation of [s2]L-dopa[e2] and the introduction of valproate sodium (VPA).
	(5, 15)	seizures	L-dopa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5717	Myoclonus and [s1]seizures[e1] disappeared after discontinuation of [s2]L-dopa[e2] and the introduction of valproate sodium (VPA).
	(0, 17)	Myoclonus	levodopa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5718	 [s1]Myoclonus[e1] and seizures in a patient with parkinsonism: induction by [s2]levodopa[e2] and its confirmation on SEPs.
	(5, 17)	seizures	levodopa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5719	Myoclonus and [s1]seizures[e1] in a patient with parkinsonism: induction by [s2]levodopa[e2] and its confirmation on SEPs.
	(9, 17)	L-dopa	generalized seizures	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5720	Myoclonus was induced and enhanced by [s1]L-dopa[e1]  developing into [s2]generalized seizures[e2] 
	(0, 11)	Myoclonus	L-dopa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5721	 [s1]Myoclonus[e1] was induced and enhanced by [s2]L-dopa[e2]  developing into generalized seizures.
	(5, 12)	L-dopa	myoclonus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5722	We described the occurrence of [s1]L-dopa[e1] induced [s2]myoclonus[e2] and seizures in a case of parkinsonism with its SEPs findings.
	(5, 17)	L-dopa	seizures	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5723	We described the occurrence of [s1]L-dopa[e1] induced myoclonus and [s2]seizures[e2] in a case of parkinsonism with its SEPs findings.
	(5, 23)	acyclovir	excessive maternal and physician anxiety	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5724	Unintended exposure to [s1]acyclovir[e1] early in pregnancy, which is not uncommon, may cause [s2]excessive maternal and physician anxiety[e2] 
	(4, 13)	exophthalmos	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5725	A severe form of [s1]exophthalmos[e1] resulting from [s2]lithium[e2] therapy has not been described in the literature.
	(0, 17)	Lithium	polyuria	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5726	 [s1]Lithium[e1] therapy was discontinued because of poor compliance to the medication and intolerable [s2]polyuria[e2] 
	(2, 14)	thyrotoxic ophthalmopathy	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5727	Regression of [s1]thyrotoxic ophthalmopathy[e1] following [s2]lithium[e2] withdrawal.
	(14, 24)	severe exophthalmos	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5728	The case of a bipolar patient who developed thyrotoxicosis with [s1]severe exophthalmos[e1] while on [s2]lithium[e2] therapy is described.
	(8, 24)	thyrotoxicosis	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5729	The case of a bipolar patient who developed [s1]thyrotoxicosis[e1] with severe exophthalmos while on [s2]lithium[e2] therapy is described.
	(1, 17)	exophthalmos	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5730	The [s1]exophthalmos[e1] improved dramatically within 72 hours of the withdrawal of [s2]lithium[e2] 
	(1, 9)	abdominal pain	clofazimine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5731	Severe [s1]abdominal pain[e1] in low dosage [s2]clofazimine[e2] 
	(17, 31)	clofazimine	abdominal pain	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5732	We describe a 41 yr old leprosy patient treated for 10 yrs with [s1]clofazimine[e1] who underwent laparotomy for severe [s2]abdominal pain[e2] 
	(0, 13)	Amphotericin B	cardiac arrest	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5733	 [s1]Amphotericin B[e1] overdose in pediatric patients with associated [s2]cardiac arrest[e2] 
	(2, 12)	Amphotericin B	fatal	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5734	CONCLUSIONS: [s1]Amphotericin B[e1] overdose can be [s2]fatal[e2] in children and infants.
	(12, 23)	cardiac arrhythmias	amphotericin B	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5735	Hydrocortisone may decrease the incidence of mortality associated with [s1]cardiac arrhythmias[e1] in children receiving [s2]amphotericin B[e2] overdoses.
	(9, 23)	mortality	amphotericin B	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5736	Hydrocortisone may decrease the incidence of [s1]mortality[e1] associated with cardiac arrhythmias in children receiving [s2]amphotericin B[e2] overdoses.
	(4, 30)	Cardiac complications	amphotericin B	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5737	INTERVENTIONS AND RESULTS: [s1]Cardiac complications[e1] were observed in five pediatric patients who received between 4.6 and 40.8 mg/kg/d of [s2]amphotericin B[e2] 
	(9, 19)	amphotericin B	cardiac complications	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5738	OBJECTIVE: To report the first five cases of [s1]amphotericin B[e1] overdose with secondary [s2]cardiac complications[e2] in a pediatric population.
	(0, 21)	Hypertension	cyclosporine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5739	 [s1]Hypertension[e1] develops in most patients after transplantation when immunosuppression is based on [s2]cyclosporine[e2] and prednisone.
	(0, 27)	Hypertension	prednisone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5740	 [s1]Hypertension[e1] develops in most patients after transplantation when immunosuppression is based on cyclosporine and [s2]prednisone[e2] 
	(0, 17)	Sudden death	sweet spirits of nitre	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5741	 [s1]Sudden death[e1] in an infant from methemoglobinemia after administration of  [s2]sweet spirits of nitre[e2] .
	(10, 33)	4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol	acute methemoglobinemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5742	"The administration of ""sweet spirits of nitre""  [s1]4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol[e1]  was followed by [s2]acute methemoglobinemia[e2] and severe anoxic metabolic acidosis in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin died from the consequences of hypoxemia."
	(3, 33)	sweet spirits of nitre	acute methemoglobinemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5743	The administration of  [s1]sweet spirits of nitre[e1]  (4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol) was followed by [s2]acute methemoglobinemia[e2] and severe anoxic metabolic acidosis in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin died from the consequences of hypoxemia.
	(10, 69)	4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol	died	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5744	"The administration of ""sweet spirits of nitre""  [s1]4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol[e1]  was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin [s2]died[e2] from the consequences of hypoxemia."
	(3, 69)	sweet spirits of nitre	died	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5745	The administration of  [s1]sweet spirits of nitre[e1]  (4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin [s2]died[e2] from the consequences of hypoxemia.
	(10, 74)	4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol	hypoxemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5746	"The administration of ""sweet spirits of nitre""  [s1]4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol[e1]  was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin died from the consequences of [s2]hypoxemia[e2] "
	(3, 74)	sweet spirits of nitre	hypoxemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5747	The administration of  [s1]sweet spirits of nitre[e1]  (4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin died from the consequences of [s2]hypoxemia[e2] 
	(10, 41)	4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol	severe anoxic metabolic acidosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5748	"The administration of ""sweet spirits of nitre""  [s1]4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol[e1]  was followed by acute methemoglobinemia and [s2]severe anoxic metabolic acidosis[e2] in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin died from the consequences of hypoxemia."
	(3, 41)	sweet spirits of nitre	severe anoxic metabolic acidosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5749	The administration of  [s1]sweet spirits of nitre[e1]  (4% ethyl nitrite CH3CH2ONO in 70% ethyl alcohol) was followed by acute methemoglobinemia and [s2]severe anoxic metabolic acidosis[e2] in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin died from the consequences of hypoxemia.
	(0, 17)	Hepatotoxic effects	carnitine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5750	 [s1]Hepatotoxic effects[e1] in a child receiving valproate and [s2]carnitine[e2] 
	(0, 13)	Hepatotoxic effects	valproate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5751	 [s1]Hepatotoxic effects[e1] in a child receiving [s2]valproate[e2] and carnitine.
	(13, 25)	fatal hepatotoxic effects	valproic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5752	L-Carnitine supplementation has been recommended to prevent the [s1]fatal hepatotoxic effects[e1] associated with [s2]valproic acid[e2] 
	(6, 9)	fatal	valproate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5753	We report on a child with [s1]fatal[e1]  [s2]valproate[e2] related hepatotoxic effects despite this supplementation.
	(7, 13)	valproate	hepatotoxic effects	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5754	We report on a child with fatal [s1]valproate[e1] related [s2]hepatotoxic effects[e2] despite this supplementation.
	(16, 31)	IL-2	cognitive dysfunction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5755	A case is reported of a 40 year old woman treated with intraventricular [s1]IL-2[e1] for leptomeningeal disease who developed progressive [s2]cognitive dysfunction[e2] 
	(1, 13)	neurotoxicity	interleukin-2	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5756	Delayed [s1]neurotoxicity[e1] of intraventricular [s2]interleukin-2[e2]  a case report.
	(4, 17)	brain injury	IL-2	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5757	The potential for progressive [s1]brain injury[e1] and subsequent disability related to intraventricular [s2]IL-2[e2] therapy is discussed.
	(8, 17)	disability	IL-2	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5758	The potential for progressive brain injury and subsequent [s1]disability[e1] related to intraventricular [s2]IL-2[e2] therapy is discussed.
	(7, 11)	lithium	thyroid dysfunctions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5759	Albeit rare among Western patients, such [s1]lithium[e1] associated [s2]thyroid dysfunctions[e2] appeared to be more likely to occur in Hong Kong Chinese.
	(25, 34)	thyrotoxicosis	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5760	Four Chinese female patients who suffered from manic-depressive disorder and underlying autoimmune thyroiditis developed transient episodes of [s1]thyrotoxicosis[e1] during maintenance [s2]lithium[e2] therapy.
	(0, 4)	Lithium	transient thyrotoxicosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5761	 [s1]Lithium[e1] associated [s2]transient thyrotoxicosis[e2] in 4 Chinese women with autoimmune thyroiditis.
	(20, 32)	toxic and immunomodulatory roles	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5762	They seemed to involve multiple aetiological factors, such as autoimmune thyroid disease, the [s1]toxic and immunomodulatory roles[e1] of [s2]lithium[e2] and perhaps genetic and dietary factors.
	(1, 21)	retinoic acid	fatal complication	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5763	"Although [s1]retinoic acid[e1] is well tolerated by the majority of patients with this disease, a potentially [s2]fatal complication[e2] of this kind of treatment has been reported: ""the retinoic acid syndrome""."
	(1, 35)	retinoic acid	retinoic acid syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5764	"Although [s1]retinoic acid[e1] is well tolerated by the majority of patients with this disease, a potentially fatal complication of this kind of treatment has been reported: ""the [s2]retinoic acid syndrome[e2] ."
	(6, 15)	foscarnet	electrolyte disorders	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5765	CONCLUSIONS: It is probable that [s1]foscarnet[e1] contributed to the [s2]electrolyte disorders[e2] and symptomatology in this patient.
	(2, 10)	Electrolyte disorders	foscarnet	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5766	DISCUSSION: [s1]Electrolyte disorders[e1] associated with [s2]foscarnet[e2] are reviewed.
	(0, 16)	Foscarnet	electrolyte disorders	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5767	 [s1]Foscarnet[e1] induced severe hypomagnesemia and other [s2]electrolyte disorders[e2] 
	(0, 7)	Foscarnet	severe hypomagnesemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5768	 [s1]Foscarnet[e1] induced [s2]severe hypomagnesemia[e2] and other electrolyte disorders.
	(8, 24)	foscarnet	electrolyte disorders	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5769	OBJECTIVE: To report a case of possible [s1]foscarnet[e1] induced severe hypomagnesemia and other [s2]electrolyte disorders[e2] 
	(8, 15)	foscarnet	severe hypomagnesemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5770	OBJECTIVE: To report a case of possible [s1]foscarnet[e1] induced [s2]severe hypomagnesemia[e2] and other electrolyte disorders.
	(13, 20)	anxiety	foscarnet	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5771	The patient experienced muscle twitches, tremulousness, and [s1]anxiety[e1] on day 17 of [s2]foscarnet[e2] therapy.
	(3, 19)	muscle twitches	foscarnet	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5772	The patient experienced [s1]muscle twitches[e1]  tremulousness, and anxiety on day 17 of [s2]foscarnet[e2] therapy.
	(7, 19)	tremulousness	foscarnet	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5773	The patient experienced muscle twitches, [s1]tremulousness[e1]  and anxiety on day 17 of [s2]foscarnet[e2] therapy.
	(0, 16)	Interference with the cortisol axis	CPH82	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5774	 [s1]Interference with the cortisol axis[e1] by the microtubule antagonist, [s2]CPH82[e2] 
	(5, 39)	CPH82	hypercortisolism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5775	The results clearly demonstrate that [s1]CPH82[e1] was associated with suppression of the endogeneous production of ACTH and cortisol with a concomitant paradoxical picture of clinical [s2]hypercortisolism[e2] 
	(5, 14)	CPH82	suppression of the endogeneous production of ACTH and cortisol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5776	The results clearly demonstrate that [s1]CPH82[e1] was associated with [s2]suppression of the endogeneous production of ACTH and cortisol[e2] with a concomitant paradoxical picture of clinical hypercortisolism.
	(3, 14)	movement disorders	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5777	A variety of [s1]movement disorders[e1] are known to occur in association with [s2]carbamazepine[e2] (CBZ) therapy in adults and children, but development of tics has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders.
	(3, 19)	movement disorders	CBZ	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5778	A variety of [s1]movement disorders[e1] are known to occur in association with carbamazepine  [s2]CBZ[e2]  therapy in adults and children, but development of tics has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders.
	(12, 32)	carbamazepine	tics	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5779	A variety of movement disorders are known to occur in association with [s1]carbamazepine[e1] (CBZ) therapy in adults and children, but development of [s2]tics[e2] has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders.
	(17, 30)	CBZ	tics	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5780	A variety of movement disorders are known to occur in association with carbamazepine  [s1]CBZ[e1]  therapy in adults and children, but development of [s2]tics[e2] has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders.
	(0, 8)	Carbamazepine	tics	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5781	 [s1]Carbamazepine[e1] induced [s2]tics[e2] 
	(6, 12)	tics	CBZ	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5782	In the third child, the [s1]tics[e1] ceased after [s2]CBZ[e2] discontinuation.
	(4, 11)	CBZ	motor tics	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5783	These cases demonstrate that [s1]CBZ[e1] can induce simple [s2]motor tics[e2] in children.
	(10, 19)	facial motor tics	CBZ	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5784	We report 3 children with epilepsy who developed [s1]facial motor tics[e1] after initiation of [s2]CBZ[e2] for complex partial seizures.
	(0, 8)	Acyclovir	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5785	 [s1]Acyclovir[e1] induced [s2]neurotoxicity[e2]  concentration-side effect relationship in acyclovir overdose.
	(5, 22)	neurotoxicity	acyclovir	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5786	CONCLUSIONS: The observation that [s1]neurotoxicity[e1] developed with a delay of 24 to 48 hours after [s2]acyclovir[e2] peak serum concentrations could explain the wide range of acyclovir levels reported in similar cases.
	(5, 22)	neurotoxicity	acyclovir	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5787	CONCLUSIONS: The observation that [s1]neurotoxicity[e1] developed with a delay of 24 to 48 hours after [s2]acyclovir[e2] peak serum concentrations could explain the wide range of acyclovir levels reported in similar cases.
	(12, 22)	acyclovir	coma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5788	METHODS: Repeated blood samples were drawn in a patient with severe [s1]acyclovir[e1] overdose who developed [s2]coma[e2] and nonoliguric renal failure.
	(12, 24)	acyclovir	nonoliguric renal failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5789	METHODS: Repeated blood samples were drawn in a patient with severe [s1]acyclovir[e1] overdose who developed coma and [s2]nonoliguric renal failure[e2] 
	(15, 40)	acyclovir	central nervous system side effects	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5790	PURPOSE: To investigate the concentration-side effect relationship in a patient with severe [s1]acyclovir[e1] induced neurotoxicity and to summarize the information available in the literature about [s2]central nervous system side effects[e2] due to acyclovir.
	(15, 23)	acyclovir	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5791	PURPOSE: To investigate the concentration-side effect relationship in a patient with severe [s1]acyclovir[e1] induced [s2]neurotoxicity[e2] and to summarize the information available in the literature about central nervous system side effects due to acyclovir.
	(19, 40)	eosinophilia myalgia syndrome	tryptophan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5792	A 16-year-old white male with acute biphenotypic leukemia developed evidence of the [s1]eosinophilia myalgia syndrome[e1] associated with total parenteral nutritional support with solutions containing [s2]tryptophan[e2]  which were given during his initial induction chemotherapy and also after autologous marrow transplantation.
	(0, 27)	Fatal eosinophilia myalgia syndrome	tryptophan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5793	 [s1]Fatal eosinophilia myalgia syndrome[e1] in a marrow transplant patient attributed to total parenteral nutrition with a solution containing [s2]tryptophan[e2] 
	(3, 20)	eosinophilia myalgia syndrome	tryptophan	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5794	Thus, the [s1]eosinophilia myalgia syndrome[e1] can be associated with parenteral [s2]tryptophan[e2] administration.
	(14, 33)	fatal rhabdomyolysis	vasopressin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5795	A patient with acute esophageal variceal bleeding developed [s1]fatal rhabdomyolysis[e1] during treatment with a continuous intravenous infusion of [s2]vasopressin[e2] 
	(6, 54)	vasopressin	impaired tissue perfusion	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5796	Idiosyncratic factors involving [s1]vasopressin[e1] receptor affinity and distribution, vasopressin-associated vasodilation in some vascular beds, and the effect of vasopressin on the renin-angiotensin system may further contribute to [s2]impaired tissue perfusion[e2] 
	(6, 23)	vasopressin	vasodilation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5797	Idiosyncratic factors involving [s1]vasopressin[e1] receptor affinity and distribution, vasopressin-associated [s2]vasodilation[e2] in some vascular beds, and the effect of vasopressin on the renin-angiotensin system may further contribute to impaired tissue perfusion.
	(0, 15)	Rhabdomyolysis	vasopressin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5798	 [s1]Rhabdomyolysis[e1] associated with the use of intravenous [s2]vasopressin[e2] 
	(7, 20)	rhabdomyolysis	vasopressin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5799	These multiple overlapping factors probably lead to [s1]rhabdomyolysis[e1] in a minority of patients receiving [s2]vasopressin[e2] infusion.
	(4, 14)	disulfiram	teratogen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5800	In one case, [s1]disulfiram[e1] was the only potential [s2]teratogen[e2] exposed to the fetus.
	(5, 19)	significant abnormalities	disulfiram	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5801	Nonspecific but [s1]significant abnormalities[e1] have been described in the infants of women treated with [s2]disulfiram[e2] in the first trimester of their pregnancies.
	(5, 23)	PV	penicillamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5802	Although the essential cause of [s1]PV[e1] is unclear, its onset has occasionally been associated with drug therapy, in particular [s2]penicillamine[e2] 
	(0, 13)	Pemphigus vulgaris	glibenclamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5803	 [s1]Pemphigus vulgaris[e1] precipitated by [s2]glibenclamide[e2] therapy.
	(19, 28)	oral lesions of PV	glibenclamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5804	The patient described in this paper was a 78-year-old diabetic man who developed [s1]oral lesions of PV[e1] following institution of [s2]glibenclamide[e2] therapy.
	(0, 8)	Piritrexim	pulmonary toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5805	 [s1]Piritrexim[e1] induced [s2]pulmonary toxicity[e2] 
	(1, 9)	pulmonary toxicity	piritrexim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5806	The [s1]pulmonary toxicity[e1] is probably induced by [s2]piritrexim[e2] 
	(21, 40)	abnormal chest x-ray with diffuse interstitial opacities	piritrexim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5807	We describe a patient with transitional cell carcinoma of the renal pelvis who developed respiratory dysfunction and an [s1]abnormal chest x-ray with diffuse interstitial opacities[e1] while on chemotherapy with [s2]piritrexim[e2]  a methotrexate analog.
	(17, 40)	respiratory dysfunction	piritrexim	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5808	We describe a patient with transitional cell carcinoma of the renal pelvis who developed [s1]respiratory dysfunction[e1] and an abnormal chest x-ray with diffuse interstitial opacities while on chemotherapy with [s2]piritrexim[e2]  a methotrexate analog.
	(17, 25)	adenosine	acceleration of the heart rate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5809	A 12 year old patient with atrial flutter is presented, in whom intravenous [s1]adenosine[e1] was followed by [s2]acceleration of the heart rate[e2] to a potentially dangerous arrhythmia.
	(17, 34)	adenosine	arrhythmia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5810	A 12 year old patient with atrial flutter is presented, in whom intravenous [s1]adenosine[e1] was followed by acceleration of the heart rate to a potentially dangerous [s2]arrhythmia[e2] 
	(0, 16)	Acceleration of ventricular response	adenosine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5811	 [s1]Acceleration of ventricular response[e1] to atrial flutter after intravenous [s2]adenosine[e2] 
	(0, 18)	Lymphoma	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5812	 [s1]Lymphoma[e1] developing in a patient with rheumatoid arthritis taking [s2]methotrexate[e2] 
	(11, 34)	methotrexate	lymphoproliferative diseases	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5813	The mild immunosuppression that occurs with [s1]methotrexate[e1] therapy probably places patients with rheumatoid arthritis at added risk of developing [s2]lymphoproliferative diseases[e2]  but coincidence cannot be excluded.
	(5, 38)	non-Hodgkin lymphoma	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5814	We report one case of [s1]non-Hodgkin lymphoma[e1] in a patient, with a 30-year history of rheumatoid arthritis, taking low dose [s2]methotrexate[e2] weekly over a 10-month period.
	(0, 9)	Hepatotoxicity	paracetamol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5815	 [s1]Hepatotoxicity[e1] of [s2]paracetamol[e2] enhanced by ingestion of alcohol: report of two cases.
	(3, 29)	paracetamol	hepatotoxic effects	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5816	The biochemistry of [s1]paracetamol[e1] hepatotoxicity is outlined and the increased susceptibility of alcoholic patients to the [s2]hepatotoxic effects[e2] of paracetamol is remarked upon.
	(3, 9)	paracetamol	hepatotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5817	The biochemistry of [s1]paracetamol[e1]  [s2]hepatotoxicity[e2] is outlined and the increased susceptibility of alcoholic patients to the hepatotoxic effects of paracetamol is remarked upon.
	(1, 8)	fatal	paracetamol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5818	Two [s1]fatal[e1] cases of poisoning by [s2]paracetamol[e2] are described.
	(8, 48)	Kaposi's sarcoma	prednisolone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5819	We report a case of drug-induced [s1]Kaposi's sarcoma[e1] (KS) on the sole of the right foot in a 71-year-old man, treated for 6 months with corticosteroid therapy  [s2]prednisolone[e2] 25 mg/day) for pericardial effusion.
	(0, 11)	Acute dystonic reaction	pimozide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5820	 [s1]Acute dystonic reaction[e1] with low-dose [s2]pimozide[e2] 
	(21, 30)	acute dystonic reactions	pimozide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5821	This paper reports on a 6.9-year-old autistic male who developed repeated episodes of [s1]acute dystonic reactions[e1] associated with [s2]pimozide[e2] administration at the doses of 0.096 mg/kg/day and 0.032 mg/kg/day and 32 hours following pimozide withdrawal, as well as during subsequent thioridazine administration.
	(21, 30)	acute dystonic reactions	pimozide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5822	This paper reports on a 6.9-year-old autistic male who developed repeated episodes of [s1]acute dystonic reactions[e1] associated with [s2]pimozide[e2] administration at the doses of 0.096 mg/kg/day and 0.032 mg/kg/day and 32 hours following pimozide withdrawal, as well as during subsequent thioridazine administration.
	(21, 73)	acute dystonic reactions	thioridazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5823	This paper reports on a 6.9-year-old autistic male who developed repeated episodes of [s1]acute dystonic reactions[e1] associated with pimozide administration at the doses of 0.096 mg/kg/day and 0.032 mg/kg/day and 32 hours following pimozide withdrawal, as well as during subsequent [s2]thioridazine[e2] administration.
	(15, 49)	t-PA	atheroembolic acute renal failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5824	Although there is one case report of cholesterol crystal embolization following [s1]t-PA[e1] therapy with only extrarenal manifestations (N Engl J Med 321:1270, 1989), this is the first reported case of [s2]atheroembolic acute renal failure[e2] following t-PA therapy.
	(7, 17)	cholesterol crystal embolization	t-PA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5825	Although there is one case report of [s1]cholesterol crystal embolization[e1] following [s2]t-PA[e2] therapy with only extrarenal manifestations (N Engl J Med 321:1270, 1989), this is the first reported case of atheroembolic acute renal failure following t-PA therapy.
	(15, 23)	t-PA	extrarenal manifestations	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5826	Although there is one case report of cholesterol crystal embolization following [s1]t-PA[e1] therapy with only [s2]extrarenal manifestations[e2] (N Engl J Med 321:1270, 1989), this is the first reported case of atheroembolic acute renal failure following t-PA therapy.
	(0, 19)	Cholesterol crystal embolization	tissue-type plasminogen activator	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5827	 [s1]Cholesterol crystal embolization[e1] associated renal failure after therapy with recombinant [s2]tissue-type plasminogen activator[e2] 
	(9, 20)	renal failure	tissue-type plasminogen activator	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5828	Cholesterol crystal embolization-associated [s1]renal failure[e1] after therapy with recombinant [s2]tissue-type plasminogen activator[e2] 
	(9, 28)	cholesterol crystal embolization	recombinant tissue-type plasminogen activator	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5829	We report the occurrence of renal failure due to [s1]cholesterol crystal embolization[e1] following thrombolytic therapy with intravenous [s2]recombinant tissue-type plasminogen activator[e2] (t-PA).
	(9, 42)	cholesterol crystal embolization	t-PA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5830	We report the occurrence of renal failure due to [s1]cholesterol crystal embolization[e1] following thrombolytic therapy with intravenous recombinant tissue-type plasminogen activator  [s2]t-PA[e2] .
	(5, 28)	renal failure	recombinant tissue-type plasminogen activator	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5831	We report the occurrence of [s1]renal failure[e1] due to cholesterol crystal embolization following thrombolytic therapy with intravenous [s2]recombinant tissue-type plasminogen activator[e2] (t-PA).
	(5, 42)	renal failure	t-PA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5832	We report the occurrence of [s1]renal failure[e1] due to cholesterol crystal embolization following thrombolytic therapy with intravenous recombinant tissue-type plasminogen activator  [s2]t-PA[e2] .
	(3, 15)	haloperidol	multiform ventricular tachycardia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5833	Intravenous [s1]haloperidol[e1] is generally well tolerated, but [s2]multiform ventricular tachycardia[e2] has been reported.
	(2, 16)	mucocutaneous side effects	gold	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5834	All developed [s1]mucocutaneous side effects[e1] within 20 weeks of beginning im [s2]gold[e2] therapy, at a time when RA had improved markedly compared to pretreatment status.
	(13, 19)	gold	mucocutaneous reactions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5835	How low can you go? Use of very low dosage of [s1]gold[e1] in patients with [s2]mucocutaneous reactions[e2] 
	(0, 15)	Anterior spinal artery syndrome	phenol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5836	 [s1]Anterior spinal artery syndrome[e1] -a complication of cervical intrathecal [s2]phenol[e2] injection.
	(20, 38)	anterior spinal artery syndrome	phenol-glycerine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5837	We have seen a case of terminal malignant melanoma in which clinical manifestations, indicative of [s1]anterior spinal artery syndrome[e1]  developed following the injection of 0.3 ml of 10% [s2]phenol-glycerine[e2] into the cervical subarachnoid space at the C4--C5 level for the control of severe right arm pain.
	(8, 25)	feeding gastrostomy	risperidone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5838	One patient required nursing home placement and a [s1]feeding gastrostomy[e1] as a result of the worsening parkinsonism during [s2]risperidone[e2] treatment, but was able to return home and have the gastrostomy removed after switching from risperidone to clozapine.
	(8, 25)	feeding gastrostomy	risperidone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5839	One patient required nursing home placement and a [s1]feeding gastrostomy[e1] as a result of the worsening parkinsonism during [s2]risperidone[e2] treatment, but was able to return home and have the gastrostomy removed after switching from risperidone to clozapine.
	(18, 25)	worsening parkinsonism	risperidone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5840	One patient required nursing home placement and a feeding gastrostomy as a result of the [s1]worsening parkinsonism[e1] during [s2]risperidone[e2] treatment, but was able to return home and have the gastrostomy removed after switching from risperidone to clozapine.
	(18, 25)	worsening parkinsonism	risperidone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5841	One patient required nursing home placement and a feeding gastrostomy as a result of the [s1]worsening parkinsonism[e1] during [s2]risperidone[e2] treatment, but was able to return home and have the gastrostomy removed after switching from risperidone to clozapine.
	(11, 19)	encephalopathy	risperidone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5842	Two of the five patients who worsened motorically also developed [s1]encephalopathy[e1] during [s2]risperidone[e2] treatment; the encephalopathy resolved when the patients were switched to clozapine treatment.
	(6, 19)	worsened motorically	risperidone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5843	Two of the five patients who [s1]worsened motorically[e1] also developed encephalopathy during [s2]risperidone[e2] treatment; the encephalopathy resolved when the patients were switched to clozapine treatment.
	(0, 9)	Azathioprine	myelosuppression	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5844	 [s1]Azathioprine[e1] can cause severe [s2]myelosuppression[e2] 
	(0, 7)	Azathioprine	myelosuppression	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5845	 [s1]Azathioprine[e1] induced [s2]myelosuppression[e2] due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis.
	(1, 17)	azathioprine	pancytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5846	The [s1]azathioprine[e1] dose was low (1 mg/kg) and [s2]pancytopenia[e2] occurred after 56 days therapy.
	(23, 36)	myelosuppression	azathioprine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5847	Thiopurine methyltransferase deficiency occurs at a frequency of one in 300 and is associated with profound [s1]myelosuppression[e1] after a short course of [s2]azathioprine[e2] 
	(7, 15)	azathioprine	myelosuppression	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5848	We describe the first documented case of [s1]azathioprine[e1] induced severe [s2]myelosuppression[e2] due to thiopurine methyltransferase deficiency in autoimmune liver disease.
	(0, 7)	Nabumetone	interstitial nephritis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5849	 [s1]Nabumetone[e1] associated [s2]interstitial nephritis[e2] 
	(4, 26)	nabumetone	edema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5850	She had been taking [s1]nabumetone[e1] for 6 months, but had discontinued the agent 2 weeks before admission due to progressive [s2]edema[e2] 
	(0, 21)	Acute myeloid leukemia	hydroxyurea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5851	 [s1]Acute myeloid leukemia[e1] evolving from essential thrombocythemia in two patients treated with [s2]hydroxyurea[e2] 
	(11, 33)	AL	hydroxyurea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5852	In this report, two cases of ET which evolved into [s1]AL[e1] without prior exposure to radiation or alkylating agents, and which were treated with long-term [s2]hydroxyurea[e2] therapy, are described.
	(3, 19)	hydroxyurea	acute leukemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5853	Prolonged used of [s1]hydroxyurea[e1] in patients with ET may lead to therapy-associated [s2]acute leukemia[e2] 
	(18, 29)	cardiac effects	halofantrine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5854	However, in 1993, a clinical study involving 400 patients on the Thai-Burmese border revealed [s1]cardiac effects[e1] of antimalarial treatment with [s2]halofantrine[e2]  including one sudden death after the treatment.
	(27, 35)	halofantrine	sudden death	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5855	However, in 1993, a clinical study involving 400 patients on the Thai-Burmese border revealed cardiac effects of antimalarial treatment with [s1]halofantrine[e1]  including one [s2]sudden death[e2] after the treatment.
	(15, 25)	QT interval was prolonged	halofantrine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5856	In the present paper, we discuss the first Japanese vivax malaria patient whose [s1]QT interval was prolonged[e1] after treatment with [s2]halofantrine[e2] 
	(0, 22)	Prolongation of the QT interval	halofantrine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5857	 [s1]Prolongation of the QT interval[e1] observed in a Japanese patient with vivax malaria following treatment with [s2]halofantrine[e2] 
	(4, 11)	Halfan	cardiac arrests	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5858	The pharmaceutical company producing [s1]Halfan[e1] has reported 8 [s2]cardiac arrests[e2]  leading to 6 deaths, when a higher dose than recommended was used, there was recent or concomitant treatment with mefloquine, there was pre-existing prolongation of the QT interval or the patient had a thiamine deficiency.
	(9, 37)	cardiac arrests	mefloquine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5859	The pharmaceutical company producing Halfan has reported 8 [s1]cardiac arrests[e1]  leading to 6 deaths, when a higher dose than recommended was used, there was recent or concomitant treatment with [s2]mefloquine[e2]  there was pre-existing prolongation of the QT interval or the patient had a thiamine deficiency.
	(4, 17)	Halfan	deaths	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5860	The pharmaceutical company producing [s1]Halfan[e1] has reported 8 cardiac arrests, leading to 6 [s2]deaths[e2]  when a higher dose than recommended was used, there was recent or concomitant treatment with mefloquine, there was pre-existing prolongation of the QT interval or the patient had a thiamine deficiency.
	(15, 37)	deaths	mefloquine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5861	The pharmaceutical company producing Halfan has reported 8 cardiac arrests, leading to 6 [s1]deaths[e1]  when a higher dose than recommended was used, there was recent or concomitant treatment with [s2]mefloquine[e2]  there was pre-existing prolongation of the QT interval or the patient had a thiamine deficiency.
	(0, 13)	Supravenous hyperpigmentation	CHOP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5862	 [s1]Supravenous hyperpigmentation[e1] in association with [s2]CHOP[e2] chemotherapy of a CD30 (Ki-1)-positive anaplastic large-cell lymphoma.
	(6, 18)	supravenous hyperpigmentation	CHOP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5863	We report an unusual pattern of [s1]supravenous hyperpigmentation[e1] occurring after [s2]CHOP[e2] chemotherapy.
	(0, 20)	Phenytoin toxicity	Phenytoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5864	 [s1]Phenytoin toxicity[e1] due to concomitant antituberculosis therapy [s2]Phenytoin[e2] toxicity due to concomitant antituberculosis therapy.
	(28, 42)	phenytoin	blood levels in the toxic range	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5865	Seventy-four per cent of patients with epileptogenic disorders seen at the Emergency Unit at Groote Schuur Hospital were on [s1]phenytoin[e1] and 11.6% of these had [s2]blood levels in the toxic range[e2] 
	(27, 34)	phenytoin toxicity	phenytoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5866	Slow acetylators, who comprise roughly 50% of the South African population, are likely to develop clinical and biochemical features of [s1]phenytoin toxicity[e1]  [s2]phenytoin[e2] toxicity when this drug is given together with antituberculosis therapy.
	(4, 33)	phenytoin	phenytoin toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5867	The wide use of [s1]phenytoin[e1] during the recent tuberculosis epidemic makes it imperative to suspect this drug interaction in patients exhibiting clinical features that might be related to [s2]phenytoin toxicity[e2] 
	(4, 33)	phenytoin	phenytoin toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5868	The wide use of [s1]phenytoin[e1] during the recent tuberculosis epidemic makes it imperative to suspect this drug interaction in patients exhibiting clinical features that might be related to [s2]phenytoin toxicity[e2] 
	(0, 18)	Nephrogenic diabetes insipidus	foscarnet	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5869	 [s1]Nephrogenic diabetes insipidus[e1] and renal tubular acidosis secondary to [s2]foscarnet[e2] therapy.
	(10, 18)	renal tubular acidosis	foscarnet	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5870	Nephrogenic diabetes insipidus and [s1]renal tubular acidosis[e1] secondary to [s2]foscarnet[e2] therapy.
	(12, 32)	nephrogenic diabetes insipidus	foscarnet	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5871	No cases of renal acidosis, and only one case of [s1]nephrogenic diabetes insipidus[e1]  has been previously reported as a complication of [s2]foscarnet[e2] treatment.
	(4, 29)	nephrogenic diabetes insipidus	foscarnet	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5872	Our patient developed both [s1]nephrogenic diabetes insipidus[e1] and renal tubular acidosis with a temporal pattern that demonstrated a link between [s2]foscarnet[e2] therapy and these abnormalities.
	(14, 29)	renal tubular acidosis	foscarnet	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5873	Our patient developed both nephrogenic diabetes insipidus and [s1]renal tubular acidosis[e1] with a temporal pattern that demonstrated a link between [s2]foscarnet[e2] therapy and these abnormalities.
	(16, 33)	foscarnet	polyuria	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5874	We present a patient with human immunodeficiency virus infection under treatment with [s1]foscarnet[e1] for CMV retinitis who complained of thirst and [s2]polyuria[e2] 
	(16, 31)	foscarnet	thirst	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5875	We present a patient with human immunodeficiency virus infection under treatment with [s1]foscarnet[e1] for CMV retinitis who complained of [s2]thirst[e2] and polyuria.
	(0, 12)	Choroidal hemorrhage	tissue plasminogen activator	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5876	 [s1]Choroidal hemorrhage[e1] associated with systemic [s2]tissue plasminogen activator[e2] 
	(5, 22)	tissue plasminogen activator	hemorrhage	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5877	CONCLUSION: The administration of [s1]tissue plasminogen activator[e1] was responsible for the large extent of [s2]hemorrhage[e2] and should be considered in the differential diagnosis of hemorrhagic choroidal detachment.
	(5, 35)	tissue plasminogen activator	hemorrhagic choroidal detachment	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5878	CONCLUSION: The administration of [s1]tissue plasminogen activator[e1] was responsible for the large extent of hemorrhage and should be considered in the differential diagnosis of [s2]hemorrhagic choroidal detachment[e2] 
	(7, 36)	spontaneous choroidal hemorrhage	tissue plasminogen activator	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5879	PURPOSE: To determine the cause of [s1]spontaneous choroidal hemorrhage[e1] in a 67-year-old man after a myocardial infarction and administration of [s2]tissue plasminogen activator[e2] 
	(0, 7)	Accelerated nodulosis	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5880	 [s1]Accelerated nodulosis[e1] during [s2]methotrexate[e2] therapy for juvenile rheumatoid arthritis.
	(6, 29)	nodules	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5881	Although they had only a few [s1]nodules[e1] at diagnosis, the nodules increased in number and size 3 to 4 months after the start of [s2]methotrexate[e2] therapy in both patients.
	(6, 29)	nodules	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5882	Although they had only a few [s1]nodules[e1] at diagnosis, the nodules increased in number and size 3 to 4 months after the start of [s2]methotrexate[e2] therapy in both patients.
	(4, 24)	methotrexate	extraarticular side effect	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5883	Physicians treating patients with [s1]methotrexate[e1] for juvenile rheumatoid arthritis must be aware of this [s2]extraarticular side effect[e2] 
	(1, 10)	nodules	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5884	The [s1]nodules[e1] regressed after withdrawal of [s2]methotrexate[e2] therapy in one patient and were arrested with the addition of hydroxychloroquine in the other.
	(28, 36)	accelerated nodulosis	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5885	We describe two patients with rheumatoid factor-positive, polyarticular-onset juvenile rheumatoid arthritis in whom [s1]accelerated nodulosis[e1] developed during [s2]methotrexate[e2] therapy.
	(1, 11)	macrophage activation syndrome	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5886	A [s1]macrophage activation syndrome[e1]  possibly related to [s2]methotrexate[e2] toxicity, developed in a boy with systemic juvenile rheumatoid arthritis.
	(10, 18)	methotrexate toxicity	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5887	A macrophage activation syndrome, possibly related to [s1]methotrexate toxicity[e1]  [s2]methotrexate[e2] toxicity, developed in a boy with systemic juvenile rheumatoid arthritis.
	(0, 7)	Jaundice	streptokinase	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5888	 [s1]Jaundice[e1] induced by [s2]streptokinase[e2] 
	(7, 15)	jaundice	streptokinase	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5889	Only a few reports of overt [s1]jaundice[e1] are associated with [s2]streptokinase[e2] 
	(6, 41)	colitis	cisplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5890	Although both patients recovered from the [s1]colitis[e1] after the administration of vancomycin, the first case demonstrated a relapse of the colitis after receiving a subsequent course of the same chemotherapy with [s2]cisplatin[e2] 
	(10, 17)	cisplatin	C. difficile colitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5891	Based on our findings, it is thus concluded that [s1]cisplatin[e1] may cause [s2]C. difficile colitis[e2] 
	(13, 33)	cisplatin	colitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5892	Both patients were then treated with a carboplatin alternative to [s1]cisplatin[e1] in the following courses, which resulted in neither a relapse of the [s2]colitis[e2] nor a recurrence of the malignancies up to this time.
	(0, 14)	Clostridium difficile colitis	cisplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5893	 [s1]Clostridium difficile colitis[e1] associated with [s2]cisplatin[e2] based chemotherapy in ovarian cancer patients.
	(1, 23)	C. difficile colitis	cisplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5894	Severe [s1]C. difficile colitis[e1] occurred in 2 patients (6.1%) after receiving [s2]cisplatin[e2] based combination chemotherapy for ovarian malignancies.
	(13, 27)	Clostridium difficile colitis	cisplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5895	The purpose of this study was to examine the incidence and cause of [s1]Clostridium difficile colitis[e1] occurring after [s2]cisplatin[e2] based combination chemotherapy in ovarian cancer patients.
	(3, 15)	severe cholestatic jaundice	captopril	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5896	A patient with [s1]severe cholestatic jaundice[e1] induced by [s2]captopril[e2] is presented.
	(0, 6)	Captopril	pseudocholangitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5897	 [s1]Captopril[e1] associated  [s2]pseudocholangitis[e2] .
	(0, 11)	Captopril	dermatologic, hematologic, and pulmonary adverse effects	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5898	 [s1]Captopril[e1] is known to be associated with [s2]dermatologic, hematologic, and pulmonary adverse effects[e2] 
	(3, 10)	captopril	atypical cholangitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5899	Patients treated with [s1]captopril[e1] who develop  [s2]atypical cholangitis[e2]  should be suspected of having captopril-associated liver damage.
	(3, 28)	captopril	liver damage	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5900	"Patients treated with [s1]captopril[e1] who develop ""atypical cholangitis"" should be suspected of having captopril-associated [s2]liver damage[e2] "
	(2, 22)	nephrotic syndrome	macrophage-colony-stimulating factor	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5901	Development of [s1]nephrotic syndrome[e1] in a patient with acute myeloblastic leukemia after treatment with [s2]macrophage-colony-stimulating factor[e2] 
	(10, 25)	nephrotic syndrome	M-CSF	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5902	It should be emphasized that the recurrence of [s1]nephrotic syndrome[e1] was observed after the following chemotherapy, including [s2]M-CSF[e2]  whereas the bone marrow still remained completely remitted.
	(6, 38)	M-CSF	nephrotic syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5903	The possibility can be raised that [s1]M-CSF[e1] accelerated the underlying renal disease in this case through enhancing macrophage accumulation into the glomerulus, leading to the development of [s2]nephrotic syndrome[e2] 
	(6, 15)	M-CSF	renal disease	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5904	The possibility can be raised that [s1]M-CSF[e1] accelerated the underlying [s2]renal disease[e2] in this case through enhancing macrophage accumulation into the glomerulus, leading to the development of nephrotic syndrome.
	(22, 30)	M-CSF	macrophage-related glomerular injury	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5905	These evolutional changes in both proteinuria and glomerular histology suggest a close linkage between the [s1]M-CSF[e1] treatment and [s2]macrophage-related glomerular injury[e2] 
	(17, 32)	nephrotic syndrome	macrophage-colony-stimulating factor	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5906	We describe a patient with acute myeloblastic leukemia (AML) who developed [s1]nephrotic syndrome[e1] after receiving several courses of chemotherapy, including [s2]macrophage-colony-stimulating factor[e2] (M-CSF).
	(17, 40)	nephrotic syndrome	M-CSF	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5907	We describe a patient with acute myeloblastic leukemia (AML) who developed [s1]nephrotic syndrome[e1] after receiving several courses of chemotherapy, including macrophage-colony-stimulating factor  [s2]M-CSF[e2] .
	(22, 28)	betamethasone	edema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5908	On the fifth day of tocolysis with magnesium sulfate, nifedipine, terbutaline and [s1]betamethasone[e1]  [s2]edema[e2] developed in both labia.
	(9, 28)	magnesium sulfate	edema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5909	On the fifth day of tocolysis with [s1]magnesium sulfate[e1]  nifedipine, terbutaline and betamethasone, [s2]edema[e2] developed in both labia.
	(12, 28)	nifedipine	edema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5910	On the fifth day of tocolysis with magnesium sulfate, [s1]nifedipine[e1]  terbutaline and betamethasone, [s2]edema[e2] developed in both labia.
	(17, 29)	terbutaline	edema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5911	On the fifth day of tocolysis with magnesium sulfate, nifedipine, [s1]terbutaline[e1] and betamethasone, [s2]edema[e2] developed in both labia.
	(0, 9)	Milk-alkali syndrome	1,25(OH)2D	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5912	 [s1]Milk-alkali syndrome[e1] induced by [s2]1,25(OH)2D[e2] in a patient with hypoparathyroidism.
	(20, 34)	calcitriol	milk-alkali syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5913	This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and [s1]calcitriol[e1] resulting in two admissions to the hospital for [s2]milk-alkali syndrome[e2] 
	(17, 34)	calcium carbonate	milk-alkali syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5914	This article presents a patient with hypoparathyroidism who was treated with [s1]calcium carbonate[e1] and calcitriol resulting in two admissions to the hospital for [s2]milk-alkali syndrome[e2] 
	(5, 20)	ifosfamide	unresponsive	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5915	After receiving 3 doses of [s1]ifosfamide[e1] mesna, she was found to be [s2]unresponsive[e2] 
	(9, 19)	mesna	unresponsive	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5916	After receiving 3 doses of ifosfamide [s1]mesna[e1]  she was found to be [s2]unresponsive[e2] 
	(11, 26)	nonconvulsive status epilepticus	ifosfamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5917	CONCLUSIONS: There was a temporal relationship between the onset of [s1]nonconvulsive status epilepticus[e1] and initiation of [s2]ifosfamide[e2] infusion.
	(2, 16)	Central nervous system (CNS) toxicity	ifosfamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5918	DISCUSSION: [s1]Central nervous system (CNS) toxicity[e1] has been described with [s2]ifosfamide[e2]  with most cases reported in the pediatric population.
	(0, 7)	Ifosfamide	nonconvulsive status epilepticus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5919	 [s1]Ifosfamide[e1] induced [s2]nonconvulsive status epilepticus[e2] 
	(7, 14)	ifosfamide	nonconvulsive status epilepticus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5920	OBJECTIVE: To describe a patient with [s1]ifosfamide[e1] induced [s2]nonconvulsive status epilepticus[e2] 
	(6, 20)	nonconvulsive status epilepticus	ifosfamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5921	This represents the first report of [s1]nonconvulsive status epilepticus[e1] induced by [s2]ifosfamide[e2] 
	(0, 8)	Albendazole	pseudomembranous colitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5922	 [s1]Albendazole[e1] induced [s2]pseudomembranous colitis[e2] 
	(6, 17)	metronidazole	pseudomembranous colitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5923	Although a few case reports link [s1]metronidazole[e1] with the development of [s2]pseudomembranous colitis[e2]  albendazole has not been associated with the development of this condition.
	(4, 19)	albendazole	abdominal pain	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5924	While undergoing treatment with [s1]albendazole[e1]  he developed worsening diarrhea with [s2]abdominal pain[e2] and fever.
	(4, 22)	albendazole	fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5925	While undergoing treatment with [s1]albendazole[e1]  he developed worsening diarrhea with abdominal pain and [s2]fever[e2] 
	(4, 13)	albendazole	worsening diarrhea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5926	While undergoing treatment with [s1]albendazole[e1]  he developed [s2]worsening diarrhea[e2] with abdominal pain and fever.
	(0, 20)	Aluminum intoxication	Aluminum	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5927	 [s1]Aluminum intoxication[e1]  along with other factors, was considered to be the cause of TC development [s2]Aluminum[e2] intoxication, along with other factors, was considered to be the cause of TC development.
	(0, 19)	Aluminum	TC	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5928	 [s1]Aluminum[e1] intoxication, along with other factors, was considered to be the cause of [s2]TC[e2] development.
	(0, 10)	Oculomotor disturbances	5-fluorouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5929	 [s1]Oculomotor disturbances[e1] associated with [s2]5-fluorouracil[e2] chemotherapy.
	(11, 16)	5-FU	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5930	The ocular motor disturbances are probably an expression of regional [s1]5-FU[e1]  [s2]neurotoxicity[e2] primarily affecting the brain stem.
	(1, 13)	ocular motor disturbances	5-FU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5931	The [s1]ocular motor disturbances[e1] are probably an expression of regional [s2]5-FU[e2] neurotoxicity primarily affecting the brain stem.
	(4, 31)	5-fluorouracil	cerebellar dysfunction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5932	Two patients treated with [s1]5-fluorouracil[e1] (5-FU) for disseminated adenocarcinoma of the colon developed [s2]cerebellar dysfunction[e2] typical of 5-FU neurotoxicity.
	(11, 29)	5-FU	cerebellar dysfunction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5933	Two patients treated with 5-fluorouracil  [s1]5-FU[e1]  for disseminated adenocarcinoma of the colon developed [s2]cerebellar dysfunction[e2] typical of 5-FU neurotoxicity.
	(11, 29)	5-FU	cerebellar dysfunction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5934	Two patients treated with 5-fluorouracil  [s1]5-FU[e1]  for disseminated adenocarcinoma of the colon developed [s2]cerebellar dysfunction[e2] typical of 5-FU neurotoxicity.
	(4, 41)	5-fluorouracil	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5935	Two patients treated with [s1]5-fluorouracil[e1] (5-FU) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU [s2]neurotoxicity[e2] 
	(11, 39)	5-FU	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5936	Two patients treated with 5-fluorouracil  [s1]5-FU[e1]  for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU [s2]neurotoxicity[e2] 
	(11, 39)	5-FU	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5937	Two patients treated with 5-fluorouracil  [s1]5-FU[e1]  for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU [s2]neurotoxicity[e2] 
	(8, 12)	insulin	hypoglycaemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5938	Assessment of cortisol response was by [s1]insulin[e1] induced [s2]hypoglycaemia[e2] in three cases, by short tetracosactrin test in two, and by low-dose tetracosactrin and 24-hour urinary cortisol/creatinine ratio in one.
	(16, 29)	fluticasone propionate	adrenal suppression	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5939	FINDINGS: Six children with growth retardation noted after treatment with high-dose [s1]fluticasone propionate[e1] were found to have [s2]adrenal suppression[e2] 
	(5, 18)	growth retardation	fluticasone propionate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5940	FINDINGS: Six children with [s1]growth retardation[e1] noted after treatment with high-dose [s2]fluticasone propionate[e2] were found to have adrenal suppression.
	(0, 17)	Growth and adrenal suppression	fluticasone propionate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5941	 [s1]Growth and adrenal suppression[e1] in asthmatic children treated with high-dose [s2]fluticasone propionate[e2] 
	(6, 25)	fluticasone propionate	adrenal suppression	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5942	INTERPRETATION: When high doses of [s1]fluticasone propionate[e1] are used, growth may be retarded and [s2]adrenal suppression[e2] may occur.
	(6, 18)	fluticasone propionate	growth may be retarded	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5943	INTERPRETATION: When high doses of [s1]fluticasone propionate[e1] are used, [s2]growth may be retarded[e2] and adrenal suppression may occur.
	(2, 22)	Growth retardation	fluticasone propionate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5944	METHODS: [s1]Growth retardation[e1] was observed in six severely asthmatic children after introduction of high-dose [s2]fluticasone propionate[e2] treatment (dry powder).
	(0, 8)	Metipranolol	granulomatous anterior uveitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5945	 [s1]Metipranolol[e1] associated [s2]granulomatous anterior uveitis[e2]  not so uncommon as thought.
	(4, 28)	bilateral granulomatous anterior uveitis	metripranolol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5946	Two case reports of [s1]bilateral granulomatous anterior uveitis[e1] are described in patients with open angle glaucoma treated with [s2]metripranolol[e2] 0.6% eye drops.
	(16, 37)	desmopressin	altered mental status	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5947	A review of the literature found 11 children and 2 adults in whom intranasal [s1]desmopressin[e1] was associated with hyponatremia, all of whom experienced seizures or [s2]altered mental status[e2] 
	(16, 25)	desmopressin	hyponatremia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5948	A review of the literature found 11 children and 2 adults in whom intranasal [s1]desmopressin[e1] was associated with [s2]hyponatremia[e2]  all of whom experienced seizures or altered mental status.
	(16, 35)	desmopressin	seizures	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5949	A review of the literature found 11 children and 2 adults in whom intranasal [s1]desmopressin[e1] was associated with hyponatremia, all of whom experienced [s2]seizures[e2] or altered mental status.
	(3, 10)	desmopressin	hyponatremia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5950	Intranasal [s1]desmopressin[e1] induced [s2]hyponatremia[e2] 
	(5, 13)	desmopressin	hyponatremia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5951	When vague symptoms develop during [s1]desmopressin[e1] therapy, [s2]hyponatremia[e2] must be considered as part of the differential diagnosis.
	(1, 7)	vague symptoms	desmopressin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5952	When [s1]vague symptoms[e1] develop during [s2]desmopressin[e2] therapy, hyponatremia must be considered as part of the differential diagnosis.
	(11, 20)	desmopressin	hyponatremia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5953	Within 24 hours of fluid restriction and cessation of [s1]desmopressin[e1]  her symptoms and [s2]hyponatremia[e2] resolved.
	(5, 29)	hyponatremia	desmopressin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5954	Without other causes for the [s1]hyponatremia[e1]  she was diagnosed with the syndrome of inappropriate antidiuretic hormone, presumably caused by [s2]desmopressin[e2] 
	(16, 29)	syndrome of inappropriate antidiuretic hormone	desmopressin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5955	Without other causes for the hyponatremia, she was diagnosed with the [s1]syndrome of inappropriate antidiuretic hormone[e1]  presumably caused by [s2]desmopressin[e2] 
	(0, 33)	Uveitis	clarithromycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5956	 [s1]Uveitis[e1] during treatment of disseminated Mycobacterium avium-intracellulare complex infection with the combination of rifabutin, [s2]clarithromycin[e2] and ethambutol.
	(0, 40)	Uveitis	ethambutol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5957	 [s1]Uveitis[e1] during treatment of disseminated Mycobacterium avium-intracellulare complex infection with the combination of rifabutin, clarithromycin and [s2]ethambutol[e2] 
	(0, 28)	Uveitis	rifabutin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5958	 [s1]Uveitis[e1] during treatment of disseminated Mycobacterium avium-intracellulare complex infection with the combination of [s2]rifabutin[e2]  clarithromycin and ethambutol.
	(1, 8)	acyclovir	increase serum lithium levels	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5959	Does [s1]acyclovir[e1]  [s2]increase serum lithium levels[e2] 
	(4, 15)	acyclovir	lithium toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5960	Six days after starting [s1]acyclovir[e1] she exhibited signs of [s2]lithium toxicity[e2] 
	(13, 17)	lithium toxicity	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5961	Six days after starting acyclovir she exhibited signs of [s1]lithium toxicity[e1]  [s2]lithium[e2] toxicity.
	(4, 26)	acyclovir	increased serum lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5962	This case suggests that [s1]acyclovir[e1] when given intravenously in doses of 10 mg/kg may result in [s2]increased serum lithium[e2] concentrations.
	(24, 29)	increased serum lithium	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5963	This case suggests that acyclovir when given intravenously in doses of 10 mg/kg may result in [s1]increased serum lithium[e1]  [s2]lithium[e2] concentrations.
	(10, 31)	acyclovir	lithium toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5964	Until additional data are available, if intravenous [s1]acyclovir[e1] is administered concurrently with lithium, we recommend closely monitoring patients for signs of [s2]lithium toxicity[e2] and measuring serum lithium levels every second or third day.
	(19, 30)	lithium	lithium toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5965	Until additional data are available, if intravenous acyclovir is administered concurrently with [s1]lithium[e1]  we recommend closely monitoring patients for signs of [s2]lithium toxicity[e2] and measuring serum lithium levels every second or third day.
	(4, 15)	serum lithium level had increased	acyclovir	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5966	When measured, the [s1]serum lithium level had increased[e1] 4-fold during [s2]acyclovir[e2] therapy.
	(4, 11)	serum lithium level had increased	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5967	When measured, the [s1]serum lithium level had increased[e1]  [s2]lithium[e2] level had increased 4-fold during acyclovir therapy.
	(0, 16)	Dapsone syndrome	Dapsone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5968	 [s1]Dapsone syndrome[e1] in cutaneous lupus erythematosus [s2]Dapsone[e2] syndrome in cutaneous lupus erythematosus.
	(7, 13)	lethal	dapsone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5969	Physicians should be aware of the potentially [s1]lethal[e1] side effects of [s2]dapsone[e2] 
	(17, 23)	dapsone reaction	dapsone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5970	We describe 2 patients with cutaneous lupus erythematosus who developed severe [s1]dapsone reaction[e1]  [s2]dapsone[e2] reaction after low dose therapy, with a fatal outcome in one.
	(17, 30)	dapsone	fatal	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5971	We describe 2 patients with cutaneous lupus erythematosus who developed severe [s1]dapsone[e1] reaction after low dose therapy, with a [s2]fatal[e2] outcome in one.
	(8, 13)	fatal interaction	minoxidil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5972	A case is presented which illustrates a probably [s1]fatal interaction[e1] between [s2]minoxidil[e2] and a coagulation disorder.
	(9, 21)	NDI	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5973	Nephrogenic diabetes insipidus  [s1]NDI[e1]  is a well-documented complication of [s2]lithium[e2] use.
	(0, 23)	Nephrogenic diabetes insipidus	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5974	 [s1]Nephrogenic diabetes insipidus[e1] (NDI) is a well-documented complication of [s2]lithium[e2] use.
	(10, 14)	lithium	CDI	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5975	Potential mechanisms regarding the pathophysiology of [s1]lithium[e1] associated [s2]CDI[e2] are discussed.
	(9, 14)	CDI	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5976	The association of central diabetes insipidus  [s1]CDI[e1]  with [s2]lithium[e2] use is rare.
	(3, 16)	central diabetes insipidus	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5977	The association of [s1]central diabetes insipidus[e1] (CDI) with [s2]lithium[e2] use is rare.
	(9, 13)	lithium	polyuria	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5978	This case emphasizes the importance of the evaluation of [s1]lithium[e1] associated [s2]polyuria[e2] with a direct measurement of plasma vasopressin, interpreted with simultaneous plasma and urine osmolality to secure the correct diagnosis and ensure appropriate therapeutic management.
	(13, 17)	lithium	CDI	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5979	To the best of our knowledge, this is the first case of [s1]lithium[e1] associated [s2]CDI[e2] and NDI presenting concurrently.
	(13, 20)	lithium	NDI	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5980	To the best of our knowledge, this is the first case of [s1]lithium[e1] associated CDI and [s2]NDI[e2] presenting concurrently.
	(0, 26)	Transient central diabetes insipidus	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5981	 [s1]Transient central diabetes insipidus[e1] in the setting of underlying chronic nephrogenic diabetes insipidus associated with [s2]lithium[e2] use.
	(6, 15)	lithium	CDI	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5982	We report a patient receiving chronic [s1]lithium[e1] therapy who presented with a transient [s2]CDI[e2] occurring in the setting of underlying chronic NDI.
	(11, 16)	human insulin	lipoatrophy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5983	CASE: We report a case of a woman with severe [s1]human insulin[e1] induced [s2]lipoatrophy[e2] who has been treated exclusively with recombinant DNA human insulin since the onset of IDDM.
	(15, 27)	lipoatrophy	recombinant DNA human insulin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5984	CASE: We report a case of a woman with severe human insulin-induced [s1]lipoatrophy[e1] who has been treated exclusively with [s2]recombinant DNA human insulin[e2] since the onset of IDDM.
	(18, 23)	human insulin	lipoatrophy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5985	CONCLUSIONS: Jet-injection devices might constitute a helpful method to treat those patients affected by severe [s1]human insulin[e1] induced [s2]lipoatrophy[e2] 
	(0, 5)	Human insulin	lipoatrophy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5986	 [s1]Human insulin[e1] induced [s2]lipoatrophy[e2] 
	(26, 31)	human insulin	lipoatrophy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5987	OBJECTIVE: To evaluate the efficacy of the administration of insulin by a jet-injector device in stopping and reversing severe [s1]human insulin[e1] induced [s2]lipoatrophy[e2] 
	(8, 17)	neurotoxic effects	ofloxacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5988	Improved awareness of and further investigation into the [s1]neurotoxic effects[e1] of [s2]ofloxacin[e2] may enhance its safe use.
	(0, 5)	Seizures	ofloxacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5989	 [s1]Seizures[e1] associated with [s2]ofloxacin[e2] therapy.
	(1, 22)	renal insufficiency	ofloxacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5990	The [s1]renal insufficiency[e1] of three patients and the timing of the seizures implicate accumulation of [s2]ofloxacin[e2] as a contributing factor.
	(14, 22)	seizures	ofloxacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5991	The renal insufficiency of three patients and the timing of the [s1]seizures[e1] implicate accumulation of [s2]ofloxacin[e2] as a contributing factor.
	(6, 11)	seizures	ofloxacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5992	We describe four patients who had [s1]seizures[e1] while receiving [s2]ofloxacin[e2]  no other causes were evident.
	(9, 50)	phenytoin	abnormal liver function tests	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5993	A patient is described with the characteristic features of [s1]phenytoin[e1] hypersensitivity syndrome (PHS) including fever, erythroderma, tibial and facial oedema, pinhead-sized facial pustules and [s2]abnormal liver function tests[e2] 
	(9, 27)	phenytoin	erythroderma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5994	A patient is described with the characteristic features of [s1]phenytoin[e1] hypersensitivity syndrome (PHS) including fever, [s2]erythroderma[e2]  tibial and facial oedema, pinhead-sized facial pustules and abnormal liver function tests.
	(9, 25)	phenytoin	fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5995	A patient is described with the characteristic features of [s1]phenytoin[e1] hypersensitivity syndrome (PHS) including [s2]fever[e2]  erythroderma, tibial and facial oedema, pinhead-sized facial pustules and abnormal liver function tests.
	(9, 20)	phenytoin hypersensitivity syndrome	phenytoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5996	A patient is described with the characteristic features of [s1]phenytoin hypersensitivity syndrome[e1]  [s2]phenytoin[e2] hypersensitivity syndrome (PHS) including fever, erythroderma, tibial and facial oedema, pinhead-sized facial pustules and abnormal liver function tests.
	(9, 41)	phenytoin	pinhead-sized facial pustules	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5997	A patient is described with the characteristic features of [s1]phenytoin[e1] hypersensitivity syndrome (PHS) including fever, erythroderma, tibial and facial oedema, [s2]pinhead-sized facial pustules[e2] and abnormal liver function tests.
	(9, 33)	phenytoin	tibial and facial oedema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5998	A patient is described with the characteristic features of [s1]phenytoin[e1] hypersensitivity syndrome (PHS) including fever, erythroderma, [s2]tibial and facial oedema[e2]  pinhead-sized facial pustules and abnormal liver function tests.
	(8, 19)	phenytoin hypersensitivity syndrome	phenytoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	5999	Systemic corticosteroids in the [s1]phenytoin hypersensitivity syndrome[e1]  [s2]phenytoin[e2] hypersensitivity syndrome.
	(9, 15)	sarcoma	cyclophosphamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6000	A patient is described who developed a poorly differentiated [s1]sarcoma[e1] after [s2]cyclophosphamide[e2] was used to treat his rheumatoid arthritis.
	(0, 11)	Sarcoma	cyclophosphamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6001	 [s1]Sarcoma[e1] complicating therapy with [s2]cyclophosphamide[e2] 
	(10, 27)	nitrofurantoin	pulmonary fibrosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6002	A chronic reaction associated with long-term treatment with [s1]nitrofurantoin[e1] has also been reported and causes irreversible [s2]pulmonary fibrosis[e2] 
	(0, 6)	Acute pulmonary reactions	nitrofurantoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6003	 [s1]Acute pulmonary reactions[e1] to [s2]nitrofurantoin[e2] are an uncommon side effect of therapy and can cause minor or life-threatening pulmonary dysfunction.
	(4, 26)	nitrofurantoin	pulmonary dysfunction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6004	Acute pulmonary reactions to [s1]nitrofurantoin[e1] are an uncommon side effect of therapy and can cause minor or life-threatening [s2]pulmonary dysfunction[e2] 
	(3, 9)	pulmonary side effects	nitrofurantoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6005	Despite the known [s1]pulmonary side effects[e1] of [s2]nitrofurantoin[e2]  there is no report of this toxicity occurring in pregnant patients.
	(0, 8)	Nitrofurantoin	pulmonary toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6006	 [s1]Nitrofurantoin[e1] induced [s2]pulmonary toxicity[e2] during pregnancy: a report of a case and review of the literature.
	(5, 24)	respiratory failure	nitrofurantoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6007	We present a case of [s1]respiratory failure[e1] occurring in a woman at 16 weeks' gestation who was being treated with [s2]nitrofurantoin[e2] for a urinary tract infection.
	(5, 23)	dapsone	agranulocytosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6008	Less common adverse events to [s1]dapsone[e1] include the idiosyncratic reactions of leukopenia and [s2]agranulocytosis[e2]  cutaneous eruptions, peripheral neuropathy, psychosis, toxic hepatitis, cholestatic jaundice, nephrotic syndrome, renal papillary necrosis, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints.
	(5, 77)	dapsone	an infectious mononucleosis-like syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6009	Less common adverse events to [s1]dapsone[e1] include the idiosyncratic reactions of leukopenia and agranulocytosis, cutaneous eruptions, peripheral neuropathy, psychosis, toxic hepatitis, cholestatic jaundice, nephrotic syndrome, renal papillary necrosis, severe hypoalbuminemia without proteinuria, [s2]an infectious mononucleosis-like syndrome[e2]  and minor neurological and gastrointestinal complaints.
	(5, 44)	dapsone	cholestatic jaundice	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6010	Less common adverse events to [s1]dapsone[e1] include the idiosyncratic reactions of leukopenia and agranulocytosis, cutaneous eruptions, peripheral neuropathy, psychosis, toxic hepatitis, [s2]cholestatic jaundice[e2]  nephrotic syndrome, renal papillary necrosis, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints.
	(5, 29)	dapsone	cutaneous eruptions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6011	Less common adverse events to [s1]dapsone[e1] include the idiosyncratic reactions of leukopenia and agranulocytosis, [s2]cutaneous eruptions[e2]  peripheral neuropathy, psychosis, toxic hepatitis, cholestatic jaundice, nephrotic syndrome, renal papillary necrosis, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints.
	(5, 18)	dapsone	leukopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6012	Less common adverse events to [s1]dapsone[e1] include the idiosyncratic reactions of [s2]leukopenia[e2] and agranulocytosis, cutaneous eruptions, peripheral neuropathy, psychosis, toxic hepatitis, cholestatic jaundice, nephrotic syndrome, renal papillary necrosis, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints.
	(5, 88)	dapsone	minor neurological and gastrointestinal complaints	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6013	Less common adverse events to [s1]dapsone[e1] include the idiosyncratic reactions of leukopenia and agranulocytosis, cutaneous eruptions, peripheral neuropathy, psychosis, toxic hepatitis, cholestatic jaundice, nephrotic syndrome, renal papillary necrosis, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and [s2]minor neurological and gastrointestinal complaints[e2] 
	(5, 52)	dapsone	nephrotic syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6014	Less common adverse events to [s1]dapsone[e1] include the idiosyncratic reactions of leukopenia and agranulocytosis, cutaneous eruptions, peripheral neuropathy, psychosis, toxic hepatitis, cholestatic jaundice, [s2]nephrotic syndrome[e2]  renal papillary necrosis, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints.
	(5, 33)	dapsone	peripheral neuropathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6015	Less common adverse events to [s1]dapsone[e1] include the idiosyncratic reactions of leukopenia and agranulocytosis, cutaneous eruptions, [s2]peripheral neuropathy[e2]  psychosis, toxic hepatitis, cholestatic jaundice, nephrotic syndrome, renal papillary necrosis, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints.
	(5, 38)	dapsone	psychosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6016	Less common adverse events to [s1]dapsone[e1] include the idiosyncratic reactions of leukopenia and agranulocytosis, cutaneous eruptions, peripheral neuropathy, [s2]psychosis[e2]  toxic hepatitis, cholestatic jaundice, nephrotic syndrome, renal papillary necrosis, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints.
	(5, 58)	dapsone	renal papillary necrosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6017	Less common adverse events to [s1]dapsone[e1] include the idiosyncratic reactions of leukopenia and agranulocytosis, cutaneous eruptions, peripheral neuropathy, psychosis, toxic hepatitis, cholestatic jaundice, nephrotic syndrome, [s2]renal papillary necrosis[e2]  severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints.
	(5, 65)	dapsone	severe hypoalbuminemia without proteinuria	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6018	Less common adverse events to [s1]dapsone[e1] include the idiosyncratic reactions of leukopenia and agranulocytosis, cutaneous eruptions, peripheral neuropathy, psychosis, toxic hepatitis, cholestatic jaundice, nephrotic syndrome, renal papillary necrosis, [s2]severe hypoalbuminemia without proteinuria[e2]  an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints.
	(5, 41)	dapsone	toxic hepatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6019	Less common adverse events to [s1]dapsone[e1] include the idiosyncratic reactions of leukopenia and agranulocytosis, cutaneous eruptions, peripheral neuropathy, psychosis, [s2]toxic hepatitis[e2]  cholestatic jaundice, nephrotic syndrome, renal papillary necrosis, severe hypoalbuminemia without proteinuria, an infectious mononucleosis-like syndrome, and minor neurological and gastrointestinal complaints.
	(0, 15)	Methemoglobinemia	dapsone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6020	 [s1]Methemoglobinemia[e1] is another common finding among patients receiving [s2]dapsone[e2] therapy, but rarely does it result in prominent symptoms other than transient pallor.
	(0, 13)	Acetazolamide	osteomalacia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6021	 [s1]Acetazolamide[e1] accelerated anticonvulsant [s2]osteomalacia[e2] 
	(0, 13)	Acetazolamide	osteomalacia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6022	 [s1]Acetazolamide[e1] may have accelerated the development of [s2]osteomalacia[e2] by several mechanisms, including increased renal calcium excretion.
	(0, 40)	Severe osteomalacia	acetazolamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6023	 [s1]Severe osteomalacia[e1] was present in two epileptic patients who were under long-term treatment with congeners of phenytoin, phenobarbital, and [s2]acetazolamide[e2] 
	(0, 33)	Severe osteomalacia	phenobarbital	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6024	 [s1]Severe osteomalacia[e1] was present in two epileptic patients who were under long-term treatment with congeners of phenytoin, [s2]phenobarbital[e2]  and acetazolamide.
	(0, 28)	Severe osteomalacia	phenytoin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6025	 [s1]Severe osteomalacia[e1] was present in two epileptic patients who were under long-term treatment with congeners of [s2]phenytoin[e2]  phenobarbital, and acetazolamide.
	(2, 23)	encephalopathy	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6026	The delayed [s1]encephalopathy[e1] developed 9 and 22 months respectively after the first dose of intrathecal [s2]methotrexate[e2] 
	(38, 64)	hydrocephalus	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6027	We report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed leukoencephalopathy and [s1]hydrocephalus[e1] related to central nervous system prophylaxis by, in the first case intrathecally administered [s2]methotrexate[e2] and, in the second by intrathecally administered methotrexate and cranial irradiation.
	(38, 64)	hydrocephalus	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6028	We report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed leukoencephalopathy and [s1]hydrocephalus[e1] related to central nervous system prophylaxis by, in the first case intrathecally administered [s2]methotrexate[e2] and, in the second by intrathecally administered methotrexate and cranial irradiation.
	(30, 64)	leukoencephalopathy	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6029	We report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed [s1]leukoencephalopathy[e1] and hydrocephalus related to central nervous system prophylaxis by, in the first case intrathecally administered [s2]methotrexate[e2] and, in the second by intrathecally administered methotrexate and cranial irradiation.
	(30, 64)	leukoencephalopathy	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6030	We report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed [s1]leukoencephalopathy[e1] and hydrocephalus related to central nervous system prophylaxis by, in the first case intrathecally administered [s2]methotrexate[e2] and, in the second by intrathecally administered methotrexate and cranial irradiation.
	(7, 14)	loperamide poisoning	loperamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6031	A retrospective study was conducted of 40 [s1]loperamide poisoning[e1]  [s2]loperamide[e2] poisoning cases recorded at the Centre National d'Informations Toxicologiques Veterinaires.
	(0, 10)	Loperamide poisoning	Loperamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6032	 [s1]Loperamide poisoning[e1] in the dog [s2]Loperamide[e2] poisoning in the dog.
	(12, 24)	Creutzfeldt-Jakob like syndrome	lithium carbonate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6033	a 67-year-old man with bipolar disorder developed a [s1]Creutzfeldt-Jakob like syndrome[e1] during [s2]lithium carbonate[e2] treatment.
	(0, 4)	Lithium	Creutzfeldt-Jakob syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6034	 [s1]Lithium[e1] induced [s2]Creutzfeldt-Jakob syndrome[e2] 
	(0, 12)	Lithium	Creutzfeldt-Jakob disease	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6035	 [s1]Lithium[e1] neurotoxicity should be considered in [s2]Creutzfeldt-Jakob disease[e2] differential diagnosis, serial electroencephalograms being the most valuable.
	(0, 33)	Lithium neurotoxicity	Lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6036	 [s1]Lithium neurotoxicity[e1] should be considered in Creutzfeldt-Jakob disease differential diagnosis, serial electroencephalograms being the most valuable [s2]Lithium[e2] neurotoxicity should be considered in Creutzfeldt-Jakob disease differential diagnosis, serial electroencephalograms being the most valuable.
	(3, 7)	lithium	Creutzfeldt-Jakob syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6037	"Several cases of [s1]lithium[e1] induced [s2]Creutzfeldt-Jakob syndrome[e2] have been reported to date; all of them were elderly patients and a half had ""therapeutic"" lithium serum levels."
	(3, 7)	lithium	Creutzfeldt-Jakob syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6038	"Several cases of [s1]lithium[e1] induced [s2]Creutzfeldt-Jakob syndrome[e2] have been reported to date; all of them were elderly patients and a half had ""therapeutic"" lithium serum levels."
	(18, 22)	magnesium	protracted neuromuscular block	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6039	A noninvasive method in the differential diagnosis of vecuronium-induced and [s1]magnesium[e1] induced [s2]protracted neuromuscular block[e2] in a severely preeclamptic patient.
	(11, 22)	vecuronium	protracted neuromuscular block	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6040	A noninvasive method in the differential diagnosis of [s1]vecuronium[e1] induced and magnesium-induced [s2]protracted neuromuscular block[e2] in a severely preeclamptic patient.
	(3, 20)	neuromuscular blockade	magnesium sulfate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6041	The occurrence of [s1]neuromuscular blockade[e1] and the resulting potentiation of muscle relaxants during [s2]magnesium sulfate[e2] (MgSO4) administration is well known.
	(3, 22)	neuromuscular blockade	MgSO4	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6042	The occurrence of [s1]neuromuscular blockade[e1] and the resulting potentiation of muscle relaxants during magnesium sulfate  [s2]MgSO4[e2]  administration is well known.
	(11, 20)	potentiation of muscle relaxants	magnesium sulfate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6043	The occurrence of neuromuscular blockade and the resulting [s1]potentiation of muscle relaxants[e1] during [s2]magnesium sulfate[e2] (MgSO4) administration is well known.
	(11, 22)	potentiation of muscle relaxants	MgSO4	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6044	The occurrence of neuromuscular blockade and the resulting [s1]potentiation of muscle relaxants[e1] during magnesium sulfate  [s2]MgSO4[e2]  administration is well known.
	(13, 17)	magnesium	neuromuscular block	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6045	We also describe a new, noninvasive method to assess [s1]magnesium[e1] induced [s2]neuromuscular block[e2] when curariform muscle relaxant was given simultaneously.
	(0, 13)	Hepatobiliary disorders	terbinafine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6046	 [s1]Hepatobiliary disorders[e1] associated with orally administered [s2]terbinafine[e2] have rarely been reported.
	(0, 6)	Terbinafine	cholestatic liver disease	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6047	 [s1]Terbinafine[e1] induced [s2]cholestatic liver disease[e2] 
	(6, 12)	terbinafine	cholestatic liver disease	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6048	We describe a case of prolonged [s1]terbinafine[e1] induced [s2]cholestatic liver disease[e2] 
	(19, 29)	metabolic acidosis	cetrimide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6049	A patient with a large hydatid cyst of the left lobe of the liver developed [s1]metabolic acidosis[e1] following rather liberal use of [s2]cetrimide[e2] chlorhexidine solution as a scolicidal agent.
	(19, 32)	metabolic acidosis	chlorhexidine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6050	A patient with a large hydatid cyst of the left lobe of the liver developed [s1]metabolic acidosis[e1] following rather liberal use of cetrimide [s2]chlorhexidine[e2] solution as a scolicidal agent.
	(0, 7)	Metabolic acidosis	cetrimide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6051	 [s1]Metabolic acidosis[e1] induced by [s2]cetrimide[e2] chlorhexidine solution in hydatid cyst surgery.
	(0, 10)	Metabolic acidosis	chlorhexidine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6052	 [s1]Metabolic acidosis[e1] induced by cetrimide [s2]chlorhexidine[e2] solution in hydatid cyst surgery.
	(4, 8)	Ecstasy poisoning	Ecstasy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6053	An unusual case of [s1]Ecstasy poisoning[e1]  [s2]Ecstasy[e2] poisoning.
	(5, 9)	poisoning	3,4-methylenedioxymet-amphetamine Ecstasy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6054	We describe a case of [s1]poisoning[e1] with [s2]3,4-methylenedioxymet-amphetamine Ecstasy[e2] that presented with all the features suggestive of a fatal outcome, including a creatinine phosphokinase level markedly higher than any previously reported.
	(10, 19)	photosensitivity	mequitazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6055	However, dermatologists should be cautious about a [s1]photosensitivity[e1] reaction induced by [s2]mequitazine[e2] or other phenothiazine-derivative drugs.
	(5, 23)	erythematous macule	mequitazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6056	In addition, an immediate [s1]erythematous macule[e1] was observed on the photopatch test site of [s2]mequitazine[e2] directly after UV exposure which was similar to the immediate erythema noted in chlorpromazine photoallergy.
	(4, 24)	immediate erythema	mequitazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6057	In addition, an [s1]immediate erythema[e1] ous macule was observed on the photopatch test site of [s2]mequitazine[e2] directly after UV exposure which was similar to the immediate erythema noted in chlorpromazine photoallergy.
	(27, 54)	mequitazine	cross-reaction to promethazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6058	In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken [s1]mequitazine[e1] for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, [s2]cross-reaction to promethazine[e2]  decreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the mequitazine.
	(27, 54)	mequitazine	cross-reaction to promethazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6059	In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken [s1]mequitazine[e1] for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, [s2]cross-reaction to promethazine[e2]  decreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the mequitazine.
	(52, 62)	cross-reaction to promethazine	promethazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6060	In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken mequitazine for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, [s1]cross-reaction to promethazine[e1]  [s2]promethazine[e2]  decreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the mequitazine.
	(27, 63)	mequitazine	decreased MED to both UVA and UVB	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6061	In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken [s1]mequitazine[e1] for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross-reaction to promethazine, [s2]decreased MED to both UVA and UVB[e2]  and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the mequitazine.
	(27, 63)	mequitazine	decreased MED to both UVA and UVB	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6062	In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken [s1]mequitazine[e1] for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross-reaction to promethazine, [s2]decreased MED to both UVA and UVB[e2]  and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the mequitazine.
	(56, 62)	promethazine	decreased MED to both UVA and UVB	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6063	In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken mequitazine for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross-reaction to [s1]promethazine[e1]  [s2]decreased MED to both UVA and UVB[e2]  and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the mequitazine.
	(27, 49)	mequitazine	erythema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6064	In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken [s1]mequitazine[e1] for 6 months, and there were strong positive photopatch test results with immediate [s2]erythema[e2] reaction, cross-reaction to promethazine, decreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the mequitazine.
	(27, 49)	mequitazine	erythema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6065	In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken [s1]mequitazine[e1] for 6 months, and there were strong positive photopatch test results with immediate [s2]erythema[e2] reaction, cross-reaction to promethazine, decreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the mequitazine.
	(47, 58)	erythema	promethazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6066	In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken mequitazine for 6 months, and there were strong positive photopatch test results with immediate [s1]erythema[e1] reaction, cross-reaction to [s2]promethazine[e2]  decreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3-year follow-up period after discontinuation of the mequitazine.
	(27, 74)	mequitazine	persistence of the photosensitivity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6067	In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken [s1]mequitazine[e1] for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross-reaction to promethazine, decreased MED to both UVA and UVB, and [s2]persistence of the photosensitivity[e2] over a 3-year follow-up period after discontinuation of the mequitazine.
	(27, 74)	mequitazine	persistence of the photosensitivity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6068	In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken [s1]mequitazine[e1] for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross-reaction to promethazine, decreased MED to both UVA and UVB, and [s2]persistence of the photosensitivity[e2] over a 3-year follow-up period after discontinuation of the mequitazine.
	(56, 73)	promethazine	persistence of the photosensitivity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6069	In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken mequitazine for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross-reaction to [s1]promethazine[e1]  decreased MED to both UVA and UVB, and [s2]persistence of the photosensitivity[e2] over a 3-year follow-up period after discontinuation of the mequitazine.
	(20, 27)	mequitazine	photosensitivity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6070	Mequitazine seemed to play a part similar to chlorpromazine, and absence of [s1]mequitazine[e1] induced [s2]photosensitivity[e2] may be due to a relatively low dosage of the drug.
	(3, 10)	mequitazine	photosensitivity reactions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6071	Two cases of [s1]mequitazine[e1] induced [s2]photosensitivity reactions[e2] 
	(5, 12)	mequitazine	photosensitivity reaction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6072	We experienced 2 cases of [s1]mequitazine[e1] induced [s2]photosensitivity reaction[e2] in patients who took mequitazine for their dermatologic problems.
	(5, 12)	mequitazine	photosensitivity reaction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6073	We experienced 2 cases of [s1]mequitazine[e1] induced [s2]photosensitivity reaction[e2] in patients who took mequitazine for their dermatologic problems.
	(0, 6)	Keratitis	methamphetamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6074	 [s1]Keratitis[e1] in [s2]methamphetamine[e2] abusers.
	(0, 29)	Methamphetamine	injury to the cornea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6075	 [s1]Methamphetamine[e1] s extensive physiologic effects, inconsistent street purity, and multiple routes of administration offer many possibilities for [s2]injury to the cornea[e2] 
	(10, 57)	keratitis	lidocaine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6076	"Potential causes of methamphetamine-related [s1]keratitis[e1] can be divided into four categories resulting from (a) direct pharmacologic and physical effects of methamphetamine; (b) the toxic effects of diluting or ""cutting"" agents such as [s2]lidocaine[e2] and quinine; (c) effects related to the route of drug administration (intravenous, inhalation, smoking); and (d) manufacture-related effects of exposure to unintentional caustic contaminants in the final product."
	(3, 11)	methamphetamine	keratitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6077	"Potential causes of [s1]methamphetamine[e1] related [s2]keratitis[e2] can be divided into four categories resulting from (a) direct pharmacologic and physical effects of methamphetamine; (b) the toxic effects of diluting or ""cutting"" agents such as lidocaine and quinine; (c) effects related to the route of drug administration (intravenous, inhalation, smoking); and (d) manufacture-related effects of exposure to unintentional caustic contaminants in the final product."
	(10, 61)	keratitis	quinine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6078	"Potential causes of methamphetamine-related [s1]keratitis[e1] can be divided into four categories resulting from (a) direct pharmacologic and physical effects of methamphetamine; (b) the toxic effects of diluting or ""cutting"" agents such as lidocaine and [s2]quinine[e2]  (c) effects related to the route of drug administration (intravenous, inhalation, smoking); and (d) manufacture-related effects of exposure to unintentional caustic contaminants in the final product."
	(43, 57)	toxic effects	lidocaine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6079	"Potential causes of methamphetamine-related keratitis can be divided into four categories resulting from (a) direct pharmacologic and physical effects of methamphetamine; (b) the [s1]toxic effects[e1] of diluting or ""cutting"" agents such as [s2]lidocaine[e2] and quinine; (c) effects related to the route of drug administration (intravenous, inhalation, smoking); and (d) manufacture-related effects of exposure to unintentional caustic contaminants in the final product."
	(3, 44)	methamphetamine	toxic effects	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6080	"Potential causes of [s1]methamphetamine[e1] related keratitis can be divided into four categories resulting from (a) direct pharmacologic and physical effects of methamphetamine; (b) the [s2]toxic effects[e2] of diluting or ""cutting"" agents such as lidocaine and quinine; (c) effects related to the route of drug administration (intravenous, inhalation, smoking); and (d) manufacture-related effects of exposure to unintentional caustic contaminants in the final product."
	(43, 61)	toxic effects	quinine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6081	"Potential causes of methamphetamine-related keratitis can be divided into four categories resulting from (a) direct pharmacologic and physical effects of methamphetamine; (b) the [s1]toxic effects[e1] of diluting or ""cutting"" agents such as lidocaine and [s2]quinine[e2]  (c) effects related to the route of drug administration (intravenous, inhalation, smoking); and (d) manufacture-related effects of exposure to unintentional caustic contaminants in the final product."
	(4, 39)	methamphetamine	keratitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6082	The increasing prevalence of [s1]methamphetamine[e1] abuse and the severity of the associated ulcers should alert ophthalmologists to the problem of methamphetamine-related [s2]keratitis[e2] 
	(4, 18)	methamphetamine	ulcers	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6083	The increasing prevalence of [s1]methamphetamine[e1] abuse and the severity of the associated [s2]ulcers[e2] should alert ophthalmologists to the problem of methamphetamine-related keratitis.
	(5, 14)	severe corneal ulceration	methamphetamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6084	We report four cases of [s1]severe corneal ulceration[e1] in [s2]methamphetamine[e2] abusers.
	(2, 31)	Methotrexate	cirrhosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6085	BACKGROUND: [s1]Methotrexate[e1] (MTX) may induce liver damage, which in some psoriatics will lead to fibrosis or [s2]cirrhosis[e2] 
	(7, 29)	MTX	cirrhosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6086	BACKGROUND: Methotrexate  [s1]MTX[e1]  may induce liver damage, which in some psoriatics will lead to fibrosis or [s2]cirrhosis[e2] 
	(2, 27)	Methotrexate	fibrosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6087	BACKGROUND: [s1]Methotrexate[e1] (MTX) may induce liver damage, which in some psoriatics will lead to [s2]fibrosis[e2] or cirrhosis.
	(7, 25)	MTX	fibrosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6088	BACKGROUND: Methotrexate  [s1]MTX[e1]  may induce liver damage, which in some psoriatics will lead to [s2]fibrosis[e2] or cirrhosis.
	(2, 15)	Methotrexate	liver damage	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6089	BACKGROUND: [s1]Methotrexate[e1] (MTX) may induce [s2]liver damage[e2]  which in some psoriatics will lead to fibrosis or cirrhosis.
	(7, 13)	MTX	liver damage	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6090	BACKGROUND: Methotrexate  [s1]MTX[e1]  may induce [s2]liver damage[e2]  which in some psoriatics will lead to fibrosis or cirrhosis.
	(9, 14)	MTX	liver cirrhosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6091	CONCLUSIONS: This study confirmed that in most patients [s1]MTX[e1] induced [s2]liver cirrhosis[e2] is not aggressive.
	(6, 30)	MTX	death	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6092	However, continued low-dose [s1]MTX[e1] led, in spite of normal liver tests, 8 years after the last biopsy to liver failure and [s2]death[e2] in 1 of our patients.
	(6, 27)	MTX	liver failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6093	However, continued low-dose [s1]MTX[e1] led, in spite of normal liver tests, 8 years after the last biopsy to [s2]liver failure[e2] and death in 1 of our patients.
	(0, 8)	Methotrexate	liver cirrhosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6094	 [s1]Methotrexate[e1] induced [s2]liver cirrhosis[e2] 
	(9, 15)	MTX	cirrhosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6095	Studies performed 10 years ago on 25 patients with [s1]MTX[e1] induced liver [s2]cirrhosis[e2] indicated that this type of cirrhosis was not of an aggressive nature.
	(9, 14)	MTX	liver cirrhosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6096	Studies performed 10 years ago on 25 patients with [s1]MTX[e1] induced [s2]liver cirrhosis[e2] indicated that this type of cirrhosis was not of an aggressive nature.
	(16, 40)	cresol	high fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6097	After therapy for diabetic coma with insulin (containing the preservative [s1]cresol[e1]  and electrolyte solutions was started, the patient complained of increasing myalgia, developed a [s2]high fever[e2] and respiratory and metabolic acidosis and lost consciousness.
	(8, 41)	insulin	high fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6098	After therapy for diabetic coma with [s1]insulin[e1] (containing the preservative cresol) and electrolyte solutions was started, the patient complained of increasing myalgia, developed a [s2]high fever[e2] and respiratory and metabolic acidosis and lost consciousness.
	(16, 33)	cresol	increasing myalgia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6099	After therapy for diabetic coma with insulin (containing the preservative [s1]cresol[e1]  and electrolyte solutions was started, the patient complained of [s2]increasing myalgia[e2]  developed a high fever and respiratory and metabolic acidosis and lost consciousness.
	(8, 34)	insulin	increasing myalgia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6100	After therapy for diabetic coma with [s1]insulin[e1] (containing the preservative cresol) and electrolyte solutions was started, the patient complained of [s2]increasing myalgia[e2]  developed a high fever and respiratory and metabolic acidosis and lost consciousness.
	(16, 49)	cresol	lost consciousness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6101	After therapy for diabetic coma with insulin (containing the preservative [s1]cresol[e1]  and electrolyte solutions was started, the patient complained of increasing myalgia, developed a high fever and respiratory and metabolic acidosis and [s2]lost consciousness[e2] 
	(8, 50)	insulin	lost consciousness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6102	After therapy for diabetic coma with [s1]insulin[e1] (containing the preservative cresol) and electrolyte solutions was started, the patient complained of increasing myalgia, developed a high fever and respiratory and metabolic acidosis and [s2]lost consciousness[e2] 
	(16, 43)	cresol	respiratory and metabolic acidosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6103	After therapy for diabetic coma with insulin (containing the preservative [s1]cresol[e1]  and electrolyte solutions was started, the patient complained of increasing myalgia, developed a high fever and [s2]respiratory and metabolic acidosis[e2] and lost consciousness.
	(8, 44)	insulin	respiratory and metabolic acidosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6104	After therapy for diabetic coma with [s1]insulin[e1] (containing the preservative cresol) and electrolyte solutions was started, the patient complained of increasing myalgia, developed a high fever and [s2]respiratory and metabolic acidosis[e2] and lost consciousness.
	(11, 20)	cresol	MH	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6105	However, other factors or drugs (e.g. [s1]cresol[e1]  are thought to induce [s2]MH[e2] 
	(6, 17)	MH	cresol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6106	This case supports the assessment that [s1]MH[e1] and diabetes are associated diseases and that [s2]cresol[e2] could possibly trigger MH.
	(3, 24)	beclomethasone diproprionate	eosinophilic pneumonia reaction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6107	The use of [s1]beclomethasone diproprionate[e1] inhaler complicated by the development of an [s2]eosinophilic pneumonia reaction[e2] 
	(0, 16)	Fatal intravascular autoimmune hemolytic anemia	fludarabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6108	 [s1]Fatal intravascular autoimmune hemolytic anemia[e1] after [s2]fludarabine[e2] treatment for chronic lymphocytic leukemia.
	(9, 32)	AIHA	fludarabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6109	Physicians should be aware of the risk of severe [s1]AIHA[e1] in CLL patients with a history of AIHA or positivation of the DAT during previous [s2]fludarabine[e2] administration, or in case of secondary fixation of complement to the red cell membrane occurring during fludarabine treatment.
	(9, 32)	AIHA	fludarabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6110	Physicians should be aware of the risk of severe [s1]AIHA[e1] in CLL patients with a history of AIHA or positivation of the DAT during previous [s2]fludarabine[e2] administration, or in case of secondary fixation of complement to the red cell membrane occurring during fludarabine treatment.
	(9, 32)	AIHA	fludarabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6111	Physicians should be aware of the risk of severe [s1]AIHA[e1] in CLL patients with a history of AIHA or positivation of the DAT during previous [s2]fludarabine[e2] administration, or in case of secondary fixation of complement to the red cell membrane occurring during fludarabine treatment.
	(9, 32)	AIHA	fludarabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6112	Physicians should be aware of the risk of severe [s1]AIHA[e1] in CLL patients with a history of AIHA or positivation of the DAT during previous [s2]fludarabine[e2] administration, or in case of secondary fixation of complement to the red cell membrane occurring during fludarabine treatment.
	(22, 32)	positivation of the DAT	fludarabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6113	Physicians should be aware of the risk of severe AIHA in CLL patients with a history of AIHA or [s1]positivation of the DAT[e1] during previous [s2]fludarabine[e2] administration, or in case of secondary fixation of complement to the red cell membrane occurring during fludarabine treatment.
	(22, 32)	positivation of the DAT	fludarabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6114	Physicians should be aware of the risk of severe AIHA in CLL patients with a history of AIHA or [s1]positivation of the DAT[e1] during previous [s2]fludarabine[e2] administration, or in case of secondary fixation of complement to the red cell membrane occurring during fludarabine treatment.
	(4, 14)	AIHA	fludarabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6115	The occurrence of severe [s1]AIHA[e1] in CLL patients treated with [s2]fludarabine[e2] has been reported by several authors.
	(34, 39)	AIHA	fludarabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6116	We report the case of a patient with chronic lymphocytic leukemia (CLL) who developed fatal intravascular autoimmune hemolytic anemia  [s1]AIHA[e1]  after [s2]fludarabine[e2] treatment.
	(21, 41)	fatal intravascular autoimmune hemolytic anemia	fludarabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6117	We report the case of a patient with chronic lymphocytic leukemia (CLL) who developed [s1]fatal intravascular autoimmune hemolytic anemia[e1] (AIHA) after [s2]fludarabine[e2] treatment.
	(7, 17)	fludarabine	DAT became positive with anti-IgG and anti-C3d antiglobulins	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6118	When the patient was treated again with [s1]fludarabine[e1] nine months later, the [s2]DAT became positive with anti-IgG and anti-C3d antiglobulins[e2] after the second course of treatment.
	(13, 42)	tobramycin	tetany	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6119	She had just finished a 3-week course of intravenous [s1]tobramycin[e1] for bronchiectasis and had an elevated serum tobramycin trough level 1 week before the onset of [s2]tetany[e2] 
	(0, 14)	Tetany	tobramycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6120	 [s1]Tetany[e1] in a child with AIDS receiving intravenous [s2]tobramycin[e2] 
	(6, 12)	renal toxicity	tobramycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6121	This pattern is suggestive of [s1]renal toxicity[e1] due to [s2]tobramycin[e2] 
	(27, 33)	insulin	dedifferentiation of the adipocytes	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6122	CONCLUSIONS: In our reported case, a local hyperproduction of TNF-alpha from macrophages that was induced by the injected [s1]insulin[e1] could explain the [s2]dedifferentiation of the adipocytes[e2] of the subcutaneous tissue and the reversion that was induced by the local injection of dexamethasone.
	(9, 29)	hyperproduction of TNF-alpha	insulin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6123	CONCLUSIONS: In our reported case, a local [s1]hyperproduction of TNF-alpha[e1] from macrophages that was induced by the injected [s2]insulin[e2] could explain the dedifferentiation of the adipocytes of the subcutaneous tissue and the reversion that was induced by the local injection of dexamethasone.
	(0, 4)	Insulin	lipoatrophy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6124	 [s1]Insulin[e1] induced [s2]lipoatrophy[e2] in type I diabetes.
	(37, 41)	insulin	lipoatrophies	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6125	OBJECTIVE: To test the hypothesis that tumor necrosis factor (TNF)-alpha may mediate the loss and the dedifferentiation of subcutaneous fat tissue in the [s1]insulin[e1] induced [s2]lipoatrophies[e2] of a diabetic patient who presented extensive lesions.
	(0, 12)	Erosion of psoriatic plaques	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6126	 [s1]Erosion of psoriatic plaques[e1]  an early sign of [s2]methotrexate[e2] toxicity.
	(11, 19)	methotrexate toxicity	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6127	Erosion of psoriatic plaques: an early sign of [s1]methotrexate toxicity[e1]  [s2]methotrexate[e2] toxicity.
	(0, 11)	Methotrexate	potentially toxic	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6128	 [s1]Methotrexate[e1] is an effective but [s2]potentially toxic[e2] treatment for psoriasis.
	(13, 27)	methotrexate	bone marrow suppression	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6129	Painful erosion of psoriatic plaques is a less common sign of [s1]methotrexate[e1] toxicity that may precede evidence of [s2]bone marrow suppression[e2] 
	(13, 21)	methotrexate toxicity	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6130	Painful erosion of psoriatic plaques is a less common sign of [s1]methotrexate toxicity[e1]  [s2]methotrexate[e2] toxicity that may precede evidence of bone marrow suppression.
	(0, 15)	Painful erosion of psoriatic plaques	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6131	 [s1]Painful erosion of psoriatic plaques[e1] is a less common sign of [s2]methotrexate[e2] toxicity that may precede evidence of bone marrow suppression.
	(20, 28)	methotrexate toxicity	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6132	We describe two patients in whom painful erosions of their psoriasis developed as the presenting sign of [s1]methotrexate toxicity[e1]  [s2]methotrexate[e2] toxicity and review the literature, emphasizing the risk factors associated with this manifestation.
	(6, 22)	painful erosions of their psoriasis	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6133	We describe two patients in whom [s1]painful erosions of their psoriasis[e1] developed as the presenting sign of [s2]methotrexate[e2] toxicity and review the literature, emphasizing the risk factors associated with this manifestation.
	(5, 14)	methotrexate	bone marrow suppression	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6134	Well-known signs of [s1]methotrexate[e1] toxicity include [s2]bone marrow suppression[e2] and oral and gastrointestinal ulceration.
	(5, 13)	methotrexate toxicity	methotrexate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6135	Well-known signs of [s1]methotrexate toxicity[e1]  [s2]methotrexate[e2] toxicity include bone marrow suppression and oral and gastrointestinal ulceration.
	(5, 18)	methotrexate	oral and gastrointestinal ulceration	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6136	Well-known signs of [s1]methotrexate[e1] toxicity include bone marrow suppression and [s2]oral and gastrointestinal ulceration[e2] 
	(3, 15)	cimetidine	decreased oxygen saturation and arterial PO2	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6137	After treatment with [s1]cimetidine[e1]  there was a rapid deterioration with [s2]decreased oxygen saturation and arterial PO2[e2] values.
	(4, 16)	cimetidine	upper gastrointestinal bleeding	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6138	Caution with use of [s1]cimetidine[e1] in tolazoline induced [s2]upper gastrointestinal bleeding[e2] 
	(9, 16)	tolazoline	upper gastrointestinal bleeding	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6139	Caution with use of cimetidine in [s1]tolazoline[e1] induced [s2]upper gastrointestinal bleeding[e2] 
	(17, 39)	cimetidine	upper gastrointestinal hemorrhage	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6140	However, given the clinically significant result to the interaction between tolazoline and [s1]cimetidine[e1] we report, the use of cimetidine in tolazoline induced [s2]upper gastrointestinal hemorrhage[e2] should deserve more attention.
	(17, 39)	cimetidine	upper gastrointestinal hemorrhage	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6141	However, given the clinically significant result to the interaction between tolazoline and [s1]cimetidine[e1] we report, the use of cimetidine in tolazoline induced [s2]upper gastrointestinal hemorrhage[e2] should deserve more attention.
	(12, 39)	tolazoline	upper gastrointestinal hemorrhage	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6142	However, given the clinically significant result to the interaction between [s1]tolazoline[e1] and cimetidine we report, the use of cimetidine in tolazoline induced [s2]upper gastrointestinal hemorrhage[e2] should deserve more attention.
	(12, 39)	tolazoline	upper gastrointestinal hemorrhage	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6143	However, given the clinically significant result to the interaction between [s1]tolazoline[e1] and cimetidine we report, the use of cimetidine in tolazoline induced [s2]upper gastrointestinal hemorrhage[e2] should deserve more attention.
	(7, 17)	tolazoline	gastrointestinal bleeding	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6144	Hypoxemia improved during continuous [s1]tolazoline[e1] infusion, but [s2]gastrointestinal bleeding[e2] occurred.
	(4, 29)	Ambien	death	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6145	Zolpidem  [s1]Ambien[e1] , a relatively new nonbenzodiazepine sedative-hypnotic, was involved in the [s2]death[e2] of a 39-year-old obese male who was being treated for depression and insomnia.
	(0, 31)	Zolpidem	death	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6146	 [s1]Zolpidem[e1] (Ambien), a relatively new nonbenzodiazepine sedative-hypnotic, was involved in the [s2]death[e2] of a 39-year-old obese male who was being treated for depression and insomnia.
	(11, 15)	death	Ambien	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6147	Zolpidem tissue concentrations in a multiple drug related [s1]death[e1] involving [s2]Ambien[e2] 
	(0, 13)	Zolpidem	death	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6148	 [s1]Zolpidem[e1] tissue concentrations in a multiple drug related [s2]death[e2] involving Ambien.
	(1, 7)	nitrite toxicity	nitrite	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6149	Acute [s1]nitrite toxicity[e1]  [s2]nitrite[e2] toxicity results from industrial exposure, accidental ingestion (e.g., abuse of organic nitrites as an aphrodisiac, especially in the male homosexual population), and suicidal ingestion.
	(6, 10)	nitrate	methemoglobinemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6150	Infants are particularly susceptible to chronic [s1]nitrate[e1] induced [s2]methemoglobinemia[e2] because of their low stomach acid production, large numbers of nitrite-reducing bacteria, and the relatively easy oxidation of fetal hemoglobin.
	(1, 8)	esmolol toxicity	esmolol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6151	Acute [s1]esmolol toxicity[e1]  [s2]esmolol[e2] toxicity may be self-limiting because of its extremely short half-life.
	(16, 31)	esmolol hydrochloride	asystole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6152	After induction of general anesthesia and administration of a standard dose of intravenous [s1]esmolol hydrochloride[e1]  her cardiac rhythm progressed to [s2]asystole[e2] 
	(0, 5)	Cardiac arrest	esmolol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6153	 [s1]Cardiac arrest[e1] after [s2]esmolol[e2] administration: a review of acute beta-blocker toxicity.
	(0, 7)	Atenolol	memory impairment	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6154	 [s1]Atenolol[e1] induced [s2]memory impairment[e2]  a case report.
	(1, 12)	impaired memory	atenolol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6155	His [s1]impaired memory[e1] was found to be due to the [s2]atenolol[e2] he was on and he made a complete recovery on withdrawing the beta-blocker.
	(17, 23)	amiodarone	thyrotoxicosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6156	A potential role for renal and hepatic impairment in the observed protracted course of [s1]amiodarone[e1] induced [s2]thyrotoxicosis[e2] is suggested.
	(26, 32)	amiodarone	thyroiditis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6157	Failure of plasmapheresis, corticosteroids and thionamides to ameliorate a case of protracted [s1]amiodarone[e1] induced [s2]thyroiditis[e2] 
	(5, 11)	amiodarone	thyrotoxicosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6158	We report a case of [s1]amiodarone[e1] induced [s2]thyrotoxicosis[e2] of protracted duration, unresponsive to conventional thionamide therapy, with therapy limited by severe adverse drug reactions.
	(0, 6)	Psychotic disorder	isoniazid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6159	 [s1]Psychotic disorder[e1] associated with [s2]isoniazid[e2] 
	(7, 15)	psychotic disorder	isoniazid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6160	We evaluated a patient who developed a [s1]psychotic disorder[e1] after 4 months of [s2]isoniazid[e2] prophylaxis for a positive tuberculosis tine test.
	(17, 37)	pulmonary vasoconstriction	protamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6161	A case report is presented concerning the administration of ketanserin in the treatment of [s1]pulmonary vasoconstriction[e1] and right ventricular failure following the infusion of [s2]protamine[e2] in a patient undergoing coronary artery bypass surgery and mitral valve replacement.
	(25, 37)	right ventricular failure	protamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6162	A case report is presented concerning the administration of ketanserin in the treatment of pulmonary vasoconstriction and [s1]right ventricular failure[e1] following the infusion of [s2]protamine[e2] in a patient undergoing coronary artery bypass surgery and mitral valve replacement.
	(8, 14)	protamine	pulmonary hypertension	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6163	Ketanserin in the treatment of [s1]protamine[e1] induced [s2]pulmonary hypertension[e2] 
	(7, 35)	protamine	bronchoconstriction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6164	The reversal of heparin by [s1]protamine[e1] may cause severe hemodynamic deterioration, characterized by systemic hypotension, pulmonary hypertension, and [s2]bronchoconstriction[e2] 
	(7, 30)	protamine	pulmonary hypertension	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6165	The reversal of heparin by [s1]protamine[e1] may cause severe hemodynamic deterioration, characterized by systemic hypotension, [s2]pulmonary hypertension[e2]  and bronchoconstriction.
	(7, 14)	protamine	severe hemodynamic deterioration	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6166	The reversal of heparin by [s1]protamine[e1] may cause [s2]severe hemodynamic deterioration[e2]  characterized by systemic hypotension, pulmonary hypertension, and bronchoconstriction.
	(7, 23)	protamine	systemic hypotension	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6167	The reversal of heparin by [s1]protamine[e1] may cause severe hemodynamic deterioration, characterized by [s2]systemic hypotension[e2]  pulmonary hypertension, and bronchoconstriction.
	(16, 28)	methicillin	acute nephritic syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6168	A drug addict with staphylococcal endocarditis treated with [s1]methicillin[e1]  who developed massive proteinuria and [s2]acute nephritic syndrome[e2] is described.
	(16, 24)	methicillin	massive proteinuria	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6169	A drug addict with staphylococcal endocarditis treated with [s1]methicillin[e1]  who developed [s2]massive proteinuria[e2] and acute nephritic syndrome is described.
	(0, 20)	Focal glomerulonephritis	methicillin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6170	 [s1]Focal glomerulonephritis[e1] and interstitial nephritis in [s2]methicillin[e2] treated, heroin-related infective endocarditis.
	(10, 20)	interstitial nephritis	methicillin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6171	Focal glomerulonephritis and [s1]interstitial nephritis[e1] in [s2]methicillin[e2] treated, heroin-related infective endocarditis.
	(11, 17)	rifabutin	uveitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6172	METHODS/RESULTS: This paper presents a new case of [s1]rifabutin[e1]  [s2]uveitis[e2] and a review of the various published reports to date.
	(11, 18)	uveitis	rifabutin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6173	over the past 3 years there have been several reports of [s1]uveitis[e1] associated with [s2]rifabutin[e2] therapy.
	(0, 7)	Uveitis	rifabutin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6174	 [s1]Uveitis[e1] associated with [s2]rifabutin[e2] therapy: a clinical alert.
	(21, 29)	large cerebral infarction	praziquantel	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6175	CASE DESCRIPTION: A 59-year-old man with known neurocysticercosis developed a [s1]large cerebral infarction[e1] during [s2]praziquantel[e2] therapy.
	(0, 8)	Large cerebral infarction	praziquantel	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6176	 [s1]Large cerebral infarction[e1] during [s2]praziquantel[e2] therapy in neurocysticercosis.
	(17, 54)	5-FU	diarrhea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6177	DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for [s1]5-FU[e1] catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., [s2]diarrhea[e2]  stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of 5-FU.
	(17, 54)	5-FU	diarrhea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6178	DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for [s1]5-FU[e1] catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., [s2]diarrhea[e2]  stomatitis, mucositis, myelosuppression, neurotoxicity) to standard doses of 5-FU.
	(17, 63)	5-FU	mucositis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6179	DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for [s1]5-FU[e1] catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, [s2]mucositis[e2]  myelosuppression, neurotoxicity) to standard doses of 5-FU.
	(17, 63)	5-FU	mucositis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6180	DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for [s1]5-FU[e1] catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, [s2]mucositis[e2]  myelosuppression, neurotoxicity) to standard doses of 5-FU.
	(17, 67)	5-FU	myelosuppression	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6181	DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for [s1]5-FU[e1] catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, [s2]myelosuppression[e2]  neurotoxicity) to standard doses of 5-FU.
	(17, 67)	5-FU	myelosuppression	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6182	DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for [s1]5-FU[e1] catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, [s2]myelosuppression[e2]  neurotoxicity) to standard doses of 5-FU.
	(17, 74)	5-FU	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6183	DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for [s1]5-FU[e1] catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, [s2]neurotoxicity[e2]  to standard doses of 5-FU.
	(17, 74)	5-FU	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6184	DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for [s1]5-FU[e1] catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, stomatitis, mucositis, myelosuppression, [s2]neurotoxicity[e2]  to standard doses of 5-FU.
	(17, 58)	5-FU	stomatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6185	DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for [s1]5-FU[e1] catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, [s2]stomatitis[e2]  mucositis, myelosuppression, neurotoxicity) to standard doses of 5-FU.
	(17, 58)	5-FU	stomatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6186	DATA SYNTHESIS: Genetic deficiencies in DPD, the rate-limiting enzyme responsible for [s1]5-FU[e1] catabolism, may occur in 3% or more of patients with cancer putting them at increased risk for unusually severe adverse reactions (e.g., diarrhea, [s2]stomatitis[e2]  mucositis, myelosuppression, neurotoxicity) to standard doses of 5-FU.
	(20, 26)	severe adverse reactions	5-fluorouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6187	Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing [s1]severe adverse reactions[e1] to [s2]5-fluorouracil[e2] based chemotherapy.
	(40, 46)	lethal adverse reactions	5-fluorouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6188	PURPOSE/OBJECTIVES: To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase (DPD) deficiency, which predisposes patients with cancer to potentially [s1]lethal adverse reactions[e1] following [s2]5-fluorouracil[e2] (5-FU)-based chemotherapy.
	(40, 53)	lethal adverse reactions	5-FU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6189	PURPOSE/OBJECTIVES: To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase (DPD) deficiency, which predisposes patients with cancer to potentially [s1]lethal adverse reactions[e1] following 5-fluorouracil  [s2]5-FU[e2] -based chemotherapy.
	(13, 52)	5-FU	coma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6190	The principle treatment for DPD-deficient patients with severe acute [s1]5-FU[e1] reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and [s2]coma[e2] 
	(13, 52)	5-FU	coma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6191	The principle treatment for DPD-deficient patients with severe acute [s1]5-FU[e1] reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and [s2]coma[e2] 
	(13, 46)	5-FU	encephalopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6192	The principle treatment for DPD-deficient patients with severe acute [s1]5-FU[e1] reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as [s2]encephalopathy[e2] and coma.
	(13, 46)	5-FU	encephalopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6193	The principle treatment for DPD-deficient patients with severe acute [s1]5-FU[e1] reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as [s2]encephalopathy[e2] and coma.
	(13, 40)	5-FU	neurologic symptoms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6194	The principle treatment for DPD-deficient patients with severe acute [s1]5-FU[e1] reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced [s2]neurologic symptoms[e2] such as encephalopathy and coma.
	(13, 40)	5-FU	neurologic symptoms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6195	The principle treatment for DPD-deficient patients with severe acute [s1]5-FU[e1] reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced [s2]neurologic symptoms[e2] such as encephalopathy and coma.
	(11, 19)	severe acute 5-FU reactions	5-FU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6196	The principle treatment for DPD-deficient patients with [s1]severe acute 5-FU reactions[e1]  [s2]5-FU[e2] reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma.
	(11, 19)	severe acute 5-FU reactions	5-FU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6197	The principle treatment for DPD-deficient patients with [s1]severe acute 5-FU reactions[e1]  [s2]5-FU[e2] reactions is supportive care; however, the administration of thymidine potentially may reverse severe 5-FU-induced neurologic symptoms such as encephalopathy and coma.
	(24, 35)	5-ASA	fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6198	A 49-year-old man with Crohn's disease treated with prednisone and mesalamine  [s1]5-ASA[e1]  developed worsening respiratory distress and [s2]fever[e2] 
	(21, 37)	mesalamine	fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6199	A 49-year-old man with Crohn's disease treated with prednisone and [s1]mesalamine[e1] (5-ASA) developed worsening respiratory distress and [s2]fever[e2] 
	(16, 37)	prednisone	fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6200	A 49-year-old man with Crohn's disease treated with [s1]prednisone[e1] and mesalamine (5-ASA) developed worsening respiratory distress and [s2]fever[e2] 
	(24, 30)	5-ASA	worsening respiratory distress	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6201	A 49-year-old man with Crohn's disease treated with prednisone and mesalamine  [s1]5-ASA[e1]  developed [s2]worsening respiratory distress[e2] and fever.
	(21, 32)	mesalamine	worsening respiratory distress	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6202	A 49-year-old man with Crohn's disease treated with prednisone and [s1]mesalamine[e1] (5-ASA) developed [s2]worsening respiratory distress[e2] and fever.
	(16, 32)	prednisone	worsening respiratory distress	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6203	A 49-year-old man with Crohn's disease treated with [s1]prednisone[e1] and mesalamine (5-ASA) developed [s2]worsening respiratory distress[e2] and fever.
	(0, 6)	Mesalamine	hypersensitivity pneumonitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6204	 [s1]Mesalamine[e1] induced [s2]hypersensitivity pneumonitis[e2] 
	(0, 7)	Mesalamine	hypersensitivity pneumonitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6205	 [s1]Mesalamine[e1] may cause [s2]hypersensitivity pneumonitis[e2] in patients with Crohn's disease.
	(14, 29)	prednisolone	mite infestation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6206	Immunosuppression elicited by the extensive administration of [s1]prednisolone[e1] was suspected for the initiation of the generalized [s2]mite infestation[e2] 
	(2, 10)	Colchicine	adverse effect on wound healing	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6207	BACKGROUND: [s1]Colchicine[e1] has a known [s2]adverse effect on wound healing[e2] through its inhibitory effect on tubulin-dependent cell functions and through collagenase activation.
	(2, 29)	Colchicine	collagenase activation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6208	BACKGROUND: [s1]Colchicine[e1] has a known adverse effect on wound healing through its inhibitory effect on tubulin-dependent cell functions and through [s2]collagenase activation[e2] 
	(10, 16)	colchicine	delay corneal wound healing	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6209	CONCLUSION: The findings in these two patients suggest that [s1]colchicine[e1] may [s2]delay corneal wound healing[e2] 
	(0, 12)	Delay of corneal wound healing	colchicine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6210	 [s1]Delay of corneal wound healing[e1] in patients treated with [s2]colchicine[e2] 
	(7, 26)	corneal ulcers refractory to conventional treatment	colchicine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6211	The authors report on two patients with [s1]corneal ulcers refractory to conventional treatment[e1] while the patients were undergoing oral [s2]colchicine[e2] therapy.
	(7, 23)	corneal ulcers refractory to conventional treatment	colchicine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6212	The authors suggest that in patients with [s1]corneal ulcers refractory to conventional treatment[e1] who are receiving [s2]colchicine[e2]  cessation of colchicine therapy should be considered.
	(0, 12)	Fulminant hepatic failure	bicalutamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6213	 [s1]Fulminant hepatic failure[e1] associated with [s2]bicalutamide[e2] 
	(13, 34)	minocycline	eruption	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6214	A 17-year-old female patient who had been taking oral [s1]minocycline[e1] (50 mg twice daily) for 3 weeks for acne developed an [s2]eruption[e2] that progressed to an exfoliative dermatitis.
	(13, 39)	minocycline	exfoliative dermatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6215	A 17-year-old female patient who had been taking oral [s1]minocycline[e1] (50 mg twice daily) for 3 weeks for acne developed an eruption that progressed to an [s2]exfoliative dermatitis[e2] 
	(25, 35)	dermatitis	minocycline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6216	Fever, lymphadenopathy, eosinophilia, lymphocytosis, hepatitis, and [s1]dermatitis[e1]  a severe adverse reaction to [s2]minocycline[e2] 
	(9, 35)	eosinophilia	minocycline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6217	Fever, lymphadenopathy, [s1]eosinophilia[e1]  lymphocytosis, hepatitis, and dermatitis: a severe adverse reaction to [s2]minocycline[e2] 
	(0, 35)	Fever	minocycline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6218	 [s1]Fever[e1]  lymphadenopathy, eosinophilia, lymphocytosis, hepatitis, and dermatitis: a severe adverse reaction to [s2]minocycline[e2] 
	(22, 35)	hepatitis	minocycline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6219	Fever, lymphadenopathy, eosinophilia, lymphocytosis, [s1]hepatitis[e1]  and dermatitis: a severe adverse reaction to [s2]minocycline[e2] 
	(2, 35)	lymphadenopathy	minocycline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6220	Fever, [s1]lymphadenopathy[e1]  eosinophilia, lymphocytosis, hepatitis, and dermatitis: a severe adverse reaction to [s2]minocycline[e2] 
	(15, 35)	lymphocytosis	minocycline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6221	Fever, lymphadenopathy, eosinophilia, [s1]lymphocytosis[e1]  hepatitis, and dermatitis: a severe adverse reaction to [s2]minocycline[e2] 
	(7, 34)	minocycline	lymphocyte over-activation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6222	This severe illness was likely caused by [s1]minocycline[e1]  and we speculate that minocycline may have acted as a superantigen, causing [s2]lymphocyte over-activation[e2] and massive cytokine release.
	(7, 43)	minocycline	massive cytokine release	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6223	This severe illness was likely caused by [s1]minocycline[e1]  and we speculate that minocycline may have acted as a superantigen, causing lymphocyte over-activation and [s2]massive cytokine release[e2] 
	(1, 9)	severe illness	minocycline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6224	This [s1]severe illness[e1] was likely caused by [s2]minocycline[e2]  and we speculate that minocycline may have acted as a superantigen, causing lymphocyte over-activation and massive cytokine release.
	(0, 8)	Delayed hypersensitivity	flurbiprofen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6225	 [s1]Delayed hypersensitivity[e1] to [s2]flurbiprofen[e2] 
	(0, 11)	Eye movement disorders	cyclosporin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6226	 [s1]Eye movement disorders[e1] in bone marrow transplant patients on [s2]cyclosporin[e2] and ganciclovir.
	(0, 17)	Eye movement disorders	ganciclovir	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6227	 [s1]Eye movement disorders[e1] in bone marrow transplant patients on cyclosporin and [s2]ganciclovir[e2] 
	(3, 11)	MRI T2 abnormalities	cyclosporin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6228	One patient had [s1]MRI T2 abnormalities[e1] compatible with [s2]cyclosporin[e2] neurotoxicity.
	(9, 16)	cyclosporin	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6229	One patient had MRI T2 abnormalities compatible with [s1]cyclosporin[e1]  [s2]neurotoxicity[e2] 
	(4, 31)	cyclosporin	eye movement abnormality	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6230	We postulate that [s1]cyclosporin[e1]  possibly together with ganciclovir, can produce transient brain stem or neuromuscular dysfunction with [s2]eye movement abnormality[e2] in occasional patients.
	(13, 31)	ganciclovir	eye movement abnormality	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6231	We postulate that cyclosporin, possibly together with [s1]ganciclovir[e1]  can produce transient brain stem or neuromuscular dysfunction with [s2]eye movement abnormality[e2] in occasional patients.
	(4, 21)	cyclosporin	transient brain stem or neuromuscular dysfunction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6232	We postulate that [s1]cyclosporin[e1]  possibly together with ganciclovir, can produce [s2]transient brain stem or neuromuscular dysfunction[e2] with eye movement abnormality in occasional patients.
	(13, 21)	ganciclovir	transient brain stem or neuromuscular dysfunction	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6233	We postulate that cyclosporin, possibly together with [s1]ganciclovir[e1]  can produce [s2]transient brain stem or neuromuscular dysfunction[e2] with eye movement abnormality in occasional patients.
	(3, 13)	thrombosis	GnRH-a	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6234	CONCLUSION: While [s1]thrombosis[e1] has been reported with [s2]GnRH-a[e2] therapy in men with prostate cancer, its association with treatment in this benign case may have been a consequence of the massive tumor size.
	(4, 31)	tamoxifen	endometrial carcinoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6235	The possible effects of [s1]tamoxifen[e1] upon the uterus are discussed in this article, in view of reports of tamoxifen associated with [s2]endometrial carcinoma[e2] and endometriosis.
	(4, 39)	tamoxifen	endometriosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6236	The possible effects of [s1]tamoxifen[e1] upon the uterus are discussed in this article, in view of reports of tamoxifen associated with endometrial carcinoma and [s2]endometriosis[e2] 
	(3, 8)	adverse response	clonidine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6237	Case study: [s1]adverse response[e1] to [s2]clonidine[e2] 
	(3, 8)	adverse experiences	clonidine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6238	Four cases of [s1]adverse experiences[e1] with [s2]clonidine[e2] are described.
	(17, 32)	confusion	acetohexamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6239	In one instance a systemic hypoglycemic reaction resulting in head trauma and [s1]confusion[e1] ended in an emegency hospital admission following the substitution of [s2]acetohexamide[e2] for acetazolamide.
	(14, 32)	head trauma	acetohexamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6240	In one instance a systemic hypoglycemic reaction resulting in [s1]head trauma[e1] and confusion ended in an emegency hospital admission following the substitution of [s2]acetohexamide[e2] for acetazolamide.
	(4, 32)	systemic hypoglycemic reaction	acetohexamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6241	In one instance a [s1]systemic hypoglycemic reaction[e1] resulting in head trauma and confusion ended in an emegency hospital admission following the substitution of [s2]acetohexamide[e2] for acetazolamide.
	(6, 17)	itraconazole	drug eruption	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6242	Discontinuation of the [s1]itraconazole[e1] caused resolution of the [s2]drug eruption[e2] 
	(12, 17)	drug eruption	itraconazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6243	Primary cutaneous coccidioidomycosis and subsequent [s1]drug eruption[e1] to [s2]itraconazole[e2] in a dog.
	(0, 17)	Primary cutaneous coccidioidomycosis	itraconazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6244	 [s1]Primary cutaneous coccidioidomycosis[e1] and subsequent drug eruption to [s2]itraconazole[e2] in a dog.
	(23, 34)	potentially fatal symptom	retinoic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6245	"Its overall toxicity is considerably less compared to standard induction chemotherapy; however, it is associated with a high incidence of a [s1]potentially fatal symptom[e1] complex referred to as  [s2]retinoic acid[e2] syndrome."" This report describes a patient with APL who developed the syndrome a few weeks after initiating induction therapy with ATRA despite being treated for hyperleukocytosis."
	(32, 39)	retinoic acid syndrome	retinoic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6246	"Its overall toxicity is considerably less compared to standard induction chemotherapy; however, it is associated with a high incidence of a potentially fatal symptom complex referred to as  [s1]retinoic acid syndrome[e1]  [s2]retinoic acid[e2] syndrome."" This report describes a patient with APL who developed the syndrome a few weeks after initiating induction therapy with ATRA despite being treated for hyperleukocytosis."
	(2, 34)	toxicity	retinoic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6247	"Its overall [s1]toxicity[e1] is considerably less compared to standard induction chemotherapy; however, it is associated with a high incidence of a potentially fatal symptom complex referred to as  [s2]retinoic acid[e2] syndrome."" This report describes a patient with APL who developed the syndrome a few weeks after initiating induction therapy with ATRA despite being treated for hyperleukocytosis."
	(7, 26)	amiodarone	polymorphous ventricular tachycardia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6248	Eleven days after initiation of therapy with [s1]amiodarone[e1]  the patient experienced syncope and was noted to have recurrent episodes of [s2]polymorphous ventricular tachycardia[e2] 
	(7, 15)	amiodarone	syncope	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6249	Eleven days after initiation of therapy with [s1]amiodarone[e1]  the patient experienced [s2]syncope[e2] and was noted to have recurrent episodes of polymorphous ventricular tachycardia.
	(0, 18)	Nonsustained polymorphous ventricular tachycardia	amiodarone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6250	 [s1]Nonsustained polymorphous ventricular tachycardia[e1] during [s2]amiodarone[e2] therapy for atrial fibrillation complicating cardiomyopathy.
	(2, 12)	proarrhythmic	amiodarone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6251	The probable [s1]proarrhythmic[e1] action of [s2]amiodarone[e2]  although rare, is reviewed along with a discussion of the novel use of intravenous magnesium sulfate therapy.
	(0, 9)	Acute asthma	verapamil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6252	 [s1]Acute asthma[e1] associated with sustained-release [s2]verapamil[e2] 
	(7, 40)	verapamil	acute asthma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6253	Although dyspnea associated with [s1]verapamil[e1] administration has been reported, this is the first report of an elderly asymptomatic asthmatic patient with hypertension who developed an [s2]acute asthma[e2] attack following sustained-release verapamil administration.
	(1, 9)	dyspnea	verapamil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6254	Although [s1]dyspnea[e1] associated with [s2]verapamil[e2] administration has been reported, this is the first report of an elderly asymptomatic asthmatic patient with hypertension who developed an acute asthma attack following sustained-release verapamil administration.
	(5, 19)	verapamil	asthma attack	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6255	CONCLUSIONS: Sustained-release [s1]verapamil[e1] is thought to be the cause of the [s2]asthma attack[e2] in this patient because she was not taking any other preparations; the symptoms started with the administration of sustained-release verapamil and were relieved after its discontinuation.
	(5, 19)	verapamil	asthma attack	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6256	CONCLUSIONS: Sustained-release [s1]verapamil[e1] is thought to be the cause of the [s2]asthma attack[e2] in this patient because she was not taking any other preparations; the symptoms started with the administration of sustained-release verapamil and were relieved after its discontinuation.
	(22, 32)	acute asthma	verapamil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6257	OBJECTIVE: To describe a patient with asymptomatic bronchial asthma and hypertension who developed an [s1]acute asthma[e1] attack after receiving sustained-release [s2]verapamil[e2] 
	(3, 34)	verapamil	asthma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6258	She continued taking [s1]verapamil[e1] for 6 months, then, on her own, stopped all medications including the sustained-release verapamil, and her [s2]asthma[e2] symptoms disappeared.
	(0, 13)	Cephalexin rash	Cephalexin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6259	 [s1]Cephalexin rash[e1] in infectious mononucleosis [s2]Cephalexin[e2] rash in infectious mononucleosis.
	(1, 7)	ampicillin rash	ampicillin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6260	The [s1]ampicillin rash[e1]  [s2]ampicillin[e2] rash occurring in cases of infectious mononucleosis is well documented.
	(13, 23)	cephalexin	rash	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6261	The case of a patient with infectious mononucleosis treated with [s1]cephalexin[e1] who later showed a [s2]rash[e2] is presented and the previous literature is reviewed.
	(1, 13)	rash	cephalexin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6262	The [s1]rash[e1] seen in this patient, who was treated with [s2]cephalexin[e2]  may be similar to the rash seen with ampicillin treatment of patients with infectious mononucleosis.
	(1, 26)	rash	ampicillin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6263	The [s1]rash[e1] seen in this patient, who was treated with cephalexin, may be similar to the rash seen with [s2]ampicillin[e2] treatment of patients with infectious mononucleosis.
	(4, 12)	carbamazepine	pancreatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6264	A possible case of [s1]carbamazepine[e1] induced [s2]pancreatitis[e2] 
	(7, 23)	pancreatitis	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6265	The authors report a case of acute [s1]pancreatitis[e1] (AP) occurring in a patient under treatment with [s2]carbamazepine[e2] (CBZ) for post-traumatic petit mal epilepsy, and review the current literature of drug-induced AP.
	(7, 28)	pancreatitis	CBZ	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6266	The authors report a case of acute [s1]pancreatitis[e1] (AP) occurring in a patient under treatment with carbamazepine  [s2]CBZ[e2]  for post-traumatic petit mal epilepsy, and review the current literature of drug-induced AP.
	(8, 45)	CBZ	acute pancreatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6267	The evidence of high plasmatic levels of [s1]CBZ[e1] and the absence of other aetiologic factors lead the authors to conclude that the overdose of CBZ could have represented the precipitating of the episode of [s2]acute pancreatitis[e2] 
	(8, 45)	CBZ	acute pancreatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6268	The evidence of high plasmatic levels of [s1]CBZ[e1] and the absence of other aetiologic factors lead the authors to conclude that the overdose of CBZ could have represented the precipitating of the episode of [s2]acute pancreatitis[e2] 
	(4, 80)	MTX	pneumonitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6269	Although risk factors for [s1]MTX[e1] induced pulmonary toxicity are poorly understood, the presence in 3 out of 5 of our patients of pre-existing lung disease, represented by diffuse interstitial changes on chest X-ray, and mild bronchial asthma in two RA patients and by pulmonary silicosis in the patient with PsA may account for a predisposition to the development of MTX [s2]pneumonitis[e2] 
	(4, 9)	MTX	pulmonary toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6270	Although risk factors for [s1]MTX[e1] induced [s2]pulmonary toxicity[e2] are poorly understood, the presence in 3 out of 5 of our patients of pre-existing lung disease, represented by diffuse interstitial changes on chest X-ray, and mild bronchial asthma in two RA patients and by pulmonary silicosis in the patient with PsA may account for a predisposition to the development of MTX pneumonitis.
	(0, 8)	Methotrexate	pneumonitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6271	 [s1]Methotrexate[e1] induced [s2]pneumonitis[e2] in patients with rheumatoid arthritis and psoriatic arthritis: report of five cases and review of the literature.
	(5, 10)	MTX	pneumonitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6272	On the other hand, [s1]MTX[e1] induced [s2]pneumonitis[e2] seems to be very rare in psoriatic arthritis (PsA).
	(12, 31)	MTX	pneumonitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6273	Our review of 194 RA patients and 38 PsA patients receiving [s1]MTX[e1] has identified four RA patients and one PsA patient with MTX-induced [s2]pneumonitis[e2]  giving a prevalence of 2.1% and 0.03%, respectively.
	(0, 24)	Pneumonitis	MTX	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6274	 [s1]Pneumonitis[e1] is emerging as one of the most unpredictable and potentially serious, adverse effects of treatment with [s2]MTX[e2] 
	(65, 70)	MTX	pneumonitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6275	The presence of a lymphocyte alveolitis with a predominance of CD4+ T cells in 3 RA patients and CD8+ T cells with a concomitant increase in neutrophils in another case suggests that immunologically mediated reactions may be one damage mechanism in [s1]MTX[e1] induced [s2]pneumonitis[e2] 
	(10, 67)	hepatic angiosarcoma	inorganic arsenic	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6276	A retrospective epidemiological study of deaths from [s1]hepatic angiosarcoma[e1] (HAS) in the U.S. showed that during 1964--74 there were 168 such cases, of which 37 (22%) were associated with previously known causes (vinyl chloride, 'Thorotrast', and [s2]inorganic arsenic[e2]  and 4 (3.1%) of the remaining 131 cases with the use of androgenic-anabolic steroids.
	(10, 59)	hepatic angiosarcoma	Thorotrast	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6277	A retrospective epidemiological study of deaths from [s1]hepatic angiosarcoma[e1] (HAS) in the U.S. showed that during 1964--74 there were 168 such cases, of which 37 (22%) were associated with previously known causes (vinyl chloride,  [s2]Thorotrast[e2] , and inorganic arsenic) and 4 (3.1%) of the remaining 131 cases with the use of androgenic-anabolic steroids.
	(10, 55)	hepatic angiosarcoma	vinyl chloride	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6278	A retrospective epidemiological study of deaths from [s1]hepatic angiosarcoma[e1] (HAS) in the U.S. showed that during 1964--74 there were 168 such cases, of which 37 (22%) were associated with previously known causes  [s2]vinyl chloride[e2]  'Thorotrast', and inorganic arsenic) and 4 (3.1%) of the remaining 131 cases with the use of androgenic-anabolic steroids.
	(8, 15)	ferrous sulfate	reduce the gastrointestinal absorption of orally administered levothyroxine sodium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6279	Recent studies have shown that under experimental conditions [s1]ferrous sulfate[e1] may [s2]reduce the gastrointestinal absorption of orally administered levothyroxine sodium[e2] in patients with primary hypothyroidism.
	(6, 15)	hypothyroid	ferrous sulfate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6280	We describe a patient who became [s1]hypothyroid[e1] while taking [s2]ferrous sulfate[e2] 
	(6, 21)	hepatitis B vaccination	mental nerve neuropathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6281	However, as the use of [s1]hepatitis B vaccination[e1] is growing, adverse side effects, including [s2]mental nerve neuropathy[e2]  should be observed with an increased frequency.
	(0, 11)	Mental nerve neuropathy	hepatitis B vaccination	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6282	 [s1]Mental nerve neuropathy[e1] as a result of [s2]hepatitis B vaccination[e2] 
	(7, 17)	tamoxifen	proliferative lesions of the endometrium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6283	Although its side effects are few, [s1]tamoxifen[e1] increases the incidence of [s2]proliferative lesions of the endometrium[e2]  which theoretically should be preventable with progestational agents.
	(11, 35)	tamoxifen	intermittent spotting	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6284	CASES: Two postmenopausal women treated with [s1]tamoxifen[e1] and progestational agents for breast carcinoma developed uterine enlargement and [s2]intermittent spotting[e2] 
	(11, 29)	tamoxifen	uterine enlargement	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6285	CASES: Two postmenopausal women treated with [s1]tamoxifen[e1] and progestational agents for breast carcinoma developed [s2]uterine enlargement[e2] and intermittent spotting.
	(12, 30)	carcinoma	tamoxifen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6286	CONCLUSIONS: The value of multihormonal therapy in breast [s1]carcinoma[e1] is not established, and the addition of progestogens to [s2]tamoxifen[e2] may not reduce of developing endometrial lesions, including carcinoma.
	(28, 39)	tamoxifen	endometrial lesions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6287	CONCLUSIONS: The value of multihormonal therapy in breast carcinoma is not established, and the addition of progestogens to [s1]tamoxifen[e1] may not reduce of developing [s2]endometrial lesions[e2]  including carcinoma.
	(0, 16)	Bleomycin	metastatic nodules	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6288	 [s1]Bleomycin[e1] and cyclophosphamide toxicity simulating [s2]metastatic nodules[e2] to the lungs in childhood cancer.
	(5, 16)	cyclophosphamide	metastatic nodules	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6289	Bleomycin and [s1]cyclophosphamide[e1] toxicity simulating [s2]metastatic nodules[e2] to the lungs in childhood cancer.
	(12, 24)	fibrotic lesions	bleomycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6290	Thoracoscopic biopsy to confirm metastasis revealed instead [s1]fibrotic lesions[e1] apparently attributable to [s2]bleomycin[e2] or cyclophosphamide.
	(12, 29)	fibrotic lesions	cyclophosphamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6291	Thoracoscopic biopsy to confirm metastasis revealed instead [s1]fibrotic lesions[e1] apparently attributable to bleomycin or [s2]cyclophosphamide[e2] 
	(4, 15)	procainamide hydrochloride	lupus syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6292	An elderly man with [s1]procainamide hydrochloride[e1] induced [s2]lupus syndrome[e2] had a circulating anticoagulant against factor XI and a biologic false-positive (BFP) test result for syphilis.
	(8, 15)	procainamide	lupus syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6293	Circulating anticoagulant in the [s1]procainamide[e1] induced [s2]lupus syndrome[e2] 
	(3, 19)	hypermagnesemia	magnesium sulfate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6294	Clinical signs of [s1]hypermagnesemia[e1] are an uncommon complication following oral administration of [s2]magnesium sulfate[e2] 
	(17, 22)	magnesium toxicosis	magnesium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6295	Establishment of diuresis with fluids and IV administration of calcium may provide successful treatment of [s1]magnesium toxicosis[e1]  [s2]magnesium[e2] toxicosis in horses.
	(0, 8)	Magnesium toxicosis	Magnesium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6296	 [s1]Magnesium toxicosis[e1] in two horses [s2]Magnesium[e2] toxicosis in two horses.
	(2, 33)	magnesium	magnesium toxicosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6297	Overdose of [s1]magnesium[e1] sulfate in combination with renal insufficiency, hypocalcemia, or compromise of intestinal integrity may predispose horses to [s2]magnesium toxicosis[e2] 
	(2, 33)	magnesium sulfate	magnesium toxicosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6298	Overdose of [s1]magnesium sulfate[e1] in combination with renal insufficiency, hypocalcemia, or compromise of intestinal integrity may predispose horses to [s2]magnesium toxicosis[e2] 
	(17, 25)	lovastatin	rhabdomyolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6299	CASE SUMMARIES: In each case, the patients were treated over 5 years with [s1]lovastatin[e1] and developed [s2]rhabdomyolysis[e2] that coincided with the completion of a prescribed regimen of a newer macrolide antibiotic.
	(8, 26)	rhabdomyolysis	azithromycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6300	CONCLUSIONS: The risk of drug-induced [s1]rhabdomyolysis[e1] due to the potential interaction between lovastatin and [s2]azithromycin[e2] or clarithromycin should be considered before the concomitant use of these agents.
	(8, 32)	rhabdomyolysis	clarithromycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6301	CONCLUSIONS: The risk of drug-induced [s1]rhabdomyolysis[e1] due to the potential interaction between lovastatin and azithromycin or [s2]clarithromycin[e2] should be considered before the concomitant use of these agents.
	(8, 21)	rhabdomyolysis	lovastatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6302	CONCLUSIONS: The risk of drug-induced [s1]rhabdomyolysis[e1] due to the potential interaction between [s2]lovastatin[e2] and azithromycin or clarithromycin should be considered before the concomitant use of these agents.
	(30, 38)	rhabdomyolysis	lovastatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6303	DISCUSSION: Rhabdomyolysis is a clinical syndrome resulting from the destruction of skeletal muscle that may progress to renal failure Several drugs have been associated with [s1]rhabdomyolysis[e1]  including [s2]lovastatin[e2]  a hydroxymethylglutaryl-coenzyme A reductase inhibitor.
	(0, 25)	Erythromycin	rhabdomyolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6304	 [s1]Erythromycin[e1] is a macrolide antibiotic that may increase the risk of lovastatin-induced [s2]rhabdomyolysis[e2] 
	(17, 24)	lovastatin	rhabdomyolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6305	Erythromycin is a macrolide antibiotic that may increase the risk of [s1]lovastatin[e1] induced [s2]rhabdomyolysis[e2] 
	(6, 23)	rhabdomyolysis	azithromycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6306	Lovastatin-induced [s1]rhabdomyolysis[e1] possibly associated with clarithromycin and [s2]azithromycin[e2] 
	(6, 16)	rhabdomyolysis	clarithromycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6307	Lovastatin-induced [s1]rhabdomyolysis[e1] possibly associated with [s2]clarithromycin[e2] and azithromycin.
	(0, 7)	Lovastatin	rhabdomyolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6308	 [s1]Lovastatin[e1] induced [s2]rhabdomyolysis[e2] possibly associated with clarithromycin and azithromycin.
	(7, 43)	rhabdomyolysis	azithromycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6309	OBJECTIVE: To describe two cases of [s1]rhabdomyolysis[e1] in patients taking lovastatin that were precipitated by the use of the newer macrolide antibiotics clarithromycin and [s2]azithromycin[e2] 
	(7, 36)	rhabdomyolysis	clarithromycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6310	OBJECTIVE: To describe two cases of [s1]rhabdomyolysis[e1] in patients taking lovastatin that were precipitated by the use of the newer macrolide antibiotics [s2]clarithromycin[e2] and azithromycin.
	(7, 17)	rhabdomyolysis	lovastatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6311	OBJECTIVE: To describe two cases of [s1]rhabdomyolysis[e1] in patients taking [s2]lovastatin[e2] that were precipitated by the use of the newer macrolide antibiotics clarithromycin and azithromycin.
	(18, 27)	rhabdomyolysis	azithromycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6312	To our knowledge, these cases are the first published reports of lovastatin-induced [s1]rhabdomyolysis[e1] associated with [s2]azithromycin[e2] and clarithromycin.
	(18, 33)	rhabdomyolysis	clarithromycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6313	To our knowledge, these cases are the first published reports of lovastatin-induced [s1]rhabdomyolysis[e1] associated with azithromycin and [s2]clarithromycin[e2] 
	(12, 19)	lovastatin	rhabdomyolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6314	To our knowledge, these cases are the first published reports of [s1]lovastatin[e1] induced [s2]rhabdomyolysis[e2] associated with azithromycin and clarithromycin.
	(35, 49)	died	prednisone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6315	These cases were considered unusual in light of the short delay of their onset after initiation of immunosuppressive therapy and their fulminant course: 3 of these patients [s1]died[e1] of PCP occurring during the first month of treatment with [s2]prednisone[e2] 
	(9, 32)	severe hypertension	epinephrine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6316	We report the specifics of 12 cases of [s1]severe hypertension[e1] after the intraoperative use of topical phenylephrine, submucosal [s2]epinephrine[e2]  or both.
	(9, 22)	severe hypertension	phenylephrine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6317	We report the specifics of 12 cases of [s1]severe hypertension[e1] after the intraoperative use of topical [s2]phenylephrine[e2]  submucosal epinephrine, or both.
	(0, 7)	Acute leukaemia	tamoxifen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6318	 [s1]Acute leukaemia[e1] during [s2]tamoxifen[e2] therapy.
	(0, 10)	Tamoxifen	carcinogenic	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6319	 [s1]Tamoxifen[e1] is suggested to be [s2]carcinogenic[e2] both through direct genotoxic and epigenetic mechanisms.
	(6, 20)	acute myeloid leukaemia	tamoxifen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6320	We report two cases that developed [s1]acute myeloid leukaemia[e1] (AML) during [s2]tamoxifen[e2] therapy for breast cancer.
	(13, 18)	AML	tamoxifen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6321	We report two cases that developed acute myeloid leukaemia  [s1]AML[e1]  during [s2]tamoxifen[e2] therapy for breast cancer.
	(0, 21)	Relapse in the external auditory canal of acute promyelocytic leukemia	all-trans retinoic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6322	 [s1]Relapse in the external auditory canal of acute promyelocytic leukemia[e1] after treatment with [s2]all-trans retinoic acid[e2] 
	(9, 24)	extramedullary relapse	ATRA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6323	This case suggests the importance of careful observation for [s1]extramedullary relapse[e1] in patients who are treated with [s2]ATRA[e2] 
	(0, 13)	Cutaneous reactions	methimazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6324	 [s1]Cutaneous reactions[e1] to propylthiouracil and [s2]methimazole[e2] occur in 3%-5% of adults.
	(0, 6)	Cutaneous reactions	propylthiouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6325	 [s1]Cutaneous reactions[e1] to [s2]propylthiouracil[e2] and methimazole occur in 3%-5% of adults.
	(0, 22)	Generalized maculopapular and papular purpuric eruptions	thionamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6326	 [s1]Generalized maculopapular and papular purpuric eruptions[e1] are perhaps the most common [s2]thionamide[e2] induced reactions.
	(0, 9)	Propylthiouracil	cutaneous vasculitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6327	 [s1]Propylthiouracil[e1] induced [s2]cutaneous vasculitis[e2] 
	(3, 14)	cutaneous vasculitis	propylthiouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6328	The observation of [s1]cutaneous vasculitis[e1] during administration of [s2]propylthiouracil[e2] suggested that clinical awareness of this complication should be of considerable importance.
	(23, 31)	heat stroke	zonisamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6329	A 2-year-old mentally retarded boy with frontal lobe epilepsy presented with an episode that resembled [s1]heat stroke[e1] during the administration of [s2]zonisamide[e2] 
	(2, 20)	zonisamide	neurological symptoms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6330	Children receiving [s1]zonisamide[e1] should be monitored for oligohidrosis and the development of [s2]neurological symptoms[e2] associated with an elevation of body temperature.
	(2, 12)	zonisamide	oligohidrosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6331	Children receiving [s1]zonisamide[e1] should be monitored for [s2]oligohidrosis[e2] and the development of neurological symptoms associated with an elevation of body temperature.
	(0, 12)	Heat stroke-like episode	zonisamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6332	 [s1]Heat stroke-like episode[e1] in a child caused by [s2]zonisamide[e2] 
	(1, 9)	oligohidrosis	zonisamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6333	The [s1]oligohidrosis[e1] caused by [s2]zonisamide[e2] was reversible in that the patient regained the ability to sweat within 2 weeks of the cessation of drug administration.
	(0, 11)	Acute renal failure	suramin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6334	 [s1]Acute renal failure[e1] in a patient receiving treatment with [s2]suramin[e2] 
	(1, 14)	renal failure	suramin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6335	Acute [s1]renal failure[e1] should be recognized as a potential complication of [s2]suramin[e2] treatment.
	(4, 26)	renal failure	suramin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6336	Other potential causes of [s1]renal failure[e1] were not present in our patient and his renal function gradually recovered with the cessation of [s2]suramin[e2] treatment.
	(11, 22)	nonoliguric renal failure	suramin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6337	We describe a patient with metastatic prostate cancer who developed [s1]nonoliguric renal failure[e1] during treatment with [s2]suramin[e2] 
	(0, 6)	Clozapine	polyserositis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6338	 [s1]Clozapine[e1] induced [s2]polyserositis[e2] 
	(13, 38)	pericardial effusion	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6339	We report the case of a patient who developed polyserositis  [s1]pericardial effusion[e1]  pleural effusion, and pericarditis) after being started on [s2]clozapine[e2]  and whose symptoms remitted upon discontinuation of clozapine.
	(13, 38)	pericardial effusion	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6340	We report the case of a patient who developed polyserositis  [s1]pericardial effusion[e1]  pleural effusion, and pericarditis) after being started on [s2]clozapine[e2]  and whose symptoms remitted upon discontinuation of clozapine.
	(29, 39)	pericarditis	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6341	We report the case of a patient who developed polyserositis (pericardial effusion, pleural effusion, and [s1]pericarditis[e1]  after being started on [s2]clozapine[e2]  and whose symptoms remitted upon discontinuation of clozapine.
	(29, 39)	pericarditis	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6342	We report the case of a patient who developed polyserositis (pericardial effusion, pleural effusion, and [s1]pericarditis[e1]  after being started on [s2]clozapine[e2]  and whose symptoms remitted upon discontinuation of clozapine.
	(21, 39)	pleural effusion	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6343	We report the case of a patient who developed polyserositis (pericardial effusion, [s1]pleural effusion[e1]  and pericarditis) after being started on [s2]clozapine[e2]  and whose symptoms remitted upon discontinuation of clozapine.
	(21, 39)	pleural effusion	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6344	We report the case of a patient who developed polyserositis (pericardial effusion, [s1]pleural effusion[e1]  and pericarditis) after being started on [s2]clozapine[e2]  and whose symptoms remitted upon discontinuation of clozapine.
	(9, 40)	polyserositis	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6345	We report the case of a patient who developed [s1]polyserositis[e1] (pericardial effusion, pleural effusion, and pericarditis) after being started on [s2]clozapine[e2]  and whose symptoms remitted upon discontinuation of clozapine.
	(9, 40)	polyserositis	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6346	We report the case of a patient who developed [s1]polyserositis[e1] (pericardial effusion, pleural effusion, and pericarditis) after being started on [s2]clozapine[e2]  and whose symptoms remitted upon discontinuation of clozapine.
	(7, 25)	amphotericin B	severe side effects	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6347	When the disease recurred conventional [s1]amphotericin B[e1] was used again, but had to be stopped because of [s2]severe side effects[e2] 
	(34, 54)	ARA-C	fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6348	Thirty-six patients with AL received, in a three-month period, 51 cycles of combined chemotherapy which included, in all of them, cytosine arabinoside  [s1]ARA-C[e1] ; among them, along with myelosuppression, five experienced [s2]fever[e2]  infectious complications, gastrointestinal tract symptoms and severe myalgias.
	(28, 56)	cytosine arabinoside	fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6349	Thirty-six patients with AL received, in a three-month period, 51 cycles of combined chemotherapy which included, in all of them, [s1]cytosine arabinoside[e1] (ARA-C); among them, along with myelosuppression, five experienced [s2]fever[e2]  infectious complications, gastrointestinal tract symptoms and severe myalgias.
	(34, 59)	ARA-C	gastrointestinal tract symptoms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6350	Thirty-six patients with AL received, in a three-month period, 51 cycles of combined chemotherapy which included, in all of them, cytosine arabinoside  [s1]ARA-C[e1] ; among them, along with myelosuppression, five experienced fever, infectious complications, [s2]gastrointestinal tract symptoms[e2] and severe myalgias.
	(28, 61)	cytosine arabinoside	gastrointestinal tract symptoms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6351	Thirty-six patients with AL received, in a three-month period, 51 cycles of combined chemotherapy which included, in all of them, [s1]cytosine arabinoside[e1] (ARA-C); among them, along with myelosuppression, five experienced fever, infectious complications, [s2]gastrointestinal tract symptoms[e2] and severe myalgias.
	(34, 56)	ARA-C	infectious complications	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6352	Thirty-six patients with AL received, in a three-month period, 51 cycles of combined chemotherapy which included, in all of them, cytosine arabinoside  [s1]ARA-C[e1] ; among them, along with myelosuppression, five experienced fever, [s2]infectious complications[e2]  gastrointestinal tract symptoms and severe myalgias.
	(28, 58)	cytosine arabinoside	infectious complications	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6353	Thirty-six patients with AL received, in a three-month period, 51 cycles of combined chemotherapy which included, in all of them, [s1]cytosine arabinoside[e1] (ARA-C); among them, along with myelosuppression, five experienced fever, [s2]infectious complications[e2]  gastrointestinal tract symptoms and severe myalgias.
	(34, 66)	ARA-C	severe myalgias	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6354	Thirty-six patients with AL received, in a three-month period, 51 cycles of combined chemotherapy which included, in all of them, cytosine arabinoside  [s1]ARA-C[e1] ; among them, along with myelosuppression, five experienced fever, infectious complications, gastrointestinal tract symptoms and [s2]severe myalgias[e2] 
	(28, 68)	cytosine arabinoside	severe myalgias	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6355	Thirty-six patients with AL received, in a three-month period, 51 cycles of combined chemotherapy which included, in all of them, [s1]cytosine arabinoside[e1] (ARA-C); among them, along with myelosuppression, five experienced fever, infectious complications, gastrointestinal tract symptoms and [s2]severe myalgias[e2] 
	(12, 18)	rhGH	hypercalcemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6356	CONCLUSION: We believe this to be the first reported case of [s1]rhGH[e1] induced [s2]hypercalcemia[e2] in an HIV-infected patient.
	(0, 12)	Hypercalcemia	growth hormone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6357	 [s1]Hypercalcemia[e1] in an AIDS patient treated with [s2]growth hormone[e2] 
	(1, 14)	hypercalcemia	rhGH	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6358	The [s1]hypercalcemia[e1] responded to discontinuation of [s2]rhGH[e2] and a single dose of intravenous pamidronate disodium and has not recurred in 8 months of follow-up.
	(10, 21)	hypercalcemia	rhGH	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6359	We report a male patient with advanced AIDS who developed [s1]hypercalcemia[e1] 2 weeks after institution of [s2]rhGH[e2] therapy.
	(0, 8)	Hypersensitivity reactions	cisplatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6360	 [s1]Hypersensitivity reactions[e1] to [s2]cisplatin[e2] following multiple uncomplicated courses: a report on two cases.
	(13, 71)	cisplatin	abdominal pain	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6361	Two patients with ovarian cancer who had received multiple courses of [s1]cisplatin[e1] without complications experienced hypersensitivity reactions to cisplatin: one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and hypotension; the other, involving intravenous infusion, manifested [s2]abdominal pain[e2]  general erythema, and fever.
	(13, 71)	cisplatin	abdominal pain	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6362	Two patients with ovarian cancer who had received multiple courses of [s1]cisplatin[e1] without complications experienced hypersensitivity reactions to cisplatin: one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and hypotension; the other, involving intravenous infusion, manifested [s2]abdominal pain[e2]  general erythema, and fever.
	(13, 48)	cisplatin	dyspnea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6363	Two patients with ovarian cancer who had received multiple courses of [s1]cisplatin[e1] without complications experienced hypersensitivity reactions to cisplatin: one, involving intrahepatic artery infusion, manifested general erythema, [s2]dyspnea[e2]  and hypotension; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever.
	(13, 48)	cisplatin	dyspnea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6364	Two patients with ovarian cancer who had received multiple courses of [s1]cisplatin[e1] without complications experienced hypersensitivity reactions to cisplatin: one, involving intrahepatic artery infusion, manifested general erythema, [s2]dyspnea[e2]  and hypotension; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever.
	(13, 80)	cisplatin	fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6365	Two patients with ovarian cancer who had received multiple courses of [s1]cisplatin[e1] without complications experienced hypersensitivity reactions to cisplatin: one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and [s2]fever[e2] 
	(13, 80)	cisplatin	fever	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6366	Two patients with ovarian cancer who had received multiple courses of [s1]cisplatin[e1] without complications experienced hypersensitivity reactions to cisplatin: one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and [s2]fever[e2] 
	(13, 43)	cisplatin	general erythema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6367	Two patients with ovarian cancer who had received multiple courses of [s1]cisplatin[e1] without complications experienced hypersensitivity reactions to cisplatin: one, involving intrahepatic artery infusion, manifested [s2]general erythema[e2]  dyspnea, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever.
	(13, 43)	cisplatin	general erythema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6368	Two patients with ovarian cancer who had received multiple courses of [s1]cisplatin[e1] without complications experienced hypersensitivity reactions to cisplatin: one, involving intrahepatic artery infusion, manifested [s2]general erythema[e2]  dyspnea, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever.
	(13, 43)	cisplatin	general erythema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6369	Two patients with ovarian cancer who had received multiple courses of [s1]cisplatin[e1] without complications experienced hypersensitivity reactions to cisplatin: one, involving intrahepatic artery infusion, manifested [s2]general erythema[e2]  dyspnea, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever.
	(13, 43)	cisplatin	general erythema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6370	Two patients with ovarian cancer who had received multiple courses of [s1]cisplatin[e1] without complications experienced hypersensitivity reactions to cisplatin: one, involving intrahepatic artery infusion, manifested [s2]general erythema[e2]  dyspnea, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever.
	(13, 21)	cisplatin	hypersensitivity reactions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6371	Two patients with ovarian cancer who had received multiple courses of [s1]cisplatin[e1] without complications experienced [s2]hypersensitivity reactions[e2] to cisplatin: one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever.
	(13, 21)	cisplatin	hypersensitivity reactions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6372	Two patients with ovarian cancer who had received multiple courses of [s1]cisplatin[e1] without complications experienced [s2]hypersensitivity reactions[e2] to cisplatin: one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and hypotension; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever.
	(13, 54)	cisplatin	hypotension	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6373	Two patients with ovarian cancer who had received multiple courses of [s1]cisplatin[e1] without complications experienced hypersensitivity reactions to cisplatin: one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and [s2]hypotension[e2]  the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever.
	(13, 54)	cisplatin	hypotension	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6374	Two patients with ovarian cancer who had received multiple courses of [s1]cisplatin[e1] without complications experienced hypersensitivity reactions to cisplatin: one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and [s2]hypotension[e2]  the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever.
	(15, 21)	cisplatin	renal tubular salt wasting	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6375	We report an unusually short lived and asymptomatic episode of severe [s1]cisplatin[e1] induced [s2]renal tubular salt wasting[e2] in a fit 41-year-old patient with malignant teratoma.
	(4, 22)	phenolphthalein	TEN	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6376	Clinicians should include [s1]phenolphthalein[e1] in their list of possible causes of drug-induced [s2]TEN[e2] 
	(2, 32)	Phenolphthalein	TEN	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6377	DISCUSSION: [s1]Phenolphthalein[e1] is the active ingredient in several over-the-counter laxative preparations and has only rarely been reported to cause [s2]TEN[e2] 
	(7, 23)	phenolphthalein	TEN	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6378	OBJECTIVE: To report a case of [s1]phenolphthalein[e1] induced toxic epidermal necrolysis  [s2]TEN[e2]  in a patient maintained on several other medications more commonly known to be associated with TEN.
	(7, 23)	phenolphthalein	TEN	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6379	OBJECTIVE: To report a case of [s1]phenolphthalein[e1] induced toxic epidermal necrolysis  [s2]TEN[e2]  in a patient maintained on several other medications more commonly known to be associated with TEN.
	(7, 16)	phenolphthalein	toxic epidermal necrolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6380	OBJECTIVE: To report a case of [s1]phenolphthalein[e1] induced [s2]toxic epidermal necrolysis[e2] (TEN) in a patient maintained on several other medications more commonly known to be associated with TEN.
	(0, 9)	Phenolphthalein	toxic epidermal necrolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6381	 [s1]Phenolphthalein[e1] induced [s2]toxic epidermal necrolysis[e2] 
	(5, 21)	rash	phenolphthalein	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6382	The patient's previous [s1]rash[e1] and the temporal relation of this event and the ingestion of [s2]phenolphthalein[e2]  as well as the similarity of this case to other reports, point to phenolphthalein as the cause of TEN in this patient.
	(19, 51)	phenolphthalein	TEN	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6383	The patient's previous rash and the temporal relation of this event and the ingestion of [s1]phenolphthalein[e1]  as well as the similarity of this case to other reports, point to phenolphthalein as the cause of [s2]TEN[e2] in this patient.
	(0, 24)	Carbamazepine toxicity	Carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6384	 [s1]Carbamazepine toxicity[e1] induced by clarithromycin coadministration in psychiatric patients [s2]Carbamazepine[e2] toxicity induced by clarithromycin coadministration in psychiatric patients.
	(0, 10)	Carbamazepine toxicity	clarithromycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6385	 [s1]Carbamazepine toxicity[e1] induced by [s2]clarithromycin[e2] coadministration in psychiatric patients.
	(28, 45)	carbamazepine	ataxia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6386	During clarithromycin coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of [s1]carbamazepine[e1]  such as drowsiness, dizziness, and [s2]ataxia[e2]  which resolved within 5 days after clarithromycin discontinuation.
	(1, 46)	clarithromycin	ataxia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6387	During [s1]clarithromycin[e1] coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of carbamazepine, such as drowsiness, dizziness, and [s2]ataxia[e2]  which resolved within 5 days after clarithromycin discontinuation.
	(1, 46)	clarithromycin	ataxia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6388	During [s1]clarithromycin[e1] coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of carbamazepine, such as drowsiness, dizziness, and [s2]ataxia[e2]  which resolved within 5 days after clarithromycin discontinuation.
	(28, 41)	carbamazepine	dizziness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6389	During clarithromycin coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of [s1]carbamazepine[e1]  such as drowsiness, [s2]dizziness[e2]  and ataxia, which resolved within 5 days after clarithromycin discontinuation.
	(1, 42)	clarithromycin	dizziness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6390	During [s1]clarithromycin[e1] coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of carbamazepine, such as drowsiness, [s2]dizziness[e2]  and ataxia, which resolved within 5 days after clarithromycin discontinuation.
	(1, 42)	clarithromycin	dizziness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6391	During [s1]clarithromycin[e1] coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of carbamazepine, such as drowsiness, [s2]dizziness[e2]  and ataxia, which resolved within 5 days after clarithromycin discontinuation.
	(28, 37)	carbamazepine	drowsiness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6392	During clarithromycin coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of [s1]carbamazepine[e1]  such as [s2]drowsiness[e2]  dizziness, and ataxia, which resolved within 5 days after clarithromycin discontinuation.
	(1, 38)	clarithromycin	drowsiness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6393	During [s1]clarithromycin[e1] coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of carbamazepine, such as [s2]drowsiness[e2]  dizziness, and ataxia, which resolved within 5 days after clarithromycin discontinuation.
	(1, 38)	clarithromycin	drowsiness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6394	During [s1]clarithromycin[e1] coadministration, four out of the seven patients developed moderate-to-severe toxic symptoms of carbamazepine, such as [s2]drowsiness[e2]  dizziness, and ataxia, which resolved within 5 days after clarithromycin discontinuation.
	(25, 30)	toxic symptoms	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6395	During clarithromycin coadministration, four out of the seven patients developed moderate-to-severe [s1]toxic symptoms[e1] of [s2]carbamazepine[e2]  such as drowsiness, dizziness, and ataxia, which resolved within 5 days after clarithromycin discontinuation.
	(1, 27)	clarithromycin	toxic symptoms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6396	During [s1]clarithromycin[e1] coadministration, four out of the seven patients developed moderate-to-severe [s2]toxic symptoms[e2] of carbamazepine, such as drowsiness, dizziness, and ataxia, which resolved within 5 days after clarithromycin discontinuation.
	(1, 27)	clarithromycin	toxic symptoms	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6397	During [s1]clarithromycin[e1] coadministration, four out of the seven patients developed moderate-to-severe [s2]toxic symptoms[e2] of carbamazepine, such as drowsiness, dizziness, and ataxia, which resolved within 5 days after clarithromycin discontinuation.
	(20, 33)	carbamazepine	carbamazepine toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6398	The present report suggests that clarithromycin coadministration induces increased plasma [s1]carbamazepine[e1] concentrations, which may result in [s2]carbamazepine toxicity[e2] 
	(20, 33)	carbamazepine	carbamazepine toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6399	The present report suggests that clarithromycin coadministration induces increased plasma [s1]carbamazepine[e1] concentrations, which may result in [s2]carbamazepine toxicity[e2] 
	(5, 33)	clarithromycin	carbamazepine toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6400	The present report suggests that [s1]clarithromycin[e1] coadministration induces increased plasma carbamazepine concentrations, which may result in [s2]carbamazepine toxicity[e2] 
	(18, 27)	increased plasma carbamazepine	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6401	The present report suggests that clarithromycin coadministration induces [s1]increased plasma carbamazepine[e1]  [s2]carbamazepine[e2] concentrations, which may result in carbamazepine toxicity.
	(18, 27)	increased plasma carbamazepine	carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6402	The present report suggests that clarithromycin coadministration induces [s1]increased plasma carbamazepine[e1]  [s2]carbamazepine[e2] concentrations, which may result in carbamazepine toxicity.
	(5, 20)	clarithromycin	increased plasma carbamazepine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6403	The present report suggests that [s1]clarithromycin[e1] coadministration induces [s2]increased plasma carbamazepine[e2] concentrations, which may result in carbamazepine toxicity.
	(11, 21)	acetazolamide intoxication	acetazolamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6404	Acute hemorrhagic gastritis associated with [s1]acetazolamide intoxication[e1]  [s2]acetazolamide[e2] intoxication in a patient with chronic renal failure.
	(0, 13)	Acute hemorrhagic gastritis	acetazolamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6405	 [s1]Acute hemorrhagic gastritis[e1] associated with [s2]acetazolamide[e2] intoxication in a patient with chronic renal failure.
	(13, 26)	acute hemorrhagic gastritis	AZ	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6406	As far as we know, this is the first case report of [s1]acute hemorrhagic gastritis[e1] associated with [s2]AZ[e2] intoxication.
	(24, 30)	AZ intoxication	AZ	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6407	As far as we know, this is the first case report of acute hemorrhagic gastritis associated with [s1]AZ intoxication[e1]  [s2]AZ[e2] intoxication.
	(6, 12)	AZ intoxication	AZ	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6408	She was thus diagnosed as having [s1]AZ intoxication[e1]  [s2]AZ[e2] intoxication.
	(13, 26)	acute hemorrhagic gastritis	AZ	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6409	We experienced a case of chronic renal failure in a patient suffering from [s1]acute hemorrhagic gastritis[e1] associated with [s2]AZ[e2] intoxication.
	(24, 30)	AZ intoxication	AZ	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6410	We experienced a case of chronic renal failure in a patient suffering from acute hemorrhagic gastritis associated with [s1]AZ intoxication[e1]  [s2]AZ[e2] intoxication.
	(8, 13)	AZ	destroyed the gastric mucosal barrier	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6411	We thus concluded that an excessive dose of [s1]AZ[e1] had probably [s2]destroyed the gastric mucosal barrier[e2] or thrombocytopenia due to bone marrow disorder and thus eventually led to the development of hemorrhagic gastritis.
	(8, 41)	AZ	hemorrhagic gastritis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6412	We thus concluded that an excessive dose of [s1]AZ[e1] had probably destroyed the gastric mucosal barrier or thrombocytopenia due to bone marrow disorder and thus eventually led to the development of [s2]hemorrhagic gastritis[e2] 
	(8, 22)	AZ	thrombocytopenia due to bone marrow disorder	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6413	We thus concluded that an excessive dose of [s1]AZ[e1] had probably destroyed the gastric mucosal barrier or [s2]thrombocytopenia due to bone marrow disorder[e2] and thus eventually led to the development of hemorrhagic gastritis.
	(8, 15)	urinary calculus	magnesium ammonium phosphate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6414	In association with this tocolysis, [s1]urinary calculus[e1] of [s2]magnesium ammonium phosphate[e2] occurred at 34 weeks gestation.
	(0, 10)	Magnesium	urinary calculus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6415	 [s1]Magnesium[e1] tocolysis as the cause of [s2]urinary calculus[e2] during pregnancy.
	(0, 6)	Danazol	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6416	 [s1]Danazol[e1] induced [s2]thrombocytopenia[e2] 
	(14, 19)	danazol	gingival bleeding	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6417	On the next day, after a total dose of only 600 mg of [s1]danazol[e1]  [s2]gingival bleeding[e2] and purpura occurred.
	(14, 24)	danazol	purpura	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6418	On the next day, after a total dose of only 600 mg of [s1]danazol[e1]  gingival bleeding and [s2]purpura[e2] occurred.
	(5, 11)	danazol	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6419	We diagnosed this case as [s1]danazol[e1] induced [s2]thrombocytopenia[e2] 
	(6, 12)	heparin	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6420	It occasionally accompanies the [s1]heparin[e1] associated [s2]thrombocytopenia[e2] and thrombosis syndrome.
	(6, 19)	heparin	thrombosis syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6421	It occasionally accompanies the [s1]heparin[e1] associated thrombocytopenia and [s2]thrombosis syndrome[e2] 
	(0, 14)	Skin necrosis	heparin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6422	 [s1]Skin necrosis[e1] is a rare complication of subcutaneous [s2]heparin[e2] therapy that usually occurs at injection sites.
	(0, 7)	Skin necrosis	low-molecular weight heparin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6423	 [s1]Skin necrosis[e1] secondary to [s2]low-molecular weight heparin[e2] in a patient with antiphospholipid antibody syndrome.
	(15, 22)	skin necrosis	low-molecular weight heparin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6424	We describe a patient with the antiphospholipid syndrome who had [s1]skin necrosis[e1] develop from [s2]low-molecular weight heparin[e2] therapy at sites distant from injection sites.
	(2, 8)	reserpine toxicity	reserpine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6425	Finally, [s1]reserpine toxicity[e1]  [s2]reserpine[e2] toxicity, in particular central nervous system (CNS) disturbances, was reported more frequently in patients also receiving barbiturates, suggesting additive CNS effects.
	(3, 11)	contact dermatitis	sodium bisulfite	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6426	A case of [s1]contact dermatitis[e1] due to [s2]sodium bisulfite[e2] in an ophthalmic solution.
	(7, 15)	contact dermatitis	sodium bisulfite	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6427	Therefore, we diagnosed her eruption as [s1]contact dermatitis[e1] due to [s2]sodium bisulfite[e2] 
	(5, 15)	eruption	sodium bisulfite	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6428	Therefore, we diagnosed her [s1]eruption[e1] as contact dermatitis due to [s2]sodium bisulfite[e2] 
	(5, 13)	contact dermatitis	sodium bisulfite	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6429	We report a case of [s1]contact dermatitis[e1] due to [s2]sodium bisulfite[e2] in Tathion eye drops.
	(0, 11)	Acute pancreatitis	5-aminosalicylic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6430	 [s1]Acute pancreatitis[e1] after long-term [s2]5-aminosalicylic acid[e2] therapy.
	(0, 17)	Acute pancreatitis	mesalamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6431	 [s1]Acute pancreatitis[e1] is a known, although rare, complication of [s2]mesalamine[e2] treatment.
	(15, 21)	mesalamine	pancreatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6432	A rechallenge, performed in both patients, confirmed the diagnosis of [s1]mesalamine[e1] induced [s2]pancreatitis[e2] 
	(6, 18)	5-aminosalicylic acid	acute pancreatitis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6433	These case reports provide evidence that [s1]5-aminosalicylic acid[e1] may induce [s2]acute pancreatitis[e2] after long term treatment.
	(5, 17)	acute pancreatitis	mesalamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6434	We describe two cases of [s1]acute pancreatitis[e1] that occurred after long term [s2]mesalamine[e2] therapy for ulcerative colitis.
	(12, 37)	acute renal failure	enalapril	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6435	A 35-year-old nephrotic man developed [s1]acute renal failure[e1] with serum creatinine to 1543 micromol/l after a month of therapy with [s2]enalapril[e2] 
	(0, 27)	Acute renal failure	enalapril	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6436	 [s1]Acute renal failure[e1] with severe tubulointerstitial changes in a patient with minimal change nephrotic syndrome treated with [s2]enalapril[e2] 
	(4, 27)	severe tubulointerstitial changes	enalapril	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6437	Acute renal failure with [s1]severe tubulointerstitial changes[e1] in a patient with minimal change nephrotic syndrome treated with [s2]enalapril[e2] 
	(1, 8)	ritonavir	maculopapular eruption	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6438	Early [s1]ritonavir[e1] induced [s2]maculopapular eruption[e2] 
	(0, 17)	Ritonavir	adverse cutaneous reactions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6439	 [s1]Ritonavir[e1] should be added to the list of drugs that can induce [s2]adverse cutaneous reactions[e2] in HIV patients.
	(12, 37)	fever	ritonavir	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6440	We report 2 cases of maculopapular eruption and [s1]fever[e1] in patients infected with human immunodeficiency virus (HIV) on the 2nd day of first administration of [s2]ritonavir[e2]  a protease inhibitor.
	(5, 37)	maculopapular eruption	ritonavir	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6441	We report 2 cases of [s1]maculopapular eruption[e1] and fever in patients infected with human immunodeficiency virus (HIV) on the 2nd day of first administration of [s2]ritonavir[e2]  a protease inhibitor.
	(0, 8)	Nephropathy	methicillin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6442	 [s1]Nephropathy[e1] caused by [s2]methicillin[e2] therapy for staphylococcal septicemia.
	(6, 13)	methicillin	nephropathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6443	Review of the literature relating to [s1]methicillin[e1] induced [s2]nephropathy[e2] suggests a hypersensitivity origin for this disorder, but immunologic and ultrastructural investigation to date has failed to elucidate pathogenesis.
	(19, 33)	retroperitoneal fibrosis	methysergide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6444	A 25-year-old woman sought medical attention because of iliocaval manifestations of [s1]retroperitoneal fibrosis[e1] while she was taking [s2]methysergide[e2] 
	(0, 8)	Methysergide	retroperitoneal fibrosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6445	 [s1]Methysergide[e1] induced [s2]retroperitoneal fibrosis[e2]  successful outcome and two new laboratory features.
	(0, 8)	Vitiligo	alpha-interferon	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6446	 [s1]Vitiligo[e1] associated with [s2]alpha-interferon[e2] in a patient with chronic active hepatitis C.
	(5, 18)	vitiligo	interferon alpha 2a	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6447	We report a case of [s1]vitiligo[e1] that occurred during the second month of [s2]interferon alpha 2a[e2] therapy for chronic active hepatitis C.
	(10, 24)	febrile agranulocytosis	ticlopidine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6448	A case is reported of an elderly woman who developed [s1]febrile agranulocytosis[e1] several weeks after commencing [s2]ticlopidine[e2] but who had a favorable outcome after cessation of that drug and treatment with filgastrim.
	(0, 9)	Agranulocytosis	ticlopidine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6449	 [s1]Agranulocytosis[e1] associated with [s2]ticlopidine[e2]  a possible benefit with filgastim.
	(0, 37)	Ticlopidine	aplastic anemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6450	 [s1]Ticlopidine[e1] is an oral antiplatelet agent frequently utilized in the treatment of cerebrovascular disease and is rarely associated with severe bone marrow suppression, typically [s2]aplastic anemia[e2] 
	(0, 31)	Ticlopidine	severe bone marrow suppression	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6451	 [s1]Ticlopidine[e1] is an oral antiplatelet agent frequently utilized in the treatment of cerebrovascular disease and is rarely associated with [s2]severe bone marrow suppression[e2]  typically aplastic anemia.
	(9, 16)	ifosfamide	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6452	Hemodialysis was also shown to reverse [s1]ifosfamide[e1] related [s2]neurotoxicity[e2] 
	(0, 7)	Ifosfamide	neurotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6453	 [s1]Ifosfamide[e1] associated [s2]neurotoxicity[e2] was noted within hours of drug administration and improved rapidly following hemodialysis.
	(14, 25)	toxicity	ifosfamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6454	PURPOSE: We evaluated the in vitro hemodialysis ratio and subsequent [s1]toxicity[e1] and pharmacokinetics of [s2]ifosfamide[e2] in an anephric patient with Wilms' tumor.
	(1, 22)	toxicity	4-hydroxyifosfamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6455	The [s1]toxicity[e1] and plasma concentrations of ifosfamide, chloroacetaldehyde, and [s2]4-hydroxyifosfamide[e2] were then determined over 24 h after a single 1.6 g/m2 dose of ifosfamide.
	(1, 13)	toxicity	chloroacetaldehyde	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6456	The [s1]toxicity[e1] and plasma concentrations of ifosfamide, [s2]chloroacetaldehyde[e2]  and 4-hydroxyifosfamide were then determined over 24 h after a single 1.6 g/m2 dose of ifosfamide.
	(1, 8)	toxicity	ifosfamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6457	The [s1]toxicity[e1] and plasma concentrations of [s2]ifosfamide[e2]  chloroacetaldehyde, and 4-hydroxyifosfamide were then determined over 24 h after a single 1.6 g/m2 dose of ifosfamide.
	(1, 8)	toxicity	ifosfamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6458	The [s1]toxicity[e1] and plasma concentrations of [s2]ifosfamide[e2]  chloroacetaldehyde, and 4-hydroxyifosfamide were then determined over 24 h after a single 1.6 g/m2 dose of ifosfamide.
	(0, 19)	Toxicity	ifosfamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6459	 [s1]Toxicity[e1]  pharmacokinetics, and in vitro hemodialysis clearance of [s2]ifosfamide[e2] and metabolites in an anephric pediatric patient with Wilms' tumor.
	(12, 20)	hepatitis	methyldopa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6460	A 55-year-old woman developed symptoms suggestive of [s1]hepatitis[e1] 12 weeks after first receiving [s2]methyldopa[e2] for hypertension.
	(0, 6)	Methyldopa	liver injury	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6461	 [s1]Methyldopa[e1] induced [s2]liver injury[e2] 
	(7, 13)	methyldopa	liver injury	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6462	Such a rapid and relentless progression of [s1]methyldopa[e1] induced [s2]liver injury[e2] is undoubtedly rare, but it may be prevented by careful supervision of patients who exhibit liver function abnormalities early in the course of therapy.
	(0, 14)	Acute respiratory depression	morphine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6463	 [s1]Acute respiratory depression[e1] as a complication of nebulised [s2]morphine[e2] 
	(12, 20)	morphine	bradypneic	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6464	Approximately 15 min after the first administration of nebulised [s1]morphine[e1] the patient became markedly [s2]bradypneic[e2] (respiratory rate: 4-5 bpm), hypotensive (BP 70/40 mmHg), and responded only partially to command.
	(12, 35)	morphine	hypotensive	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6465	Approximately 15 min after the first administration of nebulised [s1]morphine[e1] the patient became markedly bradypneic (respiratory rate: 4-5 bpm), [s2]hypotensive[e2] (BP 70/40 mmHg), and responded only partially to command.
	(7, 19)	respiratory depression	morphine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6466	PURPOSE: To present a case of [s1]respiratory depression[e1] following the administration of nebulised [s2]morphine[e2] 
	(0, 16)	Acute dystonia	penicillamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6467	 [s1]Acute dystonia[e1] with thalamic and brainstem lesions after initial [s2]penicillamine[e2] treatment in Wilson's disease.
	(5, 16)	thalamic and brainstem lesions	penicillamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6468	Acute dystonia with [s1]thalamic and brainstem lesions[e1] after initial [s2]penicillamine[e2] treatment in Wilson's disease.
	(4, 28)	acute generalized dystonia	d-penicillamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6469	From these data, [s1]acute generalized dystonia[e1] with brainstem and thalamic lesions may occur in WD patients after an initial [s2]d-penicillamine[e2] therapy.
	(10, 28)	brainstem and thalamic lesions	d-penicillamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6470	From these data, acute generalized dystonia with [s1]brainstem and thalamic lesions[e1] may occur in WD patients after an initial [s2]d-penicillamine[e2] therapy.
	(6, 23)	acute generalized dystonia	d-penicillamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6471	We reported 3 patients who developed [s1]acute generalized dystonia[e1] and akinetic rigid syndrome following an initial therapy with [s2]d-penicillamine[e2] 125-500 mg daily.
	(12, 23)	akinetic rigid syndrome	d-penicillamine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6472	We reported 3 patients who developed acute generalized dystonia and [s1]akinetic rigid syndrome[e1] following an initial therapy with [s2]d-penicillamine[e2] 125-500 mg daily.
	(0, 16)	Ballistic movements	heroin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6473	 [s1]Ballistic movements[e1] due to ischemic infarcts after intravenous [s2]heroin[e2] overdose: report of two cases.
	(4, 16)	ischemic infarcts	heroin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6474	Ballistic movements due to [s1]ischemic infarcts[e1] after intravenous [s2]heroin[e2] overdose: report of two cases.
	(3, 14)	bilateral ballism	heroin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6475	Patient 1 presented [s1]bilateral ballism[e1] 1 week after intravenous [s2]heroin[e2] injection.
	(0, 14)	Stroke	heroin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6476	 [s1]Stroke[e1] is an infrequent but recognized complication of [s2]heroin[e2] addiction.
	(1, 14)	heroin	ballistic movements	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6477	Two [s1]heroin[e1] addicts, aged 34 and 19 years, developed [s2]ballistic movements[e2] after intravenous heroin overdose.
	(10, 18)	hypersensitivity reactions	cyclosporine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6478	A MEDLINE search identified all the reported cases of [s1]hypersensitivity reactions[e1] to [s2]cyclosporine[e2] 
	(0, 11)	Anaphylaxis	cyclosporine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6479	 [s1]Anaphylaxis[e1] to intravenous [s2]cyclosporine[e2] and tolerance to oral cyclosporine: case report and review.
	(2, 10)	Hypersensitivity reactions	cyclosporine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6480	BACKGROUND: [s1]Hypersensitivity reactions[e1] to [s2]cyclosporine[e2] are rare.
	(2, 18)	Hypersensitivity reactions	Cremophor EL	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6481	CONCLUSIONS: [s1]Hypersensitivity reactions[e1] to cyclosporine are due to [s2]Cremophor EL[e2] 
	(2, 10)	Hypersensitivity reactions	cyclosporine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6482	CONCLUSIONS: [s1]Hypersensitivity reactions[e1] to [s2]cyclosporine[e2] are due to Cremophor EL.
	(3, 14)	hypersensitivity reaction	cyclosporine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6483	Fortunately, a [s1]hypersensitivity reaction[e1] to one formulation of [s2]cyclosporine[e2] does not preclude use of a different formulation.
	(9, 24)	anaphylactic reaction	cyclosporine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6484	METHODS: We report a patient who had an [s1]anaphylactic reaction[e1] during the intravenous infusion of [s2]cyclosporine[e2] 
	(8, 16)	hypersensitivity reactions	cyclosporine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6485	OBJECTIVE: To investigate the mechanisms involved in [s1]hypersensitivity reactions[e1] to [s2]cyclosporine[e2] and determine the feasibility of future cyclosporine use.
	(8, 16)	hypersensitivity reactions	cyclosporine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6486	OBJECTIVE: To investigate the mechanisms involved in [s1]hypersensitivity reactions[e1] to [s2]cyclosporine[e2] and determine the feasibility of future cyclosporine use.
	(7, 15)	hypersensitivity reaction	cyclosporine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6487	The literature search revealed 22 cases of [s1]hypersensitivity reaction[e1] to [s2]cyclosporine[e2] 
	(0, 13)	Prothipendylhydrochloride	priapism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6488	 [s1]Prothipendylhydrochloride[e1] induced [s2]priapism[e2]  case report.
	(9, 24)	priapism	prothipendylhydrochloride	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6489	We present the first case of a patient with [s1]priapism[e1] after oral intake of the phenothiazine [s2]prothipendylhydrochloride[e2] 
	(14, 49)	actinomycin D	hepatotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6490	The chemotherapeutics, including vincristine, [s1]actinomycin D[e1]  and epirubicin in case 1 and vincristine and actinomycin D in case 2, were given before the [s2]hepatotoxicity[e2] developed.
	(14, 49)	actinomycin D	hepatotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6491	The chemotherapeutics, including vincristine, [s1]actinomycin D[e1]  and epirubicin in case 1 and vincristine and actinomycin D in case 2, were given before the [s2]hepatotoxicity[e2] developed.
	(21, 50)	epirubicin	hepatotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6492	The chemotherapeutics, including vincristine, actinomycin D, and [s1]epirubicin[e1] in case 1 and vincristine and actinomycin D in case 2, were given before the [s2]hepatotoxicity[e2] developed.
	(9, 49)	vincristine	hepatotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6493	The chemotherapeutics, including [s1]vincristine[e1]  actinomycin D, and epirubicin in case 1 and vincristine and actinomycin D in case 2, were given before the [s2]hepatotoxicity[e2] developed.
	(9, 49)	vincristine	hepatotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6494	The chemotherapeutics, including [s1]vincristine[e1]  actinomycin D, and epirubicin in case 1 and vincristine and actinomycin D in case 2, were given before the [s2]hepatotoxicity[e2] developed.
	(8, 23)	actinomycin D	hepatotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6495	We conclude that vincristine and [s1]actinomycin D[e1] were the cause of this rare from of [s2]hepatotoxicity[e2] and that chemotherapy for the underlying malignant disease could be given safely after clinical recovery.
	(3, 23)	vincristine	hepatotoxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6496	We conclude that [s1]vincristine[e1] and actinomycin D were the cause of this rare from of [s2]hepatotoxicity[e2] and that chemotherapy for the underlying malignant disease could be given safely after clinical recovery.
	(4, 46)	bleomycin	acral necrosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6497	Because the combination of [s1]bleomycin[e1] and vinca alkaloids is commonly used for the treatment of AIDS-related Kaposi's sarcoma, clinicians should be aware of the risk of provoking [s2]acral necrosis[e2] in patients who develop Raynaud's phenomenon under chemotherapy.
	(4, 54)	bleomycin	Raynaud's phenomenon	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6498	Because the combination of [s1]bleomycin[e1] and vinca alkaloids is commonly used for the treatment of AIDS-related Kaposi's sarcoma, clinicians should be aware of the risk of provoking acral necrosis in patients who develop [s2]Raynaud's phenomenon[e2] under chemotherapy.
	(8, 14)	gangrene	bleomycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6499	In this report, one patient who developed [s1]gangrene[e1] after [s2]bleomycin[e2] and vincristine/vinblastine chemotherapy for AIDS-related Kaposi's sarcoma and another HIV-infected patient who exhibited symptoms of severe Raynaud's phenomenon related to the same regimen are presented.
	(8, 23)	gangrene	vinblastine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6500	In this report, one patient who developed [s1]gangrene[e1] after bleomycin and vincristine [s2]vinblastine[e2] chemotherapy for AIDS-related Kaposi's sarcoma and another HIV-infected patient who exhibited symptoms of severe Raynaud's phenomenon related to the same regimen are presented.
	(8, 19)	gangrene	vincristine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6501	In this report, one patient who developed [s1]gangrene[e1] after bleomycin and [s2]vincristine[e2] vinblastine chemotherapy for AIDS-related Kaposi's sarcoma and another HIV-infected patient who exhibited symptoms of severe Raynaud's phenomenon related to the same regimen are presented.
	(12, 51)	bleomycin	severe Raynaud's phenomenon	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6502	In this report, one patient who developed gangrene after [s1]bleomycin[e1] and vincristine/vinblastine chemotherapy for AIDS-related Kaposi's sarcoma and another HIV-infected patient who exhibited symptoms of [s2]severe Raynaud's phenomenon[e2] related to the same regimen are presented.
	(21, 50)	vinblastine	severe Raynaud's phenomenon	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6503	In this report, one patient who developed gangrene after bleomycin and vincristine [s1]vinblastine[e1] chemotherapy for AIDS-related Kaposi's sarcoma and another HIV-infected patient who exhibited symptoms of [s2]severe Raynaud's phenomenon[e2] related to the same regimen are presented.
	(17, 50)	vincristine	severe Raynaud's phenomenon	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6504	In this report, one patient who developed gangrene after bleomycin and [s1]vincristine[e1] vinblastine chemotherapy for AIDS-related Kaposi's sarcoma and another HIV-infected patient who exhibited symptoms of [s2]severe Raynaud's phenomenon[e2] related to the same regimen are presented.
	(3, 16)	thrombocythemia	interferon alfa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6505	Development of essential [s1]thrombocythemia[e1] in a patient treated with [s2]interferon alfa[e2] and pentostatin for hairy cell leukemia.
	(3, 21)	thrombocythemia	pentostatin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6506	Development of essential [s1]thrombocythemia[e1] in a patient treated with interferon alfa and [s2]pentostatin[e2] for hairy cell leukemia.
	(6, 27)	hematological malignancy	interferon alfa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6507	Second cancers including various types of [s1]hematological malignancy[e1] have been reported in patients with hairy cell leukemia treated with chemotherapy or [s2]interferon alfa[e2] 
	(0, 27)	Second cancers	interferon alfa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6508	 [s1]Second cancers[e1] including various types of hematological malignancy have been reported in patients with hairy cell leukemia treated with chemotherapy or [s2]interferon alfa[e2] 
	(10, 18)	dexamethasone	hypertrophic obstructive cardiomyopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6509	Effect of beta-blockade on symptomatic [s1]dexamethasone[e1] induced [s2]hypertrophic obstructive cardiomyopathy[e2] in premature infants: three case reports and literature review.
	(4, 21)	lower average heart rate	propranolol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6510	One patient had a [s1]lower average heart rate[e1] and two patients had lower average mean blood pressure values during [s2]propranolol[e2] treatment, none of which was clinically significant.
	(12, 21)	lower average mean blood pressure	propranolol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6511	One patient had a lower average heart rate and two patients had [s1]lower average mean blood pressure[e1] values during [s2]propranolol[e2] treatment, none of which was clinically significant.
	(38, 50)	left ventricular outflow tract obstruction	dexamethasone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6512	STUDY DESIGN: Case reports are presented of three premature infants (mean gestational age 27 weeks) cared for in the intensive care nursery in whom clinically significant septal hypertrophy and [s1]left ventricular outflow tract obstruction[e1] developed during [s2]dexamethasone[e2] treatment for bronchopulmonary dysplasia.
	(32, 50)	septal hypertrophy	dexamethasone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6513	STUDY DESIGN: Case reports are presented of three premature infants (mean gestational age 27 weeks) cared for in the intensive care nursery in whom clinically significant [s1]septal hypertrophy[e1] and left ventricular outflow tract obstruction developed during [s2]dexamethasone[e2] treatment for bronchopulmonary dysplasia.
	(20, 32)	abdominal cramping	clindamycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6514	CASE SUMMARY: A 25-year-old postpartum white woman developed multiple watery stools and [s1]abdominal cramping[e1] on day 6 of therapy with [s2]clindamycin[e2] vaginal cream for bacterial vaginosis.
	(15, 32)	multiple watery stools	clindamycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6515	CASE SUMMARY: A 25-year-old postpartum white woman developed [s1]multiple watery stools[e1] and abdominal cramping on day 6 of therapy with [s2]clindamycin[e2] vaginal cream for bacterial vaginosis.
	(0, 18)	Clostridium difficile toxin-induced colitis	clindamycin phosphate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6516	 [s1]Clostridium difficile toxin-induced colitis[e1] after use of [s2]clindamycin phosphate[e2] vaginal cream.
	(5, 21)	clindamycin	CDIC	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6517	CONCLUSIONS: This report indicates [s1]clindamycin[e1] phosphate vaginal cream as the most probable cause of [s2]CDIC[e2] due to the temporal relationship between the occurrence of diarrhea and clindamycin administration, lack of concomitant medications, and documentation of C. difficile toxin.
	(5, 21)	clindamycin phosphate	CDIC	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6518	CONCLUSIONS: This report indicates [s1]clindamycin phosphate[e1] vaginal cream as the most probable cause of [s2]CDIC[e2] due to the temporal relationship between the occurrence of diarrhea and clindamycin administration, lack of concomitant medications, and documentation of C. difficile toxin.
	(5, 53)	clindamycin	C. difficile toxin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6519	CONCLUSIONS: This report indicates [s1]clindamycin[e1] phosphate vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of diarrhea and clindamycin administration, lack of concomitant medications, and documentation of [s2]C. difficile toxin[e2] 
	(5, 53)	clindamycin phosphate	C. difficile toxin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6520	CONCLUSIONS: This report indicates [s1]clindamycin phosphate[e1] vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of diarrhea and clindamycin administration, lack of concomitant medications, and documentation of [s2]C. difficile toxin[e2] 
	(5, 32)	clindamycin	diarrhea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6521	CONCLUSIONS: This report indicates [s1]clindamycin[e1] phosphate vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of [s2]diarrhea[e2] and clindamycin administration, lack of concomitant medications, and documentation of C. difficile toxin.
	(5, 32)	clindamycin phosphate	diarrhea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6522	CONCLUSIONS: This report indicates [s1]clindamycin phosphate[e1] vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of [s2]diarrhea[e2] and clindamycin administration, lack of concomitant medications, and documentation of C. difficile toxin.
	(9, 25)	clindamycin	C. difficile toxin in stool	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6523	DISCUSSION: No published clinical studies in patients receiving [s1]clindamycin[e1] vaginal cream for bacterial vaginosis have documented [s2]C. difficile toxin in stool[e2] samples of patients with diarrhea.
	(9, 38)	clindamycin	diarrhea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6524	DISCUSSION: No published clinical studies in patients receiving [s1]clindamycin[e1] vaginal cream for bacterial vaginosis have documented C. difficile toxin in stool samples of patients with [s2]diarrhea[e2] 
	(7, 31)	toxin-positive Clostridium difficile-induced colitis	clindamycin phosphate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6525	OBJECTIVE: To report a case of [s1]toxin-positive Clostridium difficile-induced colitis[e1] (CDIC) after use of [s2]clindamycin phosphate[e2] vaginal cream.
	(8, 15)	TEN	lamotrigine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6526	A 54-year-old man developed [s1]TEN[e1] 4 weeks after beginning [s2]lamotrigine[e2] for complex partial seizures related to a glioblastoma multiforme brain tumor.
	(2, 24)	lamotrigine	TEN	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6527	Administration of [s1]lamotrigine[e1]  especially in combination with valproic acid, may lead to the development of [s2]TEN[e2] 
	(12, 24)	valproic acid	TEN	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6528	Administration of lamotrigine, especially in combination with [s1]valproic acid[e1]  may lead to the development of [s2]TEN[e2] 
	(0, 12)	Fatal toxic epidermal necrolysis	lamotrigine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6529	 [s1]Fatal toxic epidermal necrolysis[e1] related to [s2]lamotrigine[e2] administration.
	(22, 51)	lamotrigine	accumulation of a toxic intermediate metabolite	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6530	It was hypothesized that valproic acid may interfere with glucuronidation of [s1]lamotrigine[e1]  leading to increased serum lamotrigine levels, or perhaps alter the drug's metabolism, resulting in [s2]accumulation of a toxic intermediate metabolite[e2] 
	(8, 52)	valproic acid	accumulation of a toxic intermediate metabolite	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6531	It was hypothesized that [s1]valproic acid[e1] may interfere with glucuronidation of lamotrigine, leading to increased serum lamotrigine levels, or perhaps alter the drug's metabolism, resulting in [s2]accumulation of a toxic intermediate metabolite[e2] 
	(22, 31)	lamotrigine	increased serum lamotrigine levels	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6532	It was hypothesized that valproic acid may interfere with glucuronidation of [s1]lamotrigine[e1]  leading to [s2]increased serum lamotrigine levels[e2]  or perhaps alter the drug's metabolism, resulting in accumulation of a toxic intermediate metabolite.
	(8, 32)	valproic acid	increased serum lamotrigine levels	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6533	It was hypothesized that [s1]valproic acid[e1] may interfere with glucuronidation of lamotrigine, leading to [s2]increased serum lamotrigine levels[e2]  or perhaps alter the drug's metabolism, resulting in accumulation of a toxic intermediate metabolite.
	(10, 16)	SJS	lamotrigine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6534	To date, eight cases of TEN and one of [s1]SJS[e1] related to [s2]lamotrigine[e2] administration have been reported in the literature.
	(6, 16)	TEN	lamotrigine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6535	To date, eight cases of [s1]TEN[e1] and one of SJS related to [s2]lamotrigine[e2] administration have been reported in the literature.
	(1, 10)	syndrome of increased affect	risperidone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6536	A [s1]syndrome of increased affect[e1] in response to [s2]risperidone[e2] among patients with schizophrenia.
	(18, 46)	risperidone	depression	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6537	Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of [s1]risperidone[e1] had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and [s2]depression[e2] and periods of crying and insomnia.
	(18, 42)	risperidone	feelings of agitation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6538	Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of [s1]risperidone[e1] had an initial good response to the medication followed by development of intolerable affect, including [s2]feelings of agitation[e2] and depression and periods of crying and insomnia.
	(18, 52)	risperidone	insomnia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6539	Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of [s1]risperidone[e1] had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and periods of crying and [s2]insomnia[e2] 
	(18, 36)	risperidone	intolerable affect	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6540	Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of [s1]risperidone[e1] had an initial good response to the medication followed by development of [s2]intolerable affect[e2]  including feelings of agitation and depression and periods of crying and insomnia.
	(18, 48)	risperidone	periods of crying	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6541	Six of 13 outpatients with schizophrenia who participated in a ten-week open trial of [s1]risperidone[e1] had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and [s2]periods of crying[e2] and insomnia.
	(4, 11)	risperidone	increase affect	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6542	The authors suggest that [s1]risperidone[e1] may [s2]increase affect[e2] in patients with schizophrenia and that some patients, especially those with anxiety, may have difficulty managing the increase.
	(0, 19)	Methanol	bilateral putaminal injury	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6543	 [s1]Methanol[e1] toxicity can cause severe central nervous system insult in which a characteristic pattern of [s2]bilateral putaminal injury[e2] is noted on brain imaging studies.
	(0, 30)	Methanol toxicity	Methanol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6544	 [s1]Methanol toxicity[e1] can cause severe central nervous system insult in which a characteristic pattern of bilateral putaminal injury is noted on brain imaging studies [s2]Methanol[e2] toxicity can cause severe central nervous system insult in which a characteristic pattern of bilateral putaminal injury is noted on brain imaging studies.
	(0, 8)	Methanol	severe central nervous system insult	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6545	 [s1]Methanol[e1] toxicity can cause [s2]severe central nervous system insult[e2] in which a characteristic pattern of bilateral putaminal injury is noted on brain imaging studies.
	(7, 15)	methanol intoxication	methanol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6546	Putaminal infarct in [s1]methanol intoxication[e1]  [s2]methanol[e2] intoxication: case report and role of brain imaging studies.
	(0, 9)	Putaminal infarct	methanol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6547	 [s1]Putaminal infarct[e1] in [s2]methanol[e2] intoxication: case report and role of brain imaging studies.
	(9, 15)	methanol poisoning	methanol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6548	Theoretical basal ganglia toxicologic mechanisms of [s1]methanol poisoning[e1]  [s2]methanol[e2] poisoning are reviewed, and the role of brain imaging studies will regard to diagnosis, prognosis and impact on management is discussed.
	(9, 22)	methanol	bilateral putaminal necrosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6549	We present a fatal case of subacute [s1]methanol[e1] toxicity with associated diffuse brain involvement, including [s2]bilateral putaminal necrosis[e2] and cerebral edema with ventricular compression.
	(9, 29)	methanol	cerebral edema	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6550	We present a fatal case of subacute [s1]methanol[e1] toxicity with associated diffuse brain involvement, including bilateral putaminal necrosis and [s2]cerebral edema[e2] with ventricular compression.
	(9, 17)	methanol	diffuse brain involvement	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6551	We present a fatal case of subacute [s1]methanol[e1] toxicity with associated [s2]diffuse brain involvement[e2]  including bilateral putaminal necrosis and cerebral edema with ventricular compression.
	(3, 11)	fatal	methanol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6552	We present a [s1]fatal[e1] case of subacute [s2]methanol[e2] toxicity with associated diffuse brain involvement, including bilateral putaminal necrosis and cerebral edema with ventricular compression.
	(9, 15)	methanol toxicity	methanol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6553	We present a fatal case of subacute [s1]methanol toxicity[e1]  [s2]methanol[e2] toxicity with associated diffuse brain involvement, including bilateral putaminal necrosis and cerebral edema with ventricular compression.
	(9, 33)	methanol	ventricular compression	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6554	We present a fatal case of subacute [s1]methanol[e1] toxicity with associated diffuse brain involvement, including bilateral putaminal necrosis and cerebral edema with [s2]ventricular compression[e2] 
	(15, 30)	risperidone	dyskinetic movements	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6555	A 28 year old white schizophrenic male has been under [s1]risperidone[e1] monotherapy for about one year when he developed [s2]dyskinetic movements[e2] 
	(0, 7)	Risperidone	tardive dyskinesia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6556	 [s1]Risperidone[e1] induced [s2]tardive dyskinesia[e2] 
	(7, 14)	risperidone	tardive dyskinesia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6557	This report presents a potential case of [s1]risperidone[e1] induced [s2]tardive dyskinesia[e2] 
	(0, 18)	Increased ocular pressure	venlafaxine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6558	 [s1]Increased ocular pressure[e1] in two patients with narrow angle glaucoma treated with [s2]venlafaxine[e2] 
	(8, 53)	clinical lupus syndrome	procainamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6559	A 61-year-old man developed [s1]clinical lupus syndrome[e1] with positive antinuclear antibody, positive lupus erythematosus (LE) cell preparation, and diffuse proliferative glomerulonephritis following 26 months of [s2]procainamide[e2] therapy.
	(35, 53)	diffuse proliferative glomerulonephritis	procainamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6560	A 61-year-old man developed clinical lupus syndrome with positive antinuclear antibody, positive lupus erythematosus (LE) cell preparation, and [s1]diffuse proliferative glomerulonephritis[e1] following 26 months of [s2]procainamide[e2] therapy.
	(21, 53)	lupus erythematosus	procainamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6561	A 61-year-old man developed clinical lupus syndrome with positive antinuclear antibody, positive [s1]lupus erythematosus[e1] (LE) cell preparation, and diffuse proliferative glomerulonephritis following 26 months of [s2]procainamide[e2] therapy.
	(0, 11)	Glomerulonephritis	procainamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6562	 [s1]Glomerulonephritis[e1] in [s2]procainamide[e2] induced lupus erythematosus: report of a case and review of the literature.
	(9, 16)	procainamide	lupus erythematosus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6563	Glomerulonephritis in [s1]procainamide[e1] induced [s2]lupus erythematosus[e2]  report of a case and review of the literature.
	(12, 23)	acute blistering eruption	penicillin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6564	We report a 76-year-old man who developed an [s1]acute blistering eruption[e1] following high-dose [s2]penicillin[e2] treatment for pneumococcal septicaemia.
	(4, 11)	suxamethonium	apnoea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6565	A case of prolonged [s1]suxamethonium[e1]  [s2]apnoea[e2] successfully terminated by the infusion of a commercial preparation of serumcholinesterase is reported.
	(0, 7)	Suxamethonium	apnoea	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6566	 [s1]Suxamethonium[e1]  [s2]apnoea[e2] terminated with commercial serumcholinesterase.
	(0, 6)	Cardiac arrest	sulprostone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6567	 [s1]Cardiac arrest[e1] associated with [s2]sulprostone[e2] use during caesarean section.
	(8, 23)	sulprostone	cardiac arrest	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6568	We postulate that the bolus of [s1]sulprostone[e1] resulted in possible coronary spasm that resulted in [s2]cardiac arrest[e2] 
	(8, 16)	sulprostone	coronary spasm	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6569	We postulate that the bolus of [s1]sulprostone[e1] resulted in possible [s2]coronary spasm[e2] that resulted in cardiac arrest.
	(24, 38)	desmethylsertraline	doubling of the lamotrigine blood level	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6570	In case 1, a total daily dose of 25 mg sertraline, with nondetectable sertraline and [s1]desmethylsertraline[e1] blood levels, resulted in a [s2]doubling of the lamotrigine blood level[e2] with symptoms of toxicity.
	(36, 48)	doubling of the lamotrigine blood level	lamotrigine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6571	In case 1, a total daily dose of 25 mg sertraline, with nondetectable sertraline and desmethylsertraline blood levels, resulted in a [s1]doubling of the lamotrigine blood level[e1]  [s2]lamotrigine[e2] blood level with symptoms of toxicity.
	(11, 37)	sertraline	doubling of the lamotrigine blood level	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6572	In case 1, a total daily dose of 25 mg [s1]sertraline[e1]  with nondetectable sertraline and desmethylsertraline blood levels, resulted in a [s2]doubling of the lamotrigine blood level[e2] with symptoms of toxicity.
	(11, 37)	sertraline	doubling of the lamotrigine blood level	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6573	In case 1, a total daily dose of 25 mg [s1]sertraline[e1]  with nondetectable sertraline and desmethylsertraline blood levels, resulted in a [s2]doubling of the lamotrigine blood level[e2] with symptoms of toxicity.
	(24, 49)	desmethylsertraline	symptoms of toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6574	In case 1, a total daily dose of 25 mg sertraline, with nondetectable sertraline and [s1]desmethylsertraline[e1] blood levels, resulted in a doubling of the lamotrigine blood level with [s2]symptoms of toxicity[e2] 
	(39, 49)	lamotrigine	symptoms of toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6575	In case 1, a total daily dose of 25 mg sertraline, with nondetectable sertraline and desmethylsertraline blood levels, resulted in a doubling of the [s1]lamotrigine[e1] blood level with [s2]symptoms of toxicity[e2] 
	(11, 48)	sertraline	symptoms of toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6576	In case 1, a total daily dose of 25 mg [s1]sertraline[e1]  with nondetectable sertraline and desmethylsertraline blood levels, resulted in a doubling of the lamotrigine blood level with [s2]symptoms of toxicity[e2] 
	(11, 48)	sertraline	symptoms of toxicity	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6577	In case 1, a total daily dose of 25 mg [s1]sertraline[e1]  with nondetectable sertraline and desmethylsertraline blood levels, resulted in a doubling of the lamotrigine blood level with [s2]symptoms of toxicity[e2] 
	(0, 13)	Lamotrigine toxicity	Lamotrigine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6578	 [s1]Lamotrigine toxicity[e1] secondary to sertraline [s2]Lamotrigine[e2] toxicity secondary to sertraline.
	(0, 10)	Lamotrigine toxicity	sertraline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6579	 [s1]Lamotrigine toxicity[e1] secondary to [s2]sertraline[e2] 
	(0, 11)	Flutamide	decrease in prostate-specific antigen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6580	 [s1]Flutamide[e1] withdrawal syndrome is characterized by a [s2]decrease in prostate-specific antigen[e2] (PSA) after flutamide withdrawal in a subset of patients with progressing metastatic carcinoma of the prostate.
	(9, 22)	decrease in prostate-specific antigen	flutamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6581	Flutamide withdrawal syndrome is characterized by a [s1]decrease in prostate-specific antigen[e1] (PSA) after [s2]flutamide[e2] withdrawal in a subset of patients with progressing metastatic carcinoma of the prostate.
	(0, 41)	Flutamide withdrawal syndrome	Flutamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6582	 [s1]Flutamide withdrawal syndrome[e1] is characterized by a decrease in prostate-specific antigen (PSA) after flutamide withdrawal in a subset of patients with progressing metastatic carcinoma of the prostate [s2]Flutamide[e2] withdrawal syndrome is characterized by a decrease in prostate-specific antigen (PSA) after flutamide withdrawal in a subset of patients with progressing metastatic carcinoma of the prostate.
	(0, 22)	Flutamide withdrawal syndrome	flutamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6583	 [s1]Flutamide withdrawal syndrome[e1] is characterized by a decrease in prostate-specific antigen (PSA) after [s2]flutamide[e2] withdrawal in a subset of patients with progressing metastatic carcinoma of the prostate.
	(7, 14)	flutamide withdrawal syndrome	flutamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6584	Prolonged prostate-specific antigen response in [s1]flutamide withdrawal syndrome[e1]  [s2]flutamide[e2] withdrawal syndrome despite disease progression.
	(0, 9)	Prolonged prostate-specific antigen response	flutamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6585	 [s1]Prolonged prostate-specific antigen response[e1] in [s2]flutamide[e2] withdrawal syndrome despite disease progression.
	(5, 18)	decoupling of PSA response	flutamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6586	This case illustrates the potential [s1]decoupling of PSA response[e1] from disease status in [s2]flutamide[e2] withdrawal.
	(13, 27)	PSA continued to decrease	flutamide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6587	We describe a patient with androgen-independent prostate cancer in whom [s1]PSA continued to decrease[e1] for a period of 15 months after [s2]flutamide[e2] withdrawal.
	(0, 9)	Anaphylactic reaction	prednisone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6588	 [s1]Anaphylactic reaction[e1] to oral [s2]prednisone[e2]  a case report and review of the literature.
	(31, 40)	anaphylactic reaction	prednisone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6589	We describe the case of a nonatopic 17-year-old girl with bronchial asthma and aspirin intolerance who developed a dramatic [s1]anaphylactic reaction[e1] to oral [s2]prednisone[e2] 
	(3, 9)	HAL	significant 32%-46% loss of tyrosine hydroxylase (TH) immunoreactive neurons	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6590	Animals treated with [s1]HAL[e1] showed a highly [s2]significant 32%-46% loss of tyrosine hydroxylase (TH) immunoreactive neurons[e2] in the substantia nigra, and 20% contraction of the TH stained dendritic arbour.
	(23, 40)	vomiting	Pancrease MT 16	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6591	METHODS: Double-blind, placebo-controlled titrated oral challenges with pancreatic enzymes resulted in definite [s1]vomiting[e1] within 1 to 1.5 hours after challenges with Viokase and [s2]Pancrease MT 16[e2]  but not with placebo.
	(23, 36)	vomiting	Viokase	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6592	METHODS: Double-blind, placebo-controlled titrated oral challenges with pancreatic enzymes resulted in definite [s1]vomiting[e1] within 1 to 1.5 hours after challenges with [s2]Viokase[e2] and Pancrease MT 16, but not with placebo.
	(4, 14)	Pancrease MT 16	vomiting	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6593	She was treated with [s1]Pancrease MT 16[e1]  but had consistent [s2]vomiting[e2] 1 to 2 hours after administration of enzymes.
	(1, 17)	vomiting	Creon 10	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6594	The [s1]vomiting[e1] occurred on switching to different pancreatic enzymes preparations, ie, [s2]Creon 10[e2]  Viokase, and Pancrease MT 16.
	(1, 26)	vomiting	Pancrease MT 16	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6595	The [s1]vomiting[e1] occurred on switching to different pancreatic enzymes preparations, ie, Creon 10, Viokase, and [s2]Pancrease MT 16[e2] 
	(1, 21)	vomiting	Viokase	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6596	The [s1]vomiting[e1] occurred on switching to different pancreatic enzymes preparations, ie, Creon 10, [s2]Viokase[e2]  and Pancrease MT 16.
	(1, 11)	valproate	symptomatic methemoglobinemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6597	Acute [s1]valproate[e1] ingestion induces [s2]symptomatic methemoglobinemia[e2] 
	(9, 33)	symptomatic methemoglobinemia	Depakote	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6598	We report for the first time the development of [s1]symptomatic methemoglobinemia[e1] after an acute ingestion of divalproex sodium  [s2]Depakote[e2] , resulting in serum concentrations 10 times greater than the therapeutic range.
	(9, 28)	symptomatic methemoglobinemia	divalproex sodium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6599	We report for the first time the development of [s1]symptomatic methemoglobinemia[e1] after an acute ingestion of [s2]divalproex sodium[e2] (Depakote), resulting in serum concentrations 10 times greater than the therapeutic range.
	(3, 30)	mitomycin C	hemolytic anemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6600	In rare cases [s1]mitomycin C[e1] (MMC) may induce cancer-associated hemolytic uremic syndrome, which is characterized by [s2]hemolytic anemia[e2]  thrombocytopenia and progressive renal failure.
	(7, 28)	MMC	hemolytic anemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6601	In rare cases mitomycin C  [s1]MMC[e1]  may induce cancer-associated hemolytic uremic syndrome, which is characterized by [s2]hemolytic anemia[e2]  thrombocytopenia and progressive renal failure.
	(3, 18)	mitomycin C	hemolytic uremic syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6602	In rare cases [s1]mitomycin C[e1] (MMC) may induce cancer-associated [s2]hemolytic uremic syndrome[e2]  which is characterized by hemolytic anemia, thrombocytopenia and progressive renal failure.
	(7, 16)	MMC	hemolytic uremic syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6603	In rare cases mitomycin C  [s1]MMC[e1]  may induce cancer-associated [s2]hemolytic uremic syndrome[e2]  which is characterized by hemolytic anemia, thrombocytopenia and progressive renal failure.
	(3, 43)	mitomycin C	progressive renal failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6604	In rare cases [s1]mitomycin C[e1] (MMC) may induce cancer-associated hemolytic uremic syndrome, which is characterized by hemolytic anemia, thrombocytopenia and [s2]progressive renal failure[e2] 
	(7, 41)	MMC	progressive renal failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6605	In rare cases mitomycin C  [s1]MMC[e1]  may induce cancer-associated hemolytic uremic syndrome, which is characterized by hemolytic anemia, thrombocytopenia and [s2]progressive renal failure[e2] 
	(3, 36)	mitomycin C	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6606	In rare cases [s1]mitomycin C[e1] (MMC) may induce cancer-associated hemolytic uremic syndrome, which is characterized by hemolytic anemia, [s2]thrombocytopenia[e2] and progressive renal failure.
	(7, 34)	MMC	thrombocytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6607	In rare cases mitomycin C  [s1]MMC[e1]  may induce cancer-associated hemolytic uremic syndrome, which is characterized by hemolytic anemia, [s2]thrombocytopenia[e2] and progressive renal failure.
	(0, 7)	Mitomycin C	hemolytic uremic syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6608	 [s1]Mitomycin C[e1] related [s2]hemolytic uremic syndrome[e2] in cancer patients.
	(5, 10)	MMC	hemolytic uremic syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6609	We report a case of [s1]MMC[e1] related [s2]hemolytic uremic syndrome[e2]  and discuss the etiologic parameters, clinical aspects, prognosis and treatment modalities of this severe syndrome.
	(0, 31)	CD4 T-lymphocyte depletion	fludarabine phosphate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6610	 [s1]CD4 T-lymphocyte depletion[e1]  myelosuppression, and subsequent severe infections are the major side effects of [s2]fludarabine phosphate[e2] therapy.
	(13, 31)	myelosuppression	fludarabine phosphate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6611	CD4 T-lymphocyte depletion, [s1]myelosuppression[e1]  and subsequent severe infections are the major side effects of [s2]fludarabine phosphate[e2] therapy.
	(22, 32)	severe infections	fludarabine phosphate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6612	CD4 T-lymphocyte depletion, myelosuppression, and subsequent [s1]severe infections[e1] are the major side effects of [s2]fludarabine phosphate[e2] therapy.
	(0, 15)	Severe respiratory syncytial virus pulmonary infection	fludarabine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6613	 [s1]Severe respiratory syncytial virus pulmonary infection[e1] in a patient treated with [s2]fludarabine[e2] for chronic lymphocytic leukemia.
	(14, 45)	respiratory syncytial virus (RSV) infection	fludarabine phosphate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6614	We report here on a heretofore undescribed [s1]respiratory syncytial virus (RSV) infection[e1] in a patient with a long-standing history of refractory CLL that was treated with [s2]fludarabine phosphate[e2] 
	(0, 11)	Serotonin syndrome	phenelzine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6615	 [s1]Serotonin syndrome[e1] induced by transitioning from [s2]phenelzine[e2] to venlafaxine: four patient reports.
	(0, 16)	Serotonin syndrome	venlafaxine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6616	 [s1]Serotonin syndrome[e1] induced by transitioning from phenelzine to [s2]venlafaxine[e2]  four patient reports.
	(2, 9)	G-CSF	leucocytosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6617	Although this [s1]G-CSF[e1] driven [s2]leucocytosis[e2] was alarming it did not appear to have adversely affected the patient's prognosis.
	(0, 17)	Leukaemoid monocytosis	G-CSF	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6618	 [s1]Leukaemoid monocytosis[e1] in M4 AML following chemotherapy and [s2]G-CSF[e2] 
	(15, 24)	G-CSF	monocytosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6619	We describe a patient with M4 AML treated with standard chemotherapy followed by [s1]G-CSF[e1] who developed marked [s2]monocytosis[e2] on day 8 of G-CSF therapy.
	(15, 24)	G-CSF	monocytosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6620	We describe a patient with M4 AML treated with standard chemotherapy followed by [s1]G-CSF[e1] who developed marked [s2]monocytosis[e2] on day 8 of G-CSF therapy.
	(7, 19)	chlorambucil	balanced translocation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6621	Case 2 demonstrated after 40 months on [s1]chlorambucil[e1] the presence of a [s2]balanced translocation[e2]  t (1;5) (p36;q31) in 90% of the cells.
	(0, 5)	Chromosome abnormalities	chlorambucil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6622	 [s1]Chromosome abnormalities[e1] after [s2]chlorambucil[e2] therapy of polycythaemia vera.
	(9, 20)	PTU	ANCA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6623	Administration of steroid and decreasing the dose of [s1]PTU[e1] produced a good clinical response and the [s2]ANCA[e2] disappeared.
	(0, 26)	Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis	propylthiouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6624	 [s1]Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis[e1] associated with [s2]propylthiouracil[e2] therapy.
	(15, 36)	antineutrophil cytoplasmic antibody	propylthiouracil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6625	A teenage girl with crescentic glomerulonephritis had [s1]antineutrophil cytoplasmic antibody[e1] (ANCA) detected after she had received [s2]propylthiouracil[e2] (PTU) for hyperthyroidism without cutaneous vasculitis.
	(15, 42)	antineutrophil cytoplasmic antibody	PTU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6626	A teenage girl with crescentic glomerulonephritis had [s1]antineutrophil cytoplasmic antibody[e1] (ANCA) detected after she had received propylthiouracil  [s2]PTU[e2]  for hyperthyroidism without cutaneous vasculitis.
	(4, 30)	ANCA	PTU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6627	It was concluded that [s1]ANCA[e1] is closely related to the pathogenesis of crescentic glomerulonephritis and that treatment with [s2]PTU[e2] appeared to induce ANCA.
	(4, 30)	ANCA	PTU	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6628	It was concluded that [s1]ANCA[e1] is closely related to the pathogenesis of crescentic glomerulonephritis and that treatment with [s2]PTU[e2] appeared to induce ANCA.
	(1, 12)	drug interaction	theophylline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6629	A [s1]drug interaction[e1] between zafirlukast and [s2]theophylline[e2] 
	(1, 6)	drug interaction	zafirlukast	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6630	A [s1]drug interaction[e1] between [s2]zafirlukast[e2] and theophylline.
	(9, 31)	theophylline	reaction to the drug became more toxic	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6631	Attempts were made to stop and then restart the [s1]theophylline[e1] therapy at progressively lower doses; however, with each attempt, the patient's [s2]reaction to the drug became more toxic[e2]  with serum theophylline levels ranging between 99.9 and 149.9 micromol/L (18 and 27 microg/mL).
	(9, 31)	theophylline	reaction to the drug became more toxic	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6632	Attempts were made to stop and then restart the [s1]theophylline[e1] therapy at progressively lower doses; however, with each attempt, the patient's [s2]reaction to the drug became more toxic[e2]  with serum theophylline levels ranging between 99.9 and 149.9 micromol/L (18 and 27 microg/mL).
	(5, 15)	increase in the theophylline level	theophylline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6633	One explanation for the noted [s1]increase in the theophylline level[e1]  [s2]theophylline[e2] level is that metabolism occurs mainly by cytochrome P450 (CYP 1A2), an enzyme that is known to be inhibited with high concentrations of zafirlukast.
	(5, 47)	increase in the theophylline level	zafirlukast	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6634	One explanation for the noted [s1]increase in the theophylline level[e1] is that metabolism occurs mainly by cytochrome P450 (CYP 1A2), an enzyme that is known to be inhibited with high concentrations of [s2]zafirlukast[e2] 
	(4, 44)	theophylline levels had increased to the toxic range	Accolate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6635	Recently, her serum [s1]theophylline levels had increased to the toxic range[e1] (133.2 micromol/L [24 microg/mL]) shortly after the addition of zafirlukast  [s2]Accolate[e2]  Zeneca Pharmaceuticals, Wilmington, Del) to her regimen.
	(4, 17)	theophylline levels had increased to the toxic range	theophylline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6636	Recently, her serum [s1]theophylline levels had increased to the toxic range[e1]  [s2]theophylline[e2] levels had increased to the toxic range (133.2 micromol/L [24 microg/mL]) shortly after the addition of zafirlukast (Accolate, Zeneca Pharmaceuticals, Wilmington, Del) to her regimen.
	(4, 39)	theophylline levels had increased to the toxic range	zafirlukast	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6637	Recently, her serum [s1]theophylline levels had increased to the toxic range[e1] (133.2 micromol/L [24 microg/mL]) shortly after the addition of [s2]zafirlukast[e2] (Accolate, Zeneca Pharmaceuticals, Wilmington, Del) to her regimen.
	(2, 12)	increase in the theophylline level	theophylline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6638	The noted [s1]increase in the theophylline level[e1]  [s2]theophylline[e2] level after zafirlukast administration is in contrast to the original reports by the manufacturer.
	(2, 13)	increase in the theophylline level	zafirlukast	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6639	The noted [s1]increase in the theophylline level[e1] after [s2]zafirlukast[e2] administration is in contrast to the original reports by the manufacturer.
	(14, 27)	drug-drug interaction	theophylline	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6640	We present the first case (to our knowledge) of a potentially serious [s1]drug-drug interaction[e1] between zafirlukast and [s2]theophylline[e2] 
	(14, 21)	drug-drug interaction	zafirlukast	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6641	We present the first case (to our knowledge) of a potentially serious [s1]drug-drug interaction[e1] between [s2]zafirlukast[e2] and theophylline.
	(8, 22)	rhabdomyolysis	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6642	A 21-year-old patient developed [s1]rhabdomyolysis[e1] during his nineteenth week of treatment with [s2]clozapine[e2] for drug-resistant schizophrenia.
	(0, 9)	Clozapine	rhabdomyolysis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6643	 [s1]Clozapine[e1] is speculated to cause [s2]rhabdomyolysis[e2] in patients with defective calcium-activated K+ channels.
	(0, 9)	Rhabdomyolysis	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6644	 [s1]Rhabdomyolysis[e1] associated with [s2]clozapine[e2] treatment in a patient with decreased calcium-dependent potassium permeability of cell membranes.
	(23, 34)	anticholinergic symptoms	diphenhydramine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6645	We describe children and adolescents with chronic hematologic and oncologic diseases who exhibited drug-seeking behavior or [s1]anticholinergic symptoms[e1] with the use of [s2]diphenhydramine[e2] 
	(18, 34)	drug-seeking behavior	diphenhydramine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6646	We describe children and adolescents with chronic hematologic and oncologic diseases who exhibited [s1]drug-seeking behavior[e1] or anticholinergic symptoms with the use of [s2]diphenhydramine[e2] 
	(4, 10)	Pentasa	pancytopenia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6647	Excluding other causes, [s1]Pentasa[e1] associated [s2]pancytopenia[e2] was considered.
	(6, 23)	diarrhea	Pentasa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6648	He developed fever, nausea, [s1]diarrhea[e1]  and malaise and stopped taking on the third day after commencing [s2]Pentasa[e2] 
	(2, 23)	fever	Pentasa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6649	He developed [s1]fever[e1]  nausea, diarrhea, and malaise and stopped taking on the third day after commencing [s2]Pentasa[e2] 
	(11, 24)	malaise	Pentasa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6650	He developed fever, nausea, diarrhea, and [s1]malaise[e1] and stopped taking on the third day after commencing [s2]Pentasa[e2] 
	(4, 23)	nausea	Pentasa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6651	He developed fever, [s1]nausea[e1]  diarrhea, and malaise and stopped taking on the third day after commencing [s2]Pentasa[e2] 
	(0, 8)	Pancytopenia	5-aminosalicylic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6652	 [s1]Pancytopenia[e1] associated with [s2]5-aminosalicylic acid[e2] use in a patient with Crohn's disease.
	(5, 30)	pancytopenia	5-aminosalicylic acid	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6653	We report a case of [s1]pancytopenia[e1] in a 23-year-old man with Crohn's disease who was treated with [s2]5-aminosalicylic acid[e2] (Pentasa; Nisshin, Tokyo, Japan) 3.0 g/day.
	(5, 38)	pancytopenia	Pentasa	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6654	We report a case of [s1]pancytopenia[e1] in a 23-year-old man with Crohn's disease who was treated with 5-aminosalicylic acid  [s2]Pentasa[e2]  Nisshin, Tokyo, Japan) 3.0 g/day.
	(2, 28)	Changes in the plasma cortisol level	alprazolam	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6655	1. [s1]Changes in the plasma cortisol level[e1] were reported in a male patient with panic disorder during the period of low-dose [s2]alprazolam[e2] treatment (mean 0.62 +/- 0.15 mg/day) compared with during the period of high-dose period (mean 1.08 +/- 0.28 mg/day).
	(5, 14)	decreased plasma cortisol level	alprazolam	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6656	3. Thus, the [s1]decreased plasma cortisol level[e1] during [s2]alprazolam[e2] treatment of panic disorder was suggested to be caused not by symptom alleviation due to alprazolam but by alprazolam administration itself.
	(0, 9)	Decreased plasma cortisol level	alprazolam	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6657	 [s1]Decreased plasma cortisol level[e1] during [s2]alprazolam[e2] treatment of panic disorder: a case report.
	(8, 21)	cyclosporine	Nocardia Asteroides brain abscess	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6658	We describe a renal transplant recipient maintained on [s1]cyclosporine[e1] and prednisone developing [s2]Nocardia Asteroides brain abscess[e2] 
	(14, 21)	prednisone	Nocardia Asteroides brain abscess	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6659	We describe a renal transplant recipient maintained on cyclosporine and [s1]prednisone[e1] developing [s2]Nocardia Asteroides brain abscess[e2] 
	(3, 16)	cisplatin	progressive sensorineural hearing loss	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6660	Young children undergoing [s1]cisplatin[e1] chemotherapy are known to be at risk for [s2]progressive sensorineural hearing loss[e2] 
	(17, 34)	pentazocine	gradual stiffness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6661	A 47 year-old woman who had a 4-year history of intramuscular [s1]pentazocine[e1] injections in the lower extremities, developed [s2]gradual stiffness[e2] and weakness of the lower extremities.
	(17, 38)	pentazocine	weakness of the lower extremities	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6662	A 47 year-old woman who had a 4-year history of intramuscular [s1]pentazocine[e1] injections in the lower extremities, developed gradual stiffness and [s2]weakness of the lower extremities[e2] 
	(10, 38)	pentazocine	fibrous myopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6663	Caution in longterm usage and early recognition of [s1]pentazocine[e1] toxicity as a neuromuscular complication are important in order to prevent irreversible drug-induced [s2]fibrous myopathy[e2] and localized neuropathy.
	(10, 19)	pentazocine	neuromuscular complication	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6664	Caution in longterm usage and early recognition of [s1]pentazocine[e1] toxicity as a [s2]neuromuscular complication[e2] are important in order to prevent irreversible drug-induced fibrous myopathy and localized neuropathy.
	(10, 46)	pentazocine	neuropathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6665	Caution in longterm usage and early recognition of [s1]pentazocine[e1] toxicity as a neuromuscular complication are important in order to prevent irreversible drug-induced fibrous myopathy and localized [s2]neuropathy[e2] 
	(10, 17)	pentazocine toxicity	pentazocine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6666	Caution in longterm usage and early recognition of [s1]pentazocine toxicity[e1]  [s2]pentazocine[e2] toxicity as a neuromuscular complication are important in order to prevent irreversible drug-induced fibrous myopathy and localized neuropathy.
	(0, 7)	Pentazocine	fibrous myopathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6667	 [s1]Pentazocine[e1] induced [s2]fibrous myopathy[e2] and localized neuropathy.
	(0, 15)	Pentazocine	neuropathy	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6668	 [s1]Pentazocine[e1] induced fibrous myopathy and localized [s2]neuropathy[e2] 
	(5, 14)	akathisia	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6669	In two of these cases [s1]akathisia[e1] resolved after withdrawal of [s2]olanzapine[e2] and substitution by a classical or an atypical neuroleptic agent, respectively.
	(10, 23)	olanzapine	extrapyramidal side effects	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6670	Like other atypical neuroleptics [s1]olanzapine[e1] is considered to show a reduced prevalence of [s2]extrapyramidal side effects[e2] when compared to classical neuroleptic drugs.
	(7, 16)	extrapyramidal side effects	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6671	One should therefore be aware of possible [s1]extrapyramidal side effects[e1] with [s2]olanzapine[e2] that are reduced compared to classical neuroleptic drugs but not completely eliminated.
	(0, 7)	Severe akathisia	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6672	 [s1]Severe akathisia[e1] during [s2]olanzapine[e2] treatment of acute schizophrenia.
	(11, 20)	severe akathisia	olanzapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6673	We report on three patients with acute schizophrenia, who developed [s1]severe akathisia[e1] during treatment with [s2]olanzapine[e2] (20-25 mg/d).
	(0, 21)	Seizures	metrifonate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6674	 [s1]Seizures[e1] occurred in two patients with probable Alzheimer's disease who were receiving long-term treatment with [s2]metrifonate[e2]  an irreversible acetylcholinesterase inhibitor.
	(5, 19)	vitreous hemorrhage	tPA	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6675	However, 1 eye had [s1]vitreous hemorrhage[e1] after repeated injections of [s2]tPA[e2] 
	(6, 18)	tPA	vitreous hemorrhage	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6676	However, repeated intracameral [s1]tPA[e1] injections may cause unwanted complications such as [s2]vitreous hemorrhage[e2] 
	(1, 29)	praziquantel	inflammation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6677	Although [s1]praziquantel[e1] administration may have been effective in killing the parasite in both patients, we are concerned about the production of marked [s2]inflammation[e2] as a result of treatment.
	(0, 16)	NMS	Haloperidol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6678	 [s1]NMS[e1] is a drug-related response to various medications, such as [s2]Haloperidol[e2]  which the patient was receiving.
	(0, 7)	Methimazole	aplastic anemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6679	 [s1]Methimazole[e1] induced [s2]aplastic anemia[e2] in third exposure: successful treatment with recombinant human granulocyte colony-stimulating factor.
	(19, 27)	AA	methimazole	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6680	We present a case of a 58-year-old female patient with Graves' disease who developed [s1]AA[e1] in the third exposure to [s2]methimazole[e2] (MMI).
	(0, 7)	FSGS	Adriamycin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6681	 [s1]FSGS[e1] induced by [s2]Adriamycin[e2] (Pharmacia & Upjohn, Columbus, OH) has been observed experimentally in rats.
	(10, 19)	pranlukast	ATIN	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6682	The case demonstrates that hypersensitivity reaction to [s1]pranlukast[e1] and resultant [s2]ATIN[e2] is possible, and that periodic urine testing in patients receiving pranlukast should be considered.
	(10, 19)	pranlukast	ATIN	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6683	The case demonstrates that hypersensitivity reaction to [s1]pranlukast[e1] and resultant [s2]ATIN[e2] is possible, and that periodic urine testing in patients receiving pranlukast should be considered.
	(4, 12)	hypersensitivity reaction	pranlukast	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6684	The case demonstrates that [s1]hypersensitivity reaction[e1] to [s2]pranlukast[e2] and resultant ATIN is possible, and that periodic urine testing in patients receiving pranlukast should be considered.
	(4, 12)	hypersensitivity reaction	pranlukast	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6685	The case demonstrates that [s1]hypersensitivity reaction[e1] to [s2]pranlukast[e2] and resultant ATIN is possible, and that periodic urine testing in patients receiving pranlukast should be considered.
	(0, 22)	Tubulointerstitial nephritis	pranlukast	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6686	 [s1]Tubulointerstitial nephritis[e1] induced by the leukotriene receptor antagonist [s2]pranlukast[e2] 
	(4, 13)	pranlukast	anemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6687	Within 6 months of [s1]pranlukast[e1] withdrawal, [s2]anemia[e2] resolved and urinary sediment and renal function normalized.
	(15, 27)	syncope	isosorbide dinitrate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6688	A 65-year-old woman with angina pectoris presented with [s1]syncope[e1] after sublingual ingestion of [s2]isosorbide dinitrate[e2] (5 mg).
	(4, 17)	nitrate	hypotension	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6689	Elderly patients for whom [s1]nitrate[e1] has been prescribed should be warned of the occurrence of [s2]hypotension[e2]  leading to unconsciousness.
	(4, 25)	nitrate	unconsciousness	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6690	Elderly patients for whom [s1]nitrate[e1] has been prescribed should be warned of the occurrence of hypotension, leading to [s2]unconsciousness[e2] 
	(9, 23)	isosorbide dinitrate	blood pressure decreased	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6691	In a postural challenge test after administration of [s1]isosorbide dinitrate[e1] (5 mg), [s2]blood pressure decreased[e2] from 120/67 to 65/35 mmHg, followed by syncope with a sudden decrease in pulse rate from 85 to 60 beats/min.
	(9, 43)	isosorbide dinitrate	sudden decrease in pulse rate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6692	In a postural challenge test after administration of [s1]isosorbide dinitrate[e1] (5 mg), blood pressure decreased from 120/67 to 65/35 mmHg, followed by syncope with a [s2]sudden decrease in pulse rate[e2] from 85 to 60 beats/min.
	(9, 39)	isosorbide dinitrate	syncope	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6693	In a postural challenge test after administration of [s1]isosorbide dinitrate[e1] (5 mg), blood pressure decreased from 120/67 to 65/35 mmHg, followed by [s2]syncope[e2] with a sudden decrease in pulse rate from 85 to 60 beats/min.
	(0, 13)	Syncope	nitrate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6694	 [s1]Syncope[e1] in a 65-year-old woman after [s2]nitrate[e2] ingestion.
	(6, 16)	acute dizziness	voglibose	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6695	Three diabetic cases of [s1]acute dizziness[e1] due to initial administration of [s2]voglibose[e2] 
	(8, 36)	intolerable dizziness	voglibose	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6696	We observed 3 diabetic patients with [s1]intolerable dizziness[e1] followed by nausea and vomiting immediately after an initial administration of the alpha-glucosidase inhibitor, [s2]voglibose[e2] 
	(15, 36)	nausea	voglibose	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6697	We observed 3 diabetic patients with intolerable dizziness followed by [s1]nausea[e1] and vomiting immediately after an initial administration of the alpha-glucosidase inhibitor, [s2]voglibose[e2] 
	(17, 36)	vomiting	voglibose	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6698	We observed 3 diabetic patients with intolerable dizziness followed by nausea and [s1]vomiting[e1] immediately after an initial administration of the alpha-glucosidase inhibitor, [s2]voglibose[e2] 
	(0, 7)	Naproxen	sudden sensorineural hearing loss	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6699	 [s1]Naproxen[e1] associated [s2]sudden sensorineural hearing loss[e2] 
	(0, 26)	Naproxen	tinnitus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6700	 [s1]Naproxen[e1] is a commonly used nonsteroidal anti-inflammatory drug (NSAID) whose side effects include [s2]tinnitus[e2] and transient hearing loss.
	(0, 30)	Naproxen	transient hearing loss	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6701	 [s1]Naproxen[e1] is a commonly used nonsteroidal anti-inflammatory drug (NSAID) whose side effects include tinnitus and [s2]transient hearing loss[e2] 
	(13, 25)	sensorineural hearing loss	naproxen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6702	This article reports the case of an otherwise healthy patient who experienced permanent [s1]sensorineural hearing loss[e1] after a brief course of [s2]naproxen[e2] and reviews the literature on NSAID-related permanent sensorineural hearing loss.
	(0, 12)	Dental and gingival pain	niacin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6703	 [s1]Dental and gingival pain[e1] as side effects of [s2]niacin[e2] therapy.
	(12, 38)	niacin	hyperalgesia of sensory nerve receptors	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6704	The cause of these previously unreported side effects of [s1]niacin[e1] therapy is uncertain but may be related to prostaglandin-mediated vasodilatation, [s2]hyperalgesia of sensory nerve receptors[e2]  and potentiation of inflammation in the gingiva with referral of pain to the teeth.
	(12, 61)	niacin	pain to the teeth	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6705	The cause of these previously unreported side effects of [s1]niacin[e1] therapy is uncertain but may be related to prostaglandin-mediated vasodilatation, hyperalgesia of sensory nerve receptors, and potentiation of inflammation in the gingiva with referral of [s2]pain to the teeth[e2] 
	(12, 48)	niacin	potentiation of inflammation in the gingiva	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6706	The cause of these previously unreported side effects of [s1]niacin[e1] therapy is uncertain but may be related to prostaglandin-mediated vasodilatation, hyperalgesia of sensory nerve receptors, and [s2]potentiation of inflammation in the gingiva[e2] with referral of pain to the teeth.
	(12, 25)	niacin	prostaglandin-mediated vasodilatation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6707	The cause of these previously unreported side effects of [s1]niacin[e1] therapy is uncertain but may be related to [s2]prostaglandin-mediated vasodilatation[e2]  hyperalgesia of sensory nerve receptors, and potentiation of inflammation in the gingiva with referral of pain to the teeth.
	(15, 32)	niacin	intense dental and gingival pain	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6708	Two 65-year-old white men with coronary heart disease, given [s1]niacin[e1] therapy for dyslipidemia for 5 months, developed [s2]intense dental and gingival pain[e2] that was associated with increases in dose and that was relieved with discontinuance of niacin treatment.
	(15, 32)	niacin	intense dental and gingival pain	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6709	Two 65-year-old white men with coronary heart disease, given [s1]niacin[e1] therapy for dyslipidemia for 5 months, developed [s2]intense dental and gingival pain[e2] that was associated with increases in dose and that was relieved with discontinuance of niacin treatment.
	(20, 40)	calcitriol	potassium loss	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6710	Although major hazards of treatment of hypophosphatemic osteomalacia with phosphate and [s1]calcitriol[e1] are secondary hyperparathyroidism and vitamin D intoxication, [s2]potassium loss[e2] also should be kept in mind.
	(8, 38)	phosphate	potassium loss	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6711	Although major hazards of treatment of hyp [s1]phosphate[e1] ic osteomalacia with phosphate and calcitriol are secondary hyperparathyroidism and vitamin D intoxication, [s2]potassium loss[e2] also should be kept in mind.
	(20, 27)	calcitriol	secondary hyperparathyroidism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6712	Although major hazards of treatment of hypophosphatemic osteomalacia with phosphate and [s1]calcitriol[e1] are [s2]secondary hyperparathyroidism[e2] and vitamin D intoxication, potassium loss also should be kept in mind.
	(8, 25)	phosphate	secondary hyperparathyroidism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6713	Although major hazards of treatment of hyp [s1]phosphate[e1] ic osteomalacia with phosphate and calcitriol are [s2]secondary hyperparathyroidism[e2] and vitamin D intoxication, potassium loss also should be kept in mind.
	(20, 34)	calcitriol	vitamin D intoxication	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6714	Although major hazards of treatment of hypophosphatemic osteomalacia with phosphate and [s1]calcitriol[e1] are secondary hyperparathyroidism and [s2]vitamin D intoxication[e2]  potassium loss also should be kept in mind.
	(8, 32)	phosphate	vitamin D intoxication	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6715	Although major hazards of treatment of hyp [s1]phosphate[e1] ic osteomalacia with phosphate and calcitriol are secondary hyperparathyroidism and [s2]vitamin D intoxication[e2]  potassium loss also should be kept in mind.
	(3, 9)	phosphate	hypokalemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6716	High-dose [s1]phosphate[e1] treatment leads to [s2]hypokalemia[e2] in hypophosphatemic osteomalacia.
	(18, 22)	phosphate	hypokalemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6717	It was concluded that potassium loss occurred by a non-renal (intestinal) route in [s1]phosphate[e1] induced [s2]hypokalemia[e2] 
	(4, 20)	potassium loss	phosphate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6718	It was concluded that [s1]potassium loss[e1] occurred by a non-renal (intestinal) route in [s2]phosphate[e2] induced hypokalemia.
	(0, 10)	Progressive hypokalemia	phosphate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6719	 [s1]Progressive hypokalemia[e1] developed during [s2]phosphate[e2] treatment.
	(4, 12)	decrease in plasma potassium	phosphate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6720	The mechanism of the [s1]decrease in plasma potassium[e1] induced by [s2]phosphate[e2] treatment was investigated in a 24-year-old hypertensive patient with hypophosphatemic osteomalacia, who was the youngest of four patients, belonging to a 23 number kindred of five generations.
	(0, 27)	Transtubular potassium gradient (TTKG) also decreased	phosphate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6721	 [s1]Transtubular potassium gradient (TTKG) also decreased[e1] and an inverse correlation was found between TTKG and doses of [s2]phosphate[e2] (r = -0.37; p < 0.02; N = 38).
	(0, 15)	Alveolar-interstitial pneumopathy	gold	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6722	 [s1]Alveolar-interstitial pneumopathy[e1] after [s2]gold[e2] salts compounds administration, requiring mechanical ventilation.
	(1, 6)	pulmonary toxicity	gold	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6723	The [s1]pulmonary toxicity[e1] of [s2]gold[e2] salts is an uncommon cause of life-threatening respiratory failure.
	(4, 16)	gold	respiratory failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6724	The pulmonary toxicity of [s1]gold[e1] salts is an uncommon cause of life-threatening [s2]respiratory failure[e2] 
	(6, 12)	respiratory failure	gold	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6725	We report a case of severe [s1]respiratory failure[e1] due to [s2]gold[e2] salt toxicity in a patient suffering from rheumatoid arthritis requiring mechanical ventilation.
	(14, 22)	hypersensitivity response	tuberculin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6726	As this relapse coincided with development of a strong delayed-type [s1]hypersensitivity response[e1] to [s2]tuberculin[e2] and improved after treatment with the anti-inflammatory agent oxpentifylline, it was probably caused by restoration of pathogen-specific cellular immunity.
	(35, 56)	glycosuria	halcinonide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6727	A patient with psoriasis is described who had an abnormal response to the glucose tolerance test without other evidence of diabetes and then developed postprandial hyperglycemia and [s1]glycosuria[e1] during a period of topical administration of a corticosteroid cream, [s2]halcinonide[e2] cream 0.1%, under occlusion.
	(26, 56)	postprandial hyperglycemia	halcinonide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6728	A patient with psoriasis is described who had an abnormal response to the glucose tolerance test without other evidence of diabetes and then developed [s1]postprandial hyperglycemia[e1] and glycosuria during a period of topical administration of a corticosteroid cream, [s2]halcinonide[e2] cream 0.1%, under occlusion.
	(11, 25)	postprandial hyperglycemia	betamethasone valerate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6729	A second patient with a similar glucose tolerance test result showed [s1]postprandial hyperglycemia[e1] when treated similarly with [s2]betamethasone valerate[e2] cream 0.1%.
	(4, 17)	nefazodone	confusion	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6730	"After 1 week of [s1]nefazodone[e1] therapy the patient experienced headache, [s2]confusion[e2]  and ""gray areas"" in her vision, without abnormal ophthalmologic findings."
	(4, 20)	nefazodone	gray areas	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6731	After 1 week of [s1]nefazodone[e1] therapy the patient experienced headache, confusion, and  [s2]gray areas[e2]  in her vision, without abnormal ophthalmologic findings.
	(4, 15)	nefazodone	headache	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6732	"After 1 week of [s1]nefazodone[e1] therapy the patient experienced [s2]headache[e2]  confusion, and ""gray areas"" in her vision, without abnormal ophthalmologic findings."
	(13, 43)	nefazodone	interfere with tacrolimus metabolism	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6733	Coadministration of antidepressant agents such as [s1]nefazodone[e1]  or any other drug that inhibits the CYP3A4 isoenzyme subfamily, should be anticipated to [s2]interfere with tacrolimus metabolism[e2] 
	(42, 51)	interfere with tacrolimus metabolism	tacrolimus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6734	Coadministration of antidepressant agents such as nefazodone, or any other drug that inhibits the CYP3A4 isoenzyme subfamily, should be anticipated to [s1]interfere with tacrolimus metabolism[e1]  [s2]tacrolimus[e2] metabolism.
	(0, 9)	Interaction	nefazodone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6735	 [s1]Interaction[e1] between tacrolimus and [s2]nefazodone[e2] in a stable renal transplant recipient.
	(0, 4)	Interaction	tacrolimus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6736	 [s1]Interaction[e1] between [s2]tacrolimus[e2] and nefazodone in a stable renal transplant recipient.
	(3, 10)	nefazodone	inhibits metabolism of tacrolimus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6737	We suspect that [s1]nefazodone[e1]  [s2]inhibits metabolism of tacrolimus[e2] 
	(8, 18)	inhibits metabolism of tacrolimus	tacrolimus	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6738	We suspect that nefazodone [s1]inhibits metabolism of tacrolimus[e1]  [s2]tacrolimus[e2] 
	(5, 24)	intoxication	mirtazapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6739	We report the case of [s1]intoxication[e1] of a 41-year-old female patient suffering from major depression with [s2]mirtazapine[e2] complicated by severe hypothermia.
	(22, 28)	acute vitamin D poisoning	vitamin D	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6740	CONCLUSION: We report a case of the use of pamidronate for significant hypercalcemia secondary to [s1]acute vitamin D poisoning[e1]  [s2]vitamin D[e2] poisoning.
	(16, 25)	hypercalcemia	vitamin D	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6741	CONCLUSION: We report a case of the use of pamidronate for significant [s1]hypercalcemia[e1] secondary to acute [s2]vitamin D[e2] poisoning.
	(17, 23)	acute vitamin D poisoning	vitamin D	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6742	Pamidronate therapy should be considered in patients with hypercalcemia secondary to [s1]acute vitamin D poisoning[e1]  [s2]vitamin D[e2] poisoning.
	(11, 20)	hypercalcemia	vitamin D	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6743	Pamidronate therapy should be considered in patients with [s1]hypercalcemia[e1] secondary to acute [s2]vitamin D[e2] poisoning.
	(9, 16)	furosemide	congestive heart failure	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6744	The patient was initially treated with hydration and [s1]furosemide[e1] but developed [s2]congestive heart failure[e2] 
	(15, 22)	vitamin D intoxication	vitamin D	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6745	The use of pamidronate for hypercalcemia secondary to acute [s1]vitamin D intoxication[e1]  [s2]vitamin D[e2] intoxication.
	(12, 24)	severe hypercalcemia	vitamin D	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6746	We report the use of pamidronate for acute, [s1]severe hypercalcemia[e1] secondary to iatrogenic [s2]vitamin D[e2] poisoning.
	(22, 27)	vitamin D poisoning	vitamin D	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6747	We report the use of pamidronate for acute, severe hypercalcemia secondary to iatrogenic [s1]vitamin D poisoning[e1]  [s2]vitamin D[e2] poisoning.
	(22, 34)	MTX	overwhelming hepatic necrosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6748	A 40-year-old man with a long standing history of rheumatoid arthritis was treated with [s1]MTX[e1] over a 6 month period and developed an [s2]overwhelming hepatic necrosis[e2] 
	(0, 8)	Methotrexate	hepatic necrosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6749	 [s1]Methotrexate[e1] induced [s2]hepatic necrosis[e2] requiring liver transplantation in a patient with rheumatoid arthritis.
	(0, 5)	MTX	hepatic injury	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6750	 [s1]MTX[e1] induced [s2]hepatic injury[e2] and liver enzyme elevations have been demonstrated after treatment of leukemia, gestational disease and during treatment of psoriasis and rheumatoid arthritis.
	(0, 10)	MTX	liver enzyme elevations	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6751	 [s1]MTX[e1] induced hepatic injury and [s2]liver enzyme elevations[e2] have been demonstrated after treatment of leukemia, gestational disease and during treatment of psoriasis and rheumatoid arthritis.
	(9, 22)	vinorelbine	hypokalemia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6752	Clinicians should be aware of the possibility that [s1]vinorelbine[e1] may cause SIADH and possibly [s2]hypokalemia[e2] 
	(9, 17)	vinorelbine	SIADH	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6753	Clinicians should be aware of the possibility that [s1]vinorelbine[e1] may cause [s2]SIADH[e2] and possibly hypokalemia.
	(16, 28)	vinorelbine	SIADH	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6754	CONCLUSIONS: Because of its structural similarity to the other vinca alkaloids, [s1]vinorelbine[e1] is believed to be responsible for [s2]SIADH[e2] in our patient.
	(14, 21)	SIADH	vinorelbine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6755	OBJECTIVE: To describe onset of syndrome of inappropriate antidiuretic hormone  [s1]SIADH[e1]  associated with [s2]vinorelbine[e2] therapy for advanced breast cancer.
	(6, 23)	syndrome of inappropriate antidiuretic hormone	vinorelbine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6756	OBJECTIVE: To describe onset of [s1]syndrome of inappropriate antidiuretic hormone[e1] (SIADH) associated with [s2]vinorelbine[e2] therapy for advanced breast cancer.
	(0, 12)	Syndrome of inappropriate antidiuretic hormone	vinorelbine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6757	 [s1]Syndrome of inappropriate antidiuretic hormone[e1] associated with [s2]vinorelbine[e2] therapy.
	(0, 11)	Pirmenol hydrochloride	QT prolongation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6758	 [s1]Pirmenol hydrochloride[e1] induced [s2]QT prolongation[e2] and T wave inversion on electrocardiogram during treatment for symptomatic atrial fibrillation.
	(0, 17)	Pirmenol hydrochloride	T wave inversion	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6759	 [s1]Pirmenol hydrochloride[e1] induced QT prolongation and [s2]T wave inversion[e2] on electrocardiogram during treatment for symptomatic atrial fibrillation.
	(14, 21)	pirmenol	QT prolongation	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6760	Thus, an immunological mechanism might be involved in the mechanism of [s1]pirmenol[e1] induced [s2]QT prolongation[e2] and T wave inversion on the electrocardiogram.
	(14, 27)	pirmenol	T wave inversion	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6761	Thus, an immunological mechanism might be involved in the mechanism of [s1]pirmenol[e1] induced QT prolongation and [s2]T wave inversion[e2] on the electrocardiogram.
	(29, 60)	prolongation of the QT interval	pirmenol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6762	We report on a 56-year-old female who exhibited drug refractory paroxysmal atrial fibrillation, in which marked [s1]prolongation of the QT interval[e1] and T wave inversion on electrocardiogram was demonstrated reproducibly shortly after the administration of oral [s2]pirmenol[e2] therapy.
	(38, 60)	T wave inversion	pirmenol	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6763	We report on a 56-year-old female who exhibited drug refractory paroxysmal atrial fibrillation, in which marked prolongation of the QT interval and [s1]T wave inversion[e1] on electrocardiogram was demonstrated reproducibly shortly after the administration of oral [s2]pirmenol[e2] therapy.
	(10, 17)	myositis	praziquantel	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6764	Disseminated muscular cysticercosis with [s1]myositis[e1] induced by [s2]praziquantel[e2] therapy.
	(22, 46)	diffuse myalgia	praziquantel	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6765	We describe a case of disseminated muscular cysticercosis followed by myositis (fever, [s1]diffuse myalgia[e1]  weakness of the lower limbs, and inflammatory reaction around dying cysticerci) induced by [s2]praziquantel[e2] therapy, an event not described previously.
	(19, 45)	fever	praziquantel	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6766	We describe a case of disseminated muscular cysticercosis followed by myositis  [s1]fever[e1]  diffuse myalgia, weakness of the lower limbs, and inflammatory reaction around dying cysticerci) induced by [s2]praziquantel[e2] therapy, an event not described previously.
	(34, 46)	inflammatory reaction around dying cysticerci	praziquantel	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6767	We describe a case of disseminated muscular cysticercosis followed by myositis (fever, diffuse myalgia, weakness of the lower limbs, and [s1]inflammatory reaction around dying cysticerci[e1]  induced by [s2]praziquantel[e2] therapy, an event not described previously.
	(16, 47)	myositis	praziquantel	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6768	We describe a case of disseminated muscular cysticercosis followed by [s1]myositis[e1] (fever, diffuse myalgia, weakness of the lower limbs, and inflammatory reaction around dying cysticerci) induced by [s2]praziquantel[e2] therapy, an event not described previously.
	(27, 46)	weakness of the lower limbs	praziquantel	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6769	We describe a case of disseminated muscular cysticercosis followed by myositis (fever, diffuse myalgia, [s1]weakness of the lower limbs[e1]  and inflammatory reaction around dying cysticerci) induced by [s2]praziquantel[e2] therapy, an event not described previously.
	(0, 11)	Massive subfascial hematoma	alteplase	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6770	 [s1]Massive subfascial hematoma[e1] after [s2]alteplase[e2] therapy for acute myocardial infarction.
	(12, 21)	alteplase	subfascial hemorrhage	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6771	Physicians should be aware of the possible association between the use of [s1]alteplase[e1] and the development of [s2]subfascial hemorrhage[e2] 
	(10, 26)	alteplase	subfascial hematoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6772	The authors report a case of a patient who received [s1]alteplase[e1] for acute myocardial infarction and developed spontaneous [s2]subfascial hematoma[e2] without any evidence of direct trauma.
	(3, 25)	cutaneous ecchymosis	alteplase	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6773	The development of [s1]cutaneous ecchymosis[e1] associated with a sudden fall in hemoglobin after the administration of [s2]alteplase[e2] should strongly suggest the possibility of diffuse subfascial hematoma.
	(23, 34)	alteplase	diffuse subfascial hematoma	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6774	The development of cutaneous ecchymosis associated with a sudden fall in hemoglobin after the administration of [s1]alteplase[e1] should strongly suggest the possibility of [s2]diffuse subfascial hematoma[e2] 
	(12, 25)	sudden fall in hemoglobin	alteplase	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6775	The development of cutaneous ecchymosis associated with a [s1]sudden fall in hemoglobin[e1] after the administration of [s2]alteplase[e2] should strongly suggest the possibility of diffuse subfascial hematoma.
	(1, 12)	fatal case of pancytopenia	levomepromazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6776	A [s1]fatal case of pancytopenia[e1] due to [s2]levomepromazine[e2] 
	(1, 39)	fatal pancytopenia	diazepam	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6777	A [s1]fatal pancytopenia[e1] occurred in a patient with an history of depression with hypomanic rebounds, admitted for a manic episode and treated with levomepromazine, [s2]diazepam[e2] and lithium carbonate.
	(1, 33)	fatal pancytopenia	levomepromazine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6778	A [s1]fatal pancytopenia[e1] occurred in a patient with an history of depression with hypomanic rebounds, admitted for a manic episode and treated with [s2]levomepromazine[e2]  diazepam and lithium carbonate.
	(1, 43)	fatal pancytopenia	lithium carbonate	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6779	A [s1]fatal pancytopenia[e1] occurred in a patient with an history of depression with hypomanic rebounds, admitted for a manic episode and treated with levomepromazine, diazepam and [s2]lithium carbonate[e2] 
	(0, 6)	Amiodarone	thyrotoxicosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6780	 [s1]Amiodarone[e1] induced [s2]thyrotoxicosis[e2] associated with thyrotropin receptor antibody.
	(0, 13)	Amiodarone	thyrotropin receptor antibody	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6781	 [s1]Amiodarone[e1] induced thyrotoxicosis associated with [s2]thyrotropin receptor antibody[e2] 
	(29, 39)	amiodarone	thyrotoxicosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6782	Among 12 thyrotoxic patients, a patient with arrhythmogenic right ventricular dysplasia, who had been taking [s1]amiodarone[e1] for 4 years, developed [s2]thyrotoxicosis[e2] with subacute onset, accompanied by transiently positive thyrotropin (TSH) receptor antibody (TRAb), or thyrotropin-binding inhibiting immunoglobulin (TBII).
	(29, 71)	amiodarone	thyrotropin-binding inhibiting immunoglobulin	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6783	Among 12 thyrotoxic patients, a patient with arrhythmogenic right ventricular dysplasia, who had been taking [s1]amiodarone[e1] for 4 years, developed thyrotoxicosis with subacute onset, accompanied by transiently positive thyrotropin (TSH) receptor antibody (TRAb), or [s2]thyrotropin-binding inhibiting immunoglobulin[e2] (TBII).
	(29, 52)	amiodarone	transiently positive thyrotropin (TSH) receptor antibody	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6784	Among 12 thyrotoxic patients, a patient with arrhythmogenic right ventricular dysplasia, who had been taking [s1]amiodarone[e1] for 4 years, developed thyrotoxicosis with subacute onset, accompanied by [s2]transiently positive thyrotropin (TSH) receptor antibody[e2] (TRAb), or thyrotropin-binding inhibiting immunoglobulin (TBII).
	(1, 27)	amiodarone	AIT	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6785	Since [s1]amiodarone[e1] was first marketed in 1992 in Japan, the incidence of amiodarone-induced thyrotoxicosis  [s2]AIT[e2]  has been increasing.
	(1, 22)	amiodarone	thyrotoxicosis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6786	Since [s1]amiodarone[e1] was first marketed in 1992 in Japan, the incidence of amiodarone-induced [s2]thyrotoxicosis[e2] (AIT) has been increasing.
	(24, 30)	amiodarone	destructive thyroiditis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6787	These in vitro findings and clinical course suggest that TRAb/TBII without thyroid-stimulating activity may develop in patients with [s1]amiodarone[e1] induced [s2]destructive thyroiditis[e2]  as reported in patients with destructive thyroiditis, such as subacute and silent thyroiditis.
	(24, 30)	amiodarone	destructive thyroiditis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6788	These in vitro findings and clinical course suggest that TRAb/TBII without thyroid-stimulating activity may develop in patients with [s1]amiodarone[e1] induced [s2]destructive thyroiditis[e2]  as reported in patients with destructive thyroiditis, such as subacute and silent thyroiditis.
	(24, 31)	amiodarone	thyroiditis	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6789	These in vitro findings and clinical course suggest that TRAb/TBII without thyroid-stimulating activity may develop in patients with [s1]amiodarone[e1] induced destructive [s2]thyroiditis[e2]  as reported in patients with destructive thyroiditis, such as subacute and silent thyroiditis.
	(9, 26)	TRAb/TBII without thyroid-stimulating activity	amiodarone	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6790	These in vitro findings and clinical course suggest that [s1]TRAb/TBII without thyroid-stimulating activity[e1] may develop in patients with [s2]amiodarone[e2] induced destructive thyroiditis, as reported in patients with destructive thyroiditis, such as subacute and silent thyroiditis.
	(2, 11)	Lipoid pneumonia	mineral oil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6791	CONCLUSION: [s1]Lipoid pneumonia[e1] as a result of [s2]mineral oil[e2] aspiration still occurs in the pediatric population.
	(11, 23)	mineral oil	ELP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6792	In patients with swallowing dysfunction and pneumonia, a history of [s1]mineral oil[e1] use should be obtained and a diagnosis of [s2]ELP[e2] should be considered in the differential diagnoses if mineral oil use has occurred.
	(11, 23)	mineral oil	ELP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6793	In patients with swallowing dysfunction and pneumonia, a history of [s1]mineral oil[e1] use should be obtained and a diagnosis of [s2]ELP[e2] should be considered in the differential diagnoses if mineral oil use has occurred.
	(6, 12)	pneumonia	mineral oil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6794	In patients with swallowing dysfunction and [s1]pneumonia[e1]  a history of [s2]mineral oil[e2] use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if mineral oil use has occurred.
	(6, 12)	pneumonia	mineral oil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6795	In patients with swallowing dysfunction and [s1]pneumonia[e1]  a history of [s2]mineral oil[e2] use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if mineral oil use has occurred.
	(3, 13)	swallowing dysfunction	mineral oil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6796	In patients with [s1]swallowing dysfunction[e1] and pneumonia, a history of [s2]mineral oil[e2] use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if mineral oil use has occurred.
	(3, 13)	swallowing dysfunction	mineral oil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6797	In patients with [s1]swallowing dysfunction[e1] and pneumonia, a history of [s2]mineral oil[e2] use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if mineral oil use has occurred.
	(0, 10)	Lipoid pneumonia	mineral oil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6798	 [s1]Lipoid pneumonia[e1]  a silent complication of [s2]mineral oil[e2] aspiration.
	(0, 19)	Mineral oil	impair mucociliary transport	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6799	 [s1]Mineral oil[e1]  a hydrocarbon, may not elicit a normal protective cough reflex and may [s2]impair mucociliary transport[e2] 
	(16, 21)	potential hazards	mineral oil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6800	Our case points to the need for increased awareness by the general pediatricians of the [s1]potential hazards[e1] of [s2]mineral oil[e2] use for chronic constipation.
	(2, 29)	ELP	mineral oil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6801	Treatment of [s1]ELP[e1] in children is generally supportive, with the symptoms and roentgenographic abnormalities resolving within months after stopping the use of [s2]mineral oil[e2] 
	(14, 29)	roentgenographic abnormalities	mineral oil	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6802	Treatment of ELP in children is generally supportive, with the symptoms and [s1]roentgenographic abnormalities[e1] resolving within months after stopping the use of [s2]mineral oil[e2] 
	(26, 46)	mineral oil	ELP	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6803	We report a case of a child with neurodevelopmental delay with chronic constipation and a history of chronic [s1]mineral oil[e1] ingestion presenting as asymptomatic exogenous lipoid pneumonia  [s2]ELP[e2] .
	(26, 40)	mineral oil	exogenous lipoid pneumonia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6804	We report a case of a child with neurodevelopmental delay with chronic constipation and a history of chronic [s1]mineral oil[e1] ingestion presenting as asymptomatic [s2]exogenous lipoid pneumonia[e2] (ELP).
	(4, 18)	burn injury	psoralens	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6805	An unusual cause of [s1]burn injury[e1]  unsupervised use of drugs that contain [s2]psoralens[e2] 
	(1, 16)	psoralens	phototoxic reactions	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6806	Because [s1]psoralens[e1] sensitize skin to ultraviolet A light, [s2]phototoxic reactions[e2] are the most frequent adverse effect of this treatment.
	(23, 32)	intense burn	8-methoxypsoralen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6807	In this article, we present the case of a vitiligo patient who was admitted to our facility with an [s1]intense burn[e1] after the topical use of [s2]8-methoxypsoralen[e2] solution as a suntanning agent.
	(9, 27)	psoralen	skin extremely sensitive	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6808	Sunburn may sometimes be a major injury in [s1]psoralen[e1] users because high doses or inappropriate use of the drug may render the [s2]skin extremely sensitive[e2] 
	(0, 11)	Sunburn	psoralen	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6809	 [s1]Sunburn[e1] may sometimes be a major injury in [s2]psoralen[e2] users because high doses or inappropriate use of the drug may render the skin extremely sensitive.
	(2, 15)	Metoclopramide	nonthrombocytopenic vascular-type palpable purpura	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6810	CONCLUSIONS: [s1]Metoclopramide[e1] may cause reversible [s2]nonthrombocytopenic vascular-type palpable purpura[e2] 
	(10, 28)	nonthrombocytopenic palpable purpura	metoclopramide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6811	OBJECTIVE: To report a case of reversible [s1]nonthrombocytopenic palpable purpura[e1] associated with [s2]metoclopramide[e2] 
	(3, 21)	nonthrombocytopenic palpable purpura	metoclopramide	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6812	Reversible [s1]nonthrombocytopenic palpable purpura[e1] associated with [s2]metoclopramide[e2] 
	(0, 16)	Lithium	diabetes insipidus-like syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6813	 [s1]Lithium[e1] treatment was terminated in 1975 because of lithium intoxication with a [s2]diabetes insipidus-like syndrome[e2] 
	(8, 16)	lithium	diabetes insipidus-like syndrome	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6814	Lithium treatment was terminated in 1975 because of [s1]lithium[e1] intoxication with a [s2]diabetes insipidus-like syndrome[e2] 
	(0, 10)	Lithium	lithium intoxication	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6815	 [s1]Lithium[e1] treatment was terminated in 1975 because of [s2]lithium intoxication[e2] with a diabetes insipidus-like syndrome.
	(8, 14)	lithium intoxication	lithium	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6816	Lithium treatment was terminated in 1975 because of [s1]lithium intoxication[e1]  [s2]lithium[e2] intoxication with a diabetes insipidus-like syndrome.
	(0, 9)	Eosinophilia	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6817	 [s1]Eosinophilia[e1] caused by [s2]clozapine[e2] was observed in challenge, preceded by a faster neutrophil production and consecutive decrease (z = 2.27, p = 0.01).
	(0, 20)	Eosinophilia	clozapine	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6818	 [s1]Eosinophilia[e1] has been encountered from 0.2 to 61.7% in [s2]clozapine[e2] treated patients, mostly with a transient course and spontaneous remission.
	(3, 12)	clozapine	eosinophilia	DRUG-AE	0	DRUG	AE	-1	-1	N/A	N/A	6819	Successful challenge with [s1]clozapine[e1] in a history of [s2]eosinophilia[e2] 
	(20, 27)	methotrexate	1500 mg/m2	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	0	An episode of subacute encephalopathy after the infusion of a moderate dose of [s1]methotrexate[e1]  [s2]1500 mg/m2[e2]  (MTX) is reported in a young adult with metastastic gastric cancer.
	(5, 8)	insulin	4 times per day	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	1	She continued to receive regular [s1]insulin[e1]  [s2]4 times per day[e2] over the following 3 years with only occasional hives.
	(16, 21)	1 drop	brimonidine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	2	A 5-month-old infant became lethargic and poorly responsive after receiving [s1]1 drop[e1] of [s2]brimonidine[e2] in each eye.
	(6, 10)	200 mg	TCA	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	3	The presented patient was treated with [s1]200 mg[e1]  [s2]TCA[e2] and developed Cushing's syndrome 6 weeks later (cortisol and ACTH concentrations were below limits of detection, TCA concentrations were > 3 micrograms/l).
	(7, 13)	ibuprofen	overdose	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	4	Central nervous system manifestations of an [s1]ibuprofen[e1]  [s2]overdose[e2] reversed by naloxone.
	(0, 6)	Ibuprofen	overdose	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	5	 [s1]Ibuprofen[e1]  [s2]overdose[e2] is usually characterized by GI upset, dizziness, and mild sedation.
	(20, 24)	low	methotrexate	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	6	In this case, it was suspected that a combination of cigarette smoking, pulmonary fibrosis, and [s1]low[e1] dose [s2]methotrexate[e2] therapy might have promoted the development of lung cancer.
	(14, 18)	high	methylprednisolone	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	7	A case of normotensive scleroderma renal crisis after [s1]high[e1] dose [s2]methylprednisolone[e2] treatment.
	(20, 26)	regular	colchicine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	8	A 60 year-old woman with chronic renal failure developed acute proximal muscle weakness after receiving a [s1]regular[e1] dosage of [s2]colchicine[e2] 
	(7, 12)	25 UI	Miacalcic	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	9	The intramuscular challenge test with [s1]25 UI[e1] of [s2]Miacalcic[e2] was positive with an immediate anaphylactic reaction.
	(11, 16)	ARA-C	2 g/m2 intravenously every 12 hours	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	10	On the fifth day after administration of a high dose of [s1]ARA-C[e1]  [s2]2 g/m2 intravenously every 12 hours[e2] , she developed bullous lesions on the hands and soles that disseminated, evolving to necrosis, sepsis, and death on the 22nd day.
	(8, 13)	high	ARA-C	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	11	On the fifth day after administration of a [s1]high[e1] dose of [s2]ARA-C[e2] (2 g/m2 intravenously every 12 hours), she developed bullous lesions on the hands and soles that disseminated, evolving to necrosis, sepsis, and death on the 22nd day.
	(11, 15)	high	cytosine arabinoside	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	12	Toxic epidermal necrolysis after the use of [s1]high[e1] dose [s2]cytosine arabinoside[e2] 
	(19, 30)	high	ARA-C	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	13	We report a fatal case of toxic epidermal necrolysis (TEN) resulting from a [s1]high[e1] dose of cytosine arabinoside  [s2]ARA-C[e2] .
	(19, 24)	high	cytosine arabinoside	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	14	We report a fatal case of toxic epidermal necrolysis (TEN) resulting from a [s1]high[e1] dose of [s2]cytosine arabinoside[e2] (ARA-C).
	(14, 20)	clomipramine	150 mg/d	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	15	The day after clozapine was stopped, while he was still receiving [s1]clomipramine[e1]  [s2]150 mg/d[e2]  he began behaving oddly, started sweating profusely, shivering, and became tremulous, agitated, and confused.
	(3, 20)	clozapine	150 mg/d	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	16	The day after [s1]clozapine[e1] was stopped, while he was still receiving clomipramine [s2]150 mg/d[e2]  he began behaving oddly, started sweating profusely, shivering, and became tremulous, agitated, and confused.
	(13, 17)	15 mg	meloxicam	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	17	We describe a patient who presented with bloody diarrhoea after [s1]15 mg[e1]  [s2]meloxicam[e2] daily for 10 days for osteoarthritis.
	(22, 45)	lansoprazole	standard	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	18	Pheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole, [s1]lansoprazole[e1]  or pantoprazole for 7-15 days for peptic acid diseases in recommended [s2]standard[e2] doses.
	(17, 45)	omeprazole	standard	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	19	Pheripheral edema was observed in five female patients after taking proton pump inhibitors [s1]omeprazole[e1]  lansoprazole, or pantoprazole for 7-15 days for peptic acid diseases in recommended [s2]standard[e2] doses.
	(28, 46)	pantoprazole	standard	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	20	Pheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or [s1]pantoprazole[e1] for 7-15 days for peptic acid diseases in recommended [s2]standard[e2] doses.
	(29, 34)	12 mg	adenosine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	21	We observed ventricular fibrillation in 2 patients who presented to the emergency department with pre-excited atrial fibrillation and were given [s1]12 mg[e1] of [s2]adenosine[e2] 
	(4, 15)	methylprednisolone	40 mg	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	22	After the dose of [s1]methylprednisolone[e1] was reduced from [s2]40 mg[e2] to 20 mg i.v. q6h and shifted to other anti-asthma treatment by procaterol metered dose inhaler via spacer, the psychotic reaction disappeared a few hours later.
	(16, 20)	CBZ	OD	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	23	Continuous EEG monitoring is helpful in managing seizures that occur as a complication of [s1]CBZ[e1]  [s2]OD[e2]  after the course of recovery or worsening, and in providing assistance with prognosis.
	(1, 5)	CBZ	OD	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	24	Massive [s1]CBZ[e1]  [s2]OD[e2] may produce a reversible encephalopathy that includes cortical hyperexcitability, a profound burst-suppression EEG pattern, and cranial nerve areflexia.
	(39, 43)	taxol	80 mg/m(2)x3	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	25	We describe a case of advanced ovarian carcinoma who developed difficulty walking because of marked pain in the lower extremities and loss of proprioception 25 days after treatment with weekly [s1]taxol[e1]  [s2]80 mg/m(2)x3[e2] .
	(8, 12)	low	IFN-alpha	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	26	Myasthenia gravis during [s1]low[e1] dose [s2]IFN-alpha[e2] therapy for chronic hepatitis C.
	(21, 26)	100 mg	sodium aurothiomalate	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	27	A patient with rheumatoid arthritis developed an acute intrahepatic cholestasis after [s1]100 mg[e1] of [s2]sodium aurothiomalate[e2] 
	(2, 6)	LTG	overdose	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	28	CONCLUSIONS: [s1]LTG[e1]  [s2]overdose[e2] may result in a severe but reversible encephalopathy, a previously undescribed phenomenon.
	(14, 18)	overdose	lamotrigine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	29	METHODS: A 55-year-old woman became stuporous after [s1]overdose[e1] with [s2]lamotrigine[e2] (LTG) and valproic acid (VPA) tablets.
	(14, 23)	overdose	LTG	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	30	METHODS: A 55-year-old woman became stuporous after [s1]overdose[e1] with lamotrigine  [s2]LTG[e2]  and valproic acid (VPA) tablets.
	(14, 28)	overdose	valproic acid	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	31	METHODS: A 55-year-old woman became stuporous after [s1]overdose[e1] with lamotrigine (LTG) and [s2]valproic acid[e2] (VPA) tablets.
	(14, 32)	overdose	VPA	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	32	METHODS: A 55-year-old woman became stuporous after [s1]overdose[e1] with lamotrigine (LTG) and valproic acid  [s2]VPA[e2]  tablets.
	(29, 37)	10 g	carbamazepine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	33	A 53 year old Greenlandic male was admitted twice over a period of 4 years with a new complete right bundle branch block after ingestion of [s1]10 g[e1] and 4 g of [s2]carbamazepine[e2] respectively.
	(32, 37)	4 g	carbamazepine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	34	A 53 year old Greenlandic male was admitted twice over a period of 4 years with a new complete right bundle branch block after ingestion of 10 g and [s1]4 g[e1] of [s2]carbamazepine[e2] respectively.
	(48, 53)	2 mg	vincristine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	35	We report a 31-year-old women with recurrent Hodgkin's lymphoma and unrecognized HMSN-1 who developed severe motor neuropathy 3 weeks after the first cycle of treatment including [s1]2 mg[e1] of [s2]vincristine[e2] 
	(12, 17)	benztropine	abuse	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	36	A 33-year-old man with a history of recreational [s1]benztropine[e1]  [s2]abuse[e2] presented to the emergency department with confusion, abdominal pain, and distention.
	(35, 53)	metoclopramide	conventional	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	37	CONCLUSIONS: Clinicians should be aware of a risk of serotonin syndrome with serious extrapyramidal reactions in patients receiving sertraline or venlafaxine when [s1]metoclopramide[e1] is coadministered even in a single, [s2]conventional[e2] dose.
	(25, 53)	sertraline	conventional	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	38	CONCLUSIONS: Clinicians should be aware of a risk of serotonin syndrome with serious extrapyramidal reactions in patients receiving [s1]sertraline[e1] or venlafaxine when metoclopramide is coadministered even in a single, [s2]conventional[e2] dose.
	(29, 53)	venlafaxine	conventional	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	39	CONCLUSIONS: Clinicians should be aware of a risk of serotonin syndrome with serious extrapyramidal reactions in patients receiving sertraline or [s1]venlafaxine[e1] when metoclopramide is coadministered even in a single, [s2]conventional[e2] dose.
	(5, 11)	lansoprazole	60 mg twice daily	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	40	He was started on oral [s1]lansoprazole[e1]  [s2]60 mg twice daily[e2] and, on hospital day 2, his platelet count decreased to 102 x 10(3)/mm(3); on hospital day 3, the platelet count was 36 x 10(3)/mm(3).
	(11, 20)	mitomycin C	144 mg/m2	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	41	We describe a patient who developed HUS after treatment with [s1]mitomycin C[e1] (total dose [s2]144 mg/m2[e2]  due to a carcinoma of the ascending colon.
	(15, 31)	rosiglitazone	4 mg twice/day	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	42	A 53-year-old man developed lower leg edema 4 weeks after [s1]rosiglitazone[e1] was increased from 4 mg once/day to [s2]4 mg twice/day[e2] 
	(21, 26)	lidocaine	overdose	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	43	We present a neonate with a seizure disorder who acutely developed pupillary mydriasis secondary to [s1]lidocaine[e1]  [s2]overdose[e2] 
	(5, 9)	low	vasopressin	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	44	CONCLUSIONS: Peripheral administration of [s1]low[e1] dose [s2]vasopressin[e2] for septic shock should be discouraged because of the risk of ischemic skin complications.
	(23, 28)	500 mg	ticlopidine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	45	The first case concerns a 70-year-old man who developed severe aplastic anemia 7 weeks after treatment with [s1]500 mg[e1] of [s2]ticlopidine[e2] daily.
	(5, 30)	gemcitabine	21.9 +/- 10.9	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	46	Mean time between initiation of [s1]gemcitabine[e1] therapy and onset of HUS was 7.4 +/- 3.5 months, or [s2]21.9 +/- 10.9[e2] doses of gemcitabine.
	(5, 30)	gemcitabine	21.9 +/- 10.9	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	47	Mean time between initiation of [s1]gemcitabine[e1] therapy and onset of HUS was 7.4 +/- 3.5 months, or [s2]21.9 +/- 10.9[e2] doses of gemcitabine.
	(7, 14)	amiodarone HCl	200 mg/day	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	48	"CASE REPORT: Soon after initiation of [s1]amiodarone HCl[e1]  [s2]200 mg/day[e2] , a 76-year-old man came to us with symptoms of visual ""shining,"" glare, color vision anomalies, and gradually decreased vision."
	(6, 10)	high	methotrexate	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	49	Successful desensitization to [s1]high[e1] dose [s2]methotrexate[e2] after systemic anaphylaxis.
	(1, 8)	40 mg/day	prednisolone	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	50	While [s1]40 mg/day[e1] of [s2]prednisolone[e2] improved hepatic dysfunction dramatically, her diabetic milieu deteriorated seriously.
	(19, 32)	clonazepam	0.02 mg/kg/day	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	51	This report describes an individual with mental retardation who experienced behavioral exacerbation associated with [s1]clonazepam[e1] prescribed at 2 mg/day  [s2]0.02 mg/kg/day[e2]  to treat aggression, self-injurious behavior, property destruction, and screaming, which was measured with a 15-minute partial interval recording measurement method.
	(9, 20)	high doses	vecuronium	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	52	This entity is probably related to a combination of [s1]high doses[e1] of corticosteroids, [s2]vecuronium[e2] administration and metabolic abnormalities associated with respiratory failure.
	(20, 33)	bleomycin	100 U	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	53	We describe the development of cutaneous scleroderma in 3 patients coincident with the use of [s1]bleomycin[e1] in low cumulative doses of less than [s2]100 U[e2] 
	(24, 47)	low or moderate dosage	CBZ	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	54	We consider asterixis to be an easily overlooked sign of neurotoxicity, which may occur even at [s1]low or moderate dosage[e1] levels, if certain drugs as lithium or clozapine are used in combination with [s2]CBZ[e2] 
	(24, 39)	low or moderate dosage	clozapine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	55	We consider asterixis to be an easily overlooked sign of neurotoxicity, which may occur even at [s1]low or moderate dosage[e1] levels, if certain drugs as lithium or [s2]clozapine[e2] are used in combination with CBZ.
	(24, 37)	low or moderate dosage	lithium	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	56	We consider asterixis to be an easily overlooked sign of neurotoxicity, which may occur even at [s1]low or moderate dosage[e1] levels, if certain drugs as [s2]lithium[e2] or clozapine are used in combination with CBZ.
	(31, 38)	400 mg/day	L-dopa	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	57	A 74-year-old patient with idiopathic Parkinson's disease was evaluated for unintended sleep episodes that occurred after long-term treatment with [s1]400 mg/day[e1] of [s2]L-dopa[e2] 
	(15, 20)	900 mg	glyburide	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	58	We present a case of a 20-year-old woman who ingested [s1]900 mg[e1] of [s2]glyburide[e2] causing refractory hypoglycemia resistant to treatment with intravenous dextrose, glucagon, and diazoxide.
	(17, 24)	dexamethasone	10 mg/m(2)/day	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	59	We describe the infectious toxicities experienced by the first two patients in our institution treated with [s1]dexamethasone[e1]  [s2]10 mg/m(2)/day[e2] for 4 weeks with gradual tapering) during induction according to the dexamethasone arm of BFM 2000 and review the relevant literature that suggests an increased risk of infectious complications with dexamethasone.
	(17, 24)	dexamethasone	10 mg/m(2)/day	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	60	We describe the infectious toxicities experienced by the first two patients in our institution treated with [s1]dexamethasone[e1]  [s2]10 mg/m(2)/day[e2] for 4 weeks with gradual tapering) during induction according to the dexamethasone arm of BFM 2000 and review the relevant literature that suggests an increased risk of infectious complications with dexamethasone.
	(4, 12)	vitamin D3	20 micro g/g	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	61	After initiation of topical [s1]vitamin D3[e1] ointment  [s2]20 micro g/g[e2] of tacalcitol) 10 g/day for the skin lesions, both the serum level of calcium and urinary excretion of calcium increased gradually.
	(21, 29)	ciprofloxacin	250 mg bid	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	62	DATA SYNTHESIS: A 49-year-old man developed symptoms of severe psychosis concomitant with [s1]ciprofloxacin[e1]  [s2]250 mg bid[e2]  treatment.
	(11, 15)	high	colchicine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	63	However here we reported two patients, presenting with PD during [s1]high[e1] dose [s2]colchicine[e2] treatment for familiar mediterranean fever (FMF).
	(9, 14)	overdose	pilocarpine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	64	We report a case of unintentional [s1]overdose[e1] of oral [s2]pilocarpine[e2] tablets that resulted in bradycardia, mild hypotension, and muscarinic symptoms in a patient with Sjogren's syndrome.
	(37, 41)	BCNU	600 mg/m2	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	65	We report here a 26-year-old female with diffuse large B-cell lymphoma who died of severe pulmonary fibrosis 81 days after the administration of high-dose [s1]BCNU[e1]  [s2]600 mg/m2[e2] .
	(34, 39)	high-dose	BCNU	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	66	We report here a 26-year-old female with diffuse large B-cell lymphoma who died of severe pulmonary fibrosis 81 days after the administration of [s1]high-dose[e1]  [s2]BCNU[e2] (600 mg/m2).
	(8, 14)	nimodipine	overdosage	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	67	In this paper we report a case of [s1]nimodipine[e1]  [s2]overdosage[e2] resulting in prolonged hypotension and hypoxemia, which was successfully treated with calcium gluconate.
	(0, 5)	Tiagabine	overdose	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	68	 [s1]Tiagabine[e1]  [s2]overdose[e2] causes an unusual array of neurological symptoms, many similar to reported adverse effects during therapeutic use.
	(7, 29)	CAP	2000 mg/m2	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	69	Neurologic symptoms resolved after stopping [s1]CAP[e1] for 4 weeks in Patient A, with no recurrence after reinitiating CAP alone at [s2]2000 mg/m2[e2] 
	(7, 29)	CAP	2000 mg/m2	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	70	Neurologic symptoms resolved after stopping [s1]CAP[e1] for 4 weeks in Patient A, with no recurrence after reinitiating CAP alone at [s2]2000 mg/m2[e2] 
	(14, 20)	CAP-XRT	1600 mg/m2	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	71	Patient A reported right leg weakness (foot drop) during week 4 of [s1]CAP-XRT[e1]  [s2]1600 mg/m2[e2] .
	(19, 23)	CAP	2500 mg/m2	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	72	Patient B developed perioral and upper extremity paresthesias during the fourth cycle of [s1]CAP[e1] alone  [s2]2500 mg/m2[e2] .
	(8, 37)	quetiapine	overdose	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	73	In all cases, drugs in addition to [s1]quetiapine[e1] were detected, but in cases #1 and #2, the cause of death was considered to be a quetiapine [s2]overdose[e2] and the other drugs were not considered to be contributory.
	(18, 25)	overdose	quetiapine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	74	We present three cases from the Provincial Toxicology Center of British Columbia, Canada in which suicidal [s1]overdose[e1] deaths were associated with [s2]quetiapine[e2] 
	(11, 17)	flupirtine	overdose	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	75	Paradoxical cerebral cortical hyperexcitability following [s1]flupirtine[e1]  [s2]overdose[e2] 
	(21, 28)	400 mg/day	carbamazepine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	76	The patient was found to have no motile sperm with a normal sperm count, while taking a dose of [s1]400 mg/day[e1] of [s2]carbamazepine[e2] 
	(18, 23)	higher doses	quetiapine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	77	A 64-year-old man with schizophrenia developed myoclonic jerks when given [s1]higher doses[e1] of [s2]quetiapine[e2] 
	(15, 22)	cerivastatin	0.15 mg/day	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	78	A 74-year-old hypercholestrerolaemic woman taking [s1]cerivastatin[e1]  [s2]0.15 mg/day[e2]  for 22 days complained of general muscle weakness and muscle pain.
	(0, 12)	Carboplatin	low-dose	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	79	 [s1]Carboplatin[e1] hypersensitivity induced by [s2]low-dose[e2] paclitaxel/carboplatin in multiple platinum-treated patients with recurrent ovarian cancer.
	(10, 19)	low-dose	carboplatin	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	80	Carboplatin hypersensitivity induced by [s1]low-dose[e1] paclitaxel [s2]carboplatin[e2] in multiple platinum-treated patients with recurrent ovarian cancer.
	(10, 15)	low-dose	paclitaxel	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	81	Carboplatin hypersensitivity induced by [s1]low-dose[e1]  [s2]paclitaxel[e2] carboplatin in multiple platinum-treated patients with recurrent ovarian cancer.
	(4, 62)	CBDCA	low-dose	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	82	Our report suggested that [s1]CBDCA[e1] hypersensitivity was correlated with the total dose of previously administered platinum agents and that CBDCA should be excluded in patients who have received multiple platinum-based chemotherapy, even in platinum-sensitive cases, because CBDCA hypersensitivity can occur even with [s2]low-dose[e2] CBDCA administration.
	(4, 62)	CBDCA	low-dose	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	83	Our report suggested that [s1]CBDCA[e1] hypersensitivity was correlated with the total dose of previously administered platinum agents and that CBDCA should be excluded in patients who have received multiple platinum-based chemotherapy, even in platinum-sensitive cases, because CBDCA hypersensitivity can occur even with [s2]low-dose[e2] CBDCA administration.
	(4, 62)	CBDCA	low-dose	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	84	Our report suggested that [s1]CBDCA[e1] hypersensitivity was correlated with the total dose of previously administered platinum agents and that CBDCA should be excluded in patients who have received multiple platinum-based chemotherapy, even in platinum-sensitive cases, because CBDCA hypersensitivity can occur even with [s2]low-dose[e2] CBDCA administration.
	(5, 29)	carboplatin	60 mg/m2	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	85	We report five cases of [s1]carboplatin[e1] (CBDCA) hypersensitivity after weekly low-dose paclitaxel  [s2]60 mg/m2[e2] /CBDCA (area under the concentration curve = 2) therapy in patients with recurrent ovarian cancer receiving multiple platinum-based chemotherapy.
	(9, 27)	CBDCA	60 mg/m2	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	86	We report five cases of carboplatin  [s1]CBDCA[e1]  hypersensitivity after weekly low-dose paclitaxel  [s2]60 mg/m2[e2] /CBDCA (area under the concentration curve = 2) therapy in patients with recurrent ovarian cancer receiving multiple platinum-based chemotherapy.
	(23, 29)	paclitaxel	60 mg/m2	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	87	We report five cases of carboplatin (CBDCA) hypersensitivity after weekly low-dose [s1]paclitaxel[e1]  [s2]60 mg/m2[e2] /CBDCA (area under the concentration curve = 2) therapy in patients with recurrent ovarian cancer receiving multiple platinum-based chemotherapy.
	(5, 22)	carboplatin	low-dose	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	88	We report five cases of [s1]carboplatin[e1] (CBDCA) hypersensitivity after weekly [s2]low-dose[e2] paclitaxel (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy in patients with recurrent ovarian cancer receiving multiple platinum-based chemotherapy.
	(9, 20)	CBDCA	low-dose	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	89	We report five cases of carboplatin  [s1]CBDCA[e1]  hypersensitivity after weekly [s2]low-dose[e2] paclitaxel (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy in patients with recurrent ovarian cancer receiving multiple platinum-based chemotherapy.
	(20, 25)	low-dose	paclitaxel	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	90	We report five cases of carboplatin (CBDCA) hypersensitivity after weekly [s1]low-dose[e1]  [s2]paclitaxel[e2] (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy in patients with recurrent ovarian cancer receiving multiple platinum-based chemotherapy.
	(6, 9)	massive	fluoxetine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	91	We report an unusual case of [s1]massive[e1]  [s2]fluoxetine[e2] ingestion resulting in neurological and cardiovascular toxicity resulting in death.
	(16, 22)	iron sucrose	16 mg/kg	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	92	The case reported here is of a child given a large dose of intravenous [s1]iron sucrose[e1]  [s2]16 mg/kg[e2]  over 3 hours, who subsequently developed features of systemic iron toxicity.
	(6, 11)	high-dose	busulfan	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	93	Fatal radiation myelopathy after [s1]high-dose[e1]  [s2]busulfan[e2] and melphalan chemotherapy and radiotherapy for Ewing's sarcoma: a review of the literature and implications for practice.
	(6, 15)	high-dose	melphalan	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	94	Fatal radiation myelopathy after [s1]high-dose[e1] busulfan and [s2]melphalan[e2] chemotherapy and radiotherapy for Ewing's sarcoma: a review of the literature and implications for practice.
	(6, 12)	epinephrine	overdose	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	95	Inadvertent and accidental [s1]epinephrine[e1]  [s2]overdose[e2] might result in potentially lethal complications.
	(6, 14)	high-dose	phenylephrine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	96	Prominent positive U waves appearing with [s1]high-dose[e1] intravenous [s2]phenylephrine[e2] 
	(24, 31)	venlafaxine	75 mg/day	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	97	A 56-year-old white woman with a diagnosis of reactive depression developed severe UI after a 30 days' treatment with [s1]venlafaxine[e1]  [s2]75 mg/day[e2] 
	(30, 37)	methotrexate	5 g/m2	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	98	A 17-year-old boy with acute lymphoblastic leukemia developed acute renal failure within 48 h of an intravenous high-dose [s1]methotrexate[e1]  [s2]5 g/m2[e2]  infusion.
	(27, 32)	high-dose	methotrexate	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	99	A 17-year-old boy with acute lymphoblastic leukemia developed acute renal failure within 48 h of an intravenous [s1]high-dose[e1]  [s2]methotrexate[e2] (5 g/m2) infusion.
	(0, 5)	High-dose	methotrexate	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	100	 [s1]High-dose[e1]  [s2]methotrexate[e2] associated acute renal failure may be an avoidable complication.
	(28, 33)	500 mg	cloxacillin	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	101	A 55-year-old woman presented an episode of acute urticaria and labial angioedema 60 minutes after ingesting [s1]500 mg[e1] of [s2]cloxacillin[e2] for a skin abscess.
	(8, 13)	high-dose	carmustine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	102	Myocardial ischemia associated with [s1]high-dose[e1]  [s2]carmustine[e2] infusion.
	(8, 13)	high-dose	methylprednisolone	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	103	Acute myocardial infarction during [s1]high-dose[e1]  [s2]methylprednisolone[e2] therapy for Graves' ophthalmopathy.
	(15, 20)	high-dose	glucocorticoids	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	104	We conclude that myocardial infarction may develop in patients treated with [s1]high-dose[e1]  [s2]glucocorticoids[e2] for Graves' ophthalmopathy, and increased blood pressure may herald this complication.
	(17, 22)	35 g	caffeine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	105	We present the case of a 58-year-old woman who ingested more than [s1]35 g[e1] of [s2]caffeine[e2] in a suicide attempt.
	(0, 6)	Flecainide	overdose	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	106	 [s1]Flecainide[e1]  [s2]overdose[e2] can rapidly result in profound cardiovascular collapse, and is associated with a relatively high mortality.
	(5, 11)	flecainide	overdose	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	107	Managing cardiovascular collapse in severe [s1]flecainide[e1]  [s2]overdose[e2] without recourse to extracorporeal therapy.
	(20, 24)	114 g	metronidazole	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	108	Two patients are described who developed sensory neuropathy after the ingestion of 30.6 and [s1]114 g[e1]  [s2]metronidazole[e2] respectively.
	(16, 24)	30.6	metronidazole	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	109	Two patients are described who developed sensory neuropathy after the ingestion of [s1]30.6[e1] and 114 g [s2]metronidazole[e2] respectively.
	(19, 26)	methotrexate	15 mg/week	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	110	We report a case of a patient with rheumatoid arthritis treated with low-dose [s1]methotrexate[e1]  [s2]15 mg/week[e2]  who developed infection with both M. tuberculosis and M. chelonae after the revision of a prosthetic hip.
	(16, 21)	low-dose	methotrexate	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	111	We report a case of a patient with rheumatoid arthritis treated with [s1]low-dose[e1]  [s2]methotrexate[e2] (15 mg/week) who developed infection with both M. tuberculosis and M. chelonae after the revision of a prosthetic hip.
	(18, 23)	low-dose	acetylsalicylic acid	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	112	The authors describe pericardial hemorrhage, which is related to the use of [s1]low-dose[e1]  [s2]acetylsalicylic acid[e2] in a patient with essential thrombocythemia.
	(6, 11)	low-dose	carbamazepine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	113	Hyponatraemia during [s1]low-dose[e1]  [s2]carbamazepine[e2] therapy.
	(30, 38)	muzolimine	240 to 1440 mg per day	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	114	We report on 7 patients (2 women, 5 men) with chronic renal failure, who developed under a high dosage of the new diuretic [s1]muzolimine[e1] (range [s2]240 to 1440 mg per day[e2]  fatal neuromyeloencephalopathy.
	(21, 32)	high dosage	muzolimine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	115	We report on 7 patients (2 women, 5 men) with chronic renal failure, who developed under a [s1]high dosage[e1] of the new diuretic [s2]muzolimine[e2] (range 240 to 1440 mg per day) fatal neuromyeloencephalopathy.
	(13, 19)	20-mg daily	olanzapine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	116	The fourth patient showed RLS symptoms that were initially caused by a [s1]20-mg daily[e1]  [s2]olanzapine[e2] dosage and were later mitigated when olanzapine was reduced and ropinirole was administered.
	(4, 9)	Copaxone	20 mg/day	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	117	She had been on [s1]Copaxone[e1]  [s2]20 mg/day[e2] treatment for 2 years when she first exhibited gastrointestinal symptoms.
	(3, 9)	bupropion	overdose	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	118	Multiple seizures after [s1]bupropion[e1]  [s2]overdose[e2] in a small child.
	(24, 34)	48 mg/kg	bupropion	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	119	The patient experienced hallucinations, agitation, vomiting, tachycardia and seizures after ingestion of 1050  [s1]48 mg/kg[e1]  of extended-release [s2]bupropion[e2] 
	(26, 32)	propafenone	900 mg/d	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	120	CASE SUMMARY: An 80-year-old white female, followed up at the Memory Clinic for mild cognitive impairment, had been taking [s1]propafenone[e1]  [s2]900 mg/d[e2] for >10 years for paroxysmal atrial fibrillation without adverse effects.
	(17, 22)	low-dose	aspirin	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	121	Hemorrhage from a falx meningioma after internal use of [s1]low-dose[e1]  [s2]aspirin[e2] 
	(33, 38)	low-dose	aspirin	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	122	We report a case in which hemorrhage occurred in an asymptomatic falx meningioma known beforehand, after the internal use of [s1]low-dose[e1]  [s2]aspirin[e2] for 16 months.
	(34, 39)	high-dose	methylprednisolone	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	123	CONCLUSIONS: Life-threatening adrenal suppression, requiring hydrocortisone supplementation and intensive therapy, was observed and successfully treated in a newborn, whose mother had received [s1]high-dose[e1]  [s2]methylprednisolone[e2] in late pregnancy.
	(0, 5)	High-dose	methylprednisolone	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	124	 [s1]High-dose[e1]  [s2]methylprednisolone[e2] in a pregnant woman with Crohn's disease and adrenal suppression in her newborn.
	(61, 72)	methotrexate	12 g/m2	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	125	A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose [s1]methotrexate[e1] (MTX)  [s2]12 g/m2[e2] , and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later.
	(66, 70)	MTX	12 g/m2	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	126	A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of high-dose methotrexate  [s1]MTX[e1]   [s2]12 g/m2[e2] , and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later.
	(58, 63)	high-dose	methotrexate	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	127	A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of [s1]high-dose[e1]  [s2]methotrexate[e2] (MTX) (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later.
	(58, 68)	high-dose	MTX	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	128	A 10-year-old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4-hour infusion of [s1]high-dose[e1] methotrexate  [s2]MTX[e2]  (12 g/m2), and went on to develop acute renal failure with life-threatening hyperkalemia 29 hours later.
	(6, 11)	high-dose	methotrexate	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	129	Early recognition of renal toxicity of [s1]high-dose[e1]  [s2]methotrexate[e2] therapy: a case report.
	(8, 30)	dexmedetomidine	5.0 microg/kg	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	130	We report on three cases wherein treatment of [s1]dexmedetomidine[e1] induced bradycardia with i.v. glycopyrrolate  [s2]5.0 microg/kg[e2]  not only resulting in resolution of bradycardia but also resulting in an exaggerated increase of arterial blood pressure.
	(23, 31)	glycopyrrolate	5.0 microg/kg	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	131	We report on three cases wherein treatment of dexmedetomidine-induced bradycardia with i.v. [s1]glycopyrrolate[e1]  [s2]5.0 microg/kg[e2]  not only resulting in resolution of bradycardia but also resulting in an exaggerated increase of arterial blood pressure.
	(10, 17)	bevacizumab	1.25 mg in 0.1 ml	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	132	Three days after receiving intravitreal injection of [s1]bevacizumab[e1]  [s2]1.25 mg in 0.1 ml[e2] , he developed acute vision loss and change of consciousness.
	(8, 14)	adalimumab	160 mg	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	133	One week after the initial-dose of [s1]adalimumab[e1]  [s2]160 mg[e2] , which was initiated due to an acute exacerbation of Crohn's disease, the patient developed a fulminant cardiomyopathy.
	(7, 12)	high-dose	methylprednisolone	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	134	Hepatotoxicity after [s1]high-dose[e1]  [s2]methylprednisolone[e2] for demyelinating disease.
	(13, 18)	high-dose	methylprednisolone	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	135	We observed 2 cases of hepatotoxicity after a [s1]high-dose[e1]  [s2]methylprednisolone[e2] treatment of a demyelinating disease and evaluated the potential relationship in the light of available evidence.
	(21, 26)	imatinib	400 mg/d	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	136	CONCLUSIONS: We present a case of a patient with CML who developed KS 12 months after starting treatment with [s1]imatinib[e1]  [s2]400 mg/d[e2] 
	(15, 20)	high-dose	cytosine arabinoside	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	137	Bulbar and pseudobulbar palsy complicating therapy with [s1]high-dose[e1]  [s2]cytosine arabinoside[e2] in children with leukemia.
	(9, 17)	lacosamide	600 mg/day	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	138	Common adverse events (frequency 10%) of [s1]lacosamide[e1] doses up to [s2]600 mg/day[e2] include nonspecific central nervous system effects (e.g., dizziness, ataxia, diplopia, and somnolence).
	(56, 64)	methotrexate	12 mg	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	139	An episode of leukoencephalopathy is reported in a 13-year-old girl who, after standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4-hour infusion of 500 mg/m2 [s1]methotrexate[e1] and [s2]12 mg[e2] intrathecal methotrexate.
	(52, 58)	500 mg/m2	methotrexate	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	140	An episode of leukoencephalopathy is reported in a 13-year-old girl who, after standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4-hour infusion of [s1]500 mg/m2[e1]  [s2]methotrexate[e2] and 12 mg intrathecal methotrexate.
	(8, 14)	glipizide	10 mg	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	141	An 83-year-old man receiving [s1]glipizide[e1]  [s2]10 mg[e2] bid developed symptomatic hypoglycemia within three days of adding trimethoprim/sulfamethoxazole (TMP/SMX) to his regimen.
	(12, 48)	10 mg	SMX	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	142	An 83-year-old man receiving glipizide [s1]10 mg[e1] bid developed symptomatic hypoglycemia within three days of adding trimethoprim/sulfamethoxazole (TMP [s2]SMX[e2]  to his regimen.
	(12, 37)	10 mg	sulfamethoxazole	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	143	An 83-year-old man receiving glipizide [s1]10 mg[e1] bid developed symptomatic hypoglycemia within three days of adding trimethoprim [s2]sulfamethoxazole[e2] (TMP/SMX) to his regimen.
	(12, 45)	10 mg	TMP	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	144	An 83-year-old man receiving glipizide [s1]10 mg[e1] bid developed symptomatic hypoglycemia within three days of adding trimethoprim/sulfamethoxazole  [s2]TMP[e2] SMX) to his regimen.
	(12, 33)	10 mg	trimethoprim	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	145	An 83-year-old man receiving glipizide [s1]10 mg[e1] bid developed symptomatic hypoglycemia within three days of adding [s2]trimethoprim[e2] sulfamethoxazole (TMP/SMX) to his regimen.
	(35, 43)	5 g/m2	ifosfamide	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	146	A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after [s1]5 g/m2[e1] bolus [s2]ifosfamide[e2] 
	(7, 11)	high dose	ifosfamide	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	147	Lethal anuria complicating [s1]high dose[e1]  [s2]ifosfamide[e2] chemotherapy in a breast cancer patient with an impaired renal function.
	(16, 21)	high-dose	cytosine arabinoside	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	148	Horner's syndrome and demyelinating peripheral neuropathy caused by [s1]high-dose[e1]  [s2]cytosine arabinoside[e2] 
	(10, 15)	high-dose	cytosine arabinoside	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	149	Peripheral nerve dysfunction is a potentially serious complication of [s1]high-dose[e1]  [s2]cytosine arabinoside[e2] 
	(30, 35)	high-dose	cytosine arabinoside	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	150	We describe a patient with acute leukemia who developed Horner's syndrome and a severe demyelinating peripheral neuropathy leading to death after receiving [s1]high-dose[e1]  [s2]cytosine arabinoside[e2] 
	(11, 15)	low dose	cyclophosphamide	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	151	Life-threatening acute hyponatraemia induced by [s1]low dose[e1]  [s2]cyclophosphamide[e2] and indomethacin.
	(11, 22)	low dose	indomethacin	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	152	Life-threatening acute hyponatraemia induced by [s1]low dose[e1] cyclophosphamide and [s2]indomethacin[e2] 
	(31, 38)	low dose	cyclophosphamide	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	153	We report the case of a patient with multiple myeloma who developed acute life-threatening water intoxication following treatment with oral indomethacin and [s1]low dose[e1] intravenous [s2]cyclophosphamide[e2] 
	(26, 33)	indomethacin	low dose	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	154	We report the case of a patient with multiple myeloma who developed acute life-threatening water intoxication following treatment with oral [s1]indomethacin[e1] and [s2]low dose[e2] intravenous cyclophosphamide.
	(23, 28)	high doses	clofazimine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	155	Two cases of lepromatous leprosy with erythema nodosum leprosum who were on [s1]high doses[e1] of [s2]clofazimine[e2]  showed discoloration of nail plate, subungual hyperkeratosis and onycholysis.
	(16, 40)	Ara-C	100 mg/m2/d	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	156	Paraplegia following prophylactic intrathecal cytosine arabinoside  [s1]Ara-C[e1]  is described in a patient with acute myelogenous leukemia in remission who received doses of [s2]100 mg/m2/d[e2] for 5 consecutive days.
	(10, 42)	cytosine arabinoside	100 mg/m2/d	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	157	Paraplegia following prophylactic intrathecal [s1]cytosine arabinoside[e1] (Ara-C) is described in a patient with acute myelogenous leukemia in remission who received doses of [s2]100 mg/m2/d[e2] for 5 consecutive days.
	(6, 12)	isotretinoin	1 mg/kg/day	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	158	Three of 50 patients treated with [s1]isotretinoin[e1]  [s2]1 mg/kg/day[e2]  for cystic acne complained of poor night vision and/or excessive glare sensitivity.
	(9, 33)	chloral hydrate	overdosage	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	159	The pharmacology and toxicology of [s1]chloral hydrate[e1] are discussed with particular reference to the cardiac arrhythmias that are seen with [s2]overdosage[e2] 
	(8, 13)	single dose	vincristine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	160	A case of severe visual loss following a [s1]single dose[e1] of [s2]vincristine[e2] is described.
	(5, 10)	single dose	vincristine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	161	Severe visual loss after a [s1]single dose[e1] of [s2]vincristine[e2] in a patient with spinal cord astrocytoma.
	(4, 10)	single small dose	vincristine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	162	Visual loss after a [s1]single small dose[e1] of [s2]vincristine[e2] has never been reported.
	(19, 23)	1 g	doxycycline	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	163	Renal hypophosphatemia in this patient was caused by the erroneous intake of [s1]1 g[e1]  [s2]doxycycline[e2] 
	(7, 12)	low-dose	cyclosporine A	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	164	After a six-week course of [s1]low-dose[e1]  [s2]cyclosporine A[e2]  she developed a severe but reversible loss of glomerular filtration rate and effective renal plasma flow despite of low cyclosporine A plasma levels.
	(40, 48)	propylthiouracil	100 mg orally, three times a day	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	165	A patient is presented with typical hyperthyroidism, who developed a severe proximal muscle weakness and a raised creatine phosphokinase after treatment for hyperthyroidism with [s1]propylthiouracil[e1]  [s2]100 mg orally, three times a day[e2] .
	(39, 53)	D-penicillamine	1,200 g	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	166	A 56-year-old woman with scleroderma developed rapidly progressive glomerulonephritis with epithelial crescents associated with hemoptysis after 27 months of [s1]D-penicillamine[e1] therapy and a cumulative dose of [s2]1,200 g[e2] 
	(17, 22)	amiodarone	1400 mg	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	167	We report a case of torsade de pointes following a single oral dose of [s1]amiodarone[e1]  [s2]1400 mg[e2] or 30 mg kg-1) administered after short intravenous loading for prevention of paroxysmal atrial flutter.
	(17, 26)	amiodarone	30 mg kg-1	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	168	We report a case of torsade de pointes following a single oral dose of [s1]amiodarone[e1] (1400 mg or [s2]30 mg kg-1[e2]  administered after short intravenous loading for prevention of paroxysmal atrial flutter.
	(5, 13)	prazosin	0.5 to 1 mg	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	169	A small initial dose of [s1]prazosin[e1] ranging from [s2]0.5 to 1 mg[e2] has been recommended to avoid the first-dose phenomenon characterized by a sudden and severe drop in blood pressure after the administration of the first dose of prazosin.
	(5, 13)	prazosin	0.5 to 1 mg	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	170	A small initial dose of [s1]prazosin[e1] ranging from [s2]0.5 to 1 mg[e2] has been recommended to avoid the first-dose phenomenon characterized by a sudden and severe drop in blood pressure after the administration of the first dose of prazosin.
	(11, 17)	phenytoin	1 g	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	171	Phenytoin was discontinued after admission; however, [s1]phenytoin[e1]  [s2]1 g[e2] i.v. was given for a tonic-clonic seizure two days after admission, after which swelling of the face and legs and pruritus developed.
	(13, 20)	carbamazepine	200 mg	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	172	She was receiving phenytoin sodium 300 mg/day; [s1]carbamazepine[e1]  [s2]200 mg[e2] four times daily had been discontinued four days before admission because of leukopenia.
	(3, 10)	phenytoin sodium	300 mg/day	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	173	She was receiving [s1]phenytoin sodium[e1]  [s2]300 mg/day[e2]  carbamazepine 200 mg four times daily had been discontinued four days before admission because of leukopenia.
	(5, 10)	amiodarone	2300 mg in 3 days	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	174	After therapy with parenteral [s1]amiodarone[e1]  [s2]2300 mg in 3 days[e2]  and other measures, signs of congestive heart failure disappeared; subsequently the patient developed jaundice, marked increase in serum transaminase levels and fall in prothrombin time, and histologic changes of severe centrilobular necrosis were observed in hepatic biopsy.
	(67, 71)	20 mg	methimazole	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	175	The main clinical features of this 58-year-old female patient were laboratory evidence of leucopenia and cholestasis, and biopsy features of fatty liver parenchyma degeneration with granulocytic portal infiltration and bile stasis, demonstrated 20 days after the initiation of antithyroid therapy with [s1]20 mg[e1]  [s2]methimazole[e2] daily.
	(3, 9)	propranolol	overdose	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	176	A case of [s1]propranolol[e1]  [s2]overdose[e2] complicated by esophageal spasm preventing extrication of an orogastric lavage tube and relieved by intravenous glucagon is presented.
	(8, 14)	propranolol	overdose	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	177	Esophageal spasm following [s1]propranolol[e1]  [s2]overdose[e2] relieved by glucagon.
	(13, 18)	low-dose	heparin	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	178	Our findings suggest that hyperkalemia can develop with the use of [s1]low-dose[e1]  [s2]heparin[e2]  within seven days of initiating heparin therapy, and that patients with diabetes mellitus or chronic renal insufficiency are especially predisposed to this complication.
	(13, 18)	low-dose	heparin	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	179	Our findings suggest that hyperkalemia can develop with the use of [s1]low-dose[e1]  [s2]heparin[e2]  within seven days of initiating heparin therapy, and that patients with diabetes mellitus or chronic renal insufficiency are especially predisposed to this complication.
	(18, 27)	lithium	high doses	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	180	A 65-year-old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance [s1]lithium[e1] therapy developed a movement disorder following [s2]high doses[e2] of trazodone for treatment of an acute depression.
	(25, 30)	high doses	trazodone	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	181	A 65-year-old woman with bipolar disorder and complicated cardiovascular disease who was on maintenance lithium therapy developed a movement disorder following [s1]high doses[e1] of [s2]trazodone[e2] for treatment of an acute depression.
	(26, 31)	15 g	desferrioxamine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	182	Two other patients who did not receive prochlorperazine, developed retinal problems which later improved, one after only [s1]15 g[e1] of [s2]desferrioxamine[e2] 
	(20, 25)	Intralipid	20%	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	183	Four cases of fat embolism are described in infants receiving prolonged intravenous infusion of fat  [s1]Intralipid[e1]  [s2]20%[e2] .
	(7, 15)	175 mg	methotrexate	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	184	Three patients received respectively 190 mg, [s1]175 mg[e1]  and 196 mg of [s2]methotrexate[e2] and developed bilateral pulmonary infiltrates without evidence of peripheral blood eosinophilia.
	(4, 15)	190 mg	methotrexate	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	185	Three patients received respectively [s1]190 mg[e1]  175 mg, and 196 mg of [s2]methotrexate[e2] and developed bilateral pulmonary infiltrates without evidence of peripheral blood eosinophilia.
	(11, 16)	196 mg	methotrexate	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	186	Three patients received respectively 190 mg, 175 mg, and [s1]196 mg[e1] of [s2]methotrexate[e2] and developed bilateral pulmonary infiltrates without evidence of peripheral blood eosinophilia.
	(15, 20)	high-dose	aspirin	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	187	Two children with rheumatic fever developed anicteric hepatitis while on [s1]high-dose[e1]  [s2]aspirin[e2] therapy.
	(30, 35)	300 mg	cytarabine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	188	In three of these patients the infection was clinically unsuspected; in the fourth, cutaneous herpes zoster developed after administration of [s1]300 mg[e1] of [s2]cytarabine[e2] daily for the preceding five days.
	(3, 8)	high-dose	tamoxifen	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	189	Four patients receiving [s1]high-dose[e1]  [s2]tamoxifen[e2] for greater than 1 year have demonstrated similar retinal changes.
	(30, 39)	200 mg	lorcainide	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	190	In eight patients, a mean decrease in serum Na+ of 8.25 +/- 3.2 mEq/L was observed after a single [s1]200 mg[e1] intravenous dose of [s2]lorcainide[e2] 
	(10, 16)	low-dosage	amiodarone	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	191	In a 61-year-old man receiving chronic [s1]low-dosage[e1]  [s2]amiodarone[e2] an interstitial pneumopathy was observed.
	(9, 15)	low-dosage	amiodarone	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	192	Interstitial pneumopathy and [s1]low-dosage[e1]  [s2]amiodarone[e2] 
	(32, 36)	80 mg	propranolol	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	193	Alternating sinus rhythm and intermittent sinoatrial (S-A) block was observed in a 57-year-old woman, under treatment for angina with [s1]80 mg[e1]  [s2]propranolol[e2] daily.
	(6, 11)	high doses	CCNU	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	194	Pulmonary fibrosis subsequent to [s1]high doses[e1] of [s2]CCNU[e2] for chronic myeloid leukemia.
	(13, 17)	CCNU	1100 mg/m2	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	195	Two patients treated for chronic myeloid leukemia with high doses of [s1]CCNU[e1]  [s2]1100 mg/m2[e2] and 1240 mg/m2, respectively) developed a fatal pulmonary fibrosis.
	(13, 23)	CCNU	1240 mg/m2	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	196	Two patients treated for chronic myeloid leukemia with high doses of [s1]CCNU[e1] (1100 mg/m2 and [s2]1240 mg/m2[e2]  respectively) developed a fatal pulmonary fibrosis.
	(10, 15)	high doses	CCNU	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	197	Two patients treated for chronic myeloid leukemia with [s1]high doses[e1] of [s2]CCNU[e2] (1100 mg/m2 and 1240 mg/m2, respectively) developed a fatal pulmonary fibrosis.
	(19, 24)	fluoresone	750 mg	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	198	Gynecomastia developed in two epileptic patients some months after the addition of oral [s1]fluoresone[e1]  [s2]750 mg[e2] daily to the phenobarbital and phenytoin already being administered.
	(22, 29)	750 mg	phenobarbital	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	199	Gynecomastia developed in two epileptic patients some months after the addition of oral fluoresone [s1]750 mg[e1] daily to the [s2]phenobarbital[e2] and phenytoin already being administered.
	(22, 35)	750 mg	phenytoin	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	200	Gynecomastia developed in two epileptic patients some months after the addition of oral fluoresone [s1]750 mg[e1] daily to the phenobarbital and [s2]phenytoin[e2] already being administered.
	(10, 24)	quinacrine hydrochloride	100 mg	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	201	Drug-induced psychosis resulted from the administration of [s1]quinacrine hydrochloride[e1] at a dosage of [s2]100 mg[e2] twice daily for the treatment of discoid lupus.
	(13, 20)	0.05 mg	ergonovine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	202	In four patients, spasm occurred spontaneous and in one patient after [s1]0.05 mg[e1] of [s2]ergonovine[e2] 
	(13, 20)	disopyramide	300 to 600 mg/day	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	203	Two years later, 24 hours following an increase in the dose of [s1]disopyramide[e1] from [s2]300 to 600 mg/day[e2]  AVT with syncope occurred; isoproterenol abolished the arrhythmia instantly.
	(4, 9)	digoxin	0.25 mg	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	204	He was started on [s1]digoxin[e1]  [s2]0.25 mg[e2] daily, because of echocardiographically demonstrated left ventricular dilatation and functional impairment; he died of ventricular fibrillation 15 days later.
	(9, 13)	high dose	vinblastine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	205	Inappropriate antidiuretic hormone secretion after [s1]high dose[e1]  [s2]vinblastine[e2] 
	(35, 40)	high dose	vinblastine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	206	We report on a patient with an embryonal teratocarcinoma of the testicle who had the syndrome of inappropriate secretion of antidiuretic hormone after receiving a [s1]high dose[e1] of [s2]vinblastine[e2] 
	(10, 16)	high-dose	chlorambucil	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	207	Fatal interstitial pneumonitis following [s1]high-dose[e1] intermittent [s2]chlorambucil[e2] therapy for chronic lymphocyte leukemia.
	(44, 50)	procainamide	750 mg/day	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	208	A 71-year-old man with paroxysmal atrial fibrillation who had a previous anterior myocardial infarction exhibited granulocytopenia 8 days following the administration of oral sustained-release [s1]procainamide[e1]  [s2]750 mg/day[e2] .
	(44, 50)	40 mg/m2	methotrexate	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	209	A 64 year old man with recurrent metastatic squamous cell carcinoma of the head and neck developed severe skin rash and bone marrow aplasia 4 and 7 days, respectively, following a single dose of [s1]40 mg/m2[e1]  [s2]methotrexate[e2] (MTX).
	(44, 55)	40 mg/m2	MTX	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	210	A 64 year old man with recurrent metastatic squamous cell carcinoma of the head and neck developed severe skin rash and bone marrow aplasia 4 and 7 days, respectively, following a single dose of [s1]40 mg/m2[e1] methotrexate  [s2]MTX[e2] .
	(12, 17)	low dose	methotrexate	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	211	Bone marrow aplasia and severe skin rash after a single [s1]low dose[e1] of [s2]methotrexate[e2] 
	(34, 42)	30 mg	ketoralac	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	212	We report the case of a 20-year-old female with polyarteritis nodosa (PAN) who developed bilateral sensorineural hearing loss 25 minutes after receiving [s1]30 mg[e1] of intravenous [s2]ketoralac[e2] 
	(15, 22)	acyclovir	30 mg/kg per day	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	213	A 9-year-old boy developed acute renal failure following intravenous [s1]acyclovir[e1]  [s2]30 mg/kg per day[e2]  administered for 6 days to treat herpetic encephalitis.
	(12, 20)	mefloquine	1,500 mg over two days	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	214	We report a case of hypoglycaemia after [s1]mefloquine[e1] therapy  [s2]1,500 mg over two days[e2]  for severe gastrointestinal cryptosporidiasis in a cachectic AIDS patient with protracted diarrhoea.
	(3, 18)	doxorubicin	'low' doses	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	215	Aggressive management of [s1]doxorubicin[e1] induced cardiomyopathy associated with [s2]'low' doses[e2] of doxorubicin.
	(3, 18)	doxorubicin	'low' doses	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	216	Aggressive management of [s1]doxorubicin[e1] induced cardiomyopathy associated with [s2]'low' doses[e2] of doxorubicin.
	(0, 8)	High-dose	mannitol	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	217	 [s1]High-dose[e1] intravenous [s2]mannitol[e2] infusion in various clinical settings may result in acute renal failure (ARF).
	(14, 19)	high-dose	mannitol	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	218	This is a report of a case of anuric ARF after [s1]high-dose[e1]  [s2]mannitol[e2] infusion for treatment of narrow-angle glaucoma that readily responded to acute hemodialysis.
	(16, 21)	high-dose	methotrexate	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	219	Temporary neurologic abnormalities were observed in one out of 23 patients undergoing chemotherapy with [s1]high-dose[e1]  [s2]methotrexate[e2] (HD-MTX) for osteogenic sarcoma.
	(26, 32)	HD-MTX	8 gm/m2 by 6 h continuous infusion	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	220	This patient developed sequential symptoms including alternative hemiparesis, dysarthria and altered consciousness 5 days after the second course of [s1]HD-MTX[e1]  [s2]8 gm/m2 by 6 h continuous infusion[e2]  with leucovorin rescue.
	(8, 13)	high-dose	methotrexate	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	221	Transient neurological disturbances induced by the chemotherapy of [s1]high-dose[e1]  [s2]methotrexate[e2] for osteogenic sarcoma.
	(23, 35)	metronidazole	21 g over 14 days	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	222	We describe a patient with a liver abscess due to Entamoeba histolytica, in whom [s1]metronidazole[e1] therapy (total dose, [s2]21 g over 14 days[e2]  was complicated by reversible deafness, tinnitus, and ataxia and who relapsed 5 months later with a splenic abscess.
	(21, 26)	ibopamine	100 mg	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	223	Reversible leukopenia was documented in an 81-year-old woman treated with adjunctive [s1]ibopamine[e1]  [s2]100 mg[e2] t.i.d. for chronic congestive heart failure.
	(22, 27)	low-dose	bromocriptine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	224	A 53-year-old male, without any prior history of psychosis, developed schizophrenia 4 days after starting [s1]low-dose[e1]  [s2]bromocriptine[e2] therapy for a macroprolactinoma.
	(21, 26)	low-dose	methotrexate	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	225	Concurrent acute megaloblastic anaemia and pneumonitis: a severe side-effect of [s1]low-dose[e1]  [s2]methotrexate[e2] therapy during rheumatoid arthritis.
	(23, 28)	low-dose	methotrexate	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	226	In a patient suffering from rheumatoid arthritis, we report the first simultaneous occurrence of two side effects of [s1]low-dose[e1]  [s2]methotrexate[e2]  an acute megaloblastic anaemia and a pneumonitis.
	(13, 27)	high dose	Levemepromazine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	227	An 11-year-old boy who was treated with a relatively [s1]high dose[e1] of methotrimeprazine meleate  [s2]Levemepromazine[e2]  a phenothiazine antipsychotic drug, was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome.
	(13, 18)	high dose	methotrimeprazine meleate	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	228	An 11-year-old boy who was treated with a relatively [s1]high dose[e1] of [s2]methotrimeprazine meleate[e2] (Levemepromazine) a phenothiazine antipsychotic drug, was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome.
	(3, 10)	phenothiazine	overdose	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	229	The association of [s1]phenothiazine[e1]  [s2]overdose[e2] and respiratory distress syndrome merits consideration.
	(4, 13)	450-mg	morphine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	230	She received an accidental [s1]450-mg[e1] bolus injection of [s2]morphine[e2] intrathecally and developed hypertension, status epilepticus, intracerebral hemorrhage, and respiratory failure.
	(1, 6)	high	cotrimoxazole	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	231	A [s1]high[e1] dose of [s2]cotrimoxazole[e2] induced hyperkalaemia with the elevation of serum creatinine and blood urea, and increased urinary N-acetyl glucosaminase after several days of the drug administration in these patients; one patient became unconscious.
	(4, 9)	low	clofazimine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	232	Severe abdominal pain in [s1]low[e1] dosage [s2]clofazimine[e2] 
	(0, 7)	Amphotericin B	overdose	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	233	 [s1]Amphotericin B[e1]  [s2]overdose[e2] in pediatric patients with associated cardiac arrest.
	(2, 9)	Amphotericin B	overdose	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	234	CONCLUSIONS: [s1]Amphotericin B[e1]  [s2]overdose[e2] can be fatal in children and infants.
	(21, 28)	amphotericin B	overdoses	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	235	Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving [s1]amphotericin B[e1]  [s2]overdoses[e2] 
	(14, 30)	between 4.6 and 40.8 mg/kg/d	amphotericin B	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	236	INTERVENTIONS AND RESULTS: Cardiac complications were observed in five pediatric patients who received [s1]between 4.6 and 40.8 mg/kg/d[e1] of [s2]amphotericin B[e2] 
	(9, 16)	amphotericin B	overdose	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	237	OBJECTIVE: To report the first five cases of [s1]amphotericin B[e1]  [s2]overdose[e2] with secondary cardiac complications in a pediatric population.
	(12, 19)	acyclovir	overdose	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	238	METHODS: Repeated blood samples were drawn in a patient with severe [s1]acyclovir[e1]  [s2]overdose[e2] who developed coma and nonoliguric renal failure.
	(34, 38)	low	methotrexate	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	239	We report one case of non-Hodgkin lymphoma in a patient, with a 30-year history of rheumatoid arthritis, taking [s1]low[e1] dose [s2]methotrexate[e2] weekly over a 10-month period.
	(46, 53)	prednisolone	25 mg/day	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	240	We report a case of drug-induced Kaposi's sarcoma (KS) on the sole of the right foot in a 71-year-old man, treated for 6 months with corticosteroid therapy  [s1]prednisolone[e1]  [s2]25 mg/day[e2]  for pericardial effusion.
	(6, 10)	low	pimozide	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	241	Acute dystonic reaction with [s1]low[e1] dose [s2]pimozide[e2] 
	(28, 49)	pimozide	0.032 mg/kg/day	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	242	This paper reports on a 6.9-year-old autistic male who developed repeated episodes of acute dystonic reactions associated with [s1]pimozide[e1] administration at the doses of 0.096 mg/kg/day and [s2]0.032 mg/kg/day[e2] and 32 hours following pimozide withdrawal, as well as during subsequent thioridazine administration.
	(28, 39)	pimozide	0.096 mg/kg/day	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	243	This paper reports on a 6.9-year-old autistic male who developed repeated episodes of acute dystonic reactions associated with [s1]pimozide[e1] administration at the doses of [s2]0.096 mg/kg/day[e2] and 0.032 mg/kg/day and 32 hours following pimozide withdrawal, as well as during subsequent thioridazine administration.
	(1, 15)	low	gold	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	244	How [s1]low[e1] can you go? Use of very low dosage of [s2]gold[e2] in patients with mucocutaneous reactions.
	(30, 39)	0.3 ml	phenol-glycerine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	245	We have seen a case of terminal malignant melanoma in which clinical manifestations, indicative of anterior spinal artery syndrome, developed following the injection of [s1]0.3 ml[e1] of 10% [s2]phenol-glycerine[e2] into the cervical subarachnoid space at the C4--C5 level for the control of severe right arm pain.
	(1, 10)	azathioprine	1 mg/kg	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	246	The [s1]azathioprine[e1] dose was low  [s2]1 mg/kg[e2]  and pancytopenia occurred after 56 days therapy.
	(4, 21)	Halfan	higher	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	247	The pharmaceutical company producing [s1]Halfan[e1] has reported 8 cardiac arrests, leading to 6 deaths, when a [s2]higher[e2] dose than recommended was used, there was recent or concomitant treatment with mefloquine, there was pre-existing prolongation of the QT interval or the patient had a thiamine deficiency.
	(19, 38)	higher	mefloquine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	248	The pharmaceutical company producing Halfan has reported 8 cardiac arrests, leading to 6 deaths, when a [s1]higher[e1] dose than recommended was used, there was recent or concomitant treatment with [s2]mefloquine[e2]  there was pre-existing prolongation of the QT interval or the patient had a thiamine deficiency.
	(13, 17)	high	fluticasone propionate	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	249	FINDINGS: Six children with growth retardation noted after treatment with [s1]high[e1] dose [s2]fluticasone propionate[e2] were found to have adrenal suppression.
	(12, 16)	high	fluticasone propionate	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	250	Growth and adrenal suppression in asthmatic children treated with [s1]high[e1] dose [s2]fluticasone propionate[e2] 
	(3, 8)	high	fluticasone propionate	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	251	INTERPRETATION: When [s1]high[e1] doses of [s2]fluticasone propionate[e2] are used, growth may be retarded and adrenal suppression may occur.
	(17, 21)	high	fluticasone propionate	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	252	METHODS: Growth retardation was observed in six severely asthmatic children after introduction of [s1]high[e1] dose [s2]fluticasone propionate[e2] treatment (dry powder).
	(26, 33)	metripranolol	0.6	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	253	Two case reports of bilateral granulomatous anterior uveitis are described in patients with open angle glaucoma treated with [s1]metripranolol[e1]  [s2]0.6[e2]  eye drops.
	(4, 19)	acyclovir	10 mg/kg	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	254	This case suggests that [s1]acyclovir[e1] when given intravenously in doses of [s2]10 mg/kg[e2] may result in increased serum lithium concentrations.
	(17, 28)	10 mg/kg	lithium	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	255	This case suggests that acyclovir when given intravenously in doses of [s1]10 mg/kg[e1] may result in increased serum [s2]lithium[e2] concentrations.
	(17, 24)	dapsone	low	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	256	We describe 2 patients with cutaneous lupus erythematosus who developed severe [s1]dapsone[e1] reaction after [s2]low[e2] dose therapy, with a fatal outcome in one.
	(13, 20)	minocycline	50 mg twice daily	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	257	A 17-year-old female patient who had been taking oral [s1]minocycline[e1]  [s2]50 mg twice daily[e2]  for 3 weeks for acne developed an eruption that progressed to an exfoliative dermatitis.
	(8, 29)	CBZ	overdose	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	258	The evidence of high plasmatic levels of [s1]CBZ[e1] and the absence of other aetiologic factors lead the authors to conclude that the [s2]overdose[e2] of CBZ could have represented the precipitating of the episode of acute pancreatitis.
	(8, 29)	CBZ	overdose	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	259	The evidence of high plasmatic levels of [s1]CBZ[e1] and the absence of other aetiologic factors lead the authors to conclude that the [s2]overdose[e2] of CBZ could have represented the precipitating of the episode of acute pancreatitis.
	(0, 4)	Overdose	magnesium	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	260	 [s1]Overdose[e1] of [s2]magnesium[e2] sulfate in combination with renal insufficiency, hypocalcemia, or compromise of intestinal integrity may predispose horses to magnesium toxicosis.
	(0, 4)	Overdose	magnesium sulfate	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	261	 [s1]Overdose[e1] of [s2]magnesium sulfate[e2] in combination with renal insufficiency, hypocalcemia, or compromise of intestinal integrity may predispose horses to magnesium toxicosis.
	(5, 10)	excessive	AZ	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	262	We thus concluded that an [s1]excessive[e1] dose of [s2]AZ[e2] had probably destroyed the gastric mucosal barrier or thrombocytopenia due to bone marrow disorder and thus eventually led to the development of hemorrhagic gastritis.
	(11, 16)	600 mg	danazol	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	263	On the next day, after a total dose of only [s1]600 mg[e1] of [s2]danazol[e2]  gingival bleeding and purpura occurred.
	(21, 29)	d-penicillamine	125-500 mg daily	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	264	We reported 3 patients who developed acute generalized dystonia and akinetic rigid syndrome following an initial therapy with [s1]d-penicillamine[e1]  [s2]125-500 mg daily[e2] 
	(14, 17)	heroin	overdose	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	265	Ballistic movements due to ischemic infarcts after intravenous [s1]heroin[e1]  [s2]overdose[e2]  report of two cases.
	(1, 21)	heroin	overdose	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	266	Two [s1]heroin[e1] addicts, aged 34 and 19 years, developed ballistic movements after intravenous heroin [s2]overdose[e2] 
	(18, 22)	high	penicillin	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	267	We report a 76-year-old man who developed an acute blistering eruption following [s1]high[e1] dose [s2]penicillin[e2] treatment for pneumococcal septicaemia.
	(9, 26)	25 mg	desmethylsertraline	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	268	In case 1, a total daily dose of [s1]25 mg[e1] sertraline, with nondetectable sertraline and [s2]desmethylsertraline[e2] blood levels, resulted in a doubling of the lamotrigine blood level with symptoms of toxicity.
	(9, 41)	25 mg	lamotrigine	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	269	In case 1, a total daily dose of [s1]25 mg[e1] sertraline, with nondetectable sertraline and desmethylsertraline blood levels, resulted in a doubling of the [s2]lamotrigine[e2] blood level with symptoms of toxicity.
	(9, 13)	25 mg	sertraline	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	270	In case 1, a total daily dose of [s1]25 mg[e1]  [s2]sertraline[e2]  with nondetectable sertraline and desmethylsertraline blood levels, resulted in a doubling of the lamotrigine blood level with symptoms of toxicity.
	(9, 13)	25 mg	sertraline	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	271	In case 1, a total daily dose of [s1]25 mg[e1]  [s2]sertraline[e2]  with nondetectable sertraline and desmethylsertraline blood levels, resulted in a doubling of the lamotrigine blood level with symptoms of toxicity.
	(28, 51)	5-aminosalicylic acid	3.0 g/day	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	272	We report a case of pancytopenia in a 23-year-old man with Crohn's disease who was treated with [s1]5-aminosalicylic acid[e1] (Pentasa; Nisshin, Tokyo, Japan) [s2]3.0 g/day[e2] 
	(36, 49)	Pentasa	3.0 g/day	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	273	We report a case of pancytopenia in a 23-year-old man with Crohn's disease who was treated with 5-aminosalicylic acid  [s1]Pentasa[e1]  Nisshin, Tokyo, Japan) [s2]3.0 g/day[e2] 
	(23, 27)	low	alprazolam	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	274	1. Changes in the plasma cortisol level were reported in a male patient with panic disorder during the period of [s1]low[e1] dose [s2]alprazolam[e2] treatment (mean 0.62 +/- 0.15 mg/day) compared with during the period of high-dose period (mean 1.08 +/- 0.28 mg/day).
	(18, 23)	olanzapine	20-25 mg/d	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	275	We report on three patients with acute schizophrenia, who developed severe akathisia during treatment with [s1]olanzapine[e1]  [s2]20-25 mg/d[e2] .
	(25, 34)	isosorbide dinitrate	5 mg	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	276	A 65-year-old woman with angina pectoris presented with syncope after sublingual ingestion of [s1]isosorbide dinitrate[e1]  [s2]5 mg[e2] .
	(9, 18)	isosorbide dinitrate	5 mg	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	277	In a postural challenge test after administration of [s1]isosorbide dinitrate[e1]  [s2]5 mg[e2] , blood pressure decreased from 120/67 to 65/35 mmHg, followed by syncope with a sudden decrease in pulse rate from 85 to 60 beats/min.
	(0, 4)	High	phosphate	DRUG-DOSE	1	DRUG	DOSE	-1	-1	N/A	N/A	278	 [s1]High[e1] dose [s2]phosphate[e2] treatment leads to hypokalemia in hypophosphatemic osteomalacia.
